For the long-term treatment of acromegaly, Sandostatin® LAR® delivers...

POWERFUL EFFICACY.

Important note: Before prescribing, consult full prescribing information. Presentation: Octreotide acetate. Vials containing 10 mg, 20 mg or 30 mg octreotide free base supplied as powder microsponges for suspension for injection together with a prefilled syringe (syringe for parental use, containing: sodium carboxymethylcellulose 12.5 mg, mannitol 15 mg; water for injection as ad 2.5 mL). For use: reconstitute 10 mg (20 mL) of octreotide per dose, i.e. essentially "ready-to-use". Indication: Acromegaly in patients who are adequately controlled on oral treatment with Sandostatin® in patients in whom surgery or radiotherapy is inappropriate or ineffective; in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, GIPomas. Dose: 10 to 30 mg every 4 weeks, administered as a deep intramuscular injection. Contraindications: Known hypersensitivity to octreotide or to any of the excipients. Warnings/Precautions: These adjustments of drugs such as beta-blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary. Caution in patients with insufficiency, diabetes mellitus, thyroid function should be monitored in patients receiving prolonged treatment with octreotide. Periodic examination of gallbladder; monitoring of vitamin B🎃 levels in patients who have a history of vitamin B🎃 deficiency. Caution in patients with pregnancy. Patients should be advised to use adequate contraception if necessary. Patients should not breast-feed during Sandostatin LAR treatment. Interactions: Increased intestinal absorption of diuretics, cholestyramine; increased bioavailability of tramadol. Caution with concomitant use of drugs mainly metabolized by CYP3A4 and which have a low therapeutic index. Adverse reactions: Very common (<1/10) adverse drug reactions are diarrhoea, abdominal pain, nausea, constipation, flatulence, headache, cholelithiasis, hypercholesterolaemia, and injection-site localised pain. Common (1/100, <1/10) adverse drug reactions are dyspepsia, vomiting, abdominal distension, postembolic bleeding, loose stools, discoloration of urine, flatulence, hypocalcaemia, hypo/hyperkalaemia, increased transaminase levels, pruritus, rash, alopecia, dyspepsia, and hypoglycaemia. Uncommon (<1/1000, <1/100) adverse drug reactions are urticaria, acne purpuracea, acute hepatitis, acute hepatitis without cholestasis, cholestatic hepatitis, jaundice, cholestatic jaundice, arthralgia, increased alkaline phosphatase levels, and increased gamma glutamyl transferase levels. Pack and prices: Country specific. Legal classification: Country specific.

15th International and 14th European Congress of Endocrinology
5–9 May 2012
Florence, Italy

www.ice-ece2012.com

European Society of Endocrinology
UNPARALLELED EVIDENCE.

Sandostatin® LAR®—
Proven long-term efficacy in the control of GH and IGF-1 levels¹-³

Backed by unparalleled evidence, Sandostatin® LAR® is chronic therapy for patients with acromegaly.¹-³

- Up to 68% of patients experienced both GH <2.5 ng/mL + IGF-1 normalisation²
- Up to 72% of patients experienced reduction in GH <2.5 ng/mL²
- Up to 75% of patients experienced IGF-1 normalisation²
- Tumour reduction of over 20% occurred in a significant number of untreated patients³
- Well tolerated with an established safety profile¹,³
- Over 4 million doses of Sandostatin® LAR® administered worldwide¹¹
- Over 800,000 patient years of experience¹¹
- Over 6000 published articles and 600 clinical trials¹¹,⁴

STRENGTH, BUILT ON EVIDENCE.


European Society of Endocrinology

The European Society of Endocrinology promotes research, education and clinical practice in endocrinology. It aims to strengthen endocrinology by enabling scientists and doctors across Europe to work together more successfully by providing high-quality education and communication opportunities. The European Society of Endocrinology is a charity and a company limited by guarantee.

Membership

Ordinary Membership
Open to researchers, clinicians and students with an interest in the field of endocrinology and hormonal systems.

Benefits of ordinary membership include:
- Free online access to European Journal of Endocrinology
- Reduced registration fees to the annual ECE and training courses
- Access to ESE prizes, grants and awards
- Members’ only section with access to a web-based directory of European endocrinologists
- ESE news alerts highlighting important topical issues
- Tri-annual newsletter
- Grants forum
- Voting rights and attendance at general meetings
- ESE journal subscriptions

Affiliated Society Membership
ESE values its links with the 42 national endocrine societies and 9 specialist societies that are currently members.
Membership is open to national endocrine societies in Europe and in countries bordering the Mediterranean sea as well as pan-European sub-specialist endocrine societies.

Corporate Membership
Corporate membership is open to companies working in the field of endocrinology. Thank you to all our Corporate Members for their generous and continued support of ESE and activities:
- Amgen
- CMM Global
- DuoCort AB
- Eli Lilly
- Ipsen
- Laboratoire HRA Pharma
- Merck-Serono
- Novartis
- Novo Nordisk
- Otsuka Pharmaceuticals Europe Limited
- Pfizer
- Roche
- Sandoz International GmbH

Major activities

Major activities include the annual European Congress of Endocrinology and training courses which, provide outstanding updates for basic scientists and clinicians. The Society also runs regular postgraduate educational courses aimed at both basic scientists and clinicians.

Save the Dates!

10th ESE Postgraduate Course in Clinical Endocrinology
Polanczyk, Poland
26-28 May 2011

Summer School on Endocrinology
Bregenz, Austria
24-28 July 2011

11th ESE Postgraduate Course in Clinical Endocrinology
Belgrade, Serbia
22-24 September 2011

ESE Clinical Update 2011
Limassol, Cyprus
4-6 November 2011

NEW

ESE Meeting Grant

ESE offer 50 ESE Meeting Grants per year, worth up to €400 each, for ESE members to attend an ESE meeting. The grant is made as a contribution towards the total cost of attending either the annual European Congress of Endocrinology (ECE) or an ESE Training Course in accordance with the eligibility criteria.
**NEW**

**ENDO ESE International Endocrine Scholars Programme (IESP)**

In collaboration with The Endocrine Society (USA), the IESP is aimed at promoting the career development of young endocrinologists from around the globe by identifying talented young investigators and offering them an exceptional training experience.

Ideal candidates are post-doctoral endocrinologists with promising leadership skills and at the top rank with respect to intelligence, motivation, prior accomplishments, and English language skills. Once selected, the recipients receive counsel through a unique mentoring programme that helps them find financial support, advice and esteemed training opportunities.

Successful candidates will attend both The Endocrine Society and European Society of Endocrinology annual meetings. The successful candidates will participate in an interview process at both annual meetings, where they will have the opportunity to meet principal investigators of several laboratories with the purpose of choosing the most appropriate laboratory for postdoctoral training.

The closing date for 2011 applications has now passed but check the ESE website for the application requirements for 2012!

---

**Journals**

The Society has four official journals; between them they cover the full spectrum of endocrinology and help to raise the profile of European endocrinology.

**European Journal of Endocrinology**

The official clinical journal of the European Society of Endocrinology. The journal publishes original research papers, reviews, short communications and case reports within clinical endocrinology. Invited commentaries also feature regularly. ‘Highlights’ are concise summaries of new breakthroughs. ESE members receive free on-line access to the journal.

**IMPACT FACTOR:** 3.539 (as at June 2009)

**Journal of Endocrinology**

Journal of Endocrinology provides a wide coverage of research in all aspects of endocrinology. It is in the top ranks of global endocrine journals and publishes high quality, leading-edge research from all over the world.

**IMPACT FACTOR:** 2.860 (as at June 2009)

**Journal of Molecular Endocrinology**

Journal of Molecular Endocrinology provides a forum for papers devoted to describing molecular mechanisms by which hormones and related compounds regulate physiological and pathological processes. JME publishes high quality, leading-edge research from all over the world and its readership is worldwide.

**IMPACT FACTOR:** 3.221 (as at June 2009)

**Endocrine-Related Cancer**

Endocrine-Related Cancer offers a global forum for basic, clinical and experimental investigations which concern endocrine-related cancer in human and animal subjects.

**IMPACT FACTOR:** 4.282 (as at June 2009)

---

**Executive Committee**

ESE is governed by an Executive Committee, members of which have been elected by members of the ESE, thus representing a broad range of endocrine interests and a wide geographical area of Europe and ensuring fair representation. In addition to this there are 7 specialist sub-committees.

- **Professor Eberhard Nieschlag**, Germany, 2007-2011
- **Professor Paolo Beck-Peccoz**, Italy, 2009-2013
- **Professor Barbara Jarzab**, Poland, 2010-2014
- **Professor Aart J van der Lely**, The Netherlands, 2008-2012
- **Professor Maria Alevizaki**, Greece, 2007-2011
- **Professor Wiebke Arlt**, UK, 2009-2013
- **Professor Justo Castaño**, Spain, 2010-2014
- **Professor Andrea Giustina**, Italy, 2009-2013
- **Professor Vera Popovic-Brkic**, Serbia, 2007-2011
- **Professor Martin Reincke**, Germany, 2009-2013
- **Professor Peter Trainer**, UK, 2007-2011
- **Professor Rolf Galliard**, Switzerland, ex-officio UEMS representative
- **Professor Christian Strasburger**, Germany, ex-officio Editor-in-Chief, European Journal of Endocrinology

**Congress Sub-committee, currently chaired by Maria Alevizaki**

- Corporate Liaison Sub-committee currently chaired by Aart J van der Lely
- Education Sub-committee currently chaired by Peter Trainer
- International Liaison Sub-committee currently chaired by Eberhard Nieschlag
- Nominations Sub-committee currently chaired by Vera Popovic
- Publications Sub-committee currently chaired by Paolo Beck-Peccoz
- Young Active Research (YAR) Sub-committee currently co-chaired by Wiebke Arlt

Further information about the ESE can be found at [www.euro-endo.org](http://www.euro-endo.org) or by contacting the ESE Secretariat at info@euro-endo.org.
13th European Congress of Endocrinology
30 April – 4 May 2011, Rotterdam, The Netherlands

Abstract Book

EDITORS
The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee

ECE 2011 Programme Organising Committee
Peter Trainer Chair

Members
Maria Alevizaki
Wiebke Arlt
Tadej Battelino
Philippe Bouchard
Wouter de Herder
Troels Hansen
Michal Krsek
Marek Niedziela
Tarvo Rajasalu
Patrice Rodien
Peter Selby
Manuela Simoni
Anna Spada
A J van der Lely
Theo Visser

Abstract Marking Panel

B Abrahamsen Denmark
J Argente Spain
S Arver Sweden
E Arzt Argentina
J Bertherat France
F Beuschlein Germany
H Biegermann Germany
J P Bourguignon Belgium
N Bratin Slovenia
A Brinkmann Netherlands
J Brkko Slovakia
P Chanson France
R Chapurlat France
S Christine-Maitre France
P E Clayton UK
M Cooper UK
G Cvijovic Serbia
K Dahlman-Wright Sweden
M Dattani UK
C Daumerie Belgium
C De Block Belgium
F de Jong Netherlands
R de Kloet Netherlands
M Drent Netherlands
M Erdogan Turkey
L Etienne France
S Ezzat Canada
M Fassnacht Germany
U Feldts-Rasmussen Denmark
D Ferone Italy
E Ferranni Italy
L Fugazzola Italy
L Gennari Italy
C Gerard France
D Glintborg Denmark

B Granata Italy
C H Gravholt Denmark
J Gromoli Sweden
A Grossman Argentina
V Hainer Germany
S F Hillier Germany
I Huhtaniemi Belgium
Hunyady Slovenia
E Husebye Netherlands
J Isaard Slovakia
G Johannsson France
G Kaltsas France
E D Kandikris France
F Krestimur UK
J Kohrl Germany
M Korbonits UK
B Krahnve Sweden
B K Kudla UK
K Kula Belgium
F Kumanov Belgium
M Kunsova Czech Republic
N Lahlou Netherlands
E Lammert Netherlands
P Larurberg Turkey
J Leenders France
L Leenhardt Canada
F Lombardo Germany
M Ludgate Denmark
M M Malagon Italy
E Malecka-Tendera Italy
M Manelli Italy
C Mattieu Italy
J McKenna France
C Missale Denmark

J Mittag Italy
D Montanya Denmark
A Neu Germany
K Oberg Sweden
C Ohlsson Sweden
C J Partsch Germany
R Paschke Germany
A Pereira Netherlands
L Persani Italy
S Petersenn Germany
P-F Plouin France
T M Poulsen Denmark
M B Ranke Germany
C Rizzo Malta
G Rossi Italy
M Buchala Poland
G K Stalla Germany
H J Schneider Germany
A Sommez Turkey
A Sonmez Poland
K Stewart UK
M Santoro Italy
C Sutan Turkey
C Tack Netherlands
M Terzolo Italy
V Toogood Denmark
A Vaug UK
E van den Akker Netherlands
R Voutilainen Finland
B Walker UK
J M Wit Netherlands
L Zabiliene Lithuania
M C Zatelli Italy
K Ziomecka Poland
M Zitzmann Germany
The ESE would like to thank the ECE 2011 sponsors:

**Gold Sponsors**
Ipsen
Novartis
Otsuka
Pfizer

**Other Sponsors & Exhibitors**
American Association of Clinical Endocrinologists (AACE)
BioScientifica Ltd
BioVendor-Laboratorni Medicina a.s.
HRA Pharma
Mercodia
Perkin Elmer Inc
Phoenix Pharmaceuticals Inc.
Pronokal
Sandoz International
S. Karger AG
Society for Endocrinology
Wisepress Online Bookshop Ltd
CONTENTS

13th European Congress of Endocrinology 2011

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The European Journal of Endocrinology Prize Lecture ................................................................. EJE1
The Geoffrey Harris Prize Lecture ............................................................................................... GH1

PLENARY LECTURES

Disorders of sex development ...................................................................................................... PL1
Making sense with thyroid hormone ............................................................................................ PL2
Targets for the management of diabetes in 2011 .......................................................................... PL3
Gonadotrophin signalling in health and disease ........................................................................ PL4
Endocrine hypertension .............................................................................................................. PL5
Neurosteroids as Regenerative Agents in Brain: Therapeutic Implications for Cognition and Neurodegenerative Disease PL6
Androgen use and misuse: A 2011 view ........................................................................................ PL7
Genetics of bone disease ............................................................................................................ PL8

SYMPOSIA

Keep cool, lose weight: brown fat and energy metabolism ........................................................... S1.1–S1.3
Controversies in hyperaldosteronism ............................................................................................. S2.1–S2.3
Molecular mechanisms in neuroendocrine tumours .................................................................... S3.1–S3.3
Subclinical hormone excess ........................................................................................................ S4.1–S4.3
Novel therapies in type 1 diabetes ............................................................................................... S5.1–S5.3
Long term effects of bisphosphonates ........................................................................................ S6.1–S6.3
Novel approaches to in vitro and in vivo imaging ........................................................................ S7.1–S7.3
The biological clock and metabolism .......................................................................................... S8.1–S8.3
New endocrine aspects of diabetes mellitus ............................................................................... S9.1–S9.3
New developments in the therapy for NETs .............................................................................. S10.1–S10.3
Genetics of male infertility ......................................................................................................... S11.1–S11.3
Novel insights into phosphate metabolism .................................................................................. S12.1–S12.3
Endocrine response to critical illness .......................................................................................... S13.1–S13.3
Female contraception update ..................................................................................................... S14.1–S14.3
Emerging therapies in type 2 diabetes ......................................................................................... S15.1–S15.3
TSH Receptor and thyroid disorders ............................................................................................ S16.1–S16.3
Pituitary update .......................................................................................................................... S17.1–S17.3
Management of endocrine disease in pregnancy ....................................................................... S18.1–S18.3
Management of endocrine disease in adolescence ................................................................. S19.1–S19.3
Thyroid function: it is in your genes ............................................................................................. S20.1–S20.3
Vitamin D, pregnancy and development .................................................................................... S21.1–S21.3
Non traditional effects of pituitary hormones ............................................................................. S22.1–S22.3
Optimising thyroid hormone replacement .................................................................................. S23.1–S23.3
Management of phaeochromocytoma ........................................................................................ S24.1–S24.3
GNAS locus: imprinting, animal models and human diseases ................................................... S25.1–S25.3
The role of plasma binding proteins in tissue hormone delivery .............................................. S26.1–S26.3
Breaking news in adrenal malignancy ......................................................................................... S27.1–S27.3
Polycystic ovary syndrome: Classification, genetics and therapy ............................................... S28.1–S28.3
JOE/JME PRIZE PRESENTATION
The central nervous system and the control of adipocyte and hepatic metabolism .................................................. JP1

MEET THE EXPERT SESSIONS .................................................. MTE1–MTE24

ORAL COMMUNICATIONS
Thyroid/Adrenal ................................................................. OC1.1–OC1.6
Neuroendocrinology ........................................................ OC2.1–OC2.6
Bone/Reproduction ........................................................ OC3.1–OC3.6
Diabetes/Thyroid ................................................................. OC4.1–OC4.6
Hormone metabolism and action ........................................ OC5.1–OC5.6

POSTER PRESENTATIONS
Adrenal cortex ................................................................. P1–P41
Endocrine disruptors ........................................................ P42–P52
Endocrine tumours and neoplasia ........................................ P53–P89
Female reproduction ......................................................... P90–P128
Growth factors ................................................................. P129–P135
Male reproduction ........................................................... P136–P154
Neuroendocrinology ........................................................ P155–P190
Pituitary ......................................................................... P191–P301
Obesity .......................................................................... P302–P348
Steroid metabolism ........................................................ P349–P358
Nuclear receptors ............................................................ P359
Adrenal medulla ............................................................. P360–P366
Signal transduction ........................................................ P367–P370
Thyroid (non cancer) ......................................................... P371–P448
Thyroid cancer ................................................................. P449–P491
Bone/calcium/Vitamin D ....................................................... P492–P548.1
Cardiovascular endocrinology and lipid metabolism .......... P549–P582
Clinical case reports ........................................................ P583–P655
Developmental endocrinology .......................................... P656–P659
Diabetes therapy ............................................................. P660–P685
Diabetes complications ..................................................... P686–P708
Diabetes (epidemiology, pathophysiology) ............................. P709–P740

INDEX OF AUTHORS
Prize Lectures and Biographical Notes
**European Journal of Endocrinology Prize Winner**

The *European Journal of Endocrinology* Prize is awarded to a candidate who has significantly contributed to the advancement of the knowledge in the field of endocrinology through publication. This year’s recipient is Professor Manuel Tena-Sempere. The prize will be presented as part of the ECE 2011 opening ceremony where Prof. Tena-Sempere will deliver his lecture. Prof. Tena-Sempere will also write a review article based on this lecture to be published in the *European Journal of Endocrinology*. Further information can be found on [http://www.euro-endo.org/prizes/default.htm](http://www.euro-endo.org/prizes/default.htm)

Manuel Tena-Sempere, Spain

Manuel Tena-Sempere (1969) MD, PhD is full Professor of Physiology at the Department of Cell Biology, Physiology and Immunology of the University of Córdoba, Spain. His expertise lies in Reproductive and Metabolic Endocrinology, with special attention to the neuroendocrine regulation of puberty onset and the reproductive axis (i.e. study of the molecular events responsible for the proper activation and function of the hypothalamic-pituitary unit and the gonads), and their modulation by energy balance and metabolic and nutritional cues. In this context, Dr Tena-Sempere and his group have significantly contributed to the characterization of the physiological roles of kisspeptins and GPR54 in the control of key aspects of reproductive function, including puberty onset, gonadotropin secretion, positive and negative feedback effects of sex steroids, ovulation and metabolic gating of fertility. Overall, his research activities in this area have resulted to date in more than 55 articles and invited reviews in international peer-reviewed journals, and more than 40 invited lectures and international seminars over the last 6 years. In addition, Dr Tena-Sempere and co-workers have provided novel evidence for the reproductive effects and mechanism of action of different signals primarily involved in energy homeostasis, and several studies of his group have been recently published concerning the characterization of the physiological role of those signals (leptin, ghrelin, PYY3-36, GALP, 26RFa, neuromedins, nesfatin-1) in the control of several aspects of reproductive function, including the regulation of puberty onset as well as gonadotropin secretion and gonadal function. Overall, Dr Tena-Sempere has published 185 articles in international peer-reviewed journals over the last 18 years (PubMed database; February 2011), including a significant number (>95) of research papers and invited reviews in authoritative, highly-ranked journals in the last 6 years. The total number of citations of Tena-Sempere’s work is presently >4495, with an H-index of 38.

In addition, Dr Tena-Sempere has participated as invited speaker in numerous international meetings and seminar series (>50 in the last 7 years), and has served/serves as member of the Editorial Boards of prestigious journals of the field, such as Neuroendocrinology (acting as Associate Editor), Endocrinology, Molecular & Cellular Endocrinology, PLoS ONE, Journal of Neuroendocrinology, Peptides, Frontiers in Endocrinology, Frontiers in Pituitary Endocrinology and Journal of Physiology & Biochemistry. Dr Tena-Sempere is scientific partner (PI) and member of the steering board of the Spanish Centre of Excellence for Research in Obesity and Nutrition, where he serves also as responsible for its formative program. In addition, Dr Tena-Sempere is PI of one of the groups of the recently created Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), and panel member of the area of Biomedicine of the Spanish Agency for Evaluation of Research Activities (ANEP). The research group of Dr Tena-Sempere, that keeps active international collaborations with numerous leading groups in the field of Endocrinology, is currently composed of 18 members, including senior scientists, post- and pre-doctoral fellows and technicians, and is funded by numerous projects from different Spanish and European agencies, as well as private institutions.
The European Journal of Endocrinology Prize Lecture

(Aiming at) Deciphering puberty

Manuel Tena-Sempere, Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain

Puberty, as the key developmental period when reproductive capacity is attained and sexual and somatic maturation completed, is under the control of a complex series of regulatory mechanisms that are sensitive to endogenous factors and environmental cues. The mechanisms of normal puberty onset and its potential deviations have been deeply scrutinized in humans and model species. However, characterization of the neuro-hormonal basis of puberty remains incomplete. In addition, evidence (and concern) is mounting that the timing of puberty is changing in several countries, with a trend for earlier puberty onset, especially in girls, whose underlying causes are ill defined. In the last decade, our laboratory has aimed at deciphering some of the basic neuroendocrine and molecular mechanisms responsible for the control of puberty onset, using rodents as pre-clinical models. In this presentation, a synoptic overview of the experimental work conducted by our group towards this aim will be presented, with special attention to our studies on the roles of the Kiss1 system in the control of the gonadotropic axis in general and pubertal timing in particular, as well as on the mechanisms for the metabolic regulation of puberty. Likewise, recent studies of our group on the putative roles of additional neuropeptide pathways (e.g., neurokinin B and nesfatin-1) and molecular mechanisms (e.g., mTOR and AMPK signalling) in the central regulation of puberty will be briefly described. Our basic studies will be discussed in the context of recent seminal findings regarding key regulatory mechanisms of human puberty and their potential contribution to disorders of pubertal timing and reproductive function. Ideally, such debate will highlight the relevance of translational research for widening our understanding of the basis of human physiology and disease; fields where Reproductive Endocrinology has provided paradigmatic examples in recent years.
Geoffrey Harris Prize winner

This prestigious prize is intended for established workers in the field of basic and clinical neuroendocrinology and is generally supported by Ipsen. This year’s recipient is Professor Ezio Ghigo. The prize will be presented as part of the ECE 2011 opening ceremony where Professor Ghigo will deliver his lecture. Professor Ghigo will also deliver two other lectures at future ESE scientific meetings. Further information can be found at http://www.euro-endo.org/prizes/default.htm

Ezio Ghigo, Italy

Ezio Ghigo, MD, is Professor of Endocrinology in the School of Medicine at the University of Turin, Head of Endocrinology, Diabetology and Metabolism, and Chairman of the Department of Medicine in the SGB-Molinette University Hospital of Turin, Italy. He is currently also Dean of the School of Medicine of the University of Turin.

His research interests include the neural control of anterior pituitary function, ghrelin, glucose and lipid metabolism, the endocrinology of ageing, obesity and anorexia nervosa.

He has authored over 400 papers. He has been Editor-in-chief of the Journal of Endocrinological Investigation and is member of the editorial board of other international endocrine journals. He is a member of a many endocrine societies, was vice president of the European Society of Endocrinology and is now president elect of the Italian Society of Endocrinology.
The acylated form of ghrelin (GRLN) was discovered as the natural ligand of the GHS-R1a. GRLN is acylated by a specific octanoyl-transferase (GOAT) and is predominantly produced by the stomach, although expressed by many other endocrine and non-endocrine, peripheral and central tissues. Also GHS-R1 is widely expressed by several central and peripheral tissues. Acylated GRLN displays strong GH-releasing activity but is not specific for GH exhibiting other neuroendocrine actions such as stimulation of PRL and ACTH and inhibition of LH. Acylated GRLN is now recognized as a potent orexigenic factor that also modulates energy expenditure as well as other important central functions. At the peripheral level, GRLN modulates gastrointestinal motility and secretion, exerts cardiovascular actions and, most of all, plays major physiological regulation of glucose and lipid metabolism. Acylated GRLN plays a diabetogenic role while non-acylated GRLN (like smaller fragments and its analogues) positively influences glucose and lipid metabolism, as indicated also by recent studies in GOAT KO mice. GRLN receptors different from GHS-R1a are likely to mediate the metabolic actions of non acylated GRLN. In all, acylated and non acylated GRLN, but also obestatin, another relevant product of the GRLN gene, play a major role in regulating peripheral metabolism and it is not by chance that their secretion is mostly under metabolic regulation.
Plenary Lectures
Disorders of sex development

**PL1**

Disorders of sex development: recent progress

Tsutomu Ogata & Maki Fukami

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Disorders of sex development (DSD) can occur as a single gene disorder, a multifactorial disorder, and an imprinting/epigenetic disorder. Here, I will report our recent progress on two causative genes for DSD. MAML1: Mastermind domain containing gene 1

We have reported that MAML1 is a causative gene for hypospadias, a mild form of 46,XY DSD. This is primarily based on the identification of several pathologic mutations of MAML1 in patients with hypospadias. The murine homolog was specifically expressed in fetal Sertoli and Leydig cells around the critical period for sex development, and transient knockdown experiments showed significantly reduced testosterone production and Cyp17a1 expression in murine Leydig tumor cells. We also found that MAML1 was controlled by SF1 and transactivated the non-canonical Notch target gene Hes3 in nuclear bodies. Notably, Maml1 knockout mice had no abnormal genitalia but exhibited metabolic syndrome. POR: P450 Oxidoreductase

POR deficiency (PORD) is a rare autosomal recessive disorder characterized by skeletal dysplasia referred to as Antley–Bixler syndrome, adrenal dysfunction, 46,XY and 46,XX DSD, and maternal virilization during pregnancy. We have studied 38 patients with POR, and classified them into two major groups: group A, homozygosity for R457H with low residual POR activity; and group B, compound heterozygosity for R457H and one apparently null mutation. Phenotypic comparison between group A and group B suggest that the residual POR activity reflected by the R457H dosage constitutes the underlying factor for clinical variability in some features but not in other features, probably due to the simplicity and complexity of POR dependent metabolic pathways relevant to each phenotype. Notably, PORD is almost invariably associated with 46,XX DSD, and this is primarily explained by placenta-derived testosterone exposure and backdoor pathway (fetal adrenal)-derived dihydrotestosterone exposure. Furthermore, we have identified the promoter region of POR gene by analyzing three patients with apparently heterozygous mutations.

Conclusions

Although DSD is a highly heterogeneous condition with many unknown underlying factors, the black box is gradually shrinking with progress in molecular endocrinology.

Making sense with thyroid hormone

**PL2**

Making sense with thyroid hormone

Douglas Forrest, Emily Cordus, Yulou Fu, Hong Liu, Ailing Lu, Michelle Ma, Lily Ng, Robin Peeters & David Sharlin

Clinical Endocrinology Branch, NIDDK, NIH, Bethesda, Maryland 20892, USA.

Thyroid hormone has long been known as a key developmental factor in human and model species. Insufficient thyroid hormone during development can impair the growth and maturation of diverse tissue and organ systems. One of the most serious risks associated with congenital hypothyroidism is defective brain and skeletal dysplasia referred to as Antley–Bixler syndrome, adrenal dysfunction, 46,XY and 46,XX DSD, and maternal virilization during pregnancy. We have studied 38 patients with POR, and classified them into two major groups: group A, homozygosity for R457H with low residual POR activity; and group B, compound heterozygosity for R457H and one apparently null mutation. Phenotypic comparison between group A and group B suggest that the residual POR activity reflected by the R457H dosage constitutes the underlying factor for clinical variability in some features but not in other features, probably due to the simplicity and complexity of POR dependent metabolic pathways relevant to each phenotype. Notably, PORD is almost invariably associated with 46,XX DSD, and this is primarily explained by placenta-derived testosterone exposure and backdoor pathway (fetal adrenal)-derived dihydrotestosterone exposure. Furthermore, we have identified the promoter region of POR gene by analyzing three patients with apparently heterozygous mutations.

Conclusions

Although DSD is a highly heterogeneous condition with many unknown underlying factors, the black box is gradually shrinking with progress in molecular endocrinology.

Endocrine hypertension

**PL5**

Endocrine hypertension

W Young

Mayo Clinic, Rochester, Minnesota, USA.

Objective

To review the first reported cases of successfully treated pheochromocytoma and primary aldosteronism and document the diagnostic and therapeutic advances that have occurred since the initial descriptions.

The main functions of the two pituitary gonadotrophic hormones, luteinising hormone (LH) and follicle stimulating hormone (FSH), and of the placental choriogonadotropin (hCG), are well characterized today. In clinical medicine, gonadotrophin measurements in peripheral serum form a valuable tool in the diagnosis of disorders in sexual development and fertility, and gonadotrophins are the mainstay in infertility treatments. A great deal of the new information about physiology and pathophysiology of gonadotrophin secretion and actions has emerged from mutations detected in the genes of gonadotropins and their cognate receptors (R), as well as from genetically modified mouse models. The recent detection of gonadotrophin actions in extragonadal tissues both in humans and experimental animals is a topic of continuing controversy. The contributions of our laboratory to this new information include the detection of an inactivating mutation of FSHR and a functionally significant polymorphism in the LHbeta gene. We have also produced a knockout mouse for LHR, and transgenic mice overproducing hCG and expressing a constitutively activated mutant of FSHR. Our findings have clarified some of the controversies surrounding the extragonadal gonadotrophin actions. Our current research is concerned with gonadotrophin physiology and pathophysiology using a variety of genetically modified mouse models now at our disposal. Our key findings include the following: Neither the physiological high intratesticular testosterone concentration nor FSH action are necessary for the induction of spermatogenesis, extragonadal LHR expression is not necessary for the maintenance of female mouse fertility, and homodimerisation of LHR molecules is a physiologically important mode of their action. Whereas a constitutively activating mutation of FSHR induces a dramatic phenotype in the female, the consequences of such a mutation in the male are surprisingly mild. The recent developments in the field indicate that gonadotrophin function will remain in the focus of research in reproductive endocrinology.
Methods
The original case descriptions and the subsequent pertinent literature were reviewed.

Results
The successful management of the initial cases of pheochromocytoma in 1926 and primary aldosteronism in 1954 was highlighted by keen clinical observation, clinical intuition, and the application of scientific principles. Since those prismatic case descriptions, the technological advances in laboratory-based diagnosis, radiology-based tumor localization, and surgical approaches to the adrenal glands have been truly remarkable.

Conclusions
The evolution in the diagnosis and treatment of pheochromocytoma will continue to progress as we identify more genetic causes, develop biochemical markers for ‘pre-clinical’ pheochromocytoma, identify better markers for malignant disease, and develop more effective treatment options for malignant pheochromocytoma. Over the next decade we hope to determine the pathophysiology for bilateral idiopathic hyperaldosteronism, develop less invasive and less technically demanding tests to distinguish between unilateral aldosterone-producing adenoma and bilateral idiopathic hyperaldosteronism, determine where low renin hypertension stops and primary aldosteronism starts, and determine the impact of genetic and environmental factors on aldosterone secretion in patients with and without primary aldosteronism.

Neurosteroids as Regenerative Agents in Brain: Therapeutic Implications for Cognition and Neurodegenerative Disease
PL6

Neurosteroids as regenerative agents in brain: therapeutic implications for cognition and neurodegenerative disease
Robert A. Brinton
USC Clinical and Translational Science Institute, University of Southern California, Los Angeles, California, USA.

Allopregnanolone (APx), a neurosteroid, significantly increased proliferation of rodent and human neural progenitor cells in vitro via GABA receptor channel and L-type channel mechanisms that activated the cell cycle. We subsequently investigated the efficacy of APx to promote neurogenesis in the hippocampal subgranular zone (SGZ), to reverse learning and memory deficits in the 3 month-old male triple transgenic mouse model of Alzheimer’s (3xTgAD). APx significantly increased BrdU + cells in SGZ in 3xTgAD mice and restored SGZ proliferation to normal magnitude. Further, APx reversed the cognitive deficits to restore learning and memory performance to the level of normal non-Tg mice. In 3xTgAD mice, APx-induced survival of neural progenitors was significantly correlated with APx-induced memory performance. We then determined efficacy of APx to restore neural progenitor cell survival and cognition subsequent to AD pathology in male 3xTgAD and nonTg mice. APx significantly increased survival of BrdU + cells and cognition in 3xTgAD mice in the presence of intraneuronal Aβ whereas APx was ineffective subsequent to development of extraneuronal Aβ plaques. Restoration of cognition was maximal by the first day and sustained normal nonTg performance. In aged 15-month-old nonTg mice, APx restored learning and memory performance to the level of normal non-Tg mice. APx proliferation to normal magnitude. Further, APx reversed the cognitive deficits to restore learning and memory performance to the level of normal non-Tg mice. In 3xTgAD mice, APx-induced survival of neural progenitors was significantly correlated with APx-induced memory performance. We then determined efficacy of APx to restore neural progenitor cell survival and cognition subsequent to AD pathology in male 3xTgAD and nonTg mice. APx significantly increased survival of BrdU + cells and cognition in 3xTgAD mice in the presence of intraneuronal Aβ whereas APx was ineffective subsequent to development of extraneuronal Aβ plaques. Restoration of cognition was maximal by the first day and sustained normal nonTg performance.

Androgen use and misuse: A 2011 view
PL7

Androgen use and misuse: a 2011 view
David Handelsman
ANZAC Research Institute, Sydney, Australia.

Testosterone is a well established, safe, effective and affordable hormone for use in androgen replacement therapy (ART) for androgen deficiency (AD) due to pathology of the hypothalamo-pituitary-testicular axis. Newer testosterone products provide short-acting (transdermal) or long-acting (depot injectable) delivery with enhanced convenience to improve long-term compliance during life-long ART. Yet there is a striking disparity between major under-diagnosis of authentic AD (e.g. Klinefelter’s syndrome) and the steeply increasing overuse of androgens in ageing men and women as well as abuse for bodybuilding and sports doping. Within the accepted framework of the pathological basis of disease, AD remains a clinical diagnosis with a pathological basis and confirmed by hormone assays. Biochemical confirmation of AD remains hampered by the unreliability (method-dependent bias, non-specificity) of direct testosterone immunoassays which are still universal in clinical pathology labs although almost completely supplanted by mass spectrometry in clinical research labs. The epidemic use of (meaning-free) testosterone, elevating an outdated heuristic concept (‘free hormone hypothesis’) into an unquestioned quasi-axiom, usually calculated by inaccurate formulae only adds confusion. Readily available, affordable testosterone assays used in a form of ad hoc population screening together with the pathologising of ageing by invention of ‘andropause’ as a disease, have created a ‘eugonadal sick syndrome’, analogous to what is now known as ‘non-thyroidal illness syndrome’, a reversible, non-specific pan-hypothalamic reaction to systemic illness. These factors have converged to foster a striking upsurge in testosterone prescribing, a marketing-driven distortion threatening to derail endocrinology practice from a needed focus on improving under-diagnosis of genuine AD into a lifestyle consultancy treating pseudo-AD of ageing. Whether testosterone can ameliorate any biological aspect of ageing (obesity, pre-diabetes, cardiovascular disease) remains largely unestablished by adequately powered, placebo-controlled RCTs but the prospects of a WHI-style study focussed on male ageing per se seems a remote prospect of doubtful value.

Genetics of bone disease
PL8

Genetics of bone disease
Stuart Ralston
University of Edinburgh, Edinburgh, UK.

Over the past 10 years, tremendous advances have been made in understanding the role that genetic factors play in the regulation of bone metabolism and bone disease. Most bone diseases have a strong genetic component but for many of these the genetic architecture is incompletely understood. However it is clear that in some diseases, there is Mendelian inheritance of the phenotype due to alleles that have a large effect size, whereas in other diseases, the inheritance is polygenic with alleles of small effect size and additional contributions from environmental factors. Osteoporosis is the most common bone disease and is characterised by reduced bone mineral density (BMD) and increased fracture risk. The heritability of BMD is about 70% and fractures also have a heritable component although this decreases markedly with age as environmental factors assume a more important role. Multiple genes have been identified by genome wide association studies that regulate BMD and fracture risk but these have small effect sizes and (in total) so far explain only 5–6% of the genetic variance. Studies are in progress to determine if larger effect alleles also exist. Several rare bone diseases exist in which BMD levels are unusually high or low including osteopetrosis (due to mutations in genes that regulate bone metabolism and bone disease). Most bone diseases have a strong genetic component but for many of these the genetic architecture is incompletely understood. However it is clear that in some diseases, there is Mendelian inheritance of the phenotype due to alleles that have a large effect size, whereas in other diseases, the inheritance is polygenic with alleles of small effect size and additional contributions from environmental factors. Osteoporosis is the most common bone disease and is characterised by reduced bone mineral density (BMD) and increased fracture risk. The heritability of BMD is about 70% and fractures also have a heritable component although this decreases markedly with age as environmental factors assume a more important role. Multiple genes have been identified by genome wide association studies that regulate BMD and fracture risk but these have small effect sizes and (in total) so far explain only 5–6% of the genetic variance. Studies are in progress to determine if larger effect alleles also exist. Several rare bone diseases exist in which BMD levels are unusually high or low including osteopetrosis (due to mutations in genes that regulate osteoclast function) and sclerosteosis bone dysplasias (due to mutations in genes that regulate bone formation). Genetic analysis of families with these diseases has resulted in the identification of several key molecules that regulate bone turnover such as liprotein-receptor related protein 5 (LRP5), sclerostin (SOST) and Cathepsin K Pager’s disease of bone (PDB) has a frequency of about 1–2% and has a strong genetic component. Current evidence suggests that PDB is caused by a combination of rare alleles of large effect that cause Mendelian inheritance of the disease and common alleles of medium effect that increase disease risk by 30–50%. Causal genes include SQSTM1, TNFRSF11A, CSF1, OPTN, and TMS5F4 which are involved in regulating osteoclast differentiation and function. Advances in genetics have not only advanced our knowledge of the pathophysiology of bone disease but have also identified several molecules that are being targeted for the next generation of drug treatments for bone disease.
Symposia
Keep cool, lose weight: brown fat and energy metabolism

$1.1$

Brown adipocytes and energy homeostasis in mice

S Herzog$^{1,2,25}$

$^1$German Cancer Research Center, Heidelberg, Germany; $^2$ZMBH University of Heidelberg, Heidelberg, Germany; $^3$University Clinics Heidelberg, Heidelberg, Germany.

Adipose tissue can be subdivided into two distinct categories of fat cells: white adipocytes are specialized for the storage of chemical energy such as triglycerides, and under conditions of obesity white adipose tissue is characterized by tissue inflammation and energy overload.

In contrast, brown adipocytes dissipate energy in the form of heat (thermogenesis) by uncoupling of the mitochondrial electron transport chain from ATP formation through the specific expression of so-called uncoupling protein (UCP)1. Lineage tracking studies in mice have demonstrated that white adipocytes are distinct from brown adipocytes during normal embryonic development. Indeed, progenitors of the brown adipocyte lineage have been shown to share a common precursor with the myogenic lineage.

In addition, a third distinct brown adipocyte-like cell type has been identified (brown-in-white, BRITE). In response to cold exposure, many WAT depots develop an increased number of BRITE cells, which seems to be mediated – at least in part – through sympathetic beta3-adrenoceptor agonist action. Despite typical BAT-like functional properties, such as UCP-1 expression, the BRITE adipocytes are developmentally distinct from the classical brown cells and their functional contribution to systemic energy metabolism has only recently been documented.

Here, new developments and findings from animal models with respect to white versus brown versus BRITE adipocyte determination as well as its implication for the control of systemic energy homeostasis will be discussed.

$1.2$

Physiology of brown adipose tissue in humans

Pujio Nuutila

Turku PET Centre, University of Turku, Turku, Finland.

Human brown adipose tissue (hBAT) has recently been re-discovered and found to be functionally and metabolically highly active when exposed to cold. Advanced imaging technology, namely the development of hybrid positron-emission tomography (PET/computed tomography (CT) scanners has been the premise for the progress. The main areas of activated BAT have been found in supraclavicular regions and in the neck, and paravertebral regions. When we quantified glucose uptake in these supraclavicular regions during cold activation, it was found to be more than 10 times higher than in the scan performed in normal room temperature. Surgical biopsies from this location demonstrate significant mRNA and protein levels of uncoupling protein 1 (UCP1) and histology multilocular intracellular lipid droplets. In our study population of 27 normal-weighted adults $^{15}$-FDG uptake was activated in 60% of cases during experimental cold exposure. Obesity decreases this probability and female gender and younger age enhances it.

Animal studies have suggested, that BAT can be activated also by high fat diet. Our recent data shows that glucose metabolism of BAT is activated by insulin. Activation by insulin but not activation by cold is perfusion-independent. Recent studies have shown that thyroid hormones play an important role in development and function of BAT. Our data suggests that glucose metabolism of hBAT is enhanced in hyperthyroid patients with Graves disease. An explanation for this could be increased activity of the sympathetic nervous system is in hyperthyroid diseases.

Further studies are needed for the evaluation of the importance of hBAT in human physiology and for the possibilities for its manipulation. Brown adipose tissue also serves new pharmaceutical targets for drug development against the obesity pandemic.

$1.3$

Brown adipose tissue and thermogenesis in lean and obese subjects

Wouter Van Marken Lichtenbelt

Department of Human Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.

The occurrence of obesity and the related metabolic syndrome increases dramatically worldwide. A positive energy balance causes obesity. Facultative thermogenesis, which is the increase in energy expenditure in response to cold or diet, may be an effective way to affect the energy balance.

Several studies have confirmed that humans show significant (mild) cold induced thermogenesis, i.e. without shivering. Tissues shown to be involved in adults are skeletal muscle and brown adipose tissue (BAT). The most likely cellular mechanism in both tissues is mitochondrial uncoupling. Recently functional BAT has been rediscovered in adult humans. At the functional level, adipocytes can be subdivided into white and brown. The most important function of white adipocytes is energy storage, while the main function of brown adipocytes is heat production. Brown adipocytes are located in BAT or white adipose tissue, the latter is called ‘BRITE’ (brown-in-white).

From metabolic studies it is known that the facultative thermogenesis is blunted in obese humans, although there is a large individual variation. Intriguingly, functional and active BAT is also inversely correlated with body mass index (BMI) and body fat percentage in humans. An important aspect in the current studies is to find out whether BAT can be activated and recruited in obese subjects. Animal and human studies indicate that recruitment and activation of brown and brite adipocytes can potentially be accomplished by pharmacological, nutritional or environmental intervention. Crucial in the activation of adaptive thermogenesis and brown adipocytes are the sympathetic nervous system and the thyroid hormone axis.

Finally, thermogenic BAT is a major site for lipid breakdown and glucose uptake, and thus the thermogenic capacity of even small amounts of brown adipocytes has emerged as an attractive target for anti-diabetes therapies.

Report will be given from animal models with respect to white versus brown versus BRITE adipocyte determination as well as its implication for the control of systemic energy homeostasis will be discussed.

Controversies in hyperaldosteronism

$2.1$

Controversies in hyperaldosteronism: whom and how to screen

P Mulatero, C Bertello, S Monticone & F Veglio

University of Torino, Torino, Italy.

Primary hyperaldosteronism (PA) is the most frequent cause of secondary hypertension. PA detection is of particular importance, because it provides opportunity for targeted treatments (surgical for APA and medical for BAH), and because it has been demonstrated that PA patients are more prone to cardiovascular events and target organ damage than essential hypertensives. The Endocrine Society Guidelines stated the categories of hypertensive patients with relatively high prevalence of PA, that should undergo a screening test: - resistant hypertension; - hypertension grade 2 or 3; - hypertension with spontaneous or diuretic-induced hypokalaemia; - hypertension with adrenal incidentaloma; - hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age; - all hypertensive first-degree relatives of PA patients PA. However, recent studies indicate that other categories of patients may be at increased risk of PA, including hypertensive patients with metabolic syndrome (MS), type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA). Aldosterone/renin ratio (ARR) is considered the best screening test. Several confounding factor, in particular interfering drugs, should be considered during the screening. Moreover, it should be noted that the test may perform differently if renin instead of plasma renin activity is measured together with aldosterone. It remains to be determined the potential benefit of screening all hypertensives for PA. Widespread screening would result in a large increase in costs for screening and confirmation of PA, but on the other hand, would offer to all PA patients the opportunity of a cure or targeted pharmacotherapy. In light of the high prevalence of low renin hypertension, it is important to emphasize that an increased ARR is not itself diagnostic of PA and a confirmatory test is always required to avoid a high number of hypertensive patients inappropriately undergoing costly and potentially harmful lateralisation procedures. Although Endocrine Society Guidelines clearly recommend performing a confirmatory test, the choice of confirmatory test remains a matter of debate and there is currently insufficient direct evidence to recommend one over the others. In our Unit we perform the intravenous saline load and we suggest to perform a confirmatory test that includes NaCl administration and to use captopril test only for those patients at risk for volume expansion.
Adrenal vein sampling plays a central role in discriminating between unilateral (mostly aldosterone-producing adenoma) and bilateral adrenal disease (mostly bilateral hyperplasia) in primary aldosteronism. Although computed tomography or magnetic resonance are used to visualize adrenal glands, both methods are not sensitive enough to detect small tumors and they are not also specific for autonomous aldosterone production. With increasing age, prevalence of adrenal tumors or nodules is increasing reaching up to 7% in the age of 70. According recent Recommendations for diagnosis and treatment of primary aldosteronism, all subjects who agree with adrenalactectomy should undergo adrenal venous sampling to exclude incorrect subtype diagnosis.

To cannulate adrenal veins, in particular the right adrenal vein, skilled radiologist is essential due to difficult sampling. In the last time, visualization of right adrenal vein using the multi-detector computed tomography and rapid cortisol assays have been shown to increase the rate of successful cannulation of the right adrenal vein.

Although adrenal venous sampling is regarded method of choice, they exist according many authors uncertainties in using ACTH to stimulate the adrenal cortex in order to increase the success rate in cannulation of adrenal veins. However, stimulation of the non-adenomatous adrenal cortex with ACTH may be associated with the decrease of specificity. Another disadvantage of adrenal venous sampling is the absence of clear criteria for evaluating the success of adrenal vein cannulation (different cortisol (adrenal)/cortisol (periphery) ratios), and lateralization (different aldosterone (one side)/cortisol (one side) to aldosterone (other side)/cortisol (other side) ratios). Some centers use as an alternative to adrenal venous sampling nuclear medicine and lateralization (different aldosterone (one side)/cortisol (one side) to aldosterone (other side)/cortisol (other side) ratios).

The emergence of aldosterone synthase inhibitors represents another promising therapeutic alternative for the control of hormone secretion and, hopefully, to reduce tumor burden. Few initial in vitro studies revealed that some aldosterone synthase inhibitors exhibit substantial differences in their ability to inhibit aldosterone production from cortisone. Further study is required to avoid potentially dangerous hyperkalemia and azotemia. Indeed, individual NETs seem to respond differently to specific somatostatin analogs, panagonists, and new SSTR/DR chimeric compounds, depending on the SSTR and DR profile conferring signaling pathways. Although antiproliferative effects seem mainly driven by ERK/1/2 activation, additional intracellular pathways, such as JNK signalling and other proteins involved in the control of cell cycle may be targeted. The crucial point emerging from these preliminary studies is that when, in the future, a therapeutic strategy is conceived, it will require a stronger and adequate delineation of the specific receptor profile, as well as a clarification of the linked intracellular pathways of the tumor, in order to optimize an effective treatment.

Endocrine Abstracts (2011) Vol 26
cells by acting as a dominant negative for SST action. Study of these new truncated sst5 variants paves the way to explore novel aspects of sst pathophysiology and to expand their therapeutic potential.


**S3.3 Lessons from MENX**

Natalia Pellegrata  
Institute of Pathology, Helmholtz Zentrum München, München, Germany.

MENX is a recently identified multiple endocrine neoplasia (MEN) syndrome in the rat. Affected animals develop multiple neuroendocrine tumors (NETs) with high penetrance and at young age, specifically: bilateral pheochromocytoma (100%), multifocal pituitary adenoma (100%), multifocal thyroid C-cell hyperplasia, parathyroid hyperplasia, extra-adrenal pheochromocytoma (para-gangliomas) and pancreatic islet cell hyperplasia. MENX is caused by a germline frameshift mutation of the Cdkn1b gene, which leads to extremely reduced expression of the encoded mutant p27 protein in vivo. Capitalizing on this discovery, we and others identified germline mutations in CDKN1B in patients having multiple endocrine tumors (the MEN4 syndrome).

In order to exploit the MENX animal model in studies aimed at elucidating the molecular pathogenesis of NETs or in preclinical therapy-response studies, it is necessary to characterize the tumors associated with this syndrome. Thus, we assessed the histo-morphological and immunohistochemical features of the rat tumors, and demonstrated that the pituitary tumors in MENX rats are non-functioning adenomas of the gonadotroph lineage. Then, we performed transcriptome analysis to identify novel molecular mechanisms involved in the rat tumors, and correlated these findings with human NETs. Using this approach we identified novel candidate molecular markers for diagnosis and targeted therapy of pheochromocytoma. Gene expression analysis of the rat pituitary tumors is still ongoing and preliminary results will be presented. In conclusion, if properly characterized and exploited the MENX syndrome may represent a relevant translational platform for molecular and preclinical studies of NETs.

**S4.2 Normocalcemic primary hyperparathyroidism**

Filomena Cetani  
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy.

The diagnosis of normocalcemic primary hyperparathyroidism (PHPT) can be made in subjects whose total and ionized serum calcium are completely normal but in whom the PTH level is persistently elevated. In order to make the diagnosis of normocalcemic PHPT, secondary causes for an elevated PTH level should be ruled out, such as vitamin D insufficiency, or renal insufficiency. Replacing the former patients with vitamin D to reach levels now considered to be normal (i.e. >30 ng/ml) often returns the PTH to normal. Occasionally, however, these patients will become hypercalcemic with vitamin D replacement thus unmasking more typical hyperparathyroid PHPT. If the PTH remains elevated and the serum calcium remains normal, following vitamin D repletion, and other causes of an elevated PTH have been excluded, then the diagnosis of normocalcemic PHPT can be considered. Since there are limited data on the natural history of normocalcemic PHPT, it is unclear how these subjects should be regarded via a vis parathyroid surgery. A large population based study of over 5000 postmenopausal women who were screened and then retested 8 years later provided evidence for the development of hypercalcemia in some of these subjects. Two observational studies of normocalcemic PHPT have followed patients longitudinally. In one study 37 patients were followed for a mean of 3 years (range 1–9). Typical hypercalcemic PHPT emerged in 7 (19%) individuals. However, 40% developed evidence of disease progression with development of kidney stones, fractures, marked hypercalcuria or >10% increase in the serum calcium. Seven patients had successful parathyroidectomy, of whom three were hypercalcemic and the rest met other criteria for surgery. Clearly, normocalcemic PHPT is a newly recognized clinical phenotype of PHPT.

**S4.3 Subclinical hyperthyroidism**

Bernadette Biondi  
University Federico II Medical School, Naples, Italy.

Subclinical hyperthyroidism (SHyper) is defined as serum FT4 and FT3 levels within their respective reference ranges or less than the normal range of TSH levels. The most common cause of SHyper is exogenous SHyper due to unintentional excessive replacement therapy in hypothyroid patients or to intentional TSH suppressive therapy for malignant thyroid disease. Endogenous SHyper is commonly associated with autonomous thyroid function as occurs in Graves’ disease, multinodular goiter, and solitary autonomously functioning thyroid nodules. The prevalence of SHyper is dependent on age, sex, and to some extent, on the iodine intake of the population. Despite the high prevalence of SHyper and the potential progression to overt disease, the risk associated with this condition is debated. Opinions are quite divergent regarding the deleterious effects of SHyper on cardiovascular mortality. Several meta-analyses have examined the cardiovascular risk associated with SHyper with the aim of establishing whether treatment should be considered. Their results support the concept that the cardiovascular risk of SHyper depends on the age of the patients and co-morbidity conditions. There is a higher cardiovascular risk in elderly persons with SHyper and potential harmful effects are present in patients with co-morbidity conditions. Most studies on endogenous SHyper and bone health have found a decrease in bone mineral density in postmenopausal women, especially in cortical bone-rich sites, but there is little evidence of a clinically significant effect on bone in premenopausal women. Before treatment is started, it should be established whether the subnormal serum TSH is related to endogenous SHyper and whether it is persistent. Although it has not been demonstrated that early treatment of symptomatic patients with SHyper improves clinical outcome, treatment of SHyper might improve quality of life, cardiovascular risk factors and bone mineral density and would prevent a possible progression to overt disease.

**S4.4 Iodine excess**

Elena Gialanella  
University of Athens, Athens, Greece.

Iodine excess is commonly associated with autonomous thyroid function as occurs in Graves’ disease, multinodular goiter, and solitary autonomously functioning thyroid nodules. The prevalence of SHyper is dependent on age, sex, and to some extent, on the iodine intake of the population. Despite the high prevalence of SHyper and the potential progression to overt disease, the risk associated with this condition is debated. Opinions are quite divergent regarding the deleterious effects of SHyper on cardiovascular mortality. Several meta-analyses have examined the cardiovascular risk associated with SHyper with the aim of establishing whether treatment should be considered. Their results support the concept that the cardiovascular risk of SHyper depends on the age of the patients and co-morbidity conditions. There is a higher cardiovascular risk in elderly persons with SHyper and potential harmful effects are present in patients with co-morbidity conditions. Most studies on endogenous SHyper and bone health have found a decrease in bone mineral density in postmenopausal women, especially in cortical bone-rich sites, but there is little evidence of a clinically significant effect on bone in premenopausal women. Before treatment is started, it should be established whether the subnormal serum TSH is related to endogenous SHyper and whether it is persistent. Although it has not been demonstrated that early treatment of symptomatic patients with SHyper improves clinical outcome, treatment of SHyper might improve quality of life, cardiovascular risk factors and bone mineral density and would prevent a possible progression to overt disease.

Endocrine Abstracts (2011) Vol 26
Novel therapies in type 1 diabetes

§5.1
Pancreas transplantation
T Berney
Geneva University Hospitals, Geneva, Switzerland.

Vascularized whole pancreas transplantation is currently the only therapeutic approach consistently able to restore euglycemia in patients with type 1 diabetes. More than two-thirds of all pancreas transplants are performed simultaneously with the kidney (SPK: simultaneous pancreas kidney) in patients with end-stage diabetic nephropathy. The results of SPK transplantation are excellent with rates of insulin-independence >80% at 1 year and >70% at 5 years. Venous thrombosis is the major cause of early pancreatic graft loss. Successful SPK transplantation significantly prolongs patient and kidney graft survival. Additionally, there is growing evidence that successful SPK transplantation can stabilize or even reverse some of the chronic secondary complications of diabetes. Pancreas-alter-kidney (PAK) transplantation is an interesting option for candidates for SPK transplantation who have a living kidney donor. Pancreas transplantation alone (PTA) is increasingly performed and is offered to type 1 diabetic patients with glycemic lability (hypoglycaemia unawareness). PAK and PTA together comprise <50% of all pancreas transplants, and their success rate is improving, but slightly lower than for SPK, probably because rejection is more difficult to diagnose.

Current research efforts in the field are mainly focusing on the following issues:
1. Defining strategies to reduce the ischemia-reperfusion injury thought to be responsible for the majority of early ‘technical’ pancreatic graft losses.
2. Expanding the pancreas donor pool, notably through the use of living donors.
3. Exploring the potential of early PTA in preventing the development of end-stage nephropathy.
4. Identifying subsets of patients with type 2 diabetes eligible for pancreas transplantation with similar chances of success.
5. Exploring the role of minimally invasive surgery and surgical new technologies in pancreas procurement and transplantation.

§5.3
Stem cells as a treatment option in diabetes
Julie Kerr-Conte
University of Lille, Lille, France.

Cell therapy is an emerging, realistic treatment for diabetes. First we will quickly review alternative stem cell approaches including autologous Hematopoietic stem cells (CEB Court JAMA 2009) and allogeneic Mesenchymal stem cells (Prochymal, Osiris Therapeutics, Inc.: Clinicaltrials.gov NCT00690066) as an attempt to cure recent onset type 1 diabetes, before focusing on β-cell replacement therapies including an update on composite islet grafts (islets plus stem cells), or islets derived in vitro and in vivo from human embryonic stem cells (Viacyte Kroom Nat Med 2008), and induced pluripotent stem cells human (iPS). The proof of principle that type 1 diabetic patients’ cells can give rise to iPS lines which subsequently differentiate into insulin secreting human islets has been demonstrated (Mach R/Melton D PNAS 2009). The advantages and disadvantages of each pluripotent source with regards to regulatory and ethical issues, teratoma formation, genomic stability will be presented. Immunosolation strategies of pluripotent cells will attempt to allow both transplantation with minimum to no immunosuppression, and confinement in a closed chamber to reduce teratoma formation. Theracyte chambers (Baxter USA) previously used in rodent islet transplantation (Sharma Diabetologia 2006) successfully allow human fetal and embryonic derived islet survival and function but not human islets in rodent models (Ekin-Ansari P Transplantation 2009). Finally, we will discuss the strategies and progress that companies are making towards pushing pluripotent stem cells ahead to clinical application.

Islet transplantation and regeneration

Eelco de Konig
Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.

In patients with longstanding type 1 diabetes β-cell regeneration or β-cell replacement are the only options that result in normoglycemia without the risk of hypoglycemia. Although persistent C-peptide is present in ~10% of patients with type 1 diabetes, currently regeneration of eutopic pancreatic islets remains elusive due to the minimal regenerative capacity of the human pancreas and the presence of persistent autoreactivity. Islet transplantation is a form of β-cell replacement therapy that is a treatment option for a specific group of patients with type 1 diabetes that suffers from glycemic lability, recurrent hypoglycemic episodes and hypoglycemia unawareness. The minimally invasive nature of percutaneous intraportal infusion of isolated islets from human donor pancreas makes the procedure attractive compared to pancreas transplantation. There is only a small risk of portal vein thrombosis or hepatic bleeding. However, usually islet infusions from 2 to 3 donors are necessary to obtain insulin independence in islet transplant recipients. This is mostly related to the loss of islets during transplantation and islet engraftment. Although insulin independence may not be achieved after one islet infusion, partial islet graft function already leads to a substantial improvement in hypoglycemia-related problems. Over time islet graft function declines probably due to a combination of factors involving a suboptimal liver microenvironment for long-term islet function, impaired vascularity, autoreactivity, recurrent autoreactivity and toxic effects of immunosuppressive agents. So a substantial number of transplant recipients that once were insulin-alloreactivity, recurrent autoreactity and toxic effects of immunosuppressive treatment.

§5.2

§5.4

Long term effects of bisphosphonates

§6.1

The risk of fractures and osteonecrosis
B Abrahamsen1,2
1Gentofte Hospital, Copenhagen, Denmark; 2University of Southern Denmark, Odense, Denmark.

Bisphosphonates are effective in the prevention of osteoporotic fractures and have been the mainstay of osteoporosis therapy for almost two decades. Being anti-resorptives, bisphosphonates bring about a gain in bone mass that is due to diminished bone remodelling accompanied by a higher mean age of the bone tissue.

The presentation aims to review the evidence linking bisphosphonates to skeletal complications and to discuss the magnitude of the risk of these potential complications relative to the benefit in terms of osteoporotic fractures averted by treatment.

First, bisphosphonates can cause osteonecrosis of the jaw (ONJ). This is particularly true when given intravenously with a short dosing interval as is the case in the oncology setting. Though this complication is relatively rare in patients treated with oral bisphosphonates, clinicians, dentists and patients must be aware of this potential complication to bisphosphonates. The clinical diagnosis is based on the observation – by a health professional – of exposed bone in the oral cavity that fails to heal within 8 weeks. Though severe cases requiring surgery have been reported, most cases resolve on conservative treatment such as antiseptic mouth washes and in some cases antibiotics. In oncology patients treated with IV bisphosphonates at short dosing intervals it may be desirable to avoid bisphosphonates for the first 3 weeks following dental extractions, provided this does not delay treatment of patients with uncontrolled skeletal metastatic disease.

Second, in the last five years, several case series have described an unusual femur fracture (atypical femur fracture) occurring in patients who had been treated with oral bisphosphonates. These rare fractures are often spontaneous and differ from classical shaft fractures of the femur in having a transverse or short oblique presentation. Such fractures can be bilateral and are often but not always accompanied by a cortical thickening or stress reaction. More than half of the patients complain of thigh pain in the weeks prior to the fracture. Case control studies have established bisphosphonate use as a strong risk factor, though it remains unclear if bisphosphonates are the cause. Pending additional research, physicians should exercise caution and avoid long term bisphosphonate treatment in patients who are not at high risk of osteoporotic fractures.
Long term management of osteoporosis
Erik Fink Eriksen
University Hospital of Oslo, Aker, Trondheimsveien 235, 0514 Oslo, Norway.

Over the last 25 years we have been expanding our choice of treatments for os osteoporosis. The chronic nature of the disease makes long term treatment necessary. It has long been known that long term management of osteoporosis suffers the same compliance problems as chronic treatment regimens for other disease like hypertension, hyperkolesterolemia, etc.

The most widely used treatment for osteoporosis is still oral bisphosphonates, which have come under increased scrutiny due to side effects like osteonecrosis of the jaw and atypical femoral fractures being linked to long term exposure. The available data suggest, however, that the risk of these adverse events in an osteoporosis population are extremely low. These events together with the unfounded fear of oversuppression of bone turnover during long term treatment with bisphosphonates have elicited increased interest in drug holidays. The available data suggest that such holidays are possible, because bone turnover remains low many years, but in high risk individuals the risk of vertebral fractures increases. No significant increase in non vertebral fractures have been seen however.

Anabolic treatment with PTH for 2 years is necessary to exploit the full potential of the drug in terms of non-vertebral fracture reduction. Discontinuation of anabolic treatment should always be followed by an antiresorptive regimen, otherwise the bone gain is lost over a period of 2 years. Here the new long acting, parenteral regimens like Zoledronic acid and Denosumab seem expecially attractive.

Bone turnover markers in the management of osteoporosis
Abstract unavailable.

Novel approaches to in vitro and in vivo imaging
How to visualize G-protein-coupled receptor signaling by FRET
D Calebiro1,2
1Bioimaging Center/Rudolf Virchow Center, Wuerzburg, Germany; 2Institute of Pharmacology and Toxicology, University of Würzburg, Wuerzburg, Germany.

G-protein-coupled receptors (GPCRs) constitute the major family of cell surface receptors. They comprise receptors for light, taste and smell as well as ions, small transmitters, peptides and large protein hormones. Given their involvement in fundamental biological processes and their accessibility, GPCRs serve as targets for many classes of drugs, including beta-blockers, antihistamines and opiates. Whereas many biochemical steps involved in GPCR signaling have been described in good details, their spatio-temporal dynamics in living cells is still largely unknown. This is because biochemical techniques have limited temporal and, generally, no spatial resolution.

The recent introduction of a series genetically encoded fluorescent sensors allows for the first time to monitor key steps of GPCR signaling, such as ligand binding, receptor activation, G-protein coupling and second messenger generation, directly in living cells. These sensors are largely based on the physical phenomenon of fluorescence resonance energy transfer (FRET), which can be measured by different microscopy techniques. Since the temporal and spatial resolution are those of fluorescence microscopy, i.e. up to a few milliseconds in time and a few hundred nanometers in space, these techniques can capture fast signaling events and, at the same time, define their subcellular location. These methods have been instrumental for new and advanced insights in the field, including the recent finding that GPCRs can continue to signal to cAMP after agonist-dependent internalization into endosomes.

The biological clock and metabolism
Clock genes in human adipose tissue
Marta Garaulet
University of Murcia, Murcia, Spain.

Circadian rhythms are such an innate part of our lives that we rarely pause to speculate why they even exist. Some studies have suggested that the disruption of the circadian system may be causal for obesity and manifestations of metabolic syndrome (MetS). Shift-work, sleep-deprivation and bright-light-exposure at night are related to increased adiposity (obesity) and prevalence of MetS. It has been provided evidence of clock genes expression in human adipose tissue and demonstrated its association with different components of the MetS. Moreover, current studies are illustrating the particular role of different clock genes variants and their predicted haplotypes in MetS.

In the present lecture, the molecular mechanisms implicated in the interaction between chonodisruption and metabolic-related illnesses such as obesity and MetS will be treated with different approaches: i) molecular approach: to achieve a better knowledge of the adipose tissue (AT) internal clock and to identify differences among subcutaneous and visceral fat in AT cultures obtained from obese subjects (genomics techniques); ii) different epidemiological approaches in large populations will be mention considering different single nucleotide polymorphisms (SNPs) of clock genes that are related to obesity and weight loss and whether which are modulated by external factors, such as sleep and diet (nutrigenetic studies with DNA isolation and clock genotyping); iii) clinical approach: behavioral (sleep quality and duration, eating patterns and chronobiological characteristics) and hormonal factors which could explain the previously reported association between the clock genes SNPs and weight loss will be also note.

Endocrine Abstracts (2011) Vol 26
Circadian clock regulation of glucocorticoid synthesis
S Kiesling, G Eichele & H Oster
Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.

Under non-stressed conditions adrenal glucocorticoid (GC) secretion shows strong circadian rhythms with blood levels peaking around wake-up time (i.e. in the morning in humans and at the beginning of the night in nocturnal rodents). These diurnal variations are primarily regulated by rhythmic activation of the hypothalamic–pituitary–adrenal (HPA) axis and the secretion of ACTH from the pituitary. While HPA axis activity is ultimately controlled by the circadian pacemaker residing in the suprachiasmatic nuclei (SCN) of the hypothalamus, we found that clock gene activity at the level of the adrenal cortex regulates the sensitivity of the steroidogenic machinery to ACTH stimulation and, hence, the GC responsiveness during the course of the day. Using a combination of molecular, genetic and surgical approaches we describe the mechanisms of SCN-to-adrenal clock interaction in the regulation of GC rhythms in the mouse. Using a rapid light/dark cycle shifting paradigm we discovered a role for the adrenal clock and adrenal GC rhythms in the re-synchronization of rest-activity cycles during jet lag and devised a novel pharmacological strategy to accelerate jet lag adaptation based on ‘pre-flight’ manipulation of circadian GC secretion.

Feeding the clock
J Johnston

Abstract unavailable.

New endocrine aspects of diabetes mellitus
S9.1
The incretin system: from discovery to drug development
T Vilsboll

Abstract unavailable.

GLP-1 and the cardiovascular system
Michaela Diamant
Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.

The gut hormone glucagon-like peptide (GLP-1) lowers blood glucose by stimulating meal-related insulin secretion and lowering hyperglucagonemia in a glucose-dependent manner. Currently, injectable GLP-1 receptor agonists (GLP-1(2–36)am) and oral inhibitors of the dipeptidyl peptidase-4 (DPP-4) enzyme, that degrades native GLP-1, are successfully employed in the treatment of type 2 diabetes (T2DM). Clinically relevant extrapancreatic effects of GLP-1 (RA) involve slowing down gastric emptying, inducing satiety, reducing food intake and decreasing body weight. Additional benefits are improvement of islet cell function. More recently, direct effects on the cardiovascular (CV) system have been described. Indeed, GLP-1 receptors are present on vascular cells and cardiomyocytes. In rodents, GLP-1, but also GLP-1RA and DPP-4 inhibition, were shown to reduce myocardial infarct size in ischaemia–reperfusion models and pretreatment with GLP-1 improved cardiac function after ischaemia/reperfusion injury. In small-sized human studies, GLP-1 improved cardiac function in post-myocardial infarction patients with left ventricular dysfunction and in those with heart failure. Also, DPP-4 inhibition resulted in an improved myocardial response to dobutamine stress in patients with coronary artery disease. In addition, beneficial effects of GLP-1 (RA) were observed on endothelial function. However, to date it is unclear whether these effects are directly mediated by activation of the GLP-1 receptor or by another mechanisms involving the GLP-1 metabolite GLP-1(9–36). Similarly, it is unknown whether the GLP-1 effects are direct or whether the improvement of systemic metabolism is the key contributor to the observed beneficial effects. GLP-1 (RA) improved obesity-related CV risk factors, thus theoretically reducing CV risk. However, the recently initiated large-sized long-term outcome studies with the various incretin-based compounds should ultimately determine whether these promising agents indeed reduce the excessive risk of CV disease in people with T2DM.

GLP-1 biology: beyond the pancreas
Darlen Sandoval
Division of Endocrinology, University of Cincinnati, Cincinnati, USA.

Glucagon-like peptide 1 (GLP-1) is a gut hormone that broadly promotes glucose homeostasis through the regulation of islet hormone secretion. Interestingly, GLP-1 has been reported to be both cause and cure of type 2 diabetes mellitus (T2DM). Decreased GLP-1 is thought to cause the progression from impaired glucose tolerance to frank T2DM. Conversely, the GLP-1 system has been successfully targeted as a treatment option for T2DM patients and increases in GLP-1 have been implicated in the rapid resolution of T2DM after bariatric surgery. We have confirmed that animal models of two bariatric surgeries, roux en Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), drastically increase meal-induced GLP-1 and also increase insulin levels, and improve hepatic insulin sensitivity. The benefits of VSG and RYGB on glucose homeostasis may be mediated in part through increased circulating GLP-1. However, there are few, if any, hepatic GLP-1 receptors, which argues for alternative sites of action, at least for regulation of hepatic glucose production. GLP-1 is also synthesized in the brain, where it is thought to primarily regulate food intake. Our work suggests that the CNS GLP-1 system also provides important input to regulate glucose homeostasis. Importantly, we have found that central administration of a GLP-1 receptor agonist caused relative hyperglycemia during a glucose tolerance test suggesting that activation of CNS GLP-1 receptors contributes to normal post-prandial glucose homeostasis. We have also found direct infusion of GLP-1 into the arcuate, but not the paraventricular nucleus of the hypothalamus reduced hepatic glucose production. Thus, both CNS and peripheral GLP-1 regulate normal glucose homeostasis. We hypothesize that after a meal the coordinated effects of the CNS GLP-1 system are to inhibit glucose production as well as to increase satiation. These CNS effects of GLP-1 may explain the benefits of VSG and RYGB on hepatic insulin sensitivity.

New developments in the therapy for NETs
S10.1
New developments in the therapy for NETs: risk stratification
M Pavel
Charité University Medicine Berlin, Berlin, Germany.

Neuroendocrine tumors (NETs) represent a rare and diverse group of tumors with predominant location in the gastro-entero-pancreatic and bronchopulmonary system. At initial diagnosis 50% of the patients present with metastatic disease whereas more than 80% develop metastases in the course of the disease with liver metastases as the most frequent ones. In consideration of the variable and sometimes indolent tumor growth behaviour, risk stratification is an important need for therapeutic decision making. Patient prognosis is currently best reflected by different classification systems according to WHO 2000/2010 and ENETS TNM staging system. These are based upon prognostic determinants such as histological differentiation (well-differentiated NET/neuroendocrine carcinoma and poorly differentiated neuroendocrine carcinoma) and biological/pathological signs of malignancy, and more recently on the TNM staging and grading system. Grading of the tumor based on the proliferation index as measured by Ki67 immunostaining (G1 2%, G2 3–20%, G3 >20%) next to staging seems to be the strongest predictor of survival. Location of the primary tumor in the pancreas (compared to GI), high liver tumor burden/extended disease and carcinoid heart disease as well as highly elevated circulating chromogranin A, are worse prognostic parameters. In contrast, surgery of liver metastases and removal of the primary tumor are reported to be beneficial for patient outcome. By integrating these and additional significant prognostic factors, a nomogram can be developed to better assess an individual patient’s disease-specific survival. However, it warrants prospective evaluation. Molecular imaging by 18F FDG PET may be helpful in identifying more dedifferentiated tumours and its prognostic value has to be validated in the future. More recently molecular tissue markers (e.g. FGFR13, TSC-2, and PTEN expression) were identified to predict survival in pancreatic NETs. In summary WHO/TNM classification provide currently the best tool to stratify patients, however specific and reliable molecular
markers have to be identified to better select patients for specific treatments and determine surveillance strategies.


$10.2$
Peptide receptor targeted radiotherapy
D Kwekkeboom

Abstract unavailable.

$10.3$
New developments in the therapy for NETs: new drugs including mTOR inhibitors
Simona Grozinsky-Glasberg
Endocrinology, Beilinson Medical Center, Petah Tikva, Israel.

Mammalian target of rapamycin (mTOR), a main serine/threonine protein kinase in the phosphoinositide 3-kinase (PI3K)/Akt/mTOR signalling pathway, is an important intracellular mediator involved in multiple cellular functions including proliferation, differentiation, apoptosis, tumorigenesis, angiogenesis, and also longevity. Recent studies indicate that mTOR is central in the integration of a multitude of signalling pathways activated by growth factors and nutritional status, receiving stimulatory signals from Ras and PI3K. PI3K localizes Akt to the cell membrane where it can be phosphorylated and activated by PDK1. Activated Akt phosphorylates tuberin (TSC2), resulting in TSC1/2 complex instability and inhibition of the tumor suppressor function of the TSC2. Noteworthy, different components of the Ras/MAP/ERK and PI3K signalling pathways are mutated in most human cancers, inducing abnormal regulation of mTOR signalling, and therefore possibly increasing its susceptibility to mTOR inhibitors. There is emerging data indicating that genetic and metabolic changes accompanying malignant transformation might cause hypersensitivity to mTOR inhibition. Rapamycin, a known immune suppressor and a macrolide lactone, and its derivatives temsirolimus (CCI-779), everolimus (RAD001) and deforolimus (AP23573), known as rapalogs, specifically inhibit the function of mTOR. Based on overexpression of the components of PI3K/Akt/mTOR signaling pathway in many different types of cancer, the use of mTOR inhibitors may result in effective anti-tumor activity in various endocrine tumor types. Combining an mTOR inhibitor with other anti-cancer drugs can sensitize endocrine tumor cells to these agents, producing additional activity and preventing drug resistance. The results of preclinical and phase I-II-III clinical studies show that mTOR inhibitors have promising anti-cancer activity, as single agents or in combination with other anti-tumor drugs, in neuroendocrine tumors.

Genetics of male infertility

$11.1$
Update on genetics in male infertility
Alberto Ferlin
University of Padova, Padova, Italy.

Despite spermatogenesis is among the most finely regulated processes in our body, few genetic tests are currently routinely used in infertile males. These include analysis of karyotype, Yq microdeletions, CFTR and androgen receptor gene mutations, which collectively account for 15–20% of male infertility. Very little is known about the pathogenic mechanism leading to spermatogenesis disruption in many of these patients, especially those carrying Yq microdeletions. Recent field of research of our group focused on the identification of molecular pathways leading to spermatogenic damage in men with AZFc microdeletions and idiopathic infertility. Testicular gene expression profiling carried out by microarray assay revealed that all the AZFc deleted samples clustered together and showed a downregulation of several genes (331) related to spermatogenesis.

Interestingly, some idiopathic patients clustered together to AZFc-deleted patients, suggesting that several forms of infertility can be triggered by a common pathogenic mechanism that is likely related to alterations in testicular mRNA storage. Our data suggest that a lack of testicular DAZ gene expression may be the trigger of such mechanism and DAZ gene dysfunctions could therefore account for a larger number of previously thought ‘idiopathic’ infertility cases. A second line of research includes the contribution of genetic polymorphisms to male infertility and, more importantly, as markers for a pharmacogenomic approach to the treatment of infertile males. In this light, we demonstrated the diagnostic and therapeutic validity of polymorphisms in the FSH receptor and FSH beta genes. These results, taken together with the most recent research published on the genetics of male infertility are shedding light on novel molecular events involved in ‘old’ causes of male infertility and are suggesting new pathogenetic mechanisms of spermatogenesis disruption. It is believable that new genetic tests could be in a near future introduced in the clinical practice as diagnostic, susceptibility or pharmacogenetic tests.

$11.2$
Clinical aspects of Klinefelter syndrome in childhood, adolescence and adulthood
Anders Juul
Department of Growth and Reproduction GR, Rigshospitalet section 5064, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Klinefelter syndrome (KS) which affects 1–2 per 1000 males, is not only challenging for the patients and their families. Professionals, who manage KS patients need a much better scientific foundation for decision making in patient care. Surprisingly little research on how to manage boys, adolescents and men with KS has been carried out in comparison to management of other clinical problems like, e.g. Turner syndrome. One of the problems has been that management, which must be a live long process in KS, most often is split between paediatricians, who take care of the boys with KS, and andrologists and endocrinologists who manage fertility problems and androgen insufficiency later in life. However, to obtain knowledge on the full spectrum of the syndrome, and the needs for intervention we should have life-long perspective from birth to old age in mind when we make our treatment strategies.

$11.3$
Genomics of azoospermia
F Tüttelmann
Institute of Human Genetics, Münster, Germany.

Azoospermia is a common condition of about 10% of all infertile men and this most severe clinical phenotype of male infertility can – in an otherwise healthy man – regularly be considered to have a genetic basis. An association of chromosomal aberrations and Y-chromosomal AZF-deletions with spermatogenic failure is well-established. However, since the latter were described over 10 years ago, basically no genetic causes have been found although many re-sequencing studies of candidate genes were performed. However, with the advent of new whole-genome analytic methods, there is hope to further elucidate the complex genetic origin of azoospermia. To-date, only one recent study analysed a relatively low number of 40 men with non-obstructive azoospermia (histology not mentioned) using whole genome single nucleotide polymorphism (SNP) arrays. Some SNPs were found significantly associated with the phenotype, but essentially none could be unequivocally replicated in a larger follow-up study.

Two studies using array comparative genomic hybridisation (CGH) to identify chromosomal gains and losses (copy number variants, CNVs) not detectable by routine chromosome analysis are currently underway: a study of 9 patients with meiotic arrest and 20 controls yielded six ‘interesting regions’ not further described. The second study analysed larger numbers of azoospermic (N=54) men with customised array-CGH specific for the X-chromosome. However, only one CNV was found significantly more frequently in patients after several CNVs had also been analysed in 150 controls. In our own experience of array-CGH in well-characterised and highly-selected patient groups with azoospermia due to mixed atrophy, meiotic arrest or Sertoli-cell-only syndrome, we could identify a number of putatively causal recurring, patient-specific and private, sex-chromosomal CNVs/genes. The novel method of genome analysis by next-generation sequencing may hold the potential to identify additional causative genes for azoospermia.
Novel insights into phosphate metabolism

$S12.1$

Abstract unavailable.

$S12.2$

Genetic disorders of phosphate metabolism

Abstract unavailable.

$S12.3$

FGF23: marker or predictor of progression in chronic kidney disease

Abstract unavailable.

Endocrine response to critical illness

$S13.1$

The HPA axis in critical illness

D Annane
University of Versailles, Garches, France.

The role of the hypothalamic–pituitary adrenal axis in host response to an infection is crucial. The initial inflammatory response to sepsis activates the endogenous release of cortisol which in turn will modulate the synthesis and release of both pro- and anti-inflammatory mediators to restrict inflammation to the infected tissues. However, a number of factors including vascular or ischemic damage, inflammation and apoptosis within the hypothalamic–pituitary adrenal axis, and drugs induced altered cortisol metabolism, may cause adrenal insufficiency. One major problem ICU physicians are faced with is the diagnosis at the bedside of sepsis induced adrenal insufficiency. A recent international task force recommended that sepsis induced adrenal insufficiency is best recognized by basal cortisol is of $<10 \mu g/dl$ or delta cortisol of $<8 \mu g/dl$. The diagnostic value of salivary free cortisol in this setting remains to be investigated. While sepsis adrenal insufficiency is undoubtedly associated with a poor prognosis, the indication and practical modalities of corticosteroids therapy remained controversial. Based on the two largest randomised, placebo-controlled trials, this author suggested that septic shock patients with hypotension poorly responsive to fluid replacement and vasopressors should receive a seven day treatment with the combination of hydrocortisone at a dose of 200 mg/day and fludrocortisone at the dose of 50 $\mu g$/day.

$S13.2$

Thyroid hormone metabolism in inflammation and sepsis

A Boelen
Academic Medical Center, Amsterdam, The Netherlands.

During illness changes in thyroid hormone metabolism occur, collectively known as the non-thyroidal illness syndrome (NTIS). NTIS is characterized by low serum thyroid hormone levels, while TSH and TRH expression do not increase, indicating a disturbance of the normal thyroid hormone feedback regulation.

Although the common view was that NTIS results in overall downregulation of metabolism in order to save energy, recent work has shown that genes involved in thyroid hormone (TH) metabolism show remarkably variable, illness-induced changes in key metabolic organs such as liver, muscle and adipose tissue, ranging from inhibition to activation. That illness-induced changes in peripheral organs appear to be very different during acute or chronic inflammation adds an additional level of complexity. Organ- and timing-specific changes in the TH deiodinating enzymes (deiodinase type 1, 2 and 3) highlight deiodinases as proactive players in the response to illness. Furthermore, the granulocyte is a novel and potentially important cell type involved in NTIS during bacterial infection. Finally, complex changes in thyroid hormone metabolism occur in muscles during critical illness that may or may not be part of the pathogenesis of respiratory failure. Although acute NTIS may represent an adaptive response to support the immune response, NTIS may turn disadvantageous when critical illness enters a chronic phase necessitating prolonged mechanical ventilation, dialysis and inotropic support.

In sum, NTIS appears to be a timing-related and organ-specific response to illness, occurring independently from the decrease in serum thyroid hormone levels and potentially relevant for disease course.

$S13.3$

Novel insights in endocrine and metabolic changes during critical illness

G Van den Berghe
Katholieke Universiteit Leuven, Leuven, Belgium.

Host responses to critical illness, such as excessive inflammation and hyperglycemia, trigger detrimental chain reactions that damage cellular proteins and organelles. Such responses to illness contribute to the risk of non-resolving multiple organ dysfunction and adverse outcome. Autophagy is a bulk degradation pathway able to remove toxic protein aggregates and damaged organelles. Morphologically, both liver and muscle of critically ill patients reveal an autophagy-deficiency phenotype. Proteins involved in initiation and elongation steps of autophagy are induced several-fold by critical illness, but mature autophagic vacuole formation is impaired and proteins normally degraded by autophagy accumulate dramatically. Also mitophagy is down-regulated. Artificial nutrition, most specifically the amount of infused amino-acids, appears to be an important factor contributing to suppressed mature autophagy in the critically ill. Although insulin-titrated maintenance of normal blood glucose preserves hepatocytic mitochondrial integrity by prevention of direct damage, the infused insulin may have a downside as it may further impair the autophagic machinery. Insufficient autophagy in prolonged critical illness may cause inadequate removal of damaged proteins and mitochondria. Such incomplete clearance of cellular damage, inflicted by illness and aggravated by hyperglycemia, could explain lack of recovery from organ failure in prolonged critically ill patients. These novel insights open perspectives for therapies that activate autophagy during critical illness.

Female contraception update

$S14.1$

Compliance and the risk of pregnancy

Anna Glasier
University of Edinburgh, Edinburgh, UK.

Unintended pregnancy is common. Most European governments are concerned by abortion rates which, if not rising, seem stubbornly difficult to reduce. Moreover by no means all unintended pregnancies are aborted: in the UK, almost one third of pregnancies which end in childbirth are unplanned or mistimed. While no method of contraception is 100% effective, few induced abortions are the result of true method failures; most are due to unprotected sex or incorrect/ inconsistent use of contraception.

Most currently available methods of contraception rely on correct and consistent use for their effectiveness. The oral contraceptive pill has a theoretical failure rate of only 1 in 1000 but in reality and during typical use the failure rate is actually 8 in 100. So-called ‘pill failures’ account for a substantial percentage of abortions in countries where oral contraceptives are widely used. Forgetting to take a pill (or pills) is extremely common and continuation rates are usually $<50\%$ at the end of 1 year of use.

Endocrine Abstracts (2011) Vol 26
The so-called long acting reversible contraceptives (intrauterine, implantable and injectable methods) are much less (or not at all) dependent on compliance for their effectiveness and typical use failure rates are not different from those estimated for perfect use. Moreover for contraceptive implants and intrauterine methods discontinuation rates are much lower because the method cannot simply be stopped but has to be removed by a health provider.

Interventions to assist women with compliance with contraception have proved disappointing. Reminding women to return to the clinic for their next injection of Depo Provera made no difference to compliance or to continuation rates at the end of a year of use. A randomised trial of daily telephone text messages reminding women to take their pill was similarly ineffective.

Since compliance with regular medication is often poor, even when the result of non-adherence is death; since most European women have to use contraception for more than 30 years of their lives; and since each act of sexual intercourse carries with it a risk of pregnancy of only 30% it is important that new contraceptive methods take into particular account the ease or difficulty of compliance.

§14.2
New Pills
Regine Sitruk-Ware
Population Council and Rockefeller University, New York, USA.

The balance between the benefits and the risks of contraceptive steroids is generally positive in particular when comparing to the risks of pregnancy and especially in women with risk factors. Since recently the most common estrogen contained in the OCs remained ethinyl-estradiol although the doses used per tablet decreased dramatically in the most recent combinations. In parallel with the change in the progestin content from androgenic to non or anti-androgenic molecules, the estrogen have also been shifted recently to more natural compounds such as estradiol (E2) and estradiol valerate (E2 V) with the objective of improving the safety of OCs.

Ethinyl-estradiol (EE) exerts a stronger effect that natural estradiol (E2) on hepatic metabolism including estrogen-dependent markers such as liver proteins. Current combined oral contraceptives (COC) affect a variety of hemostatic variables and estrogen-sensitive liver proteins, and these effects can be modulated by the associated progestin. In contrast, metabolism studies using the same surrogate markers as end-points indicate that the impact of estradiol-based novel COCs is similar or even lower than that of the second-generation COCs combining EE and an androgenic progestin such as Levonorgestrel.

Several new progestins have been designed to minimize side-effects related to androgenic, estrogenic or glucocorticoid receptor interactions. Dienogest (DNG), nomegestrol acetate (NOMAc) and trimegestone (TMG) have been combined and drospirenone (DRSP) and the 19-norpregnanes including Nestorone (NES), have been carefully studied, results changing with type of surgery and protocols used. The role of changes of GLP-1 and GIP in diabetes improvement deserves great interest. The roles of caloric restriction, weight loss and alterations in the small intestinal anatomy, the importance of foregut exclusion and of rapid ileal exposure to nutrients, the changes in gut hormones, changes of the gut brain axis and the role of the vagus nerve as well as changes in gastric emptying and gut motility need to be better elucidated.

Experimental procedures such as ileal interposition and foregut exclusion trying to better elucidate the importance of changes in gut hormones in diabetes improvement.

Controlled studies comparing diet versus surgery and different types of surgery are scarce and are urgently needed.

The length of follow up is of utmost importance to characterize diabetes improvement. Even with diabetes recurrence will there be a legacy effect as happened with other type of interventions as in UKPDS, DPS and DPP4.

Several reports related poor responders to longer duration of diabetes preoperatively, revealing the importance of early surgical intervention for diabetes resolution. Bariatric surgery in type 2 diabetic patients poorly controlled with a BMI ≥ 30 is matter of debate last but not least short term and long-term safety is a very important issue.

§14.3
Emerging therapies in type 2 diabetes

§15.1
Emerging therapies in type 2 diabetes: bariatric surgery
Helena Cardoso
Instituto de Ciencias Biomédicas Abel Salazar, Porto, Portugal.

The biggest achievement of bariatric surgery was to demonstrate that obesity co-morbidity improve or even reverse with long-term weight control. This evidence was achieved with the Swedish Obesity Study for mortality and diabetes incidence.

Diabetes resolution rates range from 55 to 96% depending on the surgical procedure and length of follow-up. Diabetes improvement or resolution almost reaching the 100%. The type of surgery seems to play a role in diabetes and other co-morbidity improvement, the procedures associated with a greater percentage of excess weight loss presenting better results. This could suggest that diabetes improvement is directly related to excess weight loss. Although systematic review and meta-analysis suggest this is true, changes in gut hormones have been claimed for procedures involving changes in gut anatomy. Several hormones, namely GLP-1, GIP, PYY and ghrelin, have been carefully studied, results changing with type of surgery and protocols used. The role of changes of GLP-1 and GIP in diabetes improvement deserves great interest. The roles of caloric restriction, weight loss and alterations in the small intestinal anatomy, the importance of foregut exclusion and of rapid ileal exposure to nutrients, the changes in gut hormones, changes of the gut brain axis and the role of the vagus nerve as well as changes in gastric emptying and gut motility need to be better elucidated.

Experimental procedures such as ileal interposition and foregut exclusion trying to better elucidate the importance of changes in gut hormones in diabetes improvement.

Controlled studies comparing diet versus surgery and different types of surgery are scarce and are urgently needed.

The length of follow up is of utmost importance to characterize diabetes improvement. Even with diabetes recurrence will there be a legacy effect as happened with other type of interventions as in UKPDS, DPS and DPP4.

Several reports related poor responders to longer duration of diabetes preoperatively, revealing the importance of early surgical intervention for diabetes resolution. Bariatric surgery in type 2 diabetic patients poorly controlled with a BMI ≥ 30 is matter of debate last but not least short term and long-term safety is a very important issue.

§15.2
11β-Hydroxysteroid dehydrogenase inhibitors for treatment of metabolic syndrome
P Stewart, M Cooper, G Lavery & J Tomlinson University of Birmingham, Birmingham, UK.

Harvey Cushing’s work informed us of the deleterious consequences of circulating cortisol excess – hypertension, osteoporosis and obesity that contributes to diabetes and premature mortality. Conversely, Hench, Kendall and Reichstein were Nobel Laureates in Physiology 1950 for the discovery of cortisone and demonstrating efficacy in patients with Rheumatoid Arthritis – in effect the birth of the anti-inflammatory actions of glucocorticoids.

The tissue-specific generation of cortisol, independent of circulating levels, is catalysed by 11β-hydroxysteroid dehydrogenase (11β-HSD1) that converts cortisone (E) to cortisol (F). High levels are expressed in liver and omental adipose tissue where the enzyme amplifies glucocorticoid-mediated hepatic glucose output and adipocyte differentiation. The former effect occurs through induction of hepatic glucogenogenesis (GNG); recombiant mice with global deletion of 11β-HSD1 or liver-specific deletion of the GR demonstrate reduced GNG. Conversely over expression of 11β-HSD1 in both liver and fat reproduce features of the metabolic syndrome.

Selective 11β-HSD1 inhibitors lower blood glucose, improve insulin sensitivity and cause weight loss in animal models. Biomarkers have been validated to confirm target inhibition in primate and human studies. Recent clinical trials show reduction in HbA1c and blood pressure in obese patients with diabetes mellitus who have failed on metformin therapy. Potentially the therapy offers a ‘magic bullet’ for patients with Metabolic syndrome with reduced blood glucose accompanying improved insulin sensitivity, lower lipids and blood pressure and reversal of hepatic steatosis secondary to reduced autocrine generation of cortisol in liver, adipose tissue, pancreas and muscle. Liabilities include activation of the HPA axis secondary to increased cortisol clearance with hyperandrogenism, though the extent and significance of this is debated. Perhaps of more concern is the potential impact upon the inflammatory process since 11β-HSD1 expression is significantly induced at the site of inflammation.

Modulation of glucocorticoid hormone action via selective 11β-HSD1 inhibitors represents a novel therapeutic advance to treat the global epidemic of metabolic syndrome.
Incretin-based therapies, such as the injectable GLP-1 receptor agonists and orally administered DPP-4 inhibitors, have recently been introduced into clinical practice. At present, the GLP-1 receptor agonists need to be administered once or twice daily. Several once weekly GLP-1 receptor agonists are in phase 3 development. This review examines the efficacy, safety and perspective for the future of the once weekly GLP-1 receptor agonist: exenatide once weekly, taspoglutide, albiglutide, LY2189265 and CJC-1134-PC and compare them to the currently available agonists, exenatide BID and lilaglutide QD. A greater reduction in HbA1c and fasting plasma glucose was found with the once weekly GLP-1 receptor agonist compared with exenatide BID, while the effect on postprandial hyperglycemia was modest with the once weekly GLP-1 receptor agonist. The reduction in HbA1c was in most studies greater compared to oral antidiabetic drugs and insulin glargine. The reduction in weight did not differ between the short and long acting agonists. The gastrointestinal side effects were less with the once weekly agonists compared with exenatide BID, except for taspoglutide. Antibodies seem to be more frequent with exenatide once weekly, while hypersensitivity has been described in few patients treated with taspoglutide. Injection site reactions differ among the long acting GLP-1 receptor agonists and are observed more frequently than with exenatide BID and lilaglutide. In humans no signal has been found indicating an association between the once weekly agonists and C-cell cancer. The cardiovascular safety, durability of glucose control and effect on weight will emerge from several ongoing major long-term trials. The once weekly GLP-1 receptor analogues are promising candidates for the treatment of type 2 diabetes although their efficacy may not be superior to once daily analogue lilaglutide.

Small molecule TSH receptor agonists and antagonists
S Neumann & M C Gershengorn
National Institutes of Health, NIDDK, Bethesda, Maryland, USA.

TSH activates the TSH receptor (TSHR) thereby stimulating the function of thyroid follicular cells (thyrocytes) leading to biosynthesis and secretion of thyroid hormones. Because TSHR is involved in several thyroid pathologies there is a strong rationale for the design of small molecule ‘drug-like’ ligands (SMLs). rhTSH (Thyrogen®) has been used in the follow-up of patients with thyroid cancer to increase the sensitivity for detection of recurrence or metastasis. rhTSH, which is a heterodimeric 30 kDa glycoprotein, is difficult to produce and must be administered by injection. A small molecule TSHR agonist could produce the same beneficial effects as rhTSH but with greater ease of oral administration. We developed a SML that is a full agonist at TSHR with an EC 50 of 40 nM and interacts with the receptor’s serpentine domain. In primary cultures of human thyrocytes, the agonist increases mRNA levels for thyroglobulin, thyroperoxidase, sodium-iodide symporter and deiodinase type 2. More importantly for its clinical potential, this agonist elevated serum thyroxine and stimulated thyroidal radioiodide uptake in mice after its absorption from the gastrointestinal tract following oral administration. Graves’ disease (GD) is caused by persistent, unregulated stimulation of thyrocytes by thyroid-stimulating antibodies (TSAbs) that activate TSHR. We identified the first small molecule TSHR antagonists that inhibited TSH- and TSHB-stimulated signaling. Noteworthy, in primary cultures of human thyrocytes one of the antagonists inhibited cAMP production stimulated by all thirty GD sera tested by an average of 39%. Our results provide proof-of-principle for effectiveness of small molecule agonists and antagonists for TSHR. Chemical optimization of these SMLs will be performed in an effort to produce more potent molecules for future clinical development.
Transphenoidal neurosurgery is the gold standard treatment for pituitary adenomas; however, it can be contra-indicated or ineffective. In these cases, medical treatment based on somatostatin analogs or GH receptor antagonist, can be used. Another approach is to use radiation therapy.

Stereotactic radiosurgery (SR) is a procedure aiming at controlling hormone hypersecretion and tumor size of pituitary adenomas. This talk will mainly deal with the long-term efficacy and adverse effects of Gamma knife, a modality of stereotactic radiosurgery, in secreting and non-secreting pituitary adenomas. Recent long-term data confirm the anti-secretory efficacy of the procedure (about 50% remission in hypersecreting tumors) but also a previously unknown low risk of recurrence (about 2–10% cases), in contrast with conventional radiotherapy. The main drawback is the time to remission estimated to range from 12 to 60 months. The anti-tumoral efficacy is observed in about 90% cases. Hypopituitarism is the main side-effect, observed in 20–40% cases. Comparison with conventional radiotherapy reveals a lower rate of remission counterbalanced by a more rapid efficacy, and a lower rate of hypopituitarism for radiosurgery. Recent short-term results about stereotactic fractionated radiotherapy suggest a risk of hypopituitarism similar to the one observed with radiosurgery. SR is thus probably still useful in the therapeutic algorithms of pituitary adenomas, despite the fact that antisecretory drugs, particularly for acromegaly, are becoming more and more effective and well tolerated.

References

Castinetti et al. JCEM 2009 94(9) 34000–7.

Management of endocrine disease in pregnancy

S18.3

Type-1 diabetes and pregnancy

P Damm

Obesity and DM2 increasingly affect young adults worldwide, to the point of warranting the description of ‘epidemic’. This means that greater numbers of women of reproductive age are at risk. Frequently DM2 remains undiagnosed until pregnancy. The rate of gestational diabetes is of similar magnitude and the risk of fetal macrosomia is very high. Frequently, DM2 is diagnosed during pregnancy and postpartum. It is important to advise these women for the need to plan any future pregnancy.

Thyroid autoimmunity in pregnancy

Kris Gustave Poppe

UZ Brussels - VUB, Brussels, Belgium.

To adapt the working of the thyroid to the changes occurring during pregnancy, an adequate availability of iodine and the integrity of the thyroid gland are needed. With regard to thyroid function assessment during pregnancy, it is important to be aware of the differences in accuracy of the different FT3 assays. Thyroid autoimmunity (TAI) is the most common cause of hypothyroidism before and during pregnancy and many women with TAI and a normal thyroid function in

Endocrine Abstracts (2011) Vol 26
early gestation tend to become hypothyroid during gestation. In euthyroid women, with and without TAI, similar pregnancy rates have been reported, but many studies showed that the presence of TAI is associated with a significantly increased risk in the overall miscarriage rate, independently of the presence of other autoantibodies. The association between TAI and miscarriage does not imply a causal relationship, and underlying causes might be (a combination of) immune disorders, inappropriate TH levels for the pregnancy period, and an increased maternal age in women with TAI. Concerning intervention trials, Negro et al. showed that LT4 in TAI + euthyroid pregnant women, reduced the miscarriage rate to that in women without TAI, a finding that was recently confirmed in an assited reproductive setting by an other group. The risk of spontaneous abortion during early gestation is also known to be increased in women with overt and subclinical hypothyroidism independently of the presence of TAI and in one study a positive linear relationship between fetal/child loss and serum TSH was shown. i-thyroxine is the drug of choice for the treatment of hypothyroidism and in women already receiving it, it should be adjusted before or during pregnancy to reach a serum TSH level ≤ 2.5 mIU/l during the first trimester. In women in whom hypothyroidism is diagnosed during pregnancy, LT4 should immediately be initiated according to their body weight. The increase in the LT4 dose becomes manifest after 4–8 weeks gestation and the magnitude of LT4 changes depends on the etiology of the hypothyroidism. For all hypothyroid LT4-treated women, serum TSH levels should be monitored every 6–8 weeks unless an increase in dosage is needed. After parturition, most hypothyroid women need to decrease the LT4 dose received during pregnancy, and when TAI was associated, monitoring of thyroid function for at least 6 months after delivery is advised.

Management of endocrine disease in adolescence
S19.1
Management of congenital adrenal hyperplasia (CAH) in adolescence
H L Claasen-van der Grinten
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Aim of the current glucocorticoid treatment strategies in patients with classic types of CAH due to 21 hydroxylase deficiency is to replace the lack of cortisol (substitution) and, secondly, to suppress excess adrenal androgen production by restoring the negative feedback on ACTH release (suppression). In adolescence, besides adequate substitution, achieving normal puberty and menstrual cycle, preventing hyperandrogenism (hirsutism) and prevention of the development of testicular adrenal rest tumors in male patients are considered relevant medical treatment goals. All these aims require individualized treatment strategies. Mostly supraphysiological dosages of glucocorticoids are necessary to suppress the ACTH release. Glucocorticoid overtreatment could lead to iatrogenic Cushing’s syndrome and increased cardiovascular risk. In adolescence, there is a decreased conversion of cortisol to cortisone and an increase in renal clearance of cortisol contributing to a relative lower cortisol concentration. Therefore, it is often necessary to increase dosages of hydrocortisone. However, current studies show that at this age glucocorticoids may have a deleterious effect on pubertal growth and therefore daily hydrocortisone dosage should not exceed 17 mg/m2. Therefore, it is a difficult task to find the right balance between under- and overtreatment especially in adolescence thereby avoiding important long-term complications.

In adolescence issues of sexual activity and contraception have to be discussed and genetic counseling has to be given to the patients. General information about CAH (including the need for wearing medical identification) should be given together with a crisis prevention training performed by an experienced nurse. In female patients with virilizing CAH consultation of an experienced gynecologist should be arranged before or during puberty to decide whether additional surgery is needed. A good preferably gradual transition to the adult endocrinologist has to be planned carefully at the end of adolescence.

S19.2
The challenges of managing childhood cancer survivors during adolescence
H L Claasssen
Leicester Royal Infirmary, Leicester, UK.

In the UK 1 in 500 children will develop cancer in childhood. Survival from childhood cancer has more than doubled since the 1960s. Survivorship is increasingly on the agenda and the National Cancer Survivorship Initiative has been launched in the UK.

During adolescence the endocrinologist is faced with four challenges in managing childhood cancer survivors:
1. Managing the immediate endocrine consequences of cancer therapy, in particular, those relating to timing of puberty and growth.
2. Recognising that these patients are young people first and childhood cancer survivors second, and the importance of addressing the wider issues of adolescence.
3. Working as part of a multidisciplinary team and considering the wider implications of cancer therapy on reproductive potential, bone and cardiovascular health, risk of second malignancies, sexuality and morbidity and mortality.
4. Identifying a suitable adult endocrinologist with the expertise to provide ongoing endocrine care for childhood cancer survivors in adulthood.

Thyroid function: it is in your genes
S20.1
Genetics versus environment: what determines thyroid function?
P S Hansen1 2
1 Odense University Hospital, Odense, Denmark; 2 University of Southern Denmark, Odense, Denmark.

The circulating levels of serum TSH and thyroid hormones represent biochemical phenotypes reflecting thyroid homeostasis. Studying the regulation of biochemical measures related to the thyroid in healthy individuals could prove essential in understanding the pathways that eventually lead to thyroid disease. It is the combined effect of genetic and environmental factors that give rise to these endophenotypes. It has been established that the measures reflecting thyroid homeostasis have a substantial heritable component. Thyroid hormone levels are partly genetically correlated – although most of the genetic variance for these measures is trait specific. Genetic as well as environmental risk factors (such as iodine intake and smoking) with significant influence on the thyroid related phenotypes have been identified. Several specific polymorphisms within obvious candidate genes are associated with serum TSH and thyroid hormone levels, respectively; however these specific polymorphisms account for <2% of the total

Endocrine Abstracts (2011) Vol 26
Phenotypic variance. Using simple interaction models it has not been possible to detect any modifying effect of iodine intake (measured as iodine excretion) or cigarette smoking on the effect of a specific polymorphism in the TSHR gene. Conclusion Genetic as well as environmental determinants with significant influence on various thyroid related phenotypes in healthy twins has been identified, but neither of these factors have a strong impact on the various thyroid related phenotypes. Many unmeasured genetic variants as well as environmental exposures with influence on thyroid homeostasis remain to be uncovered.

S20.2
Polyomorphic variation in thyroid pathway genes
Robin Peeters
Erasmus University Medical Centre, Rotterdam, The Netherlands.

Adequate thyroid hormone (TH) levels are essential for normal growth and differentiation, for the regulation of energy metabolism, and for the physiological function of virtually all human tissues. Epidemiological evidence shows that minor variation in TH serum levels, even within the normal range, can have important effects on different TH related clinical endpoints, such as bone mineral density, atrial fibrillation, metabolic syndrome and cardiovascular mortality. In healthy subjects, serum TSH and TH levels show substantial inter-individual variability leading to wide laboratory reference ranges, whereas the intra-individual variability is within a much more narrow range. This suggests that every person has its own individual thyroid function 'set-point'. Approximately 45–65% of this inter-individual variation in serum TSH and TH levels is determined by genetic factors, but the causative genes are not yet well established. Recent genome wide association studies have demonstrated associations of polymorphisms located in Phosphodiesterase 8β and the CAPZB locus with serum TSH levels, and well-known TH pathway genes such as the deiodinases, TSH receptor and TH transporters have been associated with TH serum levels in candidate gene analyses.

However, the variation that can be explained by these gene variants so far is only modest. This could be due to the presence of not-anaalyzed rare variants, or gene-environment and gene-gene interactions. Novel analytic approaches and the availability of whole-genome sequencing of large numbers of individuals will provide important new information on this topic in the upcoming years. This presentation will focus on the interpretation of different genetic studies in thyroid hormone research and discusses its clinical relevance.

S20.3
Genetics of autoimmune thyroid disease
Stephen Gough
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.

Autoimmune thyroid disease (AIDT) is the commonest of the autoimmune disorders. Strong familial clustering supports a hereditary component to the development of disease. However, the pattern of inheritance suggests that many genes with relatively small effect size are contributing to the genetic architecture of both Graves’ disease and autoimmune hypothyroidism. Whilst early candidate gene studies helped to identify some of the major effects conferring risk to AITD, the most recent studies have also looked at other DNA variants such as common number variants (CNVs) and large detailed understanding of the TSHR locus. The most recent studies have also looked at other DNA variants such as common number variants (CNVs) and large deletions. TSHR receptor and TH transporters have been associated with TH serum levels in candidate gene analyses. However, the variation that can be explained by these gene variants so far is only modest. This could be due to the presence of not-anaalyzed rare variants, or gene-environment and gene-gene interactions. Novel analytic approaches and the availability of whole-genome sequencing of large numbers of individuals will provide important new information on this topic in the upcoming years. This presentation will focus on the interpretation of different genetic studies in thyroid hormone research and discusses its clinical relevance.

S21.1
Evolutionary perspective in vitamin D and its receptor VDR
Zeev Hochberg
Rambam Medical Centre, Haifa, Israel.

Vitamin D is photosynthesized in all forms of life from the phytoplankton 750 mya. Evolutionary pressures due to variation in climate play an important role in shaping phenotypic variation and influence variation in phenotypes. Migration out-of-Africa and change of living latitude placed human vit D as part of an evolutionary complex that adapted hominids to changing u.v. radiation. The ‘vit D hypothesis’ to explain skin pigmentation is based on the observation that the skin color follows a clinical distribution; the darkest populations inhabit the equatorial and tropical belt; the most pale-skinned the regions above 50°N; and those of intermediate pigmentation the middle latitudes. Exposure to u.v. light has to balance the need for UVB for vit D photosynthesis and damage by u.v. for folic acid generation. This balance is maintained by melanism, which determines skin color, reflecting a compromise solution to the conflicting physiological need for vit D and the detrimental effect of u.v. on folic acid generation. A multi-stage genome-wide association study of natural hair color identified several loci highly associated with hair color. But the strongest determinant of skin color remains MC1R. I propose that the VDR gene is epistatic with skin color-determining genes for the phenotype of fitness; both MC1R and the VDR are strongly implicated in immune system regulation, with obvious fitness consequences. VDR may be the original nuclear receptor gene, functioning initially as pregnancy X receptors and constitutive androstane receptors, to induce P450 enzymes for xenobiotic detoxification. The broad abundance of the VDR may be also related to the multitude of recent reports claiming a role for vit D in cell differentiation and proliferation, immune function, muscle strength, blood pressure control and more.

S21.2
Vitamin D deficiency and supplementation in pregnancy
P Lips
VU University Medical Center, Amsterdam, The Netherlands.

Vitamin D deficiency is more common in pregnant women than in non-pregnant women of similar age. Clinical vitamin D deficiency, associated with rickets and osteomalacia, may occur when serum 25-hydroxyvitamin D (25(OH)D) is lower than 25 nmol/l. The required serum 25(OH)D is currently set at 50 mmol/l, as lower levels are associated with lower bone mineral density, increased fracture risk and other outcomes such as lower physical performance than a vitamin D adequate state, i.e. serum 25(OH)D above 50 mmol/l. Many studies show low serum levels of 25-hydroxyvitamin D (25(OH)D) in pregnant women and their offspring. Serum 25(OH)D is about 20% lower in the neonate (cord blood) than in the mother. During normal pregnancy, the concentration of the active metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D) increases in the first trimester, due to the increase of the vitamin D binding protein. The free concentration of 1,25(OH)2D increases in the third trimester when the daily transfer of calcium through the placenta increases to more than 300 mg/day. Vitamin D deficiency in the mother is associated with a higher risk of pre-eclampsia and gestational diabetes. Severe vitamin D deficiency in the mother can lead to neonatal hypocalcaemia and tetany, low birth weight and rickets. Vitamin D deficiency in the mother is also associated with asthma in the child, with lower bone mineral density in the first year and at 9 years of age. The most important risk group for vitamin D deficiency in pregnancy are non-western immigrants. A survey in The Hague in the Netherlands showed that the lowest serum 25(OH)D levels in Turkish and Moroccan women was 15.2 ± 12.1 and 20.1 ± 13.5 mmol/l respectively, and 25(OH)D was not detectable in 22% of the Turkish women.

The most recent guideline of the Institute of Medicine (2011) concluded that the required serum 25(OH)D level meeting the needs of 97.5% of the population is 50 mmol/l. The recommended dietary allowance for pregnant women is 600 IU/day. However, many uncertainties remain regarding the consequences of vitamin D deficiency in pregnancy. There is a lack of double blind randomized trials in pregnant women with sufficiently long follow-up to determine the effects of vitamin D supplementation in mother and child.
Maternal vitamin D intake during pregnancy and the risk of type 1 diabetes in the offspring
Suvi Virtanen
Tampere University Hospital, Tampere, Finland.

The pre-diabetic autoimmune process leading to clinical type 1 diabetes may start already during early infancy. As the incidence of type 1 diabetes is increasing most rapidly among children younger than 5 years in many high and middle income countries (Patterson et al. 2009), there is increasing interest in the impact of early exposures such as diet even before birth. Vitamin D has several effects on the immune system, which could be of potential relevance in the pathogenesis of type 1 diabetes. Maternal vitamin D intake and status during pregnancy affects the vitamin D status of the fetus and the newborn baby. Vitamin D supplementation during infancy may protect from type 1 diabetes as suggested by case-control findings from an European wide study (The EURODIAB Substudy 2 Study Group 1999) as well as by cohort findings from Finland (Hyppönen et al. 2001). In a Norwegian case-control study, the use of cod liver oil (rich in vitamin D) but not vitamin D supplementation as such during the first year of life was associated with lower risk of type 1 diabetes (Stene et al. 2003).

Findings whether maternal vitamin D intake protects the child from pre-clinical type 1 diabetes are discordant. In an US cohort, maternal intake of vitamin D from food, but not from supplements during pregnancy was associated with a decreased risk of early islet autoimmunity appearance in the offspring (Fronczak et al. 2003). In a Swedish cohort study a weak inverse association was observed between maternal vitamin D supplementation and appearance of diabetes-associated autoantibodies at the age of 1 year but not at 2.5 years (Bremke & Ludvigsson 2007). In a Finnish cohort study in which a more advanced pre-type 1 diabetes endpoint was used and where the number of endpoints outnumbered the previous studies, no association was shown between maternal intake of vitamin D either from food or supplements (Marjamäki et al. 2010). Neither was vitamin D intake related to the development of clinical type 1 diabetes in that study.

Non traditional effects of pituitary hormones
S22.1
Non-thyroidal effects of TSH
G R Williams
Imperial College London, London, UK.

The glycoprotein hormone, TSH, is synthesized and secreted by thyrotrhops in the anterior pituitary gland. It acts at the TSH receptor (TSHR), a 7-transmembrane G-protein coupled cell membrane receptor expressed in thyroid follicular cells. TSH-R is a key regulator of the regulation of thyroid hormone production. In recent years TSHR expression has also been identified in a wide variety of extra-thyroidal tissues including: anterior pituitary; hypothalamus; ovary; testis; skin; immune system; bone marrow and peripheral blood cells; white and brown adipose tissue; orbital preapocyte fibroblasts and bone. Considerable data are emerging that describe possible functional roles of TSHR at these various sites, but their physiological importance in many cases remains a subject of controversy and much interest. In particular, expression of TSHR in bone and the possible role of TSH in the skeleton have attracted considerable controversy. Thus, TSH has been proposed to act as a negative regulator of bone remodeling, acting directly via effects on the TSHR expressed in bone-forming osteoblasts and bone-resorbing osteoclasts. This hypothesis has challenged the conventional view that such skeletal responses to abnormal thyroid status result from altered thyroid hormone action in bone. Thus, in thyrotoxicosis, high bone turnover and osteoporosis are considered to result from thyroid hormone excess. By contrast, in the TSH model, these consequences are proposed to result from TSH deficiency. Unfortunately, because of the reciprocal physiological relationship between thyroid hormones and TSH it has been difficult to distinguish the actions of thyroid hormones from those proposed to result from TSH deficiency. This presentation will address these issues in particular as well as considering the wider actions of TSH in other extra-thyroidal tissues.

Central vasopressin facilitates social recognition and modulates numerous complex social behaviours in mammals, including parental behaviour, aggression, affiliation and pair-bonding. In rodents, social interactions are primarily mediated by the exchange of olfactory information, and there is evidence that vasopressin signalling is important in brain areas where olfactory information is processed. We recently discovered that the rat olfactory bulb (OB) and the anterior olfactory nucleus (AON) contain large populations of interneurones which express and release vasopressin. In the OB, single cell recordings from mitral cells in vivo showed that vasopressin modulates the processing of information by olfactory bulb neurones. Blocking the actions of vasopressin in the OB (using antagonists or small interference RNA against the vasopressin V1a receptor, or local selective destruction of vasopressin neurones with diphtheria toxin in transgenic rats) impairs the social recognition abilities of rats. The treatments impaired habituation/dishabituation to juvenile cues, but not to volatile odours or object recognition, and did not affect locomotor activity or anxiety-related behaviours. Adult rats exposed to a conspecific juvenile showed increased Egr-1 expression in vasopressin neurones in multiple subdivisions of AON as compared to animals exposed to no odour or a non-social odour. These data suggest that vasopressin neurones in the AON may also play an important role in the coding of social odour information. The findings indicate that the vasopressin process olfactory signals relevant to social discrimination and vasopressin release may be involved in filtering out familiar signals.

Optimising thyroid hormone replacement
S23.1
Is there a place for combined T4 and T3 replacement therapy?
A Weetman
University of Sheffield, Sheffield, UK.

This review will address the following questions i) what is the evidence that levotiroxine replacement alone is insufficient to deal with the treatment of...
hypothyroidism; ii) what is the evidence form randomised control studies that combinations of tri-iodothyronine and levothyroxine are superior to levothyroxine alone in replacement treatment for hypothyroidism; iii) what other factors may be involved in the optimal replacement of thyroid hormone deficiency and iv) what conclusions may we draw and what future directions are likely in this area?

There is accumulating evidence that around 10% of patients feel dissatisfied with levothyroxine replacement although it is not clear whether these results in part stem from selection or treatment biases. There is no evidence so far that animal studies showing inadequate tissue levels of T3 on T4-only replacement are replicated in man. A meta-analysis of 11 trials of T3 and T4 combination treatment up to 2006 concluded that this was not superior to T4 alone although three subsequent trials have found some weak evidence for benefit. Amongst the factors that must be taken into account in judging these trials are the heterogeneity of the causes of hypothyroidism, different durations of disease and treatment, variation in T3:T4 dose ratio (by weight) of 20:1–1:1 and the use of differing outcome measures. Liothyronine is so far available only as a 20 μg tablet: unavoidable supraphysiological peaks of T3 are inevitable. Moreover T3 up to 2006 concluded that this was not superior to T4 alone although three combination T3 and T4 treatment cannot be recommended for routine use, there is still a need physiological replacement trials, stratified by genotype and with meticulous, dynamic TSH monitoring.

Management of phaeochromocytoma

Biochemical screening for phaeochromocytoma using plasma free metanephrines: utility beyond diagnosis

G Eisenhofer

Technische Universita¨t Dresden, Dresden, Germany.

Measurements of plasma concentrations of the O-methylated metabolites of catecholamines including metanephrine, normetanephrine and methoxytryptamine have advantages over other biochemical tests used to diagnose phaeochromocytoma for several reasons: i) the metabolites are produced within chromaffin cells continuously from catecholamines leaking from storage vesicles; ii) the single largest source of these metabolites is from adrenal medullary chromaffin cells, but this production normally represents a minor pathway of catecholamine metabolism; iii) in phaeochromocytoma tumour cells the O-methylation pathway dominates; iv) intra-tumoural production of the metabolites occurs independently of variations in catecholamine release; and v) other catecholamine metabolites, including sulfate-conjugated metanephrines measured in urine, are produced largely downstream of chromaffin tumour cells. The consequences of these influences, as shown using data from 365 patients with phaeochromocytoma, go well beyond utility of the metabolites for diagnosis. Increases in the metabolites can be used to predict tumour size, important for assessing disease burden and response to therapy in patients with malignant disease. Measurements of plasma methoxytryptamine also provide a novel biomarker for malignancy and together with succinate dehydrogenase type B subunit mutation status, tumour size and location provide useful information to assess malignant risk. Furthermore, patterns of increases of metanephrine, normetanephrine and methoxytryptamine show distinct differences according to hereditary syndrome and thus provide an easily utilised tool to guide cost-effective genotyping of underlying disease-causing mutations. Differences in ages of tumour presentation according to different biochemical phenotypes and tumour locations also suggest origins from different chromaffin progenitor cells with variable susceptibility to disease causing mutations.

Imaging of phaeochromocytoma and paragangliomas

H J L M Timmers1,2

1Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2National Institutes of Health, Bethesda, Maryland, USA.

The standard technique for the functional imaging of phaeochromocytoma and paraganglioma (PPGL) is [¹²³I]-methyl-iodobenzylguanidine single photon emission computed tomography (MBI SPECT). However, metastases are more accurately detected by 2-[¹⁸F]-Fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET). In a large prospective study of 216 patients evaluated at the NMI for benign or malignant PPGL, we investigated the sensitivity and specificity of FDG PET as compared to MIBG SPECT for localization of metastases of PPGL. We also explored whether clues for a genetic diagnosis underlying PPGL can be gained from functional characterization by FDG PET. Cut-off values for FDG PET suv to distinguish PPGL from normal adrenal glands were established.
The two main subtypes of pseudohypoparathyroidism (PHP), PHP-Ia and -Ib, are
S25.2
Genomic imprinting of the GNAS locus
G Kelsey
The Babraham Institute, Cambridge, UK.
Genomic imprinting is an epigenetic mechanism by which a subset of our genes
displays unequal expression of the maternal and paternal alleles; in many cases,
one allele is fully silenced. It occurs because these genes are marked differently
(by DNA methylation and/or histone modifications) in male and female gametes.
These gamete-specific marks are maintained at fertilisation and perpetuated
throughout development and adult life, such that the alleles of imprinted genes
retain a permanent memory of the parent in which they originated.
The GNAS locus on chromosome 20q13.11 (and chromosome 2 in mouse) is the
archetypal complex imprinted locus. It comprises a set of overlapping transcripts
determined by alternative promoters with different patterns of imprinted expression. It also provides the classic example of tissue-specific imprinting, in
which the canonical GNAS transcript coding for Gsα is expressed predominantly
from the maternal allele in some tissues. Functionally, this incomplete imprinting
is clinically significant, as it dictates the nature of the disease caused by
inactivating mutations in Gsα, with end organ hormone resistance specifically on
maternal transmission (pseudohypoparathyroidism type 1a, PHP1a). In addition
to Gsα, the locus encodes the proteins XLαs and NESP55 from the overlapping
transcripts. XLαs is expressed exclusively from the paternal allele and functions
similarly to Gsα at the biochemical level. However, gene knock-out studies in
mice show that Gαs and XLαs have opposite physiological effects, for example,
sym pathetic nervous activity and metabolism, suggesting that XLαs acts as a
counter-regulator of pathways dependent on Gαs. Despite the importance of
XLαs demonstrated in the mouse, the impact of XLαs function in human is not
understood.
An alternative form of pseudohypoparathyroidism, PHP1b, is an imprinting
disorder characterised by DNA methylation defects in the differentially
methylated regions (DMRs) that determine tissue-specific monoallelic expression of
GNAS. Aberrant DNA methylation in PHP1b is caused by deletions in cis, and these
mutations are helping to provide insights into the mechanisms of imprinting
establishment at GNAS and generally.

S25.3
Xlas, in vitro functions and possible physiological and pathogenic roles
A Linglart1,2
1Pediatric Endocrinology, Bicêtre Hospital, Paris, France; 2INSERM U986,
Paris, France.
The GNAS locus is a complex imprinted locus which encodes Gsa and four
additional alternative transcripts including Xlas; Gsa is the ubiquitous α-subunit of
the G-protein involved in major biological pathways including hormonal
signaling and cell differentiation. Xlas is the only transcript sharing with Gsa the
domain encoded by exon 2 to 13 of, which plays a key role in
co-activating receptors to adenylyl cyclase stimulation. However, Xlas differs
from Gsa by its tissue-specific paternal exclusive expression. Epi-genomic
defects at the GNAS locus cause a series of diseases called pseudohypoparathyroid-
isms (PHPs) whereas post-zygotic mutations in the domain of the Gsa protein
coding for the GTPase intrinsic activity cause endocrine activation and McCune–
Albright syndrome (MAS). In both contexts, the symptoms were until recently
attributed solely to the modified function or expression of Gsa. Recent findings
clarify that changes in Xlas expression or function may contribute to these
phenotypes. In vitro in transfected cells that endogenously lack both Gsa and Xlas (Gnas−/− cells), human Xlas shares with Gsa the ability to couple
Gαs-coupled receptors to adenylyl cyclase upon agonist stimulation (including
PTHR1 activation by PTH), thereby generating an increase in intracellular cAMP.
Loss of function mutations of GNAS (exons 2–13) impair receptor-mediated
cAMP signaling for both Gsa and Xlas; interestingly in these studies, Xlas
appears more potent than Gsa in mediating basal and stimulated cAMP
generation. Animal models demonstrated the importance of Xlas in many
processes including post-natal adaptation to feeding, energy metabolism and
adipocyte biology. In humans, indirect observations suggest that Xlas contributes
to pre and post-natal growth and hormonal signaling in early life and that Xlas
alteration in PHPs or MAS influences the patient phenotypes. Although there is no reported human ‘model’ of Xlas inactivation, the above data
point to a specific role for Xlas in major biological functions. However, it is still
debated if Xlas potentializes, replaces and/or antagonizes Gsa function.

The role of plasma binding proteins in tissue hormone delivery
S26.1
Sex hormone-binding globulin: beyond plasma transport
G Hammond1,2
1Child and Family Research Institute, Vancouver, British Columbia, Canada; 2University of British Columbia, Vancouver, British Columbia, Canada.
Sex hormone-binding globulin (SHBG) transports sex steroids (andro
genols and estrogens) in the blood and regulates their access to tissues. In humans and other
vertebrates, the liver produces the SHBG that circulates in the blood, and in most
species the gene encoding SHBG is also expressed in the testis. The testicular cell
median in which SHBG is produced vary between species; in most mammals,
expression of the Sbg gene in Sertoli cells gives rise to a secreted protein that
binds androgens in the seminiferous tubules and male reproductive tract. By
contrast, the human SHBG gene is expressed in developing sperm cells rather
than Sertoli cells. In spermatids and spermatozoa, human SHBG accumulates as an
amino-terminally truncated isoform in the acrosome, the concentrations of which
decrease with aging and are correlated with sperm motility. Studies in transgenic
mice have indicated that human SHBG is also produced as distinct glycoforms in

Endocrine Abstracts (2011) Vol 26
13th European Congress of Endocrinology, Rotterdam, The Netherlands
European Network for the Study of Adrenal Tumors: Adrenal Cancer Consortium (ENS@T-CANCER)
Felix Beuschlein
University Clinic, Munich, Germany.

Among patients with adrenal masses adenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavourable prognosis. Owing to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which are affected by fragmentation and low cohort sizes. The European Network for the Study of Adrenal Tumors (ENS@T) has recently implemented a collection of adrenal tumor related databases and defined an associated network of Biological Resource Centers devoted to research on adrenal tumors. The concurrence of recent achievements of this evolving network, that is the progress in the understanding of molecular mechanisms and increasing availability of specific diagnostic and therapeutic tools for adrenal cancers provides the unique opportunity to achieve unmatched progress in the implementation of both translation and clinical research dedicated to ACC and MPH. Specifically, the newly formed ENS@T-CANCER consortium will address the following topics: i) structuring European clinical and translational research through implementation of a virtual research environment, ii) improving clinical outcome of patients with adrenal cancer by conducting interventional trials carried out by European centers of excellence, iii) improvement of differential diagnosis and risk stratification of adrenal cancer, iv) identification and validation of tools for follow-up of patients with adrenal cancer, v) identification of novel biomarkers for treatment response.

The ultimate aim of the ENS@T-CANCER Consortium is to develop research in the field of adrenal cancers to improve diagnosis and treatment abilities. The Network will allow recruiting sufficient patients in all relevant European centers, to harmonize diagnosis criteria and to use the various technological approaches of a number of laboratories.

Endocrine Abstracts (2011) Vol 26
In advanced ACC, the first ever randomised trial (FIRM-ICT study) will set the new standard in first-line cytotoxic therapy. Preliminary results showed a clear trend for improved overall survival by the combination of etoposide, doxorubicin, cisplatin, and mitomycin (EDP-M) in comparison to cisplatin, mitomycin, and streptozocin (14.8 vs 12.0 months; P = 0.069) and progression-free survival was clearly prolonged by EDP-M (5.7 vs 2.1 months; P < 0.0001). The first experience using targeted therapies is disappointing: gefitinib, sorafenib, erlotinib+gemcitabine, or bevacizumab+capcitabine exhibited only limited efficacy in pretreated patients. An interesting observation was found in the SIRAC study investigating sunitinib in refractory ACC. The preliminary analysis indicated that in 5 of 35 evaluable patients (15.3%) a prolonged stable disease for > 12 weeks was seen. Of note, concomitant mitotane did rather impair the clinical outcome, which might be related to an induction of CYP3A4 enzyme. Another important study investigating the efficacy of the IGF1 receptor inhibitor OSI-906 in a placebo controlled phase III trial, is currently still recruiting.

Overall the prognosis of ACC is still poor and 5-year survival rate is about 45%. However, recent collaborative efforts (e.g. by the European adrenal network ENSAT) and ongoing international trials will further advance the field in the near future.

Polycystic ovary syndrome: classification, genetics and therapy

S28.1
Phenotypes and environmental factors in PCOS
E Diamanti-Kandarakis
Medical School University of Athens, Athens, Greece.

PCOS is a complex endocrine syndrome characterized by the combination of reproductive aberrations, namely hyperandrogenism and chronic anovulation, with metabolic defects. Insulin resistance is a major component in metabolic as well as reproductive aspects of PCOS. The pathogenesis of the syndrome remains under investigation. However, environmental factors appear to unmask a genetically determined susceptibility to PCOS and also determine the specific phenotypic expression of the syndrome. Particularly, environmental triggers acting during early stages of human development, from prenatal life to puberty, may convert a predisposed genotype to the phenotypical manifestation of PCOS. In addition, environmental determinants may modulate the clinical severity of PCOS, ranging from a mild phenotype (nonhyperandrogenic anovulatory, as determined by Rotterdam criteria1, or normoovulatory hyperandrogenic, as determined by Rotterdam and Androgen Excess Society criteria2) to the full-blown phenotype of classic PCOS.

The environmental component in the pathogenesis of PCOS includes dietary factors and other exogenously derived substances. Overnutrition with consumption of calorie-rich diets leads to obesity which may accelerate the development or aggravate the clinical course of PCOS3–5. Beyond calorie excess, the high intake of dietary advanced glycation end products (AGEs) may also contribute to the pathogenesis and perpetuation of PCOS. In particular, increased AGEs levels were reported in lean, normoglycemic and non-insulin resistant women with PCOS6 and AGEs were found to accumulate in human polycystic ovaries7. These bioactive molecules may exert actions on both ovarian compartments, since circulating AGEs levels were positively correlated with serum levels of testosterone8 and Antimullerian hormone (AMH)9, a theca cell and a granulosa cell product respectively. Bisphenol A (BPA) emerges as another environmental contributor to the pathogenesis of PCOS. BPA belongs to endocrine-disrupting chemicals, which are substances in our environment, food, and consumer products that interfere with hormone biosynthesis, metabolism, or action resulting in a deviation from normal homeostasis or reproduction. Most importantly, data from experimental animals have demonstrated that neonatal exposure to BPA leads to PCOS development10. Extending these findings to humans, a recent study has shown that serum BPA levels are increased in lean and obese PCOS women compared to age and BMI matched controls11. Moreover, serum BPA levels were positively associated with serum androgen levels and insulin resistance indices12, the latter finding suggests a role of BPA in androgen synthesis in addition to its potential contribution to insulin resistance in PCOS.

Overall, PCOS may arise from a combination of genetic predisposition and environmental insults that lead to failure of reproductive and metabolic functions. Environmental exposure may start in utero and persist during early life until adulthood. The evidence for the involvement of specific environmental components of the pathogenesis of PCOS may help to elucidate the etiology and the ideal treatment of the syndrome.

References

S28.2
Genetics
S Franks
Abstract unavailable.

S28.3
PCOS: treatment of infertility and prediction of success
Bart Fauser
University Medical Centre, Utrecht, The Netherlands.

Polycystic ovary syndrome is a complex genetic condition, diagnosed based on oligo/anovulation, hyperandrogenemia and polycystic ovaries. Moreover, these women frequently present with obesity, insulin resistance and other signs of metabolic disease. In a gynaecology practice, the great majority of PCOS women present with anovulatory infertility. In fact, it is often suggested that around 20–30% of all infertility is due to PCOS. The medical treatment aiming to restore normo-ovulatory cycles in anovulatory women should be referred to as ‘ovulation induction’. This approach is under increasing pressure in relation to the widespread use of assisted reproduction (ovarian hyperstimulation and intra-uterine insemination, or IVF) or surgical procedures such as laparoscopic ovarian cystectomy.

Recently, an ESHRE/ASRM sponsored consensus workshop on ovulation induction strategies in PCOS was organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008). In brief, life style induction strategies in PCOS was organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008). In brief, life style strategies in PCOS were organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008). In brief, lifestyle strategies in PCOS were organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008). In brief, life style strategies in PCOS were organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008). In brief, life style strategies in PCOS were organised in Thessaloniki, Greece (published in both Human Reproduction and Fertility Sterility in 2008).
compound can be recommended for large scale clinical use. As second line treatment both exogenous gonadotrophins or ovarian cautery can be applied depending on patient (and doctor) preference. The major shortcoming of even low-dose, step-up gonadotrophin protocols remains increased chances for multiple gestation. The drawback of the surgical approach is that surgery is needed and the relatively low efficacy, requiring additional ovulation inducing drugs is many women. However, multiple pregnancies following ovarian cautery are negligible. There is no need for IUI in addition to ovulation induction provided that sperm quality is normal. IVF should generally be considered as third line treatment after failed ovulation induction. Ovarian hyperstimulation for IVF remains a challenge in PCOS patients, with a distinct tendency to over-respond. Overall, success rates are quite good, with the major benefit that multiple pregnancy can be prevented by the transfer of just a single embryo. Therefore, IVF may be considered an earlier treatment option in women of more advanced reproductive age. Overall, ovulation induction treatment is effective and singleton live birth rates of over 70% have been reported. We have worked extensively on assessing possible predictors of treatment outcomes based on initial screening characteristics. Using multi-variate prediction models we could show that factors such as body mass index, high androgen levels, female age, and insulin resistance are fairly good predictors of both ovulation and pregnancy chances. Such approaches may help to render ovulation induction more patient tailored, helping to choose the best treatment option and individualize dosing.
JOE/JME Prize Presentation

Sponsored by

Journal of Molecular Endocrinology
The central nervous system and the control of adipocyte and hepatic metabolism

R Nogueiras
Department of Physiology, School of Medicine-Instituto de Investigación Sanitaria (IDIS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

The central nervous system (CNS) is crucial in the regulation of energy homeostasis. Apart from endocrine signaling and nutrient sensing, there is an important neuronal network that connects the CNS with peripheral metabolic processes. Many neuroanatomical studies have shown that the white adipose tissue (WAT) and the liver are innervated by the autonomic nervous system. For instance, there is evidence that, as the levels of various peripheral signals change, specific neuronal circuits within the CNS respond by adjusting ongoing autonomic nervous system activity to a wide spectrum of organs.

During the last years, several reports have demonstrated that signals from the CNS directly control the amount of fat by modulating the storage or oxidation of fatty acids in WAT and liver. Importantly, some CNS pathways regulate these processes independent of food intake, suggesting that those signals possess alternative mechanisms to regulate energy homeostasis. Different neuronal circuits within the hypothalamus, such as leptin-ghrelin-insulin-GLP1- and resistin-responsive neurons, as well as melanocortins, neuropeptide Y exert their direct actions on lipid metabolism in peripheral tissues such as WAT or liver. Contrary, other signals including the cannabinoid system, seem to play more important functions at peripheral level. Dissecting the complicated interactions between peripheral signals and neuronal circuits regulating lipid metabolism might open new avenues for the development of new therapies preventing and treating obesity and its associated disorders.

Endocrine Abstracts (2011) Vol 26
Meet the Expert
Bariatric surgery has become the most effective therapeutic option for morbid obesity (BMI ≥ 40 or >35 with major complications). All established surgical techniques are followed by significant body weight reduction as well as clear improvement/remission of main obesity-associated comorbidities such as type 2 diabetes (DM2), dyslipidaemia, hypertension, sleep apnoea and cardiac dysfunctions. Mixed restrictive-malabsorptive techniques, such as Roux-en-Y gastric bypass (RYGB), induce more weight loss, better metabolic improvement and make postoperative weight regain (WR) less likely than restrictive procedures such as vertical gastroplasty or gastric banding (GB). Therefore, individualization and a complete preoperative assessment by a multidisciplinary team are needed in order to tailor bariatric surgery to patient characteristics. More recently, BS has shown to induce DM2 remission in a significant percentage of patients, which vary depending on the technique (GB; RYGB; BPD/DS). Short DM2 duration, low needs of anti diabetic medications and good metabolic control seems to be preoperative predictive factors of success. Besides acute postoperative complications, malabsorptive BS, especially bilopancreatic diversion but also RYGB, can cause vitamin deficiencies, and nutritional as well as lifestyle and perhaps hormonal factors may contribute to WR. The effect of BS on DM2 remission has set the basis of proposing different surgical techniques in patients with BMI lower than 35, or even without obesity. The effect of BS in patients in whom the disease can remain stable for many years. Alternative treatments for small size and/or very slow development. Detected with highly sensitive tools during follow up, small recurrences raise questions regarding the benefit of BS and its reproducibility. Patients operated of BS should be strictly followed in order to prevent nutritional complications, but also to avoid WR, which can start as soon as two years following surgery leading to metabolic deterioration and partial reversal of achieved benefits. Nutritional as well as lifestyle and perhaps hormonal factors may contribute to WR. The effect of BS on DM2 remission has set the basis of proposing different surgical techniques in patients with BMI lower than 35, or even without obesity. Although the initial experimental results are encouraging, we need more experience before establishing the involved mechanisms and the possible role of this surgical approach in DM2 management.

Endocrinology came to its third revolution in the field of hormone determination. As radiomunoassays in the 60s paved the way to the knowledge of modern endocrinology, and as automated immunoassays in the 70s linked analytical measurement to the clinical practice, nowadays liquid chromatography – tandem mass spectrometry (LC–MS/MS) represents the evolution of the high-throughput approach, typical of automated platforms, toward the high reliability and specificity of the measurement, typical of gas chromatography (GC)–MS, and toward the power of simultaneous profiling of wide panels of hormones working on a small sample volume and with minimal pretreatment of the sample. First introduced for therapeutic drug monitoring and for neonatal screening of inborn errors, LC–MS/MS is breaking into clinical and research laboratories for steroids determination, as proved by a growing literature. Comparison studies between immunoassays and LC- or GC–MS methods, attested with analytical proof what clinicians had already perceived about the lack of specificity and the derived inconsistent results affecting immunoassays. The earlier and more targeted steroid, aldosterone excess, confirming the importance of detection and diagnosis of PA plays an important role in cardiovascular disease states and should be systematically sought and specifically treated. In recognition of this, the US Endocrine Society published in 2008 a clinical guideline for the case detection, diagnosis and management of PA, specifically treatable and potentially curable condition. Areas of recent, topical research include i) the demonstration of excess morbidity (including cardiovascular and renal) in patients with PA compared with other forms of hypertension and reduced quality of life, confirming the clinical relevance of non-blood pressure-dependent adverse effects of aldosterone excess; ii) the further demonstration that this excess morbidity is ameliorated with specific (but not non-specific antihypertensive) therapy directed against aldosterone excess, confirming the importance of detection and diagnosis of PA to enable optimal specific management; iii) an ongoing appraisal and refinement of diagnostic approaches including the recent demonstration that treatment with β-blockers, female gender and the luteal phase of the menstrual cycle are associated with higher aldosterone/renin ratios and hence a greater risk of false positive results whereas selective serotonin reuptake inhibitors can lower the ratio and thus may increase the risk of false negatives; iv) the importance of assay reliability and the development of new, rapid-throughput, highly reliable and reproducible mass spectrometric methods of measuring aldosterone; and v) further insights into the importance and nature of causative genetic factors, the identification of which is being sought through high-throughput next generation sequencing technologies.

Endocrine Abstracts (2011) Vol 26
MTE6
Difficult adrenal cases
W Young
Mayo Clinic, Rochester, Minnesota, USA.

Objective
To present 2 difficult adrenal cases in an interactive computer-based CPC format.

Methods
The history of present illness will be presented for 2 patients: i) A 24-year-old woman who is 13 weeks pregnant presenting with spells and marked hypertension; ii) A 56-year-old man with hypertension, hypokalemia, and renal insufficiency. For the details of these cases, please see the Meet-the-expert handbook.

Results
The attendees will use diagnostic and treatment test menus to solve the cases and direct appropriate treatment.

Conclusions
As the cases are discussed we will review many of the practical issues surrounding the evaluation and treatment of pheochromocytoma and primary aldosteronism.

MTE7
When to instigate insulin therapy in DM2
Jan Skotla
University of Prague, Prague, Czech Republic.

The main pathophysiological feature of type 2 diabetes mellitus is based on combination of impaired β-cell insulin secretion and insulin action in peripheral tissues. However, as progressive loss of the β-cells develops as a consequence of apoptosis, the insulin supply is later necessary. This picture is completely different in type 1 diabetes when insulin insufficiency is developed early in the disease and exogenous insulin is exagerated to maintain metabolic homeostasis and patient’s life as well.

The key question can be postulated: what is the proper time for insulin treatment in type 2 diabetic patient? The replies are different between specialists and frequently depend on their experience with the treatment of type 2 diabetic patients. It could be therefore important if there would exist any ‘evidence based’ data supporting the needs for insulin treatment in earlier or later time during the disease. Insulin role in the β-cell apoptosis has been evaluated with a conclusion that there is some evidence on β-cell protection due to insulin administration. From this point of view, this early insulin instigation would be appropriate. The problem will come when significant insulin resistance is developed, typically in obese individuals. Then higher doses of insulin administered may be deleterious for worsening of resistance and further of diabetes control. In those diabetic patients (with increasing obesity) may be used the insulin treatment in much more later stage than in the lean individuals.

Positive and negative influences of early insulin treatment in Type 2 diabetic patients are discussed in the light of individual selected patients for the appropriate therapy. It may be admitted that no single recommendation for each type 2 diabetic patient to introduce early insulin administration can be suggested because of heterogeneity in this population with diabetes.

MTE8
Pathogenesis and management of primary ovarian failure
Luca Persant
1,2
1Department of Medical Sciences, University of Milan, Milan, Italy; 2Division of Endocrinology and Metabolic Diseases and Lab of Experimental Endocrinology, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Primary ovarian failure (POF) is defined as a premature ovarian defect characterized by absent menarche (primary amenorrhea) or secondary amenorrhea lasting at least 6 months associated with a premature depletion of ovarian follicles before the age of 40 years. POF is a frequent disease affecting female fertility and well-being and generating several co-morbidities. Since the onset of POF is frequently silent and fertility defects occur in the occult phases of the disease several groups are working to generate novel tests for POF prediction. The availability of efficient tests would constitute the basis for the preservation of fertility in POF women. This search is however hampered by the present lack of knowledge on POF pathogenesis. The MTE session will focus on the current knowledge on the pathogenesis of premature ovarian failure and on how genetic and biochemical investigations may be applied for the counselling of POF women.

MTE9
Pleiotropic effects of vitamin D
Marita Pfeifer
Department of Endocrinology, diabetes and metabolic diseases, University Medical Centre Ljubljana, Žaloška 7, 1525 Ljubljana, Slovenia.

Vitamin D is phylogenetically an old compound present in simple organisms without skeleton for millions of years. Its primary function, acting as a cytokine, has been the defence against microbial invaders. Vitamin D modulates the innate immune response by inducing the synthesis of endogenous antibiotics in monocytes-macrophages. Epithelial ‘barrier’ tissues in lung, gut, placenta and skin employ the same antimicrobial mechanisms. Vitamin D also interacts with dendritic cells and lymphocytes to modulate the acquired immune response. Other important biological functions of vitamin D are the maintenance of muscle strength and size, stimulation of insulin production in β-cells, suppression of renin secretion from kidneys, attenuation of autoimmune inflammatory processes of atherogenesis in arterial wall. It can decrease cellular proliferation of both normal and cancerous cells and induce their differentiation. The more advanced function of vitamin D is that of a hormone, reserved for species with endo-skeleton where it regulates calcium, phosphorus and bone homeostasis.

Vitamin D3 is metabolized in the liver to 25-OH vitamin D, which levels determine patient’s vitamin D status. 25-OH vitamin D is activated in kidneys to 1,25-(OH)2 vitamin D or vitamin D hormone that binds to its nuclear vitamin D receptor and controls more than 200 genes.

There is an epidemic of vitamin D deficiency (25-OH vitamin D less than 50 nmol/l and insufficiency new vitamin D less than 75 nmol/l) in general population. Reasons are greater sun protection and increase in population body mass index. Severe vitamin D deficiency causes rickets or osteomalacia. Less severe forms have other serious consequences: increased risk of type I and type II diabetes, multiple sclerosis, rheumatoid arthritis, hypertension, cardiovascular disease, and cancer (colon, breast). Vitamin D insufficiency and deficiency are significantly associated with all-cause and cardiovascular mortality.

Optimal vitamin D levels are 75–100 nmol/l. In the absence of sun exposure 1000 IU of cholecalciferol is required daily or 7000 IU weekly to maintain normal vitamin D levels. To achieve normal levels, 2000 IU daily are needed for a month or two. Vitamin D replacement is cheap and safe.

MTE10
Biomarkers of thyroid malignancy
Manuel Sobrinho-Simões
Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.

This topic will be discussed taking into consideration the need to incorporate the continuously increasing molecular data in the old frame (imagology, cytology and histopathology and biochemistry). Using this strategy three practical issues may be addressed: diagnosis, prognosis/therapy selection and surveillance. Out of the above mentioned issues we will focus the discussion of the usefulness of molecular markers in two steps of the management of patients with thyroid tumours:

i) In the initial evaluation of thyroid nodules together with sonography and cytopathology data; the latter obtained by fine needle aspiration biopsy (FNAB) since core biopsy methods have not proved (yet?) their value in thyroid oncology.

ii) In the definitive characterization of the tumours after surgery, in conjunction with all the available clinical, imagiological and laboratorial data and with the huge amount of information that can be obtained by the thorough histopathological study of the surgical specimens.

When discussing these two ‘steps’ one has to be aware of the relatively few possible options from the therapeutic standpoint. Oversimplifying the issues (I am pathologist…) and avoiding the problems raised by poorly differentiated/undifferentiated (anaplastic) carcinomas, I would summarize the critical questions as follows: i) To operate or not? ii) If yes, what is the adequate extention of the thyroidectomy? iii) What to do about regional lymph nodes? iv) Radioactive iodine: Yes or no? v) What to do in radioactive iodine-refractory tumours? vi) When and how to use the new targeted biologic approach therapies?

In case there is time, we will also discuss the role molecular biomarkers may play in the new therapeutic approaches. Besides addressing the MAPK pathway (and...
MTE11
Protein and breast tumorigenesis: a novel concept of prolactin biology
Ph Touraine 1,2 and V Goffin1
1 GH Pitie Salpetriere, Paris, France; 2Inserm U845, Paris, France.

Prolactin was discovered 80 years ago. It is currently viewed by clinical endocrinologists as a hormone of pituitary origin, whose production is negatively controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia, which is efficiently cured using dopamine agonists. Although there is no debate about the relevance of these features, experimental and clinical studies performed during the past decade have considerably widened our perception of prolactin biology: i) in addition to the endocrine (circulating) hormone, locally-produced prolactin has been documented in various human tissues such as the mammary gland and the prostate, where it acts via autocrine/paracrine mechanisms, ii) there is increasing evidence supporting the role of prolactin in human breast and prostate tumorigenesis, especially when it is locally-produced, iii) we recently reported the first gain-of-function variant of the prolactin receptor, that was to date identified in patients presenting with breast tumors (benign or cancer), iv) we have engineered human prolactin variants acting as pure competitive antagonists of the prolactin receptor, and we have demonstrated their ability to down-regulate the actions triggered by local prolactin as well as by the constitutively active receptor variant in experimental models; these compounds thus represent a novel class of molecules of therapeutic interest as potential alternative to dopamine agonists. These novel aspects of prolactin biology will be presented, with major focus on experimental models highlighting its effects on tumor growth.

MTE13
Hypoponatraemia
Chris Thompson
Academic Department of Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin, Ireland.

Hypoponatraemia is the commonest electrolyte abnormality in hospitalised patients, with a prevalence of 20–30% and particularly high incidence in neurological, pulmonary, gastric, intensive care and oncology units. Up to 6% of patients have severe hypoponatraemia (plasma sodium <125 mmol/l). A wealth of data is available which indicates that severe hypoponatraemia is associated with cerebral irritation, causing confusion, coma and seizures, and significant excess mortality. The rapidity of onset of hypoponatraemia is equally important in determining the likelihood of cerebral symptoms and death. Recent papers have reported that in addition there is excess mortality in patients with mild/moderate hypoponatraemia (125–135 mmol/l). In addition even mild hypoponatraemia is associated with significant morbidity, including gait disturbances and falls, cognitive deficits, bone fractures and osteoporosis. The commonest cause of hypoponatraemia is SIADH; it is important to distinguish SIADH from other forms of hypoponatraemia, particularly hypovolaemic hypoponatraemia, for instance diuretic-induced. Glucocorticoid deficiency also biochemically mimics SIADH and it is particularly important to diagnose in patients with neurological conditions, in whom the cerebral insult can produce both SIADH and acute ACTH deficiency. Accurate diagnosis is essential to ensure that the correct treatment of hypoglycaemia is instituted, both for the underlying cause and the biochemical disturbance. SIADH is traditionally treated with water restriction, which patients find difficult to maintain, and which has unpredictable efficacy. Demeclomcycline, the first line pharmacological agent, also has unpredictable action, and has side effects, such as hypernatraemia, liver and renal damage, and photosensitive skin rashes. A European licence was granted in 2009 for tolvaptan, the specific vasopressin V2 receptor antagonist, whose efficacy in treating hypoponatraemia was demonstrated in the SALT-1 and SALT-2 trials. The potential use of V2 receptor antagonists will be discussed.
Cushing syndrome (CS) is associated with systemic complications, like central obesity, ‘moon’ face, limb atrophy, increased fat mass and reduced bone and lean body mass, excessive fatigue, purple striae, easy bruising and skin ulceration, hirsutism, hypogonadism and decreased libido. Morbidity like hypertension, insulin resistance and/or diabetes mellitus, dyslipidemia, prothrombotic state, vascular disease, atherosclerosis and increased cardiovascular risk, acquired metabolic syndrome, depression, loss of brain volume, cognitive decline and impaired health-related quality of life -HRQoL- may also occur. Mortality is higher than in age- and gender-matched subjects, due to complications directly and/or indirectly correlated with GC excess. Altogether, despite being a rare disease, difficulties in early diagnosis and residual morbidity represent a significant burden for the patients and for the health system. Biochemical ‘cure’ of hypercortisolism is not followed by normalization of morbidity and mortality, which are still increased. Cardiovascular and metabolic risk, central fat and an unfavorable adipokine profile persist. Bone mass is reduced not only due to endogenous hypercortisolism, but also to duration and dose of exogenous glucocorticoid (GC) replacement therapy. Thus, therapy in operated patients with inhibition of the hypothalamic-pituitary-adrenal axis should be reduced to the lowest dose and minimum duration possible. Specific treatments should be considered in patients with decreased bone mass, aimed at reducing increased fracture incidence. Cognitive and health related quality of life impairments, described in active disease, are still present after endocrine remission. Thus, residual morbidity persists in cured CS, suggesting irreversibility of GC-induced phenomena typical of chronic hypercortisolism. Thus, the primary goal in the prevention and treatment of complications of Cushing’s syndrome is correction of hypercortisolism as soon as possible. Supported by FIS080302 and ERCUSYN 800200.

Endocrine care in HIV-infected patients

Vincenzo Rochira
Riceratore Universitario Confermatno, Modeina, Italy.

Several co-morbidities are associated with the HIV infection involving also the endocrine-metabolic system. Consistently, the recent development of HAART therapy ruled out a significant improvement both in the prognosis and life expectancy of HIV-infected patients, but disclosed also new serious drug-related toxicity. Of these, the lipodystrophy syndrome is the most frequent, occurring in up to 85% of HIV-infected patients under HAART. HIV-related lipodystrophy is associated with metabolic alterations consisting with severe dyslipidemia, insulin resistance, hyperinsulinism, impaired glucose metabolism, and diabetes mellitus. Among endocrine diseases, clinically relevant bone loss and male testosterone deficiency are very frequent. Depletion of bone mineral density accounts for both osteopenia and osteoporosis that are surprisingly observed more often in men with HIV infection. The finding of low circulating testosterone is observed in about 20% of HIV-infected men under HAART and seems to be more frequently associated with inappropriate low serum LH, suggesting a dysfunction of the hypothalamic-pituitary unit. As alterations in GH dynamics are also common in HIV-infected patients, it is possible to hypothesize that the hypothalamus-pituitary unit is affected in the setting of HIV, but if a true pituitary disorder or only a functional reduction of pituitary secretive pattern are involved in these hormonal alterations remains to be determined. The pituitary impairment has only a functional reduction of pituitary secretive pattern are involved in these hypothalamic-pituitary-thyroid axis are associated with anomalous TFTs. Failure to recognize these potential ‘pitfalls’ can lead to misdiagnosis and inappropriate management.

Managers of phaeochromocytomas and paragangliomas

Pierre-Francois Piouin

Phaeochromocytomas (PH) and functional paragangliomas (PGL) are neoplasms of chromaffin tissue that synthesize catecholamines. The diagnosis of PH or functional PGL is based on the determination of metanephrines. Most catecholamine-secreting tumors arise in the adrenal glands (PH proper) and are easily detected by computed tomography or magnetic resonance imaging. Patients may also harbor extrarenal primary tumors (PGL) or distant metastases. Adrenal imaging should therefore be combined with whole-body metaiodobenzylguanidine scintigraphy. One in four patients with PH or PGL has germline mutations conferring a predisposition to catecholamine-secreting tumors. The identification of a causative mutation should lead to presymptomatic genetic testing in the family. Patients with catecholamine-secreting tumors should be referred to centers with extensive experience in the anesthetic and surgical management of the disease. Blood pressure should be normalized before surgery, using alpha-adrenergic and possibly beta-adrenergic antagonists. Most PH and many PGL can be resected laparoscopically. Adrenal cortex-sparing surgery is feasible in patients with bilateral PH. PH and PGL may recur. Patients should be subject to life-long follow-up, with check-ups at least one yearly including blood pressure measurement and metanephrine determination.

Weird thyroid function tests

Mark Gunnell & Krish Chatterjee
Metabolic Research Laboratories, Addenbrooke’s Hospital, Cambridge, UK.

Although overt thyroid disease is easily recognised, lesser disturbances of thyroid function can prove difficult to diagnose and be mimicked by other endocrine and non-endocrine disorders. Establishing the correct diagnosis depends on accurate interpretation of thyroid function tests (TFTs), which is usually straightforward; however, in a minority of situations, the results of FT4, FT3 and TSH measurement either do not ‘fit’ with the clinical picture and/or appear discordant with each other (so-called ‘funny’ or ‘weird’ TFTs) (Figure). In many such cases reassessment of the clinical context provides an explanation for the discrepant TFTs; in other instances, interference in one or other laboratory assays can be shown to account for divergent results; uncommonly, genetic defects in the hypothalamic-pituitary-thyroid axis are associated with anomalous TFTs. Failure to recognize these potential ‘pitfalls’ can lead to misdiagnosis and inappropriate management.
The clinical presentation of primary hyperparathyroidism (PHPT) has changed dramatically after increased accessibility to biochemical auto-analysers and the diagnosis is today often made by change in patients without specific symptoms. Operative treatment is recommended in patients with markedly increased calcium levels or typical symptoms. However, the vast majority of patients in the modern clinic do not present organ-related symptoms and their calcium levels are only slightly increased, or even within the upper limit of normal. It has been a matter of debate whether neuro-psychiatric symptoms is a clinical manifestation in mild PHPT and to what extent Quality of Life and cognitive function would improve following operation. Systematic randomized studies on these patients with up to two years observation time have so far not indicated benefit of surgery. Several consensus development conferences have discussed management of mild, borderline PHPT during the last twenty years.

Educational goals
- Discuss indications for treatment in PHPT
- Differential diagnoses for PHPT
- Work-up also in the elderly
- Discuss the value of clinical guidelines
- Clinicians with interest in internal medicine and endocrinology.

Teaching methods
Based on case presentations, indications for operative treatment will be presented, as will conservative management, also in the elderly. As no final answers are given due to the lack of long term prospective studies, the value of international guidelines will be discussed.

Glucocorticoid replacement therapy
Kristian Lovas
Section for Endocrinology, Institute of Medicine, University of Bergen, Bergen, Norway.

The glucocorticoid replacement therapy has been virtually unchanged since the invention of cortisone 60 years ago. Studies in patients with primary adrenal insufficiency have indicated increased mortality and unfavourable metabolic effects such as reduced bone mineral density, and evidence has accumulated that these patients suffer from reduced health-related quality of life (HRQoL). Although these endpoints possibly relate to inappropriate glucocorticoid therapy, the impact of glucocorticoid replacement regimens has been little studied. Furthermore, the source of the large interindividual variation in treatment effect is largely unknown and needs to be addressed. We will discuss how to evaluate the patient with adrenal insufficiency and a practical approach to the treatment. Recent developments in glucocorticoid replacement therapy such as modified-release formulations and subcutaneous hydrocortisone infusion will be presented.

To whom to offer genetic analysis in patients with pituitary adenoma
Beckers Albert
University of Liège, Liège, Belgium.

Genetic predisposition to pituitary adenomas is increasingly recognized and extends beyond diseases such as MEN1 and Carney complex to familial isolated pituitary adenomas (FIPA). A genetic predisposition occurs in >5% of all pituitary adenoma cases, with MEN1 and FIPA comprising the vast majority of these. The identification of the AIP gene as a predisposition gene for pituitary adenomas in 15–25% of FIPA kindreds and in a significant number of young patients with macroadenomas has stimulated much debate about familial screening and early diagnosis. In addition the MEN1-like (MENX or MEN4) caused by germline CDKN1B mutations adds to the complexity of testing choices. Clearly a systematic evaluation of familiarity and associated diseases in patients with pituitary adenomas would be helpful for clinical endocrinologists and geneticists alike.

Screening guidelines are already in place for MEN1 and the clinical features and associations of MEN1 related diseases are well established. Pituitary tumors in Carney complex are a less common disease manifestation that occur generally within the setting of more clearly diagnostic extra-pituitary manifestations. AIP mutation-related pituitary adenomas are characterized by an early onset (50% before the age of 18 years) and a large predominance of somatotropinomas (80%) followed by mixed GH/PL-like-secreting tumors, prolactinomas, and non-secreting adenomas. These tumors are usually large at diagnosis and appear to be more frequently resistant to pharmacological treatment. Based on the demonstrated clinical characteristics of AIP mutation-related pituitary adenoma patients, it is reasonable to systematically assess FIPA kindreds for AIP mutations. Similarly, patients with apparently sporadic aggressive adenomas diagnosed at age <30 years is a clinically well-delineated population that is enriched for AIP mutation positive cases Children with pituitary adenomas should be assessed for AIP mutations and consideration given to MEN1 testing also. In the case of AIP mutations, the risk for unaffected mutation carriers remains unclear. A pragmatic approach would be to offer regular hormonal assessments and an initial MRI; the optimal interval for follow up surveillance remains to be determined.


diabetes and the genome: any use for our patients?
A M Wagner1,2
1Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain; 2Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

The study of the genetics of diabetes, in its different forms, has produced a huge amount of data only very recently and new information is becoming available as this text is being written. The question, at this time, is: are they any good to our patients? As the study of the genetics of a disease progresses, one would expect several clinical applications, the most obvious being improved prediction and diagnosis, as well as tailored treatment of the disease. In diabetes, some of these expectations have been met already and more should be met in the future. This discussion will focus on what is currently available and its clinical relevance. Monogenic diabetes represents the paradigm of clinical applications of genetic information. Although rare as a whole, certain clinical features should make us suspect this diagnosis, with important implications for the patient. This is especially true for neonatal diabetes and beta-cell defects due to mutations in HNF1A and GCK, where identification may have a huge impact on the choice and effectiveness of treatment. Our main challenge now, as clinicians, is to identify these patients and offer the best treatment available. Non-genetic measurements are being developed to optimise patient selection and genotyping strategy and new whole-genome genotyping methods will soon provide a more efficient diagnosis.

Type 1 diabetes (T1D) is characterised by auto-immune destruction of beta-cells, which leads to the dependence on insulin to survive. Most genes associated with T1D play a relevant role in immune response. HLA, the major gene/region, explains about half of the genetic risk for developing the disease, and high-risk HLA haplotypes are currently being used to select individuals for diabetes prevention trials. Type 2 diabetes (T2D) is characterised by a combination of beta-cell failure and insulin resistance, often associated with increasing age, inactivity and obesity. The identification of genetic variants influencing disease predisposition have highlighted the importance of beta-cell failure in the pathogenesis of this disease and will probably have an impact on the design of new treatments and preventive measures in the future. The second main potential application of the genetics of T2D, prediction of disease risk for a given individual, is not ready for clinical application yet, though recent studies show promising results.

Transgenic animals in endocrinology
Muurvi Poutanen
University of Turku, Turku, Finland.

Mice have been used as a model system in biomedicine for several decades. As mammals their relevance to human endocrinology is substantially greater than...
many other model systems such as flies, worms and yeast. Mice are also easily adapted to various experimental conditions with human relevance. Most importantly, the mouse genome is well annotated, it can be precisely engineered by several powerful ways, and international consortia have recently produced variety novel tools for efficiently manipulate the mouse genome (http://www.knockoutmouse.org/). By applying these tools a growing number of genetically modified (GM) mice have been produced, providing novel information about the endocrine regulation of organ systems and new insight on the molecular mechanisms of actions of reproductive hormones. It is well recognized that the function of numerous of genes and their protein products have been finally resolved using GM mouse models, while several of hypotheses drawn by studies in vitro have failed when tested in whole organisms. Endocrinology, with several organ system interactions, in particular, is a research area where models in vivo are of great importance.

As the possibilities to carry out clinical research on endocrine systems in humans are limited, we need novel experimental approaches. For this, GM mice provide excellent opportunity. The techniques applied in analyzing endocrine function GM male mice include, among others, the analysis of macroscopic anatomy and histology of endocrine glands and target organs at various ages, assessment of reproductive performance and behaviour, analyses of hormones and their receptors, and analyses of the signalling pathways potentially affected. Carrying out the analyses at different periods of life, representing differentiation, development, maturation and involution allow us to obtain a global view about the putative changes in the endocrine functions during the life span. However, there are also significant differences in the structure and functions of the endocrine systems between mouse and human, and these differences are to be acknowledged when mouse models are applied.

---

**MTE24**

**Stem cell biology**

Clara Alvarez

Department of Physiology, University of Santiago de Compostela, Santiago, Spain.

Cell therapy with Embryonic, Adult or iPSS Stem cells? As knowledge and scientific data start to increase the answer to that question seems still far away. Although all of them have in common their pluripotenciality and their infinite growth in vitro, the physiological regulation of stem cells in vivo is not really defined. Embryonic stem cells isolated from different steps from the initial embryonic development present in culture some different properties. New studies need to be performed to clarify the importance and deepness of that heterogeneity.

We know that adult stem cells remain organized in a delicate structure called the stem cell niche. The concept of niche includes aside from the stem cells organized in a characteristic way, vascular, neural and stromal support. There are known a few niches in the body but not all have been described with similar characteristics. The niche is an essential part in the recruitment of the stem cells and also can be affected by disease. Thus it is important to study in detail the biology and physiological regulation of the niche. Recently, the role of oxygen in the regulation of the stem cell niche has been highlighted. It is also under discussion if the asymmetric division of stem cells is a rule or if they usually divide symmetrically either as stem cells or getting differentiated into progenitors.

In the endocrine organs, the pituitary and the testes present a well localized niche that seems to share some characteristics. Among them the organized expression of the RET/GFRα receptors and its ligands. We do not know if they could be markers of ectodermic stemness or be common to all stem cells. But they are useful for technical isolation of the stem cells.
Oral Communications
OC1.2 – ESE Young Investigator Award

Smoking habits and early pregnancy thyroid hormone and antibody levels

T Männistö1,2, A Ruokonen3, H-M Surel1, A Bloigu4, M Vääräsmäki5, A Pousta6, M-R Järvelin7,8, A-L Hartikainen4 & Eila Suvanto4
1Department of Clinical Chemistry, University of Oulu, Oulu, Finland; 2Department of Obstetrics and Gynaecology, University of Oulu, Oulu, Finland; 3Institute of Health Sciences, University of Oulu, Oulu, Finland; 4National Institute for Health and Welfare, Oulu, Finland; 5Department of Epidemiology and Biostatistics, Imperial College London, London, UK.

Introduction

Pregnancy is a stress test on maternal thyroid and pregnant women may be more susceptible to thyroid dysfunction. Consequences of this may be harmful for the mother and fetus. Smoking has been associated with alterations in thyroid hormone concentrations, but little knowledge exists on this association in pregnant women.

Subjects and methods

The study population is large, prospective population-based Northern Finland Birth Cohort 1986 (n=19062), with extensive data throughout gestation. Mothers underwent serum sampling in early pregnancy. Samples have been assayed for TSH, free thyroxine (fT4), free triiodothyronine (fT3), thyroid-peroxidase and thyroglobulin antibodies (n=5805). Mothers with thyroid dysfunction diagnosed before or during pregnancy were excluded. Smoking status of mothers and fathers were asked by questionnaires during pregnancy. Subsequent maternal morbidity to hypothyroidism 20 years after the index pregnancy was evaluated using national registers.

Results

Mother who smoked before pregnancy or during its first trimester had higher FT4 (P<0.041) and lower FT3 (P=0.023) concentrations than non-smokers. Smoking in second trimester was associated with lower TSH (P=0.021) and higher FT4 (P<0.001) concentrations, but no difference in FT3 concentrations compared to non-smokers. Cessation of smoking during pregnancy did not improve maternal thyroid hormone status. Thyroglobulin antibodies were less common among smoking than non-smoking mothers (2.5 vs 4.7% respectively, P<0.001), but the prevalence of thyroid-peroxidase antibodies was similar. Risk for subsequent hypothyroidism of the mother was similar among smokers and non-smokers. Paternal smoking did not have an independent effect on maternal early pregnancy thyroid hormone/antibody concentrations.

Discussion

Smoking during pregnancy was associated with alterations in thyroid hormone concentrations which may be due to smoking-induced changes in peripheral metabolism of thyroid hormones. Smoking may therefore render the diagnosis of thyroid dysfunction in pregnant women even more difficult. Along with other known health risks, smoking affects maternal thyroid function, providing more weight to cessation of smoking.

Endocrine Abstracts (2011) Vol 26
OC1.4
Results of 1,13-dichloro-diphenyl-dichloroethane (DDD) treatment in 76 patients with Cushings disease
C Baudry1, 2, J Coste1, R Bou KHALI3, L Guignat1, H Abbass4, J Guibourdenc-bre4, S Silvera5, X Bertagna1, and J Bertherat1, 6
1Centre of Reference des Maladies Rares de la Srrnalerne and Service d’Endocrinologie, Hopital Cochin, Assistance Publique Hopitaux de Paris, Faculte de Medecine, Universite Paris Descartes, Paris, France; 2Unit de Biostatistique et Epidemiologie, Hopital Cochin, Assistance Publique Hopitaux de Paris, Faculte de Medecine, Universite Paris Descartes, Paris, France; 3Service de Toxicologie, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France; 4Service de Hormonologie, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France; 5Institut National de la Sante et de la Recherche Medicale Unite 567, Paris, France.

Introduction
Alternative to transphenoidal pituitary surgery (TSS) may be required in Cushings disease (CD), as first or second line treatment. 1,13-dichloro-diphenyl-dichloroethane (DDD) has a potent anticoagulical action. Its place in CD treatment is not well defined. The aim of this study was to further evaluate the efficacy and tolerance of DDD in CD.

Patients and methods
Seventy-six patients treated with DDD out of a single center cohort of 219 patients with CD diagnosed between 1993 and 2009 were retrospectively studied. Remission was defined as normalization of 24-h urinary cortisol (24 h-UC). Remission, recurrence and time-to-event were estimated by the Kaplan–Meier method, and potential predictors analyzed using Cox’s proportional hazards regression models.

Results
Remission was achieved in 48 (72%) patients, with a median time of 6.7 months (5.2-8.2, 95% confidence limits). Plasma DDD (mean±s.d.) at the time of remission was 10.5 μg/ml ±8.9, with a mean daily dose of 2.6±1.1 g. A negative linear relationship was observed between plasma DDD and 24-h UC (P<0.0001). Intolerance leading to treatment discontinuation occurred in 19 patients (29%). Recurrence after drug cessation occurred in 71% of patients, with a median time of 13.2 months (5.0-67.9, 95% confidence limits). Only high plasma DDD out of a single center cohort of 219 patients with CD diagnosed between 1993 and 2009 were retrospectively studied. Remission was defined as normalization of 24-h urinary cortisol (24-h UC). Remission, recurrence and time-to-event were estimated by the Kaplan–Meier method, and potential predictors analyzed using Cox’s proportional hazards regression models.

Conclusion
DDD is useful at different steps of CD management, either as first line when pituitary adenoma is not visible or because of the severity of hypercortisolism, or as a second line after TSS failure or recurrence, with most often easily manageable side effects. Monitoring of plasma DDD allows dosage adaptation to optimize hormonal control together with drug tolerance.

OC1.5
Adrenal crisis and general morbidity in chronic adrenal insufficiency prospectively assessed in 472 patients
Stefanie Hahner1, Christina Spinelli1, Felix Beuschlein2, Martin Fassnacht3, Katharina Lang1, Marcus Quinkler2, and Bruno Allolio1
1Department of Endocrinology, University of Würzburg, Würzburg, Germany; 2Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine, Berlin, Germany; 3Department of Endocrinology and Metabolism, Medizinische Klinik-Innenstadt, University Hospital Munich, Munich, Germany.

Adrenal crisis (AC) is a life threatening condition in chronic adrenal insufficiency (AI). Furthermore, recent data demonstrate increased mortality in this patient group.

Incidence and causes of adrenal crisis as well as general morbidity and hospitalization was assessed in 472 patients in a prospective trial. Patients were contacted via mail every 6 months and in case of AC additionally by phone to evaluate the exact circumstances of AC. Criteria for AC were predefined as no commonly accepted definition exists and grading of severity was additionally performed.

Nine hundred and twenty-three patients were contacted, 472 patients (52% primary AI, 48% secondary AI) sent questionnaires and 381 patients completed the full 2 year study period, covering 815 patient years. Five hundred and thirty cases of acute clinical impairment were reported, 62 fulfilled our predefined criteria of AC, resulting in a frequency of 7.6 per 100 patient/years, which is high compared to results from previous retrospective analyses. 65.5% were treated as inpatients (grade II), with 9.5% receiving intensive care (grade III). Two patients died during the study period in the context of AC. Main precipitating factor was infectious disease (39% of cases), but also psychic distress, neglected hydrocortisone intake, strong pain, heat and other factors were reported. Ninety-five percent of patients possessed an emergency card but only 28% were equipped with an emergency set. Patients at work demonstrated a mean absence from work of 16 days per year. 12.7% of participants reported additional hospitalization for other reasons than AI.

In this prospective study, we demonstrate that despite patient education and established glucocorticoid replacement patients are at a substantial risk to experience AC which has been fatal in 3%. This demonstrates that there is still a need of improved strategies for prevention of AC, e.g. frequently repeated patient education and broader distribution of emergency sets.

OC1.6
Increased risk of infections in patients with Addison’s disease
L C C J Smans1, P C Souverein*, H G M Leufkens1, I M Hoepelman1 & P M Zelissen2
1UMC Utrecht, Utrecht, The Netherlands; 2Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, The Netherlands.

Context
Previous studies have suggested that infections are an important cause of death in patients with Addison’s disease, but epidemiological studies on the frequency of infections in this population are scarce.

Design and setting
We conducted a cohort study, using data from the Dutch PHARMO record linkage system, linking patients’ demographics and medical histories to the use of prescription drugs, diagnostic and therapeutic data from hospital and general practitioner records.

Participants
From a cohort of oral glucocorticoid users, 390 patients with Addison’s disease were identified by assessing concurrent use of glucocorticoids and mineralocorticoids using pharmacy dispensing records. A reference cohort (n=1933) with the same age and sex distribution was sampled from patients not using glucocorticoids.

Outcome measure
Incidence rates and incidence rate ratios (IRR) of infectious events and hospital admission for infection.

Results
The risk of infectious episodes among patients with Addison’s disease was 1.5 times higher compared to controls, yielding an overall incidence rate of 59.2/100 person-years, with a crude IRR of 1.61 (95% CI 1.51–1.72). The IRR decreased slightly to 1.58 (95% CI 1.47–1.70) after adjustment for confounding co-medication and -morbidity. Regarding hospital admission for infection we also found higher rates among Addison patients (3.8/100 person-years versus 0.8/100 person-years) with a crude and adjusted IRR of respectively 5.02 (95% CI 3.66–6.87) and 4.34 (95% CI 3.04–6.22).

Conclusion
Patients with Addison’s disease had an increased risk of infectious events and hospital admissions related to infection.

NEUROENDOCRINOLOGY
OC2.1
Etoposide, doxorubicin, cisplatin, and mitotane versus streptozotocin and mitotane in adrenocortical carcinoma: preliminary results from the first international phase III trial: the FIRM-ACT study
Martin Fassnacht1, Massimo Terzolo2, Bruno Allolio1, Eric Baudin3, Harm Haak4, Alfredo Berruti2, Hans-Helge Mueller5 & Britt Skogseid6
1University Hospital Würzburg, University of Würzburg, Würzburg, Germany; 2University Hospital Orbassano, University of Turin, Turin, Italy; 3Institute Gustave-Roussy, University of Paris Sud Villejuif, Paris, France; 4Maxima Medical Centre, Eindhoven, The Netherlands; 5University of Munich, Munich, Germany; 6Uppsala University Hospital, Uppsala, Sweden.

Background
No randomized trials have been conducted in adrenocortical carcinoma (ACC) patients. Treatment recommendations for this rare but aggressive disease have been based on data from small phase II trials. We have now performed the first
randomized phase III trial, comparing etoposide, doxorubicin, cisplatin, plus mitotane (EDP-M) against streptozotocin plus mitotane (Sz-M).

Methods

Three hundred and four chemotherapy-naïve patients with ACC not amenable to radical surgery were randomly assigned to receive either EDP-M or Sz-M until progression. In case of progression, the alternative regimen was offered to the patient. The primary endpoint was overall survival. Key secondary endpoints were time to progression and response to second line therapy.

Results

One hundred and fifty-one patients randomized to EDP-M as first-line treatment received 608 cycles (scheduled every 28 days) and 153 patients received 608 cycles (scheduled every 28 days) and 153 patients in the Sz-M group (107 and 124 deaths, respectively) were 14.8 and 12.0 months, respectively (HR 0.79, 95% CI, 0.61 to 1.02, P = 0.069). Median time to progression was 5.0 vs 2.1 months (HR 0.54, 0.42 to 0.68, P < 0.001). Patients treated with EDP-M after failure of Sz-M (n = 83) had a median time to progression of 6.2 months. In contrast, time to progression in 75 patients treated with Sz-M as second line was only 2.1 months. In both groups, patients pretreated with mitotane had a similar outcome compared to mitotane-naïve patients.

Conclusions

Although a trend towards better overall survival in patients with advanced ACC treated with EDP-M as first-line therapy was observed, overall survival was not significantly different between groups. However, EDP-M significantly prolonged time to tumor progression compared with Sz-M. Thus, new treatment regimens for advanced ACC should be tested against EDP-M.

Gonadotropin responses to kisspeptin are modulated by changes in aminoacidergic and neuropeptidergic neurotransmission: studies in peripheral male rats

R Pineda1, F Ruíz-Pino1, D García-Galiano1,2, M A Sanchez-Garrido1,2, M Romero1, J M Castellano1,2, L Pinilla1,2 & M Tena-Sempere1,2

1University of Cordoba, Cordoba, Spain; 2CIBERObn, ISCiii, Cordoba, Spain.

Introduction

Kisspeptins, the products of the Kiss1 gene that act via the receptor, GPR54 (or Kiss1R), are pivotal elements in the neuroendocrine control of GnRH neurons and, thereby, gonadotropin secretion. Extensive efforts have been devoted recently to elucidate the pharmacological effects and major putative regulators of the kisspeptin system. Yet, our knowledge on the potential interactions of kisspeptins with other key neurotransmitters involved in the central regulation of the gonadotropin axis remains superficial.

Design

We present herein a series of hormonal analyses addressing the impact of pharmacological manipulations (either activation or inactivation by the use of suitable agonists or antagonists) of major central aminoacidergic (glutamate, GABA) and neuro-peptidergic (neurokinin-B, dynorphin) pathways on the patterns of gonadotropin responses to kisspeptin-10 (Kp-10) in peripheral male rats.

Results

Blockade of ionotrophic glutamate receptors decreased (to a variable extent) LH responses to a sub-maximal dose of Kp-10, whereas activation of both isotropic and metabotropic receptors, which enhanced LH release per se, failed to evoke further increases in LH responses to Kp-10. Conversely, selective activation of GABA-A receptors decreased Kp-evoked LH secretion, while central inhibition of GABA-A transmission elicited robust LH secretory peaks, and protracted responses to Kp-10 when combined with GABA-B receptor blockade. In addition, antagonization of dynorphin (K-opiod) receptors enhanced LH responses to Kp-10, while activation of dynorphin or NKB signaling evoked mild inhibitory effects in peripheral male rats.

Conclusion

Our present data document the roles of glutamate-, GABA-, dynorphin- and NKB-neurotransmission as putative modifiers of gonadotropin responses to kisspeptin. These studies, together with on-going analyses of gonadotropin secretory profiles following activation or inactivation of aminoacidergic and neuropeptidergic pathways in models of genetic or pharmacological blockade of kisspeptin signaling, will aid to dissect out the central interactions and eventual hierarchy of different neuroendocrine pathways with key functions in the control of the gonadotropin axis.

Distribution of serotonin transporters in the human hypothalamus

A J Borgers, P H Bisschop, E Fliers & A Alkemade

Department of Endocrinology and Metabolism, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

Background

Serotonergic signalling has been implicated in numerous hypothalamic functions including circadian rhythmicity, feeding and the modulation of neuroendocrine systems. In spite of the importance of these functions, the neuroanatomy of the serotonergic system in the human hypothalamus is still unknown.

Aim and methods

To increase insight in hypothalamic serotonin signalling in humans, we investigated the distribution of serotonin transporters (SERT) by means of immunohistochemistry, using a monoclonal antibody raised against human SERT. The distribution of SERT immunoreactivity was systematically examined over the entire rostro-caudal axis in each 50th μm coronal section of six post-mortem human hypothalami (Netherlands Brain Bank).

In addition, we performed immunofluorescent double-labelling of SERT with respectively the neuropeptides VIP, AVP, NPY, AgRP and nMSh to identify cell types showing basket-like staining of SERT-immunoreactive fibers.

Results

SERT-immunoreactivity was ubiquitously expressed in fibers throughout the hypothalamus. A dense track of fibers was seen in the perifornical area and in close proximity to the anterior commissure. The ependymal lining of the third ventricle showed also strong SERT-immunoreactivity.

The suprachiasmatic nucleus and infundibular nucleus contained a high density of SERT-immunoreactive fibers. Clusters of SERT-immunoreactive fibers outlining capillaries and basket neurons were present in these areas, highly suggestive of synaptic endings. A minority of these basket cells were VIP-, AVP-, NPY-, AgRP- and nMSh-immunoreactive.

Conclusion

We report the distribution of SERT in post-mortem human hypothalami. The strong immunoreactivity in the suprachiasmatic and infundibular nucleus suggests a modulatory role for serotonin in a number of hypothalamic functions including circadian rhythmicity and the regulation of feeding behaviour.

Genetic and molecular cytogenetic investigations in Turner syndrome patients with spontaneous pubertal development

R Rossetti1,2, C Castronovo2, C Cacciatore1,2, D Rusconi2, V Calcaterra3, P Finelli2, D Latzza1, L Persani1,2

1Dipartimenti di Scienze Mediche e di Biologia e Genetica, Università degli Studi di Milano, Milan, Italy; 2IRCCS Istituto Auxologico Italiano, Milan, Italy; 3Dipartimento di Pediatria, Università di Pavia, Pavia, Italy.

Spontaneous puberty occurs in a subset of Turner syndrome (TS) patients with significant 45,X/46,XX mosaicism. This observation leads to the belief that haploinsufficiency of still unidentified genes on the X chromosome is the cause of the accelerated follicle atresia in TS. Examination of particular X chromosome rearrangements/deletions led to the identification of 2 Xq and 1 Xp loci associated to the ovarian defect in TS. The availability of new generation genetic and cytogenetic investigations leads us to reexamine this issue on 39 TS patients aged 12–46 years. Spontaneous menarche (SM) was registered in 6 of them and 33 had primary amenorrhea (PA). Conventional techniques assigned the 45,X karyotype to 2/6 with SM and 28/33 with PA. Array CGH analysis was performed on blood DNA of 6 SM cases and 6 PA, used as negative controls, and revealed the unique case of a 45,X TS woman with SM harboring a duplication containing entirely the only BMP15 gene. The BMP15 duplication was confirmed by FISH analysis and Taqman RT-PCR excluded significant 45,X/46,XX mosaicism in vaginal and buccal epithelia. Interestingly, this 45,X TS patient with a double dose of the only BMP15 gene had regular menses for > 4 years. Array CGH and FISH analyses revealed the presence of mosaicism at variable levels in the other 5 TS cases with SM and at very low levels (1–10%) in those with PA, including those previously karyotyped as 45,X. Therefore, our data indicate that likely all TS patients are indeed mosaics but only those with a 46,XX cell line above 10% in circulating leukocytes are likely to have spontaneous puberty. A double dose of the only BMP15 gene at Xp11.2 appears sufficient to support spontaneous menarche in a TS patient, but double dose of other X-linked genes is indeed required to sustain prolonged ovarian function.


**OC2.5**

**Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperparathyroidism**

G Trifirò1,2, M Moldolesi1, J Dielemann1, E van Soest1, G Mazzaglia1, R Herings1, C de Luise3, D Ross4, G Brusselle3, A Colao5, W Haverkamp5, R Schade1, G van Camp1, R Zanetti11,12 & M Sturkenboom3

1Erasmus Medical Center, Rotterdam, The Netherlands; 2IRCSS Centro Neurolesi Bonino-Pulejo, Messina, The Netherlands; 3Health Search, Florence, Italy; 4PHARMO Institute, Utrecht, The Netherlands; 5Pfizer Inc., New York, New York, USA; 12University of Ghent, Gent, Belgium; 3Federico II University, Naples, Italy; 4Universitätsmedizin Berlin, Berlin, Germany; 5UZ Brussel, Brussels, Belgium; 11Istituti Clinici di Perfezionamento, Milan, Italy.

**Background**

There is growing evidence that ergot dopamine agonists (DA) may induce cardiac valve regurgitation (CVR) in persons with Parkinson’s disease (PD). It is unclear whether the CVR risk is increased with ergot-DA use in persons with hyperparathyroidism, in whom the dose is much lower.

**Objective**

To assess the association between ergot and non-ergot DAs and CVR in patients with hyperparathyroidism and PD.

**Methods**

Nested case–control studies were separately conducted in two cohorts: i) DA-naïve patients and new users of DA with hyperparathyroidism; ii) PD patients who were newly treated with DA or Levodopa. The cohorts were identified from three general practice databases in Europe: THIN (UK), Health Search (Italy) and IPCI (NL). Cases of CVR were manually validated and matched to controls on age, gender, index date and database. Relative risks and 95% confidence intervals (CI) of CVR were estimated through conditional logistic regression for different DAs using non-use as reference in hyperparathyroidism cohort and levodopa in PD cohort.

**Results**

In the cohort of 21 044 patients with hyperparathyroidism, 37 cases of CVR were identified but no association between individual Ergot DAs and CVR was observed. In the cohort of 19 656 PD patients, 85 incident cases of CVR were identified during follow-up. Compared to levodopa the class of ergot-DAs was associated with CVR. Among individual drugs only cabergoline was associated with significantly increased risk of CVR (OR: 4.6; 95% CI: 2.4–8.8).

**Conclusions**

Increased risk of CVR was confirmed in PD patients who were treated only with ergot-DAs, mostly due to cabergoline. On the other hand, ergot-DA use in patients with hyperparathyroidism was not associated with increased risk of CVR.

---

**OC2.6**

**The spectrum and causes of gonadal dysfunction in adolescents and adults with Prader–Willi syndrome (PWS)**

Talia Eldar-Geva1, Harry J Hirsch1, Fortu Benarroch1 & Varda Gross-Tsur1,2,3

1Shaare-Zedek Medical Center, Jerusalem, Israel; 2The Hebrew University, Jerusalem, Israel.

**Introduction**

Hypogonadism is a cardinal feature of PWS and was generally attributed to hypothalamic dysfunction. Recently, however, primary gonadal defects were also documented. We characterized the spectrum and causes of hypogonadism in PWS adolescents and adults.

**Methods**

We measured reproductive hormonal profiles of 19 males (m) and 16 females (f) ages 15 to 32 years with genetically confirmed PWS. Puberty was assessed by Tanner staging; blood was sampled for gonadotropins, sex-steroids and the gonadal-specific peptides, inhibin B (INB) and anti-Mullerian hormone (AMH).

**Results**

We found four distinct hormonal profiles based on INB and FSH levels: Group A (m/f; 8:1): hypogonadotropic (primary gonadal) hypogonadism with elevated FSH levels (>15 IU/L) and undetectable inhibin B. Group B (m/f; 4:4): hypogonadotropic hypogonadism with FSH <0.5 IU/L and inhibin B <7 pg/mL. Group C (m/f; 3:5): partial gonadal and hypothalamic function with inhibin B >20 pg/mL and FSH >10 IU/L. Group D (m/f; 4:6): mild hypogonadal and severe gonadal dysfunction (FSH >0.5–10 IU/L and INB <20 pg/mL). There were significantly more males in Group A versus C or D (P<0.05). Mean breast Tanner stage and testosterone levels were highest in Group C (P<0.03), mean LH was highest in Group A (P<0.001), and mean AMH was highest in Group B (P<0.005). No differences were found in genetic subtype, age and BMI among the four groups.

**Conclusion**

We characterized four distinct phenotypes of hypogonadism in PWS ranging from primary gonadal to hypothalamic hypogonadism; the minority had gonadotropin deficiency. Determining individual reproductive hormone patterns, including inhibin B, may be important for assessing the possibility of fertility in women and for recommending the need for contraception or hormonal replacement therapy.

---

**Bone/Reproduction**

**OC3.1**

**Mild hyponatremia as a risk factor for fractures: the Rotterdam study**

E J Hoorn, F Rivadeneira, J B J van Meurs, G Ziere, B H Ch Stricker, Albert Hofman, Huibert Pols, R Zietse, A G Uitterlinden & M C Zillikens

**Introduction**

Recent studies suggest that mild hyponatremia is associated with fractures, but prospective studies are lacking.

**Aim**

Our aim was to study whether hyponatremia is associated with fractures, falls and/or bone mineral density (BMD).

**Methods**

Five thousand two hundred and eight elderly men and women with serum sodium assessed at baseline were included from the prospective, population-based Rotterdam Study. The following data were analyzed: BMD, vertebral fractures (at baseline and after mean follow-up of 6.4 years), non-vertebral fractures (mean follow-up of 7.4 years), recent falling, co-morbidity, medication, and mortality.

**Results**

Hyponatremia was detected in 399 subjects (7.7%, 133.4 ±2.0 mmol/l). Subjects with hyponatremia were older (73.5 ±10.3 vs 70.0 ±9.0 years, P<0.001), had more recent falls (23.8 vs 16.4%, P<0.01), higher (type 2 diabetes mellitus prevalence (22.2 vs 10.3%, P<0.001), and more often used diuretics (31.1 vs 15.0%, P<0.001). Hyponatremia was not associated with BMD, but was associated with increased risk of incident non-vertebral fractures (HR =1.39, 95% CI 1.11–1.73, P=0.004) after adjustment for age, sex and body mass index. Further adjustments for disability index, use of diuretics or psychopharmics, recent falls and prevalent diabetes did not modify results. Subjects with hyponatremia also had increased risk of vertebral fractures at baseline (OR =1.78, 95% CI 1.04–3.06, P=0.037) but not at follow-up, after adjustment for all covariates. Finally, all-cause mortality was higher in subjects with hyponatremia (HR =1.21, 95% CI 1.03–1.43, P=0.022).

**Conclusion**

Mild hyponatremia in the elderly is associated with increased risk of prevalent vertebral fractures and incident non-vertebral fractures but not with BMD.

**OC3.2**

**Changes in serum magnesium levels during cinacalcet therapy for primary hyperparathyroidism**

V Daraki, F Spyrou, E Volanaki, K Stamou, G Kalikakis, E Mamalaki & S Papavasiliou

**Introduction**

Cinacalcet is a calcium-sensing receptor (CaR) agonist that is approved for use in the treatment of primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism (SHPT). The calcium receptor (CaR) participates in Ca^{2+} and Mg^{2+} metabolism at the parathyroid gland and the kidney. Cinacalcet, a calcimimetic, increases the sensitivity of CaR and has been introduced for the treatment of patients with primary hyperparathyroidism (PHPT). However, there are no data for the influence of cinacalcet on serum Mg^{2+} levels in the literature.
Aim

To evaluate the effect of cinacalcet treatment on magnesium levels in patients with primary hyperparathyroidism.

Methods

Sixteen patients, aged 65 ± 11 years with primary hyperparathyroidism receiving cinacalcet therapy were enrolled in the study. Six patients were diagnosed with parathyroid adenoma and ten patients with parathyroid hyperplasia. Median daily cinacalcet dose was 60 mg (range 30–90 mg). Patients were evaluated for a period of 2–8 months. Adverse effects of the drug were reported and serum calcium and magnesium were determined.

Results

During cinacalcet therapy thirty eight percent of patients reported cramps with normal CPK, 12% myalgia, and 12% atrial arrhythmia. Mean serum calcium levels were reduced to the normal range (P < 0.0001) within the first 2 weeks of treatment and remained constant throughout the study in all patients. The reduction was dose-dependent (P < 0.0001). Serum magnesium concentrations were significantly reduced in 14 patients (88%), (P = 0.03). The reduction was also dose-dependent (P = 0.006). In contrast to Ca levels a time-dependent fluctuation of Mg²⁺ at steady state was observed. Ca²⁺ and Mg²⁺ serum levels changes were highly correlated at all doses (r = 0.9; P = 0.037).

Conclusions

Cinacalcet treatment in patients with primary hyperparathyroidism results in normal serum Ca²⁺ levels but reduces the Mg²⁺ serum levels below normal values in the majority of the patients. Hypomagnesemia may cause symptoms like cramps, myalgia, and arrhythmia. It has been stated that activation of the CaR in the thick ascending limb of loop of Henle leads to reduced reabsorption of Ca²⁺ and Mg²⁺ – and activating CaR mutations result in hypomagnesemia in some patients. Cinacalcet is responsible for the reduction both calcium and magnesium levels and may cause the reported adverse effects.

OC3.4

Low doses of bisphenol A promote human seminoma cell proliferation in vitro by activating PKA and PKG via the non classical membrane G protein-coupled estrogen receptor (GPER)

P Fénichel1,2, A Vega1, A Bouskine1, Fr Brucker-Davidi1,2, M Benahmed1, N Chevalier2,3

1UMR INSERM 895, Nice, France; 2University Hospital of Nice, Nice, France.

Fetal exposure to environmental estrogens may contribute to hypofertility and/or to testicular germ cell cancer. However, many of these endocrine disruptors have only a weak affinity for the classical ERs and other mechanisms have been suggested. Bisphenol A, a chemical pollutant, used as monomer to manufacture polycarbonate plastic, released from lining canned food or beverages or from dental sealants, was able to promote human testicular seminoma cell (JKT-1) proliferation in vitro at very low environmental relevant concentrations (10⁻¹⁰ to 10⁻¹² M), (seminoma cells are supposed to derive from germ stem cells (fetal gonocytes or adult undifferentiated spermatogonia). BPA activated both PKA and PKG pathways and triggered a rapid (15 min) phosphorylation of the transcription factor CREB and the cell cycle regulator Rb. This non genomic activation, did not involve classical ERs since it could not be reversed by ICI182780, an ER antagonist, nor reproduced either by E₂ or by DES a potent synthetic estrogen which triggered instead, a suppressive effect. It was only reproduced by E₂ coupled to BSA, unable to enter the cell. As E₂-BSA, BPA promoted JKT-1 cell proliferation through a G protein coupled receptor (GPCR) involving a Gαq and a Gα12/13 subunit as shown by the reversible effect observed by the corresponding inhibitors NF449 and Pertussis toxins. This promoting effect on JKT-1 cells was completely inhibited by G15, a specific antagonist of the G protein coupled estrogen receptor (GPER) (also known as GPR30) and by invalidation of GPER by siRNA and reproduced by G1, a GPER agonist. This GPER-mediated non genomic action represents a new basis for evaluating BPA, which could at low doses and with a high affinity for this GPER, interfere, when crossing the placenta, with the developmental programming of fetal germ cell proliferation and/or differentiation.

OC3.5

IGF1 promotes survival of mast cells and regulates their number in the developing mammary gland

P Ameri1,2, Y Yozgat3, W Ruan2, G Murialdo1, P Besmer4, D Ferone1, D Kleinberg2

1Department of Endocrinological and Medical Sciences, University of Genova, Genova, Italy; 2The Bannie Joan Sachs Laboratory and Neuroendocrine Unit, Department of Medicine (Division of Endocrinology), New York School of Medicine, New York, USA; 3Developmental Biology, Sloan-Kettering Institute, New York, USA.

We found that mast cells were present in pubertal mammary glands, and hypothesized that they participate in mammary morphogenesis and are sensitive to IGF1, which is essential for mammary development.

As independently reported in another model of mast cell deficiency (Developmental Biology 2010 337 124), mast-cell-deficient W/Wv mice had significantly less terminal end buds and ducts and smaller gland areas than controls at 3, 6, and 9 weeks of age (P < 0.01). In 75-day-old oophorectomized Ames dwarf mice (deficient in GH, PRL, and TSH) IGF1 + E2 for 5 days significantly increased the number of tryptase-positive periglandular and stromal mast cells as compared with vehicle (P < 0.01 and < 0.02 respectively). Mast cell increase coincided with mammary development. Mammary cell dependence on IGF1 was confirmed by treatment with pasireotide, which blocks IGF1 action in the mammary gland probably by inducing IGF1 binding protein 5. Pasireotide for 7 days reduced periglandular and stromal mast cell density in 28-day-old intact CD rats (P < 0.02 and < 0.05 respectively), and prevented GH + E2 from increasing mammary mast cell number in hypophysectomized, oophorectomized 28-day-old CD rats (P < 0.02). To determine whether IGF1 also had an effect on mast cells elsewhere in the body, we cultured bone marrow-derived mast cells from C57Bl/6 mice. Formazan-producing viable mast cells were significantly increased in number in response to 100 ng/ml IGF1 added to serum-free culture medium during prolonged serum starvation (P < 0.05 after 24 h and < 0.01 after 48 h), IGF1 effect was associated with activation of the anti-apoptotic AKT/FKB pathway. PQ401, an IGF1 receptor phosphorylation inhibitor, blocked AKT activation and prevented IGF1 from rescuing serum-starved mast cells, while somatostatin-14 had no effect.

OC3.3

Evolution of neurobehavioral and cognitive symptoms in patients with primary hyperparathyroidism belonging to the Swiss primary hyperparathyroidism cohort

A Trombetti1, C Meier2, G Gold3, C Torriani1, C Henzen1, E R Herrmann1, E R Christ1, M Braendle4, M E Kraenzlin5 & R Rizzoli1

1University Hospital, Geneva, Switzerland; 2University Hospital, Basel, Switzerland; 3Kantonsspital, Luzern, Switzerland; 4Kantonsspital, St Gallen, Switzerland; 5University Hospital, Bern, Switzerland.

Objective

To describe the evolution of neurobehavioral and cognitive symptoms in patients with primary hyperparathyroidism as measured by mini-mental state (MMS), Hamilton’s anxiety and depression scale (HADS) and Clock tests. Scores were also compared with biochemical data.

Methods

The Swiss primary hyperparathyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional national project collecting clinical, biochemical and outcome data in patients with PHPT. Newly diagnosed patients were enrolled. All three tests applied were interpreted centrally. Thereafter, follow-up data were recorded every 6 months as recommended by the NIH guidelines at the time of study onset. The tests were re-administered on a yearly basis. Patients with parathyroidectomy had one follow-up visit 3 to 6 months after surgery. We applied a multiple regression model comparing test results with serum calcium, serum parathyroid hormone (PTH) and serum 25-hydroxyvitamin D, adjusting for age and gender.

Results

From June 2007 to December 2010, 253 patients (mean age 68.8 ± 14.5 years; 77.5% female) were included. To avoid the effect of age, we limited our analysis to the 100 subjects aged 65 years old and less. Fifty-one had completed at least one of the neuropsychological tests. We found a positive correlation between PTH levels and the HADS anxiety scores (r = 0.23, P = 0.01) and a negative one with MMS scores (r = -0.13, P = 0.03). A Wilcoxon matched-pairs signed-rank test showed an improvement in MMS (P = 0.04), anxiety (P = 0.01) and depression (P = 0.02) scores in the 16 operated patients.

Conclusion

The severity of PHPT as evaluated by serum markers is correlated with impaired cognitive functions, increased anxiety and depression. These alterations may be reversible upon treatment by parathyroidectomy.
Our results support that mast cells are involved in mammary development. They further suggest that growth of mammary mast cell may depend, in part, on IGF1.

OC3.6 – ESE Young Investigator Award
Materno-fetal cardiovascular complications in Turner syndrome after oocyte donation: a French multicenter retrospective study

N Chevalier1, D Lelannou1, H Letur3, D Cornet2, C Chalas-Boissom3, R Frydman1, J Ohl1, Th Greck4, A Papaxanthos-Roche6, M C Dulucq6, M L Coat1, J L Cedrin-Durnerin1, J L Pouly1 & P Fenichel1

1University of Nice, Nice, France; 2Institut Mutualiste Montsouris, Paris, France; 3University of Rennes, Rennes, France; 4CHU Tenon, Paris, France; 5CHU Tours, Tours, France; 6AMP Jean Verdier, Bondy, France; 1CHU Clermont-Ferrand, Clermont-Ferrand, France; 2CHU Nice, Nice, France.

Context
Recombinant human GH treatment and oocyte donation (OD) have improved the quality of life in women with Turner syndrome (TS). However, life expectancy is reduced, mainly due to cardiovascular complications. Pregnancy may itself increase that risk and be associated with hazardous materno-fetal outcome.

Objective
The objective of this study was to evaluate the materno-fetal outcome of ongoing pregnancies beyond 20 weeks of gestation obtained by OD in TS.

Design
This was a multicenter retrospective study including all assisted reproductive technology centers affiliated with the French Study Group for Oocyte Donation.

Results
Among 93 patients, only 37.6% were prescreened with echocardiography or thoracic magnetic resonance imaging. Maternal outcome was dominated by 37.8% of pregnancy-associated hypertensive disorders including preeclampsia in 54.8% and severe eclampsia in four patients. Prematurity occurred in 38.3% and 37.8% of pregnancy-associated hypertensive disorders including preeclampsia in 93% of the population.

Conclusions
Among 93 patients, only 37.6% were prescreened with echocardiography or thoracic magnetic resonance imaging. Maternal outcome was dominated by 37.8% of pregnancy-associated hypertensive disorders including preeclampsia in 54.8% and severe eclampsia in four patients. Prematurity occurred in 38.3% and 37.8% of pregnancy-associated hypertensive disorders including preeclampsia in 93% of the population.

Diabetes/Thyroid
OC4.1
Obestatin improves in vitro generation of novel insulin and glucagon secreting islet-like cell clusters from islet-derived non differentiated cells

A Baragli, C Grande, M Taliano, F Settanni & R Granata
University of Torino, Torino, Italy.

Introduction
The obestatin gene products ghrelin and obestatin (Ob) protect mice from STZ-induced β-cell death, inflammation and STZ-induced diabetes. A possible effect is ghrelin/Ob-induced regeneration of damaged β-cell population through the recruitment of pancreatic progenitor cells (PPC). We hypothesized that Ob affects proliferation and endocrine commitment of PPC within the islets of Langerhans. Methods

Islets of Langerhans were isolated from pancreas of 6 months old mice and plated for enrichment. Enriched islets were cultured to permit adhesion and stimulate islet-derived cell proliferation (emersion phase). Part of these islets were chronically treated with 40 nM Ob. After a week, culture medium was changed into a serum-free medium supplemented with leukemia inhibitory factor and fibroblast growth factor 2 to allow proliferation of undifferentiated cells. The expression of staminal and endocrine markers was studied for the next 15 days. During this period cells proliferated (proliferation phase) and aggregated into islet-like cell clusters (ILCC) (differentiation phase).

Results
During the proliferation phase Ob-treated cells expressed more Ngn3 with respect to controls. At the end of the differentiation phase Ob-ILCC expressed higher levels of insulin and glucagon. Furthermore, glucose-induced insulin release was increased. Ob effect depended on its modulation of specific signalling molecules essential to endocrine pancreas development.

Conclusions
Ob efficiently stimulated islet-derived cell proliferation and precursor cell differentiation into novel insulin and glucagon secreting ILCC. Thus, in vitro Ob might ameliorate diabetic conditions through stimulation of PPC. Ob may also improve in vitro islet generation for transplantation purpose.

OC4.2
Hepatic insulin resistance in rats on free-choice high-fat diets

C Diepenbrock1, L Eggels1, M T Ackermans2, E Fliers1, M J M Serlie1, A Kalsbeek1 & S E la Fleur1
1Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands; 2Laboratory of Endocrinology, Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands.

Background
Recently, we showed that rats on a free-choice high-fat high-sugar (fcHFHS) diet became rapidly obese and developed glucose intolerance within a week. Interestingly, rats on a free-choice high-fat diet (fcHF), although equally obese and hyperphagic as rats on a fcHFHS diet, did not develop glucose intolerance. Glucose tolerance was also unaffected in rats on a free-choice high-sugar diet, although they consumed more liquid sugar than rats on a fcHFHS diet. Hence, the diet-induced glucose intolerance is specific for rats on a fcHFHS diet. We investigated whether changes in (hepatic) insulin sensitivity contribute to the observed glucose intolerance.

Methods
Male Wistar rats received a jugular vein and carotid artery catheter. After recovery, rats were subjected to either a fcHFHS diet, a fcHF diet or a chow (control) diet for one week. We subsequently performed a hyperinsulineemic-euglycemic clamp, with insulin concentrations two times basal insulin values, combined with stable isotope dilution to measure the decrease in endogenous glucose production (EGP) as a measure of hepatic insulin sensitivity.

Results
Rats on a fcHF and fcHFHS diet increased caloric intake significantly and gained more fat mass compared to rats on chow. EGP suppression by hyperinsulinemia in rats on a fcHFHS diet and on a fcHF diet was more than 50% less compared to suppression in rats on a control chow diet. Moreover, rats on a fcHFHS diet showed a decreased rate of disappearance for glucose compared to chow controls (90 vs 67 μmol/kg min respectively), which was not observed in rats on a fcHF diet.

Conclusions
These data suggest that both obesogenic diets resulted in hepatic insulin resistance whereas a fcHFHS diet also reduced peripheral insulin sensitivity.

OC4.3
Association of genetic polymorphisms in the organic cation transporters OCT1, OCT2 and multidrug and toxinn extrusion 1 transporter protein with the metformin intolerance and weight lowering in patients of type 2 diabetes

I Tarasova1, J Klovins1, I Kalnina1, A Bumburo2, R Ritenberga3, K Geldner2, L Nikitina-Zake1 & V Pirags2
1Latvian Biomedical Research and Study Center, Riga, Latvia; 2Department of Endocrinology, Pauls Stradins Clinical University Hospital, University of Latvia, Riga, Latvia.

Objective
Metformin is one of the most widely used drugs in primary therapy for the treatment of type 2 diabetes (T2D). Despite its overall efficiency in T2D treatment
metformin shows significant proportion of patients suffering from number of side effects. So far number of polymorphisms mainly in genes coding for various metformin transporter proteins have been described in association with metformin efficiency. However, no information exists on influence of genetic variation of metformin transporters on metformin side effects. OCT1, OCT2 and MATE1 transporters are involved in pharmacokinetics of metformin. In this study, we assessed whether 5 SNP and 2 indel polymorphisms are associated with metformin side effects in Latvian patients of type 2 diabetes.

Methods
We used information from Genome Database of Latvian Population and METFOGENE study to identify all metformin users and their response to metformin intake. Polymorphisms in SLC22A1 (rs36056065, rs34059080, rs628031; rs36056065 and rs72552763; SLC22A1 – rs316019; SLC7A1 – rs2896966 were compared between 74 type 2 diabetes patients with metformin intolerance and 236 metformin users without symptoms of metformin intolerance.

Results
We found a statistically significant association between A allele of rs628031 (P = 0.008175, OR = 0.58, CI 95% (0.38–0.8703)) as well as 8 bp insertion (rs36056065) (P = 0.008527, OR = 0.546, CI 95% (0.3929–0.8749)) and presence of metformin intolerance. Additionally carriers of rs2896966 A allele (SLC7A1) displayed significantly lower (P = 0.002118) mean BMI (32.67 kg/m²) compared to wt GG genotype (36.49 kg/m²) among regular metformin users.

Conclusion
Genetic variation in OCT1 encoded by SLC22A1 may predispose to increased intolerance in patients with type 2 diabetes. Our results may also suggests that rs2896969 located in SLC7A1 gene coding for MATE1 transporter may be associated with increased efficiency of metformin effect on the weight lowering, which is in accordance with MATE1 function in hepatocytes.

OC4.4
HLA-G polymorphism and papillary thyroid cancer histological aggressiveness
A Dardano1, R Rizzo2, A Polini3, M Stignani2, S Tognini2, M Ferdeghini3, O Baricordi4 & F Monzani2
1University of Pisa, Pisa, Italy; 2University of Ferrara, Ferrara, Italy; 3University of Verona, Verona, Italy.

Introduction
Human leukocyte antigen-G (HLA-G) is a non-classical HLA-class Ib molecule with multiple immunoregulatory properties. Its main role is the maintenance of maternal immune system and semiallogenic fetus. The expression of HLA-G antigen has been reported in several cancers and seems to play an important role in the escape of tumour cells from immune surveillance. A 14 bp insertion/deletion polymorphism in exon 8 of the 3′ untranslated region of the HLA-G gene has been reported to be associated with HLA-G mRNA stability.

Aim
To evaluate the prevalence of the 14 bp insertion (+14 bp) and deletion (−14 bp) polymorphism in the HLA-G gene in patients affected by papillary thyroid carcinoma (PTC) as well as autoimmune thyroiditis. The possible association between HLA-G 14 bp polymorphism and thyroid cancer aggressiveness was assessed.

Patients and methods
We studied 182 patients (147 F) with PTC; 120 patients (104 F) with autoimmune thyroiditis and 245 healthy subjects (191 F), matched for sex and age, served as control groups. HLA-G polymorphism was studied by PCR techniques.

Results
The frequency of the 14 bp insertion polymorphism was significantly higher in patients with PTC and autoimmune thyroiditis as compared to healthy controls (0.48 and 0.46 vs 0.38, P = 0.0003 and P = 0.01, respectively). Among PTC patients, a significant correlation was found between + 14 bp allele and advanced TNM stage (P = 0.37, P < 0.0001), as well as higher autoreactivity, aggressiveness, expressed as lymph node and/or multifocality and/ or thyroid capsule invasion (P = 0.39, P < 0.0001). A positive correlation between + 14 bp allele and cancer dimension was also observed (P = 0.15, P < 0.05).

A Final accounts data show, for the first time, an increased frequency of the 14 bp insertion polymorphism in PTC patients, suggesting a potential role of the HLA-G polymorphism in PTC immune escape and aggressiveness. The polymorphism may be also involved in the reported increased prevalence of PTC in patients with autoimmune thyroiditis.

Endocrine Abstracts (2011) Vol 26

OC4.5
Comparison of four strategies of radioidine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized, prospective ESTIMABL study
L Leenhardt1, B Calarg2, J Boret1, S Zerdoud3, B Bridji2, S Bardet4, M E Toubert5 & M Schlumberger6
1Endocrine Department, Pitie Salpetriere, Paris, France; 2Endocrine Department, CHU Bordeaux, Bordeaux, France; 3Biostatistic and Epidemiology Service, Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, Paris, France; 4Nuclear Medicine and Radiotherapy Department, Institut Claudius Regaud, Toulouse, France; 5Nuclear Medicine Department, Centre Rene Gauduchau, Nantes, France; 6Nuclear Medicine Department, Centre Francois Baclesse, Caen, France; 7Nuclear Medicine Department, Hopital Saint-Louis, Paris, France; 8Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Paris, France.

Objective
The objective of this clinical trial is to compare four strategies of management of postoperative radioidine ablation in a 2 × 2 factorial design, each strategy combining a method of TSH stimulation and an activity of 131I. The primary endpoint is the rate of thyroid ablation.

Patients and methods
This multicentric, randomized, controlled, phase III trial involved 24 French centers, and compared 4 strategies for postoperative radioidine ablation in a 2 × 2 factorial design: a method of TSH stimulation (either thyroid hormone withdrawal (THW) or rhTSH (Thyrogen, Genzyme)) and an activity of 131I (either 1.1 or 3.7 GBq). Study patients met the following criteria: age ≥ 18 years; total thyroidectomy for differentiated papillary or follicular (no aggressive histology) thyroid carcinoma, between 30 and 120 days before randomization, treatment with TSH for at least one month; TNM stage pT1 < 1 cm, N1 or Ns, pT1 > 1 cm (any N) or pT2, NO; absence of distant metastasis, no iodine contamination. Thyroid ablation was assessed at 6–10 months after radioidine ablation with rhTSH stimulated Tg determination and neck-US; whole-body scan was performed in case of positive Tg antibodies (TgAb). The comparison between the four strategies is based on equivalence framework, with two-side a = 0.05.

Results
Seven hundred and fifty-three patients who gave written informed consent were included in the study between April 2007 and February 2010 and currently data on radioidine ablation are available for 693 patients (92%) who form the basis of the present report: 79% were females, mean age was 49 years, and 90% had papillary cancer; 30% of tumors were pT1NO, 17% were pT1N1, 39% were pT1, Ns and 12% were pT2, NO. Mean time between thyroidectomy and randomization was 50 days, and mean time between randomization and radio-iodine ablation was 39 days. Data on the follow-up control are currently available for 477 patients. Neck-US was normal in 444 patients (93%) or suspicious or abnormal in 33 (7%). Stimulated Tg level was > 1.0 ng/ml in 25 (5%) patients and 31 patients had TgAb. Thyroid ablation was considered complete in 417 patients (87%), incomplete or doubtful in 58 patients (12%) and non-evaluable in 2 patients.

Conclusion
These data will be updated for the ECE meeting, and results of ablation will be presented.

OC4.6
No causal relationship between Yersinia enterocolitica infection and autoimmune thyroid disease: evidence from a prospective study
G Effraimidis, J G P Tijssen & W M Wiersinga
Academical Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

Objective
To evaluate prospectively the relationship between Yersinia Enterocolitica (YE) infection and the development of overt autoimmune hypo- or hyperthyroidism (study A) and the de novo occurrence of thyroid antibodies (study B).

Subjects and methods
Prospective cohort study of 790 euthyroid women who were 1st or 2nd degree relatives of AITD patients. Follow-up was 5 years, with annual assessments. Study A. Nested case–control study in which YE serological status was measured between cases (subjects who developed overt hypothyroidism (TSH > 5.7 mU/l and FT4 < 9.3 pmol/l) or overt hyperthyroidism (TSH < 0.4 mU/l and FT3 > 20.1 pmol/l) and matched controls. Study B. Three hundred and eighty-eight euthyroid women without thyroid antibodies at baseline were enrolled. The YE serological status was compared
between subjects who developed TPO-Ab and/or Tg-Ab at 4-year follow-up and those who remained negative.

Results
Study A. The proportion of subjects positive for YOP-IgG or YOP-IgA did not differ between cases and controls at baseline. One year before the development of overt hypo- or hyperthyroidism, the proportion of subjects with YOP-IgG was not different between cases and controls, but YOP-IgA was less prevalent in cases. Study B. De novo occurrence of TPO (or TPO Ab and/or Tg-Ab) did not differ between subjects in whom at baseline YOP-IgG was positive or negative. Neither persistence nor emergence of YOP-IgG at 4-year follow-up was associated with the occurrence of TPO-Ab or Tg-Ab. Similar results were observed with respect to YOP-IgA.

Conclusions
Yersinia enterocolitica infection does not contribute to an increased risk of thyroid autoimmunity.

Hormone metabolism and action
OC5.1 – ESE Young Investigator Award
HDL receptor metabolism and action
OC5.1 – ESE Young Investigator Award
HDL receptor SR-BI dysfunction is associated with a diminished adrenal glucocorticoid output in mice and man
M Hoekstra1, M Vergeer2, R B Hildebrand1, R J van der Sluis1, J J Kastelein1, M Van Eck, J A Kuivenhoven1 & T J C Van Berkel1
1Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands; 2Department of Vascular Biology, Amsterdam Medical Center, Amsterdam, The Netherlands.

Adrenal-derived glucocorticoids originate from their precursor cholesterol. Scavenger receptor B1 (SR-B1) is a major high-density lipoprotein (HDL) receptor that mediates the selective uptake of cholesteryl esters (CE) from this lipoprotein in the circulation. In our present studies in SR-BI knockout (KO) mice and human carriers of a functional mutation in the extracellular domain of SR-BI (P297S), we determined whether SR-BI-mediated uptake of HDL-CE is required for adrenal glucocorticoid production. Impaired uptake of HDL-CE in SR-BI knockout mice induced depletion of adrenal lipid stores and adrenal hypertrophy. Basal steroidogenesis was, however, not affected by murine SR-BI deficiency. In contrast, fasting- and lipopoly saccharide (LPS)-induced plasma corticosterone levels were markedly lower in SR-BI KO mice compared to controls, which coincided with fasting hypoglycemia and an increased susceptibility to inflammation. A compensatory 2-fold increase in hepatic and plasma corticosteroid-binding globulin (CBG) and >2-fold higher ACTH levels were detected. ‘Humanizing’ SR-BI KO mice through transgenic expression of human cholesterol ester transfer protein (CETP; mice are naturally CETP deficient) partially restored CE delivery to the adrenals due to transfer of CE from HDL to apoB-containing lipoproteins for uptake via the adrenal LDL receptor. However, CETP was unable to rescue the glucocorticoid insufficiency phenotype in SR-BI KO mice. In parallel, human heterozygotes for the SR-BI P297S mutation exhibited a diminished urinary excretion of most steroids in the context of higher plasma HDL-cholesterol and CBG levels. ACTH (tetracosactrin) stimulation tests revealed unchanged baseline plasma levels of free cortisol, while the percentage increase in free cortisol levels was lower in controls (55% in controls). ACTH (tetracosactrin) stimulation tests revealed unchanged baseline plasma levels of free cortisol, while the percentage increase in free cortisol levels was lower in controls (55% in controls).

In conclusion, our studies show that disruption of SR-BI function is associated with a diminished adrenal glucocorticoid output in mice and man and suggest that HDL fulfills a thus far unanticipated role in human adrenal steroid synthesis.

OC5.2
Site specific overexpression of urocortin 2 results in modulation of steroidogenesis in vivo
A Spyroglou1, A Hill, K Mueller-Peltzer1, J Deussing & F Beuschlein1
1Endocrine Research Unit, Medical Clinic Innenstadt, LMU, Munich, Germany; 2Max Planck Institute of Psychiatry, Munich, Germany.

Urocortin 2 (Ucn2) is a recently identified neuropeptide of the CRF-Family, involved in homestatic mechanisms for stress response and control of ACTH. To further elucidate Ucn2 effects on steroidogenesis, we developed a mouse model with Ucn2 overexpression in the adrenals, gonads and parts of the hypothalamus, by crossingbreeding SF1-Cre+/− mice with R26+R26R R26+R26R Ucn2+−/− mice. Following genotypes were obtained: SF1-Cre+/− R26+R26R Ucn2+−/− mice (controls) and SF1-Cre+/− R26+R26R Ucn2+−/− mice. Following genotypes were obtained: SF1-Cre+/− R26+R26R Ucn2+−/− mice (controls) and SF1-Cre+/− R26+R26R Ucn2+−/− mice (controls) and SF1-Cre+/− R26+R26R Ucn2+−/− mice (controls). Adrenal glands, ovaries, testes and tumor blood of two-month-old animals were collected. Plasma concentration of corticosterone and Ucn2 were measured with commercially available immunoassays. Expression levels of Ucn2 and steroidogenic genes were quantified by real-time PCR analysis. A 3.5-fold elevated plasma Ucn2 (P<0.001) and a 20-fold increased Ucn2 expression in adrenals (P<0.001) of male and female Ucn2OE could be documented. A lower expression of StAR (P<0.05) and cyp11a1 (P<0.001) and cyp11b1 (P<0.05) could be documented in adrenals of female Ucn2OE, together with reduced plasma corticosterone values (P<0.05). In contrast, 6-fold higher Ucn2 expression in ovaries was associated with significant increase of StAR (P<0.05) and cyp11a1 (P<0.05). On the contrary, steroidogenic enzymes' expression in male adrenals and plasma corticosterone levels did not differ from controls (StAR P=0.29, cyp11a1 P=0.70, cyp11b1 P=0.99, corticosterone P=0.47). Surprisingly, Ucn2 expression in testes was comparable to controls and no effects on steroidogenesis could be documented.

These data demonstrate that Ucn2 overexpression in the female mouse results in downregulation of steroidogenesis in the adrenal, suggesting a stress coping behaviour and increased steroidogenesis in the ovary, an observation not confirmed in male gonads. The gender specific discrepancies will be further investigated.

OC5.3
Identification of melanocortin 2 receptor structures responsible for specific membrane expression and ACTH binding specificity
J Friedmans1, R Petrotskvs2, H B Schiøtz2 & J Klovins1
1Latvian Biomedical Research and Study Center, Riga, Latvia; 2Department of Neuroscience, Uppsala University, Uppsala, Sweden.

Membrane expression of ACTH receptor MC2R is specifically limited to adrenal cells. In addition, unlike the other members of the evolutionary related MCXRs that recognize different melanocortin peptides, the MC2R solely binds ACTH. We used cassette substitutions and mutagenesis of individual amino acids for systematic construction of 30 chimeric and mutant MC2R/MC4R receptors to identify the receptor structures determining the selectivity of MC2R in membrane trafficking and ACTH binding as well as interaction with MC2 receptor accessory protein (MRAP). We developed a new analysis method to quantify the localization of the recombinant receptors fused with enhanced green fluorescent protein in a cell membrane from the results of confocal fluorescent microscopy. NMD-MSH and ACTH mediated cAMP response was measured for all receptors. We have found that substitution of MC4R N-terminal part with homologues part from ACTHR significantly decreased the membrane trafficking of receptor. We have also identified the signal localized in TM3 and TM4 regions that is responsible for trapping MC2R in the endoplasmatic reticulum (ER) of the cell. Replacement of two sets of amino-acids (3aa each) in TM3 and one set of four amino-acids in TM4 with the corresponding amino acids from MC4R enabled the membrane transport of MC2R in ordinary BHK cell line without the MRAP. For control purposes all constructs were also co-expressed with MRAP protein in the same cell line. Results indicate that a specific structural conformation formed by TM2 and TM4 rather then primary aa sequence is important for ER arrest of MC2R. We have also found that the TM4 and TM5 in the MC2R are involved in MC2R binding selectivity. Bypassing of these arrest signals involves MRAP protein. In summary we have identified presence of ‘dual protection’ system that helps to avoid the membrane expression of MC2R involving N-terminal part and specific TM3-TM4 interaction.
Methods
Expression levels of MRAP, MRAP2 and MC2R were studied in adrenal tissues from 37 patients and related to clinical data. Primary adrenal cultures from 40 patients were stimulated with ACTH, forskolin, angiotensin (AngII) or PMA in order to study the regulation of expression of these mRNAs. Induction of ACTH-responsive genes was related to MRAP, MRAP2 and MC2R mRNA expression levels.

Results
MRAP and MRAP2 levels were lower in adrenocortical carcinomas (ACCs) than in adrenal ACTH-dependent or -independent hyperplasia or adenoma tissues ($P < 0.001$), whereas MC2R levels were comparable in all groups. The expression of MRAP, MRAP2 and MC2R did not differ between ACTH-dependent or -independent hyperplasia. Patient plasma ACTH and serum cortisol levels were positively associated with MRAP and MC2R levels in adrenal hyperplasia samples ($P < 0.05$), but not in tumors. In vitro, ACTH and forskolin both potently induced expression of MRAP and MC2R in all adrenal tissue types ($P < 0.0001$), whereas AngII augmented these mRNAs in all tissue types as well ($P < 0.001$), with the exception of ACCs. MRAP2 expression was reduced by PMA ($P = 0.001$). The ACTH induction of CYP21A2 relative to that by forskolin was inversely related to MRAP2 levels ($r = -0.84, P = 0.038$), whereas there was no association between MRAP or MC2R expression and ACTH responsiveness.

Conclusions
MRAP and MC2R are controlled by ACTH and AngII, but expression levels do not directly relate to ACTH responsiveness. MRAP2 levels are negatively associated with the effects of ACTH.

OC5.5
The effect of MCT8 on the biological activity of T3
A A van Mullem, R P Peeters & T J Visser
Erasmus MC, Rotterdam, The Netherlands.

Introduction
The biological activity of thyroid hormone (TH) is largely mediated by binding of T3 to nuclear T3 receptors (TRs). Before TH can mediate its effects, it needs to be transported across the plasma membrane. Several TH transporters, such as MCT8, facilitate this transport. Inactivating mutations in MCT8 lead to a severe phenotype of psychomotor retardation. In addition to transport into the cell, MCT8 is also able to transport TH out of the cell. Aim of this study was to investigate if MCT8 does not only increase cellular T3 uptake, but also increases the availability of T3 for its nuclear receptor.

Method
JEG3 cells, transiently transfected with TRβ1 and a construct with a T3 response element (TRE)-dependent luciferase reporter and a control renilla reporter (pdV-L1; gift from Dr W S Simonides, VUMC), were used as a model. α-crystallin (CRYM), an intracellular TH binding protein, was used to block efflux of TH. In addition to TRβ1 and the reporter construct, cells were transfected with CRYM and/or MCT8. Forty-eight hours after transfection, cells were incubated for 10, 30 or 60 min or 24 h with 0, 0.5 or 1 nM T3.

Results
After 30 min with 1 nM T3, cells transfected with TRβ1, reporter and CRYM had a significantly higher luciferase/renilla ratio after co-transfection with MCT8 than without MCT8 ($0.60 \pm 0.07$ vs $0.20 \pm 0.01$, $P < 0.001$). Similar differences were seen after the other incubation times, and with 0.5 nM T3. However, in cells transfected with TRβ1 and reporter, but without CRYM, co-transfection with MCT8 had no effect on the luciferase/renilla ratio at any of the incubation times or ligand concentrations.

Conclusion
MCT8 contributes to both influx and efflux of TH. Our data suggest that in cells with high intracellular binding capacity, MCT8 increases the availability of T3 for its receptor, and has a positive effect on T3-mediated gene transcription.

OC5.6 – ESE Young Investigator Award
A novel non-radioactive assay detects PTU-sensitive enzymatic deiodination of natural and synthetic iodinated compounds
K Renko, C S Höftig, L Schombok & J Kohlme
Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Enzymatic 5′- and 5-deiodination represent key pathways for local and systemic issues with respect to the thyroid hormone axis. The classical radioactive DIO activity assay depends on radioactively labelled components, it expands the spectrum of the classical assay regarding the substrates to additional iodinated compounds. Comparison of DIO1 activity in tissue samples from hypo- and hyperthyroid mice and concentration–response experiments with PTU, an established DIO1 inhibitor, yielded the expected results. Incubation of iopanoic acid, a well-known, non-selective pan-inhibitor of all three DIO, with active DIO1 preparations revealed a significant release of iodide that was suppressible by PTU and exhibited features of an enzymatic reaction. We conclude that iopanoic acid itself might serve as substrate for DIO1, thereby contributing to the mobilization of iodoide from the X-ray contrast agent and its re-utilization by the thyroid gland. This reaction might enhance the persistent iodide overload observed after administration of iodinated X-ray contrast agents.

This work is supported by the Bundesministerium für Bildung und Forschung.
Poster Presentations
Adrenal cortex

P1
Pituitary–adrenal axis in male rats after exposure to high ambient temperature
F Percinic-Popovska1, V Ajdanicova2, S Trifunovic2, M Jordanova2, V Iliiski1, L Fendovski1 & V Milosevic1.
1Faculty of Veterinary Medicine, Skopje, the Former Yugoslav Republic of Macedonia; 2Institute for Biological Research. ‘Sinisa Stankovic’, Belgrade, Serbia; 2Faculty of Natural Sciences, Institute of Biology, Skopje, the Former Yugoslav Republic of Macedonia.

The global warming and its impact on the summer average temperature elevation, in the south-eastern parts of Europe, represent an inevitable stress for living organisms in this region. Heat stress was shown to be the strongest one, when compared to immobilization or cold stress. Activation of the hypothalamo-pituitary-adrenal (HPA) axis during exposure to various types of stressors is well-known physiological concept. The effect of 24 h exposure to heat stress on the morphology of pituitary adrenocorticotropes (ACTH cells) and adrenal cortex, especially zona fasciculata (ZF), in adult male Wistar rats, was examined. The experimental animals (n = 7) were exposed for 24 h to high ambient temperature (35 ± 1 °C). The control group (n = 7) was kept at room temperature (20 ± 2 °C).

The pituitary and left adrenal glands were fixed in Bouin’s solution and serially cut (5 μm). The ACTH cells were identified by the peroxidase-antiperoxidase (PAP) immunohistochemical procedure, while the cells of adrenal cortex were stained with hematoxylin–eosin. The volume of ACTH- and ZF- cells and their nuclei were estimated using the multipurpose test system M2Z. The body weight in heat stressed rats was decreased (P < 0.05) by 15.3%, compared to the controls. The relative pituitary weight was significantly increased (P < 0.05) by 16.5%, in comparison with the corresponding control. The ACTH cell volume, as well as the volume density, were significantly decreased (P < 0.05) by 12.3 and 26.7%, respectively, in comparison with the controls. Absolute volumes of the adrenal gland, adrenal cortex, ZF, as well as the ZF cells were also decreased (P < 0.05) by 10.7, 8.6, 15.2 and 3.3% respectively, compared to the controls. These findings suggest that one day exposure of adult male rats to high ambient temperature (35 ± 1 °C) has the inhibitory effect on the morphological characteristics of ACTH- and ZF-cells in adult male rats.

P2
Relatival adrenal failure in trauma patient: therapy approach
Eduard Circo, Marian Beciu & Razvan Circo
‘Ovidius’ University, Constanta, CT, Romania.

Introduction
Relative adrenal insufficiency is considered a life threatening event, especially when associated with a serious event like trauma. Recognition and treatment of relative adrenal insufficiency is a challenge for clinical practitioner.

Objectives
We wanted to study adrenal dysfunction, diagnostic methods corresponding to the emergency situation for a trauma patient, adaptive capability of hypothalamo-pituitary-adrenal axis and therapeutic methods for trauma patients.

Materials and methods
We studied 15 patients brought to the Emergency Department. We determined basal serum cortisol and after 1 μg tetracosactide (Synachten) stimulation test – we measured cortisol at 15 min and then at 60 min. We appreciated survival rate function basal and stimulated cortisol values.

Results
For 9 patients (group A) basal cortisol levels (7.37 μg/dl) and stimulated cortisol levels (11.30 μg/dl) were lower than normal. For 3 patients (group B), basal cortisol levels were less than normal (8.11 μg/dl), but after the stimulation test – levels were normal (20.71 μg/dl). For 3 patients (group C), basal (14.53 μg/dl) and stimulated (25.05 μg/dl) cortisol levels were both normal.

Survival rate was 22% for group A, 33% for group B and 100% for group C. All patients received i.v. hydrocortisone 100–200 mg daily. We observed a high mortality rate for those patients with low cortisol values and adaptive cortisol dysfunction as for those with adequate basal and stimulated cortisol values. It still remains the problem of using a cortisone dose for treatment that is lower than it should be for the adaptive capability.

Conclusions
Relative adrenal insufficiency is a stress-induced situation. A high clinical suspicion, a correct diagnosis and cortisone replacement could higher the survival rate.

P3
MicroRNAs as endogenous modulators of glucocorticoid receptor expression in the adrenal gland after ACTH stimulation test
A Hill1, O Issler2, A Spyrouoglou3, S Harunzati4, A Chen5 & F Beuschlein1
1Endocrine Research Unit, Medical Clinic Innenstadt, LMU, Munich, Germany; 2Neurobiology Department, Weizmann Institute of Science, Rehovot, Israel.

MicroRNAs (miRs) are a subset of small RNA molecules that regulate gene expression post-transcriptionally. Little is known about the expression and the role of miRs in the adrenal gland. Thus, we determined the miRs expression pattern under baseline condition and 10, 30 and 60 min after ACTH stimulation test in mice adrenal glands using miRs microarray. The miRs expression profile of adrenals obtained from the array was bioinformatically analyzed to indentify miRs that putatively target important genes. After selecting 20 miRs, with a significant change in their expression level upon ACTH stimulation test, it was found that four of these miRs putatively target the glucocorticoid receptor (GR, Nr3c1): mir96, mir101a, mir142-3p, mir1433, in addition to mir18a, which is already known from previous studies to influence GR expression in the brain.

The array data could be confirmed with real-time PCR analysis showing an upregulation of mir96 10 min after ACTH test (baseline: 100 ± 27%, 10 min post ACTH: 244 ± 18%, P < 0.05), and also of mir433 in all investigated timepoints (baseline: 100 ± 22%, 10 min: 197 ± 24%, 30 min: 161 ± 14%, 60 min: 163 ± 9%, P < 0.05). Furthermore, a decrease of mir142 expression was found 30 min (100 ± 29%, 30 min: 20 ± 8%, P < 0.05) and of mir101 10 min after ACTH stimulation test (baseline: 100 ± 20%, 10 min: 20 ± 1%, P < 0.05). GR expression measured with real-time PCR was elevated 10 min after ACTH stimulation (14 ± 19%) in comparison to the control group (100 ± 10%, P < 0.05). Targeting predictions of these four miRs GR 3'UTR was further tested by in vitro luciferase assays. Preliminary data show that mir96, mir101a and mir142 target the GR 3'UTR region and result in a 20–40% decreased mRNA level of GR 3'UTR.

Thus, ACTH stimulation influences the expression of these miRs, which target the GR; at least, three miRs, mir96, mir101a and mir142, regulate the GR expression post-transcriptionally. The impact of this regulation in physiological stress response awaits further investigation.

P4
Effects and kinetics of mitotane in in vitro and in vivo models of adrenocortical carcinoma
M Luconi1, G Poli1, M Mangoni1, P Pezzati2, M Francalanci1, S Gelmini1, L Canu1, G Canti1, M Serio1 & M Mannelli1
1University of Florence, Florence, Italy; 2AOU Careggi, Florence, Italy.

Adrenocortical carcinoma (ACC) is a rare aggressive tumor with a poor prognosis. At present, early diagnosis followed by total surgical tumor resection is the only valuable option for ACC cure and mitotane (MTT) is the only specific drug available for pharmacological treatment. However, its effects seem to be modest due to its adrenocortical cytotoxicity and its bioavailability and cellular mechanism of action are still unknown, making it difficult to develop less toxic multidrug strategies for ACC treatment. We investigated MTT metabolism and effects on cell activity and proliferation in the human ACC line H295R and in an in vivo xenograft model obtained by s.c. injection of H295R cells in athymic mice. MTT and its metabolite DDA dose-dependently accumulated intracellularly in H295R with a peak at 24 h administration, resulting in a dose- and time-dependent inhibition of cell proliferation, evaluated by MTS assay (inhibition: 50.0 ± 2.1% at 48 h, 85.0 ± 2.5% at 5 days, P < 0.001, 20 μM MTT) and cell count (inhibition: 54.0 ± 3.2% at 48 h, 89.0 ± 2.2% at 5 days, P < 0.001, 20 μM MTT).

We demonstrated that MTT interferes with MAPK signalling pathways. In vivo oral/t.p. administration of MTT resulted in a significant accumulation of MTT in adrenals and in the ACC xenograft model determined a significant inhibition of tumor growth versus the untreated control animals (tumor growth fold decrease following 21 day treatment: 0.74 ± 0.20, P < 0.01, n = 10), accompanied with a reduced expression of angiogenic, vascular and proliferation genes in tumors of MTT treated mice. In prevention experiments where MTT was started contemporarily with H295R inoculation, we observed an even greater reduction in tumor growth compared with the untreated control animals (tumor growth fold decrease following 21 day treatment: 0.38 ± 0.10, P < 0.001, n = 10). In conclusion, we contributed to elucidate MTT kinetics in vitro and in vivo highlighting the antiproliferative effects of such drug.
P5 The utility of FDG-PET CT in differentiating malignant from benign adrenal lesions
Basak Oguz1, Sayid Shafi Zuhur2, Ozcan Karaman3, Selvinaz Velet2 & Yusuf Altuntas2
1 Internal Medicine, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 2 Sisli Etfal Training and Research Hospital, Endocrinology and Metabolism Clinic, Istanbul, Turkey.

Background
With the increasing use of USG, MRI and CT, adrenal lesions are frequently found in the daily practice. These lesions may be primary or secondary in origin. However, it is important to resolve whether these lesions are benign or malignant.

Purpose
The aim of this case detection study was to compare FDG-PET CT with MRI in differentiating benign from malignant adrenal mass lesions.

Patients
All patients were admitted to our out-patient clinic between 2006 and 2010 for evaluation of adrenal mass lesions. FDG-PET CT and MRI were performed to all patients. We analyzed the laboratory data of the patients and compared FDG-PET CT results with MRI results.

Results
The study included 21 patients ((13 female, 8 male, mean age 55 years old (between 26 and 71)) with 29 adrenal lesions (mean size 2.77 ± 1.07 cm; 16 bilateral and 13 unilateral). Five out of 29 lesions were malignant according to MRI. Three of malignant lesions on MRI were also malignant according to FDG-PET CT (SUVmax > 2.5). Of the 3 malignant lesions on FDG-PET CT, 1 diagnosed as tuberculosis, 1 as primary adrenal carcinoma and 1 as atypical lipoma, according to histopathological/microbiological analysis. Six out of the 29 lesions were interpreted as benign by MRI but malignant according to FDG-PET CT (SUVmax > 2.5).

Conclusion
According to our study results, FDG-PET CT is not better than MRI for differentiating malignant from benign adrenal lesions. FDG-PET CT leads to unnecessary invasive investigations in some patients. However, it could be used in detecting metastases in patients with known malignancies.

P6 CT imaging in patients with adrenal incidentaloma
J Brunova1 & J Bruna2
1 Institute for Clinical and Experimental Medicine, Diabetes Centre, Prague, Czech Republic; 2 Diagnostic Radiology Department, Second Medical Faculty Hospital, Charles University, Prague, Czech Republic.

Adrenal masses which are found unexpectedly with US or CT examination of abdomen are called adrenal incidentalomas. The aim of study was to evaluate the contribution of imaging characteristics of accidentally discovered adrenal mass to the differential diagnosis.

We have studied 60 patients with adrenal mass (21 M, 39 F, age 34–85 years) who had CT scan of abdomen for various diagnoses but they were not suspected to have adrenal pathology. The right adrenal gland was solitary affected in 20 cases, left in 28 cases and both adrenals in 12 cases. To determine the endocrine status of adrenal mass the usual tests for Cushing’s syndrome and pheochromocytoma were performed. The aldosterone/PRA ratio was measured in hypertensive patients. The benign character of adrenal mass was confirmed operatively or by follow up of tumor size for >1 year and lately washout test was used.

Results
None of our patients had Cushing’s syndrome or primary hyperaldosteronism. The non-functioning adrenal adenoma was confirmed in 45 patients, subclinical hypercortisolism had 5 patients, metastases to adrenal glands were found in 5 patients, two patients had lymphoma, myelolipoma 2 patients and one patient had asymptomatic pheochromocytoma. The density of metastases on plain CT images was >20–45 HU and myelolipomas had density minus 70 HU. The adrenal adenosmas had low precontrast density in 100% cases. Most of adenosmas showed low contrast enhancement but 8/50 adenosmas (16%) enhanced over 55 HU (55–90 HU). Adenomas larger than 3 cm were found in 17/50 cases (34%).

Conclusion
From the imaging point of view the low density of lesion seems to be more important sign for the determination of the nature of lesion (myelolipoma, adenoma, malignancy) than the size of adrenal mass. We recommend CT scans in long-term followed-up patients for 3 years minimally once a year.

P7 Self-management in patients with adrenal insufficiency
J P van Eck1, R J Bobbens2, J Beukers3, W Geilvoet1, A J van der Lely1 & S J C M M Neggers3
1 Erasmus MC, Rotterdam, The Netherlands; 2 School of Health Care Studies, University of Applied Sciences, Rotterdam, The Netherlands.

Objectives
The objective of this study was to assess the quality of self-management in patients with primary and secondary adrenal insufficiency and to find patient-related factors that influence quality of self-management.

Methods
The quantitative research was assessed by a questionnaire. Mainly focused topics were i) demographic data ii) daily medication intake iii) en route precautions and iv) dose adaptation during medical emergencies. One hundred and ninety-eight patients with primary and secondary adrenal insufficiency were assessed by the survey.

Results
Sixty percent (n = 116) of the patients completed the questionnaire. For the propositions about daily medication intake, the score was 3.5 of 4 (mean: max).

Conclusion
Patients demonstrate a high level of self-management according to daily medication intake. En route precautions and dose adaptation during medical emergencies need to be improved to prevent life threatening situations. Therefore, patients must be educated continuously to improve these self-management aspects that come with life-long substitution therapy. Involvement of endocrine nurses and nurse practitioners is likely to be a key factor in the effectiveness of patient education and training.

P8 Validation of the disease-specific quality of life questionnaire AddiQoL in European Addison patients
M Oksnes1,2 & K Løvås3
1 University of Bergen, Bergen, Norway; 2Haukeland University Hospital, Bergen, Norway; 3Euradrenal SP7, Bergen, Norway.

Introduction
Patients with Addison’s disease (AD) self-report impairment in specific dimensions on well-being questionnaires. An AD disease-specific quality of life questionnaire (AddiQoL) was developed to aid evaluation of patients. We here aimed to validate translated questionnaires in terms of internal consistency and reliability and to improve the construct of the scale.

Methods
After translation by a multistep approach, the final versions were tested in AD patients from Norway (n = 107), Sweden (n = 101), Italy (n = 165) and Germany (n = 200). Internal consistency was examined by exploratory factor analysis (EFA) and Rasch analysis, aiming at unidimensionality and fit to the Rasch model. Conbach’s s and person separation index (PSI) were calculated for reliability. Longitudinal reliability was tested by differential item functioning (DIF, or item bias for time) in stable patient subgroups in Norway, Sweden and Italy.

Results
EFA identified four sub-dimensions of AddiQoL; fatigue (8 items), emotions (8), symptoms (11) and miscellaneous (sleep, sexuality and impact of intercurrent disease, 6). Three items concerning nocturia, weight gain, and dry skin did not fit any dimension and were discarded. The sub-dimensions fatigue, emotion and miscellaneous showed non-significant χ2 interactions, implying fit to the Rasch model, also supported by the overall fit residual statistics. The symptoms sub-dimension initially displayed misfit, hence three items concerning salt cravings, light headedness and sweating were removed. The 30 remaining items, rearranged in four subtests by sub-dimensions, fitted the Rasch model; supported by a non-significant χ2 interaction of 0.65 and no significant pattern deviation among the fit
residuals. Cronbach’s α was 0.94, and PSI was 0.86, indicating good reliability. Longitudinal reliability was excellent, as no significant DIF between separate time points was detected.

Conclusion

The Norwegian, Swedish, Italian and German AddiQoL versions have high internal consistency and reliability, and can be fitted to the Rasch model for optimisation of psychometric properties.

---

**P9**

**Diagnostic value of urinary steroid profiling for detecting adrenocortical carcinoma**

T M A Kerkhofs1, M N Kerstens1, I P Kema2, I G C Hermse1 & H R Haak1

1Maxima Medical Center, Veldhoven, The Netherlands; 2University Medical Center, Groningen, The Netherlands.

The finding of an adrenal incidentaloma warrants a careful diagnostic work-up to assess hormonal activity and potential malignancy. Current diagnostic algorithms depend largely on imaging studies, which is time-consuming, expensive and carries a health risk. Urinary steroid profiling using gas chromatography/mass spectrometry (GC/MS) might be a valuable diagnostic test for differentiating benign from malignant adrenal lesions, as adrenocortical carcinomas (ACC) often cause abnormalities in steroidogenesis. The value of this tool was retrospectively studied in 44 patients referred for analysis of an adrenal tumor or adrenal incidentaloma. The final diagnosis was histologically confirmed ACC (n = 14), liposarcoma (n = 1), or benign adrenal tumor (n = 29). In the latter group, the diagnosis was either histologically confirmed (n = 6) or based on radiological features and the absence of metastases during clinical follow-up (n = 23). Patients were monitored with regular imaging studies (median follow-up 20 months, range 8–38 months). Patients were not treated with drugs interfering with adrenal steroidogenesis. The concentrations of 22 steroids were measured in 24-h urine samples. Differences in steroid metabolite excretion between patients with and without ACC were analyzed using the Mann-Whitney U test. We found that by taking the sum of four steroid metabolites (etiocholanolone, dehydroepiandrosterone, pregnanediol, tetrahydrodeoxycortisol) it was possible to distinguish ACC from other adrenal tumors with 100% sensitivity and 93% specificity. Our data confirm the relevance of national cooperation and centralized surgery in ACC. In selected patients with stage 4 disease surgery can be beneficial in extending survival. On the basis of the retrospective analysis surgery in The Netherlands will and can be improved.

---

**P10**

**Surgery in adrenocortical carcinoma; importance of national cooperation and centralized surgery**

I G C Hermse1, T M A Kerkhofs2, G Den Butter2, J Kievit2, C Eijck1, E Nieveen van Dijkum6 & H R Haak1

1Maxima Medical Center, Veldhoven/Eindhoven, The Netherlands; 2Leiden University Medical Centre, Leiden, The Netherlands; 6Erasmus Medical Centre, Rotterdam, The Netherlands; 3Academic Medical Center, Amsterdam, The Netherlands.

Introduction

The low incidence rate of adrenocortical carcinoma requires a multidisciplinary approach in which specialised surgery has an essential role as complete resection of the primary tumour is the only chance of cure. In order to improve patient care, insight into surgical results within the ACC population is essential. In 2007, a Dutch Adrenal Network Registry has been created encompassing care and outcome of patients treated for ACC in The Netherlands since 1965. Using this database a study was performed with the following objectives: i) to gain insight into surgical performance in The Netherlands, ii) to compare surgical data with international literature.

Patients and methods

The data of 175 patients treated from 1965 until January 2008, were studied. The following data were collected: age, gender, functionality of the tumour, stage at diagnosis (ENS®/T staging), surgical procedure, completeness of surgery, disease recurrence, adjuvant mitotane therapy, recurrence free survival and overall survival.

Results

One hundred and forty-nine patients were operated. Patients with complete resection had significantly longer survival than patients with incomplete resection (P = 0.01). Patients operated in a Dutch Adrenal Network centre had significantly longer survival in both univariate (P = 0.01) and multivariate analysis (P = 0.01). Significant longer survival was observed in operated stage IV patients compared to non-operated patients (P = 0.00).

Conclusion

Our data confirm the relevance of national cooperation and centralized surgery in ACC. In selected patients with stage 4 disease surgery can be beneficial in extending survival. On the basis of the retrospective analysis surgery in The Netherlands will and can be improved.

---

**P11**

**Arthritis after removal of adrenal adenoma in Cushing’s syndrome**

Maria-Christina Ungureanu, Adriana Cernohuz, Carmen Gorduza, Viorel Scripcariu, Carmen Vulpoi & Cristina Preda

University of Medicine and Pharmacy Gi T Popa, Iasi, Romania.

Endogenous hypercortisolism is a well-known immunosuppressive condition. Such endogenous cortisol secretion could suppress the clinical presentation of an ongoing autoimmune process.

A 49-year-old woman was admitted in our service in august 2010 for Cushing clinical signs, arterial hypertension and hypokalemia. She had high plasma cortisol not suppressed by 1 and 8 mg dexamethasone overnight, low ACTH. Abdominal computed tomography demonstrated a tumor (3.0 × 2.7 × 2.8 cm) in the right adrenal gland. Waiting one month for the surgical cure we initiated treatment with Ketokonazole 800 mg/day but she developed adrenal insufficiency under treatment so we interrupted it. The patient underwent a right adrenalectomy and the diagnosis of a cortisol secreting benign adenoma was histologically confirmed. Blood pressure declined and cushingoid features regressed, but 2 months after the operation and while the patient was on replacement, she complained of pain on motion, marked tenderness and swelling of fingers, wrists, elbows, knees and foot joints. We founded normal tests for cortisol, no positive inflation tests except high level of transaminase and positive serology for toxoplasma. Two months of treatment with Rovamycin normalized transaminases and lowered the titer for toxoplasma antibodies but has no effect at articular level. Rheumatological exam suggest a rheumatoid arthritis with negative rheumatoid factor and treatment with low doses of medrol have a very good effect at joint level.

In summary, we report a patient with Cushing’s syndrome due to an adrenal adenoma, in which joint symptoms were triggered after curing the hypercortisolism; there are two possibilities of diagnosis: rheumatoid arthritis with negative rheumatoid factor revealed after Cushing therapy or reactive arthritis after toxoplasma infection with no amelioration after antibiotics treatment and no interaction with Cushing disease (but no certain date still now about reactive arthritis and toxoplasmosis).
The baby was aggressively treated with i.v. sodium and sodium resonium rectally resulting in improvement in electrolyte balance and facilitation of an early discharge home on very high doses of oral sodium supplements and continued sodium resonium rectally with regular monitoring of electrolytes at home. She remains well at 6 months of age with acceptable electrolytes (see Table).

<table>
<thead>
<tr>
<th>Age (days)</th>
<th>5</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>11</th>
<th>16</th>
<th>35</th>
<th>93</th>
<th>182</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Na+ (mmol/l)</td>
<td>139</td>
<td>127</td>
<td>128</td>
<td>130</td>
<td>139</td>
<td>136</td>
<td>139</td>
<td>134</td>
<td>133</td>
</tr>
<tr>
<td>Serum K+ (mmol/l)</td>
<td>5.5</td>
<td>9.4</td>
<td>7.2</td>
<td>8.1</td>
<td>6.8</td>
<td>6.3</td>
<td>5.6</td>
<td>6.3</td>
<td>6.0</td>
</tr>
<tr>
<td>Oral NaCl (mmol/kg per day)</td>
<td>4–7</td>
<td>10–20</td>
<td>28</td>
<td>24</td>
<td>15</td>
<td>20</td>
<td>20</td>
<td>24</td>
<td>24</td>
</tr>
</tbody>
</table>

Genetics investigations have demonstrated four variants in the SCN11A gene (coding for epithelial sodium channel) of which three are thought to be polymorphisms but one of which is likely to be functionally important. Further investigations into this are underway.

Our case highlights the importance of instituting early and continued use of potassium chelator (sodium resonium) along with aggressive electrolyte management in cases of pseudohypoaldosteronism.
P16 Potential role of mast cells in the physiopathology of aldosterone-producing adenoma
Céline Dupuy1, Lucile Moreau1, Véronique Perraudin1, Françoise Gobel1, Téhao Meachi1, Pierre-François Plouin1, Maria-Christina Zennero1, Estelle Louise1 & Hervé Lefèvre1,2
1INSERM U982, Institut de Biomedical Innovation, University of Rouen, Mont Saint Aignan, France; 2Department of Endocrinology, Institute for Biomedical Innovation, University Hospital of Rouen, Rouen, France; 3Department of Pathology, Institute for Biomedical Innovation, University Hospital of Rouen, Rouen, France; 4Department of Pathology, European Hospital Georges Pompidou, Paris, France; 5Hypertension Unit, Paris Cardiovascular Research Center, European Hospital Georges Pompidou, Paris, France; 6INSERM U970, Paris Cardiovascular Research Center, European Hospital Georges Pompidou, Paris, France.

We have shown that 5-hydroxytryptamine (5-HT) receptor type 4 (5-HT4R) agonists stimulate aldosterone production in patients with aldosterone-producing adenoma (APA). Moreover, 5-HT-positive cells were observed in APA tissues and 5-HT4R mRNAs were markedly overexpressed in APAs in comparison with normal adrenals. All these results suggested that 5-HT produced by adrenal mast cells could be involved in the physiopathology of APAs. The aim of this work was to investigate the role of mast cells in the physiopathology of APA. Mast cells were characterized by specific immunohistochemical stainings using antibodies against tryptase. A high density of mast cells was observed in peritumoral adrenal tissue surrounding adenomas or in the tumor tissues. Tryptase labelling was also detected in some steroidogenic cells in the vicinity of mast cells, suggesting interactions between these two cell types. In addition, staining of APA tissues with antibodies anti-tryptophane hydroxylase, the key enzyme of 5-HT biosynthesis, revealed the presence of immunoreactivity in both mast cells and a subpopulation of steroidogenic cells. Interactions between mast cells and adrenocortical cells were explored using the LAD2 human mast cell line and the human adrenocortical cell line H295R. Administration of LAD2 cell culture supernatant to H295R cells induced a significant increase in aldosterone production which was potentiated when LAD2 cells were pre-incubated with the mast cell degranulator, compound 48/80. On the other hand, we observed that 5-HT stimulated H295R cells steroidogenesis via 5HT4R activation suggesting that the effect of mast cells supernatant could be at least in part due to 5-HT. These studies will be completed by co-cultures of mast cells and adrenocortical cells. Interactions between mast cells and steroidogenic cells in the vicinity of mast cells, suggesting interactions between these two cell types. In addition, staining of APA tissues with antibodies anti-tryptophane hydroxylase, the key enzyme of 5-HT biosynthesis, revealed the presence of immunoreactivity in both mast cells and a subpopulation of steroidogenic cells. Interactions between mast cells and adrenocortical cells were explored using the LAD2 human mast cell line and the human adrenocortical cell line H295R. Administration of LAD2 cell culture supernatant to H295R cells induced a significant increase in aldosterone production which was potentiated when LAD2 cells were pre-incubated with the mast cell degranulator, compound 48/80. On the other hand, we observed that 5-HT stimulated H295R cells steroidogenesis via 5HT4R activation suggesting that the effect of mast cells supernatant could be at least in part due to 5-HT. These studies will be completed by co-cultures of mast cells and adrenocortical cells. Altogether, our results show that APA tissues contain numerous mast cells which may influence aldosterone secretion through local release of soluble regulatory factors.

Supported grants from the ANR (PHYSIO, ISPA), the FRHTA and the COMETE network (PHRC AOM 06179).

P17

Abstract withdrawn.

P18 Bilateral primary adrenocortical carcinomas developing severe muscle weakness
N Kumatagi, M Shimodaira, K Tsuchawa, E Sorimachi, M Kamesaka & K Honda
Tokyo Metropolitan Hiroo Hospital, Shibuya, Tokyo, Japan.

Introduction Primary adrenocortical carcinoma (ACC) is a rare adrenal tumor and bilateral tumors are reported in 10% of total patient with ACC in Japan. We present a case of bilateral ACCs accompanied by severe muscle weakness.

Case report A 63-year-old male patient with bilateral adrenal masses was referred to our department for the examination and treatment of progressive muscle weakness and appetite loss lasting over 2 months. He was not able to stand up by himself because of loss of muscle power. Computed tomography showed bilateral huge adrenal tumors (110 mm in diameter each) extending into the inferior vena cava. No significant uptake was found in 131-I MIBG scintigraphy. Plasma levels and 24-h urinary excretion of catecholamines and their metabolites were normal. Serum cortisol levels were slightly low and plasma ACTH levels were slightly high. These findings suggested presence of primary adrenocortical insufficiency and we began replacement therapy with low doses of hydrocortisone. His symptoms, such as appetite loss and muscle weakness were immediately improved after replacement therapy and it enabled him to walk by himself. To establish the diagnosis, we performed open biopsy and histological findings revealed adrenocortical carcinoma. In spite of medical therapy with mitotane, the development of ACCs was aggressive and he died from multiple organ failure.

Conclusion To the best of our knowledge, a case of ACC accompanied by serious muscle weakness is very rare. Bilateral ACCs can cause primary adrenal insufficiency by their invasion to both adrenal glands. It is known that muscle weakness can be developed in patients with adrenocortical insufficiency but its exact mechanism is still unknown. Marked and immediate improvement of muscle power after the hydrocortisone replacement therapy strongly suggests that cortisol deficiency plays a critical role in developing severe muscle weakness in this case.
The European Registry on Cushing’s syndrome (ERCUSYN) is designed to collect prospective and follow-up data at EU level on patients with Cushing’s syndrome (CS). Baseline data on 481 CS patients (390 females, 91 males; mean age \( \pm \) SD): 44 (14) years) collected from 36 centres in 23 countries. This cohort included new patients since 2008 and retrospective cases since 2005. Patients were divided into four major etiologic groups: pituitary-dependent CS (PIT-CS) (66%), adrenal-dependent CS (ADR-CS) (27%), CS from an ectopic source (ECT-CS) (5%) and CS from other etiologies (OTH-CS) (2%). Proportion of men in the ECT-CS group was significantly higher than in the other etiologic groups \((P<0.05)\). Patients in the ADR-CS group were significantly older than those in the PIT-CS group \((P<0.05)\).

Prevalence of hirsutism and irritable bowel syndrome (IBS) in ECT-CS patients was 92 and 74%, respectively, which was significantly higher as compared with the other etiologic groups \((P<0.05)\) for hirsutism and \(P<0.01\) for diabetes). Patients with PIT-CS had significantly more skin alterations, menstrual irregularities and hirsutism than those with ADR-CS \((P<0.05)\). Reduced libido was more prevalent in men than in women \((P<0.01)\). Prevalence of osteoporosis at spine was significantly higher in men as compared with women \((P<0.05)\), and males had significantly more vertebral and rib fractures than females \((52 \text{ vs } 18\% \text{ for vertebrae}; \! P<0.001; \! 34 \text{ vs } 23\% \text{ for ribs}; \! P<0.05)\).

This study is part of the ERCUSYN project and was supported by a PHP grant 800200 of the EU.

P22
Cardiac structure and function in patients with adrenal incidentaloma with and without subclinical Cushing’s syndrome

M De Leo, M Galdersi, A Cozzolino, C Simeoli, P Vitale, R Raia, A Colao & R Pivonello
Department of Molecular and Clinical Endocrinology and Oncology, ‘Federico II’ University, Naples, Campania, Italy; 2Department of Internal Medicine, ‘Federico II’ University, Naples, Campania, Italy.

Subclinical Cushing’s syndrome (SCS) is increasingly being reported in incidentally observed adrenal tumors; its hallmark is a mild autonomous cortisol hypersecretion without specific clinical syndrome of glucocorticoid excess. The aim of this study was to compare cardiac structure and function in patients with adrenal incidentaloma. Thirty patients (10 men, 15 women, 32–74 years) and 30 sex- and age-matched healthy controls entered the study: among patients, 11 had SCS and the remaining 14 had normal cortisol secretion. All patients and controls were submitted to Doppler echocardiography, with evaluation of left ventricular (LV) mass index (LVMI), ejection fraction (EF), main parameter of systolic function, and early (E) to late or atrial (A) peak velocity (E/A), main parameter of diastolic function, together with the measurement of systolic (SBP) and diastolic (DBP) blood pressure. SBP \((P<0.01)\) but not DBP, was higher in patients than in controls. At Doppler echocardiography, EF and E/A were significantly reduced in patients compared to controls. However, no significant difference was found in LVMI. In particular, both patients with and without SCS had reduced EF and E/A compared to controls. A slight but not significant increase in LVMI was found in patients with but not in patients without SCS. No significant difference in SBP and DBP, and only slight difference in cardiac parameters, were found between patients with and without SCS. In conclusion, patients with adrenal incidentaloma have a mild impairment of cardiac performance, represented by both a systolic and diastolic dysfunction independently on the presence of SCS. These findings suggest that patients with incidentally discovered, or clinically non-functioning adrenal tumors need to be monitored for cardiac performance during their follow-up.
surgery resulted in reversal of her cardiomyopathy which would have otherwise disrupted her cardiomyopathy. An EF of more than 45% and her 3 month post operative echo showed reversal of her cardiomyopathy screen (autoantibodies, virology and thyroid) was negative but suggested a steroid induced dilated cardiomyopathy with severe LVF (ejection fraction – EF 26%). Her dilated cardiomyopathy was confirmed on echocardiogram, which also suggested a diagnosis of Cushing’s syndrome. She had an angiogram a month later that ruled out any arterial hypotenstion and ashenia. For what concerns the high ACTH serum levels, it is well known that LH receptors on Leydig cells are down-regulated by ACTH, so it is possible that AD leads to a relative hypogonadism which can contribute to sexual dysfunction. Moreover, a relative hypogonadism could be also due to GnRH serum levels lowered by CRH.

Conclusions

Several data and our results suggest the presence of mood disturbances in AD patients even if it is not clear which factor linked with cortisol has the prominent role in affecting sexual life, sexual behaviour and mood in hyposurrenism.

P24

Hormones failing the heart

M Pierides, J Cullen, S Al-Hamali, K Patel & B O’Malley
University of Leicester, Leicester, UK.

Cardiovascular disease and diastolic hypertension are major causes of morbidity in Cushing’s although left ventricular failure is more rarely described. There are three other cases of documented dilated cardiomyopathy with subsequent left ventricular failure.

Thirty-five year old lady who presented with obesity and striae was found to have a suppressed ACTH, elevated cortisol (914 post dexamethasone suppression test) and a right adrenal adenoma (on CT), confirming a diagnosis of Cushing’s syndrome. She was started on metyrapone 250 mg TDS and was referred for a right adrenalectomy. During the next 2 months, she was admitted to hospital with acute dyspnea. Her CT pulmonary angiogram revealed no pulmonary embolus. She was discharged on oral antibiotics for a chest infection. She was readmitted a week later with left ventricular failure (LVF) and type 1 respiratory failure requiring high flow oxygen and diuretics. She clinically had moderate mitral regurgitation confirmed on echocardiogram, which also suggested a diagnosis of dilated cardiomyopathy with severe LVF (ejection fraction – EF 26%).

Her cardiomyopathy screen (autoantibodies, vireology and thyroidology) was negative but her cortisol day curve had values over a thousand suggesting a steroid induced cardiomyopathy. She gradually responded well to doubling of her metyrapone to 500 mg TDS and supportive care in the form of oxygen, ACE inhibition, beta blockade and diuretics. She had an angiogram a month later that ruled out any ischaemic causes for her cardiomyopathy and showed an improving LVEF of 40%. She had her adrenalectomy (right) 3 months later. This revealed a benign cortical adenoma (55 x 45 x 28 mm). Her post operative echocardiogram showed an EF of more than 45% and her 3 month post operative echo showed reversal of her cardiomyopathy.

Monotherapy (metyrapone blockade) of her Cushing’s with subsequent curative surgery resulted in reversal of her cardiomyopathy which would have otherwise had a significant effect on her morbidity.

Endocrine Abstracts (2011) Vol 26

P25

Cushing’s syndrome in pregnancy due to LH/hCG receptor positive adrenocortical carcinoma: case report

S Tigaš, K Zikopoulos, Z Leit, C Raou & A Tsatsoulis
1Department of Endocrinology, University of Ioannina, Ioannina, Greece; 2Department of Obstetrics and Gynaecology, University of Ioannina, Ioannina, Greece; 3Department of Obstetrics, Gynaecology and Women’s Health, University of Louisville, Louisville, Kentucky, USA; 4Department of Genetics, Obstetrics and Gynecology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.

Introduction

Cushing’s syndrome is rare during pregnancy perhaps because hypersecretion of glucocorticoids supresses pituitary gonadotrophin secretion resulting in subfertility. When present, the syndrome is usually due to adrenal disease and less commonly to pituitary adenomas or ectopic ACTH production. In the contrary, Cushing’s syndrome outside pregnancy is usually due to pituitary adenomas whereas non ACTH-dependent Cushing’s is less frequent.

Case report

We describe the case of a 27-year-old female primigravida, who was admitted during the 22nd week of pregnancy with hypertension and probable preeclampsia. On admission, blood pressure was 130/90 mmHg on oral nifedipine and methylldopa. Clinical examination revealed signs of florid Cushing’s syndrome. Laboratory investigations: plasma glucose 103 mg/dl, routine biochemical testing within normal range. Urine collection revealed proteinuria of 5.6 g/24 h. Serum cortisol: 49.7 µg/dl (5.0–23.0) with loss of diurnal variation and low ACTH (5.2 pg/ml). DHEAS was normal, total testosterone raised at 4.5 ng/ml (0.3–1.4) due to raised SHBG. Serum cortisol following overnight dexamethasone (1 mg) suppression testing was raised (> 50 µg/dl). Abdominal ultrasound showed a 5.6 cm hypechoic mass in the left adrenal. The patient underwent laparoscopic left adrenalectomy; a 5.9 cm mass was excised. Histological and immunohistochemical findings were consistent with adrenocortical carcinoma (Weiss score 5/9).

In addition, immunohistochemistry showed expression of LH/hCG receptors in the tumour tissue. Postoperatively, the patient’s condition improved with normalization of the blood pressure and gradual improvement of the proteinuria (0.9 g/24 h). The patient underwent caesarian section (36th week of pregnancy), giving birth to a healthy male infant weighing 1800 g.

Conclusion

This is the second report of adrenocortical carcinoma presenting with Cushing’s syndrome during pregnancy. The presence of abberant LH/hCG receptors in adrenal tumour tissue might have contributed to the development of Cushing’s syndrome in pregnancy and possibly to tumour growth in this case.

P26

Predictive value of acute cortisol response to cabergoline administration on the responsiveness of cortisol secretion to short and long term treatment with cabergoline

P Vitale, A Cozzolino, M De Leo, C Simeoli, M Gallardo, G Lombardi, A Colao & R Pivonello
Department of Clinical and Molecular Endocrinology and Oncology, ‘Federico II’ University, Naples, Campania, Italy.

Cabergoline (CAB), a potent dopamine agonist, is one of the most effective neuroreulatory drug in the second line treatment of patients with Cushing’s disease (CD). The aim of the current study was to estimate the predictive value of the acute CAB administration on short and long term responsiveness to CAB treatment. Twenty CD patients (6 males, 14 females, 12–60 years) entered the study. The acute CAB test was performed evaluating serum cortisol every hour for 6 h after 1 mg CAB administration. Serum cortisol and urinary cortisol (UC) levels were evaluated at baseline and after three (short-term) and six (long-term) months of treatment with CAB (dose 1–9 mg weekly). Patients were considered responsive when UC levels were ≤ 50% compared with baseline after 3 months or normalized after 6 months of treatment. A ROC curve was performed to establish the cut-off of the percentage of serum cortisol percent reduction (%C) which guaranteed the highest sensitivity (SS) and specificity (SP) in predicting the responsiveness after short and long-term CAB treatment. The positive and negative predicting values (PPV and NPV) were estimated at both 3 and 6 months of treatment. Ten of the 20 patients (50%) showed responsiveness after either 3 or 6 months. A direct correlation was found between %C and the percentage of reduction of UC at 3 months (r = 0.467; P = 0.038), while no direct correlation was found between %C and the percentage of reduction of UC at 6 months. The 18% (SS = 100%, SP = 67%) and 20% (SS = 100%, SP = 50%) were considered as the best %C cut-offs of the acute test response to predict the chronic responsiveness at 3 and 6 months, respectively using these values we obtained a PPV of 83% and a NPV of 100% after 3 months and a PPV of 67% and a NPV of 67% after 6 months of treatment. In conclusion, the acute CAB test is useful to predict short-term but not long-term responsiveness, on the other hand it is completely reliable to select patients non responders to chronic CAB treatment.

Endocrine Abstracts (2011) Vol 26
P27
Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

A Ardito, A Al Ghuzian, M Fassnacht, P Duffara, S Leboulleux, S Wortmann, B Zaglia, S De Francia, Marco Volante, Luigi Gonzaga, Alfredo Berruti, Bruno Alloio, Eric Baudin & Massimo Terzolo

1Internal Medicine I, Faculty of Medicine S. Luigi Gonzaga, University of Turin, Orbassano, Italy; 2Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France; 3Department of Medicine I, University Hospital of Würzburg, Würzburg, Germany; 4Pathology, Faculty of Medicine S. Luigi Gonzaga, University of Turin, Orbassano, Italy; 5Medical Oncology, Faculty of Medicine S. Luigi Gonzaga, University of Turin, Orbassano, Italy.

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 16–76) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31, IV in 6; 62 patients had secreting ACC. Forty patients were treated with 8–10 g/daily and 80 patients with 1–6 g/daily. Target mitotane concentrations of 14–20 mg/l were attained within 3 months from treatment start in 49 patients (41%), within 6 months in additional 61 patients (51%), while 10 patients (8%) never got them. Mitotane levels >14 mg/l were maintained in more than 75% of determinations in 64 patients (53%). Median duration of treatment was 25.5 months (range: 4–165) and median duration of follow-up was 36 months (6–165). Only 11 patients (9%) experienced severe adverse events (CCTC 3), but none of the patients discontinued mitotane definitively for toxicity. At the last follow-up, 58 patients (48%) relapsed and 33 patients (27%) died. RFS was significantly longer in patients who attained target mitotane concentrations within 3 months (P=0.01) and in patients who maintained consistently levels >14 mg/dl during follow-up (P=0.004). In a multivariate analysis (including sex, age, stage, number of mitoses or Ki-67 value) maintenance of target mitotane concentrations was an independent factor influencing RFS (HR=0.41, 95% CI 0.21–0.77; P=0.006). The effect on overall survival was significant only in univariate but not in multivariate analysis (HR=0.61, 0.26–1.43). The present data demonstrate for the first time that target mitotane concentrations may have a therapeutic impact in an adjuvant setting. This finding supports indirectly the efficacy of adjuvant mitotane treatment.

P28
Impact of long-term cabergoline treatment on clinical, metabolic and hormonal features in patients with Cushing’s syndrome

A Cozzolino, P Vitale, M De Leu, C Simeoli, L F S Grasso, G Lombardi, A Colao & R Fussi

Department of Clinical and Molecular Endocrinology and Oncology, Federico II University, Naples, Italy.

Cabergoline (CAB) was demonstrated to be effective in normalizing cortisol secretion in a subset of patients with Cushing’s disease (CD). The aim of the study was to evaluate the impact of chronic treatment with CAB on clinical, metabolic and hormonal parameters in CD patients. Twenty-six patients with CD (11 males, 15 females, 12–72 years) entered the study. Patients were divided into two groups, responders and non responders, according to the achievement or not of normalization of urinary cortisol (UC) levels. The evaluation of clinical, metabolic and hormonal parameters were performed before and after 6 months treatment with CAB, administered at the dose of 1–9 mg weekly. The clinical parameters included weight, BMI, waist, systolic and diastolic blood pressure, Back Depression Inventory-II, International Index of Erectional Function (IIEF) and Female Sexual Function Index (FSFI) scores, the metabolic parameters included serum glucose, triglycerides, cholesterol levels, whereas hormonal parameters included plasma ACTH and serum cortisol, androstenedione, DHEAS, renin and aldosterone levels. After 6 months of treatment, 15 patients were responsive (UC decrease =63.2%) whereas 11 patients were not responsive (UC decrease =44.3%). In responsive patients, a significant decrease of plasma ACTH and serum cortisol, systolic and diastolic blood pressure, serum glucose, androstenedione, DHEAS, renin and aldosterone (P<0.05) and a significant increase of IIEF and FSFI (P<0.05) was found. Conversely, in non responsive patients, a significant decrease of plasma ACTH, serum cortisol and androstenedione as well as blood pressure levels (P<0.05) was found, whereas weight and waist significant increased (P<0.05). In conclusion, long-term CAB treatment is able to ameliorate blood pressure, metabolic and hormonal parameters as well as sexual function in responsive patients, but is also able to improve blood pressure and decrease androgen levels in non responsive patients. These results demonstrated that long-term CAB treatment has a relevant impact of the clinical syndrome and complications of patients with CD.

P29
TP53 and adrenocortical cancer: analysis of germline mutations and polymorphic changes in 140 patients

Leonie Herrmann, Britta Heine, Martin Fassnacht, Holger Willenborg, Marcus Quinkler, Nicole Reisch, Bruno Alloio & Stefanie Hahner

1Department of Endocrinology, University of Würzburg, Würzburg, Germany; 2Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düesseldorf, Düesseldorf, Germany; 3Department of Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Berlin, Germany; 4Department of Endocrinology and Metabolism, Medizinische Klinik-Innenstadt, University Hospital Munich, Munich, Germany.

Adrenocortical carcinoma (ACC) is part of the Li-Fraumeni tumour syndrome which is due to germline mutations in TP53. Recent studies demonstrate low penetrance mutations leading to later tumour manifestation. Furthermore, in ACC mutations outside the hotspot region have been found. TP53 polymorphisms have also been described to impact on p53 function. We, therefore investigated TP53 sequence alterations in a large cohort of adult patients with ACC.

Methods
Germline DNA of 140 ACC-patients was extracted from leucocytes. Mutation and polymorphism analysis was performed by amplification and sequencing of exons 2–11 of TP53. Corresponding tumour DNA of mutation carriers was also investigated and LOH analysis was performed.

In 103 evaluable cases 5 TP53 germline mutations were found in 4 patients (4%). Three mutations have not been described previously. Three mutation carriers were diagnosed at young age (<40 years), had a short survival time (<3 years) and 2 had a family history of cancer. One young female was found to have 2 mutations and a family history of ACC (mother and uncle) indicating an adrenal specific phenotype. Furthermore, the brazilian hot spot mutation R337H was found in a male patient diagnosed at high age and with a current survival time of 10 years. LOH of one TP53 allele in the tumour was detected in all cases with loss of the mutated allele in one patient. Analysis of 11 TP53-polymorphisms revealed significantly different distributions for 3 polymorphisms in ACC compared to controls. However, correlation with clinical outcome did not reveal a prognostic impact of these polymorphisms in multivariate analysis.

TP53 germline mutations can also be found in a significant but lower percentage of adult ACC patients and may appear outside the hot spot region (2 of 5 mutations in exon 10). TP53-polymorphisms seem to be of minor relevance in ACC.

P30
Is plasma mitotane level > 30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

S M D Maucere-Denost, A T Tabarin, D D Druil, L C Chaillous, S S Salenave, S L Leboulleux, O C Chalve, C D C Do-Cao, H D Dubourg, M L C Cuvelier, J Y Young & E B Baudin

1Department of Endocrinology, Haut-Lévêque Hospital, University of Bordeaux, Pessac, France; 2Department of Endocrinology, University of Nantes, Nantes, France; 3Department of Endocrinology, Kremlin Bicêtre Hospital, Le Kremlin Bicêtre, France; 4Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France; 5Department of Endocrinology, University of Grenoble, Grenoble, France; 6Department of Endocrinology, University of Lille, Lille, France; 7Department of Pedriatry, University of Calais, Calais, France.

Background
Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).

Methods
Mitotane plasma levels, SAE and grade 3–4 toxicities were recorded in ACC patients, followed between 09/2006 and 05/2010 in the French COMETE network.
network. Plasma mitotane levels were monitored by the Lyosafe service. Grading of toxicity was done with NCI. NCTAE (version 3) criteria. SAE is defined by death, life-threatening, hospitalization, persistent disability, congenital anomaly / birth defect or other medically important events.

Results
A mitotane plasma levels >30 mg/ml was observed in 15 out of 310 (4.8%) patients. Fifteen assays >30 mg/l were identified among 2057 analysed (0.7%). The median mitotane plasma level was 35.76 mg/l, after a median time of 8 months from mitotane initiation, corresponding to a median mitotane dosage of 4.5 g/day. Grade-3 toxicity was observed in 8/15 (53.3%) patients (vertigo, nausea, anorexia, alopecia, hypotension and gynecologic bleeding) and a grade 4 toxicity in 6/15 (40%) patients (asthma, vigilance trouble, anorexia, abdominal pain and aplasia). Hospitalization was required in 6/15 patients (40%). A life threatening SAE was observed in 1/15 (6.7%) due to severe sepsis in aplasia, related to mitotane therapy. No patient died or suffered from sequelae, and no unexpected SAE was observed.

Conclusion
Mitotane plasma levels >30 mg/ml is a rare event. A SAE was observed in 8/15 (53%) patients and 10/15 (66.7%) experienced a grade 3–4 toxicity. We therefore suggest that the plasma mitotane cut-off of 30 mg/l should not be exceeded until a better understanding of the mechanisms that drive clinical toxicity.

P31
18-Oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism
F Satoh, Y Nakamura, R Morimoto, M Kudo, K Takase, H Sasano & S Ito
Tohoku University Hospital, Sendai/Miyagi, Japan.

Context
18-Oxocortisol (18-oxoF) is a derivative of cortisol that is produced by aldosterone synthase (CYP11B2). The potential for this steroid, as a biomarker for differentiating patients with aldosterone-producing adenoma (APA) from those with idiopathic hyperaldosteronism (IHA), has not been examined.

Objectives
We measured 18-oxoF, aldosterone (A) and cortisol (F) in plasma from adrenal vein sampling (AVS) patients. We compared 18-oxoF and 18-oxoF/A and A/F levels for their potential to differentiate APA from IHA.

Design, setting, and subjects
We measured 18-oxoF, F and A in AVS samples obtained from unilateral APAs (14 cases) and bilateral IHAs (7 cases, 14 samples total), using liquid chromatography–mass spectrometry (LC/MS/MS) and RIA analyses, and performed in Tohoku University Hospital.

Results
The levels of 18-oxoF and the ratios of 18-oxoF/F, before and after ACTH stimulation, were significantly higher in blood-draining APAs than in those from the contralateral adrenal gland and from adrenal glands with IHA.

Conclusions
The 18-oxoF levels and ratios of 18-oxoF/F in AVS samples can be a clinically useful biomarker for differentiating APA from IHA and for determining the localization or lateralization of APA in patients with primary aldosteronism.

P32
Mission study: an international observational study on the mortality in Cushing’s syndrome
R Pivonello1, G Melnichenko2, S Zacharieva1, F Gu1, B Oscar3, N S Shah1, R Gaillard1 & A Colao1
1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy; 2National Research Center for Endocrinology of the Russian Academy of Medical Science, Moscow, Russian Federation; 3Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria.

Introduction
Cushing’s syndrome (CS) is a rare but severe disease associated with an increased mortality especially due to cardiovascular diseases, and associated with various systemic complications, including hypertension, glucose intolerance or diabetes mellitus, dyslipidemia and coagulopathy. Few studies have systematically evaluated the mortality of CS in a large and worldwide population of CS. The MISSION study is a retrospective study aimed at assessing the mortality in a large population of patients with all types of CS followed-up in many clinical centres around the world. This report describes the preliminary results of the study. The total number of patients registered in the database was 5092, (79% females and 21% males), with the following distribution of race: 83% Whites, 9% Oriental, 4% Indians, 3% Hispanics and 1% Blacks. Pituitary tumors (66%) represent the most frequent etiology, followed by adrenal diseases (21%), and ectopic disease (5%); a certain number of patients with non definitive diagnosis were classified as ACTH-dependent diseases (5%), ACTH-independent diseases (2%) and disease of unknown origin (1%). The overall mortality accounts for 7% (356 deaths) with a statistically significant difference between patients with active and with inactive disease (P<0.01) and between males and females (P<0.01).

Methods
The mortality was defined by: death, life threatening, hospitalization, persistent disability, congenital anomaly / birth defect or other medically important events.

Results
The mortality increased from 2% at 5 years from mitotane initiation, to 31% at 10 years. A statistically significant difference was observed between patients with active and with inactive disease (P<0.01). The mortality was significantly higher among patients with pituitary adenoma (5%) than among patients with adrenal carcinoma and ectopic tumor, the mortality is significantly higher than pituitary and adrenal adenoma, being 43.5% (89/206) and 26% (66/245) respectively. Excluding the unknown causes, and the caused associated with tumor progression (21/356, 6%), severe infections or sepsis represent the most frequent (60/356, 17%), while heart stroke (32/356, 9%) and brain stroke (21/356, 6%) are the second and third causes of death. Hypertension represents the most common complication (72%), followed by dyslipidemia (44%) and glucose intolerance (39%), psychiatric diseases (17%), and infections (12%), and brain diseases (6%). In conclusion, the preliminary results of this study including more than 5000 patients confirms that CS is associated with an high mortality rate due to sepsis and cardiovascular accidents, and associated with cardiovascular, metabolic and infective complications.
P34
Norwegian patients with congenital adrenal hyperplasia have a high frequency of adrenal myelolipomas and adrenal hypoplasia, and testicular adrenal rest tumours was only detected in men with the saltwasting form

I N Neremo1,2, J R Rørvik3,4, S H H Holmedal3, D L H Hykkerud5, K J Fougner6,1, J S Svartberg7,8, E S H Huseby9,10 & K L Løvås9,10
1 Institute of Clinical Medicine, Akerhus University Hospital, University of Oslo, Lørenskog, Norway; 2 Division of Medicine, Akerhus University Hospital, Lørenskog, Norway; 3 Department of Surgical Sciences, University of Bergen, Bergen, Norway; 4 Department of Radiology, Haukeland University Hospital, Bergen, Norway; 5 Department of Radiology, Akershus University Hospital, University of Oslo, Lørenskog, Norway; 6 Division of Medicine, University Hospital of North Norway, Tromsø, Norway; 7 Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway; 8 Institute of Medicine, University of Bergen, Bergen, Norway; 9 Department of Medicine, Haukeland University Hospital, Bergen, Norway; 10 Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Background
Increased frequencies of adrenal tumours and testicular adrenal rest tumours (TART) have been reported in congenital adrenal hyperplasia (CAH).

Objective
To investigate the frequency of adrenal abnormalities and TART in an unselected adult population of CAH due to 21-hydroxylase deficiency (21-OH) and whether adrenal and testicular pathology correlate with disease categories, current hormone levels and treatment.

Patients, methods and design
From a cross-sectional population-based study of 101 adult Norwegian patients with classical CAH, sixty-three men (n = 23) and women (n = 40) participated in this study (age range 18–75, response rate 62%); thirty-three were salt-wasting (SW) and 30 were simple virilising (SV).

Methods
Adrenal tumours were detected in seven (11%) patients (bilateral tumours in two); four were myelolipomas and one was a phaeochromocytoma. Adrenal hypoplasia was found in eight (13%) patients, whereas 36 (57%) had hyperplasia, and 17 (27%) normal adrenal size. Abnormal adrenal CT scans were significantly more frequent in SW compared to SV. Males had significantly larger adrenal volumes (27%) normal adrenal size. Abnormal adrenal CT scans were significantly more frequent in CAH men with SW. Morning ACTH levels correlated positively with total adrenal volume and the frequency of TART.

Results
TART was frequently found in CAH men with SW. TART was more frequent in CAH men with SW compared to SV. Males had significantly larger adrenal volumes than females. TART was present in 33% of the men and 17% of the women. Morning ACTH levels correlated positively with total adrenal volume and the frequency of TART.

Conclusions
In this population-based survey of patients with classical CAH, we found a high frequency of adrenal tumours, particularly myelolipomas, hypoplasia and hyperplasia. TART was frequently found in CAH men with SW.

P35
Presence of liver X receptors alfa (LXRA) and beta (LXRbeta) in cortisol-secretting adrenal adenomas

G Bellastella, D Visconti, G Conzo, V Rossi, V Palumbo, A De Bellis, A Bellastella & A A Sinisi
Clinical and Experimental Medicine and Surgery, Second University of Napoli, Napoli, Italy.

Liver X receptors (LXRA and LXRbeta) act on the cholesterol homeostasis in several tissues, including adrenals. In particular, LXRA regulates the expression of several genes involved in the cholesterol efflux and storage and modulates glucocorticoid synthesis in mice. The level of the expression of LXRs in the human adrenal adenomas is unknown. We evaluated LXRA and LXRbeta mRNA levels in cortisol-secretting adenomas (CSA) and in the surrounding normal tissue, obtained from patients with Cushing syndrome underwent unilateral adrenalectomy; moreover, we studied the effects of the LXR agonist T09 on LXRs expression level and on cortisol release in adrenal cell primary cultures derived from CSA.

Methods
Total RNAs was extracted from 10 CSA and from 6 surrounding adrenal tissues. Quantitative real-time PCR was used to measure LXRA and LXRBeta transcripts. Primary culture of adrenal cells were set up from 2 CSAs and treated with 1 μM T09 or solvent as control. Cultures were harvested after 6 h (for expression study), and after 24–48 h (for cortisol measurement by ELISA assay). Results
LXRA and LXRBeta transcripts were found in CSA and surrounding adrenal tissue samples, and in primary cultured cells. LXRA resulted less abundant than LXRBeta in all samples; moreover, LXRA mRNA levels were lower in CSA than in surrounding adrenal tissues. LXRA expression increased after T09 treatment (P < 0.01) in cultured adrenal cells. T09 induced also a 35% decrease of cortisol level after 48 h.

Conclusion
We demonstrate that LXRs are expressed in CSAs, with a lesser evidence of LXRA. LXR agonist modulates positively LXRA level and negatively cortisol secretion in primary cultured adrenal cells derived from CSAs. These data suggest a role of LXR mediated pathway in the pathogenesis of CSAs, and a potential use of LXR ligands in the control of cortisol secretion.

P36
Radiosurgery with application of proton beam in patients with Cushing’s disease: a hormonal monitoring of the long-term results

E Marova, N Goncharov, G Kolesnikova, S Arapova, M Zhimirikina & O Manchenko
National Research Centre of Endocrinology, Moscow, Russian Federation.

Patients with Cushing’s disease were treated with proton beam surgery (pituitary irradiation) and the long-term results were studied. Hormone levels in 197 patients with the verified Cushing’s disease (161 woman and 36 men) were monitored after proton irradiation. Age of patients before irradiation is 17–54 years. Duration of supervision is 1–24 years. In peripheral blood, the concentration of pituitary hormones (ACTH, prolactin, LH, FSH, TSH, GH), and hormones of peripheral glands (cortisol, estradiol, testosterone, free thyroxine) and free cortisol in daily urine were measured. ACTH and cortisol were measured at 0800 and 2300 h in order to follow the daily dynamics of their secretion.

Full remission of the basic disease as judged by the hormonal parameters was found in 83.6% (1.5 ± 1.8 years after the therapy). Remission without the subsequent decrease of pituitary functions was observed in 21.8%. Multiple side effects of irradiation were observed in 50.1%, whereas single side effects were registered in 27.4%. The main side effects were: adrenal insufficiency – 29.7%, secondary hypothyroidism – 33.8%, hypogonadism – 47.4%, hyperprolactinemia – 36.7%.

We conclude that the first side effect to appear is adrenal insufficiency (2.5 ± 2.3 years), then increase of prolactin and decrease of gonadotropins (consecutively, 3.0 ± 2.9 and 3.0 ± 3.1 years). The last side effect to appear is secondary hypothyroidism (5.0 ± 3.2 years).

Biochemical hormonal monitoring is essential requirement of the dynamic follow-up of patients with Cushing’s disease during lifelong period of time for timely revealing of hypopituitarism and appointments of corresponding therapy.

P37
Thoracic and gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and the ectopic ACTH syndrome (EAS)

K Kamp, A Alwani, R A Feeders & W W de Herder
Erasmus MC, Rotterdam, The Netherlands.

Introduction
The ectopic ACTH syndrome (EAS) is associated with a variety of malignancies, mostly of (neo-)endocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) is virtually absent.
Study design
In our tertiary academic referral centre for NET patients and also for patients with Cushing’s syndrome, a large consecutive series of thoracic NET and GEP NET patients was screened for the presence/occurrence of EAS.

Patients
Four hundred and ninety-one patients, diagnosed with thoracic or GEP NETs, referred between 1-1-2000 and 1-12-2009, were studied.

We differentiated between previous, synchronous and metachronous occurrence of EAS. Synchronous EAS was defined as occurring between 6 months before and 6 months after the date of first diagnosis of the thoracic or GEP NET.

Patients with MEN-1 were excluded. Small cell lung cancer was also excluded.

Results
This series comprised of 491 patients with thoracic and GEP NETs (258 males, 233 females; female to male ratio, 1:1.1; mean age, 58.1 years).

Ten patients (2.0%) had EAS (5 males, 7 females; mean age, 53.1 years). All patients had synchronous EAS. Five patients had a bronchial NET; three had a thymic NET and two had a pancreatic NET.

Conclusions
The incidence of EAS in patients with thoracic and GEP NETs is very low (2.0%).

In line with the literature thoracic NETs (thymus and bronchial carcinoids) were the most frequent cause of EAS. Pancreatic NETs are the most common GEP-NE Ts causing EAS.

P38
The role of insulin tolerance test (ITT) and ACTH/cortisol ratio in chronic fatigue patients
F Coucke1, T Hertoghe2, G Rindsig1, L Coucke1 & H Lammens1
1Metares VZW, Gent/Charlottenlund, Denmark; 2University de Charleroi, Charleroi, Belgium.

Rationale
In chronic fatigue syndrome (CFS) there is a great controversy about the role of the ACTH/cortisol axis. To examine this phenomena we performed ITT tests in CFS patients with low fasting cortisol (<20 µg/dl). A group of CFS patients with other hypophysal dysfunction were also examined.

Methods
One hundred and one patients who underwent classical fasting ITT were registered and analyzed: glucose, cortisol, ACTH and GH were measured and patients were divided in five groups according to the cortisol response or the presence of other hypophysy deficiencies. ACTH/cortisol in groups was measured with the peak values during ITT.

Result/conclusion
Sixty-seven patients have an elevated ACTH/cortisol ratio: 8 and 29 had a normal ratio of 1.9. Patients with peak cortisol response above 30 show no ACTH increase. The elevated ACTH/cortisol ratio is a very useful tool in the early detection of adrenal insufficiency.

Therefore, ITT testing is preferred in CFS patients, instead of synacthen testing, because the phenomenon of ACTH compensation can be measured and reflected in the ACTH/cortisol ratio.

P39
Quality of life in patients in long-term remission of Cushing’s syndrome is impaired, regardless of etiology, treatment strategy or remaining hormonal deficiencies
M Wagenmakers, R Netea-Maier, T Dekkers, M den Heijer & A Hermus
Radboud University Medical Centre, Nijmegen, The Netherlands.

Background
Impaired health related quality of life (QOL) in patients in long-term remission of Cushing’s syndrome (CS) has previously been reported. However, the major determinants of the impaired QOL have not yet been established.

Aim
To investigate QOL of patients in long-term remission of CS treated in our hospital (1969–2007) and to investigate the influence of the etiology of CS, treatment strategy, coexistent hypothyroidism and glucocorticoid deficiency on the QOL.

Patients and methods
Seven validated questionnaires to evaluate QOL were sent to 182 patients in remission of CS. One hundred and twenty-four patients (107 women, age 52.2 ± 12.0 years, 80% Cushing’s disease (CD) and 20% adrenal CS) completed the questionnaires. Mean duration of remission was 13.3 ± 10.4 years (range 2–39).

Questionnaire results of the patient group were compared with those of an age and sex matched control group of 105 healthy subjects. Furthermore, the results of different subgroups of patients were compared.

Results
The average QOL scores in the total patient group and each patient subgroup were significantly worse on all scales of all questionnaires compared to healthy controls (P<0.05). The subgroup analysis revealed no difference between the QOL scores in the different patient groups. In particular, there was no significant difference in QOL between patients without any hormonal deficiencies and patients with one or more hormonal deficiencies.

No other patient and disease related factors significantly influenced the QOL.

Conclusion
Our patients in long-term remission of CS experience an impaired QOL compared to healthy control subjects, regardless of the etiology of CS, treatment strategy, coexistent hypothyroidism and glucocorticoid deficiency. Based on these results we hypothesize that the previous longstanding exposure to high cortisol levels may have irreversible effects resulting in impaired QOL, although the previous experience of a severe disease may also influence QOL.

P40
Sunitinib in refractory adrenocortical carcinoma: results of a phase II trial
M Fassnacht1, M Kroiss1, S Hahner1, C Strasburger2, B Allolio1 & M Quinkler2
1Department of Medicine I, University of Würzburg, Würzburg, Germany; 2Clinical Endocrinology, Charité Campus Mitte, Charité University, Berlin, Germany.

Background
Adrenocortical carcinoma (ACC) is a rare solid tumor with poor prognosis in advanced stages. The adrenolytic drug mitotane and cytotoxic chemotherapies are current treatment options with limited clinical efficacy. Animal experiments pointed to an adrenotoxic effect of sunitinib suggesting potential antineoplastic activity in ACC.

Study population
Thirty-eight patients with advanced ACC progressing after mitotane and 1–3 cytotoxic chemotherapies were included. Mitotane treatment was ongoing in 20 patients.

Primary endpoint
Response defined as progression free survival of ≥12 weeks.

Results
Three patients were un evaluable for response due to withdrawal of consent, noncompliance with the study procedures or a serious adverse event. Of the 35 patients analyzed for response, 5 patients (14%) experienced stable disease (median time to progression 5.8 months, range 5.6–11.2), 24 had progressive disease according to RECIST criteria and 6 patients died of the disease before the first evaluation. Median time to progression was 2.8 months (0.3–5.7). In total, 36 serious adverse events were recorded of which 10 were possibly treatment related. Only 41 treatment-related adverse events were documented (mostly CTC grade 1–2). Surprisingly, the response rate was higher in patients not receiving mitotane (4 of 15 vs 1 of 20) suggesting that concomitant mitotane treatment may negatively affect clinical outcome (HR for progressive disease 6.9 (95% CI 0.7–69.9). Therefore, we hypothesize that mitotane may lead to decreased sunitinib plasma concentrations, probably by induction of metabolizing enzymes. This could also explain the low frequency of adverse events which was much lower than expected from other sunitinib trials.

Conclusion
Sunitinib has a modest single-agent activity in ACC. Drug interaction with mitotane may abrogate a more impressive anti-tumor effect of sunitinib. Therefore, a clinical trial of sunitinib in mitotane naive patients might be warranted.
The diagnosis of the adrenal insufficiency requires complex clinical, laboratory and imagistic investigations. The study group was represented by 59 cases of adrenal insufficiency hospitalized in the Clinic of Endocrinology Timisoara, Romania, during the period 2000-2010 (age = 42.10 ± 16.30 years; F/M ratio = 43/16). The patients were divided in two groups: primary adrenal insufficiency (42.37%) and secondary adrenal insufficiency (57.63%). In the group of primary adrenal insufficiency, the autoimmune Addison's disease represented 84% cases while the pituitary tumors had the highest incidence (44.12%) between the causes of the secondary adrenal insufficiency followed by Sheehan’s syndrome (29.41%). Forty-eight percent cases of autoimmune Addison’s disease associated different autoimmune disorders, like: chronic autoimmune thyroiditis (66.67% cases), Graves’ disease (25% cases), gonadal failure, vitiligo, rheumatoid arthritis. Two patients with autoimmune Addison’s disease presented subclinical adrenal insufficiency and were diagnosed by using tetracosactrin stimulation test. Only 6 cases of secondary adrenal insufficiency presented a normal rise of the cortisol serum levels at 24-48 h after depot tetracosactrin administration. The patients with secondary adrenal insufficiency and associated central hypothyroidism presented a significant lower serum FT4 level than the patients with autoimmune Addison’s disease associated with primary hypothyroidism (P<0.01).

**Conclusions**

Glyceregulation disorders in endocrine are frequently, hormone excess or deficit resulting for impaired metabolism of glucose by different mechanisms.

**Methods**

The study was conducted on 118 patients with hyperthyroidism, acromegaly and hypercortisolism. The inclusion criteria were: patients nondiagnoses that have not followed the treatment with drugs that could induce hyperglycemia (epinephrine, oral contraceptives, glucocorticoids, mineralcorticoids etc.), no-collateral family history of diabetes mellitus. Making glucose tolerance test with 75 g glucose pulvis with glucose assessment at 1 and 2 h after glucose ingestion, allowed in varying proportions the detection of diabetes mellitus in the study.

**Results**

Glyceregulation disorders were present in 58% of hyperthyroidism, 46% of patients with acromegaly, 53% of those with hypercortisolism. Altered carbohydrate metabolism was directly proportional to the excess hormone level, on the types of diseases studied.

**Conclusions**

Differential treatment specific endocrine disease, improves the disorder of glyceregulation occurred in the context of hormonal dysfunction.

---

**Endocrine disruptors**

**P42**

**Evaluation of the effect of L-thyroxine therapy on endothelial functions in patients with subclinical hypothyroidism**

Fatima Alibaz Oner1, Selen Yurdakul2, Ender Oner3, Ayse Kubat Uzum4 & Mecdi Erguney5

1Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey; 2Cardiology Division, Istanbul Florence Nightingale Hospital, Istanbul, Turkey; 3Corony Intensive Care Unit, Istanbul Education and Research Hospital, Istanbul, Turkey; 4Istanbul Education and Research Hospital, Clinic of Internal Medicine, Istanbul, Turkey.

**Objectives**

Subclinical hypothyroidism (SH) is characterized by normal serum free T4 (FT4), free T3 (FT3) levels and increased serum TSH levels. Endothelial dysfunction that is accepted an early step of the atherosclerosis, has been reported in patients with subclinical hypothyroidism. The aim of this study was to evaluate endothelial functions and the effect of L-thyroxine (L-T4) therapy on endothelial functions in SH.

**Methods**

Twenty-seven patients with SH and 22 healthy controls were evaluated by brachial ultrasonography for endothelial functions. After restoring euthyroidism in SH, measurements were repeated.

**Results**

The patients with subclinical hypothyroidism and healthy control group were similar in terms of baseline and nitrate induced diameters of brachial artery. Compared to the control group, the patients with SH showed significantly reduced FMD. The baseline and nitrate induced diameters of brachial artery were significantly high after L-T4 in SH group. Besides, FMD significantly increased in patients with SH.

**Conclusions**

Hypothyroidism accelerates atherogenesis through modification of atherosclerotic risk factors and direct effects on the blood vessels. In the present study, we found significantly improvement in FMD with L-T4 therapy. This improvement in endothelial function could translate into reduction in cardiovascular mortality and morbidity.

---

**P43**

**Evaluation of the incidence of disorders glyceregulation in some diseases endocrine**

I Birstriceanu1, M E Preda1, M Birstriceanu1, I. Putineliu2, S Bondari3, A Cov12, A Turcu12 & A Voscan1

1Department of Endocrinology, Emergency Hospital, Craiova, Romania; 2Department of Endocrinology, University of Medicine and Pharmacy, Craiova, Romania; 3Department of Geriatry, Chronic Afections and Geriatric Hospital’s, Stefanesti Arges, Romania.

Glyceregulation disorders in endocrine are frequently, hormone excess or deficit resulting for impaired metabolism of glucose by different mechanisms.

**Methods**

The study was conducted on 118 patients with hyperthyroidism, acromegaly and hypercortisolism. The inclusion criteria were: patients nondiagnoses that have not followed the treatment with drugs that could induce hyperglycemia (epinephrine, oral contraceptives, glucocorticoids, mineralcorticoids etc.), no-collateral family history of diabetes mellitus. Making glucose tolerance test with 75 g glucose pulvis with glucose assessment at 1 and 2 h after glucose ingestion, allowed in varying proportions the detection of diabetes mellitus in the study.

**Results**

Glyceregulation disorders were present in 58% of hyperthyroidism, 46% of patients with acromegaly, 53% of those with hypercortisolism. Altered carbohydrate metabolism was directly proportional to the excess hormone level, on the types of diseases studied.

**Conclusions**

Differential treatment specific endocrine disease, improves the disorder of glyceregulation occurred in the context of hormonal dysfunction.

---

**P44**

**Real-idiopathic precocious puberty: therapeutic approach**

I Birstriceanu1, M E Preda1, M Birstriceanu1, I. Putineliu2, S Bondari3, A Cov12, A Turcu12 & D Bondari3

1Department of Endocrinology, Emergency Hospital, Craiova, Romania; 2Department of Endocrinology, University of Medicine and Pharmacy, Craiova, Romania; 3Department of Geriatry, Chronic Afections and Geriatric Hospital’s, Stefanesti Arges, Romania.

Early sexualisation defines the appearance of any sign of sexual maturation at a younger age than 2 S.D. from the mean, namely < 8 years at girls and 9 years at boys. The really precocious puberty is always isosexual, sexuality program runs in line with genetic sex and gonads of the subject. In making her part of the whole system gonadal function: the hypothalamus-pituitary–gonad-receptors, and gonads is fully enabled not only hormonogenetic, both also gametogenetic.

**Methods**

The study was conducted on six girls, aged 6–8 years whose sexual characters were installed early (thelarche – 4 years) and one of them (MF – 7 years), menarche at 6 years with the cyclical trend (monthly). Diagnostic algorithm that we applied was represented by: assessing LH and FSH to GnRH test. As MRI brain imaging was performed.

**Results**

LH and FSH values were increased (> 190 mIU/ml) and the GoRH test, the response was normal. MRI brain showed no signal changes or gadolinium signal the pituitary parenchyma, which is why the cases were labeled as the treatment of precocious idiopathic puberty. Is established analogues of LH–RH agonists (Triptorellin 3.75 mg/month) to reduce low-level regulation of gonadotrophin receptors and LH-RH. After 6 months of treatment, her periods have been suspended from patient MF – 7 years, and leap stature was only 1 cm.

**Conclusions**

Differential treatment specific endocrine disease, improves the disorder of glyceregulation occurred in the context of hormonal dysfunction.
Haematological and reproductive toxicity of nicotine and protective role of green tea extract in male rats
Moshab Rachid1, Haroun Naçera1, Boulakoud Mohamed Salah1 & Yousef Mokhtar Ibrahim1
1Department of Biology, Faculty of Sciences/University of Boumerdes, Boumerdes, Algeria; 2University of Annaba, Annaba, Algeria; 3University of Alexandria, Alexandria, Egypt.

Nicotine (N) is known as the main toxic and addictive component of cigarette smoke. By within group therapy oxygens species (ROS) and oxidative damage in organism, it can induce major public health problems such as cancer, cardiovascular diseases and infertility. Green tea extract (GTE) is an important source of polyphenols catechins; it has attracted a great deal of attention around the world because of its potential antioxidants role in scavenging free radicals. This research was conducted to determine the potential role of green tea extract in attenuating the toxic effects that may be caused by nicotine on haematological and reproductive parameters in rat. Thirty-two adult Wistar male rats were randomly divided into four groups/8 for each. Group I served as control. Group II rats received orally GTE (2% w/v) as the sole drinking fluid. Group III rats were injected i.p. by nicotine (1 mg/kg bw). Group IV received i.p. nicotine (1 mg/kg bw) and GTE (2% w/v) concomitantly. After 2 months of treatment, blood samples were collected for measuring haematological parameters. Then, after necropsy, reproductive organs (testes, epididymes, and seminal vesicles) were removed, weighed and used for measuring semen quality and histology. The results show a decrease in red blood cells (RBC) count, haemoglobin and haematocrit with an increase in VGM in all treated groups as compared to control; while leucocytes (WBC) count has increased in nicotine group, diminished in GTE group and adjusted to normal values in GTE plus nicotine treated animals. Furthermore, nicotine decreases significantly the body weight gain and relative weights of reproductive organs; this toxic effect was removed by GTE coadministration. Sperm analysis and histological examination of testes revealed that nicotine reduced significantly sperm count, spermatid number, sperm daily production, motility, percentage of normal sperm morph as well as increased histological alterations pronounced by atrophy, degenerative aspect of the seminal epithelium in some seminiferous tubules, large interstitial spaces with small number of Leydig cells, perturbation in spermatogenesis leading to absence of spermatooza and presence of cell debris in the lumen of some seminiferous tubules. All these adverse reproductive effects of nicotine were attenuated by GTE coadministration. It is concluded that GTE beverage produces a deleterious synergistic effect with nicotine on hematological parameters and plays protective role against nicotine-induced reproductive effects to improve semen quality and histological damage of testis.

Bone remodeling parameters and bone mass in patients with schizophrenia treated with long-acting injectable risperidone
M Dokić1, N Maric Bojovic2, D Britvic2, A Damjanovic2, M Jasovic Gasic2 & V Popovic1
1Institute of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center Serbia and School of Medicine, University of Belgrade, Belgrade, Serbia; 2Institute of Psychiatry, Clinical Center Serbia and School of Medicine, University of Belgrade, Belgrade, Serbia.

Introduction
Studies suggest that schizophrenia and prolactin raising antipsychotics, one of them being risperidone, may be associated with low bone mass. On the other hand, weight gain as a consequence of antipsychotics in these patients may be the protective factor against osteoporosis.

Objective
Determine bone remodeling parameters and bone mass in patients with schizophrenia treated with long-acting injectable risperidone (LAIR) under naturalistic conditions.

Patients
Twenty-six out-patients with controlled schizophrenia (age 31.3 ± 1.3 years; BMI 28.1 ± 1.0 kg/m²) on maintenance therapy with LAIR for mean 18 ± 1.6 months (range 6-36 months) with mean dose 38 ± 2 mg. Thirty-five subjects matched by sex, age, BMI and education served as healthy controls.

Methods
Serum osteocalcin, C-terminal telopeptide of type I collagen (CTX), vitamin D, prolactin, sex steroids and PTH were assessed. Bone mineral density (BMD) was measured by dual-X ray absorptiometry at lumbar spine (LS) and femoral neck (FN).

Results
Osteocalcin did not differ between patients with schizophrenia compared with healthy subjects, while serum CTX was significantly higher in patients with schizophrenia (P = 0.023). Patients with schizophrenia had lower LS BMD and LS Z-scores than healthy subjects, but not statistically significant (P = 0.094, P = 0.072 respectively) while at femoral neck (FN) there was no difference between two groups. Vitamin D deficiency was prevalent in patients with schizophrenia. Hyperprolactinemia was detected in 85% of patients, more commonly in females than males (all females and 67% males). Serum estradiol levels were lower in female patients than in healthy female subjects (P = 0.001), while serum testosterone in males showed no significant differences (P = 0.675). The percentage increase in body weight for all patients with schizophrenia on LAIR therapy was 4.7 ± 1.5%.

Conclusion
Despite weight gain long-term administration of LAIR increased bone resorption marker CTX possibly by hyperprolactinemia-induced hypogonadism and/or possibly by decreasing brain serotonin activity. Brain serotonin has been recently shown to increase bone accrual and influence weight.

The role of progesterins in the interplay of estradiol and genistein: influences on the steroid hormone receptor expression patterns in distinct uterine compartments
F Möller1, P Honisch2, O Ziera1, P Diel3 & G Vollmer3
1Technische Universität Dresden, Institute for Zoology, Chair for Molecular Cell Physiology and Endocrinology, Dresden, Germany; 2Department of Molecular and Cellular Sports Medicine, Institute of Sports Medicine, German Sports University Cologne, Cologne, Germany.

Ovariectomized (OVX) rats are commonly used for the investigation of estrogenic compounds in vivo. We previously showed that estrogen treated...
OVX animals apparently respond differently to Genistein (GEN) treatment than hormonally intact animals. An observation, that indicated that progesterins might interfere in the estradiol (E2)-GEN interaction. The molecular effects of GEN seem to be modified by progesterone (P4), its role should be determined in presence and absence of E2. Therefore, we performed an animal experiment with adult Wistar rats which were either OVX or sham operated. These animals were s.c. treated with E2 (1 µg/kg BW and d), P4 (40 mg/kg BW and d) or GEN (10 mg/kg BW and d) either as single compounds or as their respective mixtures. As readout, we assessed the mRNA and protein expression pattern of the progesterone receptor (PGR) as well as both estrogen receptor subtypes. Performing immunohistochemical staining of OVX rat uterus cross-sections, we generally found higher PGR protein expression levels in the luminal epithelium compared to the stroma. Following E2 treatment, the PGR expression level was increased in both luminal epithelium and stroma respectively. The comparison of the two uterine tissue compartments showed, that the expression increases predominantly in the stroma (twofold increase). In contrast to the other combinatorial treatments involving E2 (E2-P4) and E2-P4–GEN), the E2-free combination of ‘P4–GEN’ showed no effect on overall PGR expression, although there might be a shift from epithelial to the stromal expression. In conclusion, our results indicate that E2 triggered estrogenic responses on PGR expression are detectable throughout all uterine tissue compartments. With regard to the fact that they are more pronounced in the stroma, compared to the luminal epithelium, the importance of the stroma as a hormone response regulating tissue is accentuated.

Serum procalcitonin measurement as a marker of sepsis

E Cakir1, E Cakir2, A Dilili1, N Colak1, I Ozturk1, M Ozbek1, M Kilic3, T Dellibas1
1Department of Endocrinology and Metabolism, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; 2Department of Radiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; 3Department of Surgery, Etlik Hititas Training and Research Hospital, Ankara, Turkey.

Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin. Procalcitonin is synthesized by a large number of tissues and organs in response to infection by pathogenic bacteria, fungi and some parasites. Its a new and innovative parameter which reacts with high sensitivity and specificity to generalized infection and sepsis. The serum concentration of PCT blood level is a simple and specific test and may be performed to 88.8% of them. Based on clinical and laboratory features (a cut off value 3.1) 29.8% of patients were confirmed as sepsis. Mean age of them was 46.5 years old.

Methods and materials

The aim of the study was to assess PCT value for the diagnosis of systemic infection and sepsis. Objective

The aim of the study was to assess PCT value for the diagnosis of systemic infection. Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin. Procalcitonin is synthesized by a large number of tissues and organs in response to infection by pathogenic bacteria, fungi and some parasites. Its a new and innovative parameter which reacts with high sensitivity and specificity to generalized infection and sepsis.

Objective

The aim of the study was to assess PCT value for the diagnosis of systemic infection. Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin. Procalcitonin is synthesized by a large number of tissues and organs in response to infection by pathogenic bacteria, fungi and some parasites. Its a new and innovative parameter which reacts with high sensitivity and specificity to generalized infection and sepsis.

Methods

We used Elycsys BRAHMS PCT test electro chemiluminescent immunoassay (ECLIA) for the determination of procalcitonin. In Albania, PCT 2 ng/ml was used as a serum marker for bacterial sepsis since May, 2010. We used Elycsys BRAHMS PCT test electro chemiluminescent immunoassay (ECLIA) for the determination of procalcitonin. In Albania, PCT 2 ng/ml was used as a serum marker for bacterial sepsis since May, 2010.

Results

Mean age was 44.53 years old ±17.25 s.d., range 15–75. Female 52.3% and males 42.7%. 67.1% of patients were admitted to hospital and blood culture was performed to 88.8% of them. Based on clinical and laboratory features (a cut off PCT ≥ 2 ng/ml) 29.8% of patients were confirmed as sepsis. Mean age of them was 46.5 years old ±20.7 s.d. PCT was very high (41–100 ng/ml) in patients with sepsis with average value 23.65 ng/ml. A statistically significant higher PCT level was observed in patients with sepsis compared to those without sepsis (23.65 ± 21.3 vs 0.5 ± 1.4 respectively). In 71.2% of cases (patients without sepsis) PCT was under 2 ng/ml.

Conclusion

The serum concentration of PCT is specifically elevated in sepsis patients. Measurement of PCT blood level is a simple and specific test and may be recommended in the diagnosis of systemic infection. Procalcitonin should be included in diagnostic and clinical practice guidelines for sepsis. Both absolute values and variations should be considered and evaluated in further studies.

Introduction

Glucosinolates (GLS) are secondary plant metabolites found in members of the order Brassicales (e.g. broccoli, pak choi, cauliflower, kale, mustard or rapeseed), but they are also present in plants of Moringaceae (moringa) and Caricaceae (papaya). Some GLS-derived breakdown products, i.e. sulforaphane, were extensively studied for their beneficial effects on colon-cancer incidence. This preventive nutritional approach might require the prophylactic use of highly dosed, enriched GLS-preparations of Brassica plant extracts. Goitrogenicity is a known consequence of nutrition containing high Brassica content due to the release of thiocyanate and inhibition of thyreoperoxidase (TPO). Detailed and recent studies about this topic are rare, but nevertheless needed for a potential preventive or therapeutic use of GLS. Therefore, we used several in vitro approaches to assess the goitrogenic potential of various GLS-extracts.

Hypothesis

Some GLS exert potential goitrogenic effects via competitive inhibition of the sodium-iodide-sympporter (NIS) by thiocyanate ions and/or direct effects of specific GLS breakdown products on type 1 deiodinase or thyreoperoxidase (TPO) activity. Methods

NIS-inhibition was tested by their interference with non-isotopic iodide uptake into rat thyrocytes (FRTL5). Interference with D10 activity was detected via a non-isotopic iodide-release assay. SCN– release from GLS was tested by a colorimetric reaction. TPO-interference was detected by applying the test compounds to recombinant TPO enzyme.
Results/conclusion

To investigate and exclude possible adverse GLS effects, we established a screening platform for the potential gastrointestinal action of GLS and their bile-soluble products. Several of the GLS extracts inhibited DSO1 or TPO activity within a high supra-physiological μM concentration range. Furthermore, several extracts released significant amounts of SCN – after hydrolysis, thus potentially enhancing to the overall SCN – load of the organism. It appears mandatory that appropriate in vivo studies address these adverse GLS effects. This work is supported by the Bundesministerium für Bildung und Forschung.

PS52
Phytoestrogen genistein causes downregulation of oestrogen receptor α in uterus of female Sprague Dawley rats
Siti Rosmani Md Zin, Normaliah M Kassim & Siti Zawiah Omar
University Malaya, Kuala Lumpur/Wilayah Persekutuan Kuala Lumpur, Malaysia.

Phytoestrogen genistein is one of the endocrine disrupting chemicals found mostly in soybean. It has become a topic of interest since decades ago in view of its benefits in reducing the risks of breast cancer, cardiovascular disease, obesity and premenopausal symptoms. However, it has been reported that genistein can cause adverse consequences on female reproductive system and may cause infertility. Its action was said to be associated with its binding affinity to oestrogen receptor (ER) which produce both oestrogenic and antioestrogenic effects depending on dosage, time and duration of exposure. In this study, intact female juvenile Sprague Dawley rats were fed orally with genistein (10 mg/kg per day) from postnatal day 22 (PND 22) till PND 42. At the end of the experiment, animals were sacrificed and selected organs were harvested and processed for light microscopy. We found that ER-α in uterine tissue of rats treated with genistein were downregulated compared to the control group. This is supported by the reduced uterine weight and myometrium thickness of the uterus of genistein treated animals. In conclusion, prepubertal exposure of prepubertal female rats to genistein (10 mg/kg per day) has altered development of their uteri through its antioestrogenic effect.

Endocrine tumours and neoplasia

PS53
Insulinoma in Crete: a rare tumor?
V Daraki, K Stamatou, G Kalikakis, F Spyrou, A M Golac, E Karipidou, E Mamalaki & S Papavasiliou
University Hospital of Crete, Heraklio, Crete, Greece.

Insulinoma, a pancreatic β-cell tumor, comprises 55% of Neuroendocrine tumors with an annual incidence of 3-10/million. Female to male ratio is 3:2 presenting in their 4th decade. The main clinical symptom is severe hypoglycemia irrespective of tumor size.

Aim

Presentation of four newly diagnosed insulinoma patients aged 18-60, within an eight month interval.

All patients presented with neuroglycopenic symptoms (irritability, emotional lability, sluggish speech, blurred vision). On admission one patient presented with semicoma, another with acute coronary syndrome, the third had a car accident and hypoglycaemia was an incidental finding in the fourth. All patients underwent prolonged fasting test. Whipple’s triad, insulin glucose ratio > 0.4, c-peptide > 2.5 mg/ml during hypoglycaemia established the diagnosis. CT and MRI scan of the abdomen revealed hypervascular lesions with intense arterial phase enhancement in the pancreas (three patients). Multiple metastatic hepatic lesions without a primary pancreatic tumor (no pancreatic lesions) were found in the fourth patient (malignant insulinoma). Chromogranin A was marginally increased only in the primary pancreatic tumor (no pancreatic lesions) were found in the fourth patient (malignant insulinoma). Chromogranin A was marginally increased only in the primary pancreatic tumor (no pancreatic lesions) were found in the fourth patient (malignant insulinoma). Chromogranin A was marginally increased only in the primary pancreatic tumor (no pancreatic lesions) were found in the fourth patient (malignant insulinoma).

One patient is scheduled for surgery. The fourth patient underwent partial pancreatic resection and complete remission of their hypoglycemia. Surgery is the treatment of choice for benign, malignant or recurrent disease.

Conclusion

High clinical suspicion is a prerequisite for the diagnosis and treatment of these slow growing usually benign tumors. The sudden cluster of four insulinomas over an 8 month period in our department with complete absence of cases over the past 23 years demands increased vigilance in case this is a non-random but a causal effect in need of further elucidation.

P54
Frequency, localisation of unusual metastases of medullary thyroid cancer and impact on survival; an observational study in 102 patients L Chrigue1, P Pierie1, E Bauduin2, S Guyardt1 & P Leconte1
1University Hospital, Tours, France; 2Institut Gustave Roussy, Villejuif, France.

Medullary thyroid carcinoma (MTC) early spreads to cervical lymph nodes and to distant sites: mostly to the liver, lungs or bones. Unusual sites such as breast, skin or orbit have been also described. The aim of the study was to evaluate the frequency, localisation of unusual metastases of MTC and their impact on survival.

Eligibility criteria for this study were the presence of a pathological confirmed diagnosis of MTC with distant metastases (other than lymph nodes) and a follow-up of at least one visit between January 1st 2000 and May 1st 2010 in 7 University French hospitals. We retained 102 patients (men/women: 57/45; multiple endocrine neoplasia (MEN) 12.7%; median age at MTC diagnosis: 50.5 yr). At the end of the study, 68.6% patients had bone metastases, 64.7% pulmonary metastases, 59.8% liver metastases. Unusual sites, diagnosed in 21 patients (20.6%), were brain, skin, pancreas, breast, peritoneum, adrenals, prostate, retina, and endometrium. Sex ratio, age at MTC diagnosis, proportion of MEN, tumor staging and calcitoninemia or ECA of metastatic patients with unusual sites were not statistically different from those of other patients. On May 1st 2010, 50 patients (49.0%) were alive, and 45 patients (44.1%) were deceased (data not available for 7 patients). The 10-year overall survival was 55.5% years after MTC diagnosis. Survival of patients with unusual metastases was 54.4% (no significant difference compared with the remaining population).

In a French population of 102 cases of distant metastatic MTC, the frequency of unusual metastases was 20.6%. These metastases were not associated with specific characteristics of patients and had no impact on 10-year survival. These metastases have to be localised in case of elevated calcitoninemia without lymph nodes, lung, bone or liver metastases.

Endocrine Abstracts (2011) Vol 26
evaluation revealed lymph nodes (n = 2) or liver metastases (n = 2) attesting recurrence of malignant insulinoma.

Conclusion
After initial post-operative remission, the diagnosis of recurrence of malignant insulinoma cannot be based only on clinical and biological criteria, but CT or MRI scan evaluation is mandatory during post surgical follow-up of such patients.

P56
The T-box transcription factor TBX1, the candidate gene of 22q11.2 microdeletion/DiGeorge syndrome, is involved in human parathyroid tumorigenesis
C Verdeli1,2, A Donnangelo1,2, V Vaira3, M Meregalli4, M Belicchi4, V Guarnieri2, A Scillitani2, L Vicentini2, Filomena Cetani2, Stefano Ferrero2, Marcello Frigerio1, Elena Costa1, Bruno Ambrosi1, Yvan Torrente1, Silvano Bosari1, Anna Spada1 & Sabrina Corbetta1
1Endocrinology and Diabetology Unit, Department of Medical-Surgical Sciences, University of Milan, IRCCS Policlinico San Donato, San Donato M.se (MI), Italy; 2Molecular Biology Laboratory, IRCCS Policlinico San Donato, San Donato M.se (MI), Italy; 3Pathology Unit, Department of Medicine, Surgery and Dentistry, University of Milan, AO San Paolo, Milan, Italy; 4Stem Cell Laboratory, Department of Neurological Sciences, University of Milan, IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Milan, Italy; 5Endocrinology Unit, IRCCS H. Med. Casal Solli Sole, Sant’Arena della Sofferenza, San Giovanni Rotondo (FG), Italy; 6Endocrine Surgery, IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico, Milan, Italy; 7Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy; 8Pathology Unit, Department of Medicine, Surgery and Dentistry, University of Milan, IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico, Milan, Italy; 9Endocrine Unit, Department of Medical Sciences, University of Milan, IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.

The embryonic transcription factor TBX1 plays a critical role in cell differentiation during organogenesis of the parathyroid glands. Here we demonstrated that TBX1 mRNA and protein were detected in human adult normal parathyroid tissues (n = 3). Immunostaining showed that TBX1 protein was expressed in endothelial CD31+, alfa-SMA+ cells. By contrast, TBX1 mRNA and protein was expressed at higher levels in parathyroid typical adenomas (n = 23), where TBX1 staining was positive in parathyroid PTH+ cells with a cytoplasmatic and nuclear localisation. Functional studies were performed in HEK293 cells as they expressed TBX1. The activation of the calcium sensing receptor (CaSR) by simulating for 24 h HEK293 cells stably transfected with the human CaSR with 1–5 mM calcium as well as with 10–100 nM R-568, the CaSR agonist cinacalcet, induced a significant reduction in TBX1 mRNA levels. Thus, CaSR downregulation in parathyroid tumours might be related with the TBX1 overexpression. Overexpression of TBX1 mRNA and protein were observed also in paralimbromin-expressing parathyroid cancers (n = 3). TBX1 mRNA and protein were downregulated in parafibromin negative parathyroid carcinomas (n = 14), suggesting that Wnt/β-catenin activation might inhibit TBX1 expression. In HEK293 cells TBX1 mRNA were inhibited by β-catenin accumulation induced by 24-h treatment with 1–20 mM lithium chloride, while β-catenin degradation induced by 40-min pretreatment with 10–100 mM calyculin A determined an increase in TBX1 mRNA levels. Further functional studies on the effect of silencing and transfection of TBX1 are ongoing. In conclusion, the present data demonstrated that: i) TBX1 is expressed in adult parathyroid tissues; ii) TBX1 impaired expression contributes to parathyroid tumorigenesis; iii) TBX1 is a new target of the CaSR and Wnt/β-catenin pathways. TBX1 provides a potential therapeutic target for parathyroid tumors.

P58
A large adrenal tumour as a phenotypic manifestation of the Birt–Hogg–Dube syndrome
A Juszczak1, D Halliday3, R Mihai2 & A Ail1
1Department of Endocrinology and Diabetes, Milton Keynes Hospital, Milton Keynes/Buckinghamshire, UK; 2Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford/Oxfordshire, UK; 3Department of Clinical Genetics, Churchill Hospital, Oxford/Oxfordshire, UK.

Introduction
The Birt-Hogg-Dube syndrome (BHDS) is a rare autosomal dominant germline mutagenesis characterised by presence of at least one of the following: benign skin fibrofolliculomas, lung cysts with recurrent pneumothoraces or renal tumours. The phenotypic constellation is due to heterozygous germline mutations of the tumour suppressor gene FLCN, located on 17p11.2, encoding a 579 aminoacid protein termed folliculin. Case reports have described endocrine tumours of the thyroid, parathyroid, in addition to neuroendocrine tumours, colon cancer, melanomas, meningiomas and squamous cell carcinoma. To our knowledge, only one case of an adrenal tumour has been previously reported in association with BHDS.

Case report
A 36-year-old woman, presenting to the urologists with urinary frequency, was found to have a 110×95×56 mm left adrenal tumour on CT imaging, following a preliminary ultrasound. She underwent an uncomplicated open adrenalectomy for a presumed non-functioning adrenal carcinoma. Histology revealed a non-functioning adrenocortical tumour with no malignant features. In the view of the family history of BHDS, FLCN mutational analysis was requested. The presence of a frameshift mutation in exon 11 (p.His429ProfsX27) confirmed the diagnosis of BHDS. Post-operative PET scanning did not show any evidence of metastatic disease. A decision was made not to commence adjuvant mitotane chemotherapy and to arrange follow-up imaging. Genetic screening for her two children was discussed.

Conclusions
Adrenal tumours are likely to be a rare feature of BHDS, however their presence should be sought in people affected with this condition. The likely mechanism of tumourigenesis is the ‘two-hit’ process. The relative sparing of the adRenals compared to other endocrine organs merits further investigation.

P57
Clinicopathological characteristics of pancreatic neuroendocrine tumors at diagnosis
M Argente Pla, M I Del Olmo García, M Rubio Almanza, A Moya Herráiz, A Segura Huerta, A Ramos Pról, R Cámara Gómez & J F Merino Torres
1Department of Endocrinology and Diabetes, Milton Keynes Hospital, Milton Keynes/Buckinghamshire, UK; 2Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford/Oxfordshire, UK; 3Department of Clinical Genetics, Churchill Hospital, Oxford/Oxfordshire, UK.

Introduction and objective
Neuroendocrine tumors (NETs) are a rare kind of tumor that can have various locations. Pancreatic location is the most common after the gastrointestinal tract.
Introduction
The adrenal incidentaloma is defined as a mass lesion found unexpectedly in an adrenal gland by an imaging procedure performed for another reason than suspected adrenal pathology.

Objective
To estimate the incidence of the adrenal mass and to define the algorithm for managing patients with incidental adrenal mass; a comparative analysis to the treatises data. The observational study was set one’s face towards by the adrenal incidental features who was diagnose between November 2008 and May 2010 and it was specific the presence of some diseases proper to metabolic syndrome.

Methods
We studied clinical historical of 34 patients (5 men and 29 women) with typical computed tomography features of adrenal mass. The structure of the patients batch with adrenal incidentaloma (n = 34) was: batch A-nonsecretory tumors (n = 21) (61.8%-TN) and batch B-secretor tumors (n = 13) (38.2%-TS) whereby four patients with one-sided pheochromocytoma; five patients with Cushing syndrome; two patients with subclinical Cushing syndrome and two patients with adrenal hypertrophy.

Results
Overweight or obesity were found in 33.3% by batch A and 30.8% by batch B; hypertension in 61.9% by batch A and 69.2% by batch B; diabetes mellitus in 19% by batch A and 30.8% by batch B; dislipidemia in 42.9% by batch A and 30.8% by batch B; osteoporosis in 14.3% by batch A and 23.1% by batch B. Diameter was less than 4 cm in 85.7% by batch A and 36.5% by batch B of the tumors, and more than 4 cm in 14.3% by batch A and 63.5% by batch B. 90.5% by batch A and 76.9% by batch B were detected by computed tomography. Surgical adrenal resection was performed in 69.2% TS and one TN with cyst character. Beside the histopathologic examination wherefore three carcinomas described by CT just two was performed in 69.2% TS and one TN with cyst character. Beside the histopathologic examination wherefore three carcinomas described by CT just two was performed in 69.2% TS and one TN with cyst character.

Conclusions
The tumor assess, the imagistic features and the quality of secretory/nonsecretory tumor is essential. Some features of the metabolic syndrome described to the patients with adrenal incidentalomas are enlarged the medically problem and it can form an argument to supplementary investigations.

P61 Liposomatostatin analogs for neuroendocrine tumors: a comparative model study

C Hantel1, F Schell1, A Ozimek2, C Chiapponi2, T Mussack2 & F Beuschlein1

1Endocrine Research Unit, Medical Clinic Innenstadt, LMU, Munich, Germany; 2Department of Pharmaceutical Technology and Biopharmacy, University of Freiburg, Freiburg, Germany.

Medical treatment of adrenocortical carcinoma (ACC) is limited to common cytotoxic agents, which are usually given in combination with mitotane. Recently we have developed a novel therapeutic approach by coupling a monoclonal IGF1 receptor blocking antibody (IHT) to sterically stabilized liposomal doxorubicin (SSLD). IHT coupled liposomes showed in vitro high and significant cellular association and furthermore internalization in various human tumor cell lines as well as in vivo superior anti-tumor efficacy against neuroendocrine tumors of the gastroenteropancreatic system. Flow cytometry and fluorescence microscopy demonstrated high internalization of IHT coupled liposomes (50.13 ± 2.2) also for the adrenocortical tumor cell line NCh295, but surprisingly an even higher uptake of plain liposomes (84.57 ± 0.82; P = 0.0001). This extraordinary uptake phenomenon was independent on liposomal cholesterol content (cholesterol free preparation, 82.92 ± 0.63; P = 0.11) and was not exclusively dependent on caveolae- (66.47 ± 2.2) and clathrin-mediated endocytosis (57.27 ± 1.9) since specific inhibitors were only partially able to inhibit the investigated effect. We evaluated the therapeutic efficacy of liposomal preparations in an in vivo model for ACC. A significant reduction in tumor size (cm) was detectable 32 days after a single treatment of NCh295 tumor-bearing mice with SSLD-IHT (0.89 ± 0.15; P = 0.006) and diminished for SSLD (1.01 ± 0.19; P = 0.04) compared with untreated controls (1.5 ± 0.1) while no significant effects were seen for treatments with free IHT (1.38 ± 0.11; P = 0.36) LD (1.2 ± 0.3; P = 0.36), unspecific SSLD-IgG (1.45 ± 0.5; P = 0.36) or SSLD + free IHT (1.29 ± 0.17; P = 0.25). Thus, SSLD-IHT could represent a promising approach for the treatment of ACCs in the future. Moreover, a combination of mitotane plus encapsulated cytostatic agents instead of the free drugs could also represent an interesting novel treatment option.

P62 Injection systems for long-acting somatostatin analogs: a comparative assessment of preparation times and nurses’ perceptions

D T Adelman1, A Burgess2 & P R Davies3

1Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; 2The Christie, Neuroendocrine Tumour Department, Manchester, UK; 3Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK.

Introduction
The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumours and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR). The aim of this study was to gain nurses’ insights on the use and ease of administration of SSA devices, including Somatuline Autogel new device (SA-ND), in Europe and the US.

Methods/design
Seventy-seven qualified nurses with ≥ 3 SSA patients/year were interviewed to gather views regarding SSA injection use. Nurses were timed while preparing and performing test injections with SA-ND and LAR. Attributes of SA-ND and current SSA devices were evaluated and an overall preference score (attributes weighted by importance to nurses) calculated for each.

Results
SA-ND scored higher than LAR and SA for nearly all attributes. Mean time for administration was 66 s for SA-ND versus 329 s for LAR. Low clogging risk, prefilled device, safety feature and time to administer were the main perceived advantages of SA-ND. Overall preference score was 63% higher for SA-ND versus LAR (114 vs 70 respectively).

Conclusion
Preference for a new SSA device was high among interviewed nurses. Conceivably, the short administration time, confidence that a full dose is delivered and perceived ease-of-use of the new device compared to existing SSA devices could lead to improvement in clinical practice and a benefit to patients/caregivers when administering SSAs at home.
P63
The influence of different ACTH assays on the ACTH concentrations of patients with small cell lung cancer
J A P Bos\textsuperscript{1}, A C Dingemans\textsuperscript{2} & P P C A Menheere\textsuperscript{1}
\textsuperscript{1}Department of Clinical Chemistry, Maastricht University Medical Centre, Maastricht, The Netherlands; \textsuperscript{2}Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

Introduction
ACTH is measured to confirm impairments in the hypothalamic–pituitary–adrenal axis. Patients with small cell lung cancer (SCLC) can have ectopic adrenocorticotropic secretion. In December 2009, a SCLC patient showed an enormous discrepancy between the ACTH results obtained with two different ACTH assays. The aim of this study was to compare different ACTH assays in SCLC patients.

Methods
In a pilot study EDTA plasma samples of nine SCLC patients were measured with three different ACTH assays: IRMA, electrochemiluminescent immunoanalytical assay (Elecsys), RIA. Twelve EDTA plasma samples of patients who underwent an insulin tolerance test (ITT) were measured with the IRMA and RIA assays. At our laboratory the specific IRMA assay is used as standard method.

Results
The average ACTH Elecsys/IRMA and RIA/IRMA ratios were respectively 0.84 (range: 0.61–0.94) and 4.66 (range: 1.52–17.0) for the nine SCLC patients. The RIA/IRMA ratio was 1.96 (range: 0.90–5.25) for the ITT group. The average RIA/IRMA ratio in the SCLC group is 2.4 times higher with respect to the ITT group.

Conclusions
Ectopic adrenocorticotropic secretion can lead to discrepancies in the ACTH concentrations measured with different ACTH assays. In the case of ectopic adrenocorticotropic secretion, not only the concentration of the intact ACTH is of interest, but also in the total ACTH concentration including fragments, degradation products, and precursors. In those cases it happened to be meaningful to use a RIA assay. Mostly, non-competitive ACTH are used in standard laboratory practice. When interpreting ACTH results one should be aware of the specifications of the assay. If there is any doubt that biochemical effects of ACTH-like molecules, not measured with the routine assay, could explain clinical status of a patient, a competitive assay should be used additionally. Competitive assays appear to cross react with more ACTH-like analytes than non-competitive assays.

P64
Primary hyperparathyroidism in MEN1 patients: preferred surgical procedure and relation with genotype
C R C Pieterman\textsuperscript{1}, L J van Hulsteijn\textsuperscript{2}, M den Heijer\textsuperscript{3}, R B van der Luijt\textsuperscript{4}
\textsuperscript{1}Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands; \textsuperscript{2}Department of Endocrinology, Currently Leiden University Medical Center, Leiden, The Netherlands; \textsuperscript{3}Department of Endocrinology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; \textsuperscript{4}Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; \textsuperscript{5}Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Background
Primary hyperparathyroidism (pHPT) is the most prevalent manifestation of multiple endocrine neoplasia type 1 (MEN1). Surgery is the preferred treatment but which type of surgery offers the best chance of cure combined with the lowest risk of postoperative hyperparathyroidism is still uncertain.

Aims
Identifying the optimal surgical technique for MEN1 related pHPT. Describing the course of postoperative hyperparathyroidism. To see if a genotype-phenotype correlation exists with regard to recurrent pHPT.

Methods
A retrospective longitudinal cohort study performed at the departments of endocrinology of the University Medical Centers (UMC’s) of Utrecht and Nijmegen in The Netherlands. Patients were selected from the Dutch MEN1 database which includes all Dutch patients aged ≥ 16 years who are treated for MEN1 in one of the Dutch UMC’s between 1990 and 2009. Data were collected by medical record review.

Results
Seventy-three patients who underwent parathyroidectomy for MEN1-related pHPT were included. The studied surgical procedure was the primary surgery for 42 (57.5%) patients. Persistent or recurrent pHPT was seen in 19 (26%) patients: after less than three parathyroids resected (<SPTX) in 53%, after subtotal resection (SPTX) in 17% and after total resection (TPTX) in 19% of patients. Persistent (≥2 months) postoperative hyperparathyroidism was seen in 34 (46.6%) patients: after <SPTX in 23.5%, after SPTX in 39.1% and after TPTX in 65.6% of patients. The median duration of postoperative hyperparathyroidism was 1.5 years. In 65% of the patients successful cessation of substitution therapy (calcium supplements and vitamin D) was possible, even after ≥10 years. Patients with nonsecreting or frameshift mutations in exons 2, 9 and 10 had a significantly lower risk of persistent or recurrent pHPT than patients with other mutations.

Conclusions
SPTX is the procedure of choice in MEN1-related pHPT. Patients with nonsecreting or frameshift mutations in exons 2, 9 or 10 have less risk of persistent or recurrent pHPT. Postoperative hyperparathyroidism lasting ≥6 months should not be considered permanent and it is advisable to try to taper off the substitution therapy even several years after surgery.

P65
Significance of BRAF expression in nodular thyroid disease: prognostic and therapeutic implications
Ioana Golu\textsuperscript{1}, Adriana Neghina\textsuperscript{2}, Marianna Cornianu\textsuperscript{3}, Daniela Amzar\textsuperscript{1}, Melania Balas\textsuperscript{1}, Dana David\textsuperscript{2} & Mihaela Vlad\textsuperscript{1}
\textsuperscript{1}Department of Endocrinology, University of Medicine and Pharmacy ‘V Babes’, Timisoara, Romania; \textsuperscript{2}Department of Biochemistry, University of Medicine and Pharmacy ‘V Babes’, Timisoara, Romania; \textsuperscript{3}Department of Pathology, University of Medicine and Pharmacy ‘V Babes’, Timisoara, Romania.

Background
Whereas many papers have reported on clinical and morphological features of thyroid cancer with BRAF\textsuperscript{V600E} mutation, a limited number of studies have been focused on the quantification of BRAF mRNA expression in thyroid tumors. The present study aimed to assess the expression of BRAF transcript in fine needle aspiration specimens, prevalent from cases with nodular thyroid disease.

Material and methods
The mRNA expression levels of BRAF and GAPDH (housekeeping gene) were evaluated in 23 malignant and 34 benign thyroid tumors by means of semiquantitative RT-PCR, with the assessment of the crossing point values for each sample in triplicates.

Results
The mean age of the study group was 49.1 ± 19.0 years, with a female to male ratio (F/M) of 8.6/1. An over expression was documented in about 50% of analyzed carcinomas, with the following distribution in patients with papillary thyroid carcinomas (PTC): four out of seven cases presented the classical variant of the disease, two out of five cases micro PTC and four out of nine cases the follicular variant of PTC. A significant over expression was noticed in the tumor (2\textsuperscript{ΔΔCt} = 40.082.24) and also in the perinodular tissue (2\textsuperscript{ΔΔCt} = 39.291.1) of one case with follicular thyroid carcinoma (FTC) and follicular adenoma, as compared with the samples with benign tumors (2\textsuperscript{ΔΔCt} = 0.98). The significant over expression of BRAF mRNA could be a feature of FTC, highlighting an over activity of Ras–BRAF–MAP kinase pathway, with subsequent increase of their invasive potential.

P66
Metabolic endocrine tumor activity is reflected by total \textsuperscript{18}F-DOPA PET tumor uptake in patients with a carcinoid tumor
University Medical Center Groningen, Groningen, The Netherlands.

Introduction
Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (\textsuperscript{18}F-DOPA) has an excellent sensitivity to detect carcinoid tumor lesions.
**P68**

**Significant prognostic survival factors in patients with pancreatic neuroendocrine tumors**

B Popovic1, Dj Macat1, M Petakov1, I Bozic1, T Bogavac1, S Ogjaniouc1, T Isailovic1, V Elicovic1, Marijan Micev2, Nemanja Menkovic1 & Svetozar Damjanovic1

1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia; 2Clinic for Digestive Surgery, Belgrade, Serbia; 3Centre for Radiology and Magnetic Resonance, Belgrade, Serbia.

Introduction

Pancreatic neuroendocrine tumors (PNETs) are generally clinically more indolent than adenocarcinomas. But relevant, clinically applicable prognostic survival factors still need to be more precisely defined.

Aim

To identify survival factors in patients with PNETs.

**Methods**

We analyzed 66 patients with PNETs (52.62±13.3 years old) treated at our department during 2003–2010. Patients with insulinomas were not included in survival analysis unless manifesting malignant behavior. Kaplan-Meier method was used for univariate survival analysis, and Cox regression model for the estimation of influence of risk factors.

**Results**

Minority of PNETs were hormonally active (13 insulinomas, 7 somatostatinomas, 6 gastrinomas). Majority (53.7%) presented with metastatic disease, in stage IV according to TNM classification. According to WHO criteria, majority were well-differentiated neuroendocrine carcinomas (48.4%). Nine patients (13.6%) had genetically confirmed MEN1 syndrome. Primary tumor was operated in 36 patients (54.5%). Overall median survival was 73 months (2–180 months) with 5-year survival of 66.7%. Significantly shorter survival was noted in patients with metastatic disease at presentation (P=0.025), those who did not underwent primary tumor operation (P=0.018), tumors with higher mitotic count (P=0.001), higher proliferation index Ki-67 (P<0.001), and more aggressive behavior as characterized by the WHO group (P<0.001). Primary tumor size, hormonal activity, heritability and tumor stage had no significant influence on survival. Significant independent predictor of mortality was group according to WHO classification. (HR 4.722; 95% CI 1.746–12.771), (P=0.002).

**Conclusion**

Biology of PNETs is best reflected by the criteria of WHO classification. Important favorable survival factor is operation of primary tumor, despite the presence of metastatic disease. Tumor stage, according to TNM classification, did not affect survival of our patients.

---

**P67**

**Ectopic mediastinal parathyroid adenoma: a case report**

C Lazureanu1, M Cornianu1, R Cornea1, M Vlad2, O Burlacu3, A Nicodin1 & E Lazar1

1Pathology Department, University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania; 2Endocrinology Department, University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania; 3Thoracic Surgery Department, University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania.

**Introduction**

Incidence of ectopic parathyroid glands in individuals is ~6%, the most common location being the thymic capsule or the superior mediastinum.

**Case**

We present the case of a 21-years-old female with a recent history of osteoelastoma affecting the maxillary bone and the mandible, together with increased values of the parathyroid hormone (over 20 times the normal value), total calcium and alkaline phosphatase and decreased serum phosphorus. A cervico-mediastinal MRI was performed with the disclosure of a well delimited 5.5/5.2 cm tumor mass in the antero-superior part of the mediastinum, as well as multiple cystic bone tumors affecting the maxillary bone, mandible, clavicle, humeral head and scapula - osteitis fibrosa cystica in context of the primary hyperparathyroidism.

In September 2010 thymectomy was performed.

**Material and methods**

Tissue fragments from the thymectomy specimen were routinely processed and stained with H&E. Supplementary Ki-67 antigen (MB 1 clone), En Vision method, DAB visualization was made.

**Results**

Within the capsule of the thymus was found a nodule, embedded in connective tissue, formed mainly by parathyroid epithelial cells, chief cell type, patterned in nests and small follicles; focal pleomorphic nuclei were observed, but no evidence of malignancy such as vascular or soft tissue invasion. Immuno-histochemistry for the cell cycle marker Ki67 has been 2%, so the final diagnosis was that of ectopic parathyroid adenoma, with mild atypia.

**Conclusion**

After surgical removal of the mediastinal mass, imagistically suspected and histopathologically confirmed as ectopic parathyroid tissue, the syndrome of primary hyperparathyroidism was resolved.

---

**Endocrine Abstracts (2011) Vol 26**

---

13th European Congress of Endocrinology, Rotterdam, The Netherlands
bronchiolitis had been suspected prior to lung biopsy. An open lung biopsy was performed which demonstrated changes compatible with DIPNECH. This twin suffers from sensori-neuronal hearing loss. When testing her basal pituitary function she showed decreased IGF1 serum, levels but all other pituitary functions were normal. Currently she is awaiting a dynamic stimulation test (ITT).

Our twin patients with histologically proven DIPNECH raise a number of questions. First, it is unknown whether modern technology of somatostatin receptor scintigraphy using Ga-DOTANOC will help with the diffuse tumour diagnosis as in pulmonary carcinoids. This could lead to early therapeutic intervention in the condition with using octreotide treatment to decrease tumour size and improve local mucus clearance. Secondly, links between DIPNECH and GH deficiency have been discussed in a single case of combined DIPNECH and acromegaly but this was attributed to potential MEN1. The familial cause in our patients and the potential relation to GH deficiency suggest a different genetic background. If confirmed it may argue for a closer surveillance of mild respiratory symptoms in patients with GHD.

Conclusions

Analysis were positive lymph node status and the size of the primary tumor. Anatomic distribution of recurrences was: local only (37%), metastatic tumor bed (7%). The median follow-up time was 36 months (5–167). Uni and multivariate analyses were performed.

Results

Recurrence was evidenced in 57 (84%) patients within a median time of 9 months (1–71). Anatomic distribution of recurrences was: local only (37%), metastatic only (19%), local and metastatic (15%). The 1-year, 2-year, and 3-year DFS rate were 44, 26, and 18%, respectively. The 1-year, 2-year, and 3-year OS rate were respectively 88, 69, and 50%. Prognostic factors of DFS at multivariate study analysis were positive lymph node status and the size of the primary tumor. Prognostic factors of survival at multivariate analysis were age and positive lymph node status. Early recurrence (before 1 year) and mitotane plasma level <14 mg/ml at the time of recurrence were associated with a poorer survival.

Conclusions

Our study demonstrated a high rate of recurrences after complete macroscopic resection of stage III-ENSAT ACC patients supporting a role for neo- and adjuvant therapy in the future in this subgroup of patients.

P71

Comparison of the efficacy and the tolerance of high-dose calcium and pentagastrin tests in patients with cured or persistent medullary thyroid cancer and in controls

C Colombo1, U Verga2, M Perrino1, L Vicentini3, P Beck-Peccoz1,2 & L Fugazzola2

1Department of Medical Sciences, University of Milan, Milan, Italy; 2Endocrine Unit, Fondazione IRCCS Ca’ Granda, Milan, Italy; 3Endocrine Surgery Unit, Fondazione IRCCS Ca’ Granda, Milan, Italy.

The recent unavailability of pentagastrin (Pg) in several European Countries, prompted us to evaluate the potency and tolerability of the ‘high dose calcium test’ (Ca) in the stimulation of serum human calcitonin (hCt). We compared Pg- and Ca-stimulated hCt in 19 patients already treated for medullary thyroid cancer (MTC) in remission (n=19) or in persistence (n=13), in 18 patients with chronic thyroiditis and multinodular goiter, and in 15 healthy controls. In controls, Ct never peaked above 50 pg/ml. A response of Ct was observed in 4 cases in apparent remission without differences between the 2 tests. The hCt peak in persistent patients ranged 18–3637 for Pg and 60–2932 pg/ml for Ca tests, without significant differences even in the delta increases. The hCt peak in patients with autoimmune or nodular thyroid diseases ranged 21–942 pg/ml for Pg and 5–38000 pg/ml for Ca tests, without significant differences. Four patients with a Ct response >100 pg/ml, have been submitted to thyroidectomy. At histology, an intra-thyroidal MTC was found in 3 cases while one patient, with a Ct peak after Pg of 162 and after Ca of 599, was negative either for MTC or for C-cells hyperplasia.

The number, intensity and duration of side effects were significantly lower during Ca test, being the feeling of warmth the most frequent discomfort. In conclusion, this study demonstrated that high dose Ca test has a similar or higher potency than Pg test. In addition, Ca test was well tolerated and highly preferred by patients. These data, associated with the lower cost of Ca and its worldwide availability, indicate that the high-dose calcium is the test of choice for the pre-surgical diagnosis of MTC and for the follow up. Ongoing studies will identify the cut-off point to use for this test in the pre-surgical identification of MTC.

P72

Distribution of mitotane and its two metabolites in liproprotein fractions of patients with adrenocortical carcinoma

Y Cazaubon1,2, S Broustin1, A Seck1,2, H Remy3, H Fugazzola2, M Perrino1, J M Bidart1, Y Cazaubon2, S Leboulleux1, S Schlumberger2, E Baudin1 & A Paci1

1UMR 8203 Institut Gustave Roussy, Villejuif, France; 2Endocrine Unit, Fondazione IRCCS Ca’ Granda, Milan, Italy; 3Endocrine Surgery Unit, Fondazione IRCCS Ca’ Granda, Milan, Italy.

Introduction

Adrenocortical carcinoma (ACC) is a rare tumor of the adrenals with poor prognosis (survival rate for metastatic patients <15% at 5 years). Mitotane (o,p\textsubscript{-}DDD) is the main therapeutic option with up to 66% objective response rates in patients with serum levels between 14 and 20 mg/l. Its two main metabolites are o,p\textsubscript{-}DDA and o,p\textsubscript{-}DDE which plasma levels are not correlated to therapeutic response. Mitotane is a lipophilic drug that accumulates in lipoproteins and induces hypercholesterolemia by activation of HMGCoA reductase. Looking for predictive/prognostic markers of response we assessed the distribution of o,p\textsubscript{-}DDD and its metabolites in lipoprotein fractions of ACC patients.

Materials and methods

Levels of o,p\textsubscript{-}DDD, o,p\textsubscript{-}DDA and o,p\textsubscript{-}DDE were measured using HPLC-UV method after liquid-liquid extraction with o,p\textsubscript{-}DDE as internal standard. Lipoprotein fractions from plasma of ACC patients treated with mitotane were obtained by differential ultracentrifugation process.

Results

We developed and validated an HPLC-UV method. The extraction yields of o,p\textsubscript{-}DDD, o,p\textsubscript{-}DDA and o,p\textsubscript{-}DDE are 75, 73 and 38% respectively. This method is linear, precise, accurate and no matrix effect was observed (<2%). The method of separation of lipoproteins by differential ultracentrifugation allowed us isolating VLDL, LDL and the mixture HDL-proteins. Analyses in a few plasma patients showed a major distribution of o,p\textsubscript{-}DDA in HDL (99%) while o,p\textsubscript{-}DDD and o,p\textsubscript{-}DDE were mainly measured in LDL (>70%), partially in LDL (12–25%) and barely in VLDL (<5%).

Conclusion

This work allowed us to define conditions for the study of o,p\textsubscript{-}DDD, o,p\textsubscript{-}DDA and o,p\textsubscript{-}DDE distribution in the different lipoprotein fractions. The preliminary
results showed a different distribution profile for op'-DDA. The perspectives of this study are multiple: evaluation of lipoprotein distribution over time in a large cohort of patients; dyslipoproteinemia impact; relationship between op'-DDD, op'-DDA and op'-DDD lipoprotein plasma levels and therapeutic response.

P73

Ga-DOTATATE PET shows a better diagnostic performance than octreoscan in patients with neuroendocrine tumors

Antongiulio Faggiano1, Luigi Alo2, Corradina Caracò2, Valeria Ramundo1, Rosa Severino1, Gaetano Lombardi1, Annamaria Colao1 & Secondo Lastoria2

1Department of Molecular and Clinical Endocrinology and Oncology, ‘Federico II’ University of Naples, Naples, Italy; 2Nuclear Medicine, National Cancer Institute, ‘Fondazione G. Pascale’, Naples, Italy.

Background and objective

In-DPTA-Octreotide (Octreoscan) has limited spatial resolution and a somewhat lower receptor affinity of the radioligand compared to DOTATATE, a novel somatostatin analogue, which can be radiolabelled with 68Ga and adapted for PET imaging, resulting in an increased spatial resolution. The aim of this study was to evaluate the diagnostic performance of 68Ga-DOTATATE PET in patients with NET and to compare this technique with Octreoscan.

Patients and methods

Fifty-seven patients with NET were enrolled, located in pancreas (27), duodenum/ileum (4), lung (7), stomach (6), thyroid (12), paraganglia (1). Forty patients had a sporadic and 17 a MENI-related NET. 68Ga-DOTATATE PET was performed in all cases by acquiring whole body studies 40-60 min after the radioligand i.v. injection (range 74–111 MBq). Octreoscan was also performed in a subgroup of 27 patients using intravenous injection of Indium-111-DTPA-Phe1-octreotide (Octreoscan, Mallinkrodt Medical, Petten, The Netherlands; 120–200 MBq). At the time of PET/Octreoscan evaluation 40 patients had tumor lesions and 17 were negative as confirmed by CT/MRI examination and clinical follow-up.

Results

The patient based sensitivity was 77% with a specificity of 100% while the lesion based sensitivity was 64% with a specificity of 85%. Positive and negative predictive values were 100 and 65% respectively. The sensitivity of PET was about 100% in pancreatic and gut NET, about 75% in lung and thyroid NET and lower than 50% in gastric NET. In a subgroup of 27 patients undergone both PET and Octreoscan, the result was concordant in 21 and discordant in six cases. The discordant results included five PET positive and Octreoscan negative NET (three pancreatic NET, two medullary thyroid cancer) and one PET negative and Octreoscan positive NET (an atypical bronchial carcinoid).

Conclusions

68Ga-DOTATATE PET shows high sensitivity and excellent specificity in patients with NET, revealing a higher diagnostic performance than Octreoscan.

P74

In vitro effect of the somatostatin analogue BIM 23704 on cell cycle timecourse in an ovarian carcinoma cell line

Cristina de Angeli1, Claudia Pivonello1, Gaia Cuomo1, Attilio di Spiezo Sardo2, Giuseppe Bifulco2, Carmine Nappi1, Francesco Scaffati2, Federica Cariati1, Annamaria Colao1 & Rosario Pivonello1

1Department of Endocrinology and Clinical and Molecular Oncology, University of Naples Federico II, Naples, Italy; 2Department of Gynecology and Obstetrics, University of Naples Federico II, Naples, Italy.

Ovarian carcinoma (OC) is associated with poor prognosis and low survival rate. Eligible treatment for advanced OC is surgery followed by chemotherapy based on a combination of Platinum and Taxol, but unfortunately long-term outcome of such therapy is disappointing. Moreover, systemic administration of cytotoxic agents is usually accompanied by a series of side effects. On the basis of this evidence, more selective and tumour cell-targeted therapeutic approaches are warranted. Somatostatin receptors (SSTRs) are widely distributed in normal and tumour tissues and mediate anti-proliferative, anti-angiogenic and pro-apoptotic effects acting on different molecular pathways. The aim of this study was to analyze SSTR expression in A2780 human ovarian adenocarcinoma cell line and tested the effect of a SSTR selective agonist on cell line proliferation. PCR analysis showed SSTR1 and SSTR2 expression, suggesting to test the effect of the SSTR agonist BIM 23704, which has high affinity for these two receptors. BIM 23704, administered at the dose of 10^{-7} –10^{-9} M, showed a dose-dependent inhibitory effect on cell proliferation with a maximum effect after 48 h of continuous exposure (30% at 10^{-7} M and 25% at 10^{-9} M). This effect persist until 96 h of exposure, then treated cells become insensitive. FACS analysis indicated that this inhibitory effect is not due to induction of apoptosis nor to block of cell cycle but to a slowdown of cell cycle timecourse (reduction of 11%). Western blot analysis showed a reduction of pERK1/2(Tyr 204) kinases in treated cells protein extracts compared with untreated control cells suggesting an involvement of these proteins in A2780 cell cycle. These preliminary data, if confirmed, might suggest the use of this compound as adjuvant of chemotherapy agents in the effort to reduce their dose and consequent side effects and to bypass the onset of chemoresistance due to high dosage and continuous exposure in the management of OC.

P75

T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a medullary thyroid cancer cell line

R Pivonello1, C Pivonello1, A Cavaccini2, M Sarnataro2, F Cariati1, A Faggiano1, A Colao1 & M Cataldi2

1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy; 2Division of Pharmacology, Department of Neuroscience, Federico II University, Naples, Italy.

Medullary thyroid carcinoma (MTC) accounts for ~5–10% of thyroid cancers. Intense efforts are currently directed toward the identification of new druggable targets for the treatment of MTC. The aim of this study was to investigate whether drugs acting at voltage-gated T-type calcium channels could affect hormone release and/or cell proliferation in a MTC cell line, the TT cells. The expression of the three isoforms of T-type calcium channels (CaV3.1, CaV3.2 and CaV3.3) was evaluated by RT-PCR whereas T-type currents were recorded by whole cell patch clamp electrophysiology. The effect of T-type calcium channel blockers (Ni2+, mibebradil and NNC 53-0396) on calcitonin secretion and cell proliferation and viability was evaluated respectively by measuring calcitonin levels, and the percentage of cell cycle arrest and/or apoptosis by WST assay, flow cytometry and FLICA assay. At RT-PCR analysis, all three isoforms of T-type channels were found. Whole cell patch clamp experiments showed that T-type currents represent the only form of Ca2+ currents elicited by depolarization in these cells. The amplitude of T-type currents was reduced to <30% of their basal values when TT cells were perfused with an extracellular solution containing either the transition metal Ni2+ (150 M) or mibebradil (10 M) or NNC 53-0396 (10 M). Basal calcitonin release from cultured TT cells was dose-dependently inhibited in the presence of T-type blockers (IC50: ~15 M). The viability of TT cells was inhibited by Ni2+ (32%), NNC 53-0396 (76%) and Mibebradil (70%) at the concentrations 1 mM, 10–30 μM and 30 μM respectively. Moreover, NNC 53-0396 dramatically increased the percentage of cells undergoing apoptosis whereas only limited effects were observed on cell cycle. At FLICA assay a significant apoptotic effect was observed by binding of red fluorochrome to caspases in cells treated with NNC 53-0396, confirming the evidence that upon NNC 53-0396 exposure TT cells underwent apoptosis. In conclusion, T-type channel blockers seem to play a relevant role in controlling both hormone secretion and cell viability in MTC cells. These data prompt further studies aimed to investigate the potential of T-type channel blockers in the pharmacological treatment of MTC.

P76

Management of type III neuroendocrine tumors of the stomach

A G J Gilis-Januszewska1,2, E B Baczynska1,2, A S S Sowa-Staszczak1,2, M T Trofimuk2, D P Pach1,2, R T Tomaszewska1,2 & A H D Hubalewska-Dydekczyk1,2

1Department of Endocrinology, Jagiellonian University, Krakow, Poland; 2Jagiellonian University, Krakow, Poland.

Background

Type 3 neuroendocrine tumors of the stomach (type 3 NETV) are very rare subtypes of NETV with poor prognosis, not fully understood biology and not well investigated diagnostic and therapeutic procedures. The aim of the study was to analyze tumor biology and the outcome of differentiated treatment in patients with type 3 neuroendocrine tumors of the stomach.

Methods

A prospective 10 years follow up of five patients with type 3 NETV treated in our institution was undertaken.

Results

We investigated and followed up for 11 years five patients with histopathologically confirmed type 3 NETV. The diagnosis and gastric resection (total 3/5,
partial 2/5, palliative 1/5) was performed 3–12 months after first tumor related symptoms presentation 5/5. The solitary tumors 5/5, were from 20 to 90 mm in diameter, located in fundus 4/5 and in cardia 1/5, infiltration beyond submucosa occurred in all cases. Metastases to regional lymph nodes were present in 5/5 cases during surgery, liver and distant (peritoneum, retroperitoneal space) metastases occurred in 4/5 in 0–11 months from diagnosis/gastrectomy. Chemotherapy was given in 5/5 in 2–6 months from diagnosis/gastrectomy. One patient was treated with 90Y in 6 months after diagnosis. 3/5 patients died in 8–18 months from diagnosis/gastrectomy. 2/5 patients are alive in 20–38 months from diagnosis/gastrectomy. 1/5 patient is free of disease in 38 months from diagnosis/gastrectomy.

Conclusions

The increasing number of type 3 NETV related probably to improved diagnostic methods and their poor prognosis require more profound investigation of the tumor biology and improvement of the treatment procedures.

P77 Could 99mTc labeled long-acting agonist of GLP-1 (Exendin-4) scintigraphy be a new tool in the diagnostics of unknown focus of insulinoma? preliminary results

A H D Hubalewska-dydejczyk1,2, D P Pach1,2, A S Sowa-Staszczak1,2, A J H Jabrocka-Hybel1,2, A S Stefanska1,2, A G J Gilis-Januszewska1,4, R M K elekowicz1,2 & B J Janoet1,2
1Chair and Department of Endocrinology, Jagiellonian University, Krakow, Poland; 2Institute of Atomic Energy POLATOM, Swierk, Poland.

Introduction

GLP-1 receptors have been fund on different types of neoplasm' cells and density of these receptors appears to be more frequent in some of them. GLP-1 receptor scanning offers a new approach for successful localization of small not detectable by other methods insulinomas and other cancers such as MTC, gastrinoma, pheochromocytoma, gastrinoma, etc.

Aim of the study

The aim of study was to present first successful experiences with the use of 99mTc-labeled [Lys40(Ahx-HYNIC)NH2]-Exendin-4 (Exendin-4 is a long-acting GLP-1 agonist) scintigraphy in localization of unknown insulinoma focus.

Material and method

[Lys40(Ahx-HYNIC)99mTc/EDDA]NH2]-Exendin-4 receptor scintigraphy was performed in three patients. The insulinoma was suspected in two of them: a 57-year-old women with severe clinical hypoglycaemias, no lesion in CT and no uptake of the tracer in SRS. In 16-year-old man with hyperinsulinemia, small unclear lesion in CT and no uptake of the tracer in SRS. A 62-year-old women with malignant insulinoma after surgery with metastases to the liver in CT was qualified to scintigraphy with suspicion of the disease recurrence and no pathological uptake in SRS.

Results

In both suspected insulinoma cases, the uptake of [Lys40(Ahx-HYNIC)99mTc/EDDA]NH2]-Exendin-4 in pancreas was found. The first patient had successful surgery, revealing small lesions of insulinoma. For the second patient, fusion of images confirmed that pathological accumulation of tracer localized in pancreas; patient has been referred to surgery. In patient with malignant insulinoma the images confirmed that pathological accumulation of tracer localized in pancreas; uptake of the tracer was in the place suspected as recurrence.

Conclusion

Promising pharmacokinetic data and the preliminary results of our study showed that [Lys40NH2(Ahx)-HYNIC]-Exendin – 4 – 99mTc could be suitable candidate for clinical GLP-1 receptor imaging in clinical practice.

P78 A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3): updated safety results

D Horsch1, W Kocha2, J Lincy3, S Saletan4 & C Lombard-Bohas4
1Zentralklinik Bad Berka GmbH, Bad Berka, Germany; 2London Regional Cancer Center, London, Ontario, Canada; 3Novartis Oncology, Basel, Switzerland; 4Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France.

Background

In the phase III RADIANT-3 trial, everolimus, an oral mTOR inhibitor, demonstrated superior in progression-free survival with a median of 11.0 vs 4.6 months for placebo (hazard ratio, 0.35; 95% confidence interval, 0.27 to 0.45; P < 0.0001) in patients with advanced pNET (ESMO 2010, Abstract LLBA8). Here we present an update of the safety analysis from this trial.

Methods

Patients with progressive advanced low- or intermediate-grade pNET were randomized to everolimus 10 mg/day orally or placebo (n = 203); both arms received best supportive care. Adverse events (AEs) were collected and coded to a preferred term using the medical dictionary for regulatory activities. AEs were graded using the National Cancer Institute’s Common Terminology Criteria (v 3.0). Safety population included 407 patients (204 for everolimus; 203 for placebo).

Results

Median study follow-up was 20.1 months. Safety of everolimus was consistent with the primary analysis (median follow-up 28 months). Most frequent drug-related AEs (everolimus + octreotide LAR versus placebo + octreotide LAR, %) were stomatitis (47.4 vs 10.9), rash (37.2 vs 12.3), fatigue (31.6 vs 24.2) and diarrehea (27.4 vs 15.6). Most frequent drug-related grade 3/4 events (everolimus + octreotide LAR versus placebo + octreotide LAR, %) were fatigue (6.5 vs 2.8), diarrehea (6.0 vs 2.4), hyperglycemia (5.1 vs 0.5), thrombocytopenia (4.7 vs 0) and stomatitis (3.7 vs 0). Drug-related AEs rates leading to study drug discontinuation were 19.5% for everolimus + octreotide LAR vs 3.8% for placebo + octreotide LAR. Disease progression was the primary reason for treatment discontinuation in both arms.

Acknowledgment

Study sponsored by Novartis.

P79 A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3): updated safety results

D Horsch1, W Kocha2, J Lincy3, S Saletan4 & C Lombard-Bohas4
1Zentralklinik Bad Berka GmbH, Bad Berka, Germany; 2London Regional Cancer Center, London, Ontario, Canada; 3Novartis Oncology, Basel, Switzerland; 4Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France.

Background

In the phase III RADIANT-3 trial, everolimus, an oral mTOR inhibitor, demonstrated superior in progression-free survival with a median of 11.0 vs 4.6 months for placebo (hazard ratio, 0.35; 95% confidence interval, 0.27 to 0.45; P < 0.0001) in patients with advanced pNET (ESMO 2010, Abstract LLBA8). Here we present an update of the safety analysis from this trial.

Methods

Patients with progressive advanced low- or intermediate-grade pNET were randomized to everolimus 10 mg/day orally (n = 207) or placebo (n = 203); both arms received best supportive care. Adverse events (AEs) were collected and coded to a preferred term using the medical dictionary for regulatory activities. AEs were graded using the National Cancer Institute’s Common Terminology Criteria for AEs (v 3.0). Safety population included 407 patients (204 for everolimus; 203 for placebo).

Results

Median study follow-up was 20.1 months. Safety of everolimus was consistent with the primary analysis (median follow-up 17 months). Median exposure to everolimus was 2.3-fold longer than placebo (37 vs 16 weeks), corresponding to exposures of 175.2 vs 104.9 patient-years, respectively. Most common drug-related AEs with everolimus versus placebo were stomatitis (52.9 vs 12.3%), rash (48.5 vs 10.3%), diarrehea (34.3 vs 10.3%) and fatigue (32.4 vs 14.3%). Anemia (5.9 vs 0%), hyperglycemia (5.9 vs 2.5%), stomatitis (4.9% vs 0), and thrombocytopenia (3.9 vs 0%) were the most common drug-related grade 3/4 events for everolimus and placebo, respectively. Most AEs resolved with dose modification/interruptions or concomitant medication. Rate of drug-related AEs leading to discontinuation was relatively low (13.7% everolimus versus 2.0% placebo). Disease progression remained the primary reason for discontinuation from both treatment arms.

Acknowledgment

Study sponsored by Novartis.
13th European Congress of Endocrinology, Rotterdam, The Netherlands

P80 Mitotane reduces the chemoresistance phenotype in an adrenocortical carcinoma cell line
T Gagliano, A R Robustelli, D Mole, E degli Uberti & M C Zatelli
Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy.

Adrenocortical carcinoma (ACC), a rare tumor, with incidence of 1–2 per million population annually, has a bimodal distribution by age, with cases clustering in children under 6, and in adults 30–40 years old. ACC has a dismal prognosis. The only curative treatment is complete surgical excision of the tumor, but also diagnosis prevents surgical cure, since ACC frequently recurs and metastasizes. Chemotherapy is frequently ineffective, due to the overexpression of the MDR-1 gene, encoding for detoxifying pump P-gp, which confers chemoresistance to ACC. Mitotane, an adrenolytic drug, is being used as adjuvant therapy to prevent recurrence, despite several and important side effects appearing at therapeutic concentrations (14–20 mg/l; 40–60 μM).

We aimed at identifying therapeutic strategies to overcome adrenocortical carcinoma chemoresistance by using mitotane. Human adrenocortical cells, NCI-H295R, expressing high P-gp levels, were treated with mitotane (2.5–80 μM) and doxorubicin (1–100 nM), identifying minimal cytotoxic concentrations. Cell viability and caspase 3/7 activity under 25 μM mitotane were tested. These drug concentrations are much lower than those reached in vivo. Combination treatments significantly and more potently reduced cell viability (40–60%) by inducing caspase-3/7 activity. In addition, we found that mitotane significantly reduced P-gp activity, promoting the intracellular accumulation of fluorescent compounds.

Our results indicate that mitotane enhances the cytotoxic effects of doxorubicin in a chemoresistant adrenocortical carcinoma cell line, likely inhibiting P-gp activity.

P82 The role and extent of surgical resection in patients with gastric carcinoid tumours type 1
S Antoniou, A Zilos, I Mpanaka, G Kanakis, P Rousaki, M Schini, J Griniatios & G R Kaltzas
Endocrinology Unit, Department of Pathologic Physiology, 21st Department of Surgery, LAIKO Hospital, University of Athens, Athens, Greece.

Background
The exact indications and/or the type of operation requiring for the treatment of gastric carcinoids (GC) type 1, are not clearly stated. The present study was designed to evaluate the value of the oncological gastrectomy in the treatment of GC type 1.

Materials and method
Between January 2004 and December 2010, we advocated gastric resection in cases of GC type 1 when at least one of the following criteria was present: i) multiple recurrent lesions, ii) lesions with positive margins following endoscopic resection, iii) lesions with malignant potential (deep gastric parietal wall invasion, lymph node enlargement, Ki67 proliferative index >2%) and/or iv) presence of metastatic disease. Preoperatively, all patients had undergone laboratory tests (serum gastrin and chromogranin A measurements) and imaging investigations for exclusion of the Zollinger–Ellison and the MEN1 syndromes.

In addition, all patients underwent either computed tomography (CT) and/or magnetic resonance imaging (MRI) of the abdomen, as well as scintigraphy with 111In-pentetreotide (Octreoscan), endoscopic ultrasound (EUS) was performed in four patients. A modified subtotal D2 lymphadenectomy was routinely performed.

Results
Seven patients (five females) were surgically treated. Four patients fulfilled one and three patients fulfilled two criteria. Fifteen to thirty-six perigastric lymph nodes were histologically retrieved per patient, but metastatic infiltration was noticed only in a patient with hepatic metastases. Within a median follow-up of 34 months, all patients are alive without any evidence of recurrence.

Conclusion
Extended peri- and extra-gastric lymphadenectomy did not prove to be necessary for non-malignant localized GC type 1, either for staging or therapeutically.
The demethylating agent 5-aza-2-deoxycytidine upregulates somatostatin type 2 receptor expression and enhances internalization of radiolabeled somatostatin analogue in human carcinoid tumour cells

M.J. Veenstra1, P.M. van Kooten2, W.E. Farrel3, F. Dogan4, A.M. Waijers1, M.M.S. van den Brink5, G. Vitale6,7,8, L. van Hofland1
1Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; 2Department of Human Disease and Genomics Group, Institute of Science and Technology in Medicine, School of Medicine, Keele University, Stoke on Trent, Staffordshire ST4 7QB, UK; 3Department of Medical Sciences, University of Milan, Milan, Italy; 4IRCCS Istituto Auxologico Italiano, Milan, Italy.

Introduction
Neuroendocrine tumors (NET) are rare tumors originating from various types of neuroendocrine cells. The somatostatin receptor type 2 (sst2) is expressed in NET cells and is a target for therapy with somatostatin analogues. Epigenetic changes including methylation of DNA at CpG dinucleotides, and particularly in the promoter region of genes can inhibit transcription. Methylation can be inhibited by cytidine analogues such as 5-aza-2-deoxycytidine (AZA). Since hypermethylation of the sst2 gene has been shown to influence sst2 expression we hypothesize that upregulation of sst2 expression by AZA would lead to increased uptake of [125I-Tyr3]octreotide.

Materials and methods
Cells of the human pancreatic carcinoid cell line BON were cultured 7 days with increasing doses of AZA to determine the effect on cell proliferation. To determine the effect of AZA on uptake of [125I-Tyr3]octreotide, cells were cultured 6 days at 3 conditions: untreated control and AZA 50 and 100 nM. Thereafter, the cells were plated and cultured without or with AZA for 2 days. Subsequently, an internalization experiment was performed using [125I-Tyr3]octreotide. Cells were subsequently collected for RT-qPCR of sst2.

Results
AZA induced a dose-dependent inhibition of cell proliferation with an IC50 value of 80 nM. AZA, at 50 and 100 nM, induced a 2- and 2.5-fold increased uptake of [125I-Tyr3]octreotide. RT-qPCR results showed a dose-dependent increase of sst2 mRNA expression. Partial CpG methylation of the sst2 gene was found in the CpG island, downstream of the transcription start site.

Discussion and conclusion
Measurement of internalized [125I-Tyr3]octreotide revealed increased dose dependent uptake after treatment with AZA, likely due to upregulation of sst2 expression. This indicates that either the region of the CpG island we determined to be methylated influences expression or there is an indirect mechanism causing upregulation of sst2.
P88

**cAMP induces PATZ1 and estrogen receptor β nuclear re-localization in the human seminoma TCAM-2 cell line**

F Boscia1, F Esposito1, S Kitazawa2, L Looijenga3 & P Chieffi4

1 Università di Napoli Federico II, Naples, Italy; 2 Kose University, Kobe, Japan; 3 ErasmusMC-University, Rotterdam, The Netherlands; 4 Seconda Università di Napoli, Naples, Italy.

Estrogen exposure has been linked to a risk for the development of testicular germ cell cancers. The effects of estrogen on testicular cancers are not known. Here we evaluated the impact of cAMP mediated signalling on gene expression and immunohistochemistry of proliferation markers in a human seminoma cell line (TCAM-2).

Introduction

The practicioners should be aware that hyperthyroidism does not exclude the presence of a thyroid cancer. The management of a thyroid nodule in a patient who is newly diagnosed with an endocrine disease, such as thyroid cancer but a pulmonary lung metastasis cannot be excluded. The serum calcitonin showed pulmonary tissue with neoplastasic infiltration of differentiated mixt thyroid cells.

Case presentation

B.C., 66-year-old male patient, smoker from the last 17 years, was treated with thiamazol for hyperthyroidism. A CT exam showed a right thyroid nodule of 2.5 cm, but also a left inferior lobe lung tumor of 3.8 cm, with unhomogenous proliferation with compact, trabecular, and papillary aspects, and also with squamous areas, multiple microcalcifications, suggestive for a papillary thyroid cancer. The FNAB revealed epithelial cells of normal testis. However, its expression was markedly diminished in seminomas, embryonal cell carcinomas, and in mixed germ cell tumours but remains high in teratomas. PATZ1 is one of the best discovered zinc finger protein that, due to the presence of the POZ domain, acts as a transcriptional repressor affecting the basal activity of different promoters. We have previously described that PATZ1 plays a crucial role in normal male gametogenesis and that its up-regulation and mis-localization could be associated to the development of testicular germ cell tumours. Here, we show that ERβ interacts with PATZ1, and PKA (regulatory subunit) in normal germ cells, while down regulation of ERβ associates with transcriptional coregulator PATZ1 delocalization in human testicular seminomas. Interestingly, we found that the translocation of PATZ1 from the cytoplasm into the nucleus is regulated by cAMP that induces also an ERβ increased expression and nuclear localization, while this effect is counteracted by using the anti-estrogen ICI 182-780.

Conclusions

Taken together, our results demonstrate for the first time the interaction between PATZ1 and ERβ in normal germ cells, consistently, the PATZ1 delocalization associated with ERβ down regulation in human testicular seminomas, could be associated to an impaired cAMP mediated signalling to generate the testicular neoplasia.

---

P89

**The management of thyroid nodule in a patient with a non-thyroid primary cancer**

René Baloescu1, Mara Carosice2, Raluca Trifanescu1,2, Madalina Musat1,2, Ruxandra Danciulescu-Miulescu2, Dumitru Ioachim3, Dana Terzea4 & Catalina Poiana1,2

1 Cl Parhon National Institute of Endocrinology, Bucharest, Romania; 2 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 3 Babes Institute of Development and Research, Bucharest, Romania.

Introduction

The management of a thyroid nodule in a patient who is newly diagnosed with an active cancer depends not only of the thyroid disease its self but also of the prognosis of the second neoplasia.

Aim

We present a case of a male who was admitted to an endocrinologist for a thyroid nodule evaluation. Case presentation B.C., 66-year-old male patient, smoker from the last 17 years, was treated with thiamazol for hyperthyroidism. A CT exam showed a right thyroid nodule of 2.5 cm, but also a left inferior lobe lung tumor of 3.8 cm, with unhomogenous and squamous aspects, several micromodules of maximum 6 mm under pleura (bilateral), and left hilf lymph nodes were found. The investigations lead to bilateral lobectomy (atyypical resection) of a lung tumor. The pathological exam showed pulmonary tissue with neoplastic infiltration of differentiated mixt adenocarcinoma with pleural invasion (T2N3M1). The IHC report showed positive reaction for TTF1 and CEA and negative for tregibolbin. Later, he was admitted for a recent rapid growth of the nodule. The FNAB revealed epithelial proliferation with compact, trabecular, and papillary aspects, and also with squamous areas, multiple microcalcifications, suggestive for a papillary thyroid cancer but a pulmonary lung metastasis cannot be excluded. The serum calcitonin was normal, but serum thyroglobulin was twice normal - 141.4 ng/ml (normal: 1.4 and 78 ng/ml). Total thyroidectomy was performed and the diagnosis of papillary thyroid cancer was established. Radioiodine therapy was started and also leyro-thyroxin suppressive therapy, associated with chemotherapy.

Conclusion

The practitioners should be aware that hyperthyroidism does not exclude the presence of a thyroid cancer. The management of a thyroid nodule in a patient already diagnosed with a malign non thyroid tumor is more difficult.

---

P88

**Female reproduction**

P90

**Ovulation induction by metformin in lean and obese women with polycystic ovary syndrome**

P V Popova1, L I Ivanova2, T L Karanova1 & E N Grineva1,2

1 Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation; 2 Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg, Russian Federation; 3 Kirov Military Medical Academy, Saint Petersburg, Russian Federation.

Introduction

Metformin is now one of the most common treatments for PCOS. However controversy exists about the usefulness of metformin in PCOS women with normal insulin sensitivity and normal weight. The aim of this study was to compare efficacy of metformin treatment for the purpose of restoration of ovulation in lean and obese women with polycystic ovary syndrome.

Design

Thirty-six unovulatory women with PCOS (21 lean with mean body mass index (BMI) 21.4±2.3 kg/m2 and 15 obese with BMI 32.3±3.3 kg/m2) received metformin 1700 mg/day during 6 months. We estimated ovulation induction (by ultrasound scanning), change in menstrual cycle, anthropometric measurements, endocrine parameters and insulin sensitivity.

Results

A total of 20 lean and 14 obese women completed the trial. The groups were comparable by age, androgen levels and severity of menstrual dysfunction at baseline. Ten obese patients (67%) and one lean patient (5%) had resistance to insulin (homeostasis model assessment (HOMA) index > 2.5), P < 0.001. Lean women with PCOS treated with metformin had restoration of menstrual function (55%) and ovulation (45%) more often than obese women with PCOS (only one patient - 7% - responded to the treatment), P = 0.018. Significant decrease of testosterone level (from 3.1±1.0 to 2.7±0.8 mmol/l; P = 0.049), fasting glucose (from 5.2±0.4 to 4.9±0.4 mmol/l, P = 0.013) and HOMA (from 1.6±0.7 to 1.2±0.7, P = 0.045) during metformin treatment was shown only in lean women with PCOS. There was no change in BMI and waist circumference in both groups.

Conclusions

Treatment with metformin 1700 mg daily was more effective in lean than in obese women with PCOS. Its efficacy was independent of initial surrogate markers of resistance to insulin.

---

P91

**Detection and exploring the left shift kurtosis of the fertile window in ovulatory cycles by biophysical biomarkers of the cervical secretion**

Jose María Murcia Lora & María Luisa Esparza Encina

Clinical Consulting G&E, Logroño La Rioja, Spain.

Introduction

The main purpose of this case is to present a case in which the left kurtosis interval of the fertile phase curve, may be evaluated by checking the biophysical changing pattern of reproducible methods of viscoelasticity and transparency of the cervical secretion. Case report

This case report included a 24 years old woman who plots a curve in which integrates two biomarkers in relation to the fertile window at the follicular phase. It was recording the evolution of biophysical parameters of the cervical secretion when approaching to the fertile window. Filancia is quantified by measuring the distance in cm of cervical secretion and transparency in tree degrees of density. Biomarkers are located within the window of fertility in relation to the maximum peak day of filancia plotted on the chart. The fertile window was detected with the threshold level of urinary oestrone-3-glucuronide (E3G). It was identify the ovulation day (EDO) by test of LH post peak.

Results

The fertile window was 10 days estimated by cervical mucus, 4 days longer than the monitor E3G, in which the length of the fertile period was 6 days. It was possible to detect the cervical mucus evolution of 4 days at the left kurtosis of the 6-day fertile period of the fertile window when it used biophysical parameters of the cervical secretion.

Conclusion

The objective evaluation help to check better the changing pattern of the left kurtosis of the fertile window by cervical secretion, and detect better the time shift of this left kurtosis of the fertile window. Integrating the different biomarkers parameters may identify better the left changing patterns of the fertile window when it used cervical secretion.

---

**Endocrine Abstracts** (2011) Vol 26
P92
Prevalence of thyroid pathologies in patients with polycystic ovary syndrome
Didem Ozdemir, Neslihan Cuhaci, Fevzi Balkan, Alper Ushuoğullari, Reyhan Ėssoy & Bekir Çakır
Department of Endocrinology and Metabolism, Atatürk Education and Research Hospital, Ankara, Turkey.

Introduction
Polycystic ovary syndrome (PCOS) is a common disorder characterized by chronic anovulatory oligo-anovulation and signs of hyperandrogenism. In this study, we aimed to determine prevalence of thyroid nodules and autoimmune thyroid diseases in patients with PCOS.

Methods
Patients diagnosed with PCOS in our endocrinology clinic were included in the study. In patients with irregular menses and/or hirsutism, the diagnosis of PCOS was made by high serum LH/FSH ratio, high serum free testostererone levels and/or polycystic ovaries in pelvic ultrasonography. Serum thyrotropin, free thyroid hormones, antithyroid peroxidase (AntiTPO) and antithyroglobulin (AntiTg) antibody levels were evaluated. Thyroid ultrasonography was performed in all subjects by the same examiner. Thyroid fine needle aspiration biopsy (FNAB) was carried out when indicated.

Results
There were 107 women with PCOS with a mean age of 23.96 ± 5.70. Seventeen (15.9%) patients had hypothyroidism and 2 (1.8%) had hyperthyroidism. 30.5% patients had positive AntiTPO, 30.5% had positive AntiTg and 37.8% had positive AntiTPO or AntiTg antibodies. Thyroid nodules were detected in 29 (27.1%) patients, 10 had solitary and 19 had multiple nodules. FNAB was performed in 11 patients with nodules; 10 were cytologically benign and 1 was malignant (papillary thyroid carcinoma was confirmed histopathologically).

Totally, in 54 (50.5%) patients, there was a thyroid related disease such as primary thyroid antibodies, thyroid dysfunctions or nodules. Insulin resistance calculated with HOMA-IR was ≥ 2.47 (43.9%) and < 2 in 60 (56.1%) patients. Nodule prevalence, thyroid dysfunctions, thyroid autoantibody positivity and thyroid volume did not differ between PCOS patients with and without insulin resistance.

Conclusion
Thyroid pathologies are observed in half of the patients with PCOS. Measurement of thyroid hormones are usually a part of investigation in PCOS patients, but we think serum thyroid autoantibodies and presence of thyroid nodules should also be searched in these patients.

P94
Development of a mouse model with polycystic ovary syndrome
E L A F van Houten, A Mcluskey, P Kramer, B Kares, A P N Themmen & J A Visser
Erasmus MC, Rotterdam, The Netherlands.

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in their reproductive age. Based on the Rotterdam criteria PCOS is defined by two out of the following three criteria: hyperandrogenism, oligo/anovulation, and polycystic ovaries. In addition, PCOS patients are often abdominally obese, which can cause insulin resistance. The subsequent increased insulin levels stimulate the ovary to further increased androgen production. Thus, the elevated androgen and insulin levels may result in a detrimental vicious circle between ovary and adipose tissue. Our aim was to develop a mouse PCOS-like model, allowing the future use of transgenic mouse models to study the interaction between ovarian and adipose function in PCOS.

Prepubertal female mice received a 60 or 90 days continuous release pellet containing the non-aromatizable androgen dihydrotestosterone (DHT) or vehicle. At the end of the treatment period the estrous cycle was analyzed and ovaries were collected. Furthermore, body weight was measured, fat depots were morphologically analyzed and an intraperitoneal glucose tolerance test (IPGTT) was performed.

DHT treatment for 60 days did not result in differences in reproductive and metabolic characteristics compared to vehicle-treated mice. In contrast, 90 days DHT-treated mice were in continuous an-estrous and their ovaries lacked corpora lutea, consistent with anovulation. Antral folicles of 90 days DHT-treated mice had a cyst-like structure and there was an increase in the number of atretic folicles. These mice also showed a significantly higher body weight. In addition, fat depots of DHT-treated mice displayed an increased number of adipocytes of increased size. Furthermore, blood glucose levels during IPGTT were higher, suggesting that these mice are glucose intolerant.

We conclude that DHT treatment for 90 days in mice results in a metabolic and reproductive phenotype resembling the phenotype found in PCOS women.

P95
Kisspeptin: new marker of placental dysfunction?
D Miljic1, A Četkovic2, A Ljubic2, P Miljic2, M Đurovic1, M Doknić1, S Pekić1, M Stojanovic1, M Patterson3, M Ghati4, S Bloom4 & V Popovic1
1Clinic for Endocrinology, University Clinical Center, Belgrade, Serbia; 2Obstetrics and Gynecology Clinic, University Clinical Center, Belgrade, Serbia; 3Clinic for Hematology, University Clinical Center, Belgrade, Serbia; 4Hammersmith Hospital, Imperial College, London, UK.

Kisspeptin produced by placenta is involved in the regulation of early placental development. Aberrant placental development and placental dysfunction are common in pregnancies with diabetes and hypertension. Parameters of fetal growth, feto-placental circulation, pregnancy outcome, placental weight and morphology were recorded and correlated with kisspeptin levels in pregnant women with diabetes (chronic-H, pregnancy induced-PIH and pre-eclampsia-PE).

Kisspeptin was evaluated in 129 singleton pregnancies by an in-house RIA assay. Samples were collected in the 1st, 2nd and 3rd trimester (T) in patients with IDDM (n = 16), H (n = 22) and healthy pregnant women (n = 25) and in the 2nd and 3rd trimester in patients with GD (n = 20), PIH (n = 18) and PE (n = 28). In pregnancies with IDDM, GD, H and PE kisspeptin levels were significantly lower compared to control group at all time points. Kisspeptin levels in patients with PIH were not significantly different from control group. In PIH and controls no adverse events and no abnormalities in placental morphology and function were recorded. In the 1st T severely decreased kisspeptin levels were associated with an increased risk of spontaneous abortion. In the 2nd T low kisspeptin levels were associated with higher incidence of abnormal placental morphology. In the 3rd T low kisspeptin levels correlated with higher incidence of adverse outcomes (P<0.001) and disturbances in feto-placental circulation (P<0.01). Gestational age, neonatal and placental weight were significantly lower in PE group compared to others (P<0.01). No correlation was found between placental weight and kisspeptin (P>0.05). Significant associations between reduced kisspeptin levels and parameters of placental dysfunction and pregnancy outcome were found in pregnancies with pre-eclampsia, diabetes and chronic hypertension. Larger studies are needed to investigate the role of kisspeptin as a potential new marker of placental dysfunction.

Endocrine Abstracts (2011) Vol 26
Tissue specific regulation of CGB gene expression in the common marmoset (Callithrix jaccus) by SP-1 and AP-2
C Adams & J Gromoll
Centre for Reproductive Medicine and Andrology, Muenster, Germany.

Objective
In the marmoset (Callithrix jaccus) the LH is functionally replaced by the chorionic gonadotropin (CG). However, disparate to the human LH/hCG system, marmoset CG is expressed in both, the pituitary and in the placenta. Previously, we could show the presence of a tissue-specific promoter system in the marmoset. Alternative promoters, as well as different first exons, either a pituitary or a novel placenta specific one, are being employed to direct tissue specific expression of CGB. This study aims to elucidate the regulation of marmoset CG in the placenta and the general mechanism for tissue-specific expression.

Results
Sequence analysis and reporter gene assays revealed the presence of two SP-1 and AP-2 binding sites in the placental CG promoter. Mutation of any of these binding sites led to a significant decrease in promoter activity by 90%. Further sequence analysis by MethPrimer revealed the presence of a prominent CpG-island within the placental promoter. A tissue specific DNA-methylation pattern was identified for the placental promoter region, with being hypermethylated in the pituitary and hypomethylated in the placenta. In vitro methylation of the placental promoter sequence led to a drastic decrease in CGB promoter activity.

Conclusion
We propose a concurring model where AP-2 and SP-1 work synergistically in a cassette modus on placental CGB expression. Our results further indicate an epigenetic regulation of the CG promoter in the placenta. This links CGB expression to a combined epigenetic and transcription factor regulatory mechanism.

Sexual dysfunction in polycystic ovary syndrome
Selvinaz Velet, Mustafa Velet, Pinar Kadioglu & Sezai Sahmay
Cerrahpasa Faculty of Medicine, Istanbul, Turkey.

Objective
We aimed to examine sexual dysfunction frequency and relationship between sexual dysfunction and androgen level in polycystic ovary syndrome.

Patients and methods
Twenty-five PCOS patients were recruited from the outpatient clinics of the Division of Endocrinology in the Department of Internal Medicine and outpatient clinics of the Department Obstetrics and Gynecology at the Cerrahpasa Medical Faculty. Twenty-five healthy volunteer age and sex matched are included in control group. Patients and control subjects were evaluated with female sexual function index (FSFI) and thebeck depression inventory (BDI). Serum free testosterone, total testosterone, DHEA-S, androstenedione and prolactine were measured. Free androgen index (FAI) was calculated.

Results
Total FSFI score 26.17±4.2 was in the PCOS group whereas, healthy women had a total FSFI score of 28.61±4.68. FSD was diagnosed in 4 of 25 patients (%16) while 5 of 25 (%20) healthy women had FSD (P=0.57). There is no statistically significant difference between sexual desire (P=0.89), arousal (P=0.10), lubrication (P=0.057), orgasm (P=0.18) and satisfaction (P=0.78) domain scores. Pain domain score was significantly lower in PCOS women (P=0.002), BDI scores was significantly higher in PCOS women (P=0.002). No correlation was seen between androgen level, FAI and total FSFI score and domain score.

Conclusion
Change in external appearence in women with PCOS do not make them feeling less attractive and do not lead to sexual dysfunction. Sexual desire, arousal, lubrication, satisfaction and orgasm disorder in women with PCOS is similar to healthy women but depression is more frequent in women with PCOS than healthy women.

Oligo-amenorrhea and hyperandrogenaemia in postmenarcheal adolescence
P Pinoia1, H Lashen2, A Bioigou3, P Puukka4, M Ulmanen4, M R Jarvelin5,6, A L Hartikainen1 & L Morin-Papunen1
1Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland; 2Department of Human Metabolism, University of Sheffield, Jessop Wing, Sheffield, S10 2SF Sheffield, UK; 3Child and Adolescent Health and Wellbeing Unit, National Institute for Health and Welfare, Oulu, Finland; 4Department of Clinical Chemistry, University of Oulu, Oulu, Finland; 5Department of Epidemiology and Biostatistics Public Health, Imperial College London, London, UK.

Introduction
Hyperandrogenaemia in adolescence is associated with hirsutism, acne and menstrual irregularity and is considered as an important risk for polycystic ovary syndrome and subsequent risk of cardiovascular disease and type 2 diabetes. The aim of this study was to establish if self-reported oligo/amenorrhea were associated with hyperandrogenaemia and metabolic disturbances in adolescence.

Subjects and methods
A cross sectional study using postal questionnaire targeting 16 years old girls in the Northern Finland Birth Cohort 1986 (n=4567). Of them, 3237 girls (71%) responded to the questionnaire and attended a clinical examination. After excluding pregnant girls, girls taking oral contraceptives or other hormonal treatment, and the subjects with missing data, 2448 girls were included in the analyses.

Results
Seven hundred and fifteen girls reported oligo/amenorrhea (symptomatic girls) and 1753 had regular periods (symptomless girls). Girls with menstrual disorders exhibited significantly higher serum concentrations of testosterone (P=0.010), lower serum levels of sex hormone binding globulin (SHBG, P=0.042) and higher levels of free androgen index (FAI, mean: 3.37 (95% confidence interval, CI: 2.32, 4.42) versus 2.04 (95% CI: 1.50, 2.64), P=0.002). The two groups did not differ as regards body mass index (BMI), waist-hip ratio, serum levels of glucose, insulin and lipids, or insulin sensitivity. There was a significant linear trend towards higher FAI levels in the highest BMI quartiles both in symptomatic and asymptomatic girls. In the whole population there was a statistically significant linear decreasing in high-density liprotein concentrations (P<0.001) and higher triglyceride concentrations (P=0.004) in the upper FAI quartile.

Conclusion
Oligo/amenorrhea at the age 16 is a good marker of hyperandrogenaemia. Girls in the highest BMI quartiles exhibited the greatest degree of hyperandrogenaemia, and those in the highest FAI quartile had a more unfavorable lipid profile, thus confirming earlier data on an association between obesity, hyperandrogenism and metabolic risks.

Cardiovascular disease risk markers in women with polycystic ovary syndrome: systematic review and meta-analysis
K A Toulis, G Mintziori, D G Goulis, E Kintiraki, E Eukarpidis, S A Mouratoglou, A Pavlaki, S Stergianos, M Poulasouhidou, T G Tzellos & B C Tarlatzis
Aristotle University of Thessaloniki, Thessaloniki, Greece.

Introduction
The relation between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD) remains unclear. The aim of the study was to systematically review the relevant trials that have studied CVD risk factors in women with PCOS (CRP, Hcy, TNF-α, PAI-1, Lp(a), AGEs, VEGF, IL6, ADMA and fibrinogen) and to meta-analyze the best evidence available.

Patients and methods
Search was conducted in the MEDLINE, EMBASE and CENTRAL (last update June 2010). Eligible for the systematic reviews were studies, which reported on CVD risk markers levels in women with PCOS compared to controls. Weighted mean differences (WMD) and 95% confidence intervals (CI) were calculated in each of the CVD risk markers for all eligible studies and combined using random effects model. To ensure synthesis of the best available evidence, sensitivity analyses were performed.

Results
One hundred and thirty studies were including in 11 different meta-analyses, involving in total 6260 women with PCOS and 4546 controls. Women with PCOS demonstrated significantly elevated CRP (WMD (95% CI) = 0.96 (0.74 to 1.19)), Hcy (2.25 (1.46 to 3.03)), PAI-1 antigen (16.96 (7.65 to 26.28)), PAI-1 activity...
Results

DHEAS mean value of four groups are control ($n=19$, 125.7±77.6), mild ($n=24$, 122.4±72.3), moderate ($n=24$, 90.6±40.2) and severe ($n=21$, 87.7±43.8) ($P=0.069$). Comparing after recombination four group into two group, control plus mild (group 1) and moderate plus severe (group 2 $n=45$), their mean values are group 1 ($n=43$, 123.9±73.8) and group 2 ($n=45$, 89.2±41.5) ($P=0.0078$).

Conclusions

This study shows that DHEAS may inhibit the growth of leiomyoma.

Keywords: Leiomyoma, DHEAS (dehydroepiandrosterone sulfate), RIA (radioimmunoassay).

P102

The importance of PIK3R1 gene in polycystic ovary syndrome

Xita N, Chatziyiakoudi I, Georgiou & A Tsatsoulis

University of Ioannina, Ioannina, Greece.

Introduction

Insulin resistance is a main characteristic of polycystic ovary syndrome (PCOS) and contributes to the increased risk of type 2 diabetes and cardiovascular disease. It is thought that in PCOS there is an alteration in the insulin signaling pathway. An important kinase in this pathway is the phosphatidylinositol 3 kinase (PI3K), the activity of which has been found to be decreased in PCOS. Based on this observation we investigated whether a single nucleotide polymorphism (rs1043526, A>G) of PIK3R1 gene that encodes the phosphatidylinositol 3 kinase regulatory subunit 1 (p85α) is involved in PCOS. This polymorphism is located in the 3'-UTR of PIK3R1 gene, where miRNAs can bind and thus regulate gene expression.

Subjects and methods

We studied 68 women with PCOS and 136 healthy women of reproductive age. Both patients and controls had normal weight. Hormonal profile was determined on 3–5th day of menstrual cycle. Insulin resistance was assessed by fasting glucose to insulin ratio and HOMA index. DNA was extracted from peripheral blood leucocytes and the Q192R polymorphism of PON1 and the L55M polymorphisms of paraoxonase (PON). The aim of this study was to investigate the possible association of the Q192R and the L55M polymorphisms of PON1 and the Ser311Cys polymorphisms of PON2 with PCOS.

Results

The PIK3R1 genotypes were found to be in Hardy-Weinberg equilibrium in both study groups ($P>0.05$). A significant difference was found in the distribution of rs1043526 genotypes between patients and controls. Women with PCOS had a greater frequency of AG and GG genotypes than normal women (35.3% vs 19.9%, $P=0.016$). Furthermore, among patients, those with AG and GG genotypes had higher fasting glucose levels compared to those with the AA genotype (90.1 ± 6.1 mg/dl vs 86.2 ± 8.8 mg/dl, $P=0.03$). Also, a non significant increase was found in fasting insulin levels and insulin resistance indexes in women with AG and GG genotypes.

Conclusion

The rs1043526 A>G polymorphism of PIK3R1 gene may be involved in the pathogenesis of PCOS and affects glucose metabolism.

P103

Effect of paraoxonase genes on metabolic profile of women with polycystic ovary syndrome

Xita N, Lazaros, I Georgiou & A Tsatsoulis

University of Ioannina, Ioannina, Greece.

Introduction

Increased oxidative stress is considered to be implicated in the pathophysiology of polycystic ovary syndrome (PCOS). While the regulation of oxidative stress is multifactorial, many studies have been focused on the antioxidant role of paraoxonase (PON). The aim of this study was to investigate the possible association of the Q192R and the L55M polymorphisms of PON1 and the Ser311Cys polymorphisms of PON2 with PCOS.

Subjects and methods

We studied 165 women with PCOS and 168 healthy women. The body mass index (BMI) was recorded. Insulin resistance was assessed by fasting glucose to insulin ratio and HOMA index. Furthermore, 100 overweight-obese patients underwent a 75gr OGTT and areas under the curve (AUC) for insulin and glucose were estimated. DNA was extracted from peripheral blood leucocytes and the Q192R and the L55M polymorphisms of PON1 and the Ser311Cys polymorphisms of PON2 were genotyped.

Endocrine Abstracts (2011) Vol 26
Results
PON1 and PON2 gene polymorphisms were in Hardy–Weinberg equilibrium ($P$>0.05) in both PCOS and control group. There was no significant difference in the distribution of all polymorphisms between PCOS women and controls. However, the L55M polymorphism was found to be associated with insulin levels after glucose load. Patients with the LL genotype compared with those with LM or MM genotype, had higher AUCinsulin values whereas the basal insulin concentrations, fasting glucose to insulin ratio, HOMA index and AUCglucose were similar. This association remained significant after adjustment for the confounding factors BMI, age, and AUCglucose ($P$=0.012, $\beta$=−0.243).

Regarding the Q192R polymorphism of PON1 and the Ser311 polymorphism of PON2 no association with biochemical parameters was found.

Conclusion
PON1 and PON2 gene polymorphisms are not associated with PCOS. However, the association found between the L55M polymorphism and insulin levels after glucose load shows that this polymorphism may be implicated in the insulin resistant phenotype of PCOS.

P104
Glucocorticoid-induced leucine zipper (GILZ), a factor which controls tumor cell proliferation, is estradiol responsive in epithelial ovarian cancer
V Machelon1, N Redjimi1, F Gaudin1, L Delbos1, D Emile1-2, S Prevo1,2 & K Balabanian1
1INSERM U996, Clamart 92140, France; 2Hôpital A. Béclère, Clamart 92140, France.

Little is known about the molecules that contribute to tumor growth in epithelial ovarian cancer (EOC) that remain the most lethal gynecological neoplasm. Glucocorticoid-induced Leucine Zipper (GILZ), a leucine zipper protein of 17 kDa, is frequently detected in epithelial tissues with a hormonal background. We detected GILZ in EOC1 and we further demonstrated that this factor which expression is enhanced by estradiol (E2), activates tumor cell proliferation and up-regulates CXXC4, a chemokine receptor highly involved in tumor expansion. GILZ was detected by immunohistochemistry in tumors from 50 patients surgically treated for diagnosis of EOC at Antoine Béclère hospital from 1998 to 2007. Its expression scored from 1 to 7 was positively correlated to the proliferation marker Ki-67 ($P<0.00001$). It was also higher in tumors containing high amount of phosphorylated protein kinase B (p-AKT) ($P<0.01$). Cell proliferation increased in B101 cells overexpressing GILZ by stable transfection of a GILZ-encoding vector whereas it decreased after silencing GILZ by the use of small interfering RNA. Modulation of GILZ expression changed the level of p21, cyclin D1 and phospho-retinoblastoma, three proteins that regulate cell cycle and are AKT targeted. Further GILZ increased phospho-AKT cellular content and AKT kinase activity. In mice xenografted with B101 cells, tumor growth was faster in females. B101 cells treated with 10−7 M estradiol had a higher cellular content of GILZ. In parallel growth rate was faster and the expression of CXXC4 was higher, a chemokine which expression was also enhanced by GILZ as revealed by DNA microarray analysis of B101 cells overexpressing GILZ. In conclusion, GILZ, a protein produced by ovarian cancer cells and which controls their proliferation and CXXC4 expression, is up regulated in estradiol-treated cells like proliferation and CXXC4 expression. This reveals GILZ as a key molecule for estradiol action in EOC.

P105
rs7566605 SNP of INSIG2 gene is not associated with the polycystic ovary syndrome diagnosis and its phenotypic traits in Romanian subjects
D Aflorei2, S Radian1,2, N Baculescu1,2, M Gheorghiu1,2, S Fica1,2, A Albu1, F Grigorescu1 & M Cuculescu1
1Department of Endocrinology, C. Davila University of Medicine, Bucharest, Romania; 2Department of Endocrinology, Elias University Emergency Hospital, Bucharest, Romania; 4IURC, Molecular Endocrinology Laboratory, UMR-204 Montpellier, France.

Introduction
The polycystic ovary syndrome (PCOS) and obesity are related, yet different complex diseases, with the same genes possibly playing different roles in each disease. INSIG2, an obesity-associated gene (by rs7566605 C/C genotype) is a good candidate for PCOS. Its genotypes were not associated with obesity in PCOS patients. To date, there are no published association studies of rs7566605 with PCOS itself.

Aim
To perform a case-control association study between rs7566605 and PCOS in the Romanian population, and assess genotype-phenotype correlations within the PCOS cases group.

Patients and methods
We recorded anthropometric, biochemical and hormonal parameters for 141 PCOS patients (Rotterdam-criteria) and 89 healthy female controls. Insulin-resistance was evaluated by HOMA-IR. Genotyping of rs7566605 was done by an original protocol of allele-specific PCR (MS-PCR) coupled with detection by high-resolution melting (HRM) analysis.

Results
36.03% PCOS patients and 7.14% controls were obese ($P<0.0001$), rs7566605 allelic frequencies and genotypes were not significantly different between cases and controls, suggesting no association with PCOS. Stratification by obesity status showed no significant differences in rs7566605 allelic frequencies between non-obese controls (0.388), non-obese PCOS (0.383) and obese PCOS (0.408). The C/C genotype frequency was also not significantly different between these groups. A genotype-phenotype correlation analysis within the PCOS cases group showed no association with BMI, waist circumference, basal glycemia, insulinemia, HOMA-IR, blood lipids, Ferriman–Gallwey score and total testosterone.

Conclusions
This is a first association study of rs7566605 with PCOS and our results suggest that INSIG2 is not a significant PCOS gene in the Romanian population. Still, results should be regarded as preliminary, given that the statistic power of our study was limited.

This work was supported by grants no. CNCSIS 1333/2007 and PNCDI2 41-014/2007, from the Romanian Ministry of Education, Research and Youth.

P106
C-peptide serum concentration in obese women with polycystic ovary syndrome
M M J Maciejewska-Jeske, A S Szczesna & B M Mezczalski
Department of Gynecological Endocrinology, Poznan University of Medical Sciences, Poznan, Poland.

Introduction
It is believed that key pathogenic mechanism of PCOS is hyperinsulinemia. Insulin synthesis is linked to C-peptide release, but the role of C-peptide in PCOS remains unknown.

Methods
The aim of this study was to evaluate of C-peptide serum levels in obese women with PCOS with concomitant assessment of possible link between C-peptide concentrations and metabolic disturbances and androgen levels in those individuals.

Sixty obese women (aged 26.2±6.3 years; body mass index 35.0±4.45 kg/m²) diagnosed with PCOS were included to the study. The control group consisted of 10 healthy, ovulatory women with normal weight (aged 28.8±4.8 years; BMI 21.2±2.1 kg/m²).

Results
C-peptide serum concentrations in studied group were 1.31±1.05 nmol/l, whereas among healthy women 1.62±1.56 nmol/l. Obtained differences were not statistically significant ($P>0.05$). C-peptide serum level were not correlated significantly with the FSH, LH, E2, T, DHEAS and insulin serum concentrations were measured. Serum fasting glucose levels and lipid profile was assessed: total cholesterol (TCH), triglycerides (TGA), low and high density lipoproteins (LDL, HDL).

Results
C-peptide serum concentrations in studied group were 1.31±1.05 nmol/l, whereas among healthy women 1.62±1.56 nmol/l. Obtained differences were not statistically significant ($P>0.05$). C-peptide serum level were not correlated significantly with the FSH, LH, E2, T, DHEAS and insulin serum concentrations were measured. Serum fasting glucose levels and lipid profile was assessed: total cholesterol (TCH), triglycerides (TGA), low and high density lipoproteins (LDL, HDL).

Results
C-peptide serum concentrations in studied group were 1.31±1.05 nmol/l, whereas among healthy women 1.62±1.56 nmol/l. Obtained differences were not statistically significant ($P>0.05$). C-peptide serum level were not correlated significantly with the FSH, LH, E2, T, DHEAS and insulin serum concentrations were measured. Serum fasting glucose levels and lipid profile was assessed: total cholesterol (TCH), triglycerides (TGA), low and high density lipoproteins (LDL, HDL).

Results
C-peptide serum concentrations in studied group were 1.31±1.05 nmol/l, whereas among healthy women 1.62±1.56 nmol/l. Obtained differences were not statistically significant ($P>0.05$). C-peptide serum level were not correlated significantly with the FSH, LH, E2, T, DHEAS and insulin serum concentrations were measured. Serum fasting glucose levels and lipid profile was assessed: total cholesterol (TCH), triglycerides (TGA), low and high density lipoproteins (LDL, HDL).

Results
C-peptide serum concentrations in studied group were 1.31±1.05 nmol/l, whereas among healthy women 1.62±1.56 nmol/l. Obtained differences were not statistically significant ($P>0.05$). C-peptide serum level were not correlated significantly with the FSH, LH, E2, T, DHEAS and insulin serum concentrations were measured. Serum fasting glucose levels and lipid profile was assessed: total cholesterol (TCH), triglycerides (TGA), low and high density lipoproteins (LDL, HDL).

Results
Higher metabolic risk with NIH diagnostic criteria versus Rotterdam criteria for polycystic ovarian syndrome

Iinan Anaforoglou, Ekrem Algun, Omer Incceayir & Kerem Ersoy
Department of Endocrinology and Metabolism, Trabzon Numune Education and Research Hospital, Trabzon, Turkey.

Introduction
Polycystic ovary syndrome (PCOS) is a heterogenous disease with well established metabolic abnormalities among women of reproductive age. There are various diagnostic criteria to define and establish PCOS. However, there are some conflicting data regarding the optimal diagnostic criteria for PCOS and the metabolic consequences. We evaluated the clinical, endocrine and metabolic features between main PCOS phenotypes according to different diagnostic criteria.

Methods
One hundred seventy-five consecutive women with PCOS, 41 ovulatory women with idiopathic hirsutism and 109 healthy, non-hirsute, ovulatory controls were enrolled. Hirsutism was defined by a value of 8 using the modified Ferriman-Gallwey. Ovulatory function, ovarian sonography, gonadotropins, testosterone, DHEAS, 17 OH progesteron, oral glucose tolerance test, fasting insulin, homeostasis model assessment for insulin resistance, lipids, body mass index, waist circumference, frequency of metabolic syndrome were detected.

Results
In total 175 women who fulfilled the Rotterdam 2003 criteria were diagnosed with PCOS. Of these, 121 (69%) had both androgen excess and ovulatory dysfunction and met the NIH criteria. The remaining 54 (31%) had PCO confirmed by ultrasonography with either androgen excess or ovulatory dysfunction. There were 41 ovulatory women with only hirsutism, and 109 healthy, non-hirsute, ovulatory women. Among groups, body mass index, waist circumference, levels of testosterone, DHEAS, triglyceride, insulin, homeostasis model assessment (HOMA-IR) index were higher in NIH group. Also prevalence of insulin resistance (HOMA-IR >3) and metabolic syndrome were higher as well.

Conclusions
NIH criteria has detected patients with higher risk for insulin resistance and metabolic syndrome.

Relation of insulin resistance and lipid peroxidation in non-obese women with polycystic ovary syndrome

D Macut1,2, A Lissounov2, I Rozic1, T Simic1, J Bjejkic4, M Petakov1,2, S Damjanovic1,2 & A Savic-Radojevic3
1Institute of Endocrinology, Diabetes and Metabolic Disorders, Belgrade, Serbia; 2Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 3Faculty of Medicine, Institute of Biochemistry, University of Belgrade, Belgrade, Serbia; 4Department of Endocrinology, CHC Bezanjska kosa, Belgrade, Serbia.

Introduction
Polycystic ovary syndrome (PCOS) is a frequent metabolic disorder in women of the reproductive age, and is characterized by multi-factorial cardiovascular risk factors. Insulin resistance is proposed as a central factor linking PCOS to increasing risk of cardiovascular disease. The aim of our study was to explore a link between insulin resistance and oxidative stress, as a predictor of cardiovascular risk, in young, non-obese PCOS women.

Methods
A cross-sectional controlled study in 29 young PCOS women (age: 23.8±2.8 years; body mass index, BMI: 22.5±4.6 kg/m²) and 13 matched controls (age: 25.3±2.8 years; BMI: 20.6±3.3 kg/m²) was performed. Fasting blood samples were collected for the determination of malondialdehyde (MDA), glucose, insulin, testosterone, and sex hormone binding globulin. Insulin resistance was calculated using homeostasis assessment model (HOMA-IR).

Results
MDA concentrations showed no difference between PCOS and controls (4.0±1.6 vs 4.3±2.3 µM, P = 0.685). Indices of insulin resistance were significantly higher in PCOS group in comparison to controls (insulin: 16.6±7.5 vs 10.7±2.6 mU/l, P = 0.009; HOMA-IR: 3.2±1.3 vs 2.2±0.6, P = 0.015). MDA had significant positive correlation with insulin (P = 0.046) and HOMA-IR (P = 0.016) in PCOS group only.

Conclusion
Our results indicate that insulin resistance could be responsible for increased level of oxidative stress in young, non-obese PCOS women. Presence of insulin resistance, hyperinsulinemia, and oxidative damage are likely to accelerate development of cardiovascular disease in PCOS women.

MTHFR mutations in female patients with autoimmune thyroiditis

Alexandra Bulgar1, Andreia Brehera1, Diana Pau1,2 & Constantin Dumitrache12
1C.I.Paihon National Institute of Endocrinology, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Introduction
Methylenetetrahydrofolate reductase (MTHFR) is a key regulatory enzyme involved in folate and homocysteine metabolism. The enzyme is encoded by a gene located on chromosome 1p36.3. MTHFR mutations frequently met in the population are C677T and A1298C. The impairment of homocysteine metabolism due to MTHFR gene polymorphism influences the risk for diseases such as CVS diseases, certain types of cancer and is associated with certain complications of pregnancy including chromosomal abnormalities, congenital malformations, neural tube defects: spina bifida, anencephaly, recurrent abortions, diseases of the placenta and preeclampsia. Autoimmune thyroiditis is a relatively common disorder found in the female population, which can influence fertility in a negative sense.

Purpose
The study aims to assess the risk of thrombophilia in patients with autoimmune thyroiditis.

Subjects and methods
There were assessed 50 patients aged 22 years to 39 years diagnosed with autoimmune thyroid disease, diagnosis established by means of thyroid ultrasound and by detection of ATPO and antithyroglobulin antibodies titre. The reasons for presentation for examination were primary and secondary infertility. Because the patients presented in their personal history spontaneous abortions there were also performed further evaluation of coagulation profile: V Leiden factor, C protein, S protein, detection of MTHFR mutations.
Results
In this group of patients with autoimmune thyroiditis 15 patients had MTHFR mutations: 3 patients with C677T homozygous mutation, 5 patients with heterozygous C677T mutation, 2 patients with A1298C homozygous mutation, 4 patients with heterozygous A1298C mutation and 1 patient with compound heterozygous C677T/A1298C.

Conclusions
MTHFR mutations are relatively frequent in the population (11%). Additional studies are needed to explain the association of MTHFR mutations with autoimmune thyroiditis, an increased prevalence of these mutations among the patients with autoimmune thyroid disease being observed.

P111
Plasma testosterone fractions in women with hyperandrogenism
E Toldy 1,2, D Horváth 1, Z Lócsér 1, K Racz 2 & G L Kovács 1
1Central Laboratory Markusovszky Teaching Hospital of County Vas, Szonbathely, Hungary; 2Institute of Department of Diagnostics, University of Pécs, Pécs, Hungary; 1st Department of Medicine Markusovszky Teaching Hospital of County Vas, Szonbathely, Hungary, 2nd Department of Internal Medicine of Semmelweis University, Budapest, Hungary; 3Institute of Laboratory Medicine, University of Pécs, Pécs, Hungary.

Plasma total testosterone (TT) does not provide reliable information about the biological active testosterone, since a large proportion of this hormone is bound to either specific (sex hormone binding globulin, SHBG) or non-specific binding proteins (albumin). Free testosterone (fT) represents not more than 0.7-2.2% of TT while bioavailable testosterone (BA-T) in females is about 15-48% of the TT. The aim was to investigate the analytical and clinical correlations among measured TT and calculated free testosterone index (fTi), BA-T and fT levels.

Methods
Sera from 61 women (age: 26±10 years) including 12 healthy controls and 49 patients who had either high (n=26, HRP) or low risk (n=23, LRK) for true hyperandrogenism on the basis of clinical and ultrasound findings were analysed. Samples were examined for TT and SHBG using electrochemoluminescence immunoassays (Roche) and for albumin using colorimetric method, then the fTi, fT, fT and BA-T concentrations were calculated.

Results
All sera had normal albumin levels (mean ±S.E.M. 46±3 g/l). There were significant (P<0.01) but weak correlations between TT and fTi (r=0.68), between TT and BA-T (r=0.79) and between TT and fT (r=0.79), while correlations between fTi and BA-T (r=0.94) and between fTi and fT (r=0.89) were stronger. All TT fractions were the highest in HRP (P<0.001) compared to the control and LRK groups. For detecting hormonal hyperandrogenism, the sensitivities and specificities of testosterone fractions were as follows: fT, 54 and 88%; BA-T, 54 and 88%; TT, 50 and 76%; fT, 46 and 74%, respectively.

Conclusions
In patients with normal albumin levels there are only marginal differences among sensitivities of fT, BA-T, TT and fT. Our data confirm that when TT is out of the reference range the SHBG and albumin concentration should be measured to calculate the fT or BA-T because of their highest specificity.

P112
Polycystic ovary syndrome and autoimmunity
J Petrikova 1,2, D Kozakova 1, J Vrbikova 1, Y Shoenfeld 2 & I Lazurova 2
11st Department of Internal Medicine, Medical Faculty, P.J.Safárik University, Kosice, Slovakia; 2Sheba Medical Center, Tel-Hashomer, Israel; Institute of endocrinology, Prague, Czech Republic; 3National Institute of Rheumatic diseases, Piestany, Slovakia.

Polycystic ovary syndrome (PCOS) is characterized by laboratory and/or clinical features consisting of hyperandrogenism with chronic anovulation, and is currently one of the most common endocrinopathies in women of fertile age. PCOS is associated with a variety of endocrine and metabolic disturbances. It is well known that women are more prone to develop autoimmune diseases compared to men and levels of sexual hormones are thought to be responsible for such a difference. Our aim is to prove that women with PCOS are more prone for autoimmune diseases even though their protective levels of androgens. It was already demonstrated that the prevalence of autoimmune thyroiditis is 36-fold higher among these patients. Recent studies reveal a higher incidence of autoantibodies such as antihistone, anti dsDNA presented in systemic autoimmune disease, however their clinical significance is still unknown.

P113
17-hydroxysteroid dehydrogenase type 5 gene polymorphism (71A/G HSD17B5 SNP) and effects of oral contraceptive pill on hirsutism, androgens and metabolic profile in non-obese PCOS women: a pilot study
P S Maiea, S S Mattiello, L Lages 1 & P M Sprotter 2, 1Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

An association of the single nucleotide polymorphism (SNP) in the promoter gene that codify for 17b-HSD5 enzyme (17b>G) with polycystic ovary syndrome (PCOS) has been suggested in previous studies. Given the role of 17b-HSD5 in androgenic metabolism producing testosterone from precursors, the aim of this study was to assess whether non-obese PCOS women with the variant allele G have different response on hirsutism and on hormonal and metabolic variables to oral contraceptive pill (OCP) treatment. Twenty-eight PCOS outpatients, defined by the Rotterdam criteria, were included in the study. None had received any drugs known to interfere with hormonal levels for at least 3 months before the study. Patients with diabetes, BMI ≥30 or insulin resistance (HOMA-IR >3.8) were excluded. Women received OCP (ethinyl oestradiol 20 µg plus gestodene 75 µg) during 6 cycles. Hirsutism, hormone and metabolic variables were evaluated before and after the treatment. DNA was extracted from peripheral blood by a standard salting out procedure, and the samples were genotyped by allelic discrimination assay with Real Time PCR. Data were analyzed by Anova for repeated measures. Participants were stratified by the presence of the allele G (AA or AG + GG). The genotypic distribution (AA:46%, AG:42,9%, GG:11,1%) was similar to previous studies. Hirsutism regressed equally with OCP in both groups (33,5% and 45,5% for AA and AG + GG, respectively). SHBG levels were increased and androgens and LH declined from baseline (P<0.05) independently of the presence of the allele G. Triglycerides, total, and HDL-cholesterol increased in the two groups during treatment, but the levels remained normal. Data from this pilot study suggest that, for selected PCOS patients without major metabolic comorbidities, OCP may be a safe and effective treatment and the presence of allele G appears not to contribute with the improvements in the studied variables.

P114
Does uric acid predict insulin resistance in polycystic ovary syndrome? O Oz Gula, C Ersoyb, B Gulc, S Canderd, O K Unald, E Erturk 1, E Tuncel 2, S Inamoglu 3
1Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa, Turkey; 2Department of Nephrology, Uludag University Medical School, Bursa, Turkey.

Introduction
Women with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance and related disorders. Endothelial dysfunction and chronic inflammation are early findings in the atherosclerotic process. Elevated serum levels of uric acid may reflect low-grade chronic inflammation. But there are controversial data whether increased the uric acid level in PCOS patients. This study was aimed to examine the relationship between uric acid, lipoprotein levels and insulin resistance in obese and non-obese patients with PCOS.

Methods
Forty-two young women with PCOS and 42 controls of similar age were included this study. Plasma levels of glucose, insulin and uric acid were
measured. Anthropometric variables, hormonal and metabolic profiles were evaluated in both groups. Insulin resistance was evaluated by homeostasis model assessment (HOMA-IR).

Results
Plasma uric acid levels and HOMA-IR were significantly higher in women with PCOS than in healthy women. Serum fasting total cholesterol, triglycerides (TG) and hemoglobin A1c levels were similar between PCOS and control groups. Compared with non-obese PCOS subjects, obese PCOS subjects had high HOMA-IR, insulin, TG and uric acid levels. Plasma glucose levels, serum low-density lipoprotein cholesterol and androgen levels were similar between obese and non-obese women with PCOS. No correlation was observed between plasma uric acid, HOMA-IR and serum androgen levels.

Conclusion
In this study we demonstrate increased levels of uric acid in PCOS. Obesity is the main determinant of serum uric acid concentrations in PCOS patients. Our results suggest that measurement of serum uric acid does not provide new means for identification of insulin resistance and related disorders in patients with PCOS.

P115
Injected FSH overriding ageing related elevated FSH through high activity of the hypothalomo-pituitary axis, enforces wanted multiple follicle growth in women undergoing IUI

T E König1, S N Beemsterboer1, A Overbeek1, M L Hendriks1, M W Heymans1, P Hompes1, R Homburg1, R Schats1 & C B Lambalk1
1VU University Medical Center, Amsterdam, The Netherlands; 2EMGO institute for health and care research, Amsterdam, The Netherlands.

Introduction
The hypothalomo-pituitary response to the loss of ovarian function due to ageing is an increase in GnRH induced gonadotrophin activity: FSH. It is thought that the pituitary gives maximum endogenous stimulation leading to FSH levels above the ovarian threshold to develop follicular growth and it is a matter of debate whether exogenous FSH (r-FSH) will or will not improve ovarian response. In intrauterine insemination (IUI) treatment r-FSH is used to induce multifollicular growth to improve treatment efficacy. This study evaluated whether addition of r-FSH in women with endogenous elevated basal FSH levels, results in a higher percentage of cycles with multifollicular growth.

Methods
A randomized controlled trial was performed in women undergoing IUI treatment with elevated basal FSH levels (≥10 IU/l on cycle day 3). Patients were assigned to the control (3 natural cycles followed by 3 stimulated cycles) or the intervention group (6 stimulated cycles). The primary outcome was the occurrence of multifollicular growth. Statistical analysis was done using Cox regression and multivariate analysis.

Results
Forty-eight women were included; 23 in the control versus 25 in the intervention group. There were no significant differences in baseline characteristics. The intervention group was 2.7 times more likely to develop multiple follicular growth (95% CI, 1.16–6.11, P = 0.02). Lower FSH levels at the beginning of a treatment cycle compared to basal FSH levels predicted multifollicular growth with an odds ratio of 0.81 (95% CI, 0.72–0.92, P = 0.0003).

Conclusion
Administration of r-FSH in women with elevated basal FSH levels undergoing IUI treatment leads to a higher percentage of cycles showing multifollicular growth. A lower FSH level in the beginning of the treatment cycle compared to basal FSH levels predicts multifollicular growth. Therefore, women with elevated basal FSH levels should be offered controlled ovarian stimulation in order to improve treatment outcome.

P116
The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients

T E König1, L E van der Houwen1, S N Beemsterboer1, A Overbeek1, M L Hendriks1, W K Kuchenbecker2, R E Bernardus1, P Hompes1, R Schats1, R Homburg1 & C B Lambalk1
1VU University Medical Center, Amsterdam, The Netherlands; 2Isala Klinieken, Zwolle, The Netherlands; 3Tergooi Ziekenhuizen, Blaricum, The Netherlands.

Introduction
With IVF stimulation a premature pituitary LH surge can ruin the whole procedure. Traditionally prevention of this event is done by administering a GnRH antagonist against endogenous hypothalamic GnRH. The obvious consequence is low LH levels, one of the two gonadotrophines usually not given for ovarian stimulation since for adequate action FSH suffices. However there are indications that LH levels may render too low, in particular in older women. The aim of this study was to investigate whether the addition of LH to an IVF stimulation protocol with FSH and GnRH antagonist will improve the ovarian response and consequently, implantation and pregnancy rates in women of 35 years and older.

Methods
A prospective randomized multicentre study was performed in couples who were undergoing IVF/ICSI. Women were 35 years or older and received ovarian stimulation with FSH and GnRH antagonist from day 6 of stimulation. Randomization took place on day 6 of stimulation to receive both FSH and LH or continue with FSH alone. Primary endpoint of the study was implantation rate (the chance of an embryo to implant) and clinical pregnancy rate (defined as a pregnancy diagnosed by ultrasonographic visualisation of at least one gestational sac).

Results
Of 249 subjects randomized, 128 received both FSH and LH and 121 received only FSH. There were no demographic or clinical differences between the groups. Intention to treat analysis revealed that of those receiving FSH and LH, 33 (27.5%) had an clinical pregnancy, compared with 38 (30.6%) receiving only FSH (P = 0.6). Implantation rates were similar: 17.2 vs 21.1% (P = 0.4) in the 'FSH and LH' and 'FSH only' groups respectively.

Conclusions
Our study shows that replenishment of low hypothalomo-pituitary regulation of LH is not crucial for ovarian response in IVF in older women.

P117
Adiponectin and metabolic syndrome in PCOS patients – beyond obesity

L Leustean1, S Fica2, C Preda1, M C Ungureanu1, C Cristea1, S Mogoș1, V Mogoș2 & C Vulpoi1
1UMF Gr.T.Popa, Iasi, Romania; 2UMF ‘Carol Davila’, Bucuresti, Romania.

Introduction
Poly cystic ovary syndrome (PCOS) have an increased rate of metabolic syndrome (MS). Many studies have proved that adiponectin is closely associated with MS and participate in the disturbances of gonadal axis. The aim of the study was to evaluate the association of adiponectin levels with MS in PCOS.

Patients and methods
Study group included 38 patients with PCOS (Rotterdam criteria) compared to 30 healthy volunteers age and sex matched, all with BMI > 25 kg/m². Blood pressure (BP), waist circumference, serum adiponectin, fasting glucose, HOMA, lipids levels were performed in all subjects.

Results
In the PCOS group, adiponectin was lower than in the control group, but the difference was not significant (P = 0.2). There were no differences between adiponectin values in overweight versus obese women with PCOS (P = 0.15), but the difference was significant in the non-PCOS group (P = 0.018). Metabolic syndrome was more frequent in PCOS patients, but the difference was not significant (58 vs 46%); in women with MS adiponectin levels were lower, the difference being significant (P = 0.012 in control group; P = 0.014 in PCOS group). Adiponectin levels were negatively correlated with waist circumference, fasting glucose, triglycerides, and diastolic BP, and positively correlated with HDL. In both groups, adiponectin levels were significantly lower in women with abdominal obesity (P < 0.05) and in older women (>35 years old; P < 0.03). Insulin resistance had a significant negative correlation with adiponectin in PCOS subjects (r = −0.446) but not in the normal group (r = −0.08).

Discussion
Our results are similar to those of the literature. We presume that adiponectin was not significantly lower in PCOS because both groups had BMI > 25 kg/m². Despite the similar values, MS was more frequent in PCOS. Our results suggest that adiponectin is an independent risk factor for MS and probably involved in PCOS pathogenesis.
P118
Ovarian ageing and twinning
E van der Stroo1, T E König1, J Vink1, D I Boomsma2 & C B Lambalk1
1VU University Medical Center, Amsterdam, The Netherlands; 2VU University, Amsterdam, The Netherlands.

Dizygotic twinning is the result of fertilization of multiple follicles that develop during one oocyte cycle. Significant factors contributing to natural DZ multiples are heredity, increased maternal age and higher parity. Older women are at higher risk for DZ twinning because they have a strongly increased risk of multiple follicle growth as a result of diminished ovarian feedback from the due to a smaller available cohort of follicles. FSH increases allowing all follicles present to develop and potentially ovulate. With familial twinning elevations of FSH are also found. Another hormone may be a good estimate for ovarian aging; anti Mullerian hormone (AMH). Lower levels are associated with aging ovaries. AMH has been determined in the residual serum of the 16 mothers of DZ twins and 14 controls. This may reveal that the twin mothers of our study may already have shown some subtle features of limited ovarian reserve indicating protracted organ ageing. The average AMH levels were not different: 2.13 ± 0.50 μg/l the twin mothers and 1.85 ± 0.60 in the controls. The average calendar age was 35 years in both groups. Among the 16 familial twin mothers, 7 had elevated FSH values over 10 U/l in the early follicular phase compared to 1/14 in the control (P<0.04).

Our data indicates that among mothers with familial DZ twins, elevated FSH (currently 10 U/l in the early follicular phase compared to 1/14 in the control (P<0.04), Their AMH was very low compared to the 9 twin mothers with normal FSH values: 0.57 ± 0.88 μg/l (P=0.016). None of the twin mothers (currently ≥45 years), reported early menopause (<45 years).

Our data indicates that among mothers with familial DZ twins, elevated FSH occurs often and seems to be associated with signs of limited ovarian reserve. These findings support the hypothesis that with familial DZ twinning potentially inheritance of processes that advance ovarian ageing can be responsible.

P120
Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 Caucasian patients with polycystic ovary syndrome
D Glintborg1, H Munn1, M Hougaaard1, P Ravni & M Andersen1
1Department of Endocrinology and Metabolism, Odense University Hospital, Odense C, Denmark; 2Department of Gynecology and Obstetrics, Odense University Hospital, Odense C, Denmark; 3Section for Neonatal Screening and Hormones, Department of Clinical Biochemistry and Immunology, Copenhagen S, Denmark.

Objective
Smoking may be associated with changes in metabolic risk factors and sex hormones in PCOS.

Design
Retrospective trans-sectional study.

Patients
Six hundred and fifty caucasian premenopausal women with the diagnoses hirsutism or PCOS were divided according to smoking status: Non-smokers (NS-PCOS = 390) and smokers (S-PCOS = 260). 119 healthy women were studied as controls (NS-Control = 105, S-Control = 14).

Interventions
Clinical evaluation, hormone analyses, transvaginal ultrasound. Oral glucose tolerance tests (OGTT) and ACTH tests.

Main outcome measures
Clinical, metabolic, and endocrine parameters. ACTH stimulated cortisol and 17-hydroxyprogesterone (17OHP) levels.

Results
S-PCOS has significantly higher fasting lipid profile and 17OHP levels (basal and ACTH stimulated) than NS-PCOS patients, whereas prolactin levels were decreased. No significant differences were found in body composition and measures of insulin resistance between NS-PCOS and S-PCOS. POC was more prevalent in NS-PCOS patients. During multiple regression analyses, smoking was positively associated with 17OHP and cholesterol, triglycerides, and low density lipoprotein and inversely associated with prolactin and high density lipoprotein.

Conclusion
Smoking was associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in PCOS patients, whereas smoking was unassociated with body composition and insulin resistance. Smoking may be associated with the prevalence of individual Rotterdam criteria.

P119
The role of metabolic hormones ghrelin, leptin and obesatin in control of ovarian functions
Alexander Sirokin1,2, Monika Meszarosova2, Roland Grossmann1, Marina Kozhenevskaja1, Andrej Bencova & Silvia Pavlova2
1Animal Production Research Centre Nitra, Luzianky, Slovakia; 2Constantine the Philosopher University, Nitra, Slovakia; 3Institute of Animal Science, Marinede, Nuestadt, Germany; 4Pavlov State Medical University, Saint-Peterburg, Russian Federation.

The recent original data concerning interrelationships between metabolic hormones (ghrelin, leptin, obestatin) and feeding, action of metabolic hormones on basic ovarian functions (proliferation, apoptosis, secretory activity, response to gonadotropins, oocyte maturation) and intracellular mechanisms of its action in different species (rabbit, pig, human, chicken) are reviewed. It was shown, that metabolic hormones ghrelin, leptin and obestatin can control proliferation, apoptosis, release of ovarian hormones and alter response of ovarian cells to gonadotropin and other hormones, oocyte maturation and fecundity. Action of pharmacological blockers of protein kinases and of cell transfection with gene constructs for transcription factors demonstrated, that effects of metabolic hormones on ovarian cells are mediated by protein kinases A, MAP kinase and transcription factors CREB, p53 and STAT-1. Malnutrition affects release of metabolic hormones and their action on ovarian cells, whilst administration of metabolic hormones can mimic, promote or prevent effect of food restriction on ovarian cells both in vivo and in vitro. The species-specific differences in ghrelin, leptin and obestatin action are discussed.

The present data suggest that metabolic hormones play an important role in control of ovarian functions in mammals and birds. It is proposed, that food restriction can control reproductive functions via changes in metabolic hormones output, which in turn, through protein kinases and transcription factors, can affect ovarian cell proliferation, apoptosis, secretory activity, response to gonadotropins and other hormonal stimulators and fecundity.

This study was performed during realization of the project CEGEZ 26220120042 supported by the Operational Programme Research and Development funded from the European Regional Development Fund.

P121
Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/diengoest
I Fraser1, J Jensen2, M Schäfer3, U Mullinger4, S Parke4 & M Serrani4
1University of Sydney, Sydney, New South Wales, Australia; 2Oregon Health and Science University, Portland, Oregon, USA; 3Bayer Schering Pharma AG, Berlin, Germany.

Introduction
Two identically designed randomized, placebo-controlled double-blind studies (one conducted in North America and the other one in Europe and Australia) showed that an oral contraceptive containing estradiol valerate (E, V)/diengoest (DNG) in an estrogen step-down, progestogen step-up 28-day regimen was effective in women with heavy and/or prolonged menstrual bleeding without organic pathology. Both studies applied a strict definition of treatment success, based on a composite of eight individual criteria. To make these results comparable with published patient data, data were pooled and re-analyzed using a definition of successful treatment more commonly referred to in literature, applying more clinically meaningful criteria.

Methods
Women ≥ 18 years with objectively-confirmed heavy menstrual bleeding (HMB, defined as menstrual blood loss (MBL) ≥ 80 ml/cycle in two cycles during a 90-day run-in period) without organic cause were randomized to E2V/DNG (n = 220) or placebo (n = 135) for 7 cycles of 28 days. MBL was measured objectively using the alkaline-hematin method. The primary variables were

Endocrine Abstracts (2011) Vol 26
absolute change in MBL volume from baseline and proportion of women who were successfully treated at cycle 7. Treatment success was defined as MBL volume ≤30 ml and ≥50% reduction in MBL volume from baseline to cycle 7.

Results
At cycle 7, the proportion of patients with successful treatment was 63.6% with E2V/DNG and 11.9% with placebo (P<0.001). A MBL volume ≤30 ml was observed in 68.2% and 15.6% of women, respectively, and a MBL volume reduction ≥50% was observed in 70.0% and 17.0% of women, respectively (both P<0.001). From baseline to cycle 7, median MBL volume reduced from 179.8 to 35.7 ml with E2V/DNG, and from 174.9 to 163.7 ml with placebo (P<0.001 for E2V/DNG versus placebo).

Conclusions
E2V/DNG was highly effective for treating HMB and was associated with a high overall response rate.

P122

Abstract withdrawn.

P123

Self-reported health related quality of life and depression in women with polycystic ovary syndrome: associations with selected metabolic and hormonal PCOS features.
Jana Vrbikova1, Martin Hill1, Marketa Vankova1 & Ioannis Kyrou1,2
1Institute of Endocrinology, Prague 1, Czech Republic; 2Warwick Medical School, Clinical Sciences Research Institute, WISDEM, University Hospital Coventry and Warwickshire, University of Warwick, Warwick, UK.

Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age causing symptoms that can lead to depression and reduced health-related quality of life (HRQoL). Associations of depression and HRQoL indices with hormonal and metabolic PCOS features have not been adequately studied. 

Methods/design
Thirty-seven premenopausal women (age: 28 ± 6.4 years; BMI: 28.3 ± 7.2 kg/m2) with PCOS according to ESHRE criteria were recruited. HRQoL was assessed using the PCOS Questionnaire (PCQoL). Degree of depression was assessed by Beck Inventory. Hormonal (testosterone, SHBG, androstenedione, estradiol, LH, FSH) and metabolic (fasting glucose, insulin, lipids) parameters were measured. Trunk fat was determined by bioimpedance (Vocan, Tanita). Data were analyzed using multivariate regression with reduction of dimensionality.

Results
The weight dimension PCQoL score significantly correlated to i) insulin resistance parameters: HOMA-IR (R = −.84, P <0.01); fasting insulin (R = −.82, P <0.01); SHBG (R = −.70, P <0.01) and ii) obesity parameters: BMI (R = −.92, P <0.01); percent of trunk fat (R = −.95, P <0.01). Additionally, the infertility dimension PCQoL score exhibited significant correlations with HOMA-IR (R = −.86, P <0.01); fasting glucose (R = −.80, P <0.01); fasting insulin (R = −.82, P <0.01) and waist-to-hip ratio (R = −.74, P <0.01). Prevalence of mild depression was 21% and of moderate to severe depression 13%. Beck score significantly correlated with the weight dimension (R = −.91; P <0.01) and emotion dimension (R = −.75; P <0.01) PCQoL scores, but not with hormonal or metabolic parameters.

Conclusion
These results suggest that PCOS features relating to obesity and insulin resistance are associated with decreased HRQoL in the weight and infertility PCQoL domains, but not with depression. Supported by grant IGA MH NS 9839/4.
nonresponders, responders had lower AMH levels at baseline (7.2 ±3.1 vs 12.7 ±2.6 ng/ml, P=0.021). Using ROC-curves we calculated that the value of AMH <8 ng/ml can predict improvement of menses (sensitivity 72.7%, specificity 99%) and ovulation induction (sensitivity 66.7%, specificity 81.8%) by metformin in lean women with PCOS. Likewise, the mean follicle number per ovary was lower in responders than in nonresponders (11.0 ±1.5 vs 15.7 ±5.9, P=0.001). It was significantly related to the serum AMH levels (r=0.579, P=0.006).

Conclusions
AMH measurement can be useful in the prediction of ovarian response to metformin therapy in lean patients with PCOS.

P126
Cigarette smoking and progesterone and androgen metabolites in premenopausal women
Michaela Duskova1, Katerina Simunkova2, Martin Hill1, Hana Hruskovcova1, Hana Pospisilova1, Eva Kralikova2 & Luboslav Starka
1Institute of Endocrinology, Prague, Czech Republic; 2The Center for Tobacco Dependence, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Objective
Chronic smoking alters the circulating levels of sex hormones and possibly also the neuroactive steroids, however, the data available is limited.

Patients and methods
Therefore, a broad spectrum of free and conjugated steroids and related substances was quantified by GC-MS and RIA in premenopausal smokers and in age-matched (38.9 ±7.3 years of age) non-smokers in the follicular (FP) and luteal phases (LP) of menstrual cycle (10 non-smokers and 10 smokers, in the FP, and 10 non-smokers and 8 smokers in the LP). The local Ethics Committee approved the study.

Results
Smokers in both phases of the menstrual cycle showed higher levels of conjugated 17-hydroxyprogrenolone, 5α-dihydroprogesterone, conjugated isopregnanolone, conjugated 5α-pregnane-3β,20α-diol, conjugated androstenediol, androstenedione, testosterone, free testosterone, conjugated 5α-androstane-3αβ,17β-diol, and higher free testosterone index. In the FP, the smokers exhibited higher levels of conjugated pregnenolone, progesterone, conjugated pregnanolone, lutropin and higher lutropin/follitropin ratio, but lower levels of cortisol, allopregnanolone, and pregnanolone. In the LP, the smokers exhibited higher levels of free and conjugated 20α-hydroxyprogrenolone, free and conjugated dehydroepiandrosterone, free androstenediol, 5α-dihydrotestosterone, free and conjugated androsterone, free and conjugated epitriandosterone, free and conjugated epiandrosterone, 7αβ-hydroxy-dehydroepiandrosterone isomers, and follitropin but lower levels of estradiol and sex hormone binding globulin (SHBG) and lower values of lutropin/follitropin ratio.

Conclusion
Chronic cigarette smoking augments serum androgens and their 5αβ-reduced metabolites (including GABAergic substances) but suppresses levels of estradiol in the LP and SHBG and may induce hyperandrogenism in female smokers. The female smokers had pronouncedly increased serum progestogens but paradoxically suppressed levels of their GABA-ergic metabolites. Further investigation is needed concerning the machinery of these effects.

The study was supported by grant 10215-3 IGA MZCR.

P127
Influence of smoking cessation on steroid spectrum in premenopausal women
Hana Pospisilova1, Michaela Duskova1, Katerina Simunkova1, Hana Hruskovcova1, Martin Hill1, Eva Kralikova2 & Luboslav Starka
1Institute of Endocrinology, Prague, Czech Republic; 2Centre for Tobacco Dependence of 3rd Medical Department – the Department of Endocrinology and Metabolism, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Background
Smoking represents the most widespread substance dependence in the world. Several studies show the nicotine’s ability to alter women hormonal homeostasis. Women smokers have higher testosterone and lower estradiol levels throughout life compared to women non-smokers. This negatively affects women reproductive function. Furthermore, alteration of neuroactive and neuroprotective steroids occurs in women smokers, which plays an important role in the activity of the central nervous system, cognition, mental condition and substance dependence seriousness.

Methods
We monitored the effect of smoking discontinuation on steroid spectrum in 40 premenopausal women smokers. These women were examined before they began to discontinue smoking: after 6, 12, 24 and 48 weeks of abstinence. In each examination, blood was collected to determine steroid spectrum, LH, FSH and SHBG, as also basic anthropometric data were measured using GC-MS or immunoneuropsychological. Repeated measures ANOVA model was used for evaluation of the data. The local Ethics Committee approved the study.

Results
Given the small number of women who endured not to smoke, the data could be analysed only after 6 weeks. No changes in C21 steroids were found. A slight increase in androgens after the smoking discontinuation occurred.

Conclusion
Chronic smoking causes hyperandrogenism in fertile women; after smoking discontinuation its further increase occurs. Longer-term monitoring is necessary for illustrating the effect of smoking discontinuation on steroid spectrum.

Grant NS/10215-3 of the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR) supported the study.

P128
Metabolic and cardiovascular outcomes in adult patients with Turner’s syndrome under hormonal replacement therapy
R Giordano1, D Forno1, M Baldi2, F Fanfranco3 & E Ghigo1
1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; 2Division of Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy.

Turner’s syndrome (TS) is one of the more common genetic disorder, occurring in about 50 per 100,000 live-born girls. TS is caused by complete or partial X chromosome monosity in a phenotype female, and it is associated with increased morbidity and mortality for cardiovascular diseases, impaired glucose tolerance and dyslipidemia. In order to examine the metabolic and cardiovascular profile, in 30 adult TS patients under hormonal replacement therapy (HRT), 17β-estradiol (E2), BMI, waist circumference, fasting glucose and insulin, HOMA index, serum lipids, OGT, blood pressure by 24-h ambulatory monitoring (ABPM) and intima-media thickness (IMT) were evaluated and compared with those in 30 age- and sex-matched controls (CS). No difference was found between TS and CS in E2 and BMI, while waist circumference was higher (P<0.05) in TS (77.7 ±2.5 cm) than in CS (69.8 ±1.0 cm). Fasting glucose was similar in TS and in CS, while fasting insulin, HOMA index and 2 h glucose after OGGT were higher (P<0.0005) in TS (13.2 ±0.8 mU/I, 2.5 ±0.2 and 108.9 ±5.5 mg/dl, respectively) than in CS (9.1 ±0.5 mU/I, 1.8 ±0.1 and 94.5 ±5.8 mg/dl, respectively). Total cholesterol was higher (P<0.05) in TS (199.4 ±6.6 mg/dl) than in CS (173.9 ±4.6 mg/dl), while no significant differences in HDL, LDL and triglycerides were found between the two groups. In 13% of TS ABPM showed arterial hypertension, while IMT was <0.9 mm in all TS and CS. A negative correlation between insulin levels, HOMA index or 2 h-glucose after OGGT and E2 was present in TS. In conclusion, our results indicate that adult patients with Turner’s syndrome are connoted by higher frequency of central obesity, insulin resistance, hypercholesterolemia and hypertension, suggesting an increased cardiovascular risk, even under HRT.

P129
Growth factors
M Bielohlubý1, M Sawitzky2, B Stoevel1, J Ramisch1, D Menhofer1, A Hoeftich2 & M Bödlingmaier2
1Endocrine Research Unit, LMU, Munich, Germany; 2Institute of Mouse Genetics, FBN, Dummerstorf, Germany.

In rats, we have previously demonstrated that consumption of low-carbohydrate/high-fat diets (LC-HFD) led to significant reductions in circulating IGF1.
We further observed that rats fed an extreme, ketogenic, but comparably low protein LC–HFD (LC–HF-2) showed loss of bodyweight, which was mainly due to loss of lean body mass (LBM). Consumption of a moderate protein LC–HF diet (LC–HF-1) did not affect LBM acquisition compared to controls. We now investigated whether the effects on LBM could be explained by specific differences in muscle growth regulation through the local GH/IGF system.

Methods
We pair-fed 12-week old Wistar rats either a control chow (CH), LC–HF-1 or LC–HF-2 diets (n=8/diet group). After 3 weeks, GH profiles were determined by immunomassay using samples from serial blood samplings (n=80/diet group). After 4 weeks rats were sacrificed to analyze muscle samples (M. quadriceps femoris) by quantitative real-time PCR and Western blot analyses.

Results
Circulating IGF1 was lower in both LC–HF groups compared to CH. GH medians were significantly increased with LC–HF-1 (P<0.05), but unchanged in the LC–HF-2 group. Muscle GH-receptor mRNA expression was unaltered in both LC–HF groups. Muscle IGF1 mRNA expression was increased in rats fed LC–HF-1 (+110%, P<0.05). High expression of IGF-1 in muscle resulted in a specific activation of IGF1 receptor signalling pathways. Phosphorylation of AKT (+110%, P<0.001) and GSK3β (+54%, P<0.05) were higher in muscles of rats fed the LC–HF-1 diet. In conclusion, our data suggest that loss of LBM with LC–HF-1 was prevented by the rise in pituitary GH secretion, which might be triggered by low liver-derived IGF1 concentrations. With LC–HF-1, higher GH secretion resulted in increased muscle IGF1 activation of associated signalling pathways. In contrast, rats fed the ketogenic LC–HF-2 diet showed unchanged muscle IGF1 expression and loss of LBM, probably due to lower systemic IGF1 levels and normal pituitary GH output.

P130
Zilpaterol hydrochloride effects on carcass composition, growth performance and blood metabolites of Lory Bakhtryar lambs
Y Khalifeiolo, S Zietoulardini, A Towlidi, A Zalti, M Moradi Shahrab Babak & A Hatfi
Tehran university, Karaj, Tehran, Islamic Republic of Iran.

To determine the effects of zilpaterol hydrochloride (Zh) on carcass composition and growth performance of Lory growing lambs, 21 lambs with age 7–6 month and body weight 37.5 ± 1.2 kg was assigned in three groups with 7 replications: group one as control, group 2 received Zh every two days, and group 3 received Zh every day. Lambs orally received 0.2 mg/kg of live body weight mixed with their daily diets during finishing period (as zilpaterol hydrochloride, Zilmax, Intervet South Africa). Dry matter intake compared to control group was significantly decreased (P<0.001). Zilpaterol supplementation had no significant effect on gain and feed efficiency, daily and total gain in treatment groups compared to control group. Also, Zilpaterol supplementation did not affect carcass weight, longissimus muscle area (LM) and carcass dressing percentage. The results showed that the tail-fat weight in treated groups was significantly reduced (P<0.05) compared to control group. The back fat (in group 3), kidney-pelvic fat (in group 2), and liver fat compared to control group was significantly reduced (P<0.05). In treatment groups, lean protein in fillet muscle was higher than control group. Zilpaterol supplementation did not affect the level of insulin, T4 and T3, triglycerides, cholesterol and glucose in plasma. We conclude that Zh decrease the fat of tail and carcass and enhance growth performance but had no effect on carcass protein in Lory growing lambs.

P131
Comparative characterization of influence of replacement therapy with growth hormone on the level of secretion of growth hormone, insulin-like growth factor-1 and binding protein-3 in girls with endocrine and hereditary types of stunting
Nilufr Ibragimova
Republican specialized research and practical medical Centre of Endocrinology, Tashkent, Uzbekistan.

Purpose
To study comparative influence of replacement GH therapy on a level of secretion of GH, IGF1 and IGFBP-3 in girls with endocrine and hereditary stunting.

Materials and methods
Forty-six girls aged 5.5 to 17 were examined. Of them somatotropic insufficiency (STI) was found in 13 girls, multiple deficiency of adenohypophysial hormones (MDAH) in 11, idiopathic short stature (ISS) in 12, Turner syndrome (TS) in 10 girls. Patients received subcutaneous injections of rhGH NordiLet in the dose of 0.07–0.1 IU/kg of the body weight daily. GH treatment was continued during 6 months. Levels of GH, IGF1 and IGFBP-3 were measured before and after GH treatment.

Results and discussion
On the background of GH treatment all patients had a positive growth dynamics (growth rate before treatment was 2.5±0.05 cm/year and 10.1±2.45 cm/year following the GH treatment, (P<0.0001). The growth dynamics was less expressed in 4 adolescent girls with TS at 3 ones with IN, SDS made –3.3±0.92 (P<0.0001) on the background of GH treatment. The level of GH, IGF1 and IGFBP-3 was reliably low in patients with MDAH, STI-insufficiency before GH treatment in comparison with girls with IN and TS who had GH levels at the bottom normal range. On the background of GH treatment all patients had a reliable rise in IGF1 and IGFBP-3 levels. Correlation between IGF1 and IGFBP-3 (P<0.0001) was established.

Conclusion
A comparative analysis of the results obtained has shown that GH treatment accelerates reliably growth processes and increases IGF1 and IGFBP-3 levels in various types of stunting of endocrine and non-endocrine origin.
**P133**

**Effects of the d3 GHR allele on disease activity in acromegalic patients**

S Kohler\(^1\), R Bernays\(^2\), C Zwimpfer\(^2\), P Wiesli\(^2\) & Ch Schmid\(^1\)

\(^1\)University of Zurich, Zurich, Switzerland; \(^2\)Kantonsspital Frauenfeld, Frauenfeld, Switzerland.

**Background**

The exon-3 deletion in the growth hormone receptor gene (d3 GHR) leads to an enhanced GH signal transduction. Acromegalic patients with the d3 GHR genotype could be expected to have more marked clinical or biochemical manifestations for a given GH level than those with the wild (fl) type GHR. We studied acromegalic patients for clinical and/or biochemical disease recurrence after surgery in relation to GHR genotype status to assess whether d3 GHR influences the relationship between GH and disease activity.

**Methods**

Adults with initial diagnosis between 2000 and 2009 and pituitary surgery for acromegaly at our centre, with histologically proven GH-secreting adenoma and consenting to GHR genotyping were included. GH (random or during oGTT) and IGF-1 levels were analysed during follow-up.

**Results**

Forty-eight patients were included. 24 were homozygous for the fl-GHR, 24 had at least one d3 GHR allele. Transsphenoidal surgery markedly decreased disease activity in all patients. 19 of them were not cured as judged clinically and by failure to reach postoperative random low (<0.4 ug/l) GH levels or GH levels suppressible to a nadir of <1 ug/l during oGITT 2–3 months postoperatively.

29 patients had no biochemical evidence for remaining activity and could be classified as in remission. Two of these patients subsequently developed recurrent symptoms of acromegaly during follow-up, along with an increase in IGF-1. Both carried the d3 GHR genotype.

**Conclusions**

Despite biochemical ‘cure’ as inferred from low postoperative GH levels, carriers of the d3 GHR appear to be at increased risk of recurrence. Longer follow-up periods should be monitored in a larger number of patients to find out whether a ‘safe’ cut-off for postoperative nadir GH levels ought to be lower for carriers of a d3-GHR than for those with the wild (fl) type GHR.

---

**P135**

**Long acting analogs of glycoprotein hormones developed by using gene fusion and gene transfer are safe for use in human**

Fuad Fares\(^1\), Avri Havron\(^2\) & Eyal Fima\(^3\)

\(^1\)University of Haifa, Haifa, Israel; \(^2\)ModigenTech, Weizmann Science Park, Nes-Ziona, Israel.

Glycoprotein hormones are used clinically in the treatment of many diseases. One major issue regarding the clinical use of many peptides is their short half-life due to the rapid clearance from the circulation. The major strategies for overcoming this problem by pharmaceutical companies are based on chemical techniques. To overcome this problem, we used genetic engineering techniques that have been found successful for designing long acting hormones. Overlapping PCR techniques, we succeeded to add the signal sequence of O-linked oligosaccharides to the coding sequence of the hormones. The cassette gene that has been used contains the sequence of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin (b hCG)) subunit. The CTP contains 28 amino acids with four O-linked oligosaccharides recognition sites. It was postulated that the O-linked oligosaccharides add flexibility, hydrophilicity and stability to the protein. On the other hand it was suggested that the four O-linked oligosaccharides play an important role in preventing plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy we succeeded to ligate the CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO), GH and thus to increase the longevity and bioactivity of these proteins in vivo. Interestingly, the new analog of FSH was found not immunogenic in humans and it is already passed successfully clinical trials phase III. Moreover, FSH long acting was approved by the European Commission (EC) for treatment of fertility. In addition, our results indicated that long acting GH is not toxic in monkeys and the results from clinical trials phase I seem to be promising. Designing long acting peptides will diminish the cost of these drugs and perhaps reduce the number of injections in the clinical protocols.

---

**P134**

**Circulating insulin-like growth factor 1 (IGF1) and mortality: meta-analysis and dose-response meta-regression**

A M G Burgers\(^1\), M R Biermasz\(^1\), J W Schoones\(^1\), A M Pereira\(^1\), A G Renenh\(^2\), M Zwahlen\(^4\), M Egger\(^3\), O M Dekkers\(^1\)

\(^1\)Gomel State Medical University, Gomel, Belarus; \(^2\)Belarussian State Medical Academy, Gomel, Belarus; \(^3\)Gomel State Medical University, Gomel, Belarus; \(^4\)University of Berne, Berne, Switzerland; \(^5\)University of Bristol, Bristol, UK.

**Background**

Insulin-like growth factor 1 (IGF1) plays a central role in metabolism and growth regulation. High IGF1 levels are associated with an increased risk of cancer, low IGF1 levels with increased risk for cardiovascular disease. We hypothesized that the relationship between circulating total IGF1 levels and mortality is U-shaped. High IGF1 levels are associated with an increased risk of cancer, low IGF1 levels with increased risk for cardiovascular disease. We hypothesized that the relationship between circulating total IGF1 levels and mortality is U-shaped. The expected HR for the increase in mortality comparing the 10th IGF1 to the 50th percentile was 1.56 (95% CI 1.37;1.77) mmol/l to 1.33 (1.12;1.62) mmol/l (P <0.001). SHBG decreased from 43.75 (31.83;48.48) nmol/l to 30.40 (23.83;37.63) nmol/l (P <0.001). The predicted HR for the increase in mortality comparing the 10th IGF1 to the 50th percentile was 1.56 (95% CI 1.31–1.86); the predicted HR for the increase in mortality comparing the 90th to the 50th percentile was 1.20 (95% CI 1.06–1.58). A U-shaped relationship was present for both cancer mortality and cardiovascular mortality.

**Conclusions**

This meta-analysis showed that both low and high IGF1 concentrations are associated with increased mortality in the general population.

---

**P136**

**Experience with a 1% testosterone gel in treatment of aging males with hypogonadism and type 2 diabetes mellitus**

Ogol Vasilikova\(^1\) & Tatiana Mokhot\(^2\)

\(^1\)Gomel State Medical University, Gomel, Belarus; \(^2\)Belarusian State Medical University, Minsk, Belarus.

**Aim**

To study the effect of testosterone replacement treatment in the aging male with T2DM.

**Material and methods**

Twenty-six hypogonadal men with T2DM and late-onset hypogonadism (Total testosterone at diagnosis <12 nmol/l) between the age 50–65 years (55.00 (50.00:58.00)) were treated with a 1% testosterone gel (AndroGel) (5 g/day) for 6 months. Patients were assessed before the first using of AndroGel, in one week interval and in 6 months. At each consultation laboratory results, quality of life, mood, sexual function and skin reactions were monitored. Data are presented as mean ± s.d. or median (25th-75th percentile).

**Results**

Testosterone levels increased from 4.65 (2.70;6.10) nmol/l at baseline to 13.65 (12.60:15.20) nmol/l after 24 weeks of treatment (P <0.001). Free testosterone increased from 0.106 (0.062:0.152) nmol/l to 0.426 (0.345:0.533) nmol/l (P <0.001). SHBG decreased from 43.75 (31.83:48.48) nmol/l to 30.40 (26.28:32.03) nmol/l (P <0.001). We showed reduction of levels of TG from 2.09 (1.37:3.32) mmol/l to 1.33 (1.21:1.62) mmol/l (P =0.002). HbA1C from 8.6 (8.9:10.68%) to 6.8 (5.90:8.15%) (P <0.05), lepmin from 10.0 (4.0:22.7) mg/l to 5.25 (4.03:8.23) mg/l, HOMA-IR from 4.37 (1.96:5.76) to 2.46 (1.98:3.04). PSA levels fluctuated minimally within in the normal range. All patients reported improved mood, sexual function and quality of life. 13 had PSA levels elevated. 12 patients presented with low HOMA-IR levels in men with late-onset hypogonadism and T2DM.

---

**Endocrine Abstracts (2011) Vol 26**
Hypogonadism, insulin resistance and visceral adiposity in myotonic dystrophy

E Passeri1,2, E Bugiardini3, V Sansone1,2, C Fulceri2, E Costa1, B Ambrosi1, G Mecola1,2 & S Corbetta1,2
1Endocrinology and Diabetology Unit, Department Medical-Surgical Sciences, IRCCS Policlinico San Donato, San donato Milanese, Italy;
2University of Milan, Milan, Italy; 3Neurology Department, University Medical Center, Jerusalem, Israel.

Hypogonadism occurs in myotonic dystrophy (DM) type 1 and 2, a multisystemic autosomal dominant disorder. DM patients have genetically induced insulin resistance (IR) and visceral obesity, providing a model to study the impact of metabolic disruptions on hypogonadism. We assessed hypothalamic-pituitary-gonadal function and metabolic features in 22 DM1 and 8 DM2 males (mean ± s.d., 46 ± 11 years). Hypogonadism, defined as total testosterone (T) <320 ng/dl, freeT <0.4 ng/dl and sexual dysfunction, occurred in 1/5 of patients. Response to hCG was impaired in 33% of patients. Serum Insulin-Like factor 3 (INSL3), a marker of Leydig cell function, was lower in hypogonadics than eugonadics as well as 31age-BMI-matched controls (0.33 ±0.07 vs 0.47 ±0.09 and 0.41 ±0.07 ±0.004) and correlated with age and freeT. LH and FSH levels were significantly higher in DM patients and 38% of eugonadics patients showed LH and FSH >95% centile of controls. Nonetheless, GnRH failed to induce a normal response in a subset of patients. Interestingly, muscle test, using MRC score, negatively correlated with LH and FSH levels (r = 0.142, P = 0.032; r = 0.479, P = 0.011). DM patients showed an increased visceral fat versus controls: waist/hip and body fat mass were significantly higher, hepatosteatosis, abnormal liver tests and increased epicardial fat occur in 60 and 46% of patients, respectively. IR was diagnosed in 36%, 4 had overt diabetes. FreeT levels were predicted by HOMA-IR after adjustment for age and fat mass. In conclusion, nearly 30% of DM patients showed symptomatic hypogonadism and subclinical hypogonadism is even more frequent. Leydig cells impairment is associated with INSL3 reduction and is mainly related to IR rather than visceral adiposity. Interestingly, the relationship between muscle strength and gonadotropin rise suggests that LH and FSH might be a precocious and sensitive marker of muscle degeneration in male DM patients.

Perceived ejaculate volume reduction in subjects with erectile dysfunction: psycho-biological correlates

Giovanni Corona1,2, Giulia Rastrelli1, Alessandra Sforza1, Gianni Forti1, Edoardo Mannucci1 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 3Urology Unit, Azienda Usl di Bologna, Maggiore-Bellaria Hospital, Florence, Italy; 4Endocrinology Unit, University of Florence, Florence, Italy.

Introduction
Perceived reduced sleep-related erections (PR-SREs), along with erectile dysfunction (ED) and hypozoospermic sexual desire, have been recently recognized as the most important symptoms characterizing late onset hypogonadism in community-dwelling European men. However, the clinical correlates of PR-SREs have not been thoroughly investigated. The aim of this study is to evaluate the psychobiological correlates of PR-SREs in a large series of subjects consulting for ED.

Methods
A consecutive series of 3888 (mean age 51.6 ±13.0 years) ED patients attending an Outpatient ED clinic was retrospectively analyzed. PR-SREs were investigated using validated question #13 of SIEDY structured interview, which showed an accuracy of about 70% in predicting RigsicatM parameters in a consecutive subset of 199 subjects. Clinical, biochemical, hormonal, instrumental (penile color doppler ultrasound; PCDU) and intrapsychic (MHQ-questionnaire) correlates were also evaluated.

Results
63.6% of patients reported PR-SREs. After adjustment for age, total, analog free, calculated free and calculated bioavailable testosterone (T) were significantly lower in subjects reporting more severe PR-SREs. After adjusting for T levels and other confounders, PR-SREs were still associated with higher BMI, glucose and triglyceride levels, as well as with an increased 10 year-cardiovascular risk score. Accordingly, PR-SREs were more prevalent in subjects showing a reduced dynamic peak systolic velocity at PDCU or reporting severe ED. Among intrapsychic parameters, depressive and histrionic traits were significantly higher and lower, respectively, in subjects with any degree of PR-SREs.

Conclusions
Our study indicates that investigating PR-SREs represents an important step during the andrological consultation. In fact, reduced SREs might indicate an endocrine, organic and/or psychiatric ED background that might help in directing further investigation.

Sexual interests and hypogonadism in Prader–Willi syndrome (PWS)

H J Hirsch1, T Eldar-Geva2, F Benarroch2, O Rubinstein1 & V Gross-Tsur4
1Sharee Zedek Medical Center, Jerusalem, Israel; 2Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Background
Hypogonadism is a major feature of Prader–Willi syndrome, but clinical manifestations are variable. Sexual interests and behavior in this population have not been previously described.

Objectives
We studied PWS adolescents and young adults to assess: i) satisfaction with physical and sexual development ii) frequency of romantic and sexual experiences, iii) aspirations and expectations regarding marriage, iv) investigate the relation between sexual interests and hormone levels, and v) assess the desire for hormonal replacement therapy.

Methods
The study population consisted of 27 individuals (13 males) ages 17 to 32 (mean 23.5) years with genetically confirmed PWS. Mean IQ was 75 (range 50–100). We conducted structured interviews using questionnaires specifically designed for this study.

Endocrine Abstracts (2011) Vol 26
Reggio Emilia, Modena, Italy; 2Metabolic Clinic, Infectious and Tropical Endocrinology and Metabolism, Geriatrics University of Modena and Science Munich (CIPSM), Ludwig-Maximilians-University Munich, Endocrine Abstracts

L Strauss1,2, M Adam3, A Mayerhofer1 & M Poutanen1,2

Results
There was a significant negative correlation between IQ and body image in both males and females. IQ showed a positive correlation with interest in dating and romantic activities. Approximately half of PWS males and females reported having gone on a date and kissing romantically. All men and 64% of the females wished to be married. Seventy-seven percent of PWS males wanted hormonal treatment to increase phallic size. We found no correlation between hormone levels and sexual interests. Only 43% of PWS females wanted hormonal medication to achieve regular menstruation

Conclusions
Despite documented hypogonadism, PWS young adults are interested in sexual and romantic issues. The range of sexual activities and expectations is variable. Understanding specific sexual characteristics of each individual is important in order to offer proper anticipatory sexual guidance counseling and for appropriate recommendations for hormone replacement.

P142
Erectile dysfunction does not mirror endothelial dysfunction in HIV-infected patients
D Santi1, M Beggi2, G Brigante1, S Zona3, K Luzi4, G Orlando5, R Rossi1, P Bouloux4, G Guaraldi2 & V Rochira1

Background
The penis has been compared to a barometer of endothelial health, being erectile dysfunction (ED) an early sign of endothelial dysfunction. The aim of the study was to investigate the association between ED and endothelial dysfunction in patients with HIV infection on ART.

Methods
In this observational cross-sectional study we evaluated the prevalence and factors associated with ED in a cohort of 133 HIV-infected men. Evaluation tools included: the International Index of Erectile Function, ultrasound assessment of brachial artery flow mediated dilatation (FMD) and multi-slice computed tomography for coronary artery calcifications (CAC) as surrogates of endothelial dysfunction, the ATP III criteria to diagnose metabolic syndrome, plasma total testosterone (hypogonadism), and a visual analogue scale (VAS) of aesthetic satisfaction of the face and of the body (psychological distress associated with lipodystrophy).

Results
Thirty-nine (29.32%) patients had mild, 14 (10.52%) moderate and 26 (19.55%) severe ED. Prevalence of ED ranged from 45% to 65% respectively in patients less than 40 and more than 60 years old. Metabolic syndrome (MS) was present in 20 (25%) patients with ED and 13 (24%) without (P < 0.05). Prevalence of ED did not appear to be associated with MS as a single clinical pathological entity, nor with the numbers of its diagnostic components. FMD <7% was present in 25 (32%) patients with and 18 (33%) without ED (P = 0.83) and CAC > 100 was present in 8 (10%) patients with and 50% of patients without ED (P = 0.87). A multivariate multivariable logistic regression analysis was used to find predictors of ED. Independent predictor was VAS face (OR = 0.85, 95% CI 0.73–0.99, P = 0.049) and age, per 10 years of increase (OR = 1.73, 95% CI 1.02–2.94, P = 0.04).

Conclusions
Age constituted the most important risk factor for ED, which was related with aesthetic dissatisfaction of the face leading to negative body image perception.

P143
The obstructive azoospermia and TESA–ICSI
B Cibils, M Sanjić Stakor, K Peros, J Zmire & K Kljačić
University Clinic for Diabetes, Endocrinology and Metabolic Diseases Vuk Vrhovac, Zagreb, Croatia.

Introduction
We evaluated the efficiency of TESA-ICSI method in infertile men with obstructive azoospermia. Testicular spermatozoa are obtained by fine-needle aspiration of testis (23 G) and then injected into cytoplasm of the oocyte.

Methods
In the study, there were 173 married couples with 253 attempts of artificial fertilization (1.45 attempts per couple). Average age of women were 31 years and of men 36. Obstructive azoospermia was detected with clinical examination, semen analyses, hormone tests, fine-needle aspiration of testes and genetic tests (CFTR-DNA analysis). Stimulation of folliculogenesis was performed in accordance with the short/long protocol (GnRH analogues-rec. FSH-HCG) with usual oocyte aspiration time. Fertilization is performed by one single testicular spermatozoon which is injected into the oocyte’s cytoplasm (ISCI).

Results
The laboratory results are expressed as mean value (range). Volume of the semen 2.6 ml (0.2–5.1); acid phosphatase 712 U/I (125–1770); fructose 12.5 mmol/l (0.0–33.6); LDH-C4 unmeasurable; LH, FSH, testosterone, oestradiol and prolactine were normal; sperm/sertoli index: left 0.27 (0.09–1.40), right 0.29 (0.11–1.51). CFTR-DNA analysis found 9 heterozygotic mutation carriers. There were no female mutation carriers enabling fertilizations. On average 8.8 (range 2–21) aspirated oocytes, 5.3 (range 1–8) embryos were obtained. There were 88 pregnancies.

Conclusion
TESA-ICSI seems to be very safe, simple and successful technique of assisted reproduction (34.5% per embryo transfer and cumulative 50.6% of pregnancies).

P144
Does local testosterone therapy in adult men measure up to the 2006 Endocrine Society’s Guidelines?
D Hughes & A Toogood
University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.

Introduction
The 2006 Endocrine Society – testosterone therapy in adult men guidelines were audited against the clinical practice at a UK teaching hospital endocrine department. The aim of the audit was to determine whether patients were undergoing appropriate screening tests for prostate cancer and polycystaemia as described in these guidelines.

Method
Patients were initially identified by searching the endocrine clinic letter database for the names of all testosterone replacement preparations. Patients were randomised and the following data was collected: indication for testosterone use;
date testosterone replacement commenced; baseline and post treatment measurements of PSA, digital rectal examination & haematocrit.

Results
The initial search revealed a possible 499 patients that could be receiving testosterone replacement therapy. We audited 180 patients selected at random. 159 of the 180 patients were receiving testosterone replacement therapy at the time of the audit. Of these 14% of patients were commenced on testosterone therapy within the previous twelve months. The most common indication for commencing therapy was due to pituitary pathology (59%). PSA was measured in 48% of patients receiving testosterone therapy within a one year period. Digital rectal examination was never performed or recorded in any patient receiving testosterone replacement therapy. Haematocrit was measured in 47% of patients receiving testosterone therapy within a one year period.

Conclusion
This audit highlights the difference between clinical practice and the 2006 Endocrine Societies guidance. It is important that local practice is regularly audited either against national or local guidelines to ensure high standards. We were not surprised to discover digital rectal examinations were not regularly undertaken, but expected a higher rate of PSA testing. In the poster we also discuss recent US, European and Japanese recommendations on screening for prostate cancer.

P145
Criptorchidism, varicocele, azoospermia and Leydig cell tumor in a couple of identical twins with a unique de novo balanced reciprocal translocation.
M Vetri, A Stancampiano & L Licciardello
Department of Endocrinology, Catania, Italy.

Chromosomal translocations or inversions, may cause spermatogenic failure. We present a case of a 35-years-old couple of identical twins: GD and GS. Both had criptorchidism and bilateral varicocele and underwent medical treatment first, and orchiectomy and varicocelectomy subsequently at 7 years and 28 years respectively. GD at 31 years had orchietomy because of Leydig cell tumor. They were referred to our clinic for azoospermia and fatherhood desire. The patients were nonsmokers and nonalcoholics, with no history of infections or traumas in the genital area and were taking no regular medication. Physical examination showed only the right testicle in GD and both testicles in GS, all of elastic consistency and a volume of approximately 15 ml; deferent ducts, epididymes and prostate were normal at palpation. A semen analysis after 5 days of sexual abstinence (performed twice within 2 months according to the WHO guidelines), demonstrated azoospermia in both twins with a normal ejaculate volume (around 2.5 ml). Bacterial cultures excluded genital infection with pathologic bacteria. The levels of FSH and LH were elevated, testosterone levels within normal limits. A cytogenetic analysis demonstrated a balanced translocation (karyotype 46, XY – 1p13, +14q22). Both GD and GS underwent multiple testicular biopsies that revealed almost identical alterations, namely ‘seminiferous tubules with slightly diminished diameters, thickened fibrous membranes, and sparse germinative epithelial tissues. Rare spermatogonia and spermatocytes were observed within the tubules, but no spermatids or spermatozoa, with 80–90% tubules with Sertoli cells’.

To our knowledge, this is the first report about a reciprocal translocation in a couple of identical twins with cryptorchidism, varicoceles, Leydig cell tumor and azoospermia.

P146
Transcriptional regulation of germ cell differentiation.
M Weitzel
Department of Reproductive Biology, Leibniz Institute for Farm Animal Biology, Dummerstorf, Germany.

Introduction
Cellular differentiation and development of germ cells critically depend on a coordinated activation and repression of specific genes. The underlying regulation mechanisms, however, are largely unknown. Here, we describe the interplay between two transcription factors to be critical for cell type-specific expression in testis.

Methods
We investigated the binding of CREMT (cAMP response element modulator tau) and GCNF (germ cell nuclear factor) to DNA by Band Shift and ChIP assays. Cell-based assays of wild type and mutated versions were performed by reporter gene experiments. Protein-protein interactions were measured by GST-pull down and immunoprecipitation assays. Finally, in vivo relevance of the critical binding sites was monitored using a transgenic mouse model.

Results
In vivo, expression of the CREM/GCNF-driven transgene is detectable in haploid spermatids, but not in any somatic tissue or at any other stages during germ cell differentiation. CREM acts as an activator of gene transcription whereas GCNF suppresses this activity. Both factors compete for binding to the same DNA response element. Effective binding of CREM and GCNF highly depends on composition and epigenetic modification of the binding site. CREM and GCNF bind to each other via their DNA binding domains, indicating a complex interaction between the two factors. There are several testis-specific target genes that are regulated by CREM and GCNF in a reciprocal manner, showing a similar activation pattern as during spermatogenesis.

Conclusion
Our data indicate that a single common binding site for CREM and GCNF is sufficient to specifically direct gene transcription in a tissue-, cell type- and differentiation-specific manner.

P147
Efficacy of recombinant human follicle-stimulating hormone (rhFSH) in the treatment of male-factor infertility.
M Vetri, A Stancampiano & G. Licciardello
Department of Endocrinology, Catania, Italy.

To study the efficacy of rhFSH treatment on male infertility we evaluated the response of 79 hypo-normogonadotrophic patients referring to our clinic for couple infertility after a period of not <12–18 months of finalized unprotected intercourse without conception, rhFSH 150 IU were given subcutaneously every other day for 12 months (mean 15±3 months). All men, between 23 and 56 years (mean 34±8 years), were divided into three subgroups: i) hypogonadotropic hypogonadism with hypopituitarism (n=24), ii) functional hypogonadotropic hypogonadism (n=40), iii) hypogonadism associated with other conditions (n=16: betahalassemia, testicular dysgenesis syndrome, adrenogenital syndrome). FSH levels were in the low-normal range (5.9±2.8 mU/ml) in all patients. Testosterone and LH serum levels and testicular volume were compared before and after treatment in all groups. According to WHO standards the total number of sperms (NTS), the sperm morphology and motility were assessed. After hrFSH treatment, there was no significant change in either values of testosterone and LH (respectively 4.3±1.2 ng/ml and 3.5±1.8 mU/ml), or testicular volume (Prader 18±5), hrFSH treatment induces in group B a significant improvement in sperm number (NTS from 4.1±1.0 to 15.0±12.0 mln, P<0.002) and motility (23 vs 35%, P=0.03), while there was no effect on sperm morphology. Males in the group A, completely azoospermic before treatment, had a weak response of NTS (up to 4.2±2 mln in 25% of patients) after treatment. In group C there was no significant results. In conclusion rhFSH treatment in males with functional hypogonadotropic hypogonadism induces a marked increase in sperm count, a slight increase in sperm motility, no change in sperm morphology. Our preliminary data shows that rhFSH prolonged treatment can cause a noticeable improvement especially in those males with functional forms of hypogonadotropic hypogonadism.

P148
Testosterone changes over time in men with human immunodeficiency virus infection: preliminary results
G Brigante¹, D Santi¹, L Zirilli¹, C Dizzi¹, G Orlando¹, V Gnarini¹, C Carani¹, G Guaraldi² & V Rochira²
¹Unit of Endocrinology and Metabolism, Department of Medicine, Endocrinology and Metabolism and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy; ²Metabolic Clinic, Infectious and Tropical Disease Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy.

Introduction
Male hypogonadism is very frequent in men treated with highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus-1 (HIV-1) infection, reaching a prevalence of about 20%. Literature data regarding the time course of serum total testosterone (T) levels in these patients are lacking.

Aim of the study
To evaluate changes of T levels over time in HIV-positive men with an initial finding of low T (<300 ng/dl).
Methods
Measurement of T and serum LH in 111 hypogonadic HIV positive outpatients aged 31–68 years (mean 46.3 years) at baseline and after 12 months.

Results
Mean T value at baseline was 235.8 ng/dl. After 12 months, 36 subjects (32.4%) had no change in T (a variation of <50 ng/ml), 3 patients (2.7%) had a decrease (more than 50 ng/ml) and 72 patients (64.9%) had an increase in T (more than 50 ng/ml). 63 patients (56.7%) normalized T (>300 ng/ml). Mean T value at baseline of the 63 patients who restored T was 236.3±66.9 ng/ml, while mean T value at baseline of the 9 patients who didn’t normalize was 151.4±86.5 ng/ml.

Conclusions
Most of the HIV patients under HAART with an initial finding of low T present normalized T in the following months. Baseline T values seem to be predictive of the future evolution of the disease, higher T level being associated with subsequent T normalization. In HIV patients a single finding of hypotestoster-onemia needs further confirmation before starting androgen therapy and often a wait-and-see approach is mandatory.

P149
Intramuscular testosterone undecanoate for substitution in male hypogonadism – the experience of 13.5 years
F Saad1,2 & M Zitzmann3
1Scientific affairs Men’s Healthcare, Bayer Schering Pharma, Berlin, Germany; 2Gulf Medical University School of Medicine, Ajman, United Arab Emirates; 3Center for Reproductive Medicine and Andrology, University of Muenster, Muenster, Germany.

Background
Testosterone substitution with favourable kinetics and tolerance is important for hypogonadal men. Intramuscular injections of long-acting testosterone undecanoate (TU) offer a convenient modality.

Methods
We report data from 281 patients (134 with primary, 88 with secondary hypogonadism and 59 with late-onset (‘mixed’ or ‘metabolic’) hypogonadism aged 15 to 72 years (mean 40±13 years) receiving altogether 4913 intramuscular injections of 1000 mg of TU during a maximal treatment time of 13.5 years, overall corresponding to 1069 treatment years.

Components of the metabolic syndrome were assessed in 216 men receiving 2864 injections.

Results
Trough levels of testosterone were generally within the low normal range, indicating sufficient substitution. Individual dosing intervals ranged from 10 to 14 weeks. The proportion of men fulfilling the new joint consensus criteria of the International Diabetes Federation and the National Cholesterol Education Program for definition of the Metabolic Syndrome decreased from initially 87 to 52% within 2 years (χ² for trend: P<0.001). Especially waist circumference decreased from 112.0±10.3 to 96.4±9.1 cm (P<0.001) within a year (body mass index from 30.4±5.1 to 28.6±3.8 cm (P=0.001)). Lipoprotein subfractions, blood pressure and fasting glucose levels improved in a similarly meaningful manner. Hematocrit was significantly elevated under treatment but remained within the normal range, except for occasional measurements (maximal value 56.3%).

Conclusion
Injections of testosterone undecanoate represent a feasible, safe and well tolerated modality of androgen substitution in hypogonadal men of a wide age-range, substantiated by more than one decade of experience, facilitating a decrement of metabolic/cardiovascular risk factors.

P150
Testosterone administration to hypogonadal men for a period of up to 42 months improves features of the metabolic syndrome
F Saad1,2, A Haider3, A Yassim4,5 & L Gooren6
1Scientific Affairs Men’s Healthcare, Bayer Schering Pharma, Berlin, Germany; 2Gulf Medical University School of Medicine, Ajman, United Arab Emirates; 3Private Urology Practice, Bremerhaven, Germany; 4Institute of Andrology and Urology, Norderstedt, Germany; 5VUMC, Division of Endocrinology, Amsterdam, The Netherlands.

Objectives
Elderly men often show a concurrence of a decline of testosterone with features of the metabolic syndrome.

Materials and methods
One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral testosterone undecanoate for 42 months as the sole intervention.

Results
Plasma testosterone rose from 9.3±1.7 to 18.7±2.1 nmol/l reaching their maximum at 9 months and remaining stable over the next 33 months. Body weight and waist circumference declined progressively over the full study period. Plasma glucose, cholesterol, triglyceride, and LDL-cholesterol decreased significantly over the 24 month study period and then stabilized. Plasma HDL increased significantly over the first 24 months and then declined. There was a significant decrease of levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) over the first 24 months, then values leveled off. At baseline 47/122 met the criteria of the metabolic syndrome (ATPIII criteria) after two years of testosterone treatment this number had declined to 11/122.

Conclusion
With testosterone treatment over 42 months, the most significant improvement of the metabolic syndrome was noted over the first 12 months with further improvement over the following 12 months. Body weight and waist circumference declined further but glucose and lipids and liver functions did not further improve but were stable with continued testosterone treatment.

P151
Safety of 42 months of treatment with of long-acting parenteral testosterone undecanoate in men with late-onset hypogonadism
F Saad1,2, A Haider1, A Yassim4,5 & L Gooren6
1Scientific Affairs Men’s Healthcare, Bayer Schering Pharma, Berlin, Germany; 2Gulf Medical University School of Medicine, Ajman, United Arab Emirates; 3Private Urology Practice, Bremerhaven, Germany; 4Institute for Andrology and Urology, Norderstedt, Germany; 5VUMC, Division of Endocrinology, Amsterdam, The Netherlands.

Objectives
To investigate the safety of the administration of long-acting parenteral testosterone undecanoate (TU) to hypogonadal, mainly elderly men.

Design and methods
One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral TU. These 122 patients were followed for 42 months.

Results
Plasma levels of testosterone rose from 9.3±1.7 to 18.7±2.1 nmol/l reaching maximum at 9 months, never exceeding reference values. There was a slow but steady increase in prostate volume, not paralleled by an increase in serum prostate specific antigen (PSA) of similar magnitude. Serum PSA rose slightly over the first 24–36 months, then values stabilized at levels of 5–10% higher than baseline to rise again after 42 months. PSA never exceeded 4 ng/ml. The residual bladder volume decreased over the first 24 months and then stabilized. The scores on the International Prostate Symptoms Score decreased over the first 24 months and then stabilized. Hematocrit increased significantly and had reached its maximum values after 12 months. Over the 42 month study period, at any time point, nine patients had a hematocrit above 52%, the upper limit of normal. No specific measures were taken. An elevated hematocrit was never found at two occasions in the same patient.

Conclusions
Over a period of 42 months testosterone treatment with TU appeared safe. There was an increase in prostate size and PSA but not in bother.

P152
Expression of ghrelin receptor GHSR-1a in mammalian spermatozoa and their response to ghrelin in vitro
Andrzej Lukaszyk1, Małgorzata Kotwicka2, Anna Jankowska2, Marcin Rucinski2, Aldona Kasprzak1, Karolina Sterzyńska1, Agnieszka Ziolkowska2 & Marek Ruchala2
1Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland; 2Department of Cell Biology, Poznan University of Medical Sciences, Poznan, Poland; 3Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.

In this study, we attempted to demonstrate the expression of GHSR-1a receptor and possible effects of its activation in human, rat and boar spermatozoa.
For demonstration of GHSR-1a immunocytochemical, immunofluorescence and western blotting techniques were applied. The effects of receptor activation was tested in a series of in vitro incubations of spermatozoa with or without addition of ghrelin and the effects were evaluated using confocal microscopy and flow cytometry.

GHSR-1a was shown, with both immunohistochemical and immunofluorescence techniques, in rat epididymal and boar ejaculated spermatozoa in which profiles of acrosome and head membrane was marked by the reaction and the expression was confirmed by western blotting. However, we failed to demonstrate GHSR-1a expression in human ejaculated spermatozoa neither with immunohistochemical nor western blotting techniques. In vitro ghrelin affected rat and boar spermatozoa producing a dose dependent rapid (s) and prolonged (to 20 min) increase in intracellular Ca\(^{2+}\) concentration, higher percentage of spermatozoa showing progressive movement and increase in number of spermatozoa with acrosome reaction induced by ionophore. Interestingly, a response of human spermatozoa to ghrelin could be recorded as a short lasting (s) increase in intracellular Ca\(^{2+}\) concentration and poor changes in sperm motility and acrosome reaction. It is concluded that while the effects of ghrelin in rat and boar spermars arose as a result of GHSR-1a activation those in human spermatozoa probably indicate the peptide action through different than GHSR-1a receptor(s).

Supported by Polish Ministry of Science and Higher Education (3951/P01/2006/31).

**P153**

Lower serum testosterone and estradiol (E\(_2\)) in adult men with unfused epiphyses due to unrecognized and untreated congenital hypogonadotrophic hypogonadism: evidence for an E\(_2\) threshold for bone maturation in men

V Rochira\(^1\), A Balestrieri\(^2\), L Zirilli\(^3\), B Madoe\(^1\), I Sgarbi\(^1\), A Luberto\(^1\) & C Carani\(^1\)

\(^1\)Chair and Unit of Endocrinology and Metabolism, University of Modena and Reggio Emilia, Modena, Emilia Romagna, Italy; \(^2\)Unit of Endocrinology, Bufalini Hospital, Cesena, Emilia Romagna, Italy.

Introduction

At puberty, the raise of serum estradiol (E\(_2\)) (after testosterone conversion) is needed to fuse epiphses and to complete bone maturation in boys. Owing to severe hypogonadism and very low circulating testosterone, adult men with congenital hypogonadotropic hypogonadism (CHH) may present with unfused epiphyses and continuing linear growth if androgen deficiency is unrecognized and untreated. In order to establish the minimal amount of sex steroids needed to ensure bone maturation, we prospectively studied 28 caucasian men first diagnosed as CHH in adulthood (a very rare clinical condition) and we compared 11 adult CHH men (mean age ± s.d.: 22.7 ± 6.1) with fused epiphyses to 17 adult CHH men (mean age ± s.d.: 21.8 ± 4.3) with unfused epiphyses.

Methods

Serum testosterone, E\(_2\), LH, FSH were assayed. Bone age, target height, Tanner stage, anthropometric measurements (height, arm span, upper (U) and lower (L) segments) and bitecticular volume (b-TV) were calculated.

Results

Bone age, testosterone, E\(_2\), Tanner stage, b-TV were significantly lower in HH men with unfused than with fused epiphyses (\(P<0.001\)). Height, arm span, the arm span/height and the U/L ratios, and the difference between patient’s height and his target height were significantly greater in HH men with unfused than with fused epiphyses (\(P<0.001\)). All patients with unfused epiphyses had E\(_2\)<15 pg/ml and all patients with fused epiphyses had E\(_2\)>20 pg/ml, while testosterone resulted partially overlapped in the two groups.

Conclusion

A threshold of 20 pg/ml exists for serum E\(_2\) above which epiphsesal closure and bone maturation may be reached in men. Setting this threshold is challenging for targeting some kind of treatment for short or tall stature in boys, like aromatase inhibitors or androgens respectively. Unfused epiphyses, tall stature and eunuchoid skeleton all depend from circulating estrogens rather than androgens not only in genetic diseases due to congenital estrogen deficiency.

**P154**

Erectile dysfunction in endocrine patients (pituitary diseases)

Simona Juliette Mogos, Carmen Vulpoi, Teodora Ananie, Voichita Mogos & Eusebie Zbranca

University of Medicine and Pharmacy ‘Gr. T. Popa’, Iasi, Romania.

Aim of the study

Assessing prevalence and severity of erectile dysfunction in patients with pituitary diseases.

Materials and methods

International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM) questionnaires were used to assess erectile dysfunction (ED) in 83 patients having pituitary diseases (31 patients had hypopituitarism, 11 diabetes insipidus, 10 prolactinomas, 11 nonfunctional adenomas, 16 operated acromegaly, 4 GH deficiency). The presence and severity of erectile dysfunction were quantified by using IIEF questionnaire scores for erectile function (IIEF-EF) validated by Altho and Juliano in 2006. Correlation between plasma testosterone levels and severity of ED was analized by using Pearson correlations.

Results

Erectile function was most severely affected in patients with hyperprolactinemia, with a mean IIEF-EF score of 5.7, and among them 60% had severe dysfunction, 30% moderate, 10% mild dysfunction. Plasma testosterone levels were in inverse relation with prolactin adrenals. Acromegalic patients had severe impairment of EF, mean IIEF-EF 9.2, and weak correlation with testosterone levels (\(r^2=0.235\)), ED severity decreases progressively in patients presenting nonfunctional adenosas, mean IIEF-EF 12, followed by hypopituitarism, mean IIEF-EF 12.45, GH deficiency having a mean IIEF-EF 15 and diabetes insipidus IIEF-EF 18.5. Patients having nonfunctional adenosas showed a strong direct correlation between testosterone levels and IIEF-EF score (\(r^2=0.286\)). In patients with hypopituitarism IIEF test showed a high prevalence of severe ED, 41.9%, displaying a weak correlation with testosterone levels (\(r^2=0.054\)). In GH deficient patients IIEF-EF score shows moderate ED close to the mean value of the other subjects. Patients with diabetes insipidus showed elevated prevalence of ED, 63.7%, but most of them had mild to moderate ED. There was no correlation between testosterone levels and severity of ED.

Conclusions

The prevalence and severity of ED are different between the groups studied. The most severe erectile dysfunction was seen for prolactinomas, followed by acromegaly, nonfunctional adenosas, hypopituitarism, GH deficiency and diabetes insipidus.

**Neuroendocrinology**

**P155**

Short-term balneotherapy is associated with changes in salivary cortisol levels

F Matzer\(^1\), B Bahadori\(^2\) & C Fazekas\(^1\)

\(^1\)Medical University Graz, Graz, Austria; \(^2\)State Clinic St Poelten, St Poelten, Austria.

Since ancient times, physicians have speculated that balneotherapy (therapeutic bathing in medicinal and thermal springs) has a stress-relieving effect, but this has not yet been scientifically established. The aim of this study was to evaluate the stress-relieving effects of short-term balneotherapy in a controlled trial by measuring salivary cortisol as a sensitive stress marker. Forty-nine healthy probands were randomised into three intervention groups. Group one performed bathing in a thermal spring (Bad Loipersdorf, Styria Thermal Region, Austria), group two relaxed in deckchairs, and group three performed progressive muscle relaxation. In each group, the intervention lasted for 25 min. Saliva samples were collected immediately after getting up in the morning. Immediately before and after intervention saliva samples were taken again and participants rated their subjective relaxation level on a quantitative scale. Salivary cortisol was determined by ELISA. Additionally, the following psychological tests were employed: Perceived Stress Scale, Recovery-Stress Questionnaire, Symptom list. One-way ANOVAs for repeated measures were performed to detect changes in salivary cortisol and subjective stress ratings between groups. In all three groups, saliva cortisol decreased (\(F=23.532, P<0.001\)) and subjective relaxation ratings increased (\(F=132.178, P<0.001\)) after intervention. Groups did not significantly differ concerning the reduction of salivary cortisol. Interestingly, the increase of study participants’ subjective level of relaxation was significantly higher in the balneotherapy group (\(F=5.216, P=0.009\)). These findings suggest both an objective and subjective stress-relieving effect associated with short-term balneotherapy. With respect to changes in saliva cortisol levels other stress reduction interventions seem to produce similar effects but may not be experienced as similar beneficial as balneotherapy.
Character of macrovascular complications as per the Uzbekistan National Register of patients with the combined diabetes mellitus and diabetes insipidus
S I Ismailov1,2, Z Yu Khailinov1,2, Yu M Urmanovas1,2, D A Alieva1,2 & V Aripov1,2
1Republican Specialized Scientific-Practical Medical Center of Endocrinology under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan; 2Tashkent Medical Pediatric Institute, Tashkent, Uzbekistan.

Aim
To study character of macrovascular complications in combination of diabetes mellitus (DM) and diabetes insipidus (DI).

Materials and methods
Within the period from 2006 to 2010, we examined 2208 cases of DI among them 106 DM-DI combinations. The patients had their endocrine and neurologic statuses assessed with blood and urine density investigation, including complete urinalysis and Zimmitskiy urine count, RIA and measurement of pituitary hormones (GH, STH, LH, FSH, IGF1, prolactin, cortisol, etc.), ECG, echocardiography, Doppler ultrasound, Turkish saddle CT, eye fundus examination and assessment of vision fields.

Results
In 2010, the Uzbekistan National Register included 2208 patients with DI, 106 of which (4.8%) had DM-DI combination, 22 cases registered in Tashkent. The combination in question mutually burdens clinical presentation aggravating outcomes of both diseases and resulting in early cardio-vascular complications, high incidence of myocardial infarctions and strokes serving as the evidence. DM is a significant cardio-vascular risk factor in patients with diabetes insipidus. When added it results in increase of arterial hypertension and atherosclerosis, making myocardial infarctions (in 12.2 vs 5%) and cerebral circulation disturbances (in 88.4 vs 22.5%) more frequent. Progressing atherosclerosis with heart and brain vessels stenosed, myocardial contraction reduced and left ventricle overloaded, because of increase in the blood minute volume due to DI, underlie the complications of the combination. The fact is confirmed by presence of cardiac insufficiency in most patients with DI.

Delayed puberty in boys.
Yu M Urmanovas1,2 & U Kh Mavlonovs1,2,3
1Republican Specialized Scientific-Practical Medical Center of Endocrinology under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan; 2Tashkent Medical Pediatric Institute, Tashkent, Uzbekistan; 3Bukhara State Medical Institute, Bukhara, Uzbekistan.

Aim
To study clinical presentation peculiarities of constitutional puberty delay in boys.

Materials and methods
We examined 54 boys (mean age 13.8 years) with constitutional puberty delay (CPD). All examinees underwent general clinical examination as well as biochemical and hormonal investigations (levels of GH, LH, FSH, free testosterone, prolactin, cortisol, TSH, etc.), having their bone age and development stage by Tanner assessed.

Results
Most frequently the patients presented with vertigo (32%), fatigue (30%), headaches (29%), general weakness (28%), memory reduction (25%), irritability (24%), sleep disorders (17.4%), etc. As to degree of manifestation growth and puberty delay was observed in 17%, growth, puberty and speech delay in 4.3%, delay in growth, puberty, speech and psycho-motor development being found in 1.06% of the patients. Nocturnal enuresis (45%), chronic pyelonephritis (31%), neurotic asthenia (30%), vegeto-vascular dystonia (28%), chronic tonsillitis (23%) and chronic hepatitis (10%) were among the comorbidities to name.

Conclusions
Multiple clinical presentation peculiarities are typical of constitutional puberty delay necessitating further detailed study.
Hormonal disorders in patients with acromegaly in Khorezm region, Republic of Uzbekistan

Rikhisieva Urmanova1,2, Sh O Khodjaev1,2, Sh A Eshmetov1,2, M A Rakhmetov1,2, F S Khodjaeva1,2 & B A Azizov1,2
1Republican Specialized Scientific-Practical Medical Center of Endocrinology under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan; 2Republican Specialized Scientific-Practical Medical Center of Endocrinology under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan; 3Tashkent Medical Pediatric Institute, Tashkent, Uzbekistan.

Aim
To study clinical-epidemiological peculiarities of diabetic macroangiopathies in diabetes mellitus (DM) and diabetes insipidus (DI) combination.

Materials and methods
We examined 2208 cases of DI registered in the RUz in 2006–2010, 106 DM–DI combinations among them. DM–DI combination prevalence, calculated for 100 000 of adult and infant population, was assessed analysis of data on patients registered at the endocrine ambulances. The patients had their endocrine and neurologic statuses assessed with blood and urine density investigation, including RIA and measurement of pituitary hormones, ECG, perimetry and pituitary CT/MRI performed. In 15 examinees (68.2%) the latter procedure helps reveal pituitary macroadenomas.

Results
Mean levels of hormones were found as follows: GH 48.9 ng/ml, LH 3.5 mIU/l, FSH 2.9 mIU/l, IGF1 756 nmol/l, cortisol 320 nmol/l, prolactin 22.8 ng/ml. Two of the patients underwent surgery; three persons received radiotherapy and 17 are still on drug therapy preferentially with dopamine agonists.

Conclusions
Results of investigations indicate the decompensate in most patients examined.
P164
Sexual desire in female-to-male transsexual persons
K Wierckx, F Van De Peer, D Dedecker, E Van Caenegem, E Elaut & G T’Sjoen
University Hospital Ghent, Ghent, Belgium.

Objective
The current study aims to describe sexual desire in female-to-male transsexuals post SRS (sex reassignment surgery) using a validated questionnaire. The association between serum androgen levels and the intensity and frequency of sexual desire are examined. The data are compared to those of male-to-female transsexual persons.

Design
Cross sectional study.

Methods
Female-to-male transsexual persons, post SRS, (n = 48) completed a questionnaire measuring sexual desire (Sexual Desire Inventory). Also, participants were asked additional questions on current and past sexual desire, frequency of masturbation and sexual intercourse in the past month. Serum levels of testosterone and SHBG were measured on fasting morning serum samples. Data from our previous study on sexual desire in 62 male-to-female transsexual persons using the same validated questionnaire was used as reference population.

Results
In retrospect, the majority of the participants (73.9%) reported an increase in sexual desire after cross sex hormone treatment and SRS. No associations between levels of testosterone and scores of solitary and dyadic sexual desire were found. Solitary sexual desire scores were significantly correlated with frequency of masturbation (r = 0.835; P = 0.0001), whereas frequency of sexual intercourse with a partner was not correlated with dyadic nor solitary sexual desire (P = 0.515; P = 0.221).

Female-to-male transsexual persons scored significantly higher on sexual desire scores than male-to-female transsexual persons (P = 0.0001).

Conclusion
Most female-to-male transsexual persons report on a marked increase of sexual desire after testosterone treatment and SRS. No associations between levels of testosterone and measures of sexual desire were found. Sexual desire is significantly higher compared to male-to-female transsexual persons.

---

P165
Role of IGF1 system in human longevity. A study in a wide population of centenarians and centenarians’ offspring
G Vitale1,2, M P Brugts3, G Ogliari1,2, D Castalti2, L M Fatti1, J L Hollaad1, D Monti1, E Cavagnini1,2, C Franceschi3, M Mari4,5 & J M J L Janssen
1Dipartimento di Scienze Mediche, Universita degli Studi di Milano, Milan, Italy; 2IRCCS Istituto Auxologico Italiano, Milan, Italy; 3Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 4Geriatric Unit IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, Milan, Italy; 5Department of Experimental Pathology and Oncology, University of Florence, Florence, Italy; 6Department of Experimental Pathology, University of Bologna, Bologna, Italy.

Increasing evidence has recently accumulated suggesting that IGF1 system is involved in the regulation of longevity. While in animal models alterations of IGF1 signalling increase life expectancy, in humans there are contradictory data. Centenarians are an extraordinary model to study human longevity, however, they present a number of drawbacks: rarity, frailty due to extreme age and lack of a control group of the same age. The availability of an age-matched control group is crucial in studies evaluating IGF system, considering that age impacts on IGF1 production. Centenarians’ offspring, for whom it is possible to obtain an appropriate control group (subjects of same age born from not long-lived parents), represent a new model of longevity, showing a lower morbidity and mortality. The aim of the present study was to investigate the role of IGF1 in the modulation of longevity. We recruited: 106 centenarians, 192 centenarians’ offspring and 80 offspring of both non long-lived parents (controls) living in Northern Italy. No significant difference in age was observed between centenarians’ offspring and controls. Serum total IGF1 levels and IGF1 bioactivity, using an in-house KIRA assay, were evaluated in all subjects. Mean serum total IGF1 values were significantly lower in centenarians compared to centenarians’ offspring and controls (both P < 0.0001). IGF1 levels were lower in centenarians’ offspring than controls (P = 0.002). Circulating IGF1 bioactivity were lower in centenarians and their offspring than in controls (P < 0.001 and P = 0.002, respectively), while no significant difference was observed between centenarians and centenarians’ offspring. Interestingly, these differences in total IGF1 and IGF1 bioactivity between centenarians’ offspring and controls remained significant after correction for age, gender and BMI (both P < 0.001). In conclusion, these data strongly support a role of IGF1 system in the modulation of human aging and longevity.

---

P166
Evaluation of insulin secretion and sensitivity and lipid profile in GH deficient children before and at the end of rhGH therapy
F Prodham1,2, S Savastio2, S Bellone2, C Balossini2, R Ricotti2, G Genoni2, G Aimaretti2 & G bona2
1Department of Clinical and Experimental Medicine, Endocrinology, University of Piemonte Orientale, Novara, Italy; 2Division of Pediatrics, Department of Medical Science, University of Piemonte Orientale, Novara, Italy.

Introduction
A rise in serum insulin levels during GH therapy is reported. Insulin resistance is a risk factor for type 2 diabetes, atherosclerosis, dyslipidemia, and hypertension. Few data describe insulin secretion and lipids after the end of GH therapy.

Subjects and methods
Aim of our study was to evaluate changes in insulin secretion, sensitivity and lipid profile in children with isolated GHD longitudinally followed during rhGH treatment. We measured lipid profile, glucose and insulin levels at fasting and after an oral glucose tolerance test (OGTT) in 24 GHD children at 4 times: i) before starting of GH therapy (T1); ii) during the last year of therapy (T11); iii) 6 months (T6) and iv) 12 months (T12) after stopped therapy. They were compared at T12 with 28 healthy puberty matched subjects.

Results
No subjects showed dysglycemia or hypertension. Basal glucose levels were lower at BT but similar among the last 3 times. Fasting insulin, insulin and glucose levels at each point after OGTT were progressively lower at T6 and T12 compared to T1 (P < 0.002). HOMA-IR index was higher, and Matsuda and QUICKI indexes were lower at T1 respect to T6 and T12 (P < 0.02) without returning to the BT prepubertal levels. A compensatory insulin secretion was recorded at T1 as HOMA-B and insulinogenic index both of which progressively decreased at T6 and T12 respect to T1 (P < 0.04) returning to BT levels. The disposition index was unchanged from BT to T12. HDL-cholesterol decreased after stopped therapy (P < 0.04). All the parameters were similar at T12.

Conclusions
Insulin sensitivity decreased during rhGH therapy without the onset of dysglycemia and was associated with a compensatory insulin secretion after OGTT and without changes of the disposition index. Insulin and glucose secretion progressively restored after stopping treatment being similar to controls in the next 12 months.

---

P167
Immune status and functional activity of blood neutrophils in patients with active acromegaly
M A Dudina, S A Doganov & A A Savchenko
Institute for Medical Problems of the North, Siberian Division, Krasnoyarsk Region Clinical Hospital, Krasnoyarsk State Medical University, Russian Academy of Medical Sciences, Krasnoyarsk, Krasnoyarsk Region, Russian Federation.

The chronic GH and IGF1 excess causes a specific changes in immune system due to presence of its receptors on T-, B-lymphocytes, granulocytes. The aim of this study was to evaluate the subpopulation composition and chemiluminescence’s indexes of neutrophils in patients with active acromegaly.

Thirty-three patients with active acromegaly (11 men and 22 women, mean age 51.7 ± 11.7 years) and 53 healthy subjects sex- and age-matched with the patients were enrolled in this study. The analysis of lymphocytes subset pattern were performed by indirect immunofluorescence, using of the FITC-marked monoclonal antibodies to CD3, CD4, CD8, CD16, CD19, CD25 and CD95. The De Sole P. method and ‘CL3606M’ chemiluminescent analyzer for the initial study was to evaluate the subpopulation composition and chemiluminescence’s indexes of neutrophils in patients with active acromegaly. The results demonstrate that in
acromegaly developing the population and subpopulation imbalance of immune cells, with the increasing of activated lymphocytes and functional activity of phagocytic cells.

P168

Dexamethasone supression test (BDST) and bilateral inferior petrosal sinus sampling (BIPSS) in diagnosis of ACTH-dependent hypercortisolism

A Dreval, I Komerdus, T Britvin, I Demidov, O Nechaeva, A Murzina & L Denisova
Moscow Regional Research Clinical Institute N.A. Vladimirsy, Moscow, Russian Federation.

Background

BIPSS is the most reliable procedure for differentiation Cushings’s disease (CD) from ectopic ACTH secretion (EAS).

Aim

to determine the comparability of 8-mg dexamethasone supression test (BDST) and BIPSS for differential diagnosis ACTH-dependent hypercortisolism.

Materials and methods

We present 6 patients with confirmed ACTH-dependent hypercortisolism. All of them BDST (8 mg dexamethasone at 2300 h) and BIPSS (with a cut-off central/peripheral ACTH-ratio of 2.0 or more) have been made. Also MRI and CT scan were performed.

Results

In 3 of 6 cases plasma cortisol suppression was more than 50% after BDST and pituitary adenoma was seen in MRI. Only in 1 of this 3 cases of CD a center/periphery-ACTH gradient was more than 2. Interestingly that the gradient was on the opposite to the location of pituitary microadenoma side. It was probably because of left sinus (on the side of adenoma location) contraction during catheterization. In other 2 of this 3 cases of CD a center/periphery-ACTH gradient was < 2: in 1 case it was sinus anomaly (the absence of the right petrosal sinus), in other – may be attributed to technical factors.

In 1 of 6 case plasma cortisol suppression was 53.6% in BDST and no adenoma on MRI. However, a center/periphery-ACTH gradient was 15, 2. So CD was diagnosed.

In 2 of 6 cases plasma cortisol suppression in BDST were 3.5 and 54% respectively. MRI and CT show no abnormalities. After BIPSS the center/ periphery-ACTH gradient was 1.06 and 1.27 respectively. EAS was diagnosed.

Conclusion

It should take into account data from all possible exam for the differential diagnosis of different forms of ACTH-dependent hypercortisolism.

P169

The NAD- and NADP-dependent blood lymphocytes dehydrogenases activity in acromegaly

M A Dudina, S A Dogadin & A A Savchenko
Institute for Medical Problems of the North, Siberian Division, Krasnoyarsk Region Clinical Hospital, Krasnoyarsk State Medical University, Russian Academy of Medical Sciences, Krasnoyarsk/Krasnoyarsk Region, Russian Federation.

GH and IGF1 regulate plastic and synthetic intracellular lymphocytes process. We aimed to investigate the NAD- and NADP-dependent dehydrogenases activity in blood lymphocytes in patients with active acromegaly.

Thirty-three patients (11 men and 22 women, mean age 51.7 ± 11.7 years, with the 6–10 years active phase duration of acromegaly, and 53 age- and gender matched healthy controls were determined the activity of NAD(P)-dependent dehydrogenases in blood lymphocytes. The activity of glycerol-3-phosphate dehydrogenase (G3PDH), glucose-6-phosphate dehydrogenase (G6PDH), lactate dehydrogenase, NADH-glutamate dehydrogenase (NADH-GDH), NADPH-glutamate dehydrogenase (NADPH-GDH), NAD(P)-isocitrate dehydro- genases, NAD(H)-malate dehydrogenases and glutathione reductase (GR) were measured using of biochemiluminescence method. The concentrations of somatotropin (GH) and IGF1 were measured by ELISA.

Chronic excess of GH and IGF1 in acromegaly associated with the high levels activity of GlutPhD (P < 0.001) and MDH (P < 0.001), also, reduced the activity of GR (P < 0.001), NADH-GDH (P = 0.005) and NADPH-GDH (P < 0.001). The correlation analysis revealed the inverse interaction between GH and NADH-GDH activity (r = -0.52, P = 0.014) and between IGF1 and NADPH-GDH activity (r = -0.56, P = 0.007).

GlutPhD is the key enzyme of phosphogluconate pathway, MDH characterize the intensity of substrate flux on concluding steps of Krebs cycle. The increasing activity of GR in patients with acromegaly is the sign of glutathione-dependent antioxidant system insufficiency. Thus, the lymphocytes metabolism in acromegaly is remarkable for high level of plastic and aerobic respiration process, but the decreasing activity of glutathione-dependent antioxidant system.

P170

Metabolic encephalopathy and quadriplepesis induced by severe hyponatremia in the patient with Sy Seehan

Jelena Bogdanovic1, Radmila Stojanovic Peruško1, Dragan Popovic1, Radija Dzomilija1, Vera popovic1, Marko Ercegovic2, Ljiljana Bogdanovic & Dusan Micic3
1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia; 2Clinic for Neurology, Clinical Center of Serbia, Belgrade, Serbia; 3Institute for Pathology, Belgrade, Serbia.

Sy Seehan or postpartal pituitary necrosis presents with symptoms and signs of hypopituitarism. It is usually a consequence of cific delivery followed by intensive uterine bleeding. Diagnosis can be delayed years after delivery, up to 20 years.

We present a case of 51-year-old female patient. She was admitted in the department of neurology in the Emergency center, Belgrade, with disturbance of consciousness. Few days before she felt leg weakness and numbness, become sleepless and develop disturbance of consciousness. There was no serious illness in the previous history. She born four children, the last delivery was 10 years ago and it was complicated with prolonged bleeding. After that there was no lactation or restoring of menstrual cycles, body hear disappeared in the following years. In the moment of administration patient was somnolent, dehydrated, body hear were absent, breasts atrophic, TA 100/80 mmHg. Neurologic status showed quadripareis. EEG was performed showing diffuse encephalopathic changes with irritative focal locus on the left side: NMR of endocronium revealed empty sella with thickening of stalk. Laboratory analyses showed severe hyponatremia 116 mmol/l, normocytic anemia Hb 85, RBC 2.83, MCV 88. Other routine analyses were without changes.

We made a diagnosis of hypopituitarismus and patient was tranferred to Metabolic unit of EC. Hormone analyses confirmed diagnosis: FT4 <5.1, TSH 0.22, cortisol0/800 h/344.2, ACTH 17.2, IGF1 30.2, FSH 11.6, LH 1.8, LTH/pulled blood/308, estradiol 36.9, insulin 30.2.

Therapy was started with administration of isotonic saline solutions and substitution with hydrocortison, several days later l-thyroxine was added. After few days patient felt much better, electrolyte disorders was corrected and she was able to walk 3 weeks later. After 2 months on the control, hormonal analyses were corrected.

We present a patient with Sy Seehan and severe hyponatremia that leads to metabolic encephalopathy and quadripareis. Substitution treatment with Hydrocortison and l-thyroxine diminished all signs of illness.

P171

Effects of orexin–monoaminergic interactions on vasopressin secretion in rat neurohypophyseal cell cultures

J K Kis1, M Gálfi1, M Radács2, K Kádár3, Z Molnár2, A H Molnár2, F László1, C Varga1 & F A László1
1Department of Physiology, Anatomic and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary; 2Department of Environmental Biology, Gyula Juhász Faculty of Education, University of Szeged, Szeged, Hungary; 3Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Szeged, Hungary; 4Gyula Juhász Faculty of Education, Institute of Physical Education and Sport Sciences, University of Szeged, Szeged, Hungary.

Introduction

The effects of dopamine (DA), serotonin (5-HT), histamine (HA) adrenaline (ADR), noradrenaline (NADR) and K+ administration on vasopressin (VP) secretion were studied in 13–14 days cultures of rat neurohypophyseal (NH) cells, and it was examined whether orexin (ORX) can modify the VP release enhancement induced by these monoaminergic compounds.

Methods

An enzymatic dissociation technique was used to prepare the rat NH cell cultures. The VP contents of the supernatants were determined by RIA.
Results
Following administration of ORX-A or ORX-B in increasing doses (10^{-10}, 10^{-9}, 10^{-8} M), significant changes were not observed in the VP levels (tg VP/mean percentage change ± S.E.M.) of the supernatant media (control: 50.14 ± 0.9; ORX-A: 51.6 ± 0.67; ORX-B: 52.30 ± 0.86). VP level substantially increased after NADP (222.98 ± 2.45), ADR (208.68 ± 2.36) or 5-HT (194.9 ± 2.69) treatment, while the enhancing effects of DA (166.74 ± 2.33), HA (143.56 ± 1.75) or K^+ (123.77 ± 2.53) on VP concentration were more moderate. Preincubation with ORX-A or ORX-B reduced the NADP (197.06 ± 3.35; 202.14 ± 1.61) or HA-induced (107.30 ± 1.63; 110.12 ± 2.03) VP level increases. Following ADR, 5-HT or DA administration, the VP level enhancement was slightly decreased (195.32 ± 2.22; 181.36 ± 1.8; 158.22 ± 2.37) in ORX-A; 194.62 ± 1.61; 181.16 ± 2.3; 160.94 ± 9.53 in ORX-B preincubation), though the differences proved to be significant (P<0.05), but the VP concentrations of the supernatant media remained above the control level. There was no significant difference in decreasing effect between ORX-A and ORX-B. ORX had no influence on the VP level increase induced by K^+, which causes non-specific hormone secretion. ORX-A or B did not induce any changes in VP release following monosomnergic treatment.

Conclusions
The results indicate that the changes in VP secretion induced by the monosomnergic system can be directly influenced by the ORX system. The interactions between the monosomnergic and ORX systems regarding VP secretion occur at the level of the posterior pituitary.

P172
Age related distribution of the endothelial nitric oxide synthase gene G894T polymorphism: relationship with metabolic-endocrine and cognitive features
O Ianaş, D Manda, C Heltianu, S Vloadiu, O Popa, R Rosca, S Oros, M Covic & O Joga
1'CI. Parhon' National Institute of Endocrinology, Bucharest, Romania; 2'N. Simionescu' Institute of Cellular and Molecular Biology, Bucharest, Romania; 3'Ana Aslan' National Institute of Geriatriy and Gerontology, Bucharest, Romania.

Background
Genetic variants of the endothelial nitric oxide synthase (eNOS) gene have been reported to be associated with vascular disease. We hypothesized that G894T polymorphism might trigger many of the endothelial-metabolic cognitive changes related to aging.

Study design
One hundred and eighty eight subjects aged 55-80+ years with moderately cognitive impairment (MCI) (MMSE<28) (lot 1), 140 age-matched subjects without cognitive impairment (MMSE≥28) (lot 2) and 150 healthy subjects under 55 years were studied. The biochemical and hormonal profiles and eNOS gene G894T polymorphism evaluated.

Results
The frequencies of genotypes and alleles of G894T polymorphism according to age showed considerable differences among lots. The genotype and allele frequencies deviated from the Hardy-Weinberg equilibrium in subjects over age of 55 years (P<0.001 /lot 1 and P=0.04 /lot 2) compared with lot 3 under 55 years that was in HW equilibrium. The percentages of both G allele and GG genotype significantly decreased while T allele and TT genotype increased (OR=2.3; P<0.001) and OR=4.2; P<0.001 in lot 2 compared to lot 3. In the MCI group (lot 1) the tests for association showed risk allele G (OR=2.4; P=0.015); the percentages of both G allele and GG genotype significantly increased. GG genotype was significantly associated with cortisol, PRL, T3, T4, FT4 (OR=2.87; 95% CI=1.7-4.8; P<0.001) and more significantly with Glu, C-LDL, apoB, CRP and IGFI (OR=4.6; 95% CI=2.5-8.3; P<0.001).

Conclusion
The findings suggest that there is a substantial difference in the distribution of gene G894T polymorphism between population under and over 55 years and that it is involved in aging process related to cognitive performance and endocrine changes. These results show an interaction between the G894T polymorphism and its phenotypes in conferring a higher susceptibility to the endocrine changes involved in healthy aging.

P173
Glucose homeostasis in GH deficient adults not treated with GH: more than 10 year follow-up
S Pekic Djurdevic, M Doknic, M Stojanovic, D Milicic, M Djurovic, M Medic Stojanoska & V Popovic
1'Institute of Endocrinology, University Clinical Center, Belgrade, Serbia; 2'Institute of Endocrinology, University of Novi Sad, Novi Sad, Serbia.

Study objective
We investigated prevalence of impaired glucose homeostasis in a large cohort of adult patients with GH deficiency (GHD), not treated with GH after more than 10 years of follow-up.

Design
Seventy-one adult GHD patients (30 males, 41 females; mean age 48.3±2.0 years, mean BMI 28.8±0.7 kg/m2, GH deficiency for 10.2±1.2 years) were evaluated. Ninety percent of patients had multiple pituitary hormone deficiencies which were replaced. Fasting plasma glucose, HbA1c and oral glucose tolerance test (OGTT) were analyzed at baseline and after additional 2 years of follow-up. Peak glucose and insulin levels during OGTT, area under the curve (AUC) for glucose and insulin during OGTT, index of basal insulin resistance (HOME-IR) and the whole body insulin sensitivity index (WBISI) were analyzed.

Results
At baseline, 58 unreplaced (with GH) GHD patients exhibited no abnormalities in glucose metabolism, 10 patients (14%) had impaired glucose tolerance and 3 patients (4%) had diabetes mellitus (1 patient treated with insulin, 2 patients treated with oral agents). After additional 2 years of follow-up, there were an increase in body weight (from 80.4±2.9 to 83.2±2.5 kg, P<0.006) BMI (from 28.1±0.7 to 30.3±0.8 kg/m2, P=0.004), basal insulin level (from 13.1±1.1 to 18.5±2.3 mIU/l, P=0.001), peak insulin level during OGTT (from 103.5±10.7 to 120.3±11.8 mIU/l, P=0.05) and AUCinsulin (from 662±654 to 8558±879 mIU/l per 120 min, P=0.004). HOME-IR increased after 2 years (from 2.8±0.2 to 3.7±0.4, P=0.003), while WBISI decreased (from 6.7±0.7 to 2.4±0.3, P=0.001), indicating the significant increase in insulin resistance.

Conclusion
Prevalence of impaired glucose tolerance after 10 years of follow-up of adult GHD patients without GH therapy was 14%, while 4% had overt diabetes mellitus. During additional 2 years of follow-up, insulin sensitivity decreased due to an increase in body weight and ageing.
the expression of the pro-inflammatory monocyte genes in SCZ patients, but this correlation was lost in BD patients.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>GR ( \beta )/a ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>SCZ patients</td>
<td>11.7</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>3.6</td>
</tr>
<tr>
<td>BD patients</td>
<td>1.9</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>1.1</td>
</tr>
</tbody>
</table>

Conclusions and perspectives

Our results indicate that GR \( \beta \) expression is significantly up-regulated in pro-inflammatory monocytes of SCZ patients whereas GR \( \alpha \) is down-regulated. The same results were found in BD patients, though to a lesser extent. The correlation analysis suggests that up-regulated GR \( \beta \) expression leads to glucocorticoid insensitivity and is closely linked to the pro-inflammatory expression pattern in monocytes of all investigated groups. The down-regulated GR \( \alpha \) expression is closely linked to loss of glucocorticoid sensitivity, but only in the SCZ and HC groups, this process seems to be uncoupled in BD patients.

P175

The role of food choice in the effects of a high-fat high-sugar diet on leptin sensitivity

J K van den Heuvel, L Eggeels, M C M Luijendijk, A Kalsbeek, E Fliers, R A H Adan, 1Department of Endocrinology and Metabolism, Academic Medical Center Amsterdam, Amsterdam, The Netherlands; 2Department of Neuroscience and Pharmacology, Rudolf Magnus Institute, Utrecht, The Netherlands.

Background

Rats on a free-choice (fc) diet of saturated fat and liquid sugar in addition to chow (fcHFHS) overeat persistently, and show increased hypothalamic neuropeptide Y and decreased melanocortin signaling, which reflects a hunger state despite hyperphagia. This response is specific for a fcHFHS diet, because when given the choice between fat and Chow (fcHF) or between liquid sugar and Chow (fcHS) hyperphagia is not observed. Because leptin signaling is important for the regulation of feeding behavior, we determined whether rats on a fcHFHS diet became leptin resistant, and whether this depends on the free-choice component. Methods

Rats were subjected to a Chow, fcHF, fcHS or fcHFHS diet. After either i.p. or i.c.v. injections of leptin or vehicle food intake was determined. Another group was subjected to Chow, fcHFHS or a non-choice HFHS (ncHFHS) diet and the extent of leptin resistance was determined by i.p. injections of leptin or vehicle. The ncHFHS diet consisted of pellets containing the same ingredients and the same percentages for fat, sugar and Chow as consumed by rats on a fcHFHS diet. Results

After i.p. injection of leptin, rats on a Chow, fcHF or fcHS diet significantly reduced food intake, whereas rats on a fcHFHS diet showed leptin resistance. On the contrary, upon i.c.v. injection, the fcHFHS group did respond to leptin and showed increased sensitivity when food intake was measured over 24 h. In the second experiment, again we observed leptin resistance to i.p. injections in rats on a fcHFHS, while the rats on a ncHFHS diet remained sensitive to leptin and significantly reduced their food intake. Conclusion

The fcHFHS diet results in leptin resistance peripherally but not centrally. Furthermore, the choice component is important for the peripheral leptin resistance that results from the fcHFHS diet.

P176

Hypothalamic neuropeptide Y controls the hepatic secretion of VLDL triglycerides in rats via the sympathetic nervous system

E Bruinsteijn, L Pei, M Ackermans, E Fliers & A Kalsbeek, 1Department of Endocrinology and Metabolism, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands; 2Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; 3Department of Clinical Chemistry, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands; 4Department of Neurobiology, Tongji Medical College of Huazhong University of Science and Technology, Hubei, People’s Republic of China.

During fasting neuropeptide Y (NPY) neurons in the mediobasal hypothalamus are activated to increase food intake and to conserve energy. Under conditions of food deprivation, lipid metabolism plays an important role in providing fuel for muscle. We investigated if central NPY affects VLDL-TAG secretion directly via the autonomic nervous system. We measured VLDL-TAG secretion in Wistar rats by an intravenous bolus of tyloxapol to inhibit uptake of triglycerides by peripheral tissues. In the absence of chylomicrons from the gut, the increase in plasma triglycerides reflects VLDL-TAG secretion by the liver. First, we investigated the acute effect of i.c.v. infusion of NPY (1 \( \mu \)g/\( \mu \)l) for 5 \( \mu \)l/min, followed by 5 \( \mu \)l/h) on VLDL-TAG secretion after a selective sham or sympathetic liver denervation. Second, we investigated the effects of overnight fasting (19 h fast) in sham, parasympathetic, sympathetic, or total liver-denervated animals. Finally, we tested the effects of fasting and liver denervation in rats treated neonatally with monosodium glutamate (MSG), which is an established model for chronic NPY depletion from the arcuate nucleus. We report that hepatic sympathetic innervation mediates the stimulatory effect of i.c.v. NPY on VLDL-TAG secretion. During fasting, when hypothalamic NPY tone is physiologically high, an intact hepatic sympathetic innervation is necessary to maintain VLDL-TAG secretion. Finally, in MSG treated rats VLDL-TAG secretion could not be maintained during fasting while hepatic denervation did not yield any additional effect. Our findings show that the release of hypothalamic NPY during fasting stimulates triglyceride secretion by the liver via hepatic sympathetic input. By inference, an elevated hypothalamic NPY tone may increase sympathetic tone as well as plasma TAG in pathophysiological conditions such as the metabolic syndrome.

P177

Inverse association of dehydroepiandrosterone sulfate with stroke severity and poor functional outcome in a female stroke population

T Pappa, K Vennmos, K Saltiki, E Mantzou, K Stamatoiou & M Alevizaki, 1Endocrine Unit, Department of Clinical Therapeutics, Alexandria Hospital, Athens University School of Medicine, Athens, Attika, Greece; 2Acute Stroke Unit, Department of Clinical Therapeutics, Alexandria Hospital, Athens University School of Medicine, Athens, Attika, Greece; 3Vascular Laboratory, Department of Clinical Therapeutics, Alexandria Hospital, Athens University School of Medicine, Athens, Attika, Greece.

Introduction

DHEAS is among the most abundant sex steroid products of the adrenal gland. DHEAS levels have been repeatedly associated with cardiovascular disease, but data concerning cerebrovascular disease, especially in women, is lacking. In this study, we aimed to investigate the role of DHEAS in a female population suffering an acute stroke. Patients and methods

We studied 302 consecutive female patients presenting with an acute stroke hospitalized in two tertiary Hospitals of Athens, Greece, during a time period of 2 years. A detailed medical history and physical examination were performed and risk factors for stroke were recorded. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS). One month after stroke onset, the functional outcome and degree of handicap were evaluated with the modified Rankin Scale (mRS). Besides basic biochemical investigation and lipid profile testing, a hormonal panel, including DHEAS, 4-androstenedione, testosterone and sex-hormone binding globulin, was performed in all subjects 2–5 days after stroke.

Results

A significant inverse association was found between DHEAS levels and stroke severity on admission, as expressed by NIHSS (\( r = -0.137 \), \( P = 0.02 \)). A significant inverse association was found between DHEAS levels and stroke severity on admission, as expressed by NIHSS (\( r = -0.153 \), \( P = 0.019 \)). DHEAS remained a significant determinant of stroke severity in the multivariate model (\( r = -0.137 \), \( P = 0.02 \)) independently of systolic blood pressure, HDL levels, atrial fibrillation and hemorrhagic stroke subtype, 4-androstenedione and testosterone levels were significantly associated with 1-month mortality in the univariate analysis (\( P = 0.021 \) and 0.019 respectively). DHEAS levels were inversely associated with poor outcome, i.e. combined severe handicap (mRS \( \geq 4 \)) and death, 1 month post-stroke (\( P = 0.019 \)), although this did not remain significant in the multivariate model.

Conclusions

DHEAS levels are significantly associated with the severity of stroke on admission and short-term functional outcome among female stroke subjects. Further studies may clarify the role of DHEAS in cerebrovascular disease and the possible underlying mechanisms.

Endocrine Abstracts (2011) Vol 26
Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations

Bi Francou,1,2 J. Bouligand,1,2 A. Voican,1,3 L. Amaïzi,1 S. Brailly-Tabard,1,2 P. Leconte,1 J. Young,1,2 & A. Guichon-Manet1,2

1INSERM U939, Le Kremlin-Bicêtre, France; 2Hôpital Bicêtre, Le Kremlin-Bicêtre, France; 3Universitaet de medicina si farmacie, Craiova, Romania; 4Hôpital de Tours, Tours, France.

Introduction
TAC3/TACR3 mutations have been reported in normosmic congenital hypogonadotropic hypogonadism (nCHH). In the absence of animal models, studies of human neuroendocrine phenotypes associated with neurokinin B and NK3R receptor dysfunction can help to decipher the pathophysiology of this signaling pathway. Our objective was to characterize novel TACR3 mutations and to analyze neuroendocrine profiles in nCHH patients with TAC3/TACR3 biallelic mutations.

Results
From a cohort of 352 CHH, we selected 173 nCHH patients and identified eight TACR3 variants (one frameshift, four missense and three nonsense mutation) in five adults (four sporadic cases, one familial). Molecular analyses, modeling and functional studies demonstrated the pathogenic nature of four novel variants. Three patients with TAC3/TACR3 biallelic mutations had an apulsatile LH profile and low-frequency α-subunit pulses. Using the same assays, we found a statistically significant higher mean FSH/LH ratio in 11 patients with TAC3/TACR3 biallelic mutations than in nCHH patients with biallelic mutations in GPR54/KISS1R (n=4), GNRHR (n=2) or GNAS (n=1), and nCHH patients with no identified mutations (n=32) or mutations in KAL1 (n=19), FGFR1 (n=17) or PROK2/PROKR2 (n=14) (P<0.0001). Pulsatile GnRH administration to three patients harboring TAC3/TACR3 mutations increased α-subunit pulsatile frequency and reduced the FSH/LH ratio.

Conclusion
The gonadotropin axis dysfunction associated with nCHH due to TAC3/TACR3 mutations is related to a low GnRH pulsatile frequency leading to a low frequency of α-subunit pulses and to an elevated FSH/LH ratio. This ratio might be useful for pre-screening nCHH patients for TAC3/TACR3 mutations.

X-linked adrenoleukodystrophy: an intersection between Endocrinology and Neurology


Endocrinology, Diabetes and Metabolism Department, Coimbra’s University Hospital, Coimbra, Portugal

Introduction
X-linked adrenoleukodystrophy (X-ALD) is an important cause of primary adrenocortical insufficiency (PAI) in men. It’s characterized by impairment in peroxisomal degradation of very-long-chain-fatty-acids (VLCFA), leading to its peroxisomal degradation. X-ALD is a clinically heterogeneous disease. The reported case was diagnosed due to advanced neurologic disease; a low adrenal reserve was also found. In conclusion, adrenal reserve must be regularly assessed in X-ALD in order to early diagnose PAI and avoid an adrenal crisis triggered by an eventual stress. Likewise, an early diagnosis of X-ALD in PAI might prevent progression to neurologic disability.

GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis

M. Minoia1,2, E. Gentilini1,2, F. Tagliati1,2, D. Mole1,2, M. R. Ambrosio1,2, A. Baron1,2, E. degli Uberti1,2 & M. C. Zatelli1,2

1Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy; 2Pfizer Italia s.r.l., Roma, Italy.

GH and insulin-like growth factor 1 (IGF1) are known to promote breast carcinogenesis. Breast cancer (BC) incidence in not increased in female acromegalic patients, but mortality is greater as compared to general population. We previously demonstrated that GH/IGF1 excess influences BC response to therapy, possibly accounting for the increased mortality. We indeed showed that GH and IGF1 induce cell proliferation by inducing apoptosis, and reduces phosphorylation of GSK3-β (Ser9), a downstream target of GH pathway and a pharmacodynamic marker for PIs. Moreover, treatment with the compound induces translocation of PKCζ from the cytoplasm to the nucleus, and reduces CgA expression and secretion. These data support the hypothesis that the compound reduces cell viability by inducing apoptosis, with a mechanism likely involving GSK3ζ signaling. In addition, PI inhibits BON1 secretory activity, suggesting that PIs might represent a possible medical treatment of human pancreatic neuroendocrine tumors.
P182
glycoprotein pituitary hormones in the cerebrospinal fluid of patients with pituitary adenomas
M Cuculescu1, 2 C Capatind1, 2, A Caragea-Georgopoulou1, 2, A Dumitrascu1, 3, D Hortopan1, M Raica1, A M Cimpean1, S Constantinoiu1, 2, C Gandaev4, 1, 2. I. Parhon National Institute of Endocrinology, Bucharest, Romania; 2. Carol Davila University of Medicine and Pharmacy Endocrinology Department, Bucharest, Romania; 3. V. Babes University of Medicine and Pharmacy- Histology Department, Timisoara, Romania; 4. St. Maria Emergency Hospital General Surgery Department, Bucharest, Romania.

Introduction
The concentrations of pituitary hormones in the cerebrospinal fluid (CSF) are much lower that their serum counterpart.

Aim
To study the CSF access for pituitary glycoprotein hormones (GPH) in patients with pituitary adenomas (PA).

Patients and methods
In 221 cases submitted to transsphenoidal surgery for PA (85 acromegaly – ACM, 123). The SSE are larger. They showed contact with the CSF space but even lower mortality.

Results
In all types of pituitary tumors the mean CSF levels of GPH, i.e. (FSH 3.4 ± 0.56 IU/l, LH 1.94 ± 0.28 IU/l and TSH 1.78 IU/l ± 0.47). The serum levels do not follow this pattern. The tumors with positive immunostaining for FSH (12.2%), LH (9.5%), TSH (4.5%) did not influence more the CSF levels, but the size of the tumor does (mean diameters 30.4 mm ± 0.17 NFA, 28.1 mm ± 0.23 PRM, 19.9 mm ± 0.13 ACM). The intrasellar tumors (n = 41), without contact to the CSF, showed greater CSF hormone levels than controls, but less than suprasellar expanded tumors (SSE n = 123). The SSE are larger. They showed contact with the CSF space but even in that group the GPH-immunopositive tumors were not associated with higher CSF levels than GPH-immunonegative ones. This suggests that glycoprotein hormones that originate in pituitary cells are not directly released into the CSF, but, probably, through local blood vessels.

Conclusion
In conclusion, the presence of pituitary adenomas, pituitary glycoprotein hormones (from tumor or normal pituitary cells) pass easier in the CSF than GPH-immunonegative ones. This suggests that glycoprotein functions within the CNS influencing cognition, olfaction and a range of complex social interactions and behaviours. In addition, vasopressin has been reported in the mammalian retina and we investigated the location and expression of vasopressin and vasopressin receptors (V1a, V1b and V2) in the rat retina. Transgenic Wistar rats expressing vasopressin-enhanced green fluorescent protein (vasopressin-eGFP) and wild-type controls (1–6 months of age: n = 7; n = 5) provided the retinal tissue. This was either fixed and processed for immunostaining to reveal the location of vasopressin containing neurons, or was snap frozen on dry ice and processed for mRNA extraction and cDNA production to investigate vasopressin, V1a, V1b and V2 receptor expression. Retinal sections (200–350 μm) were used for live cell imaging of eGFP positive cells and to enable the extraction of mRNA from single cells for subsequent RT-PCR.

Live and fixed retinas imaged using epifluorescent and confocal microscopy (n = 4; n = 5) showed the cell bodies of vasopressin-eGFP neurons to be located primarily within the inner nuclear layer of the retina with projections to the output ganglion cell layer. A small number of eGFP positive cells were also located in the ganglion cell layer. The specific distribution and structure of the neurons are consistent with the cells being amacrine in nature. Whole retinas were found to express significant amounts of vasopressin, V1a, and V1b receptor. Single cell PCR revealed that eGFP labelled cells expressed message for vasopressin and the V1a receptor. In conclusion, the rat retina contains vasopressin positive neurons and message for V1a and V1b receptors. Further investigation will determine whether this is consistent with a physiological role for retinal vasopressin.

Methods
We examined HPAA basal function (ACTH and cortisol concentrations measured hourly from 2200 h to 0900 h) and sensitivity (overnight low-dose (0.5 mg) dexamethasone suppression test-DST, n = 50) in men with chronic war-related PTSD (group PTSD, N = 59) in comparison to healthy non-traumatized men (group Healthy, N = 53). Participants with depressive disorder and other major psychiatric and somatic comorbidities were excluded from the study. There were no group differences in age (PTSD: 44.1 (9.9) years; Healthy: 42.2 (9.7) years; P = 0.28) and body mass index (PTSD: 26.9 (3.6) kg/m²; Healthy: 27.0 (3.6) kg/m²; P = 0.92).

Results
During the period from 2200 h to 0900 h, PTSD had lower ACTH (P = 0.043) and the same cortisol concentration (P = 0.37) while in lower ACTH/cortisol ratio (P = 0.029) in comparison to Healthy group. There were no group differences either in ACTH secretion amplitude (P = 0.63) or in cortisol secretion amplitude (P = 0.24). In comparison to Healthy, PTSD showed enhanced cortisol suppression during DST, n = 50 (P = 0.030).

Conclusion
Results of our study implicate that patients with chronic war-related PTSD without somatic comorbidities and depression, in comparison to healthy non-traumatized subjects of the same gender, age and body mass index, have concomitantly enhanced HPAA axis sensitivity to cortisol at the level of anterior pituitary and enhanced adrenal reactivity to ACTH. It is yet to be determined which of these disturbances is primary and which is compensatory.
disease (AD). Animal data shows that leptin may be implicated in the pathophysiology of AD. The aim of this study was to examine if there is any differences in serum leptin levels between patients with AD and normal controls.

Methods

 Ninety patients with AD and 95 normal controls matched for age and gender were included. The diagnosis of Alzheimer dementia was based on standard criteria provided by the ICD-10 system.

Results

 Serum leptin levels were significantly lower in AD patients compared to normal controls (17.89 ± 8.28) in AD patients versus 26.82 ± 17.77 in normal controls, P < 0.001, Mann–Whitney U).

Discussion

Our findings demonstrate that the modulatory role of estrogen in glucose metabolism is partly mediated via the hypothalamus and sympathetic signaling to the liver. Within the hypothalamus the PVN and VMH have differential roles in E2’s effects on glucose metabolism.

---

**P187**

The role of the Diphereline (Triptoreline) test in the etiological diagnosis of gonadal dysfunction

Ruxandra Dobrescu1, Roxana Militaru1, Simona Jercalau1, Vadim Gavan1, Anda Caragheorgheopol1 & Corin Badui1

1Institute of Endocrinology, Bucharest, Romania; 2University of Medicine and Pharmacy, Bucharest, Romania.

Objective

To assess the usefulness of the GnRH analogue Diphereline (Triptoreline) in the evaluation of central gonadal dysfunction in children and adults.

Methods

A 18-month retrospective study of dynamic testing of the hypothalamic pituitary gonadal axis in 36 patients, 10 prepubescent children (<13 years for girls and 14 years for boys) and 26 postpubescent subjects. The children were investigated for disorders of sexual development while the adults presented with clinical hypogonadism. In order to assess the response of the gonadal axis to the GnRH analogue Diphereline, 100 μg were subcutaneously injected. FSH, LH were sampled basally and after 4 h, while testosterone/estradiol were sampled after 24 h.

Results

Of the 26 postpubescent patients, 3 men presenting pituitary adenomas were shown to have hypergonadotropic hypogonadism, 15 patients had hypogonadotropic hypogonadism of probable pituitary origin and 8 had hypothalamic disorders. In the pituitary group the results showed a diminished response to the GnRH test in FSH, LH and the periphery, significant only for FSH (1.31 ± 1.46 to 2.72 ± 3.04 IU/l, P = 0.02). In the group with hypothalamic hypogonadism there was a significant FSH increase from an average value of 2.07 ± 0.62 to 10.75 ± 0.02, while the peripheral answer was an increase in testosterone from 2.24 ± 1.84 to 3.10 ± 1.61 ng/ml and an increase in estradiol from 14.68 ± 3.45 to 19.36 ± 13.51 ng/ml (P = NS). The response to GnRH was significantly higher for the hypothalamic then the pituitary group for both LH (P = 0.03) and FSH (P = 0.04), consistent with the original etiological hypothesis and pathophysiological mechanism. All three patients with hypergonadotropic hypogonadism had high basal LH or FSH levels, with further increase after stimulation, without reaching statistical significance. In the prepubescent group, aged 4–13 years, the subgroup aged < 10 had an increase in LH and FSH only, while the older children had both central and peripheral responses, consistent with gonadal maturation. A similar response in a 7-year-old girl helped establish the diagnosis of precocious puberty. There was no response in a 13-year-old boy with Prader Willi syndrome.

Conclusion

Although not diagnostic in itself, GnRH testing can help shed light on the aetiology of hypogonadotropic hypogonadism syndromes in complex situations. Diphereline can be used as a surrogate test.
each polymorphism with respect to improvement during pregnancy and post-partum flare. The area under the curve (AUC) was calculated for both time periods, reflecting total disease activity.

**Results**

During pregnancy, carriers of the Bcl1 polymorphism had a lower disease activity compared to carriers of the 9β minor allele. These differences were most pronounced in patients treated with glucocorticoids. Non-carriers had a disease course between those of Bcl1 and 9β carriers. Post-partum, disease activity increased in carriers of the 9β polymorphism, whereas carriers of the Bcl1 minor allele had less RA reactivation. The AUC of disease activity in the post-partum period was significantly lower for Bcl1 carriers when compared with 9β carriers.

**Conclusions**

Functional GR polymorphisms may influence RA disease course during and directly after pregnancy. Carriers of the glucocorticoid-sensitive GR polymorphism Bcl1 may benefit most from treatment with exogenous glucocorticoids.

---

**P189**

Caberigoline influence on antioxidative protection enzymes activity in complex therapy in patients with non-functioning pituitary adenoma (NFPa)

S I Ismailov, Z Yu Khaimova & D Sh Kholova

Republican Specialized Scientific-Practical Medical Center of Endocrinology under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.

**Aim**

To evaluate influence of caberigoline on LAO and BAS processes in treatment of patients with NFPa.

**Materials and methods**

We included 64 patients with NFPA in the study. Mean age was 43.6 ± 3.84 years (range 30–55 years). Of 64 patients 26 (40.6%) were men and 38 (59.4%) were women. Duration of the disease from diagnosis based on MRI constituted 1–15 years. Severity criteria used in the evaluation were LH, FSH and prolactin (PRL) growth as well as progression of neurological and vision problems.

**Results and discussion**

Before treatment FSH, LH and PRL levels in patients with NFPA were 18.3, 20.9, and 50.4% (P < 0.05, P < 0.01, P < 0.001) higher then in controls (10 healthy men and 10 healthy women). The same time there was noticed different concentration of CL and MDA which defined depending on the duration of the disease and tumor size. We revealed different variants of BAS enzymes activity such as SOD, CT, GP and GR. In patients with NFPA with the duration of the disease from 8 to 15 years LAO high intensity associated with inhibition of BAS enzymes. 0.25 caberigoline use during 3 months associated with inhibition of FSH, LH, 15.8% (P < 0.05) decrease in PRL levels.

**Conclusion**

Caberigoline increases treatment effect in patients with NFPA by decreasing pituitary hormones levels such as FSH, LH and PRL. However, it practically does not have influence on BAS enzymes activity such as SOD, CT, GP and GR and this approves the add of antioxidative therapy to main treatment.

---

**P190**

The role of centrally applied ghrelin on hypothalamic AMPK activity and pituitary–adrenal responses in differently fed rats

Darko Stevanovic1, Verica Milivojevic2, Dejan Nesic3, Dragan Micic3, Mirjana Sumarac-Dumanovic3, Vera Popovic2 & Vesna Starcevic1

1Institute of Medical Physiology, School of Medicine, University of Belgrade, Belgrade, Serbia; 2Institute for Biological Research Sinisa Stankovic, University of Belgrade, Belgrade, Serbia; 3Institute of Endocrinology, Diabetes and Diseases of Metabolism, School of Medicine, University of Belgrade, Belgrade, Serbia.

The pandemic increase of obesity, malnutrition and associated comorbidities encouraged intensive studies on energy balance control. Ghrelin is a brain-gut orexigenic hormone that is involved in both the short-term and long-term regulation of energy homeostasis. The aim of this research was to investigate the role of centrally applied ghrelin on the pituitary morphofunctional features and corticosterone secretion in normal-fed, food-restricted and obese 8 weeks old Wistar male rats, as well as to examine changes in their hypothalamic AMP-activated protein kinase (AMPK) activity. After 4 weeks of normal feeding (NF group), progressive food restriction (FR group) and high-fat diet (HF group), rats received 5 daily injections of ghrelin and/or saline i.c.v. Blood samples, hypothalami and pituitaries were excised for further analyses 1 h after the last i.c.v. injection. Results showed that i.c.v. ghrelin had orexigenic effect in all examined groups, and it increased pituitary corticosteroid cell volumes and their secretion. Corticosterone blood levels were elevated after central ghrelin treatment in NF and FR groups, while remained unchanged in HF group. Hypothalamic AMPK activity was increased in FR group and decreased in HF group when compared to NF group, and i.c.v. ghrelin treatment increased AMPK phosphorylation in NF and HF groups, while had no effect in FR group. In conclusion, centrally applied ghrelin had significant effect in energy balance regulation, mostly under preserved energy homeostasis and increased hypothalamic AMPK activity in normal-fed and obese rats.

---

**P191**

The treatment with dopamine agonists are not associated with increased prevalence of cardiac-valve regurgitation in patients with prolactinomas and acromegalia

P191

M Puma, B Lecumberri, A Fernández, F Domínguez, M Martín, M Yangüela, L Pallardo & C Alvarez

La Paz University Hospital, Madrid, Spain.

**Background**

Dopamine agonists are first-line agents for the treatment of prolactinomas and sometimes are used in patients with acromegalia. There is evidence that these drugs, especially cabergoline, are associated with an increased risk of new cardiac valve regurgitation in patients treated for Parkinson’s disease.

**Objective**

Our objective was to evaluate the prevalence of cardiac valve regurgitation in patients with prolactinomas and acromegalia treated with dopamine agonists.

**Design and settings**

An observational, case–control study was conducted at a University Hospital.

**Patients**

81 treated patients, 37 with microprolactinomas, 31 with macroprolactinomas and 13 with acromegalia; 61 were treated with cabergoline, 16 with bromocriptine and 4 with quinagolide. We used an age-matched control group of fourteen patients diagnosed of prolactinomas before starting treatment with dopamine agonists.

**Results**

Patients receiving a cumulative dose above the media were compared with those receiving a cumulative dose below it. The prevalence of cardiac-valve regurgitation of aortic (19.5 and 15%, P = 0.77); mitral (19.5 and 22.5%, P = 0.79); and tricuspid (9.8 and 12.5%, P = 0.73); valves was similar. When treated patients were compared with control patients, the prevalence of cardiac-valve regurgitation of aortic (17% and 0%, P = 0.12); mitral (21 and 14.3%, P = 0.72); and tricuspid (11.1 and 14.3%, P = 0.66); valves was also similar. There were no cases of pulmonic regurgitation in all patients.

**Conclusion**

The prevalence of cardiac-valve regurgitation was similar in patients with higher and lower cumulative doses of dopamine agonists. The result was the same in treated patients when compared with control patients. This study shows results which coincide with some publications. Nevertheless, it also found data that differ from other studies.
survival, and inflammation. Despite a favorable body composition profile, acromegalic patients present insulin resistance, increased cardiovascular risk, and higher incidence of secondary tumors.

**Aim**

Based on its relation to glucose and lipid metabolism and inflammation we hypothesized that NAMPT could be related to the metabolic disturbances in patients with acromegaly.

**Methods**

Body composition, glucose metabolism (glucose, insulin, HOMA-IR, HOMA-B), leptin and NAMPT levels were measured in 47 patients with active acromegaly (26 women, 21 men) and 25 matched control subjects. *In vitro* effects of GH/IGF1 on NAMPT expression in peripheral blood mononuclear cells (PBMC), hepatocytes, osteoblasts, human subcutaneous (SCA) and visceral (VA) adipocytes were studied.

**Results**

NAMPT was markedly increased in acromegaly in both sexes (P<0.01). NAMPT levels correlated, before and following adjustment for age, gender and leptin, negatively with total body fat mass (% fat: r = −0.35, P = 0.03) and arms fat mass (% fat: r = −0.37, P = 0.02) and positively with total lean mass (% lean: r = 0.35, P = 0.03) and arms lean mass (% lean: r = 0.42, P = 0.008). No correlation between NAMPT and glucose metabolic parameters was demonstrated. In *in vitro* studies revealed that GH increases NAMPT expression during differentiation of subcutaneous (SCA) and visceral (VA) preadipocytes and in mature SCA, but not in mature VA, PBMC, osteoblasts or hepatocytes.

**Conclusions**

NAMPT levels are increased in active acromegaly with no relation to glucose metabolism. *In vitro* findings may suggest that GH directly could induce NAMPT expression in SCA, and the positive correlation of NAMPT with lean mass suggests that skeletal muscles could be another source of NAMPT in active acromegaly.

---

**P194**

**Immunopositive ACTH cells in juvenile female rats after treatment with estradiol**

V Milosevic1, V Ajdžanovic1, D Todorovic2, B Sosic-Jurjevic1, B Filipovic1, N Nestorovic1, J Pantelic1 & M Sekulic1

1Institute for Biological Research, Sinisa Stankovic', University of Belgrade, Belgrade, Serbia; 2School of Medicine, University of Kragujevac, Kragujevac, Serbia.

It was shown that estrogens decreased the POMC gene expression level in female rats. This aim of the present study was to examine the morphometric parameters of immunohistochemically labeled ACTH cells in juvenile female rat pituitaries after estradiol dipropionate (EDP) treatment. The females in juvenile period (16th day) were divided into two groups, each of seven animals. The experimental group received five injections of EDP (i.p. 0.25 mg/kg b.w.) every second day from the 4th to 14th day after birth. The controls were treated by the same schedule with equivalent volume of sterile olive oil. All animals were sacrificed 24 h after the last treatment. Immunopositive ACTH-producing cells were studied using the peroxidase-anti-peroxidase immunohistochemical procedure. The cell volume, nuclear volume and volume density of ACTH cells were determined by the stereological method. The significance of differences between mean values was estimated by Student’s *t*-test. In juvenile females treated with EDP absolute and relative pituitary weights were significantly increased (P<0.05) by 446.7 and 447.4% respectively, in comparison with the controls. The ACTH cell and nuclei volume as well as their volume density were significantly decreased by 6.4, 33.3 and 46.2% respectively, compared to the controls. In juvenile females immunohistochemically labeled ACTH cells were stellate shaped with the cytoplasmic processes among neighbouring cells, localized between the capillaries. The nuclei follow the shape of the cell body. Small, specific secretory granules were distributed mainly at the periphery of the cytoplasm. The shape and localization of ACTH immunoreactive cells in EDP-treated female rats were not significantly changed in comparison with controls. In conclusion, the application of EDP caused the significant decrease of morphometric parameters of ACTH cells in juvenile female rats.

---

**P193**

**Pituitary mycosis complicating a Cushing’s macroadenoma**

V Edirisinghe1, P Goulden1, J Powrie2 & J Kumar

1Watford General Hospital, Watford, UK; 2Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 3Maidstone Hospital, Maidstone, UK.

**Introduction**

A 59-year-old gentleman with longstanding poorly controlled type 2 diabetes mellitus, obesity, hypertension, obstructive sleep apnoea, depression and type 2 respiratory failure was seen in diabetes review clinic and noted to have truncal obesity, moon facies and wasting of the proximal muscles.

**Investigations**

Urinary free cortisol was 782 nmol/24 h (NR < 200). Midnight cortisol was 595 and 532 nmol/l on consecutive days. After low dose dexamethasone suppression test cortisol was 580 nmol/l with ACTH of 130 nmol/l, and cortisol was 159 nmol/l after high dose test. MRI showed a pituitary macroadenoma occupying the pituitary fossa and most of the sphenoid sinus. Trans-sphenoidal hypophysectomy was carried out, and cortisol post-operatively was 60–142 nmol/l. Histology found strong ACTH staining (Ki67 index < 3%), and unexpectedly, fungal elements indicating significant infection. The patient was given 4 weeks voriconazole.

Post-operatively regular hydrocortisone was prescribed. The patient lost 20 kg in weight, antihypertensives and insulin requirements reduced by 50% and HbA1c improved from 11.4 to 7.9%. Follow-up scan showed a good surgical result.

**Conclusions**

There is increased incidence of aspergillosis and fungal infections in Cushing’s syndrome. It is postulated this is due to several effects of glucocorticoids, including reduced lymphocytic activity and proliferation, impaired neutrophilic phagocytosis and impaired macrophage formation of nitric oxide. In addition, glucocorticoids have been shown to directly increase growth of fungal hyphae. Primary pituitary aspergillosis is rarely reported in the literature, all of which have been diagnosed post-operatively and related to sphenoidal sinusitis. Sphenoid sinus mass secondary to cryptococcosis and other species have also been reported. If identified, treatment of fungal granuloma should be carried out before removal of pituitary adenomas, to prevent intracranial spread.

---

**P195**

**A case of an ectopic prolactinoma**

I Yildirim Simsir, G Unal Kocabas, O Ozdemir, F B Ozturk Ceyhan, B P Suer Yurekli, M Erdogan & A G Ogen

Ege University Medical Faculty, Bornova/Izmir, Turkey.

The most common cause of hyperprolactinemia is a prolactinoma in women after pregnancy is excluded. A 34-year-old female presented to our clinic with a 1.5 year history of secondary amenorrhea, galactorrhea and malaise. Prolactin (PRL) level was found to be 151.89 ng/ml. Pituitary imaging was reported to be normal. An examination of the patient revealed that PRL level was still high so the dose of cabergoline was further increased and subsequently, bromocriptine was added to the treatment. There was no reduction in PRL levels in controls. A scanning was performed to look for an ectopic focus. Abdominal computerized tomography revealed a heterogenous mass lesion originating from the uterus. Octreotide scintigraphy was performed and we observed an involvement consistent with the mass in the uterus. The patient underwent abdominal total hysterectomy. PRL dropped to 0.4 ng/ml the next day after the operation. The pathology result was a low-grade malignant mesenchymal tumor. Prolactin was found to be immunohistochemically negative. However, galactorrhea disappeared postoperative and PRL levels are still low. Elevated levels of PRL, resistant to bromocriptine and cabergoline, rapidly returned to normal after hysterectomy, which obviously indicates that hyperprolactinemia was associated with the myoma of the uterus. Other than pituitary PRL secretion, ectopic hyperprolactinemia may be caused by the presence of a pituitary tissue in the ectopic focus or, as in our case, secretion of dopamine antagonist or PRL stimulating factors from the tumor tissue, which is unable to detect.
Coping strategies in patients after treatment for functioning or non-functioning pituitary adenomas

Leiden University Medical Center, Leiden, The Netherlands.

Context and objective
Coping strategies may affect quality of life (QoL), which is decreased in patients after treatment for Cushing’s disease, acromegaly, or non-functioning macro- adenomas (NFMA). We aimed to explore coping strategies in these patients, since this has never been done before.

Design
A cross sectional study.

Subjects
We included patients treated for Cushing’s disease (n=42), for acromegaly (n=80), and for NFMA (n=61). These patients were compared with three reference populations: an a-select sample from the Dutch population (n=712), patients with chronic pain (n=59), and patients receiving primary care psychology services (n=525). Furthermore, the three patient groups were compared with each other. Coping strategies were assessed by the Utrecht Coping List. The protocol was approved by the Medical Ethics Committee.

Results
Compared to the a-select sample, patients with pituitary adenomas reported less active coping (P<0.0001), sought less social support (P<0.0001), and reported more avoidance coping (P=0.008). In contrast, patients treated for pituitary adenomas reported somewhat better coping strategies than patients with chronic pain and those with psychological disease. When patients with different pituitary adenomas were compared, patients treated for Cushing’s disease sought more social support than patients treated for NFMA (P=0.035).

Conclusions
Patients treated for pituitary adenomas display different and less effective coping strategies compared with healthy controls. A targeted intervention might help to stimulate patients to use a more active coping strategy and to seek social support, instead of an avoiding coping strategy. This might, in turn, improve their QoL.

P197
Polycystic ovary syndrome and prolactinoma association

J Marti
Hospital Zumarraga, Zumarraga/Guipuzcoa, Spain.

Introduction
Prolactinoma account for 40% of all pituitary tumors. It is the most common cause of hyperprolactinemia. Infertility, galactorrhea and hirsutism are the significant symptoms. Polycystic ovary syndrome affects the 5–10% of the women in reproductive age. The most common symptoms are irregular menses, hirsutism and infertility. However, prolactinoma and PCOS association is rare. A case of PCOS and prolactinoma is reported.

Case
A 21-year-old woman was admitted to internal medicine outpatient clinic for irregular menses and hirsutism for 2 years. Physical examination, revealed hirsutism (Ferriman-Gallwey score 12 points). Her laboratory results were as follows: prolactin level 70 ng/ml (range: 1.8–20.3 ng/ml), testosterone 21.9 pg/ml (normal <12 pg/ml). TSH, free T4, free T3, kidney and liver function tests, estrogens, DHEAS levels were normal. Pelvic ultrasonography was correlated with polycystic ovary syndrome. Pituitary MRI showed 5 × 6 mm microadenoma. Carbegolide 0.25 mg(Dostinex) once a week and drospirenone/etinilestradiol (Yasminelle) daily, were started.

After 6 months of carbegolide and drospirenone/etinilestradiol treatment their prolactin and testosterone levels were normal and no adenoma was detected in pituitary MRI.

Discussion
The patient was admitted to our clinic because of irregular menses, hirsutism, pelvic US result and pituitary MRI lead to PCOS and prolactinoma association.

In 15–20% of the PCOS patients mild elevated prolactin levels can be functionally found without prolactinoma. Persistent high prolactin levels in PCOS of reproductive age women, prolactinoma must be taken into account after excluding causes such as drugs and hypothyroidism.

Conclusion
PCOS and prolactinoma association should be taken into account in PCOS cases with mild hyperprolactinemia.

P198
Effects on metabolic parameters after 12-month treatment with a new once-a-week sustained release recombinant growth hormone (LB03002) in adult patients with GH deficiency (GHD)

J Roemmrich, A Gockel, B Otto, M Billingermaier & J Schopohl
Medizinische Klinik Innenstadt, Munich, Germany.

Introduction
GH substitution in GH deficiency (GHD) must be subcutaneously administered daily. Recently, a new sustained release formulation of GH (LB03002) has been developed which has to be injected only once per week. As a sub-study to the double-blind, randomized, placebo-controlled, multicenter, phase-III study we performed this prospective study to evaluate influences of the new GH formulation on metabolic parameters and the hormones leptin and ghrelin in adult patients with GHD.

Methods
Eleven patients with GHD (4f/7m, median age 58 years (29–69 years)) without any GH therapy for at least 6 months were included in the study. Eight patients were treated with LB03002 for 12 months, three patients started with placebo for 6 months and were then switched to LB03002 for another 6 months. A 3 h oral glucose tolerance test (OGTT) was performed at study entry and at study end. Additionally, IGF1, lipid parameters including cholesterol, LDL, HDL, and triglycerides, leptin, ghrelin, HbA1c and C-peptide were measured. Body composition was evaluated by dual-energy-X-ray-absorptiometry, waist/hip (WHR) and waist/height (WHHR) ratio by tape.

Results
Multiple of upper limit of normal (xULN) of IGF1 0.23 (0.90–4.0) vs 0.71 (0.4–1.1), P<0.001, WHR 0.98 (0.86–1.04) vs 1.01 (0.86–1.05), P<0.05 and ghrelin levels (119.8 ng/l (67.7–266.6) vs 137 ng/l (67–289.5), P<0.05) were significantly higher and fat mass (34.7% (20.4–49.2) vs 32.4% (16.7–48.5), P<0.05) and levins levels (11.2 μg/l (3.3–55.7) vs (7.05 μg/l (2.4–54.3), P<0.05) were significantly lower at study end. Glucose and insulin levels during OGTT as well as insulin resistance (HOMA-IR), insulin sensitivity (SI), β-cell function (HOMA-β), C-peptide and HbA1c were not statistically significantly different before and after GH substitution, neither were BMI, WHR, bone-mineral-density (BMD) and lipid parameters.

Conclusion
Substitution with LB03002 showed statistically significant reduction of fat mass, which leads to reduced levins levels and increased ghrelin levels but does not seem to influence glucose and lipid metabolism.

P199
Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency

M Elbornsson, G Götherström, B-A Bengtsson, G Johansson & J Svensson
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Objective
Few studies have determined the effects of more than 5–10 years of GH replacement in adults on bone mass and density.

Design/Participants
In this prospective, single-centre, open-label study, the effects of 15 years of GH replacement on bone mineral content (BMC) and bone mineral density (BMD) were determined in 126 hypopituitary adults (72 men) with adult onset GHD deficiency (GHD). Mean age was 49.4 (range 22–74) years at study start. BMC and BMD were measured using dual X-ray absorptiometry (DXA).

Results
The mean initial GH dose of 0.63 (S.E.M. 0.03) mg/day was gradually lowered and after 15 years the mean dose was 0.01 (0.01) mg/day. The mean serum insulin-like growth factor 1 (IGF1) SDS increased from −1.69 (0.11) at baseline to 0.63 (0.16) at study end (P<0.001 versus baseline). The 15 years of GH replacement induced a sustained increase in total body BMC (+5%; P<0.001) and BMD (+2%; P<0.001). Lumbar (L2-L4) spine BMC was increased by 9% (P<0.001) and BMD by 5% (P<0.001). In femur neck a peak increase in BMC and BMD of 7 and 3% respectively was observed after 7 years (both P<0.001). After 15 years, femur neck BMC was still 5% above the baseline value (P<0.05), whereas femur neck BMD had returned to the baseline level. In most variables reflecting bone mass and density, men had a more marked response to GH replacement than women.

Conclusions
Fifteen-year GH replacement in GHD adults induced a sustained increase in total body and lumbar (L2-L4) spine BMC and BMD. In the femur neck, BMC and BMD increased progressively up to 7 years and then slightly, but not fully, decreased towards baseline values.

Endocrine Abstracts (2011) Vol 26
Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult onset GH deficiency

M Elbornsson, G Götherström, C Franco, B-Å Bengtsson, G Johannsson & J Svensson
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Context
The effect of GH replacement in elderly GH deficient (GHD) adults on bone mineral density (BMD) is not known.

Objective
In this prospective, single-centre, open-label study, the effects of 3-year GH replacement were determined in 45 GHD adults above 65 years of age and in 45 younger GHD patients with a mean age of 39.5 (S.D.M. 1.1) years. All patients had adult onset disease and both groups were comparable in terms of number of anterior pituitary hormonal deficiencies, gender, body mass index (BMI), and waist:hip ratio. BMD was measured using dual energy X-ray absorptiometry (DXA).

Results
The mean maintenance dose of GH was 0.24 (0.02) mg/day in the elderly patients and 0.33 (0.02) mg/day in the younger GHD patients. At baseline, absolute values of total body and lumbar (L2–L4) spine BMD were similar in both study groups whereas femur neck BMD was lower in the elderly as compared to the younger patients (0.91 (0.02) vs 1.02 (0.02) g/cm²; P < 0.001). However, in the elderly GHD patients, Z-scores at baseline were approximately zero. After 3 years of GH replacement, total body BMD was unchanged compared to baseline in both study groups. The 3-year GH replacement significantly increased lumbar (L2–L4) spine BMD and femur neck BMD by 4% and 2%, respectively, in the elderly patients and by 5% and 3%, respectively, in the younger patients. There were no statistical differences between groups in the treatment responses. At study end, femur neck BMD was still lower in the elderly patients.

Conclusions
This study shows that GH replacement increases lumbar (L2–L4) spine and femur neck BMD in elderly adults with adult onset GHD. This supports that GH replacement is useful in elderly GHD patients.

Evaluation of aortic stiffness in the acromegaly patients with remission

Eylem Karatay1, Erman Cakal2, Gulsum Gonulalan3, Mehmet Dogan4, Nujen Colin Bozkurt5, Mustafa Ozbek6, & Tuncay Delibasi7
1Department of Internal Medicine, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; 2Department of Endocrinology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; 3Department of Cardiology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Objective
Cardiovascular diseases (CVD) are the most important cause of mortality in acromegaly patients. Noninvasive assessment of aortic stiffness which can be used as an predictor of atherosclerosis, may be of benefit in acromegaly patients for early diagnosis of CVD. We evaluated the aortic elasticity parameters of acromegaly patients in remission and compared with healthy controls.

Methods and results
Study subjects consisted of 20 patients with acromegaly in remission (12 females, 8 males, mean age 43.7 ± 11.5 years) and 20 age-matched controls (12 females, 8 males, mean age 38.7 ± 6.4 years). Parameters of aortic elasticity such as aortic strain, aortic dispensability and stiffness index beta were measured by echocardiography and calculated by using standard formulas. Although aortic strain rate was lower in acromegaly group than control subjects it was not statistically different (13.1 ± 7.0 vs 16.6 ± 4.1, P = 0.064). However it was found that aortic stiffness index beta was significantly higher and dispensability was significantly lower in acromegaly patients compared to control subjects (respectively; 4.0 (1.2–12.3) vs 2.6 (1.4–5.8), P = 0.009 and 0.5 (0.2–1.9) vs 0.8 (0.4–1.5), P = 0.006). Systolic and diastolic blood pressure, diameters of aortic measured in systole and diastole, total and LDL cholesterol levels were found to be effective independent variants contributing to aortic stiffness.

Conclusion
The assessment of aortic stiffness by echocardiography in terms of parameters mentioned above, were found to be statistically different in patients with acromegaly who were in remission. According to these results conducting to increased aortic stiffness, it can be suggested that cardiovascular risk increased in acromegaly patients and ongoing even in remission period.

Baseline characteristics and effects of 10 years of GH replacement therapy in adults previously treated with pituitary irradiation therapy

M Elbornsson, G Götherström, B-Å Bengtsson, G Johannsson & J Svensson
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Context
Little is known of the importance of previous irradiation therapy for baseline characteristics and responsiveness to GH replacement in GH deficient (GHD) adults.

Objective/design/patients
In this prospective, single-centre, open-label study, the effects of 10-year GH replacement on metabolic variables and safety were determined in 18 GHD adults that had previously received pituitary irradiation therapy and 18 non-irradiated GHD patients. All patients had adult onset disease and complete deficiency of anterior pituitary hormones. Both groups were comparable in terms of gender, body mass index (BMI), and waist:hip ratio.

Results
At baseline, the GHD patients previously treated with pituitary irradiation therapy had higher serum levels of triglycerides (TG) and insulin and lower serum HDL-cholesterol level than non-irradiated patients (all P < 0.05). The 10-year GH replacement improved serum lipid profile in both study groups, and in both groups variables reflecting glucose homeostasis responded similarly to GH replacement. At study end, serum HDL-cholesterol level was still lower in the GHD patients that had previously received pituitary irradiation therapy whereas serum TG and insulin levels were similar in both groups. During the 10-year GH replacement, four patients previously treated with pituitary irradiation therapy had cardiac events (two fatal) and one had a non-fatal cerebral infarction whereas only one non-fatal vascular event occurred in the non-irradiated patients.

Conclusions
GHD patients that have previously received pituitary irradiation therapy display a more severely impaired metabolic profile at baseline compared with non-irradiated patients. GH replacement can partly, but not fully, reverse these metabolic aberrations. This may be of importance for the more marked cardiovascular morbidity observed in this group.

Effects of dopamine agonist on heart and lung in patients receiving dopamine agonist due to hyperprolactinemia

Cigdem Tacyildiz, Hatice Sebila Dokmetas, Fatih Kilicli, Tamer Dogan & Hasan Arslan Turak
Cumhuriyet University, Sivas, Turkey.

Introduction
Dopamine agonists such as cabergoline and bromocriptine are used in the treatment of hyperprolactinemia to provide normoprolactinemia, to improve gonadal functions and to decrease the size of tumour if there is. Besides common side effects, fibrosis is another rare side effect of dopamine agonists. Long-term use of these drugs has been reported to cause fibrotic changes in heart valves. In addition, there are a few case reports about dopamine agonist-related pleural and pulmonary fibrosis. Patients and methods
In this study, we investigated whether cabergoline and bromocriptine cause fibrosis in heart valves and lungs. The study included 50 (47 females and 3 males) patients treated with cabergoline and/or bromocriptine for hyperprolactinemia and 30 (26 females and 4 males) healthy subjects. In all subjects, transthoracic echocardiography, pulmonary function tests and high resolution computed tomography of the chest were performed.

Results
In the patient group, the mean cabergoline dose was 139 ± 104.53 mg while the mean bromocriptine dose was 3877.77 ± 3418.04 mg. The mean treatment duration was 35.26 ± 23.24 months. Compared to controls, mild tricuspid regurgitation and mitral regurgitation were significantly more frequent in patients taking cabergoline and bromocriptine. Pulmonary fibrosis developed in nine (18%) patients, but statistically there was no difference between the two groups.
Conclusion
Transthoracic echocardiography may be useful for early detection of cardiac valvular fibrosis in patients treated with dopamine agonists. Also, pulmonary fibrosis should be kept in mind and symptomatic patients should be evaluated using radiological methods.

P204
Efficacy of transsphenoidal surgery in treatment of Cushing’s disease: factors influencing postsurgical outcome
Natalia Molitvoslovsova, Elizaveta Mamedova, Andrey Grigoryev, Galina Kolesnikova, Lyudmila Rozhinskaya, Svetlana Arapova & Evgeniya Marova
Research Center for Endocrinology, Moscow, Russian Federation.

The study analyses direct postoperative and long-term results of surgical treatment of ACTH-secreting pituitary adenomas in 158 patients, operated between 2004 and 2009. There were 143 (91%) female and 15 (9%) male. The mean age of the patients was 36 years, s.d. 10.7. In all patients the diagnosis of Cushing’s disease was confirmed by high dose dexamethasone suppression test.
Preoperative hormonal evaluation: ACTH (0800 h), pg/ml (Me-78.5 (50.5–250)); ACTH (11 pm), pg/ml (Me-69.9 (43.2–1099)), cortisol (0800 h), nmol/l (Me-707.5 (553–884)), cortisol (2300 h), nmol/l (Me-584.5 (425–725)), urinary free cortisol (UFC), nmol/l (Me-1352 (936.7–2387.5)).

In the early postoperative period morning serum cortisol level <140 nmol/l was achieved in 69%; normalization of morning and midnight serum cortisol and UFC – in 86%. In 6 months postoperative normalization of UFC level was 79%, in 12 months – 81.3%, in 24 months – 71%. Normalization of UFC level and morning serum cortisol level during low-dose dexamethasone test <50 nmol/l was reached in 72.5, 50 and 55.6% after 6, 12 and 24 months after surgery respectively.
Morning serum cortisol level in the early postoperative period correlated with serum cortisol level in 6 (P=0.00014) and 12 (P=0.0071) months after operation and also with UFC level in 6 (P=0.000007), 12 (P=0.0017) and 24 (P=0.017) months after operation. Such factors as longer duration of the disease (P=0.04), tumor invasiveness (P=0.0087), lower decrease rate of serum cortisol level immediately after surgery (P=0.000025, 0.002 and 0.005 for 6, 12 and 24 months after surgery respectively) and lower decrease rate of ACTH level immediately after surgery (P=0.006, 0.0003 and 0.00305 for 6, 12 and 24 months after surgery respectively) were shown to be predictors for unfavourable postsurgical prognosis. Age, adenoma size and detection of mitoses on pathology in our study did not influence surgical outcome.

P205
LHRH-antagonist cetrorelix may reduce postmenopausal flushing
P M van Gastel, M van der Zanden, D Telting, M Filius, L Bantsi & H de Boer
Rijnstate Hospital, Arnhem, The Netherlands.

Background
Estrogen replacement therapy is the most effective treatment for postmenopausal (PMP) flushing, but its use is often contraindicated. An effective and safe alternative is urgently needed.

Aim
To explore the effects of the LHRH receptor antagonist cetrorelix in women with severe PMP flushing who have a mean daily flush score > 15.

Methods
Open-label treatment with cetrorelix 250 μg twice a day in nine women with severe PMP flushing, for a period of 4–6 weeks. The response to treatment was evaluated by monitoring serum gonadotropin levels, flush scores, and quality of life.

Results
At baseline, the mean daily flush score was 35.9 ± 2.0 (range 29–44). All subjects demonstrated a decrease in serum LH and FSH during treatment, but premenopausal levels of both gonadotropins were reached in only two subjects. The mean daily flush score decreased by 39.6 ± 8.4% (P < 0.005).

Conclusion
Severe PMP flushing can be reduced by LHRH receptor blockade. The data suggest that a longer treatment period is required to capture the maximal effect.

P206
0-6-methylguanine-DNA methyl transferase (MGMT) immunoreexpression in GH secreting pituitary adenomas and it's correlation with Ki-67 labeling index (Ki-67 LI)
Sajid Shah Zuhar1, Canan Tanki1, Ozcan Karaman1, Ezra Cil1, Selvinaz Velet1, Feyza Yener Ozturk1, Ahmet Murat Muhuman1 & Yuksel Altuntas1
1Sisli Etfal Training and Research Hospital, Endocrinology and Metabolism Clinic, Istanbul, Turkey; 2Sisli Etfal Training and Research Hospital, Pathology Clinic, Istanbul, Turkey; 3Sisli Etfal Training and Research Hospital, Neurosurgery Clinic, Istanbul, Turkey.

Background
Currently, multiple treatment options are available for the treatment of acromegaly. However, cure is obtained only in 50% of patients with macroadenomas after surgery. Persistent tumor enlargement occurs in 2% of the patients treated with somatostatin analogs and in 1.6–2.9% of the patients treated with pegvisomant. The nuclear antigen Ki-67 is related to growth potential and is also a major prognostic indicator for pituitary adenomas. Studies demonstrated that, the mean Ki-67 LI was high in invasive tumors that could not be cured by surgery. Tumors with high Ki-67 LI are also less responsive to somatostatin analogs. Recent reports suggest the utility of temozolomide in the management of aggressive pituitary adenomas and carcinomas, resistant to conventional treatments. The response to temozolomide is inversely correlated with tumoral expression of MGMT.

Purpose
To evaluate MGMT immunoreexpression in GH secreting pituitary adenomas, in an effort to predict the likelihood of response to TMZ, and to correlate MGMT immunoreexpression with Ki-67 LI.

Methods
Our material consisted of 36 GH secreting pituitary adenomas (21 female, 15 male, mean age 42.5 ± 10.5), operated at our center between 2003 and 2010. Immunostaining for Ki-67 and MGMT was performed using avidin–biotin–peroxidase complex method. Immunoreactivity was evaluated microscopically and recorded as percentage of nuclear Ki-67 and MGMT immunostaining. MGMT immunoreexpression scored as 0=negative, 1=<10%, 2=<25%, 3=<50%, 4=>50%.

Results
Staining for MGMT was <10% (score 1) in 30 (83.3%), 10–25% (score 2) in 3 (8.3%), 25–50% (score 3) in 2 (5.6%) and >50% (score 4) in 1 (2.8%) of the tumors respectively. There is no correlation between Ki-67 LI with MGMT immunoreactivity (P > 0.05).

Conclusion
Our data suggests that more than 90% of GH secreting pituitary adenomas express negative/low MGMT. Despite high Ki-67 LI, most of these patients may respond to TMZ, if conventional treatment fails.

P207
Mechanism of anterior pituitary gene regulation by LHX3 in paediatric combined pituitary hormone deficiency
R Malik, C Hunter, S Colvin & S Rhodes
Indiana School of Medicine, Indianapolis, Indiana, USA.

LHX3, a member of the LIM-homeodomain family of developmental transcription factors, is required for establishment of mammalian anterior pituitary hormone-secreting cell types as well as the formation of specialized neurons of the nervous system. Pituitary patients with pituitary insufficiency are sometimes diagnosed with combined pituitary hormone deficiency disease (CPHD). This disease can be linked to mutations in essential pituitary developmental transcription factor genes, including LHX3. Various mutations in LHX3 have been found to cause CPHD and we recently created a mouse gene knock-in model of CPHD patients whose LHX3 gene encodes a truncated protein, resulting from an early termination signal at residue 224 (W224Ter). This mutation differs from other LHX3 mutations in that the patients (and mouse model) do not present with nervous system defects but have pituitary insufficiency. Therefore, we hypothesized that the carboxyl-terminal (C-terminus) of LHX3 is necessary for pituitary development but not nervous system development. We have previously reported that the C-terminus of LHX3 contains activation and repression domains required for pituitary gene activation. In order to understand the mechanism of LHX3-mediated pituitary gene regulation, we have characterized co-regulatory proteins that interact with the C-terminus of LHX3. An affinity purification screen of pituitary proteins revealed a transcriptional repression complex as interacting with the LHX3 C-terminus.
**P208**

High risk of central adrenal insufficiency in GH deficient long-term survivors of childhood acute lymphoblastic leukaemia

C Follin, K Link, C Moell, T Wiebe & E M Erfurth

Clinical Sciences, Lund, Sweden.

**Introduction**

Acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy and accounts for 25% of all childhood cancer. The survival rate is now 85% which emphasises the importance of long-term treatment complications. ALL patients treated with cranial radiotherapy (CRT) and chemotherapy are particularly at risk for GH deficiency (GHD), but little is known about central adrenal deficiency. Partial ACTH deficiency is often asymptomatic, but it may lead to deleterious consequences during stress.

**Methods**

Out of 44 (21 women) ALL patients (median 25 years, range 19–32), treated with 24 Gy CRT (18–24) and chemotherapy, 37 were tested with an insulin tolerance test (ITT) to evaluate GH and cortisol secretion. All were GHD based on the GH response (<3 µg/l). The normal cortisol cut-off level was ≥500 nmol/l. Basal serum ACTH- and cortisol-levels were investigated in all 44 ALL patients and 44 matched population controls.

**Results**

Fourteen out of 37 (38%) ALL patients had subnormal cortisol response to an ITT (257–478 nmol/l) while there was no significant difference in basal serum cortisol levels between 44 patients and controls (P > 0.3). ALL patients had significantly lower serum ACTH levels compared to their controls (P = 0.04), being significantly lower among the women (P = 0.03), only. There was a significantly positive correlation between peak serum cortisol after ITT and basal cortisol (P < 0.001, r = 0.6), and the GH peak after ITT (r = 0.3, P = 0.04).

**Conclusion**

Thirty-eight percent of former ALL patients with GHD, treated with CRT, have central adrenal insufficiency 20 years after ALL diagnosis. About 500 ALL survivors have been subjected to this therapy in Sweden (pop. 9 millions), and with the corresponding numbers in other countries. This is of great concern, particular as GHD masks the presence of a hidden central adrenal insufficiency.

**P209**

Rationale and design of a global hyponatraemia registry

J Verbalis1, A Greenburg2 & P Gross3

1Georgetown University, Washington, District of Columbia, USA; 2Duke University, Durham, North Carolina, USA; 3Medizin Klinik, University Medical Center, Dresden, Germany.

**Background**

Hyponatraemia (HN) is the most common electrolyte disorder of hospitalised patients with a frequency approximating 15%. HN is associated with multiple co-morbidities as well as increases in length of stay (LOS), rehospitalisation, cardiovascular events, and death. This novel HN registry represents the first large-scale international effort to document the impact of HN on clinically relevant outcomes.

**Methods**

The HN registry is an ongoing, global, multi-centre, prospective, observational study designed to collect data on hyponatraemic patients in the hospital setting. HN is defined as serum sodium [Na] ≤ 130 mmol/l. Objectives of the registry are to: i) obtain demographic data on HN patients; ii) demonstrate comparative effectiveness of available HN treatments; and iii) define and compare resource utilization in the management of HN patients. Out of a total of 2500 patients world-wide, up to 1000 patients with HN secondary to SIADH will be enrolled throughout Europe.

**Results**

Primary end points are: i) change in [Na] from beginning to end of treatment or discharge and ii) LOS from the time of diagnosis. Secondary end points includes:

- i) time to a [Na] increase of ≥5 mmol/l or time to [Na] ≥ 130 mmol/l;
- ii) effectiveness of individual therapies in correcting [Na]; and iii) effectiveness of individual therapies in achieving improvement in symptoms. Impact of HN on resource utilization will be measured by LOS and duration of intensive care unit stay.

**Conclusion**

The HN registry will add valuable information to the current literature on SIADH-related HN and will provide important insights into the efficacy of current and emerging treatment options for HN and their impact on clinically relevant outcomes.

**P210**

Screening of Cushing’s syndrome and Acromegaly in Japanese diabetic patients

A Hirai, S Nagai, H Kameda, N Wada, J Takeuchi, H Kijima, T Kondo, H Miyoshi, C Shimizu & T Koike

Hokkaido University, Sapporo, Japan.

**Introduction**

Recent reports showed that 2–9.4% of diabetic patients have Cushing’s syndrome (CS) and acromegaly. CS including its mild form, subclinical CS (subCS), but there is no report about screening of acromegaly in diabetic patients. Either 1-mg or 0.5-mg dexamethasone suppression test (DST) is used as the screening test of adrenal CS or Cushing’s disease (CD). The aim of the present study was to screen CS including CD and acromegaly in Japanese diabetic patients.

**Design, patients, and measurement**

We prospectively evaluated consecutive 225 diabetic patients who were admitted in our affiliated hospitals from November 2008 to March 2010. No patient had clear acromegalic or Cushingoid features. Screening was performed using either 0.5-mg and 1-mg DST as well as measurement of serum IGF1 concentration. The threshold of adequate suppression after either DST was set at 80 mmol/l.

**Results**

Thirty-six patients failed to suppress cortisol after 0.5-mg DST. One showed positive result in 1-mg DST. Twenty-four patients demonstrated additional diagnostic examinations. Five and one patient met Japanese subclinical CS (sub CD) and subCS criteria respectively, while none of these patients had a positive imaging study. On the other hand, in eighteen patients, the serum IGF1 levels were exceeded age- and sex-specific range. In one woman, definitive diagnosis of acromegaly was made by a surgically proven pituitary GH-producing adenoma.

**Conclusions**

The present study showed that many diabetic patients have positive CS screening test, and considerable number of patients may have subCD or subCS despite no definitive image findings. Meanwhile, this study is the first demonstration that screening for acromegaly may be feasible in a cohort of diabetic patients. Early diagnosis and treatment of acromegaly may provide the opportunity to improve the prognosis of diabetes, therefore, we simply recommend to measure serum IGF1 levels in all diabetic patients to screen acromegaly.

**P211**

Gender-related differences in prolactinomas

A Ramos-Prol, R Cármara-Gómez, B León-de Zayas, A Beltrán, J A Simal, M Argente-Pla, M I del Olmo-García & J F Merino-Torres

Hospital Universitario y Politécnico La Fe, Valencia, Spain.

**Introduction**

It has been previously described that prolactinomas may have a more aggressive behavior in men than in women.

**Methods**

We performed a retrospective study in 59 patients diagnosed of prolactinoma (19 men). The variables collected were: age at diagnosis, clinical presentation, tumor size and stage (Hardy classification) and treatment response. The results were compared between both genders.

**Results**

Age at diagnosis was 41 (18.9) years in men and 32.7 (12.5) in women (P = 0.051). At the moment of diagnosis men had higher basal prolactin (P < 0.001) and a bigger adenoma size (P < 0.05). Macroprolactinomas were more frequent in men (P < 0.001) and had a greater invasiveness (P < 0.05). The most common clinical onset in men was headache (73.7%) and erectile dysfunction (65.4%), whereas in women was menstrual disorders (74.2%), galactorrhea (39.4%) and headache (39.4%). 89.5% of men and 37.5% of women had some kind of hypophysary hormonal deficiency (P < 0.001). Complications such as visual defects and

**Endocrine Abstracts (2011) Vol 26**
haemorrhagic transformation were more prevalent in men ($P < 0.05$). A delay of 29.8 (37.9) months in the diagnosis was observed in men whereas in women it was of 7.2 (10.7) months ($P = 0.001$). There was a positive correlation between the delay at diagnosis and tumoral stage ($P = 0.001$) but not with the tumour size ($P = 0.068$). During the follow-up with medical treatment, imaging techniques showed: tumor resolution in 81.8% of women and 47.4% of men ($P = 0.01$), reduction in 50% of women and 15.8% of men ($P = 0.02$) and an increase 31.3% of men and 3% of women ($P < 0.01$). Prolactin took more time to normalize in men ($P = 0.001$). Surgery was required in 31.6% of men and only 3% of women ($P < 0.01$).

Conclusions

Clinical behavior of prolactinomas in men is more aggressive, this could be due to a delay in the diagnosis. Women presented a faster and better response to medical treatment.

P212

Efficacy and safety of the use of the recombinant GH receptor antagonist pegvisomant (PGV) in acromegaly. Evaluation of its use in 13 patients treated in a pituitary disorders unit

M Domínguez-López, I González-Molero & J García-Arnés

Endocrinology Department, Carlos Haya Hospital, Malaga, Spain.

Introduction

The recombinant GH receptor antagonist pegvisomant (PGV) is actually used for the treatment of acromegaly when surgery and medical therapy with somatostatin analogues (SSA) have failed. Long term safety and effectiveness need to be evaluated.

Material and methods

Retrospective analysis of clinical data from all patients treated with pegvisomant in a pituitary disorders unit.

Results

Thirteen patients are being treated with PGV in our unit. Medium time between diagnosis and beginning of PGV treatment is 90.71 ± 92.75 months. Basal size of the tumours was 23 ± 1.60 mm (80% macroadenomas). Before starting with PGV therapy, 63.6% of the patients had surgery and also 63.6% had radiotherapy. All the patients had been previously treated with SSA and two patients have combination treatment (SSA and PGV). Medium time of PGV treatment was 45.4 ± 19.62 months (9–72). Medium dose of maintenance is 15.8 ± mg24 h, (5–30). Medium IGF1 values measured at the beginning and after treatment stabilization were 873 ± 551 (432–1709) vs 234 ± 139 (116–464) ($P < 0.01$). Normal IGF1 values (<300) were obtained in 72.7% of the cases, being necessary a mean time of treatment of 6.66 months (2–36 months) and a mean dose of 15.8 ± 4.9 mg. Tumor size or remaining tumor did not increase in any patient. There was clinical improvement in 100% of the cases. No side-effects have been found and we have found only one case of lipodystrophia.

Conclusion

Treatment with pegvisomant seems to be effective, safe and well-tolerated in our experience.

P213

Hypothalamic tumor in a patient with Pendred syndrome

A Giestas, M Almeida, S Teixeira, A Maia, T Azevedo, D Vaz, A Carvalho & R Carvalho

Department of Endocrinology, Diabetes and Metabolism, Hospital Santo António, Centro Hospitalar do Porto, Oporto, Portugal.

Introduction

Pendred syndrome is a rare autosomal recessive disease and the classic triad is congenital sensorineural hearing impairment, goiter and impaired iodine organization with abnormal perchlorate discharge test, but hypothalamic tumors are not a feature of this syndrome.

Case report

We report a case of a 32-year-old female with Pendred syndrome confirmed by organification with abnormal perchlorate discharge test, but hypothalamic tumors or chronic ($n = 35$) pain, and patients with COPD ($n = 171$). Illness perceptions were evaluated using the illness perception questionnaire-revised. The protocol was approved by the Medical Ethics Committee.

In the absence of visual field abnormalities and endocrine dysfunction other than hyperprolactinemia, an expectant policy of no intervention and periodic follow-up was indicated (MRI scan at 12 month intervals).

She started bromocriptine (2.5mg/day) with favorable biochemical response and normalization of prolactin levels.

During 8 years of follow-up, the patient remains asymptomatic, without galactorrhea and the size of the hypothalamic mass stable in annual MRI scan.

Conclusion

The case is presented in the light of its rarity.

P214

Multimodal treatment and minimally invasive surgery for 117 pituitary adenomas: a Croatian Pituitary Centre experience

Ivan Kruljac1, Andreja Marie1, Petra Sulentic1, Maja Berkovic Čigrovski1, Davorka Herman Mahecic1, Gorana Mirosevic1, Darko Kastelan2 & Milan Vrljkan1

1University Hospital Sisters of Mercy, Zagreb, Croatia; 2University Hospital Centre Zagreb, Zagreb, Croatia.

Studies that consolidate the results of medicamentous and surgical treatment of pituitary adenomas are scarce. Pure endoscopic endonasal transsphenoidal surgery is rather new technique. The aim of this study is to report on early postoperative outcome of pure endoscopic endonasal transsphenoidal surgery and to present the results of multimodal treatment in patients with postsurgical failure.

We reviewed 117 consecutive patients who underwent pure endoscopic transsphenoidal surgery and to present the results of multimodal treatment in patients with postsurgical failure. Our results are similar to those in greater centres. In early postoperative failure multimodal treatment improves the remission rate. The multidisciplinary approach is the key to successful treatment of pituitary tumors.
Results
Patients after long-term remission of Cushing’s syndrome reported more negative illness perceptions compared to reference samples. Patients with Cushing’s syndrome scored distinctly worse compared to patients with various other illnesses, with a higher mean (S.D.) duration of Cushing’s syndrome being 3.7 (1.9) years. Patients with chronic pain and patients with COPD, but there was no distinct pattern. Illness perceptions showed a strong correlation with QoL.

Conclusion
Patients after long-term remission of Cushing’s syndrome report more negative illness perceptions compared to several reference populations. Future studies have to assess whether self-management intervention programs will improve these illness perceptions and thereby QoL.

P216
Long-term treatment of acromegaly with pegvisomant (Somavert): cross-sectional observations from ACROSTUDY, a post-marketing, international, safety, surveillance study

A J van der Lely1, F Lundgren1, B M K Biller1, T Brue2, J Cara3, E Ghigo4, J Hey Hadavi5, N Rajicic6, Bernhard Sailer1, John Sanocki2, Christian Strasburger2, Susan Webb2, & Maria Koltowska Hagstrom2

1Erasmus University Medical Centre, Rotterdam, The Netherlands; 2ACROSTUDY Pfizer Endocrine Care, Sollevtuna, Sweden; 3Massachusetts General Hospital, Boston, Massachusetts, USA; 4Université de la Mediterrannée, Marseille, France; 5Pfizer Inc., New York, USA; 6Université di Torino, Turin, Italy; 7Pfizer Ltd, Tadworth, UK; 8Pfizer Inc., New London, Connecticut, USA; 9Charité-Universitätsmedizin, Berlin, Germany; 10Hospital S Pau, CIBERER 747, Universitat Autònoma de Barcelona, Barcelona, Spain.

Introduction
Somavert is a GH receptor blocker, which inhibits hepatic production of IGF1. While it has been approved for the treatment of acromegaly since 2003 there are few data regarding its effects in everyday clinical practice.

Methods/Design
ACROSTUDY is an open-label, international, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of Somavert.

Results
As of December 31, 2009 data from 1288 patients (51% men) were available. The majority of patients came from Germany (31%), France (15%), Spain and Italy (both 14%). Mean (S.D.) age (years) of patients at diagnosis of acromegaly was 42 (13.5) and at Somavert start, 50 (14.0). Mean (S.D.) duration of Somavert treatment was 3.7 (1.9) years. Before Somavert start, other treatments were reported as follows: medical therapy and surgery in 43.5% of patients; medical therapy, radiation and surgery in 24.4%; medical therapy only in 18.3%; surgery only in 4.2%; radiation and surgery in 2%; medical therapy and radiation in 1.6%; medical therapy only in 1.6% and only radiation in 0.1%. In 5.9% of patients no previous treatment was reported. At Somavert start, 86% of patients were reported as having increased IGF1 concentrations. After 1 year of treatment (n=769), at a mean dose 14.8 mg/day, in 57%, normal IGF1 concentrations were reported. Subsequent IGF1 normalization rates were reported as follows: 2 years (n=705), mean dose 15.6 mg/day – 60%; 3 years (n=553), mean dose 15.9 mg/day – 60%; 4 years (n=406), mean dose 16.8 mg/day – 63%; 5 years (n=253), mean dose 17.5 mg/day – 63%.

Conclusions
The majority of patients experienced normalization of IGF1 on relatively low doses of Somavert. The normalization rate was lower than in clinical trials. This might be explained by insufficient upward dose titration, less rigorous, frequent monitoring and lower patient compliance than in clinical trials, longer follow-up, and unsellected patients with severe acromegaly, resistant to other medical treatments.

P217
Pituitary gland function following craniocerebral trauma III: in younger patients

R Hampel1, S Ziems1, Ch Zingerl1 & A Gabert1
1Internal Medicine Clinic II, Division of Endocrinology and Metabolic Diseases, University of Rostock, Rostock, Germany; 2Institute of Clinical Chemistry and Laboratory Medicine, University of Rostock, Rostock, Germany.

Methods
Using a prospective and standardized protocol, we investigated anterior and posterior pituitary function following craniocerebral injury III (determined by Glasgow Coma Score) in 35 young patients 14–45 years of age (mean patient age was 25 years). The combined anterior pituitary function test (CRH, TRH, GnRH, GHRH-arginine) as well as measurement of plasma and urine osmolality was performed no earlier than 3 months following the craniocerebral injury (19.8 months on average).

Results
We found isolated AACTH and FSH/LH secretion insufficiency in 8.7, 5.7 and 5.7% of cases respectively (cumulative percentage = 20.1%). Combined adenohypophysectomy and somatotropin axis insufficiency was observed in 2.9% of cases. Thyreotrophic and lactotropin function remained intact. No diabetes insipids. The prevalence of axis insufficiency correlated with the age at the time of craniocerebral injury (age <20 years 18%, 20–45 years 25%, age <30 years 20%, 30–45 years 27%).

Conclusions
The relatively high prevalence of anterior pituitary insufficiency after severe craniocerebral trauma reported in the literature applies to older patients. These results must be treated with caution since few authors have used suitable and standardized methods for measuring anterior pituitary function. Anterior pituitary insufficiency following craniocerebral trauma III is only rarely observed in younger patients. Since adenohypophysectomy insufficiency had the highest incident rate, we consider the testing of adenohypophysectomy function during follow-up after craniocerebral trauma III as being of particular importance.

P218
Macroprolactinomas in 38 children and adolescents: sex differences and long-term results of medical treatment

D A Ancelle1, G R Raverot2, B D Découdier3, S V Sulumont3, M N Nicolin02, P B Berlier2, F B C Borson-Chazot2 & B D Delemere1
1CHU Reims, Marne, France; 2CHU Lyon, Rhone, France.

Objectives
Long-term results of medical treatment of macroprolactinoma in children and adolescents (<20 years).

Patients and methods
Retrospective analysis of all the cases of macroprolactinoma occurring in children and adolescents, medically treated in two university centers.

Results
38 patients, 25 girls 13 boys, age at diagnosis: 15.7±2.8 years (only two cases before 12 years). At diagnosis, 2/3 presented with headaches, 1/3 visual disturbances, 1/2 abnormal puberal development, 1/4 growth failure, amenorrhea (primary or secondary) in 22/25 girls. Mean serum prolactin was 2700±6145 μg/l, maximum diameter of the adenoma was 22±12 mm. There were sex differences (boys/girls): age 14/16.6 years (P=0.0016), size of adenoma 28/18 mm (P=0.019), prolactin level 5176/1368 μg/l (P=0.016), growth failure 6/3 (P=0.027; OR=3.6), pituitary deficiency 7/2 (P=0.003; OR=13.4). First line treatment was dopamine agonist in all cases: cabergoline (22), bromocriptine (14) quinagolide (2) leading to normalisation of prolactin in 74% of the patients, 50% decrease of the volume of the adenoma in 58%, gonadal function normalised in 78% (10/25 girls had normal pregnancy). The patients resistant to medical treatment had surgery (9), radiotherapy (3) or high and prolonged dose of dopamine agonists (6). At this time, only one is not controlled with tumoral expansion symptoms. After a median 8 years follow-up, 1/3 of the patients had sequelae (boys/girls 8/5, P=0.014), predictive factor was initial diameter of the adenoma (P=0.022), > 20 mm.

Conclusion
This is the largest cohort of macroprolactinomas under 20 years. Sex differences are the same than in adult population with larger tumors in boys, leading to more frequent sequelae. This study confirms that development of prolactinomas is associated with puberty. Long term medical treatment in children and adolescents is effective and safe in 3/4 of the patients but must be completed by surgery or radiotherapy in a few resistant cases.
P219
Medical treatment of an aggressive non-secreting pituitary tumor and non-secreting pituitary carcinoma: a report of two cases
K Bajuk Studen & M Pfeifer
University Medical Center Ljubljana, Ljubljana, Slovenia.

Introduction
Since aggressive pituitary tumors are rare, there are no clear guidelines considering treatment of these tumors. A wide range of treatments have been used, with various success.

Case report 1
A 58-year old lady presented with sudden severe headache and paresis of the left eye. MRI revealed an expansive intrasellar, suprasellar and bilateral parasellar process with extension to the skull base which was inaccessible for neurosurgery. Pituitary function was intact, with IGF1 slightly above the normal range. A transphenoidal biopsy was performed, which revealed a pituitary tumor with accompanying necrosis, negative on immunohistochemical staining for pituitary hormones. Octreotide scintigraphy confirmed the presence of somatostatin receptors in the tumor. Treatment with octreotide LAR and cabergoline was initiated. After 3 years of treatment, the patient is in a very good shape with normal pituitary function and reduced size of the tumor on control MRI.

Case report 2
A 35-year-old patient had been transcranially operated because of a large non-secreting pituitary adenoma. Because of tumor regrowth, two reoperations followed 7 and 12 years after the first. Pathohistology revealed a pituitary tumor with central necrosis and bone infiltration. At that point elevated levels of serum alkaline phosphatase were observed. Bone scintigraphy revealed numerous osteoblastic metastases, which were confirmed to originate from the pituitary tumor by bone biopsy. The presence of somatostatin receptors in the tumor and metastases was confirmed by octreotide scintigraphy. After 2 years of treatment with zoledronic acid and octreotide LAR (both once monthly), the patient is clinically stable with no further tumor growth on control MRI and the same status of bone metastases on scintigraphy.

Conclusion
We report an aggressive pituitary adenoma and a pituitary carcinoma that were successfully managed by medical treatment. This implies that in such cases medical treatment should be considered before proceeding to more aggressive treatment modalities.

P220
Normal pregnancy in a woman with history of panhypopituitarism due to lymphocytic hypophysitis
V Dimarakis, C T Tsentidis, A Antoniou-Tsigos & A A Argyropoulos
Nicaea General Hospital, Piraeus, Athens, Greece.

Introduction
Lymphocytic hypophysitis is an uncommon autoimmune disease usually presenting during or just after pregnancy. It may be followed by panhypopituitarism. In such case is extremely rare for a woman to have a normal delivery again.

Case report
We report the case of a 28-year-old woman who had a successful delivery 2 years after lymphocytic hypophysitis which had resulted in panhypopituitarism. The young woman presented with amenorrhea, symptoms of secondary adrenal insufficiency and polyuria several months after her first labor. She reported severe headache which occurred 5 weeks after the labor and lasted for about 1 month. We performed a complete hormonal evaluation of the pituitary gland, which revealed posterior and anterior lobe insufficiency. The MRI findings were consistent with the diagnosis of lymphocytic hypophysitis. The patient was prescribed a full hormone replacement therapy, but after a few months she stopped the estrogen and progesterone therapy by herself. Five months later, she restored normal menses and after two more consecutive months she conceived again. The new pituitary gland hormonal evaluation revealed insufficiency of all other axes. She had a normal pregnancy and labor. She only needed a small increase in hydrocortisone and thyroxin dose at the third trimester.

Conclusion
It is possible for a patient with a history of lymphocytic hypophysitis to conceive and have a normal pregnancy again.

P221
PANCH tumor in a female patient
C T Tsentidis, A A Antoniou-Tsigos, V D Dimarakis, G S Georgakopoulou, P I Prokavos & A A Argyropoulos
Nicaea General Hospital, Piraeus, Athens, Greece.

Case report
We present the case of a patient with somatotroph adenoma combined with neuronal choristoma Pituitary Adenoma Neuronal CHoristoma (PANCH). A female patient, 44 years of age, manifested with acromegaly type features since 1993, while mentioning also headaches, amenorrhea, and peripheral type visual disturbances since 1997. The clinical examination revealed an obese woman with typical acromegalic features. The laboratory evaluation before pituitary surgery showed a greatly increased IGF1 value of 995 ng/ml (normal values: 101–303) and basal GH value of 13.3 ng/ml (normal values: 0–5), while for the rest frontal pituitary lobe a low basal value of FSH 1.4 mIU/ml (normal values: 3–8) and LH 0.1–mIU/ml (normal values: 1–7) was noted, with normal values of PRL 4 ng/ml (normal values: 1.9–25), TSH 0.8 μIU/ml (normal values: 0.3–4.0) and T4 9.3 μg/dl (normal values: 4.5–12.5). The first pituitary surgery took place in 2/2/01. The histological evaluation of the resected pituitary section revealed a chromophobe somatotroph pituitary adenoma with sparse granulation, combined with neuronal choristoma (PANCH tumor), immunocytochemical positive for GH and focally for PRL. Because of acromegaly remission, a second and a third pituitary surgery followed at 5/6/02 and 13/11/03. She also received conventional radiotherapy in total dose of 54 Gy from 22/9 to 4/11/04. At present, she manifests thyrotoxic, lactotroph and gonadotroph cell failure with normal IGF1 levels and the remaining pituitary tumor is stable in size. We present this case report because of its rarity (~0.5% of the hypophysyal tumors).

P222
On the effect of CRH and dexamethasone on POMC synthesis and ACTH secretion in rat pituitary primary cultures
M F Cassarino, L Pagliardini, F Cavagnini, F Pecorari Giraldi
Chair of Endocrinology, University of Milan, Milan, Italy; Ospedale San Luca, Istituto Auxologico Italiano IRCCS, Milan, Italy.

Pomc synthesis and ACTH secretion by the anterior pituitary are controlled by two major, opposing players namely CRH and glucocorticoids. Most studies were performed on the AtT-20 mouse corticotroph tumor cell line or Pomc-transfected cells.

Aim
Aim of the present study was to evaluate the effect of CRH and DEX on Pomc expression and ACTH secretion in normal rat corticotropes in vitro.

Methods
Rat anterior pituitary primary cultures were incubated with 10 nM CRH or 10 nM DEX for 4, 24, 48, 72, 96 and 120 h prior to medium and RNA collection. Pomc gene expression was evaluated by real time PCR and ACTH was measured by IRMA.

Results
CRH stimulated ACTH secretion at 4 h and the effect was maintained for 120 h; stimulation of Pomc synthesis was evident after 24 h and increased progressively over time. DEX clearly inhibited ACTH secretion starting at 4 h, but had no effect of Pomc gene expression at any time point.

Pomc and ACTH secretion in normal rat corticotropes in vitro

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Control</th>
<th>CRH</th>
<th>DEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pomc</td>
<td>0.5 ± 0.03</td>
<td>2.2 ± 0.68</td>
<td>4.2 ± 0.28</td>
</tr>
<tr>
<td>ACTH</td>
<td>2.9 ± 0.05</td>
<td>8.3 ± 0.49</td>
<td>14.9 ± 0.96</td>
</tr>
<tr>
<td>Dex</td>
<td>0.04 ± 0.05</td>
<td>1.0 ± 0.71</td>
<td>2.1 ± 0.62</td>
</tr>
</tbody>
</table>

Conclusions
The present study shows that CRH stimulates ACTH synthesis and secretion by normal corticotropes while dexamethasone blunts ACTH release but appears to have no effect on Pomc synthesis. This data contrasts with results obtained in tumoral corticotropes or transfected cells and points to the need for studies on normal corticotropes in order to better understand HPA axis physiology.

Endocrine Abstracts (2011) Vol 26
P223
KIT protein expression and mutational status of KIT gene in pituitary adenomas

O Casar-Borota1,2, S L Fougner3-6, J Bollerslev3-6 & J M Nesland1-6
1Department of Laboratory Medicine/Pathology, Umeå University Hospital and Department of Medical Biociences, Umeå University, Umeå, Sweden; 2Department of Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden; 3Faculty of Medicine, University of Oslo, Oslo, Norway; 4Research Institute for Internal Medicine, Oslo, Norway; 5Division of Pathology, Oslo University Hospital, Oslo, Norway; 6Section of Specialized Endocrinology, Oslo University Hospital, Oslo, Norway.

Introduction
The proto-oncogene KIT (CD117) is widely expressed in neoplastic tissues. Gain-of-function mutations of the KIT gene were found in some types of leukemia, gastrointestinal stromal tumors, germinal cell tumors and rarely in other malignancies. Studies on the KIT protein and gene in different tumors have been intensified by the availability of imatinib mesylate, KIT/ PDGFRα inhibitor.

Methods
We have immunohistochemically investigated KIT-expression in 252 pituitary adenomas. Mutational status of exons 9, 11, 13 and 17 of KIT gene has been examined in the tumors with membranous KIT expression and in a minority of tumors with cytoplasmic expression. Detailed clinicopathological correlation was performed for somatotroph adenomas.

Results
52.4% of adenomas showed cytoplasmic and 8.3% membranous KIT-expression. We found differences in KIT expression between NFPA, somatotroph and corticotroph adenomas with the highest proportion of adenomas with membranous expression (17.2%) among the somatotropinomas. No mutations in the examined exons were found.

Conclusions
i) The results suggest a pathogenetic role of KIT in a subset of pituitary adenomas.
ii) The membranous expression of KIT may thus suggest a potential role for KIT in pituitary adenomas.
iii) Despite the high proportion of somatotroph adenomas with membranous expression of KIT in our study, they are probably less attractive candidates for imatinib mesylate therapy due to absence of mutation in the examined exons of KIT, no correlation with clinical data and high proportion of tumors with high str2A expression among the KIT-reactive tumors. iv) No mutations in other exons of the KIT gene as well as in kinases other than KIT, such as PDGFRα would be of interest.

P224
Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly

C L Ronchi1,3, E Verrua1,2, E Ferrante1,2, G Bender3, E Sala1,2, A Lania2, M Fassnacht1, P Beck-Peccoz2,7, Bruno Allocco1, Anna Spada1,2 & Maura Arosio1,4,6
1Unit of Endocrinology and Diabetology, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy; 2Department of Medical Science, University of Milan, Milan, Italy; 3Unit of Endocrinology, University Hospital of Wuerzburg, Wuerzburg, Germany; 4Unit of Endocrine Diseases, S. Giuseppe Multimedica Hospital, Milan, Italy.

Radiation therapy is a useful adjuvant tool for the management of difficult acromegalic patients. Its effects on cardiovascular morbidity are still unknown.

Aim of the study was to investigate the long-term effects of radiotherapy on metabolic parameters and cardiovascular risk factors.

A total of 42 acromegalic patients (11 M and 31 F, age: 55 ± 12 years, RT group), cured after conventional RT (CRT, n = 31) or radiosurgery by gamma-knife (GKRS, n = 11), have been retrospectively evaluated (median follow-up: 16.5 years, range: 2–40). Fifty-six sex- and age-matched acromegalic patients cured after surgery alone served as control group. GH/IGFI levels were also comparable. As expected, the percentage of patients with pituitary failure was higher in RT patients than in controls (86 vs 30%, P < 0.0005). The number of obese, hypertensive, and dyslipidemic subjects increased over time only in the RT group, whereas the glucose response to the OGTT and the percentage of subjects with glucose alterations improve only in control group. Despite these findings, a similar number of patients in the two groups had major cardiac or cerebrovascular events (4/42, two IMA and two TIA, vs 3/56, one stroke and two TIA). No differences were found between CRT and GKRS subgroups. In conclusion, previous RT seems to be associated with a worse metabolic profile in acromegalic patients studied after a long-term follow-up. Nevertheless, a direct link between RT and cardiovascular events remains to be proven.

P225
Effect of GH as add-on treatment in severe fibromyalgia syndrome. Results from the IIIb, CT27560 placebo-controlled, multicenter trial

Guillem Cuatrecasas9, Cayetano Alegre9, Joaquim Fernandez Solà2, Maria Jose Gonzalez2, Mary Lage9, Gemma Sesmilo2, Enrique Granados6 & Manuel Puig Domingo1
1Endocrinology Department, CM Teknon, Barcelona, Spain; 2Rheumatology Department, Institut Universitari Dexeus, Barcelona, Spain; 3Internal Medicine Department, Hospital Clinic Universitari, Barcelona, Spain; 4Endocrinology Department, Hospital Clinico Universitario Santiago, Santiago Compostela, Spain; 5Endocrinology Department, Institutt Universitersklinikun, Oslo, Norway; 6Endocrinology Department, Dexeus University Hospital, Barcelona, Spain; 7Merck SL, Madrid, Spain; 8Endocrinology Department, Hospital Clinic Universitari, Barcelona, Spain.

Introduction
Functional GH deficiency has been described in fibromyalgia (FM). The efficacy of GH as add-on treatment has been suggested in small studies, but little is known in larger and homogeneous populations.

Design
Patients (120) were enrolled in a multicenter, randomized, placebo-controlled trial over 18 months (NCT00951913). Group A received GH 0.006 mg/kg per day of GH s.c. (further titrated based on IGF1) and group B, placebo, both added to standard therapy. Placebo arm was then switched to GH from 6 to 12 months (open-phase), and an extension study from 12 to 18 months was carried out after GH withdrawal. Number and intensity of tender points, FIQ and subscales, Quality of Life test (EQSD) with visual analogic scale (VAS) were evaluated at different time-points.

Results
At 12 months, 53% of the patients in group A (GH continuously) reached < 11 positive tender points (cut-off for diagnosis) versus 33% in group B (6 months of GH) (P < 0.05). Significant improvements were also seen comparing FIQ (P = 0.01), subscales (P < 0.05) and EQSD (P < 0.05). In group A, 56.5% patients reached > 30% improvement in VAS and 39.1% (severe), duration of FM > 18 months, and stability of the standard therapy (amitriptiline + opioids + SSR1) > 12 months were required. Adult GH deficiency and insensitivity were ruled out with an ITT test and IGF1-generation test respectively. In the first 6 months (blind-phase), Group A reached 0.006 mg/kg per day of GH s.c. (further titrated based on IGF1) and group B, placebo, both added to standard therapy. Placebo arm was then switched to GH from 6 to 12 months (open-phase), and an extension study from 12 to 18 months was carried out after GH withdrawal. Number and intensity of tender points, FIQ and subscales, Quality of Life test (EQSD) with visual analogic scale (VAS) were evaluated at different time-points.

Conclusions
This is the larger and longer placebo-controlled trial performed so far in FM. Added GH is comparable to some labelled drugs in term of pain reduction, FIQ and VAS and further shows a sustained pattern of action.

P226
Tumor occurrence or recurrence after five year GH replacement therapy

M C Savanelli, E Scarano, V Brunelli, G Lombardi, A Colao & C Di Somma
1Endocrinology Department, CM Teknon, Barcelona, Spain; 2Endocrinology Department, Institut Universitari Dexeus, Barcelona, Spain; 3Internal Medicine Department, Hospital Clinic Universitari, Barcelona, Spain; 4Endocrinology Department, Hospital Clinico Universitario Santiago, Santiago Compostela, Spain; 5Endocrinology Department, Institutt Universitersklinikun, Oslo, Norway; 6Section of Specialized Endocrinology, Oslo University Hospital, Oslo, Norway.

GH replacement is widely used in adults with hypopituitarism, but its effect on tumor occurrence and pituitary tumor recurrence is unknown. Furthermore, in literature there are scant with short follow-up time. The available data do not seem to suggest that GH replacement increased the incidence of regrowth of pituitary tumor and of cancer in adults with GHD, provided that IGF1 concentrations remain within the normal range for age.

Endocrine Abstracts (2011) Vol 26
The aim of our study was to evaluate the tumor occurrence and pituitary tumor recurrence in 84 adult patients with GHD (42 females, 42 males; range 16–75; 11 CO, 73 AO), admitted at our Department from 1995 to 2002 with the following diagnoses: 48 adenomas (34 clinically functionless pituitary tumors, 3 corticotropinomas, 9 prolactinomas, 2 somatotropinomas), 16 craniopharyngiomas, 1 dygserminoma, 1 arachnoid cyst, 1 tumor gigantocellular, 17 idiopathic GHD. Diagnosis of GHD was performed after 6–12 months of the treatment for primary disease. All GHD patients were replaced with rhGH. New tumors were reported in 2 (2.4%) patients during rhGH replacement (one colon carcinoma was diagnosed in a patient after 3 years, one breast carcinoma was diagnosed in another patient after 5 years). In 2 patients the occurrence of new tumor was found after the cessation of rhGH replacement (one uterus carcinoma and one hepatocarcinoma after 4 year of rhGH discontinuation). Recurrence of pituitary tumors was reported in 8 (12.5%) patients: 4 (8.3%) pituitary adenomas and 4 (25.6%) craniopharyngiomas. In conclusion, the recurrence rate of pituitary tumor and occurrence of new tumors in our population do not appear to be increased compared with published data. However, longer follow-up regarding recurrences and secondary neoplasms remains essential.

P227

Pituitary function in type 2 diabetic men with good or poor glycaemic control
S Scaltriti1, B Madeo1, M Bertolini2, S Romano2, L Zirilli1, E R Cavani2, A Balestrieri1, C Carani1 & V Rochira1
1Chair and Unit of Endocrinology and Metabolism, Department of Medicine, Endocrinology and Metabolism, Geriatrics, NOCSAE of Baggiovara, University of Modena and Reggio Emilia, Modena, Italy; 2Diabetes Care, Department of Medicine, Endocrinology and Metabolism, Geriatrics, NOCSAE of Baggiovara, University of Modena and Reggio Emilia, Modena, Italy; 3Unit of Endocrinology, Bufalini Hospital, Cesena, Italy.

Introduction
Several data suggest that male hypogonadism occurs frequently in men with type 2 diabetes mellitus (T2DM) but underlying pathophysiological mechanism remains partially unknown. In order to investigate the short term effect of hyperglycaemic state on hypothalamic–pituitary–gonadal axis we prospectively studied 18 men with T2DM younger than 55 years at the time of first diagnosis of T2DM. We compared men with HbA1c > 9.0% with men with HbA1c < 9.0% at baseline when glycaemic control was wrong and after a short and long period of treatment when a good glycaemic control had been obtained.

Methods
Basal serum fasting glucose, insulin, fructosamine, HbA1c, total, HDL-, LDL-cholesterol, triglycerides, LH, FSH, total testosterone (T), estradiol and stimulated LH and FSH after a standard GnRH test.

Results
A positive percentage increase from baseline of testosterone was observed in men with HbA1c > 9% at baseline after glycaemic control had been achieved, while in men with HbA1c < 9% a minimal decrease of testosterone was recorded, the mean percentage increase from baseline of group with HbA1c > 9% being significantly higher (P = 0.018), and it was associated with a positive trend of testosterone/LH ratio and a positive percentage increase from baseline of the response of LH to GnRH infusion in terms of area under the curve and peak.

Conclusion
Testosterone secretion by Leydig cells could be impaired in poorly controlled T2DM men and both a better glycaemic control at baseline and/or an improvement of the glycaemic control are associated with a better gonadal function in T2DM men.

P228

Non-traditional effects of GH: a survival factor for retinal ganglion cells
S Harvey, W Lin, E Parker & E Sanders
University of Alberta, Edmonton, Canada.

Introduction
GH and its receptor (GHR) are expressed in retinal ganglion cells (RGCs) in the eyes of chick embryos, and in mouse, rat and human eyes. Within the retina, exogenous GH has neuroprotective actions, mediated by caspase-dependent and caspase-independent mechanisms that may also be dependent upon IGF1 signaling. Conversely, the immunoneutralization of endogenous GH promotes apoptosis in the retina and in isolated RCGs. The functional relevance of retinal GH was further assessed in the present study, by determining the effects of retinal GH knockdown on cell survival in the retinas of developing chick embryos.

Methods
At embryonic day (ED) 4 of the 21 days incubation period, a specific GH siRNA or a non-silencing siRNA was intra-vitreally injected in 100 pl into the right optic cup. Eyes were removed 24 h afterwards and examined for TUNEL-labelled apoptotic cells or for GH mRNA and IGF1 mRNA content, using real-time PCR.

Results
The intra-vitreal injection of the GH siRNA lowered the retinal GH mRNA content and IGF1 mRNA content by ~50% within 24 h of injection. The withdrawal of retinal GH was accompanied by increased (P < 0.01) apoptosis, particularly in clusters of retinal cells close to the optic fissure.

Conclusions
These results demonstrate that retinal GH has functional significance and it directly or indirectly (through IGF1) promotes cell survival in the developing chick neural retina. Retinal GH therefore has hitherto unknown autocrine or paracrine neuroprotective roles in retinal function.

P229

Clinical and subclinical apoplexy in nonfunctioning pituitary tumors: clinical features, management and outcome
Leonor Gomes1, Isabel Paiva2, Cristina Ribeiro3, Jacinta Santos4, Alexandra Vieira5, Márcia Alves6, Sofia Gouveia7, Joana Saraiva8, Olinda Rebelo9 & Manuela Carvalheiro1
1Serviço de Endocrinologia, Diabetes e Metabolismo, Hospitais da Universidade de Coimbra, Coimbra, Portugal; 2Serviço de Endocrinologia, Universidade de Coimbra, Coimbra, Portugal.

Background
Pituitary apoplexy occurs when a tumor undergoes acute hemorrhage, infarct, or both. This often leads to acute severe symptoms (clinical) but can also occur without them and diagnosed on CT/MRI, surgery, pathology (subclinical). To investigate clinical and subclinical apoplexy in nonfunctioning tumors (n = 221) from our database.

Design
Retrospective review of clinical presentation, tumor characteristics and outcome of 24 patients, 11 females and 13 males, with pituitary apoplexy.

Results
Subclinical apoplexy occurred in 15 and clinical in 9 patients. They represented 10.9% of nonfunctioning macroadenomas. Subclinical was more frequent on females (81.8 vs 46.2%). Age at diagnosis was similar (subclinical 47.2±15.4 vs 46.3±16.2 years in clinical). Symptoms duration in subclinical was 24.4±45.3 vs 34.1±43.8 months in clinical. Neurological, endocrinological and ophthalmological symptoms were present in 86.7, 80.0, 73.3% of subclinical and in 88.9, 55.6, 77.8% of clinical. Ophthalmoplegia in subclinical 6.7 vs 22.2% of clinical.

Conclusions
Apoplexy occurred in 10.9% of nonfunctioning pituitary tumors with a higher rate of subclinical type. In clinical apoplexy, tumors were larger and male gender more frequent. Hypopituitarism and neuroophthalmological alterations were high and only the last one improved after treatment. Clinical apoplexy had higher rate of morbidity but lower disease progression. Although pituitary apoplexy is not totally predictable it is important to be aware of neurological and endocrinological symptoms in order to perform earlier diagnosis.

Endocrine Abstracts (2011) Vol 26

13th European Congress of Endocrinology, Rotterdam, The Netherlands
P230

Comparison of GH suppression response after oral and intravenous glucose tolerance tests in healthy subjects
Cevdet Aydin, Reyhan Ersoy, Didem Ozdemir, Neslihan Cuhaci, Dilek Arcapi, Alper Bugugullar, Yusuf Usta, Husniye Baser, Ahmet Dirikok & Bekir Cakir
Department of Endocrinology and Metabolism, Ataturk Education and Research Hospital, Ankara, Turkey.

Introduction
In this study, we aimed to compare GH values obtained in oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT) in healthy individuals.

Material and methods
Data of 18 healthy volunteers were analysed (10 male and 8 female). Firstly all subjects were evaluated with 75 g oral glucose tolerance test. In another day, intravenous glucose tolerance test was performed. Serum glucose, insulin and GH levels obtained during two tests were measured.

Results
Basal GH levels had a wide distribution ranging from 0.00005 μg/l (0.05 pg/ml) to 0.768 μg/l (768.92 pg/ml) (median 0.0145 μg/l). Mean nadir GH level during OGTT was 0.0376 μg/l (between 0.00011 and 0.387, median 0.0016, s.d.: 0.095, s.e.m.: 0.038) and it was obtained at 60th minute. Nadir GH level during IVGTT was observed at 10th minute and it was 0.112 μg/l (between 0.0005 and 0.770, median 0.0053, s.d.: 0.242, s.e.m.: 0.057). There was statistically significant difference between GH levels at 10th minute in IVGTT and at 60th minute in OGTT (Z=-2.201, P=0.028). GH level at 10th minute in IVGTT was higher than GH level at 60th minute in OGTT.

Conclusions
Effect of gastroenteropancreatic pathway which may show individual differences can be eliminated by IVGTT. GH suppression by IVGTT may be used in the diagnosis and follow-up of patients with acromegaly. Higher nadir GH levels in IVGTT indicates that nadir GH levels suggested for remission in acromegaly patients are relatively low. Our results show that there may be need to revise the remission criteria for acromegaly.

P231

The reliability of GH stimulation tests in the diagnosis of childhood GH deficiency
Zs Szanto, I Z Kun, K Gergely, J Balazs & A Nasalean
University of Medicine and Pharmacy, Targu Mures, Romania.

Objective
To evaluate the reliability of GH stimulation tests in multiple pituitary hormone deficiency (MPHD) and isolated GHD.

Materials and methods
In 19 children with MPHD, we analysed the results of insulin tolerance test (ITT), clonidine and sleep tests, anthropometric parameters, IGF1, bone age, pituitary hormone levels and MRI. GH provocation tests were repeated after variable periods, mostly 6–24 months. The GH provocation tests were considered positive, if peak GH-value <10 ng/ml. The results were compared with those obtained in 15 children with isolated GHD (with harmonic short stature, height-SDS <3 s.d., reduced IGF1 and bone age, at least one GH stimulation test positive).

Results
In children with MPHD, the mean age at diagnosis was 11.25±3.48 years and mean height-SDS = 5.00±(−1.40) s.d. Thyroid and adrenal function were normalised before GH provocation tests. ITT and sleep tests were positive in all children, clonidine test was false-negative in 3 cases (15%). IGF1 before rhGH therapy was decreased in 81.2% cases. Bone age before rhGH therapy was delayed with 1.4–9.25 years (mean: 4.61±2.2 years). In children with isolated GHD, mean age at diagnosis was 9.69±3.65 years, mean height-SDS = 4.00±(−0.61) s.d., bone age delayed with 3.41±1.58 years. False-negative results were obtained in 4.7% of ITT, 15.7% of clonidine tests and 20% of sleep tests, thus GH stimulation tests were discordant in five children (1/3 of isolated GHD).

Conclusion
The results of GH stimulation tests were discordant in 15.8% of MPHD (due to false-negative clonidine test), but more frequently (1/3 of children) in isolated GHD, even if IGF1 and bone age sustained the presumed diagnosis. We consider that in isolated GHD at least two tests should be used, mainly if the first GH provocation test is below the cut-off level.

P232

Copeptin in the differential diagnosis of the polydipsia–polycythemia syndrome: revisiting the direct and indirect water deprivation tests
W K Fenske1, M Quinkler2, U Haagen3, J Papassotiriou4, A F H Pfeiffer5
1Endocrine and Diabetes Unit, Medical Department, University Hospital of Wuerzburg, Wuerzburg, Germany; 2Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Berlin, Germany; 3BreA.H.M.S. AG, Research Department, Berlin, Berlin Hennigsdorf, Germany; 4Division of Endocrinology, Berlin, Germany; 5Department of Internal Medicine I – Cardiology, University of Wuerzburg, Wuerzburg, Germany.

Background
The water deprivation test (WDT) with direct or indirect measurement of plasma vasopressin (AVP) is the method of choice for the differential diagnosis of the polydipsia-polycythemia syndrome. In theory, direct measurement of AVP is highly attractive but hampered by technical difficulties.

Objective
To evaluate the utility of copeptin, a surrogate of AVP secretion, in the diagnostic work-up of the polydipsia-polycythemia syndrome, and to compare its performance with the current diagnostic standard.

Setting and design
In two tertiary referral centres, 20 healthy subjects and 50 patients with polydipsia-polycythemia syndrome underwent WDT with measurements of both plasma AVP and copeptin levels. The reference diagnosis was based on clinical information and treatment response.

Results
Twenty-two patients (44%) were diagnosed with primary polydipsia, 17 (34%) with partial central diabetes insipidus (DI), 9 (18%) with complete central DI, and 2 (4%) with nephrogenic DI. The indirect WDT led to a correct diagnosis in 35/50 patients (70%). The direct WDT with AVP or Copeptin measurement correctly diagnosed 23 patients (46%) or 36 patients (72%), respectively. Baseline copeptin values >20 pmol/l identified patients with nephrogenic DI, and concentrations <2.6 pmol/l indicated complete central DI. The ratio between delta copeptin (8 to 16 h) and serum sodium concentration at 16 h yielded optimal diagnostic accuracy, allowing to also discern partial central DI from primary polydipsia (sensitivity and specificity 87 and 100%, respectively).

Conclusion
Copeptin holds promise as a diagnostic tool in the polydipsia-polycythemia syndrome improving significantly the diagnostic accuracy of the direct WDT.

P233

GH replacement therapy in elderly GH deficient patients: a systematic review
N E Kokshoorn, N R Biermasz, F Roelfsema, J W A Smit, A M Pereira & J A Romijn
Leiden University Medical Center, Leiden, The Netherlands.

Context
Recombinant human GH (rhGH) is indicated for the treatment of adult subjects with GH deficiency (GHD). However, conflicting data are available on the efficacy of rhGH treatment in elderly GHD patients.

Objective
To assess the efficacy of rhGH treatment in elderly GHD subjects.

Methods
We searched PubMed, Cochrane Library, Web of Science, and EMBASE. Study selection Eligible studies included GHD patients, aged >60 years, treated by rhGH. Data extraction was performed by two reviewers independently.

Results
We found 11 eligible studies with a total of 534 patients. Only 2 studies had prospective, randomized, placebo-controlled study designs with a duration of rhGH treatment of 6 (n=15) and 12 months (n=62), respectively. Treatment with rhGH decreased total and LDL-cholesterol levels by 4–8 and 11–16%, respectively, but did not alter HDL or triglyceride (TG) levels. RhGH did not affect body mass index, but decreased waist circumference (by ~3 cm) and waist/hip ratio. RhGH did not consistently affect blood pressure or bone mineral density. RhGH increased lean body mass by 2–5% and decreased total fat mass by 7–10% in 4 studies, but did not affect body composition in 2 other studies. RhGH consistently improved quality of life parameters reflected in AGHDA-scores. There are no explicit data on elderly GHD patients aged >80 years.

Endocrine Abstracts (2011) Vol 26
Results In patients with somatotropinoma (GH ~ 22.8 ± 3.5 ng/ml) and somatotropinoma (GH ~ 26.3 ± 5.3 ng/ml) vital signs varied in large (SBP (80 – 176, mmHg); DBP (58–116, mmHg); HR (48–95, bpm); P (50–95, bpm)). Arterial hypertension was recorded in 64.5%, tachycardia in 12.5% and bradycardia in 4.5% of patients. It was revealed significant associations of GH and IRI with cardiovascular signs, approximated by equations: SBP = 2.32*GH + 2.13*IRI (R^2 = 75.4%; P < 0.001); DBP = 1.48*GH + 1.31*IRI (R^2 = 75.4%; P < 0.001); HR = 1.06*GH + 1.01*IRI (R^2 = 70.4%; P < 0.001); P = 1.13*GH + 1.19*IRI (R^2 = 73.54%; P < 0.001).

Conclusion High prevalence of arterial hypertension may be part of metabolic complications of chronic GH and IGF1 excess mediated by hyperinsulinemia. Increased or decreased heart rate may be due to sympathovagal imbalance in patients with acromegaly.

P235
Hormonal effects on cardiovascular function in patients with acromegaly
Myroslava Myktytyuk, Oksana Khyzhyak, Tatiana Sulima & Yuri Karachentsov
Institute for Endocrine Pathology Problems, Kharkiv, Ukraine.

Introduction Cardiovascular complications are the most relevant cause of mortality in patients with acromegaly. Aims To evaluate the effects of chronic excess of GH, IGF1 and PRL on blood pressure, heart rate and pulse in patients with active acromegaly. Subjects and methods Sixty-three patients (22 men and 41 women; aged 18–76 years) with macroadenoma of hypophysis (45 – somatotropinoma, 19 – somatotropinoma) were under investigation. Blood samples for GH, IGF1, prolactin (PRL), insulin (IRI) were taken in fasting state. Routine measurements of blood pressure (SBP and DBP), heart rate (HR) and pulse (P) were done. Disease activity was evaluated by means of OGTT according to the Consensus Conference criteria. Hypertension was diagnosed in the presence of DBP above 90 mm/Hg. Data are given as M ± S.E.M. and multiple regression model equations.

P236
Expression of canonical Wnt proteins and survivin in pituitary tumours
R Formosa¹, M Grupetta¹, S Falzon², G Santillo³, J DeGaetano³, A Xuereb-Anastasi¹ & J Vassallo²
¹University of Malta, Msida, Malta; ²Mater Dei Hospital, Msida, Malta.

Wnt developmental pathways, have been implicated in a number of cancers. Wnt signaling proteins activate the β-catenin transcription factor which induces transcription of the oncogenes Cyclin D1 and Myc (Luo et al. 2007). Elston et al. (2008) found that Wnt inhibitors were down-regulated in pituitary tumours. Overexpression of Survivin, an inhibitor of apoptosis, correlates with poor prognosis and drug resistance (Altieri 2003, Ghosh et al. 2007). Survivin also interacts directly with the aryl hydrocarbon receptor – interacting protein (AIP) mutations of which have been linked with increased susceptibility to pituitary tumour development (Kang & Altieri 2006). The aim of this study was to analyze the expression of B-catenin, Cyclin D1, Myc and Survivin in 40 pituitary adenomas (30 non-functional, 7 acromegalic, 2 prolactinomas, 1 Cushing’s) collected at transphenoidal surgery and 6 normal controls using immunohistochemistry. The results indicate that B-catenin is membrane bound with no difference between normal and tumour tissue, although smaller tumours had higher expression (P < 0.05). Cyclin D1 and Myc expression was nuclear and higher in tumour vs normal tissue (P < 0.05). Myc expression also increased with lower age at diagnosis (P < 0.001, R = 0.361) while Cyclin D1 expression was higher in males than in females (P < 0.05). Female patients also had overall younger age at diagnosis (P < 0.05) and smaller tumours. Expression of survivin was very low in tumours and absent in normal controls. Therefore, involvement of the canonical Wnt pathway appears to be low, since B-catenin was not found located in the nucleus but Myc and Cyclin D1 proteins may play an important role in early pituitary tumorigenesis. Survivin appears to play a minor role owing to its almost complete absence in tumours with < 1% of cells showing nuclear staining. Further analysis of the roles of Myc and Cyclin D1 in pituitary tumorigenesis is required.

P237
Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly
M R Postma¹, R T Netea-Maier², G van den Berg³, J Homan², W J Sluiter², A C M van den Bergh¹, B H R Wolfenbuttel¹, A R M M Hermus² & A P van Beek³
¹Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands; ²Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands; ³Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands.

Objective To assess the influence of use of long-acting somatostatin analogs on long-term health-related quality of life (HR-QoL) in relation to disease control in patients surgically-treated for acromegaly.

Design Cross-sectional study in two University Medical Centers in The Netherlands.

Patients One hundred and eight patients (47 m/61 f; mean age 54±11 years) with a minimal follow up period of 1 year after pituitary surgery for GH-producing adenoma as primary treatment. Transsphenoidal surgery was performed in 101
P238

Improvement of acromegalic cardiomyopathy following pituitary apoplexy
Hospital Son Espases, Palma of Majorca, Spain.

Introduction
Cardiovascular disease is present in up to 60% of patients diagnosed of acromegaly and is responsible of the major related morbidity and mortality.

Case report
A 79-year-old-woman with previous history of diabetes mellitus and hypertension was admitted for acute pulmonary edema. Transthoracic echocardiogram showed a severe left ventricular dysfunction with an ejection fraction of 20%, dilated left ventricle and left atrium with a moderate mitral regurgitation. On physical examination, she had rough features, with growth of acral parts, prognatism, macroglossia, diastema, acrochordons and goiter, suggestive of acromegaly, without any previous study. During the admission, she suffered a sudden episode of severe frontal headache with hypotension and hyponatremia. Pituitary apoplexy and acute secondary adrenal insufficiency was suspected and immediate treatment with intravenous steroids was initiated. MRI showed a heterogeneous intrasellar mass of 2.3 × 2.3 cm with hemorrhagic component secondary to necrosis. Hormonal analysis revealed a hypogonadotropic hypogonadism, secondary adrenal insufficiency, suppressed TSH, normal FT3 and low FT4. Serum levels of GH and IGF1 were within normal limits. Visual field was not valuable. She was discharged with the diagnosis of acromegalic cardiomyopathy. Eight months later, she presents an improvement of her acromegalic features, with hypogonadotropic hypogonadism, secondary adrenal insufficiency and normal GH and IGF1 serum levels. The echocardiogram shows an improvement of the left ventricular volume and the systolic left ventricular function with an ejection fraction of 50% and mild mitral regurgitation.

Conclusions
An early and accurate diagnosis of acromegaly is important to prevent serious cardiac related complications. Acromegalic cardiomyopathy may improve dramatically with the treatment of the disease or exceptionally following a pituitary apoplexy, as illustrated in this case.

P239

Pituitary apoplexy as initial manifestation of pituitary tumors: two case reports
J Saraiva, L Gomes, I Paiva, J Santos, A Vieira, M Alves, S Gouveia & M Carvalheiro
Serviço de Endocrinologia, Diabetes e Metabolismo, Hospitais da Universidade de Coimbra, Coimbra, Portugal.

Introduction
Pituitary apoplexy is rare (0.6 to 12.3%). Sudden expansion of pituitary tumor, from hemorrhage or infarction, may lead to permanent vision loss, paresis or death. We describe two cases of apoplexy as the initial manifestation of pituitary tumor.

Case 1
Male, 30 years, healthy, observed in the emergency room (ER) complaining of headache, visual deficit and left ptosis for 3 days. He had left ptosis and bilateral paresis of the IV pair. Magnetic resonance imaging (MRI) showed ‘sellar and suprasellar mass 2.7 × 2.4 × 1.9 cm, compatible with pituitary macroadenoma with intrasellar herniation’. Laboratory findings: FSH 3.4 mIU/ml, LH 1.6 mIU/ml, total testosterone 1.1 ng/ml, TSH 0.082 mIU/ml (0.4–4), FT4 0.4 ng/dl (0.8–1.9); IGF1 104 ng/dl (117–329), prolactin, ACTH and cortisol were normal. Transsphenoidal surgery performed three days later. Neuroradiology: necrosis of the pituitary adenoma. He had complete resolution of visual deficit, maintenance of secondary hypothyroidism and decreased IGF1 but without gonadal and adrenal insufficiency. MRI, 2 months later showed tumor residue with 7 mm. Currently on levotiroxine 0.075 mg id.

Case 2
Male, 66 years, observed in the ER for headache, diplopia and right ptosis. Background: atrial fibrillation, hypertension and dyslipidemia, all medicated. Physical examination: right ptosis and ophthalmoplegia, partial involvement of III, IV and VI pairs. MRI: ‘sellar mass 3.0 × 1.9 × 2.2 cm compatible with pituitary macroadenoma’. Laboratory findings: FSH 4.7 mIU/ml, LH 3.5 mIU/ml, total testosterone 1.7 ng/ml, prolactin 121 ng/ml (<18), without other insufficiency. Transsphenoidal surgery was performed 1 week later. Neuroradiology: prolactinoma with hemorrhagic necrosis. After surgery, he presented partial improvement of neurological deficits. Prolactin 22 ng/ml, IGF1 68 ng/dl (117–329), without other hormonal insufficiencies. MRI: residue 1.21 × 1.46 × 1.39 cm. No need for hormonal substitution therapeutic.

Conclusions
These cases call attention to the unpredictability of acute pituitary apoplexy. It should be considered in all patients with neuro-opthalmological deterioration and acute headache. Early diagnosis and timely surgical treatment leads to significant improvement in visual and hormonal deficits.
Periodontal disease frequency screening and GM studies in acromegalic patients

Periodontal disease frequency was screened and compared in 15 acromegalic patients with age and sex matched 50 healthy subjects. Periodontal evaluation included panographic radiography, plaque and gingival index and depth determination and clinical parameters. Estimated disease duration was 2–10 years in acromegalic patients (8 female, 7 male patients, 52±13 years). Five patients on somatostain analog therapy had inactive disease for at least 2 years and 10 patients had active acromegaly. Oral examination revealed macroglossia nad gingivitis in all patients. Gingivitis was found in 6 and chronic periodontitis was diagnosed in 9 patients. Presence of chronic periodontitis was found to be correlated wit serum GH/IGF1 levels. Presence of macroglossia and impaired glucose metabolism were not found to be correlated with periodontal disease. Gingivitis incidence was similar with the general population in our healthy control group which reached to about 80%. On the other hand all of the acromegalic patients revealed gingivitis or periodontitis. Routine periodontal examination is strongly recommended for acromegalic patients as it is almost always a problem.

Relationship between GH activity and markers of inflammation: a cross-over study of healthy volunteers treated with GH and a GH antagonist for 3 weeks

Observations in patients with GH disturbances and in normal populations have suggested that GH/IGF1 activity could have anti-inflammatory effects. On the other hand, in vitro studies have shown that IGF1 may stimulate the immune system.

Methods/design

The study population consisted of 12 healthy volunteers (mean age 36, range 27–49 years) treated with GH for 3 weeks (1st week 0.01 mg/day, 2nd 0.02 mg/day, 3rd 0.03 mg/day) and subsequently with a GH antagonist (pegvisomant) (1st week 10 mg/day, last 2 weeks 15 mg/day) or visa versa. Wash-out 8 weeks. Circulating levels of tumour necrosis factor-α (TNF-α), interleukin 6 (IL6), CRP, YKL-40, haptoglobin, orosomucoid and fibrinogen were measured after stimulation and inhibition of GH action.

Results

GH treatment compared to pegvisomant treatment led to an increase in serum IGF1 (median 393 (IQR 346–543) vs 91 (78–114) ng/ml, P<0.005) and in TNF-α (1.44 (0.97–1.75) vs 1.08 (0.74–1.48) pg/ml, P=0.047), haptoglobin 10.0 (8.0–18.5) vs 9.0 (6.8–13.8) µM, P=0.051) and fibrinogen (10.8 (9.2–12.2) vs 8.5 (7.4–10.6) µM, P=0.005). By contrast orosomucoid (16.0 (15.0–19.5) vs 22.0 (17.0–29.3) µM, P=0.005) and CRP (0.64 (0.55–1.71) vs 1.43 (0.71–3.29) mg/l, P=0.037) were reduced during GH treatment. IL6 and YKL-40 were unchanged. Compared to baseline there was an increase in serum GH after treatment with both GH (0.26 (0.13–0.51) vs 4.33 (1.81–7.25) ng/ml, P=0.005) and pegvisomant (0.26 (0.13–0.51) vs 1.02 (0.34–3.48) ng/ml, P=0.013). Serum pegvisomant was 8714 (3881–15666) ng/ml.

Conclusions

The data support that high GH/IGF1 activity stimulates the initial phase of the innate immune response evaluated by the pro-inflammatory cytokine TNF-α. However the opposing results on down stream acute phase proteins (haptoglobin and haptoglobin versus orosomucoid and CRP) support a complex interplay between GH/IGF1 action and the inflammatory cascade that does not allow simple conclusions on whether GH/IGF1 action has pro- or anti-inflammatory effects in vivo.

Diabetes mellitus as adjunctive risk factor for vertebral fractures in men with acromegaly

GH excess is considered as one of the causes of secondary osteoporosis with an increased risk of vertebral fractures in men and post-menopausal women with acromegaly. GH excess in acromegaly is also frequently associated with type 2 diabetes which is considered as a risk factor for fragility fractures in the general population. In this cross-sectional study, we evaluated whether type 2 diabetes may influence the prevalence vertebral fractures in acromegaly. Fifty-seven males with acromegaly (median age 47 years, range: 24–85) and 57 control males were evaluated for bone mineral density (BMD) by lumbar DXA and for vertebral fractures by a radiological and morphometric approach. Seventeen acromegalic patients were affected by type 2 diabetes. The prevalence of vertebral fractures was higher in acromegalic patients as compared with the control subjects (52.6 vs 10.5%, P<0.001). Acromegalic patients with fractures had serum IGF1 values significantly higher, and the duration of active disease significantly longer than those found in patients who did not fracture. The prevalence of fractures was significantly higher in acromegalic patients with diabetes as compared to those without diabetes (76.5 vs 42.5%, P=0.02), without significant difference in BMD-Z-score at lumbar spine. No significant difference in prevalence of vertebral fractures was observed between patients with controlled and those with uncontrolled diabetes. In the multivariate regression analysis, the correlation between diabetes and vertebral fractures was independent of activity of acromegaly (odds ratio 5.8, 95% CI 1.4–23.5; P=0.01). In conclusion, this study suggests that type 2 diabetes mellitus may be an adjunctive risk factor for vertebral fractures in men with acromegaly according to the hypothesis that GH hypersecretion and insulin resistance may exert synergic negative effects on the skeleton. On clinical point of view, our results would suggest to perform a strict skeletal monitoring of acromegalic patients with type 2 diabetes.
Efficacy of weekly pegvisomant monotherapy

R D O’Connor, A J van der Lely, M Madsen, J O Jorgenson & S J C M M Neggers
Erasmus Medical Center, Rotterdam, The Netherlands.

Introduction
Daily administration of Pegvisomant normalizes IGF1 levels >71% of acromegalic patients (1). Few studies have assessed the efficacy of weekly administration. We assessed the efficacy of weekly pegvisomant for 12 months, after withdrawal of long-acting somatostatin analogs (SSA) in acromegaly previously controlled on combination therapy.

Design
Fifteen subjects (8 males), age 58 (35–80) (median (range)) years on combination therapy of high-dose SSA and weekly pegvisomant and IGF1 levels within the normal range for >6 months, were enrolled. IGF1 at baseline was 6.02 (3.0–8.84) times the upper limit of normal (ULN) and the weekly dose of pegvisomant was 60 (30–80) mg. SSA treatment was stopped for 12 months. IGF1, HbA1c, GH and pegvisomant concentrations were assessed at baseline and thereafter every 6 weeks. When IGF1 levels increased, pegvisomant dose was increased by 20 mg weekly. Dosages were divided into two injections per week when pegvisomant exceeded 80 mg.

Results
Baseline pegvisomant and GH serum levels were 2988 (252–19 440) and 2.99 (0.19–15.95) μg/l respectively. After 12 months, in 73.3% of subjects IGF1 levels remained controlled under monotherapy of pegvisomant. One patient restarted SSA, during the study period, due to an increase in signs and symptoms of acromegaly. After 12 months, IGF1 was 0.83 (0.30–1.75) ULN, while the cumulative weekly pegvisomant dose increased to 80 (50–120) mg. Pegvisomant and GH levels increased to 4356 (1116–21 276) and 6.36 (0.180–31.45) μg/l respectively.

Pegvisomant levels tended to be different between subjects in whom IGF1 remained normal and those who did not: 5544 (1116–21 276) vs 3848 (1296–4392) μg/l, although the weekly pegvisomant dose was the same. HbA1c decreased from 6.0 (5.1–9.2) to 5.9 (5.0–9.1%) (P = 0.02).

Conclusion
After cessation of SSA treatment in acromegalic subjects on combination therapy, weekly pegvisomant could control 73.3% of patients. Pegvisomant levels seem to be lower in patients with an elevated IGF1 than in patients with a normal IGF1, with similar subcutaneous administration dosages.

AcroBel-2: the Belgian follow-up survey on acromegaly: contribution of pituitary surgery and the use of pegvisomant to an improvement in disease control

M Rex1, R Abs2, G T’Sjoen3, B Corvillain4, B Velkeniers5 & D Maiter6
1UZLeuven, Leuven, Belgium; 2Antwerp, Antwerp, Belgium; 3UZGent, Belgium; 4ULB Erasme, Brussels, Belgium; 5UZBrussel, Brussels, Belgium; 6ULC St Luc, Brussels, Belgium.

Two nationwide surveys on acromegaly (AcroBel-1 and 2) have been performed in Belgium at an interval of five years, including centralized GH and IGF1 measurements in most patients. A normal IGF1 for age was observed in 56% of 311 vs 74% of 365 treated patients, in 2004 and 2009 respectively. Factors responsible for this improvement were investigated. A selection bias was unlikely as the follow-up rate was higher in patients with active (83%) or medically controlled disease (71%) compared to those with surgical remission (61%).

In 225 patients with sampling in each survey, a normal IGF1 was observed more frequently in AcroBel-2 (80%) than in AcroBel-1 (52%), due to a first or additional surgery (n = 20; remission in 45%), long-term effects of previous radiotherapy (n = 84), initiation or intensification of medical therapy, including pegvisomant (n = 21; control in 67%).

In 106 patients newly diagnosed and treated since the first survey, 63% had a normal IGF1. Seventy-five % had pituitary surgery and the overall remission rate (including low or suppressible GH) was 43%, but reached 50% and 68% in two centres responsible for over half of surgeries. Surgical procedures elsewhere (38 patients in 18 hospitals) allowed remission in 24% (range 0–100%). Radiotherapy was used in 3 cases only. Primary medical therapy (mostly SSA, n = 24) normalized IGF1 in 42%; adjunct medical therapy (SSA or DA, n = 24) in 50%, and combined treatment with SSA and pegvisomant (n = 11) in 64%.

**
A normal IGF1 was present in 74% of the remaining 34 patients from AcroBel-2, with diagnosis before 2003 (33 operated; 13 irradiated: 10 on medical therapy).

Conclusion
In the recent survey, a more frequent disease remission or control was observed, due to a greater use of surgery with improved outcome and to intensification of medical treatment including introduction of pegvisomant.

A multicenter study on acromegalic patients treated with pegvisomant monotherapy or with d3-GHR plus somatostatin analogues: role of exon 3 deleted GH receptor polymorphism

Marcello Filopanti1, Luca Olgiati1, Andrea Lania2, Paolo Beck-Peccoz1,2, Laura De Marinis1, Silvia Grottoli3, Chiara Martini1, Salvatore Cannavo4, Fausto Bogazzi1, Diego Feroni4, Giorgio Arnaldi5, Alessandro Peri5, Patrizia Tita1, Francesca Pigliaru1, Gabriella Angeletti1, Marie-Lise Jaffrain-Rea1, Marco Losa1,2 & Anna Spada1,2
1Unit of Endocrinology and Diabetology, Fondazione IRCCS Ca’ Granda, Milan, Italy; 2Endocrinology Unit, Department of Medical Sciences, University of Milan, Milan, Italy; 3Division of Endocrinology, School of Medicine, Catholic University of Rome, Italy; 4Division of Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy; 5Internal Medicine 3, Department of Medical and Surgical Sciences, University School of Padua, Padua, Italy; 6Section of Endocrinology, Department of Medicine and Pharmacology, University of Messina, Messina, Italy; 7Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy; 8Department of Endocrinology, University of Genoa, Genoa, Italy; 9Division of Endocrinology, Department of Internal Medicine, Polytechnic University of Marche Region, Ancona, Italy; 10Endocrine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy; 11Divisione Clinizzazione di Endocrinologia, Ospedale Garibaldi, Catania, Italy; 12Endocrinology and Metabolism, Department of Medical Sciences, University of Cagliari, Cagliari, Italy; 13Section of Internal Medicine and Endocrinological and Metabolic Sciences, Internal Medicine Department, University of Perugia, Perugia, Italy; 14Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy; 15Pituitary Unit, Department of Neurosurgery, Istituto Scientifico San Raffaele, Università Vita-Salute, Milan, Italy.

Introduction
To date, two pharmacogenetic studies investigated the effect of the common exon 3 deletion of GH receptor (d3-GHR) variant in small series of acromegalic patients treated with Pegvisomant (Peg), suggesting an association of d3-GHR allele with better response to Peg.

Aim
To assess the influence of d3-GHR variant in a large cohort of acromegalic patients with active disease and resistance to somatostatin analogues (SSA) treated with either Peg monotherapy or Peg plus SSA.

Patients and methods
A multicenter cross-sectional pharmacogenetic study was conducted in 16 Italian Endocrinology Centers. Data of 127 Peg treated patients were recorded with online case report form and DNA was genotyped by the coordinating center.

Results
Eighteen patients (13.9%) were d3-GHR homozygotes, 41 (34.3%) heterozygotes, and 68 (51.9%) were homozygotes for full-length GHR (fl-GHR) without any significant differences in allele frequencies in respect of both normal subjects and non-Peg treated acromegalic patients. However, the distribution of GHR genotypes among Peg patients did not follow the Hardy–Weinberg equilibrium.

A similar frequency of d3-GHR allele was observed in 64 patients receiving Peg + SSA therapy. Pegvisomant dosage was similar in patients having or not d3-GHR both in Peg (1.3 ± 0.42 vs 1.5 ± 0.6; P = 0.396) and in combined treatment (1.2 ± 0.4 vs 1.3 ± 0.7; P = 0.482). Fourteen patients experienced adverse effects (lipohypertrophy, increased hepatic enzymes, pain) that were not associated with GHR genotype. Nine patient had tumour residue growth (5 fl-GHR homozygotes, 4 d3-GHR).

Conclusions
This study did not confirm the association of d3-GHR with better response to Peg treatment both in monotherapy and combined with SSA. Further studies are needed to assess whether the unlinked Hardy–Weinberg equilibrium exclusively found in Peg treated patients may be attributed to a random genetic drift or may reflect a role of d3-GHR in the severity of disease activity and outcome.
P248
Detection of acromegaly by automatic face classification software
H J Schneider1, R Kosilek1, M Günther1, J Römmler1, G K Stalla1, C Sievers1, M Reincke1, J Chopohl2 & R Würtz2
1Medizinische Klinik, Innerstadt, Ludwig Maximilians University, Munich, Germany; 2Institut für Neuroinformatik, Ruhr-Universität, Bochum, Germany.

Acromegaly is accompanied by increased morbidity and mortality. The delay between onset of first symptoms and diagnosis of the disease is 6 to 10 years. Acromegaly causes typical changes of the face. We hypothesized that face classification software might help distinguishing between subjects with and without acromegaly on regular photographs and, thus, might help improving early recognition of acromegaly.

Methods
We took frontal and side photographs of the faces of 57 patients with acromegaly (29 women, 28 men) and of 60 sex- and age-matched controls. We grouped patients into subjects with mild, moderate, and severe facial features of acromegaly by overall impression. We then analyzed all picture by using two principles of similarity analysis: analysis of texture using Gabor jets and analysis of geometry using facial landmarks. We used the leave-one-out cross-validation method to classify subjects by the software. Additionally we asked three acromegaly experts and three general internists to classify all pictures by visual impression.

Findings
The software correctly classified 71.9% of patients and 91.5% of controls, using a combination of texture and geometry analysis. Correct classification rates for patients by visual analysis were 63.2 and 42.1% by experts and general internists, respectively. Correct classification rates for controls were 80.8 and 87.0% by experts and internists, respectively. Patients with mild facial features of acromegaly (n=24) were correctly classified at 58.3, 38.9 and 20.8% by software, experts, and internists, respectively. Similar classification rates were achieved by the software and experts for patients with moderate or severe features of acromegaly.

Interpretation
Acromegaly can be detected by computer software using photographs of the face. Classification accuracy is higher than by medical experts or general internists. This is particularly the case for patients with mild features of acromegaly.

P249
Prolactinoma cell culture: experimental model for tumor growth
D Manda, O Popa, S Vlăduț, C Stancu, A Serban, M Coculescu & O Iancu ‘C.I. Parhon’ National Institute of Endocrinology, Bucharest, Romania.

We present an experimental study on human prolactinoma in cell culture from a patient that partially responded to cabergoline treatment and had to have surgical treatment.

Aim
The aim of the study was to assess the effect of cabergoline, dopamine and melatonin on prolactin secretion and cell proliferation in human prolactinoma cell culture from a patient that had transsphenoidal surgery.

Material and methods
Tissue specimen derived from pituitary adenoma fragments removed in routine transsphenoidal surgery. Cells were plated at 10⁵ cells/well into 24-well plate in a final volume of 1 ml. The test substances, cabergoline (CB) in doses between 0.1 mg/ml and 10⁻³ M, dopamine (DA) 10⁻⁹ M, melatonin 10⁻³ and 10⁻⁷ M or in combination were added and incubated for 4 days. The supernatant was centrifuged and kept frozen until prolactin (PRL) assay. Another 96-well plate was seeded with 10⁵ cells/well for MTT proliferation assay and treated following the same schedule in 0.1 ml/well. Proliferation was assayed by adding 20 μl of 5 mg/ml MTT, incubation 3.5 h in cell incubator, removing media and adding 150 μl MTT solvent (4 mM HCl, 0.1% Nonidet P-40 in isopropanol) and reading absorbance at 590 nm. Prolactin was assayed by electrochemiluminescence with Roche reagents.

Results
Cabergoline significantly inhibited PRL secretion in a dose dependent manner. At 10⁻⁶ M the inhibition was of 59.45%. MTT slightly increased prolactin secretion; dopamine had no effect on PRL secretion. The PRL levels in the samples treated with combination of DA/CB or MLT/TCB did not significantly changed compared to the wells treated with CB alone. All tested substances stimulated cell proliferation.

Conclusions
Results confirm the in vivo anti-secretory effect of cabergoline on prolactin without an anti-proliferative effect on tumor cells. Prolactinoma cell culture from transsphenoidal surgery proved to be a good experimental model to test substances that may inhibit tumor growth and to search for specific factors of aggressiveness in the context of personalized medicine.

Note: The study was funded by PNII 41014 research grant.

P250
Evolution of invasive treatment-resistant prolactin (PRL) adenoma
M. Vetić & P.Tita
Department of Endocrinology, Catania, Italy.

Giant prolactinomas are rare and their treatment and outcome has been addressed only in isolated case reports. Some patients develop treatment-resistant tumors. We describe a patient with an invasive PRLoma resistant to conventional therapy. A 40-year-old female was diagnosed at age 22 as a PRLoma who, although having received all available formulations of dopamine agonists over a period of 18 years, responded neither clinically, nor hormonally (PRL 9560.0 ng/ml, nv <20). At 42 years she underwent trans-sphenoidal tumor resection, but PRL levels remained elevated (1050 ng/ml) even under high cabergoline dosage (0.75 mg/die). Empirical somatostatin analog treatment (octreotide 120 mg s.c./4 weeks) was also tested with no result. After nearly 20 years from diagnosis suddenly the tumor started growing in size with severe headache, impairment of cognitive function and PRL level increase (>10,000 ng/ml). The polyethylene glycol (PEG) precipitation test recovered elevated serum prolactin indicating that no macroprolactin was present. MRI showed the further growth of the large pituitary mass, invading the left cavernous sinus, with partial internal carotid artery occlusion and compression of the hippocampus and the third ventricle. Despite the additional trans-sphenoidal surgical procedure followed by gamma-knife radiosurgery, the patient is still with size tumor progression (diameter close to 6 cm). Because the patient has been judged unsuitable for re-intervention or gamma-knife treatment, and external radiotherapy has been without efficacy, she is now waiting for treatment with receptor-mediated radiotherapy with Yttrium-90 DOTATOC. This case emphasizes the importance of giant prolactinomas monitoring, the possible sudden change of their behaviour with invasive and compression complications and the need to secure to all available treatments.

P251
Lost to follow-up in acromegaly, results of ACROSPECT observational study
B D Delenmer1, C R Reinig1, T B Brue1, C C Cortet Rudelli2, I R Raingeard3, Y R Reznik1, X P Parot4 & O C Chabre5
1CHU de Reims, Reims, France; 2Novartis Oncology, Rueil-Malmaison, France; 3Hôpital de la Timone, Marseille, France; 4Hôpital Albert Michallon, La Tronche, France; 5Clinique Marc Linquette, Lille, France.

Lost to follow-up (LTFU) is a frequent problem in chronic diseases not evaluated yet in acromegaly despite the long-term need of medical treatment and complications survey in this disease.

Objectives
Evaluation of the prevalence of LTFU patients in a multi-center cohort, characteristics of defaulters and description of their evolution after they have been searched and found.

Methods
Observational multicentric (25 centers study). Each center was asked for the number of acromegalic patients followed up between 1997 and 2007 and for the number of the LTFU patients in the same period. Patients LTFU were defined as the ones who missed follow-up appointments in at least 2 years. These patients
and their GP were recalled by phone and mail and asked about reasons to non-attendance. They were invited either to come to the former center for evaluation of acromegaly or to fill up a medical questionnaire.

Results
A total of 482 patients under 2252 were identified as LTFU, mean 21.4% of the cohort with a variation between the centers from 7.7 to 49%. At the last evaluation before LTFU, IGF1 was normal without treatment in 54%, normal with a medical treatment in 16% and not controlled in 30% of the patients. Recent news have been collected in 362 patients with 62 dead. Most frequent reason of non-attendance was follow-up by another physician in 69%. Pourcentage of patients with medical treatment decreased from 28 to 15%. Among the 87 patients who came back in the center, acromegaly was not controlled in 20% and the treatment had to be modified in 17%, lack of medical survey was observed in 16%.

Conclusion
In acromegaly LTFU concerns 21.4% of the patients. Treatments are stopped in these patients in half of the cases. When the patients are reevaluated 20% are not controlled. As acromegaly can now be controlled quality of follow-up is a real clinical challenge.
formation in the test, resulting in decreased GH measured in serum. At the same
time pegvisomant could act as an antigen and the patient may have developed a
significant immunogenic neutralizing response to PEGV.

P255
Quality of life and cortisol diurnal rhythm after 3 months of medical
treatment for Cushing’s disease
R van der Pas 1, C de Bruin 1, A Pereira 1, J Romijn 2, R Netea 3, A Hermus 3,
P Zelissen 1, F de Jong 1, A van der Lelij 1, W de Herder 1, S Webb 4,
S Lamberts 1, L Holland 2 & R Feelders 1
1 Erasmus Medical Center, Rotterdam, The Netherlands; 2 LUMC, Leiden, The
Netherlands; 3 Radboud UMC, Nijmegen, The Netherlands; 4 Utrecht
UMC, Utrecht, The Netherlands; 5 Hospital Sant Pau, Barcelona, Spain.

Introduction
Cushing’s disease (CD) is characterized by various symptoms, amongst which
fatigue, muscle weakness and depression. The chronic state of hypercortisolism
severely impairs quality of life (QoL). In addition, the physiological cortisol
diurnal rhythm (CDR) is disturbed in CD. Transsphenoidal surgery is the primary
treatment for CD, but long-term remission rates are disappointing. We performed
a prospective trial in which stepwise medical treatment was applied with the
somatostatin-analog pasireotide, the dopamine agonist cabergoline and the
adrenal-blocking agent ketoconazole. We now report the effect of this regimen
on QoL and CDR.

Methods
Seventeen patients with CD were treated for 80 days with pasireotide
monotherapy or combination therapy with cabergoline and, if necessary,
ketoconazole. Hereafter, patients continued medical therapy or underwent
surgery. Using five questionnaires, QoL, was assessed at baseline, day 80 and in
the extension period and compared to literature-derived healthy controls.

Results
At baseline, QoL was significantly reduced compared to healthy controls
according to 8/20 subscales. After 80 days, 15/17 (88%) had normalized urinary
free cortisol excretion. However, emotional reaction was the only QoL-related
according to 8/20 subscales. After 80 days, 15/17 (88%) had normalized urinary
free cortisol excretion. However, emotional reaction was the only QoL-related

P256
Low incidence of adrenal insufficiency after transsphenoidal surgery
in patients with acromegaly: a long-term follow-up study
A M G Burgers, N E Kokshoorn, A M Pereira, F Roelfsema, J W A Smit,
N R Biermasz & J A Romijn
Leiden University Medical Center, Leiden, The Netherlands.

Background
The long-term prevalence of adrenal insufficiency after transsphenoidal surgery
for GH secreting pituitary adenomas was unknown. However, recently a single
study reported a high prevalence of adrenal insufficiency after surgical and/or
medical treatment without postoperative radiotherapy in acromegalic patients.

Aim
To assess the prevalence and incidence rate of adrenal insufficiency in
consecutive patients during long-term follow-up after successful transsphenoidal
surgery for acromegaly.

Methods
In 91 consecutive patients in remission after transsphenoidal surgery, we
retrospectively reviewed insulin tolerance tests, CRH stimulation tests, metyrapone
tests and ACTH stimulation tests used to assess corticosterone function.

Results
Early postoperatively, insufficient adrenal function was observed in 18% of
patients (n = 16), which was transient in 8 and irreversible in 8 other patients in the
first year of postoperative follow-up. Therefore, after the first year, the prevalence
of adrenal insufficiency was 9%. Late, new-onset adrenal insufficiency developed
in only 3 patients, 13, 18 and 24 years postoperatively, resp. The incidence rate of
late adrenal insufficiency after successful surgery was 2/1000 person years.

After long-term follow-up, with a mean duration of 17.7 ± 8.1 years, the
prevalence of secondary adrenal insufficiency was 12% in patients in remission
after surgery for acromegaly.

Conclusion
The prevalence of adrenal insufficiency 1 year after surgery was 9%, whereas
during prolonged follow-up the incidence rate of adrenal insufficiency was
only 0.002 person years in patients in remission after surgery. Therefore,
development of late onset adrenal insufficiency is a very infrequent complication
in patients with acromegaly in remission after transsphenoidal surgery only.

P257
Fertility rate in acromegalic women: a single center experience on
70 patients before and after treatment
L F S Grasso, M Galdiero, R S Anuerra, A Cozzolino, P Vitale, C Simeoli,
R Pivonello & A Colao
Federico II University, Naples, Italy.

Women with acromegaly present often menstrual irregularity, anovularity and
infertility. A direct role of GH and IGF1 excess on the hypothalamus–pituitary–
gonadal axis, hyperprolactinemia and an impaired gonadotropin secretion
related to a tumor mass effect, or polycistic ovary syndrome have been suggested
as possible mechanisms related to infertility. However, no systematic data are
available on fertility in these patients. The aim of this retrospective study was to
evaluate the fertility rate and characteristics in 120 women with acromegaly
attending the outpatient service of our Department between 1995 and 2010, where
70 women with diagnosis of acromegaly were within the reproductive age range
(21–43 years). Gonadal function was assessed on the basis of menstrual status
and hormone profiles before and after treatment of acromegaly. Information on
the desire of pregnancy, nature of conception (spontaneous or after ovarian
stimulation) and pregnancy, was based on medical records and an ad hoc
designed questionnaire distributed to these patients. At the diagnosis, 42 women
(60%) had menstrual disturbances, mainly characterized by oligo-amenorrhea.
Of these 25 (60%) had hypogonadotrophic hypogonadism, 12 (30%) had
hyperprolactinemia, whereas 5 (10%) patients had a clear-cut polycistic ovary
syndrome. During the active disease, 25 women (35%) had desire of pregnancy
but had difficulties in conception and starting pregnancy. In the last 15 years, nine
women became pregnant only after the normalization of GH and IGF1 levels.

Three patients became pregnant after surgical treatment, whereas six women were
receiving medical treatment with somatostatin analogs when they conceived, and
treatment was continued during the pregnancy in two of them. Only one patient
underwent ovarian stimulation and intrauterine insemination. In conclusion,
fertility is commonly impaired in women with acromegaly, 60% of our patients
had gonadal dysfunction, 35% of them had desire of pregnancy and 36% of these
latter patients become pregnant but only after normalization of GH/IGF1 levels.

Effective treatment for acromegaly, represented by surgery or medical therapy
seem to improve fertility, since 30% of patients conceived after surgery and 70%
become pregnant during treatment with somatostatin analogs.

P258
Prevalence of germline mutations of AIP gene in sporadic aggressive
somatotropinomas
M Puig-Domingo 1,2, J Oriola 1,2, I Halperin 2,3, M Mora 2,3, G Diaz-Soto 1,3,
M J Perales 1,2, C Alvarez-Escaló 1,3, J Lucas-Morante 1,2, Ignacio Bernabeu 1,3,6,8,
& Mónica Marazuela 7,8
1 Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 2 Hospital
Clinic, Barcelona, Spain; 3 Hospital Clinico, Valladolid, Spain; 4 Hospital
Universitario La Paz, Madrid, Spain; 5 Hospital Universitario Puerta de
Hierro, Madrid, Spain; 6 Complejo Hospitalario Universitario, Santiago de
Compostela, Spain; 7 Hospital La Princesa, Madrid, Spain.

Most kindreds of familial isolated pituitary adenomas (FIPA) with mutated AIP
develop somatotropinomas, characterized by an aggressive clinical phenotype
including early age at diagnosis, large tumours and frequent invasiveness. In non-
family cases, the prevalence of AIP mutations in pituitary adenomas is lower than
10%. There is no information of AIP prevalence in isolated somatotropinomas
characterized by poor response to conventional treatment.

Aim
To investigate the prevalence of AIP mutations in non-family cases of
somatotropinomas with poor response to conventional treatment.
Patients and methods
A total of 50 patients (22 males/28 females, age 52 ± 15) and 16 controls were included in this study performed at six University Hospitals in Spain. None of them had family history of pituitary adenomas or other endocrine tumours. All patients failed to respond to conventional treatment including surgery and somatostatin analogs. Some of them received adjuvant radiotherapy and most cases required pegvisomant treatment to control residual GH hypersecretion. AIP gene analysis was performed by using standardized PCR protocol (Science 2012; 322: 1228–1230), in which the coding regions of exons 1, 2, 3, 4, 5, 6 were amplified. Possible deletions/duplications were studied using MLPA.

Results
One out of 50 cases showed a not previously described mutation for the AIP gene, consisting in c.26G>A (p.Arg9Gln). The patient was a female with clinical diagnosis of acromegaly performed at the age of 20 years, and bearing a macroadenoma.

Conclusion
AIP germline mutations show a low prevalence in non-family acromegalic patients with tumours resistant to conventional treatment.

P259
Predictive markers of recurrence in radically resected pituitary macroadenomas
L Curtò1, R M Ruggeri1, O R Cotta1, M Ragonese1, A Ieni2, S Puglisi1, D Costanzo1, F Trimarchi1 & Salvatore Cannavo1
1Section of Endocrinology, Department of Medicine and Pharmacology, University of Messina, Messina, Italy; 2Department of Pathology, University of Messina, Messina, Italy.

Introduction
Pituitary adenomas are benign neoplasms which grow slowly, but that can recur even after apparent radical resection. Until now, markers predicting regrowth and invasiveness have not been completely characterized.

Design
We investigated cell proliferation and apoptosis parameters in 20 radically resected pituitary macroadenomas (six GH, two PRL, two ACTH, one FSH and nine non-secretting), in order to predict recurrence risk. Tumour regrowth was demonstrated by MRI in a 5-year follow-up. Proliferative activity and DNA ploidy were analyzed by flow cytometry (FCM) performed on fresh surgical specimens. Immunohistochemical expression of proliferative index MIB-1 and of anti-apoptotic protein Bcl-2 was analyzed on paraffin-embedded specimens.

Results
Six adenomas recurred after surgery, regardless of hormonal hypersecretion. Pre-surgical tumour size was not significantly higher in recurrent than in non-recurrent adenomas (P = 0.08). Pre-surgical MRI demonstrated cavernous sinus (CS) invasiveness in all recurrent tumours and in 6 non-recurred ones (P = 0.042, by Fisher’s exact test). FCM showed aneuploid DNA content in 2/3 adenomas, one of which recurred. Cell percentages in S (%SPF) and G2 + M (%G2-M) phase and proliferative index (P = %SPF + %G2-M) were significantly higher in aneuploid than in diploid adenomas (P < 0.05), but tumour recurrence was independent of all FCM parameters. MIB-1 expression and mean percentage of MIB-1+ve cells were higher in recurrent than in non-recurrent tumours, although not significantly (P = 0.094 and P = 0.061, respectively). Bcl-2 expression was detected in 12/15 pituitary adenomas, involving 63 ± 35% of tumour cells, regardless of tumour recurrence.

Conclusion
In this group of radically resected pituitary macroadenomas, neuroradiological finding of CS invasiveness, but neither FCM parameters nor MIB-1 and Bcl-2 expressions, is useful for predicting tumour recurrence.

P260
Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers
R R Henry1, S Mudalair2, K Wettl-Hermosillo3, M Ligueros-Saylan3, S Chenji4 & G Golol5
1University of California at San Diego and VA San Diego Healthcare System, San Diego, California, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, USA; 4Novartis Healthcare Pvt Ltd, Hyderabad, India; 5Parexel International GmbH, Berlin, Germany.

Introduction
The multi-receptor targeted somatostatin analogue pasireotide has high affinity for sst1, 2, 5, and 6 receptors which may play an important role in glucose metabolism.

Two studies in healthy male volunteers evaluated the mechanism and management of hyperglycemia associated with pasireotide.

Methods
A randomized, Phase II study assessed insulin secretion and glucose metabolism during 8 days of pasireotide 600 or 900 µg sc bid (n = 19 for both) with oral glucose tolerance test (OGTT), hyperglycemic clamp (HC) with arginine stimulation, and hyperinsulinemic–euglycemic clamp (HIEC). A randomized, 1-week, five-arm Phase I study evaluated glucose metabolism following OGTT with pasireotide 600 µg sc bid co-administered with four classes of anti-thyroidal drugs (metformin, nateglinide, vildagliptin or liraglutide) or pasireotide alone (n = 18 each).

Results
Following OGTT (Phase II study), significant decreases in mean plasma insulin AUC (P < 0.001) and increases in mean plasma glucose AUC (P < 0.001) were observed during treatment in both dose groups. Following HC, final plasma insulin levels were ~50% those at baseline; decreases in AUC were significant (P < 0.001) in both dose groups. Significant decreases (P < 0.01) in glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) AUC were observed. Following HIEC there were no statistically significant changes in basal endogenous glucose production or glucose disposal rate (i.e. insulin sensitivity).

The primary glucose AUC2,16,27, on day 7 (Phase I study) decreased by a mean of 2, 10, 15, and 29%, respectively, when pasireotide was co-administered with metformin, nateglinide, vildagliptin and liraglutide, compared with pasireotide alone. Treatment was generally well tolerated in these groups. Conclusions
Hyperglycemia associated with pasireotide is related to decreases in insulin secretion, with no changes in insulin sensitivity. Pasireotide also significantly decreased incretin hormone response. The mechanism of action of GLP-1 analogues (e.g. liraglutide), DPP-4 inhibitors (e.g. vildagliptin) and insulin secretagogues (e.g. nateglinide) can effectively address the hyperglycemia on pasireotide therapy.

P261
The efficacy of octreotide LAR in acromegalic patients
Zeljka Velija–Assini
Clinic of Endocrinology and Diabetes, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

Aim
To investigate the efficacy of octreotide LAR therapy in acromegalic patients as primary or secondary therapy.

Methods
Ten acromegalic patients diagnosed at Clinic of Endocrinology in Sarajevo (seven females and three males, mean age 55 ± 7.2 years, age range 40–65 years, five patients with microadenoma and five patients with macroadenoma) were treated with octreotide LAR. Operated were 60% of patients. Concentration of IGF1 and IGF1 were evaluated at 6, 12 and 24 months, while MRI images were taken at 0 and 12 months. All patients had active acromegaly. Somatostatin suppression tests were done before octreotide were given. At our center, this is first time to use OctreotideLAR in acromegaly treatment. Eight patients received SandostatinLAR 30 mg/28 days, one patient received 20 mg and one 60 mg/28 days. Normal IGF1 concentrations for age and sex and a GH < 2.5 ng/ml were defined as biochemical control. Basic statistics were applied. Results
Before treatment GH were 20.64 ± 19.05 ng/ml (range: 5.68–74.7), IGF1 were 1075.66 ± 103.48 ng/ml (range: 542–896). Four patients (40%) were followed with primary octreotideLAR treatment. After 6 and 12 months the hGH decreased by 2.74 ± 1.70 ng/ml (range: 1.3–7.0) and 1.86 ± 0.56 ng/ml (range: 1.0–3.0) respectively, while the IGF1 became 345.33 ± 73.33 ng/ml (range: 265–489) and 254.10 ± 23.08 ng/ml (range: 210–289) respectively. Prior to treatment the size of pituitary adenomas was 9.57 mm (min 3.0; max 20), while after 12 months of treatment, the size decreases to 0.80 mm (min 1.0; max 18.0). After therapy, decrease of GH below 2.5 ng/ml were achieved in 90% patients, decrease of the tumor size were achieved in 60% while normalization of IGF1 were achieved in 100% of the patients respectively. One of patients with macroadenoma was used 60 mg octreotideLAR as secondary therapy after surgical treatment, because a dose of 30 mg was not enough for decrease of GH and IGF1. All differences were statistically significant (P < 0.05), but in group of acromegalic patients treated with octreotideLAR as primary therapy that difference was more significant.

Conclusions
OctreotideLAR treatment of acromegalic patients not only decreases hGH and IGF1 concentrations, but also appears to diminish a size of the tumour, in about 60% of patients. The somatostatin analogues are more efficient in primary treatment of acromegalic patients
A novel AIP mutation related to familial isolated pituitary adenomas (FIPA)
I Bilbao Garay, M Alvarez Coca, A Daly, A Beckers & M Goena
1Hospital Donostia, San Sebastian, Spain; 2University of Liège, Liège, Belgium.

Introduction
It has been estimated that 15–20% of FIPA families harbor an AIP gene mutation (AIPmut). To our knowledge ~50 sequence variants -pathological and otherwise have been described to date. We report a new FIPA family with an extensive genealogy, in which 4 members have pituitary adenomas in the setting of a novel AIPmut.

Patients and methods
The index patient is a 37-year-old man, who presented with childhood onset of somatotropinoma and underwent surgery and radiotherapy at the age of 17. His uncle (now aged 70 years), was diagnosed with a somatotropinoma at the age of 16, and also treated with surgery and radiotherapy. The sister of this latter man (the 72-year-old aunt of the index case) presented with secondary amenorrhea at age 18, and was later diagnosed with a macroadroma at the age of 48 after she complained of visual disturbances. She also underwent surgery and radiotherapy. The fourth affected member is the 65-year-old cousin of the latter two patients. He is 1.97 cm tall, with a long standing hypogonadal phenotype; he had hypopituitarism affecting the gonadal, thyroid and somatotrope axes. His MRI shows a wide sella with an eroded floor, and there is a clinical suggestion of potential apoplexy in the past. A genealogic tree was drawn and due to the FIPA presentation, germline AIP sequencing was performed and showed all four affected subjects to have a novel c.543delT AIPmut, which would predict a truncated AIP protein.

Conclusions
This 4-member AIPmut positive FIPA family with a presentation that typifies the range of clinical scenarios encountered in AIPmut carriers with pituitary adenomas. As the disease presentation was quite aggressive in these cases and as early intervention has appeared to control disease in some of the individuals, we are currently screening for AIPmut carriers among the family.

Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant
C Chieffi, M Ryan, S Ba, X Hu, A Decker, H Quandt, L Frohman & M Gadelha
1Endo Pharmaceuticals, Inc., Chadds Ford, Pennsylvania, USA; 2University of São Paulo School, São Paulo, Brazil; 3University of Liège, Liège, Belgium.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>52 mg (n=11)</th>
<th>84 mg (n=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 implant</td>
<td>2 implants</td>
<td>1 implant</td>
</tr>
<tr>
<td>Mean Cmax (ng/ml)</td>
<td>1705±589</td>
<td>4182±2288</td>
</tr>
<tr>
<td>Mean AUC0–24h (µg/ml)</td>
<td>6702±1944</td>
<td>4182±1229</td>
</tr>
<tr>
<td>% reduction in mean IGF1 at mo 1/2 (versus baseline)</td>
<td>45/44</td>
<td>59/52</td>
</tr>
<tr>
<td>Normalized IGF1, n (%)</td>
<td>1 (20)</td>
<td>2 (33)</td>
</tr>
<tr>
<td>Mean GH &lt;0.5 ng/ml, n (%)</td>
<td>5 (100)</td>
<td>5 (100)</td>
</tr>
<tr>
<td>Mean GH &lt;2.5 ng/ml, n (%)</td>
<td>4 (88)</td>
<td>4 (87)</td>
</tr>
<tr>
<td>Mean GH &lt;1 ng/ml, n (%)</td>
<td>1 (20)</td>
<td>2 (33)</td>
</tr>
</tbody>
</table>

The most frequent treatment-related adverse event was diarrhea (64%, study 1; 18%, study 2). The octreotide hydrogel implants provided consistent and sustained octreotide release, resulting in IGF1 and GH suppression over 6 months; the 84-mg NH octreotide hydrogel implant is currently being tested in phase III studies.

P264 Transition to endoscopic transsphenoidal pituitary surgery: a single-center experience
W Billmann, S Bilz, A van Hessling, A Jasman, M Brändle, G Hildebrandt & J Y Fournier
1Division of Endocrinology, Diabetes and Osteology, Department of Internal Medicine, Kantonsspital St Gallen, St Gallen, Switzerland; 2Department of Radiology, Kantonsspital St Gallen, St Gallen, Switzerland; 3Department of Otorhinolaryngology, Head- and Neck Surgery, Kantonsspital St Gallen, St Gallen, Switzerland; 4Department of Neurosurgery, Kantonsspital St Gallen, St Gallen, Switzerland.

Background
Surgery of the pituitary gland is increasingly being performed through an endoscopic approach. We report the results of the first 26 patients after transition from microsurgery to endoscopic transsphenoidal surgery at our institution.

Methods
Medical records of 26 consecutive patients (13 females) with a median age of 59 years who underwent endoscopic transphenoidal pituitary surgery by a single surgeon from 2008 to 2010 and had a follow-up of at least 3 months were reviewed retrospectively.

Results
Fifteen patients (58%) presented with clinically non-functioning macroadenomas, 7 (27%) with hormone secreting tumors and 4 (15%) intra- or suprasellar cysts. Complete tumor resection was achieved in 10 patients (39%), near total resection (residual tumor volume <1 cm³) in 8 (31%) and partial resection in 6 (23%, 2 missing). Visible fields remained intact in 46%, returned to normal in 12%, improved in 23% and showed no change in 15% (1 missing). Pituitary function was not affected by surgery in 18 patients (69%). Complete resolution of partial hypopituitarism was noted in 3 patients and partial recovery in 2. Three patients developed partial hypopituitarism (12%) and one a permanent diabetes insipidus.

Conclusions
Significant tumor reduction can be achieved by the endoscopic approach while endocrine function is maintained or improved in the majority of patients. The high incidence of perioperative complications was mainly due to transient salt and water disorders.

P265 Pasireotide (SOM230) demonstrates efficacy in patients with Cushing’s disease: results from a large, randomized-dose, double-blind, Phase III study
A Colao, S Petersen, J Newell-Price, J W Findling, F Gu, M Maldonado, U Schoenherz, D Mills, L R Salgado & B M K Biller
1Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy; 2ENDOC Center for Endocrine Tumors, Hamburg, Germany; 3The Medical School, University of Sheffield, Sheffield, UK; 4Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; 5Peking Union Medical College Hospital, Beijing, People’s Republic of China; 6Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland; 7Division of General Internal Medicine, Hospital das Clínicas, University of São Paulo School, São Paulo, Brazil; 8Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Introduction
Pasireotide is a multi-receptor targeted somatostatin analogue with high affinity for sst 5, which is commonly expressed in corticotroph adenomas, thus having potential as therapy for Cushing’s disease.

Methods
One hundred and sixty-two patients with persistent/recurrent or de novo (if not surgical candidates) Cushing’s disease were randomized (double-blind) to pasireotide 600 µg (n=82) or 900 µg (n=80) sc bid. After 3mo, patients with UFC>2×ULN (ULN: 145 mmol/24 h) or UFC>baseline were unblinded and the dose increased by 300µg bid. All others continued on the same double-blind

Endocrine Abstracts (2011) Vol 26
dose to 60. Months 6–12 were open-label with dose titration performed when needed. Primary endpoint: UFC ≤ ULN at 60 without dose up-titration from the randomized dose.

Results The median percent decrease in UFC from baseline to month 2 was ~50% in both treatment arms and remained stable throughout the study. At 6mo, 14.6% (600 μg) and 26.3% (900 μg) of patients met the primary endpoint; at 12mo, 12.5% (600 μg) and 25.0% (900 μg) of patients had UFC ≤ ULN. Patients with baseline UFC ≤ 5xULN were more likely to achieve normalized UFC. Most uncontrolled patients could be identified within 2mo, based on UFC. Serum and salivary cortisol and plasma ACTH were also reduced. As mean UFC decreased, clinical signs and symptoms, and QoL improved. The safety profile of pasireotide was similar to that of other somatostatin analogues (mostly transient GI discomfort), except for hyperglycemia; 70% of patients had a hyperglycemia-related AE. Elevated fasting blood glucose and HbA1c were seen soon after pasireotide initiation. Patients without diabetes at baseline had a lower degree of hyperglycemia. Thirteen (8.0%) patients had an AE of hypoglycemia, responsive to dose reduction.

Conclusion Results from this Phase III study show that pasireotide significantly reduces elevated cortisol levels and provides clinical benefit in patients with Cushing’s disease, supporting its potential for use as the first specific pituitary-targeted treatment in this disorder.

P266 Clonality analysis of pituitary adenomas: a pilot study
I Baciu 1, S Radian 1, C Capătina 1, I Botusan 1, D Aflorei 1, L Tatarau 1, V Chiabotaru 2 & M Cuculescu 1
1Department of Endocrinology, C. Davila University of Medicine, Bucharest, Romania; 2C. I. Parhon Institute of Endocrinology, Bucharest, Romania

Introduction Monoclality of pituitary adenomas is an established fact. Still, there are exceptions and polyclonality may correlate with aggressive tumor behavior. In order to test association of clonality with pituitary adenoma characteristics in a series from Romania, we implemented a protocol for X-chromosome inactivation analysis at the androgen receptor (AR) locus (HUMARA) and validated it in a number of tumor samples.

Objective To establish and validate a protocol for pituitary tumor clonality assessment using HUMARA.

Subjects and methods We tested blood DNA samples from 77 pituitary adenoma female patients and 72 healthy female controls, for assessment of average heterozygosity and identification of AR alleles in our population. DNA was extracted from RNAlater-protected tissue, for 4 somatotroph tumors (ACM) and 3 nonfunctioning adenomas (NFA). For HUMARA, DNA was incubated with HpaII or water (control) and fluorescent-labeled PCR products of AR exon1 (including the CAG repeat and 2 HpaII sites), were sized with the CEQ8000 Analyzer (Beckman) and converted to CAG-repeat numbers. The clonality ratio was calculated from the areas-under-curve of heterozygous alleles, comparing HpaII-digested versus non-digested DNA. Values <0.4 indicate monoclonality.

Results For blood DNA, average heterozygosity was 84.7%; median (range) CAG repeats was 23 (15–30), in controls (n=72), and 92.21%; 22 (11–29) in pituitary adenoma patients (n=77), respectively. HUMARA revealed that 4 out of 7 adenomas were monoclonal, 2 somatotropinomas appeared polyclonal and clonality of 1 sample could not be assessed (HpaII-digested DNA did not amplify).

Conclusions The HUMARA protocol proved reliable for RNA-later conserved pituitary adenoma tissue and will be used in a larger study. The 2 polyclonal adenomas need confirmation by HUMARA of micro-dissected tissue, in order to exclude contamination with normal cells.

P267 Effect of gender and the invasiveness of prolactinomas
S Cander, E Ertürk, Ö Öz Gül, O K Unal & S Imamoglu
Department of Endocrinology and Metabolism, Uludag University, Bursa, Turkey.

Introduction Prolactinomas, although considered benign, show various intensity of aggressiveness. Some remain constant for whole life period while some harbour initially with invasive extension to the parasellar area. We aimed to evaluate the effect of age and gender on the invasiveness of prolactinomas.

Material-methods One hundred and thirteen patients with prolactinoma were retrospectively evaluated. Magnetic resonance images were carefully examined and patients were classified as having invasive or non-invasive adenomas. Presence of cavernous sinus invasion, suprasellar extension or dimensions larger than two centimeters at the initial presentation judged as an invasive adenoma. We compared age at the diagnosis and gender in patients with and without invasive adenoma.

Results Twenty-seven (23.9%) patients were male with 40.3±12.6 years of age, while female patients’ age was 32.6±8.3 years. Within the 113 patients 45 (39.8%) had evidence of invasive tumour. Invasive group and non-invasive group were 37.6±12.0 years and 32.3±7.9 years old respectively (P<0.01). When compared patient age separately in male and female groups, age difference was not statistically significant in patients with and without invasive adenoma. Considering male patients 81.5% was classified as having invasive adenoma while in female patients invasive adenoma ratio was only 26.7% (P<0.01).

Conclusion We conclude that male gender is an important risk factor for the invasiveness of prolactin secreting adenomas. Although patients with invasive prolactinoma are slightly older than non-invasive adenomas, the difference disappears when we compare ages in gender subgroups.
Conclusions
Acute-onset symptoms were seen in 13% of patients with newly diagnosed craniohypophyseal tumor and, like hydrocephalus, more commonly among children than adults. Presenting symptoms and the extent of hypopituitarism were largely similar in men and women and across the study period.

Design
A total of 94 PES patients (39M-55F; mean age 50.3 ± 0.9 years; mean BMI 28.9 ± 0.5 kg/m²) and 126 normal subjects (C) matched for sex, age and BMI were studied. Hypothalamic-pituitary function was evaluated at baseline and following conventional dynamic tests (GHRH plus arginine, ACTH test) in all patients. Cardiovascular risk parameters were assessed in all subjects. Statistical analysis was carried out by non parametric combination test and partial correlation test.

Results
Sixty-four patients (68%) had a single or multiple pituitary hormone deficiency: growth hormone deficiency was diagnosed in 56 (87.5%), central hypothyroidism in 23 (35%) (54.6%), hypogonadotropic hypogonadism in 32 (50%) and central hypeandrofrenism in 24 (37.5%).

Mean systolic blood pressure (SBP), HOMA index, total and LDL cholesterol, triglycerides, LDL/HDL and total/HDL cholesterol ratios were significantly higher and HDL cholesterol levels were significantly lower in patients, regardless of the occurrence of endocrine dysfunction, than in C group (P < 0.02). These cardiovascular risk parameters were not significantly different between patients with or without hypopituitarism. Partial correlation test showed that occurrence of central hypothyroidism was associated with high total and LDL cholesterol levels, LDL/HDL, total/HDL cholesterol ratios and HOMA index (P < 0.02), whereas hypogonadotropic hypogonadism was associated to low HDL cholesterol, high LDL/HDL and total/HDL cholesterol ratios (P < 0.02). On the contrary, central hypeandrofrenism was associated to low systolic and diastolic blood pressure (P < 0.02).

Conclusions
Patients with empty sella show increased cardiovascular risk parameters regardless of endocrine dysfunction. In particular, occurrence of central hypothyroidism and/or hypogonadotropic hypogonadism was associated with glucidic and lipid abnormalities.

P269
Macroprolactinomas and pregnancy: analysis of a 38-women cohort treated by dopamine agonists
B Decoudier1, G Raverot2, D Ancelle1, A C Hécart1, F Borson-Chazot2 & B Dellemé1
1Centre Hospitalier Universitaire, Reims, France; 2Centre Hospitalier Universitaire Lyon Est, Bron, France.

Pregnancy is associated with an increased risk of tumor growth in macroprolactinoma leading to discuss surgery in such cases.

Objectives
Impact of pregnancy on prolactin secretion and tumor growth in a cohort of women with macroprolactinoma, including large tumors > 20 mm, and medically treated.

Methods
Retrospective study of all the women with macroprolactinomas diagnosed in two university hospitals, treated by dopamine agonists, with at least one pregnancy after diagnosis.

Results
A total of 38 women, 82 spontaneous pregnancies, 64 children for 35 women. On diagnosis: mean age 23 years, median prolactin level 305 µg/l (90–7804), prolactin level ≥ 500 µg/l in 15 women, median tumor size 15 mm (size ≥ 20 mm in 12 cases), abnormal visual field in 7 cases.

Before pregnancy, 16 patients received cabergoline, 20 bromocriptine, 2 quinagolide. Prolactin level was controlled in 37 women. Visual troubles disappeared totally in 6 patients, partially in one.

Residual tumor was not visible on RMI in 10 patients, ≥ 10 mm in 11 (maximum 23 mm). During pregnancy, medical treatment was stopped in 20 patients (5 adenomas ≥ 20 mm). 8 patients had symptomatic (5 headache, 3 visual troubles) tumor evolution which was controlled by dopamine agonists either reintroduction or dose increase in 7 patients. Surgery was mandatory in one case of apoplexy during pregnancy (second trimester) and one immediately post-partum.

Prolactinoma size at diagnosis, residual size after medical treatment and treatment stop during pregnancy were not statistically significant risk factors of tumor enlargement.

Conclusion
This study, performed in a large cohort, confirms that pregnancy is a risk period of symptomatic macroprolactinoma enlargement (21%) and apoplexy but no specific risk factor for adenoma growth was found. Medical treatment is able to control tumor enlargement in almost all the cases except apoplexy which requires surgery. Macroprolactinomas, even large ones, do not seem to require debulking before pregnancy.
P272
Topoisomerase II α expression in human pituitary adenomas as the prognostic factor
M Trofimuk1, G Sokolowski1, F Golkowski1, D Adamek2 & A Hubalewska-Dydejczyk1
1Endocrinology Department, Jagiellonian University, Collegium Medicum, Krakow, Poland; 2Pathology Department, Jagiellonian University, Collegium Medicum, Krakow, Poland.

Pituitary adenomas represent more than 80% of all sella turcica tumors and 10–15% of all intracranial tumors in adults. Topoisomerase II α (TopoIIα) is recognized as a reliable tumor proliferative activity marker. Evaluation of its expression facilitates the identification of more aggressive neoplasms.

**Aim**
To assess the topoIIα expression in pituitary adenomas as the marker of the tumor aggressiveness, recurrence and progression.

**Material and methods**
Retrospective study included 60 patients (23 males, 37 females; aged 46.7 ± 17.6 years) operated due to pituitary adenoma, followed-up for 2 years after the surgery. TopoIIα nuclear expression was assessed immunohistochemically in tissue samples in hot spot areas and indexed as % of all nuclei. The tumor recurrence, seen in 36.7% of patients, was assessed on repeated pituitary MRIs.

**Results**
73% of samples stained for topoIIα (median index of 0.71%). The statistically significant difference in topoIIα indices was noted between non-secreting and secreting adenomas (0.8 vs 0.41%). The topoIIα indices were also statistically higher in macroadenomas, in tumors causing visual impairment, invading the suprasellar space and cavernous sinuses. TopoIIα index >1% was independent risk factor of tumor recurrence or progression (RR = 4.65, 95% CI = 1.80–11.51); visual chiasm involvement (RR = 5.04, 95% CI 1.11–22.90), cavernous sinuses invasion (RR = 5.22, 95% CI 1.24–21.89), but not of suprasellar growth (RR = 4.01, 95% CI 0.94–17.10). The sensitivity and specificity of the topoIIα index >1% in predicting pituitary adenoma recurrence was 63.6 and 86.8 respectively (area under ROC curve 0.76).

**Conclusions**
The topoIIα expression in pituitary adenomas is related to the more aggressive tumor behavior. The index of topoIIα higher than 1% is independent risk factor of early pituitary adenoma recurrence and progression. The topoIIα expression should be routinely assessed in pituitary adenomas, as it gives important prognostic data.

---

P273
Cyclooxygenase 2 expression in human pituitary adenomas
G Sokolowski1, M Trofimuk1, F Golkowski1, D Adamek2 & A Hubalewska-Dydejczyk1
1Endocrinology Department, Jagiellonian University, Collegium Medicum, Krakow, Poland; 2Pathology Department, Jagiellonian University, Collegium Medicum, Krakow, Poland.

In many neoplasms, excessive angiogenesis is prognostic factor, independent from proliferation. Previous studies confirmed correlation between cyclooxygenase-2 (COX-2) expression and micro-vascularization density in pituitary tumors. Moreover, nonsteroidal anti-inflammatory drugs have strong inhibiting effect on COX-2 expression and possible anti-tumor activity.

**Aim**
To assess COX-2 expression in pituitary adenomas, its relation to adenoma type as well as to determine the role of COX-2 as prognostic factor of patients with pituitary tumors.

**Methods**
The retrospective study included 60 patients aged 18–85 years, after pituitary tumor surgery. COX-2 expression, determined by immunohistochemical methods, was analyzed in relation to the radiological and histopathological tumor features, clinical symptoms caused by adenomas and postoperative course of disease.

**Results**
COX-2 expression was present in 87% of adenomas with median index of 57.5%. The highest COX-2 indices characterized hormonally inactive adenomas and gonadotropinomas, the lowest - prolactinomas. There were no statistically significant differences in COX-2 expression regardless patients age and sex, tumor size, its invasiveness, visual impairment, recurrence/progression during postoperative course, the need to reoperate or irradiate.

**Conclusions**
COX-2 expression is of little prognostic value in patients with pituitary adenomas. However high COX-2 expression in pituitary adenomas, especially those hormonally inactive, makes it possible target for treatment of those tumors.

---

P274
Recent changes in clinical presentation and therapeutic approach in MEN1-related pituitary adenomas
Valeria Ramundo, Rosa Severino, Francesco Milone, Gaetano Lombardi, Annamaria Colao & Antongiulio Faggiano
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy.

**Background and objective**
MEN1 adenomas (PAs) affect about half of the patients with multiple endocrine neoplasia type 1 (MEN1); in the most of cases PA is a PRL-oma and generally more aggressive than the sporadic form. The aim of this study is to evaluate the recent changes in clinical presentation and therapeutic approach of MEN1-related PAs.

**Patients and methods**
The study population included 17 patients with MEN1-related PA followed-up between 1990 and 2010. The whole study population included 8 PRL-omas, 2 GH-omas (associated with PRL secretion in one), 7 non-functioning adenomas.

**Results**
Patients were divided in two groups: group A (PA diagnosed before 2008, 9 patients) and group B (PA diagnosed in 2008–2010, 8 patients).

The prevalence of macroadenoma was 67% in group A and 37% in group B. PA-related symptoms were present in 67% of patients of group A and 50% of patients of group B. PA was treated in 78% of patients group A (2 transsphenoidal surgery, 5 medical therapy) and 50% of patients group B (4 medical therapy).

**Conclusions**
Clinical presentation of MEN1-related PA is changed in the last years, resulting in early diagnosed and less aggressive tumors. For these reasons and for the availability of effective medical compounds, transphenoidal surgery is now less necessary and medical therapy with cabergoline and/or somatostatin analogues is the main therapeutic approach.

---

P275
Prolactinoma and thyroid function
I Kostoglou-Athanassiou, S Tagara, A Michou, F Xanthakou, A Chronaiou, S Kotanoglou, K Tziouras & A Karfi
Department of Endocrinology, Red Cross Hospital, Athens, Greece.

It has been hypothesized that prolactin may act on the immune system. It has been suggested that prolactin may act on the immune system and may be implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, as mild hyperprolactinemia has been found in patients with systemic lupus erythematosus.

We tested the hypothesis that prolactin may act on the immune system and induce the development of autoimmune thyroiditis.

We followed up for 2–8 years, 18 patients with prolactinoma and 2 patients with hyperprolactinemia. Within the patient population studied 10 patients were men and 10 were women. The patients were aged 37–88 years. Within the patient population 10 patients had a macroprolactinoma, 8 had a microprolactinoma.

Surgery was used for the management of 2 patients, while all others were treated by the administration of dopamine agonists.

Within the patient population studied 2 patients had pituitary deficiency and were taking thyroxine, 2 had primary hypothyroidism due to Hashimoto thyroiditis and 2 had autoimmune Hashimoto thyroiditis, being euthyroid. The rest of the patients were euthyroid at diagnosis and remained euthyroid during follow up. Long-term hyperprolactinemia observed in patients with prolactinoma does not appear to be related to the development of autoimmune thyroid disease, specifically autoimmun thyroiditis or thyroiditis Hashimoto.
Late development of resistance to cabergoline in a giant macroprolactinoma with aggressive cavernous sinus and sphenoidal bone invasion
G Mlawa, S Deshmukh, A Nasruddin & D Sandeman
Southampton General Hospital, Southampton, UK.

Background
Dopamine agonists (DA) are used as the first-line treatment in patients with macroprolactinomas. Late resistant to DA(cabergoline) therapy may occur. Patient with resistant macroprolactinoma may end up receiving a relative high dose of DA. These patients should be advised to take radiotherapy as an earlier as possible to avoid the need of high dose dopamine agonist. We present a 63-year-old man who presented in 1999 with visual loss, due to giant macroprolactinoma compressing the optic chiasma (image 1). His initial prolactin level was >130,000 mg/l. He responded well to cabergoline, with full recovery of his vision and prolactin maintained in the normal range (<500) on 1 mg/week of cabergoline. There was significant reduction in tumour size with small residual tumour extending into the right cavernous sinus. Prolactin levels gradually rose to >3000 over 2 years (2005-2007) despite moderate increase in cabergoline, but there was no change in tumour size. Few months later there was dramatic increase of prolactin to >20,000 associated with development of right 6th nerve palsy. MRI demonstrated significant tumour enlargement within the right cavernous sinus with replacement of sphenoid bone. The patient was offered radiotherapy at this stage but he declined. There was minimal response despite increasing cabergoline doses to 10 mg/week, and subsequently he underwent external beam radiotherapy in May 2008. Due to concerns of possible valvulopathy on long term high dose cabergoline (cumulative dose of 1.352 g up to June 2009), quinagolide was gradually introduced and cabergoline dose tapered down over 6 months. His ECHO revealed mild aortic regurgitation, with left ventricular dysfunction, and evidence of LBBB. Currently is 18 months post radiotherapy and remains on quinagolide 300mg daily recent prolactin of around 5000 mg/l. His 6th nerve palsy remains but with evidence of substantial tumour regression on MRI.

Discussion
Late-onset resistance to cabergoline can occur as demonstrated in our patient and in this case associated with aggressive tumour growth. Early radiotherapy should be considered, and switching to different dopamine agonist which is not ‘ergot-derive’ may be beneficial both in terms of treatment response and avoiding risk of valvulopathy.

Minimal active acromegaly may be effectively treated by prolonged injections of octreotide LAR
P Zdanowski & W Zgliczyński
Department of Endocrinology, Medical Center of Postgraduate Education, Warsaw, Poland.

In acromegaly, excessive GH secretion by pituitary adenoma, minimal active disease may be defined as slow progression of characteristic signs and symptoms at presence of slightly elevated or normal IGF1 levels and lack of GH suppression after suppression test. Nadir post-glucose GH level defining active disease is under permanent discussion and depends on assessment methods. IGF1 reference range is wide, must be age-adjusted and often is sex-dependent. From mid-60’s excess over upper limit reference range (ULN) for IGF1 is used to define disease activity. Acromegaly contributes to decrease in life expectancy, coexisting disease progression and social disability. Somatostatin analogues (SA) are effective in normalization of GH and IGF1, reducing symptoms and tumor shrinkage. Sporadically published data shows prolonged effectiveness of octreotide LAR.

Aim
To assess prospectively if octreotide LAR is effective if given every 6 weeks in group of minimal active acromegaly. Group: 11 patients (9F/2M) mean age 62 s.d. 14.8 y, with acromegaly diagnosed mean 9 years earlier, treated with somatostatin analogues for mean 7 years (s.d. 2.9). Out of 11 patient 7 received octreotide after curative surgery. In 6 of 7 surgery was preceded by SA pretreatment. In all cases minimal active acromegaly was confirmed and therapy effectiveness during standard octreotide 10–20 mg every 4 weeks (GH 1.1 ng/ml s.d. 0.9; IGF1 155 ng/ml s.d. 176=0.6 ULN s.d. 0.7) proven. No patients underwented radiotherapy. Intervention: octreotide LAR 20 mg given every 6 weeks (stable dose, injections intervals titrated accordingly to IGF1 level, target – lower than ULN.

Results
After 6 months of octreotide LAR 20 mg titration patients received injection every 5 weeks (1); 6 weeks (7); 7 weeks (1); 8 (1); 9 (1). Mean GH levels during stabilized treatment did not differ significantly (1.9 s.d. 1.9 NS v. previous therapy). IGF1 show trend to increase (mean 217 ng/ml s.d. 104 P=0.3; 0.9 ULN s.d. 0.4). No clinical worsening were observed. Clinical symptoms score did not differ in any of cases. We did not observed any changes in concomitant diseases intensity.

Conclusions
In patients with minimal active acromegaly, biochemical control and symptoms release may be controlled by titration of intervals between injections of octreotide LAR. During 2 years of observation we proven effectiveness and safety of this approach.
occur more frequently but are not diagnosed in the often times small amount of tissue sent in for neuropathological examination. Moreover, the entity gives rise to speculations about its tumorigenesis. Here, a transferridifferentiation of adenohypophysial cells into neuronal cells is discussed. Alternatively, a primary ganglion cell tumour could induce adenohypophysyal hypoplasia through hormonal stimulation. A third hypothesis involves the transformation into two cell types under the influence of a common tumorigenesis factor. Clinically, the patient described above exhibits no residual disease and is kept on clinical surveillance.

P280

Immunoglobulin G4-related infundibulo-hypophysitis: report of 4 cases and review of the literature
A Shimatsu1, K Nanba1, Y Oki2, T Tagami1, T Usui1 & M Naruse1
1Clin Res Inst, NHO Kyoto Medical Center, Kyoto, Japan; 2Hamamatsu Univ Sch Med, Hamamatsu, Japan.

Inflammatory lesions of the pituitary gland are rarely encountered. Recently, the concept of IgG4-related systemic disease was proposed and several cases associated with infundibulo-hypophysitis were reported. We report 4 additional cases and review the cases in the literature. Case 1: 75-year-old female had diabetes insipidus due to infundibulo-neurohypophysis for 25 years and chronic thyroiditis. She developed obstructive jaundice and surgery showed autoimmune pancreatitis. Case 2: 78-year-old female developed hypopitremia, headache and visual field defect. MRI showed thickened pituitary stalk and enlarged gland. Transsphenoidal surgery was performed to decompress and pathology showed marked inflammatory fibrosis. Chronic sialoadenitis and retroperitoneal fibrosis was diagnosed with elevated serum IgG4 levels. Case 3: 70-year-old male had sialoadenitis and diabetes insipidus with thickened pituitary stalk. He had chronic thyroiditis and hypogonadism. Serum IgG4 was elevated. He developed hydronephrosis caused by retroperitoneal fibrosis. Case 4: 72-year-old male had syncope, and MRI showed marked enlargement of stalk and pituitary gland. Surgery showed inflammatory pseudotumor with marked infiltration of IgG4-positive plasma cells. He had chronic thyroiditis and hypogonadism. Serum IgG4 was elevated. He developed hydronephrosis caused by retroperitoneal fibrosis. Case 4: 72-year-old male had syncope, and MRI showed marked enlargement of stalk and pituitary gland. Surgery showed inflammatory pseudotumor with marked infiltration of IgG4-positive plasma cells. He had chronic thyroiditis and hypogonadism. Serum IgG4 was elevated. He developed hydronephrosis caused by retroperitoneal fibrosis.

P281

Assessment of retinopathy in acromegaly
C Anil1, C Demir2, G Simsek Bagir3, S Szimaz2, O Bakiner1, M E Ertorer1, D Alinors-A, A Nal1 & Neslihan Bascil Tutanuc1
1Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, Ankara, Turkey; 2Department of Ophthalmology, Faculty of Medicine, Baskent University, Ankara, Turkey.

Introduction
Diabetic retinopathy (DR) is a vision threatening chronic microvascular complication of diabetes mellitus (DM). The potential roles of GH and insulin-like growth factor 1 (IGF1) in DR have been evaluated in vitro and in vivo. The present study aimed to assess the frequency and severity of retinopathy in acromegalic patients with various disease activity and glucose tolerance states (GTS).

Methods
All acromegalic patients followed in the outpatient Clinic of Endocrinology Departments of Baskent University Hospitals were included. Each patient’s fundoscopic examination was carried out by an experienced ophthalmologist in each center with a standard method. Acromegaly disease states were evaluated with basal GH and IGF1 measurements and GH measurement during an oral glucose tolerance test (OGTT) where appropriate. Glucose tolerance states were assessed with fasting and postprandial glucose, glycohemoglobin measurements and OGTT where appropriate. The relations between retinal findings, disease activity, and GTS were examined.

P282

Success rate of surgery in patients with macroprolactinoma
E Ertürk1, O K Unal1, S Cander1, O Oz Gül2, M Özdemir Oruç2, I Esen2 & S İnanoglu1
1Department of Endocrinology and Metabolism, Uludag University, Bursa, Turkey; 2Department of Internal Medicine, Uludag University, Bursa, Turkey.

In prolactin secreting pituitary adenomas, surgery markedly reduced with the efficacy of dopamine agonists in controlling prolactin hypersecretion and reducing tumor mass. Some surgeons, instead of necessity of almost life-long medical therapy, prefer and recommend surgery as a first line treatment with potentially high success rates especially in microprolactinomas. We evaluated our patients with prolactinoma operated mostly without any evidence of resistance or intolerance to dopamine agonist therapy. Retrospective analyses of 43 patients with prolactinoma treated with surgery were included in the study. Many of the patients were operated with the aim to diminish constraint effect of the adenoma on visual area or pituitary function without any evidence of resistance or intolerance to the dopamine agonists. Fifty-seven (89%) patients had got macroadrenoma while only 7 (11%) had got microadenoma. Magnetic resonance imaging of sella turcica obtained 3-6 months after operation revealed apparent remnant in 29 patients (45%). Biochemical cure was obtained in only 18 (28%) patients. Cure probability was calculated 57% (47%) in microadenomas and 25% (1457) in macroadrenomas. Success rate for visual field deficit was 38% (1028) and 14 patients (50%) inform only slight improvement. Four (12%) patient did not inform any improvement in their visual acuity. In 46 patients without cure after surgery, long term treatment with dopamine agonists attained apparent improvement of hyperprolactinemia and related symptoms in 45 of 46 patients (98%). We conclude that surgery for macroadrenomas do not achieve good success rate even for cure of prolactinoma but also for improvement of visual field deficit or hypopituitarism. Medical therapy should be the only first line treatment in all patients with prolactinoma unless in patients with urgent indication of surgical intervention.

P283

GH deficiency in cured acromegalic patients: metabolic effects of recombinant hGH replacement
C Giavoli1,2, E Verrua1,2, E Ferrante1,2, C L Ronchi1,2, E Profka1,2, M Arosio3, A Spada1,3 & P Beck-Peccoz2
1Department of Medical Sciences, University of Mian, Milan, Italy; 2Unit of Endocrinology and Diabetology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 3Ospedale San Giuseppe Multimedica, Milan, Italy.

Background
GH deficiency (GHD) may occur in about 60% of acromegals treated and cured by surgery or radiotherapy. Effects of GH replacement have not yet been extensively studied in such a patients.

Aim
To investigate whether rhGH replacement improve metabolic parameters in acromegalic patients who become GHD.

Patients and methods
Forty GHD patients (mean age (s.d.): 48 ± 10, BMI 27 ± 3 kg/m2) were evaluated: 8 were acromegals treated with rhGH (Group A: 5F&3M), whereas 12

Endocrine Abstracts (2011) Vol 26
acromegals who refused treatment (Group B: 8F&6M) and 20 subjects with non-functioning pituitary adenoma on rhGH (Group C: 10F&10M) served as controls. BMI, body fat (BF%), waist circumference, IGFI levels, glucose metabolism and lipid profile were assessed at the time of GHD diagnosis and after 12 and 36 months of rhGH treatment (mean rhGH dose 0.28 ± 0.02 mg/day).

Results At baseline Group B showed higher IGFI levels than Groups A and C (153 ± 38 vs 90 ± 27 and 80 ± 41 ng/ml respectively, P = 0.001), and higher post-OGTT glucose levels than group A (127 ± 34 vs 90 ± 32 mg/dl, P = 0.051), while no difference among Groups was recorded for the other parameters. After 12 months, IGFI levels significantly increase in group A and C, remaining in the middle-upper part of the normal range. A decrease in BF% (from 36.3 ± 5.2 to 31.7 ± 2.4 and from 33 ± 9 to 30 ± 9 in Group A and C respectively, P < 0.01) and total cholesterol (from 252 ± 50 to 203 ± 57 and from 261 ± 56 to 209 ± 51 mg/dl in Group A and C respectively, P = 0.04) was observed. In Group A fasting and post-OGTT glucose levels, HbA1c and HOMA did not change on rhGH. No side effects were recorded.

Conclusions In GHD acromegals, rhGH improved body composition and lipid profile, without deterioration of glucose tolerance. GH replacement should be considered in these patients, as in patients with GHD from other causes.

P284 Improvement in clinical signs and symptoms of Cushing’s disease following 12 months’ pasireotide therapy
R Pivonello1, J Newell-Price3, J W Findling1, F Gu2, M Maldonado3, U Schoenheir2, D Mills2, L L Salgado1 & B M K Biller1
1Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy; 2The Medical School, University of Sheffield, Sheffield, UK; 3Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; 4Peking Union Medical College Hospital, Beijing, People’s Republic of China; 5Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland; 6Division of General Internal Medicine, Hospital das Clinicas, University of Sao Paulo School of Medicine, Sao Paulo, Brazil;
7Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Introduction The multi-receptor targeted somatostatin analogue pasireotide has demonstrated efficacy in reducing cortisol in patients with Cushing’s disease in a large, randomized, double-blind, Phase III study. The effects of pasireotide on the signs and symptoms of Cushing’s disease were also investigated as secondary objectives in this trial.

Methods Adult patients with persistent/recurrent or de novo Cushing’s disease were randomized to receive pasireotide 600 mg (n = 82) or 900 mg (n = 80) mg sc bid for 12 months. Dose increases of 300 μg bid were permitted after month 3 depending on 24-h urinary-free cortisol (UFC) levels. Clinical signs and symptoms of Cushing’s disease were evaluated at regular intervals. Health-related quality of life (HRQoL) was assessed using the CushingQoL questionnaire at baseline, month 3, 6 and 12.

Results Reductions in mean UFC were accompanied by a rapid and substantial reduction in both mean (± S.D) systolic and diastolic blood pressure (from 133.5 ± 19.1 to 126.1 ± 14.1 mmHg and 86.4 ± 12.7 to 82.8 ± 9.7 mmHg respectively) over the course of the 12-month study period. Mean weight decreased from 81.6 ± 21.6 to 74.4 ± 18.7 kg, accompanied by a reduction in BMI. Mean LDL-cholesterol and triglyceride levels were reduced from 3.52 ± 1.02 to 3.04 ± 1.16 mmol/l and 1.83 ± 0.12 to 1.55 ± 0.80 mmol/l respectively. Mean HRQoL scores increased from values of 41.1 ± 20.4 at baseline to 50.4 ± 20.1 at month 6 and 52.5 ± 19.2 at month 12. Improvements in facial rubor, supraclavicular and dorsal fat pads were also observed. These clinical changes were achieved irrespective of patients achieving normalized UFC levels. Adverse effects were fairly typical of somatostatin analogues, except for hyperglycemia.

Conclusion Rapid and substantial improvements in the signs and symptoms of Cushing’s disease were seen following pasireotide treatment, and were maintained during 12 months’ therapy. Improvements in these parameters were not dependent on UFC normalization, suggesting a reduction in UFC can be associated with long-term clinical benefit.

P285 Pituitary cally transplantation into the human, 50 years after K Marczewski1,2, M Gasiorek1, M Maciejewski1,2 & J Wszola-Kleinrok1
1John Paul the II Regional Hospital, Zamosc, Poland; 2Institute of Physiology University of Management and Administration, Zamosc, Poland.

Introduction Hundred years ago Harvey Cushing attempt first human pituitary transplantation. This operation, in different modifications, was performed in the next 50 years, but now is used rather only in animal experiment. The problem of effective therapy of hypopituitarism, other that substitution, is however still open. That encouraged us to present a patient 50 years after pituitary xenotransplantation.

Case A 75-year-old woman was admitted to hospital because of weakness and malaise. The symptoms occurred when her doctor reduced the dose of levodopa (because of the low TSH). The result of physical examination was appropriate for age, blood pressure 130/70 mmHg, pulse 75 b/min. Daily rhythm of cortisol was preserved (16.0 μg/dl morning and 8.3 μg/dl afternoon) by normal morning ACTH (31 pg/ml). Serum levels of thyroid hormones were in lower limit of normal range (FT3 3 pg/ml, FT4 0.8 ng/dl), similar as thyroid antibody. TSH, however, was very low (0.04 μIU/ml), correspondingly with low prolactin (0.4 ng/ml), FSH (1.5 μIU/ml) and LH (0.75 mIU/ml). Other laboratory parameters were normal. MRI showed at the bottom of the Turkish saddle, a small, asymmetrical pituitary, bruised by the arachnoids hernia. According to medical documentation, in 1959 calf pituitary was transplanted into her peritoneal cavity(?), because of Sheehan syndrome. Patient claimed that the graft was ‘not accepted’ contrary to other patients. The menstruation did not return. After that she was treated by different physicians, but complete reconstitution of treatment was impossible.

Conclusion The postpartum pituitary failure with a preserved adrenal axis function is not so frequent, but not as rare as ectopic xenotransplantation. Was this attempt irrelevant for patient’s health? The answer would be easier if we could observe other patient after successful transplantation. Unfortunately, despite of poor HLA expression in the pituitary, we have never met such person.

P286 The impact of transphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly
Maria Stelmachowska-Banas1, Grzegorz Zielinski2, Piotr Zdukowski1, Jan Podgorski2 & Wojciech Zgliczynski1
1Department of Endocrinology, Medical Center of Postgraduate Education, Warsaw, Poland; 2Department of Neurosurgery, Military Institute of Medicine, Warsaw, Poland.

Introduction Impaired glucose tolerance and overt diabetes mellitus are frequently associated with acromegaly. The aim of this study was to find whether these alterations could be reversed after transphenoidal surgery.

Patients and methods Two hundred and thirty-nine acromegalic patients were studied before and 6–12 months after transphenoidal surgery. Diagnosis of active acromegaly was established on the basis of widely recognized criteria. In each patient, glucose and insulin concentrations were assessed during the 75 g oral glucose tolerance test (OGTT). To estimate insulin resistance we used homeostasis model assessment (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI).

Results At the moment of diagnosis, diabetes mellitus was present in 25% of the acromegalic patients. After surgery, the prevalence of diabetes mellitus normalized to the level present in the general Polish population. We found a statistically significant reduction after surgery in plasma glucose levels both fasting (89.45 ± 13.92 vs 99.12 ± 17.33 mg/dl, P < 0.001) and during OGTT. Similarly, a prominent reduction in insulin secretion was found after surgery compared to the moment of diagnosis (15.44 ± 8.80 vs 23.40 ± 10.24 mIU/ml, P < 0.001). After transphenoidal surgery, there was a significant reduction in HOMA-IR (0.08 vs 6.76, P < 0.0001) and a significant increase in QUICKI (0.32 vs 0.29, P < 0.0001). There were no statistically significant differences after surgery in fasting glucose and insulin levels between patients with controlled and inadequately controlled disease.

Conclusions We concluded that in acromegalic patients glucose homeostasis alterations and insulin sensitivity can be normalized after transphenoidal surgery, even if strict biochemical cure criteria are not fulfilled.

Endocrine Abstracts (2011) Vol 26
Parasellar extension and/or tumor size over 4 cm are associated in macroprolactinomas.

Conclusion

Regarding tumor volume outcome, tumor shrinkage (50% or small residual necrotic tumor) was noticed significantly more frequently in group A (40/71, 56.3%) versus group B (40/114), 34.8%, P = 0.005; tumor shrinkage < 50%, stationery tumor and tumor increase were similar in both A, B groups.

Conclusion

Parasellar extension and/or tumor size over 4 cm are associated in macroprolactinomas with resistance of prolactin normalization on dopamine agonist therapy, but not with resistance to tumor shrinkage.

Patients with acromegaly resistant to conventional drug treatment currently can advantage with GH-receptor antagonist pegvisomant. To date, at doses up to 40 mg/day, it is capable of normalizing circulating IGF1 in until 97% of patients. Here we present the multicenter experience in Rome with Pegvisomant as a therapeutic option in acromegaly. This is an observational study including a total of 61 patients (21 males and 40 females) treated with pegvisomant for up to 7 years. Of all patients, 59 were reported to have had surgery and 17 to have received radiation therapy; 57 had received somatostatin analogues. Before starting Pegvisomant, all patients had IGF1 values above the upper limit of normal and sex-adjusted normal range. A total of 53 patients (87%) normalized the IGF1 value on pegvisomant therapy. A transitory increase of liver enzymes was seen in 6 patients (11), pseudo-cured patients (reurrence of hyperprolactinemia after DA withdrawal) (n = 16), patients responsive to DA, but not fulfilling the criteria for DA withdrawal (n = 157), patients initially resistant to DA therapy (n = 28). Patients responsive to DA (cured, pseudo-cured and responsive) had significant lower prevalence of parasellar extension (57/184, 30.9%) versus patients resistant to DA (15/28, 53.6%), P = 0.02. Within responsive group, prevalence of parasellar extension and giant tumors was similar between cured patients (4/16, 25%), pseudo-cured patients (3/11, 27.3%), and responsive patients (50/157, 31.8%), P = NS.

Regarding tumor volume outcome, tumor shrinkage ≥ 50% or small residual necrotic tumor was noticed significantly more frequently in group A (40/71, 56.3%) versus group B (40/114), 34.8%, P = 0.005; tumor shrinkage < 50%, stationery tumor and tumor increase were similar in both A, B groups.

Introduction

Parasellar extension of macroprolactinomas defined on imaging criteria was reported to be an independent predictor of hormonal resistance to dopamine agonists (DA).

Methods

Two hundred and twelve patients with macroprolactinomas (87 M/125 F), treated with DA for 5 years median period, prolactin (fluorimunoassay or chemiluminescence), CT scan and/or MRI with contrast agents were performed; maximum diameter evolution was reported.

Results

Parasellar extension or giant tumors (≥ 4 cm) were encountered in 71 patients (33.5%) – group A, while 141 tumors formed group B. According to prolactin normalization, patients were classified into cured patients (n = 16), pseudo-cured patients (recurrence of hyperprolactinemia after DA withdrawal) (n = 11), patients responsive to DA, but not fulfilling the criteria for DA withdrawal (n = 157), patients initially resistant to DA therapy (n = 28). Patients responsive to DA (cured, pseudo-cured and responsive) had significant lower prevalence of parasellar extension (57/184, 30.9%) versus patients resistant to DA (15/28, 53.6%), P = 0.02. Within responsive group, prevalence of parasellar extension and giant tumors was similar between cured patients (4/16, 25%), pseudo-cured patients (3/11, 27.3%), and responsive patients (50/157, 31.8%), P = NS.

Regarding tumor volume outcome, tumor shrinkage ≥ 50% or small residual necrotic tumor was noticed significantly more frequently in group A (40/71, 56.3%) versus group B (40/114, 34.8%), P = 0.005; tumor shrinkage < 50%, stationery tumor and tumor increase were similar in both A, B groups.

Conclusion

Parasellar extension and/or tumor size over 4 cm are associated in macroprolactinomas with resistance of prolactin normalization on dopamine agonist therapy, but not with resistance to tumor shrinkage.
Design
Retrospective-comparative-non-randomized-case-control study.

Patients and methods
Forty-four acromegalic patients (28 men, 15 treatment-naïve, 13 SSA treated, 12 operated by TSS, aged 45–74 years) were matched for age and gender to 200 controls from the general population. Coronary risk factors were assessed by interviews and direct laboratory measurements. For purposes of the study, only controlled patients in MED and SUR group were included.

Results
Compared to matched controls ACT patients had increased prevalence of left ventricular hypertrophy (LVH) (30.8 vs 3.2% (P<0.001)), HbAlc (6.9 ± 1.4 vs 5.4 ± 0.7% (P<0.0001)), a trend of higher prevalence of hypertension (38.5 vs 36.9% (P=0.08)) and a FS in the high-risk group (22.0 ± 2.7 vs 16.1 ± 8.1% (P=0.08)). Odd’s ratio (OR) by multivariant conditional logistic regression for LVH was 1.06 (0.99–1.13) (P=0.08), MED and SUR groups were similar for gender, age, disease duration and IGF1 levels. MED patients had a significantly higher prevalence of LVH (41.7 vs 1.7% (P<0.0001), BMI (31.3 ± 5.2 vs 27.5 ± 4.4 kg/m² (P=0.02)), prevalence of diabetes mellitus (33.3 vs 10.0% (P=0.03)), HbAlc (6.8 ± 1.3 vs 5.5 ± 0.7% (P=0.0005)) and FS (21.2 ± 9.7 vs 12.4 ± 7.7% (P=0.0002), OR 1.11 (1.01–1.21) (P=0.03)) while in SUR group only prevalence of LVH (40.0 vs 4.1% (P<0.0001)) and HbAlc (6.4 ± 1.2 vs 5.5 ± 0.8% (P=0.006)) were significantly elevated but not FS (14.8 ± 8.2 vs 12.6 ± 8.1% (P=0.21), OR 1.07 (0.97–1.18) (P=0.19).

Conclusion
When comparing treatment naive, medically treated and surgically cured patients with acromegaly to age- and gender-matched cohorts of the general population, we have found an significantly increased CV risk in patients 12 months after first-line SSA treatment but not in patients after first-line surgery.

P291
GH receptor mRNA expression and the effect of pegvisomant on GH secretion by somatotroph pituitary adenomas
S J C M M Neggers1, M Bidlingmaier3, P M van Koetsveld2, R A Feelders1, D M Sprij-Mooij2, W W de Herder 1, A J van der Lely 1 & L J Hofland 2
1Department of Endocrinology, Department of Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; 2Department of Medicine, Erasmus University and Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; 3Klinikum der Ludwig-Maximilians Universität-Innenstadt, Muenchen, Germany.

Background
Of the currently available treatment regimes for acromegaly, pegvisomant (PEG-V) has the highest efficacy. During PEG-V treatment, GH serum levels increase. The exact mechanism behind this is remains unclear. It could be explained by an ultra-short feedback loop via GH receptors in the anterior pituitary gland.

Objective
To assess the level of GH receptor (GHR) mRNA expression in somatotroph adenomas and to evaluate whether GHR blockade by PEG-V can lead to an increase in GH levels.

Design
In 32 somatotroph adenomas and 4 samples of human liver tissue after RNA extraction, mRNA expression of the full length GHR and d3GHR variant were found in 27 of 32 (84%) and in 23 of 32 (72%) cases respectively. GHR mRNA levels, full length and d3GHR, in the somatotroph adenomas amounted 0.8 and 4.8% of the expression level in human liver. The addition of PEG-V GH concentrations were determined.

Results
In somatotroph adenomas, detectable levels of full length GHR and the d3GHR variant were found in 27 of 32 (84%) and in 23 of 32 (72%) cases respectively. GHR mRNA levels, full length and d3GHR, in the somatotroph adenomas amounted 0.8 and 4.8% of the expression level in human liver. The addition of PEG-V did not increase GH secretion by the cultured GH-secreting pituitary adenoma cells.

Conclusion
In human somatotroph pituitary adenomas the expression of GHR mRNA is low and PEG-V does not increase GH secretion in vitro. There was no relationship between expression of GHR in the adenoma and the effect of PEG-V. Therefore, the increase in GH level during PEG-V treatment in acromegaly patients seems not mediated by interference with an ultra-short feedback loop via GHR in the somatotroph adenoma, but rather via reduced feedback due to the lowered circulating IGF1 levels.
P294

Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality.

S D Joustra, N R Biermansz, E Donga, A M Pereira, N Van Duinen, M Van Dijk, A A Van der Klauw, E P M Corsmit, Gert Jan Lammers, Klass Van Kralingen, J G Van Dijk & J A Romijn

Leiden University Medical Centre, Leiden, The Netherlands.

Context and objective

Fatigue and excessive sleepiness have been reported after treatment of nonfunctioning pituitary macroadenomas (NFMA). Because these complaints may be caused by disturbed nocturnal sleep, we evaluated objective sleep characteristics in patients treated for NFMA.

Design

Controlled cross-sectional study.

Subjects and methods

We studied 17 patients (8 women, mean age 54 years), in remission of NFMA during long-term follow-up (8 years, range 1–18 years) after surgery (n = 17) and additional radiotherapy (n = 5) without co-morbidity except for hypopituitarism and 17 controls matched for age, gender, and BMI. Sleep was assessed by nocturnal polysomnography, sleep and diurnal movement patterns by actigraphy, and quality of life and subjective sleep characteristics by questionnaires.

Results

Compared to controls, patients had reduced sleep efficiency (P = 0.008), less REM-sleep (17.1 vs 25.4%, P < 0.001), 10% more N1 sleep (P = 0.001) and more awakenings, in the absence of excessive apnea or periodic limb movements. Actigraphy revealed a longer sleep duration and profound disturbances in diurnal movement patterns, with more awakenings at night and less activity during the day. Patients scored higher on fatigue, and reported impaired quality of life.

Conclusion

Patients previously treated for NFMA suffer from decreased subjective sleep quality, disturbed distribution of sleep stages and disturbed circadian movement rhythm. These observations indicate that altered sleep characteristics may be a factor contributing to impaired quality of life and increased fatigue in patients treated for non-functioning macroadenomas.

P295

The dual PI3K/mTOR inhibitor NVP-BEZ235 has a potent anti proliferative action in human nonfunctioning pituitary adenomas

V Cerovac, M Tichomirowa, G Stallia & M Theodoropoulos

Max Planck Institute of Psychiatry, Munich, Germany.

NVP-BEZ235 is an orally available ATP competitive inhibitor of class I PI3K and mTOR. As such it suppresses Akt phosphorylation downstreams to PI3K and to mTOR complex 2 in addition to p70S6K phosphorylation downstreams to mTOR. The dual PI3K/mTOR complex 1 and displays potent antiproliferative activity in tumors with dysregulated the PI3K/Akt pathway. Administration of NVP-BEZ235 in human nonfunctioning pituitary tumors in primary cell culture suppressed cell viability by more than 50% in 37 out of 40 cases. The effect was cytostatic causing cell cycle arrest at the G1 phase. Transition through the G1 phase is governed by a hypersecreting tumor was recorded in 1 operated and in 2 non-operated patients. After surgery, hypopituitarism was diagnosed in 21/26 patients (80.8%), transient DI in 6/26 (23%). However surgery induced complete recovery of the visual disturbances in 9/22 (41%) and partial recovery in 8/22 (36%) of the affected patients. After a median follow-up of 31.5 months (6–300 months), hypopituitarism improved in 5/24 patients (20%), none of the tumors showed regrowth, in 6/18 patients (33%) the tumors decreased spontaneously by more than 50% and 5/20 patients (25%) were tumor-free.

Conclusion

Pituitary apoplexy may result in spontaneous tumor remission in 1 operated and in 2 non-operated patients. After surgery, hypopituitarism was diagnosed in 21/26 patients (80.8%), transient DI in 6/26 (23%). However surgery induced complete recovery of the visual disturbances in 9/22 (41%) and partial recovery in 8/22 (36%) of the affected patients. After a median follow-up of 31.5 months (6–300 months), hypopituitarism improved in 5/24 patients (20%), none of the tumors showed regrowth, in 6/18 patients (33%) the tumors decreased spontaneously by more than 50% and 5/20 patients (25%) were tumor-free.

P296

Primary pituitary tumors: 10-year single center experience

A Gkountouvas, I Kostoglou-Anthassiou, M Nikas, F Chatzimarkou, I Keramidas, D Thomas, P Georgiadis & P Kaldymidis

Department of Endocrinology, Metaxa Hospital, Piraeus, Greece.

Primary pituitary tumors are relatively rare and mainly benign.

The aim was to study the primary tumors presenting during a 10-year period in a single center.

Endocrine Abstracts (2011) Vol 26

The archives of all patients with primary pituitary tumors having been hospitalized from 01.01.2000 to 30.06.2010 in the Department of Endocrinology and Metabolism of Metaxa Hospital were studied. Within this cohort of patients 128 were female (63%) and 75 (37%) were male (ratio 1:1.7). All patients had benign neoplasms. The majority of the patients had acromegaly (78 patients, 38%) and non secreting pituitary adenomas (58 patients, 28%). Patients with prolactinoma represented 17% (35 patients), while patients with Cushing’s disease 11% (23 patients). In 1 patient (<1%) a TSH secreting adenoma was diagnosed. Multiple hormone secreting adenomas had 4 patients (2%). Within this cohort 3 patients (<2%) had adenomas secreting GH and prolactin and 1 had an adenoma secreting GH and TSH. In 3 (<2%) patients cysts were found in the pituitary and in 1 of them it proved to be Rathke’s cyst. Finally, in 1 patient (<1%) a craniopharyngioma was diagnosed.

In conclusion, primary pituitary tumors are rare and mainly benign. In our cohort prolactinomas appear not to be as many as expected, as currently patients with prolactinoma are treated mainly as outpatients.

P297

Pituitary apoplexy: clinical characteristics, circumstances of diagnosis and evolution in a Romanian patient series

M L Gheorghiu1,2, C Badiu1,2, D Hortopan1, A Dumitrasc1, A Caragheorgheopol1, D Alexandrescu1 & M Cocoluscu1,2

1'C. I. Parhon' National Institute of Endocrinology, Bucharest, Romania; 2'C. Davila' University of Medicine and Pharmacy, Bucharest, Romania.

Pituitary apoplexy is a rare syndrome due to hemorrhagic infarction of a pituitary adenoma. We analyze the circumstances of diagnosis, clinical features and evolution in a retrospective review of patients with pituitary apoplexy admitted between 2000 and 2010, diagnosed by pathological exam and/or suggestive imaging for pituitary haemorrhage.

Results

From 31 patients with pituitary apoplexy (11 women, 20 men) with a mean age of 48 years at diagnosis (20–75 years), 24 patients had clinically non-functioning pituitary adenomas, 3 acromegaly, 3 prolactinomas and 1 Cushing’s disease – all macroadenomas. In 90% of patients (28/31) the pituitary adenoma has not been previously diagnosed. In all apoplexy patients was clinically overt, with headaches in 96.5%, visual disturbances in 75.6%, vomiting in 51.8%, diabetes insipidus (DI) in 6.4% of patients. Previous or current pregnancy was noted in 2 patients, dopamine agonist treatment in 3, trauma in 2, trombolysis for coronary event in 1 patient. Pituitary surgery was done in 27 patients (7 by frontal, 20 by transphenoidal approach). In 7 patients with hypopituitarism identified at diagnosis, the pituitary function recovered in 2 of the 4 operated patients. Cure of a hypersecreting tumor was recorded in 1 operated and in 2 non-operated patients. After surgery, hypopituitarism was diagnosed in 21/26 patients (80.8%), transient DI in 6/26 (23%). However surgery induced complete recovery of the visual disturbances in 9/22 (41%) and partial recovery in 8/22 (36%) of the affected patients. After a median follow-up of 31.5 months (6–300 months), hypopituitarism improved in 5/24 patients (20%), none of the tumors showed re-growth, in 6/18 patients (33%) the tumors decreased spontaneously by more than 50% and 5/20 patients (25%) were tumor-free.

Conclusion

Pituitary apoplexy may result in spontaneous tumor remission (6% in our series), but is frequently associated with hypopituitarism.

P298

Effects of short (6 months) and long (18 months) term treatment with GH-receptor antagonist pegvisomant (PEG) on rhythm disturbances in acromegaly

Renata Simona Auriemma1, Rosario Pivonello1, Maria Cristina De Martinio1, Giuseppe Cudemo1, Mariano Galdiero1, Ludovica F S Grasso1, Chiara Simone1 & Annamaria Colao1

1'Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Naples, Italy; 2'Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy.

Aim

To evaluate the effects of short and long-term treatment with PEG on rhythm disturbances in a cohort of acromegalic patients resistant to long-term high-dose therapy with SA.
Patients and methods

Thirteen patients (4 M, 9 F, aged 44±9.25 years) entered the study. All patients started PEG at initial dose of 10 mg daily, then increased of 5 mg every 6 weeks on the basis of IGF1 levels, until IGF1 normalisation or until the achievement of the maximum dose of 40 mg daily. A standard 24-h ECG registration was performed in all patients at study entry and after 6 and 18 months of PEG to evaluate: mean (HR), maximum (mHR) and minimum (mHR) heart rate, pauses number (P) and duration (PD), supraventricular episodes number (SE) and duration (SED), ectopic beats number (EB) and duration (EBD).

Results

Compared to study entry, a slight but not significant decrease in HR, mHR and mHR was observed after 6-month PEG. Moreover, compared to study entry a significant decrease in HR (P=0.03), mHR (P=0.05) and mHR (P=0.05) was found after 18-month PEG. At study entry, one patient showed 36 P with PD of 1012 g/l, Hb – 141 g/l, HCT – 44.1%. The patient was prescribed a octreotide depo injections 20 mg/mth and at 6 months from operation was feeling well, with clinical remission and normalization of IGF1 and all blood count parameters.

Conclusions

In acromegalic patients resistant to long-term high-dose SA therapy long-term treatment with PEG reduces HR, mHR and mHR so that to improve hyperkinetic syndrome.
Obesity

O302
Obesity in GDM
Luisa Ruas1, Marcia Alves1, Sandra Paiva1, Elvira Marta1,2, António Lobo1,2, Paulo Moura1,2 & Manuela Carvalheiro1
1University Hospital Endocrinology Department, Coimbra, Portugal; 2University Hospital Obstetric Department, Coimbra, Portugal.

Introduction
Retrospective study, 2003–07, of 619 GDM women.

Patients and methods
Two groups according to pre-pregnancy BMI: Go ≥30, Gno <30 kg/m². Influence of BMI in: family history of DM, previous GDM or macrosomia, gestational age at time of GDM diagnosis, weight gain, blood pressure, A1c, need and doses of Insulin, time and type of delivery, newborn weight, complications and re-evaluation post partum.

Results
Mean age 33.03 years old, mean BMI: 26.39, Go: 34.19 and Gno: 24.43. Family history Go: 65.2%, Gno: 58.5%. Previous GDM Go: 14.1%, Gno: 10.5%. Go: 0.26 Previous macrosomia Gno: 10.5%, Gno: 7.3%. P = 0.3. GA, Ws at GDM diagnosis Go: 26.72 and Gno: 28.75 P = 0.002. Weight gain was adequate in 70.7% Gno: 39.6% of Gno; excessive in 29.3% Gno: 60.4% Go: <0.05, OR = 3.684. Normal BP in 85.5% Go: 96.0% Gno; chronic hypertension in 6.7% Go: 1.4% in Gno; hypertension induced by pregnancy 3.8% Go and 2.6% Gno. A1c: 5.36% Gno: 5.15% Gno; P <0.05. Insulin 42% Go: 28.1% Gno: P = <0.05; OR = 1.851, beginning of insulin (ws) Go: 29.11, Gno: 30.27 (P = 0.28) and total dose Go: 22.4 U/d and Gno: 16.85 U/d P = 0.025. Caesarean section Go: 37%, Gno: 33.3%. Macrosomia 9.9% Go: 6.7% in Gno: P = 0.24. Fetal morbidity 8.5% Go: 5.9% Gno: P = 0.33. Re-evaluation: Normal 82% Go: 91.5% in DM 1.2% Gno.

Conclusions
In GDM obesity was found to be an increased risk factor for maternal and fetal morbidity. Earlier GDM diagnose, excessive weight gain, hypertension, earlier insulin need and higher doses, earlier delivery, caesarean delivery, high baby weight and macrosomic babies and fetal morbidity. Obesity has a positive correlation with the development of carbohydrates intolerance and is a risk factor for maternal and fetal outcomes.

Obesity, metabolic syndrome, hepatic steatosis, fibrosis and viral load as negative factors affecting early (EVR) and sustained (SVR) virological response in patients with chronic hepatitis c treated with peginterferon and ribavirin
M Tataru Abuog1, E F Georgescu1,2, R Teodorescu1 & L. Stanescu1,2
1Filantropia University Hospital, Craiova, Romania; 2University of Medicine and Pharmacy, Craiova, Romania.

Our aim was to evaluate the impact of some clinical (obesity, metabolic syndrome), biochemical (HOMA-IR), histological (fibrosis, necroinflammation, steatosis) and viral factors (HCV viraemia) on both EVR and SVR in patients with genotype 1 chronic hepatitis C (CHC) treated with peginterferon plus ribavirin.

Patients and methods
We evaluated retrospectively 188 naive patients with CHC treated with peginterferon plus ribavirin at standard weight-based doses for 48 weeks (960/252F; mean age 42.72 ± 8.4; mean weight 69.63 ± 11.1 kg; mean BMI 24.03 ± 0.4). Biopsies were assessed for inflammatory activity and fibrosis, as quantified by the modified Knodell histological activity index. Steatosis was categorized by the proportion of hepatocytes per low-power field with fatty changes: >5%, >5–33%, 34–66%, >66%. All patients were evaluated for metabolic syndrome (MS) using the NCEP-ATP III criteria. All parameters were introduced in multivariate analysis in order to evaluate their contribution to EVR and SVR.

Results
EVR was achieved in 115/188 pts (61.17%) while SVR occurred in 82/115 (71.3%). After adjusting for sex and age, independent factors that negatively interfered with both EVR and SVR were: fibrosis score (OR: 0.478; 95% CI: 0.140–0.912; P = 0.031), steatosis (OR: 0.138; 95% CI: 0.035–0.537; P = 0.004), HOMA-IR index (OR: 0.478; 95% CI: 0.266–0.857; P = 0.013) and viral load (OR: 0.424; 95% CI: 0.240–0.746; P = 0.003). After excluding the patients with MS criteria (n = 32), EVR was observed in 102/156 (65.4%) and SVR in 82/102 (80.4%). Factors that independently influenced both EVR and SVR were: fibrosis score (OR: 0.468; 95% CI: 0.295–0.743; P = 0.001), steatosis (OR: 0.535; 95% CI: 0.342–0.834; P = 0.006), obesity (OR: 0.779; 95% CI: 0.650–0.935; P = 0.007) and viral load (OR: 0.784; 95% CI: 0.650–0.945; P = 0.011).

Conclusion
Fibrosis, steatosis and obesity, as well as viral load are independent parameters that can affect both EVR and SVR in genotype 1 CHC patients treated with peginterferon and ribavirin at standard doses for 48 weeks, regardless the presence of MS. If MS is present, HOMA-IR index can also additionally impair viral response.

Abstract withdrawn.

Testosterone therapy increased muscle mass and lipid oxidation in ageing men
L Frederiksen1,2, K Højlund1,2, D M Hougard3, K Brixen1,2 & M Andersen1,2
1Department of Endocrinology, Odense University Hospital, Odense, Denmark; 2Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; 3Statens Serum Institute, Copenhagen, Denmark.

Background
The indication for testosterone therapy in ageing hypogonadal men without hypothalamic, pituitary or testicular disease remains to be elucidated. The aim of this study was to investigate the effect of testosterone therapy on insulin sensitivity, substrate metabolism, body composition and adiposity in ageing men with relative hypogonadism using a predefined cut-off level for bioavailable testosterone.

Methods
A randomized, double-blinded, placebo-controlled study of testosterone treatment (gel) on 38 men, aged 60–78 years, with bioavailable testosterone <7.3 mmol/l and a waist circumference >94 cm. Insulin-stimulated glucose disposal (Rd) and substrate oxidation were assessed by euglycemic hyperinsulinemic clamps combined with indirect calorimetry. Lean body mass (LBM) and total fat mass were measured by DXA, and serum total testosterone was measured by tandem mass spectrometry. Bioavailable testosterone was calculated. Coefficients (b) represent the placebo-controlled mean effect of intervention.

Results
Lean body mass (b = 1.9 kg, P = 0.003) increased while HDL-cholesterol (b = −0.12 mmol/l, P = 0.045) and total fat mass (TFM) decreased (b = −1.2 kg, P = 0.038) in the testosterone group compared to placebo. Basal lipid oxidation (b = 5.65 mg/min per m², P = 0.045) increased and basal glucose oxidation (b = −9.71 mg/min per m², P = 0.046) decreased in response to testosterone therapy even when corrected for changes in LBM. No change in insulin-stimulated Rd was observed (b = −0.01 mg/min per m², P = 0.92).

Conclusion
Testosterone therapy increased muscle mass and lipid oxidation in the absence of an effect on insulin-stimulated glucose uptake. These data suggest the existence of opposite-directed effects of testosterone on factors related to insulin sensitivity in ageing men with relative hypogonadism.
P306
Development and characterization of high-affinity leptins and leptin antagonists
The Hebrew University, The Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel; 2Institute for Gastroenterology and Liver Disease, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Leptin is a pleiotropic hormone acting both centrally and peripherally. It participates in a variety of biological processes including energy metabolism, reproduction and modulation of the immune response. So far structural elements affecting leptin binding to its receptor remain unknown. We employed random mutagenesis of leptin, followed by selection of high-affinity mutants by yeast-surface display and discovered that replacing residue D23 with a non-negatively charged amino acid leads to dramatically enhanced affinity of leptin for its soluble receptor. Rational mutagenesis of D23 revealed the D23L substitution to be most effective. Coupling the D23 mutation with alanine mutagenesis of three amino acids (L39A/D40A/F41A) previously reported to convert leptin into antagonist resulted in potent antagonistic activity. These novel superactive mouse and human leptin antagonists (D23L/L39A/D40A/F41A), termed respectively SMLA and SHLA, exhibited over 60-fold increased binding to leptin receptor and 14-fold higher antagonistic activity in vivo relative to the L39A/D40A/F41A mutants. To prolong and enhance in vivo activity, SMLA and SHLA were monopegylated mainly at the N-terminus. Administration of the pegylated SMLA to mice resulted in a remarkably rapid, significant and reversible 27-fold more potent increase in body weight (as compared to pegylated MLA), due to increased food consumption. Thus, recognition and mutagenesis of D23 enabled construction of novel compounds that induce potent and reversible central and peripheral leptin deficiency. In addition to enhancing our understanding of the mechanisms underlying digestion in complex organisms. Understanding of the processes of feeding regulation should also have practical applications in diseases involving leptin.

P308
TNFα plays an essential role in the downregulation of sex hormone-binding globulin production by decreasing hepatic HNF-4α through NF-κB activation
A Barbaso-Desongles, R Simo, A Lecuebe, C Hernandez & D Selva
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca, Barcelona, Spain.

The reason why obesity (a chronic low-grade inflammatory disease) is associated with low levels of sex hormone-binding globulin (SHBG) remains to be elucidated. In the present study we provide evidence that TNFα (a proinflammatory cytokine that increases with obesity) reduces SHBG production by human HepG2 hepatoblastoma cells. The effect of TNFα on human SHBG expression was mediated by NF-κB which causes the downregulation of HNF-4α, a key SHBG transcriptional regulator. Moreover, daily TNFα treatment of human SHBG transgenic mice reduced plasma SHBG levels as well as liver HNF-4α levels. Finally, a negative and independent correlation was found between plasma levels of TNFα receptor 1 and SHBG in obese patients. We conclude that sustained exposure to elevated levels of TNFα decreases plasma SHBG production by reducing hepatic HNF-4α levels via NF-κB activation. These findings open up a new mechanism linking obesity with the deleterious consequences arising from lower levels of SHBG.

P307
Ghrelin effects on nutrition and digestion in pest insects
V Perić Mataruga, M Mrdaković, B Janac´, M Vlahovic´, D Mircˇic´, L Ilijin & V Milošević
Institute for biological research ‘Siniša Stanković’, Belgrade, Serbia.

The gypsy moth, Lymantria dispar, is one of the most destructive phytophagous pests of the northern hemisphere. It shows a tremendous capacity to increase in numbers, and feeds on a wide range of trees and shrubs. However, several different systems driving feeding behavior and digestion of Lymantria dispar L. have not yet been elucidated. Ghrelin along with several other hormones has significant effects on appetite and growth in humans and animals. The aim of our study was to examine changes in nutritional indices (relative growth rate-RGR, relative consumption rate-RCR, efficiency of conversion of ingested food-ECI, efficiency of conversion of digested food-ECED), relative midgut mass, total proteases, leucine aminopeptidase and trypsin activities in the midgut and fat body mass of 4th instar caterpillars of the pest insect, Lymantria dispar L. after ghrelin treatment. Four subcuticular injections of ghrelin (0.5 pmol) or physiological saline (control) were applied every 24 h to two separate groups of fifteen caterpillars. The nutritional indices, RGR, RCR, ECI and EC1 were higher in the ghrelin treated than in the control group. Repeated administration of ghrelin in subcuticular doses also elevated relative midgut mass, induced digestive enzyme activities and increased fat body mass. Such information provides more evidence for the application of these relatively simple model systems in future studies of the mechanisms underlying digestion in complex organisms. Understanding of the processes of feeding regulation should also have practical applications in biological control of its population number.

P309
Benzofran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 in rodent adipose tissue
Y Kobayashi, K Daisuke, Y Yamaguchi, M Ueda, O Miyata & N Tagawa
Kobe Pharmaceutical University, Kobe City, Hyogo Prefecture, Japan.

Excess glucocorticoids (GC) promote visceral obesity, hyperlipidemia and insulin resistance. The main regulators of intracellular GC levels are 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive GC into bioactive forms such as cortisol in humans and corticosterone in rodents. Therefore, the inhibition of 11β-HSD1 has considerable therapeutic potential for metabolic diseases including obesity and diabetes. Benzofran is a key structure in many biologically active compounds such as benzbromarone, Malibatol A and (+)-lithagol. The aim of this study is to investigate the inhibitory effect of benzofuran derivatives on 11β-HSD1. Microsomes were prepared from mesenteric adipose tissue from male Wistar rats. 11β-HSD1 activity was determined by incubation under an NADPH-regenerating system where the incubation medium, MOPS buffer, contained G-6-P (6 mM), NADP+ (1 mM), G-6-PDH (0.35 units/ml), and 11-dehydrocorticosterone (1 μM) with and without benzofuran derivatives (Compound 1–14, 50 μM). The reaction was started by the addition of 15 μl of microsomes (1.6 mg protein/ml) and the reactions were incubated at 37°C up to 40 min. Two milliliters of CH2Cl2 solution was added to stop the reaction. Corticosterone produced was measured by HPLC. Significant inhibition of 11β-HSD1 activity was observed in compound 1 (57%), 5 (36%), 7 (37%) and 8 (50%) compared with control. Further, we investigated the effect of these compounds on 11β-HSD2 (conversion of corticosterone to 11-dehydrocorticosterone). Compound 7 and 8 did not suppressed 11β-HSD2, whereas compound 1 and 5 inhibited 11β-HSD2 by 18.7 and 56.3%, respectively. Compound 7 and 8 inhibited 11β-HSD1 in time- and dose-dependent manner. Kinetic study revealed that compound 7 (the most potent and selective inhibitor) acted as a non-competitive inhibitor of 11β-HSD1 and the apparent Km value for 11-dehydrocorticosterone was 0.25 μM. These results suggest that compound 7 may exert its inhibitory effect by interacting with the enzyme 11β-HSD1.

P310
Effect of dehydroepiandrosterone on 11β-hydroxysteroid dehydrogenase type 1 in rodent adipocytes
N Tagawa, E Minamitani, O Kyionga & Y Kobayashi
Kobe Pharmaceutical University, Kobe City, Japan.

Dehydroepiandrosterone (DHEA) has been suggested to have an anti-obesity effect; however, the mechanism underlying this effect remains unclear. The effect
of DHEA on adipocytes opposes that of glucocorticoids, which potentiate adipogenesis. The key to the intracellular activation of glucocorticoids in adipocytes is 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which catalyzes the production of active glucocorticoids (cortisol in humans and corticosterone in rodents) from an inactive 11-keto form (cortisone in humans and 11-dehydrocorticosterone in rodents). In humans and rodents, intracellular glucocorticoid reactivation is exaggerated in obese adipose tissue. Using corticosterone in rodents) from an inactive 11-keto form (cortisone in humans and catalyses the production of active glucocorticoids (cortisol in humans and corticosterone in rodents)

Effects of natural dietary antioxidants on insulin and IGF1 in obese patients with insulin resistance
A Mancini1, M Magini2, R Festà2, S Raimondi1, A Silvestrini3, A Pontecorvi2, E Meucci2 & GE Martorana4,5
1Department of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy; 2Department of Laboratory Medicine, Dietetic Service, Rome, Italy; 3Institute of Biochemistry and Clinical Biochemistry, Catholic University of the Sacred Heart, Rome, Italy; 4Department of Molecular Pathology, Marche Polytechnic University, Ancona, Italy.

Oxidative stress (OS) could play an important role in metabolic syndrome (MS)-related manifestations contributing to insulin resistance (IR). The reciprocal influences between OS and IR are not clear. We investigated the effects of dietary antioxidants on IR, studying 24 obese (7 males and 17 females, 27–66 years), with IR evaluated by HOMA index, during treatment with metformin, comparing 2 dietary treatments: hypocaloric diet (group A, n=16) or a diet enriched with natural antioxidants (group B, n=8). A personalized program, with mean caloric intake of 1500 Kcal, 25% proteins, low glycemic index CHO and a calculated antioxidant intake of 800–1000 mg/daily, derived from fruit and vegetables, was administered to group B. OGTT and evaluation of total, LDL and HDL-cholesterol, triglycerides, uric acid, albumin and IGF1 were performed before and after a 3-months treatment. Total antioxidant capacity was determined by H2O2-metmyoglobin system which, interacting with the chromogen ABTS, generates a radical with a latency time (LAG) proportional to antioxidant content. Despite a similar significant BMI decrease, we found a significant decrease of insulin AUC and a significant increase in IGF1 in group B, together with a trend in increasing LAG values in the same group.

Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>BMI (kg/m²)</th>
<th>Insulin AUC (μU/ml per 12h)</th>
<th>IGF1 (nmol/l)</th>
<th>LAG (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A pre</td>
<td>37.6 ± 1.3</td>
<td>14912.6 ± 2008.2</td>
<td>165.1 ± 14.2</td>
<td>63.2 ± 3.1</td>
</tr>
<tr>
<td>Group A post</td>
<td>36.1 ± 1.3*</td>
<td>13789.5 ± 1594.9</td>
<td>163.1 ± 10.4</td>
<td>66.3 ± 5.3</td>
</tr>
<tr>
<td>Group B pre</td>
<td>35.2 ± 2.0</td>
<td>15179.0 ± 3848.4</td>
<td>150.7 ± 12.7</td>
<td>56.2 ± 5.1</td>
</tr>
<tr>
<td>Group B post</td>
<td>32.2 ± 1.4*</td>
<td>11362.9 ± 705.8</td>
<td>140.7 ± 23.0*</td>
<td>60.6 ± 5.5</td>
</tr>
</tbody>
</table>

Mean ± S.E.M., *P<0.05, versus pretreatment values.

These data suggest that dietary antioxidants ameliorate insulin-sensitivity in obese insulin-resistant subjects enhancing the effect of insulin-sensitizing drugs, although the molecular mechanisms remain still to be elucidated. The reciprocal pattern of hormone response (insulin and IGF1) is similar to that observed after bariatric surgery-induced weight loss, suggesting an increase in GH sensitivity linked with an insulin decrease.

Environmetal and metabolic risk factors of obesity development in preschool children
L S Vizzavola1, A V Solntasava2, A V Sukalo3 & E I Dashkevich4
1st City children clinical hospital, Minsk, Belarus; 2Belarusian state medical university, Minsk, Belarus; 310th City clinical hospital, Minsk, Belarus.

Materials and methods
We investigated 79 normal (1st group) and 99 overweight (2nd group) preschool children. Deficient sport and average physical activity (APA) duration, risen appetite (point-assessment), prolonged television viewing and computer using time in children were considered as risk-factors of juvenile obesity manifestation. Height, weight, waist circumference (WC) was measured; body mass index (BMI) was calculated. Serum leptin levels were detected by immunoenzymatic method. Groups also were divided according sex. Statistical analysis was performed by using ANOVA and Hi-square criteria, Pearson’s correlation coefficient (r) (P=0.05).

Results

Deficient sport (P=0.02) and APA (P=0.01) duration, increase appetite (2.8 ± 1.8 points in girls and 3.3 ± 1.1 – in boys from the 2nd group as compared to the 1st one – 0.2 ± 0.7 and 0.2 ± 0.5 respectively (P=0.001); r=0.7 between risen appetite and BMI (P=0.0001), r=0.8 between risen appetite and WC (P=0.0001)) were noted in children from 2nd group. Prolonged television viewing and computer using were found in overweight girls (34.7 ± 22.5 and 62.1 ± 47.9 mm per day in 1st and 2nd groups appropriately (P=0.0006).

We ascertained correlations between leptin level and BMI r=0.77 (P=0.0001), leptin concentration and WC r=0.59 (P=0.001). Leptinemia also correlated with BMI and WC (r=0.77, P=0.0001) and sedentary lifestyle (r=0.77, P=0.0001). Children’s BMI and WC (r=0.77, P=0.0001). Children’s BMI and WC (r=0.77, P=0.0001) were diagonally correlated with percentage of overweight children (r=0.77, P=0.0001).

Endocrine Abstracts (2011) Vol 26
with low intensive physical activity duration ($r=0.74; P=0.04$), including TV viewing and computer using time using time $r=0.59 (P=0.004)$.

Conclusions

Deficient sport, APA duration, risen appetite are environmental risk-factors of early obesity manifestation in preschool children. We revealed positive correlations between leptin concentration and BMI, WC, low intensive physical activity duration, including TV viewing and computer using time in preschoolers.

**P314**

**Gender differences of leptin receptor gene genotypes and leptin levels in obese children**

A V Solntsa, 1 E A Aksonava, 2 N G Danilenko 3, L S Viazava 3 & A V Sukalo 1

1Belarusian state medical university, Minsk, Minsk region, Belarus; 2Institute of genetics and cytology, National Academy of Science, Minsk, Minsk region, Belarus; 32nd City children clinical hospital, Minsk, Minsk region, Belarus.

Aim

To compare gender frequency of leptin receptor gene (LEPR) genotype rates and leptinemia levels in overweight children.

Materials and methods

Three hundred children with adiposity were investigated (divided into groups: prepubertal (1st) m/f $n=51/50$, early pubertal (2nd) $n=49/51$, late pubertal (3d) $n=50/49$). 80 girls and 89 boys with obesity and 90 lean girls and 48 lean boys (control) were genotyped in 6 exon of LEPR gene (Q223R polymorphism). Serum leptin was detected by immunoenzyme method; insulin, testosterone estradiol levels – by radioimmunoassay technique. Statistical analysis was performed using SPSS 16.0 ($P=0.05$).

Results

There were no sex differences between leptin levels in 1st and 2nd groups ($P=0.7$) ($P=0.1$) in contrast to 3d group ($P=0.0001$). Leptinemia was increased in pubertal start ($P=0.021$) and subsequent leptin diminution with puberty development ($P=0.024$) in overweight boys. However we ascertained leptin levels constant rising in obese girl with pubertal progression ($P=0.001$). BMI and leptin ($r=0.355, P=0.0001$), insulin and leptin ($r=0.371, P=0.0001$) correlations were revealed. Leptinemia correlated with age ($r=0.326, P=0.009$) and serum testosterone concentration in pubertal boys ($r=-0.444, P=0.0001$), as compared to pubertal girls – only with estradiol concentration ($r=0.356, P=0.031$).

There were gender differences ($r^2=7.91; P<0.05$) between genotypes rates occurrence in obese children: 14.6% boys and 2.5% girls had RR-genotype, 21.3% girls and 15.7% boys – QQ. As compared to lean children: RR-genotype was found in 19.1% girls and 14.6% boys, QQ-genotype – in 25.8% girls and 20.8% boys ($P=0.05$).

Conclusion

There was 6 time lower incidence of RR-genotype among obese girls than normal peers. No differences were found between overweight and normal boys in Q223R LEPR genotype rates occurrence. Q223R LEPR genotypes in girls with adiposity were significant differ from normal children irrespective of gender.

---

**P315**

**Testosterone and metabolic syndrome: a meta-analysis study**

Giovanni Corona 1,2, Matteo Monami 2, Giulia Rastrelli 1, Antonio Abersa 3, Yuliya Tishova 4, Farid Saad 5,7, Andrea Lenzi 3, Gianni Forti 8 & Mario Maggi 1

1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 32nd City children clinical hospital, Minsk, Minsk region, Belarus; 4Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 5Clinical Endocrinology, Institute of genetics and cytology, National Academy of Science, Minsk, Minsk region, Belarus; 6Endocrinology Unit, Medical Department, Azienda Usl, Maggiore-Bellaria Hospital, Bologna, Italy; 7Gulf Medical University, Ajman, United Arab Emirates; 8Endocrinology Unit, University of Florence, Florence, Italy.

Introduction

Metabolic syndrome (MetS) is often associated with male hypogonadism. The role of testosterone replacement therapy (TRT) in MetS has not been completely clarified.

To systematically analyse the relationship between androgen levels and MetS we performed a review and meta-analyses of available prospective and cross-sectional studies. A specific meta-analysis on the metabolic effects of TRT in available randomised clinical trials (RCTs) was also performed.

Methods

An extensive Medline search was performed including the following words ‘testosterone’, ‘metabolic syndrome’ and ‘males’. Out of 323 retrieved articles, 302 articles were excluded for different reasons. Among the 20 published studies included, 13, 3, and 4 were cross-sectional, longitudinal, and RCTs, respectively. Another unpublished RCTs were retrieved on www.clinicaltrials.gov.

Results

MetS patients showed significantly lower T plasma levels, as compared to healthy individuals. Similar results were obtained when MetS subjects with and without erectile dysfunction were analyzed separately or when NCEP-ATPIII MetS criteria were compared to other definitions. Meta-regression analysis demonstrated that type 2 diabetes (T2DM) increased the MetS-associated T fall. In a multiple regression model, after adjusting for age and BMI, both T2DM and MetS independently predicted low testosterone (adj. $r=0.752; P<0.001$ and $-0.271; P<0.05$ respectively). Analysis of longitudinal studies demonstrated that baseline testosterone was significantly lower among patients with incident MetS in comparison to controls ($2.17(-2.41; -1.94)$ nmol/l, $P<0.0001$).

Combining the results of RCTs, TRT was associated with a significant reduction of fasting plasma glucose, HOMA index, triglycerides and waist circumference. In addition, an increase of HDL-cholesterol was also observed.

Conclusions

The meta-analysis of the available cross-sectional data suggests that MetS can be considered an independent association of male hypogonadism. Although only few RCTs have been reported, TRT seems to improve metabolic control, as well as central obesity.

---

**P316**

**Identification of a reliable biomarker for metabolic syndrome**

A R Abdullah, H Hasan & V Raigangar

University of Sharjah, Sharjah, United Arab Emirates.

Introduction

Over the last decade there has been a steady rise in obesity and co-morbidity, but little is known about the rate of metabolic dysfunction among young adults in the United Arab Emirates. Various factors have been implicated as biomarkers of metabolic syndrome (MetS). The objective of this study was to analyze the relationships of various biomarkers (leptin, C-reactive protein (CRP), adiponectin, insulin, and uric acid) to the MetS components in lean, overweight, and obese young females.

Methods

This was a cross-sectional study of 69 apparently healthy young females, who were classified according to their body mass index (BMI) (kg/m^2) into three groups: lean ($\leq 25$), overweight ($>25$ and $<30$), and obese ($\geq 30$). Estimated biomarkers were: leptin, insulin, adiponectin, high-sensitivity (hs)-CRP, uric acid, blood sugar, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, and triglycerides (TG).

Anthropometric measures, blood pressure, and homeostasis model assessment–insulin resistance (HOMA-IR) were also measured.

Results

Serum leptin, hs-CRP, insulin, and uric acid increased significantly ($P<0.01$) with increased BMI. Only one significant correlation ($P<0.05$) between the biomarkers and the MetS components was found in lean subjects (leptin versus waist circumference $r=0.48$) as opposed to six in the obese group (hs-CRP versus waist circumference and systolic blood pressure, $r=0.45$ and $r=-0.41$, respectively; insulin versus diastolic blood pressure, $r=0.47$; adiponectin versus blood sugar, $r=-0.44$; and uric acid versus waist circumference and TG, $r=0.5$ and $r=0.51$, respectively).

Conclusion

Estimation of the levels of studied biomarkers could be an important tool for early detection of MetS before the appearance of its frank components. Uric acid seems to be the most reliable biomarker to identify obese subjects with MetS.
P317

Serum Vitamin D and IGF1 levels in abdominal obesity women
O Belyaeva1, E Bazhenova1, D Azzi2, A Berezina1,2, N Katsyveva1, O Galinka1, E Micheeva1 & E Grineva1
1St Petersburg State Medical University, St Petersburg, Russian Federation; 2Federal Centre of Heart, Blood and Endocrinology, St Petersburg, Russian Federation.

Context
Decreased levels of both vitamin D and insulin-like growth factor 1 (IGF1) may be associated with obesity, however this has not been well established. We have examined the relationship of vitamin D status and circulating IGF1 with metabolic parameters in abdominal obesity women.

Methods
Serum 25(OH)D and IGF1 levels were measured by means of ELISA in 90 women (mean age 45.6 ± 4.3) with abdominal obesity (according to IDF criteria, 2005). Anthropometric, metabolic measurements and standard oral glucose tolerance test were performed. The amount of adipose tissue was determined by dual-energy X-ray absorptiometry (DEXA).

Results
The prevalence of 25(OH)D level deficiency (<50 nMol/l) and insufficiency (<75 nMol/l) was 79.6% in women with abdominal obesity. Mean 25(OH)D level was 65.1 ± 28.1 nMol/l. 25(OH)D level was inversely associated with the total body %fat and android %fat determined by DEXA (r = −0.2, P = 0.002 respectively). We did not find correlations of 25(OH)D levels with body mass index (BMI), waist-to-hip ratio, blood pressure and insulin level. However we found correlation of 25(OH)D level with fasting plasma glucose level (r = −0.36, P = 0.003) and high-density lipoprotein (HDL) (r = −0.3, P = 0.005).

Mean IGF1 level was 125.4 ± 34.0 ng/ml. Correlation analysis revealed negative correlations between IGF1 concentration and body weight (r = −0.23, P = 0.03), waist circumference (r = −0.3, P = 0.007), BMI (r = −0.28, P = 0.01), android %fat (r = −0.23, P = 0.04), A/G ratio (r = −0.21, P = 0.05) and total fat quantity (r = −0.27, P = 0.03). We did not find relationship between IGF1 level and insulin, insulin, lipids concentration as well as 25(OH)D status.

Conclusion
This study shows that both vitamin D and IGF1 concentrations are reduced in obese women and associated with the amount of adipose tissue in android region. Besides, low vitamin D levels were associated with impaired glucose and lipid metabolism. Though no correlation between 25(OH)D and IGF1 levels were found, we are planning to continue our studies using a larger sample size for more reliable results.

P318

Serum adiponecic levels in patients with type 1 gaucher disease
S Petakovic1,2, N Surajdzic1,2, S Ognjanovic1,2, T Isailovic2, D Macut1,2, M Djurovic1,2, I Bozic1 & S Damjanovic1,2
1Medical school of Belgrade university, Belgrade, Serbia; 2Clinic of Endocrinology, Belgrade, Serbia; 3Clinic for Hematology, Belgrade, Serbia.

Gaucher disease (GD) is autosomal recessive lysosomal storage disorder caused by the deficiency of glucocerebrosidase with consequent massive accumulation of lipid-laden macrophages in various tissues. Estimated life expectancy is about 9 years shorter than for the reference population. Mortality due to macrovascular diseases is higher, and probably associated with metabolic abnormalities found in GD type 1 patients, including decreases in serum adiponecic levels. Because adiponecic is thought to have antithromogenic and anti-inflammatory properties, we studied its serum concentration in a cohort of 15 patients with type 1 GD (9 females and 6 males, mean age 44.2 ± 4.4 years) and 20 age and BMI-matched healthy control subjects (13 females and 7 males, mean age 40.9 ± 3.2 years). We found no difference in serum adiponecic level in patients with GD type 1 as compared with healthy subjects (mean ± S.E.M., 69.9 ± 6.9 vs 73.0 ± 10.8 ng/ml respectively). There was no difference in serum adiponecic levels between untreated and treated patients with type 1 GD. There was no correlation between body mass index and adiponecic levels even in group of GD patients on enzyme replacement treatment (n = 10). In conclusion our results does not confirm previous results concerning the existence of hypoadiponeciciemia in untreated or treated patients with GD type 1. Probably adiponecic has no role in decreased life expectancy due to macrovascular morbidty in these patients.

P319

Unundiagnosed thyroid dysfunction, leptin and body mass index
I Olatzola1,2, M L Granada1,3, M T Juliana1,2, C Castell1,2, A Serra1,2, A Alaruste1 & A Lucas1
1Endocrinology and Nutrition Service, Germans Trias i Pujol, Hospital, Badalona, Barcelona, Spain; 2Department of Medicine, Autonomus University of Barcelona, Badalona, Barcelona, Spain; 3Biochemistry Service. Germans Trias i Pujol, Hospital, Badalona, Barcelona, Spain; 4Neepholgy Service. Germans Trias i Pujol, Hospital, Badalona, Barcelona, Spain; 5General and Digestive Surgery Service. Germans Trias i Pujol, Hospital, Badalona, Barcelona, Spain; 6General Direction of Public Health. Health Department. Generalitat of Catalonia, Barcelona, Spain.

Introduction
Leptin seems to be a major link between obesity and thyroid dysfunction. Design To analyze the relationship between thyrotropin (TSH) and leptin (LP) plasma concentrations and body mass index (BMI), in 785 subjects (448 women) of 41.27 ± 9.72 years and BMI 28.91 ± 9.8 (18.04–93.98 kg/m²), without diagnosed thyroid disease or pregnancy, concentrations of TSH, free thyroxine (FT₄), LP, glyceria and insulmina were determined and HOMA index, calculated. The group of subjects was divided into three subgroups according to BMI: 18–30 (n = 594, 1), 30–40 (n = 97, 2) and > 40 kg/m² (patients with morbid obesity, n = 94, 3). The statistical analysis was performed with the SPSS package using the logantrim of the variables without normal distribution.

Results
The undiagnosed hypothyroidism (TSH > 4 mU/l) was 2.4, 4.1 and 9.9% for subgroups 1, 2 and 3 respectively (P = 0.002, 0.002). In the global group, the TSH correlated directly and significantly with BMI and the HOMA and inversely, with FT₄ (P = 0.007, 0.04, 0.006). In men, TSH only correlated directly and significantly with LP (P = 0.01) and in women, directly, with BMI, LP and the HOMA (P = 0.015, 0.001, 0.014) and inversely with FT₄ (P = 0.001). The multivariate analysis performed with TSH as the dependent variable showed that in men, the LP was the only predictor of the TSH concentration variations (P = 0.049) while, in women, BMI and FT₄ were the predictors of these variations (P = 0.023; < 0.000).

Conclusions
Undiagnosed hypothyroidism is more prevalent in patients with obesity and even more in those with morbid obesity than in the non obese population. The predictor factors of TSH concentration variations are different in men and women.

P320

Low birth weight and obesity are associated with increased androgen levels among children with premature adrenarche
L Leka, E Kousta, K Anyfandakis, S Leka & A Papathanassiou
P & A Kyrakou Children’s Hospital, Athens, Greece.

Introduction
The aim of the study was to assess the impact of obesity and birth weight (BW) at diagnosis of premature adrenarche (PA) in a large cohort of greek children.

Methods/Design
We assessed clinical and laboratory characteristics of 221 children (175 girls and 46 boys) at diagnosis of PA.

Results
At diagnosis of PA 149 children (67.4%) had pubic hair (Tanner stage ≥ 2), 10 (4.5%) had axillary hair (Tanner stage ≥ 2) and 62 (28.1%) had both axillary and pubic hair. Mean (± S.D.) bone age was significantly higher than chronological age (7.4 ± 2.1 vs 6.6 ± 1.8 years girls; P < 0.001 and 8.6 ± 2.3 vs 7.3 ± 2.0 years boys; P < 0.001). Among the 221 children with PA, 57 (26%) were overweight and 64 (29%) were obese, which is higher than the prevalence of obesity among prepubertal greek children. There was a positive correlation between BMI and testosterone levels (r = 0.17, P = 0.02), DHEAS levels (r = 0.27, P < 0.001) and bone age versus chronological age (r = 0.19, P = 0.006). Among the 187 full term pregnancy children there was a negative correlation between BW and testosterone (r = −0.21, P = 0.005), DHEAS (r = −0.15, P = 0.038), 17-OH-progesteron (r = −0.23, P = 0.002) and D₄D,Androstenedione levels (r = −0.18, P = 0.04).

Conclusions
Obesity and lower birth weight are associated with increased androgen levels among children with PA.
P321
Prevalence of metabolic syndrome in 850 obese children from infancy to adolescence
S Bellone1, F Prodam1,2, R Ricotti1, A Petri1, V Agarla1, C Guidi1, G Genoni1 & G Bona1
1Division of Pediatrics, Department of Medical Sciences, University of Piemonte Orientale, Novara, Italy; 2Endocrinology, Department of Clinical and Experimental Medicine, University of Piemonte Orientale, Novara, Italy.

Introduction
Obesity and connected metabolic alterations are a growing problem in paediatric age, but few data are available in the youngest population. Poor evidences on metabolic syndrome (MS) definition are present in childhood and the most used definitions are those of the modified National Cholesterol Education Program and of the International Diabetes Federation (IDF). Aim of our study was to evaluate the presence of MS in obese children using these two definitions and the usefulness of clinical parameters.

Subjects and methods
We performed clinical and metabolic blood evaluations in 850 overweight and obese children ranging from 1.9 to 18.1 years of both sexes.

Results
Following NCEP criteria, some children showed glucose alterations: 4.9% showed IFG, 7.6% IGT and 0.9% type 2 diabetes mellitus. 49.6% showed low levels of HDL-cholesterol, 28.1% high levels of triglycerides; 81.7% high blood pressure and 16.1% acanthosis. Waist circumference (WC) was high in 96.7%. Waist/height ratio (W/Hr) was higher the cut-off of 0.5 in about all population. Prevalence of metabolic syndrome was 36.9% following NCEP ATP III and 55.1% following IDF definition. 28.0% of subjects demonstrated MS using both definitions. Percentage of disagreement between definitions (59.1% in the group under age of 10 years, 9.1 over 16 years) is lower increasing age of population and presence of metabolic complications.

Conclusions
In this large population of obese children WC was high in about all population demonstrating the presence of visceral obesity. W/Hr could be a simple and useful parameter to identify children at risk of metabolic syndrome. They showed in early ages high percentage of metabolic alterations like hypertension, dislipidemia, dysglycemia. IDF criteria could overestimate the presence of syndrome, above all in prepubertal children under 10 years of age. These data suggest that metabolic surveillance is needed in children with visceral obesity already in early age.

P322
The effect of androgens on adipose tissue in PCOS
Erasmus MC, Rotterdam, The Netherlands.

Introduction
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders of premenopausal women. It is also the most frequent cause of female infertility and affects 6.5-8% of women in their reproductive age. Two out of three criteria diagnoses PCOS: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism and polycystic ovaries at ultrasound. In addition, PCOS women frequently display features of the metabolic syndrome, such as abdominal obesity and type 2 diabetes mellitus. To investigate the possible interaction between ovarian dysfunction and the metabolic syndrome we determined the effect of androgens on differentiation, insulin sensitivity and lipolysis in 3T3-L1 adipocytes.

Material and methods
3T3-L1 cells, a mouse white pre-adipocyte cell line, were stimulated with androgens during differentiation. Quantitative PCR was performed to measure expression levels of adipocyte marker genes. The effect of androgens on insulin sensitivity was analyzed by western blot analysis. Further, lipolysis was determined by measuring glycerol release.

Results
Our preliminary results showed that dihydrotestosterone (DHT) stimulated expression levels of early adipogenic markers (PPARγ and C/EPBα), while the expression of important marker genes for end stage adipogenesis (AP2, adiponectin and leptin) were inhibited. Insulin-stimulated glucose metabolism is mediated through insulin-induced Akt phosphorylation. Our experiments showed that DHT suppressed insulin-induced Akt phosphorylation, suggesting that DHT-treatment results in reduced insulin sensitivity. Insulin insensitivity is also reflected by an increased lipolytic activity. In contrast, basal levels of lipolysis were significantly decreased by 30% after 24 h stimulation with testosterone.

Conclusion
Our results show that DHT reduces insulin sensitivity, a crucial feature in the pathophysiology of PCOS and metabolic syndrome. Furthermore, our results suggest that androgens may program differences in adipocyte differentiation and/or function. Concluding, adipose tissue dysfunction, possible secondary to ovarian dysfunction, may be one of the causes of increased prevalence of metabolic syndrome in PCOS patients.

P323
Functional differences between visceral and subcutaneous fat pads originate in the adipose stem cell
G Cantini1, S Bagliosi1, M Francelanç1, M Poli1, E Borgogni1, A Di Franco1, R Squazzo2, F Francini2, M Lucchese2, G Perigil1, M Serio1 & M Luconi1
1University of Florence, Florence, Italy; 2AOU Careggi, Florence, Italy.

Metabolic pathologies mainly originate from dysfunctions of the white adipose tissue (AT). Functional differences in AT and their impact on metabolism seem associated with the fat depot regional distribution, in particular the subcutaneous (SAT) and visceral (VAT) pads. Human adult adipose stem cell (ASC) populations have recently been characterized from SAT and VAT. In this study, using human ASC cultures obtained from paired biopsies of abdominal SAT, S-ASC, and VAT, V-ASC, we addressed the question whether the functional differences observed between the two compartments may be already present in the adipose stem cell instead of being restricted to mature adipocytes. V-ASC showed significantly greater dimensions than the corresponding S-ASC, as evaluated by Millipore Scepter (mean diameter: 23.4 ± 4.8 µm, V-ASC and 20.5 ± 3.9 µm, S-ASC, P < 0.005) and by electrophysiology path clamping. Investigating the ability of ASC to proliferate in vitro a statistically significant difference in the proliferation rate between the two paired populations was observed, being S-ASC growth rate significantly higher than the one observed in V-ASC, as evaluated by cell counting, Ki67 immunostaining, MTS and bromodeoxyuridine incorporation (mean fold increase respectively of 2.55, 2.07, 2.33 and 1.63, P < 0.001). Following 3 weeks of in vitro-induced adipogenic differentiation performed in parallel conditions on V-ASC and S-ASC, S-ASC demonstrated a significantly higher adipogenic potential, as evaluated by Adipored staining of intracellular lipids (mean fold increase absorbance S- versus V-adipocytes: 1.83 ± 0.09, P < 0.001), as also confirmed by a significantly higher expression in in vitro differentiated adipocytes of adipogenic genes and proteins such as PPARgamma, adiponectin, FABP4. Our findings strongly suggest that VAT and SAT functional differences already originate in the adult adipose stem cell, which maintains the memory of the fat pad of origin.

P324
Basal energy expenditure and fat mass changes in breast cancer patients
Nermin Tuncbilek1, Sibel Güldiken2, Neslihan Soysal Atile 2, Betül Ekiz Bilir2 & Deniz Kökn1
1Trakya University Medical Faculty Radiology Department, Edirne, Turkey; 2Trakya University Medical Faculty Internal Medicine Endocrinology Division, Edirne, Turkey.

Aim
Basal energy expenditure (BEE), also called basal metabolic rate, increases in cancer patients and is thought to contribute to the weight loss observed in cancer cachexia. Cancer type, pathological stage and duration of disease influence BEE. The aim of this study was to evaluate BEE and body composition in breast cancer patients.

Methods
Forty-three women with breast cancer whose received adjuvant chemotherapy and 80 healthy age and body mass index (BMI)-matched control were enrolled in the study. Anthropometric measurements were recorded. BEE was measured by Harris-Benedict (HB) formula. Fat mass assessed by the TANITA. Preperitoneal, visceral and subcutaneous fat were evaluated by ultrasonography.

Results
Compared with the controls, patients with breast cancer showed significant increase in BEE (P < 0.001), and visceral fat mass (P < 0.05). Peritoneal fat mass was significantly decreased in breast cancer group (P < 0.01). There was no
significant difference between groups. BEE showed positive correlation with total fat mass \(r = 0.8, P < 0.001\), subcutaneous fat mass \(r = 0.56, P < 0.001\) and visceral fat mass \(r = 0.4, P < 0.05\) in breast cancer patients. Regression analysis showed that total fat mass increase was an independent risk factor on BEE increase in breast cancer patients \(P < 0.001\), \(\beta = 0.79, 95\% CI = 8.0–14.4\).

Conclusion
Our data supports previous studies showed a greater BEE for breast cancer patients. Not only the local fat distribution but also the total fat mass increase affects on BEE in patients with breast cancer. When compared with healthy subjects, total fat mass increase didn’t observed in breast cancer patients but increase in visceral fat mass which is accepted as a marker of metabolic disturbances was remarkable. These body fat mass changes may have important health implications for survivors.

P325
Waist line radius to subcutaneous adipose tissue thickness—better insight to lipid stores centralisation
P Ristic, D Bokunjić & Z Andjelković
MMA, Belgrade, Serbia.

Introduction
It is well known fact that central lipid stores are related to glucose metabolism impairment. Standard anthropologic methods for measuring lipid stores centralisation are waist, waist to hip ratio and waist to height ratio. Still, often these markers fail to relate to difference in glucose metabolism between equally obese patients.

Method
We analysed relation between waist line radius and subcutaneous adipose tissue thickness, determinant with ultrasound 3 cm left of umbilicus on waist line, as a measure of lipid stores centralisation. Participants were randomly sampled males, overweight and obese divided by fasting glucose level as normoglicemic, impaired fasting glucose or diabetes mellitus type 2. Standard anthropologic measures were taken and compared. We analysed homeostatic model for insulin resistance and insulin secretion. Results were statistically analysed with analysis of variance followed by Tacky T test and analysis of correlation.

Results
We found statistically significant difference between three equally obese groups when subcutaneous tissue thickness was added compared to standard markers of lipid stores centralisation. We also notified statistically strong correlation between such new marker and HOMA IS particularly in IFG group.

Conclusion
Relation between waist line radius and subcutaneous adipose tissue thickness provides significant correlation with HOMA IS in equally obese patients when standard anthropometric markers of lipid stores centralisation failed. This could prove to be useful tool for early discovering and monitoring of deleterious lipid store centralisation particularly in IFG group.

P326
Serum leptin level and its association with body composition in obese children
M Vishnevskaya & A Solnceva
Belarusian State Medical University, Minsk, Belarus.

Body composition using dual energy X-ray absorptiometry (DEXA) can be used as an specific method for measuring fat mass and identify individual risk for cardiovascular and metabolic complications in obese children.

Objective
To investigate serum leptin level and its relationship with fat distribution in obese children.

Materials and methods
Eighty-seven children (male/female = 43/44, mean age 12.81 ± 0.5 years), obese (BMI > 95 percentile for age and sex), DEXA was used to body composition. Serum leptin level was measured using ELISA. Analysis was performed non-parametric (ANOVA, test of Mann-Whitney U) and parametric (t-Student criterion) methods \(P < 0.05\).

Results
BMI in a group of girls 28.3 ± 0.52 kg/m², a group of boys 29.7 ± 0.68 kg/m² \(P = 0.05\). DEXA data (ml): Gynoid \(\% = 51.05 \pm 0.93/53.98 \pm 0.58\) \(P = 0.05\), Android \(\% = 46.93 \pm 0.68/51.29 \pm 0.52\) \(P = 0.05\), A/G = 1.09 ± 0.02/1.05

P327
Inflammatory T-lymphocyte proliferation in morbid obesity
K van der Weerd1, W A Dik1, B Schrijver1, D H Schweitzer2, A W Langerak1, R M Kiewiet1, M O van Aken1, J J M van Dongen1, A J van der Lei1, F J T Staal1,3 & P M van Hagen1
1Erasmus MC, Rotterdam, The Netherlands; 2Reinier de Graaf Hospital, Delft, The Netherlands; 3LUMC, Leiden, The Netherlands.

Obesity is one of the leading causes of preventable death in the Western world, and its prevalence is dramatically increasing. Although obesity is primarily a metabolic disease, immunological aberrations also significantly contribute to obesity-related morbidity. The well-established state of chronic low-grade inflammation is considered to be crucial in the development of complications such as diabetes and atherosclerosis. Moreover, obesity is associated with increased susceptibility to infections, cancer and autoimmunity. Thus, disturbed immune regulation may exist in obese individuals. However, until now, a detailed description of systemic immunological changes in obesity is lacking.

We studied the effects of obesity on the T-cell compartment of morbid obese subjects. Blood was collected from eight morbid obese subjects and twenty lean control subjects. The T-cell compartment was defined phenotypically using flow cytometry and molecularly by T-cell receptor excision circle (TREC) analyses. We found a selective increase in T-lymphocyte number in morbid obese subjects, which was mainly caused by an increase in CD4+ T-lymphocytes. Also, in morbid obese subjects TREC content was decreased in all T-lymphocyte subpopulations, demonstrating that the increase in T-lymphocytes is mainly caused by increased proliferation. Moreover, in morbid obese subjects we found increased plasma levels of IL-7 and CCL5, both potent enhancers of T-lymphocyte proliferation. These data demonstrate that morbid obesity is associated with an increase in mainly CD4+ T-lymphocytes. Most likely, this is related to increased plasma levels of cytokines that stimulate T-lymphocyte proliferation. This increase in T-lymphocytes may contribute to the increased risk of autoimmunity and cancer described in morbid obesity.

P328
Letrozole normalizes serum testosterone but has no clinical effects in men with obesity-related hypogonadotropic hypogonadism
S Loves1, J de Jong1, A van Sorge1, D Teuling1, A Hermsus & H de Boer1
1Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands; 2Department of Psychology, Rijnstate Hospital, Arnhem, The Netherlands; 3Department of Clinical Chemistry, Rijnstate Hospital, Arnhem, The Netherlands; 4Department of Endocrinology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Introduction
Hypogonadotropic hypogonadism is frequently observed in morbidly obese men, due to aromatase-dependent conversion of androgens to estrogens. The clinical impact of this sex hormone imbalance is unknown.

Aim
Evaluate the clinical effects of aromatase inhibition in obesity-related hypogonadism.

Methods
Double-blind, placebo-controlled, 6-month trial in severely obese men (BMI ≥ 35 kg/m²) with obesity-related hypogonadism (serum total testosterone <10 nmol/l). Starting dose (Letrozole or placebo) 1 tablet/week, subsequent
monthly dose escalation up to a maximum of 7 tablets/week or until a serum total testosterone of 20 pmol/l. The dose was reduced if serum estradiol decreased below 40 pmol/l.

Results

Eighteen patients on Letrozole and 21 receiving placebo completed the study. Mean age 44.6 ± 1.1 years (mean ± S.E.M.), BMI 41.1 ± 0.8 kg/m². At baseline, both groups were well matched for all study parameters. Placebo treatment did not affect serum hormones levels. Letrozole decreased serum estradiol from 119 ± 10 to 59.2 ± 6.1 pmol/l (P < 0.0001), normalising serum LH (NR: 40–160 pmol/l), increased serum LH from 3.3 ± 0.3 to 8.8 ± 0.9 U/l (P < 0.0001, NR: 2–9 U/l) and free testosterone from 244 ± 19 to 691 ± 39 pmol/l (P < 0.0001, NR: 225–625 pmol/l). Both groups demonstrated a decrease in body weight of about 5 kg, and a decrease in abdominal circumference of about 4 cm. Changes in fat free mass, fat mass and bone density also did not differ between groups. Glucose metabolism, lipid profiles, physical exercise capacity and psychological characteristics did not change during treatment.

Conclusion

Despite a marked rise in serum free testosterone, low dose aromatase inhibition in abdominal circumference of about 4 cm. Changes in fat free mass, fat mass and bone density also did not differ between groups. Glucose metabolism, lipid profiles, physical exercise capacity and psychological characteristics did not change during treatment.


despite the gender

P329

Small animal PET/CT imaging reveals altered in vivo insulin function in brown adipose tissue of obese mice

C Quarta1, M Bucci2, M Colavita3, S Fant1, S Obici4, R Pasquali3, P Iozzo1 & U Pagotto2

1Turku PET Center, University of Turku, Turku, Finland; 2Department of Clinical Medicine and CRBA, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 3Department of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 4Obesity Research Center, University of Cincinnati, Cincinnati, Ohio, USA.

Brown adipose tissue (BAT) is an insulin sensitive organ having a very high uptake of glucose per gram of tissue. The role of insulin on glucose uptake in BAT is still poorly understood, moreover, it is not clear whether BAT insulin function is compromised with obesity. We used a small animal PET/CT imaging approach to analyse insulin function in vivo in lean and obese mice using a glucose analogue PET tracer (18F-FDG). Three groups of mice were analysed after administration of different diet regimens leading to progressive obesity levels: standard chow diet (SD), high fat diet (HFD, 40% fat content), super high fat diet (SHFD, 60% fat content). Each group of animals underwent two repeated PET/CT scans: the first in fasting state (basal state), the second after insulin administration (0.7 U/kg). Glucose levels, analysed during PET/CT procedures with a glucometer, revealed a slight and a severe compromise of insulin sensitivity in HFD and SHFD groups, respectively. Accordingly, PET/CT image analysis of 18F-FDG uptake in the BAT revealed that insulin strongly increased FDG uptake signal in both SD mice, whereas insulin induced 18F-FDG uptake was lower in HFD group, and completely absent in SHFD group. To confirm the data, and to analyse whether counter-regulatory mechanisms originated by insulin-induced hypoglycemia influenced PET/CT analysis, we repeated the imaging procedure described above in a new cohort of SD mice, HFD and SHFD mice in which euglycemia was maintained by external glucose infusion through a jugular catheter. Image analysis of 18F-FDG uptake in the BAT of mice analysed in euglycemic conditions was indistinguishable from the previous approach in all the three groups, confirming the presence of an altered insulin function in the BAT of obese mice. These findings, which reveal that obesity is associated with an altered insulin function of BAT, highlight small animal PET/CT as a powerful new tool for non-invasive analysis of insulin sensitivity.

P330

Haematic circulating endocannabinoids (ECs) in lean, overweight and obese: the role of the gender

F Fanelli1, V D Di Lallo1, I Belluomo1, E Casadio, M Baccini, D Ibarra Gasparini, V Viceninni, R Pasquali1 & Uberto Pagotto1

S. Orsola Hospital, Bologna, Italy.

A number of publications recently provided measurements of plasma ECs by liquid chromatography/mass spectrometry (LC-MSMS), however, the reported circulating levels in normal subjects are scattered in a very wide range of concentrations. A quantitative LC–MS/MS method for anandamide (AEA), palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and 2arachidonoyl-glycerol (2AG), chromatographically resolved by its inactive isomer 1AG, was validated in house. We firstly evaluated the stability of ECs during the early stages of the blood processing. Five blood aliquots were withdrawn in EDTA containing tubes from 20 subjects, and blood was kept at 4°C until centrifugation after 0, 30, 60, 120 and 240 min, followed by storage of plasma at –80°C. Probably due to a blood cells spill-over, we found AEA, PEA and OEA dramatically increased to about 150% of the 60 concentrations in the first 30 min, reaching 250% after 240 min, while 2AG level slowly decreases to 80% of its concentration after 240 min, maybe due to isomerisation. Once equipped for the proper storage of plasma within 15–20 min from the withdrawal, samples from 215 healthy and completely drug-free volunteers were taken. Normal values (pmol/ml) in 112 normal weight subjects were: AEA: 1.16 ± 0.31; PEA: 12.25 ± 2.71; OEA: 4.22 ± 1.44; 2AG: 0.88 ± 0.34; no gender differences were observed. In females increased AEA and PEA levels were shown both in 34 overweight (22 and 11%, respectively) and 13 obese subjects (21 and 7%, respectively), in male obese group (n=13) AEA, PEA and 2AG levels increased of 36, 31 and 42%, respectively, but no differences were observed in overweight group (n=43). No changes were observed in OEA levels. A gender specific association between circulating ECs and overweight/obesity was revealed: AEA and PEA in females, AEA, PEA and, to a greater extent, 2AG, in male obesity.

P331

Enhanced muscle mass by ALA treatment increase myostatin-mediated pathways in adipose tissue

H S Kwon, O K Hong, S S Lee, S R Kim & S J Yoo

The Catholic University of Korea, Seoul, Republic of Korea.

Myostatin is expressed predominantly in skeletal muscle and at significantly lower levels in adipose tissue. The loss of myostatin by gene disruption prevents an age-related increase in adipose tissue mass and partially attenuates the obese and diabetic phenotypes. Inhibition of myostatin signaling could be useful to prevent and/or treat obesity and diabetes. Male OLETF and LETO rats as non-diabetic controls were treated with or without ALA (100 mg/kg per day) and/or insulin (2 U/kg body weight per day) for 8 weeks from their age of 24 weeks. Using quantitative real-time polymerization chain reaction, insulin might increase AcirIib and FstL3 in skeletal muscle of diabetes rats partially through enhancing IGF1 and IGF-IR expression. Although oral intake of ALA might decrease body fat accumulation, larger amount of skeletal muscle mass from gastrocnemius relatively saved compared with insulin-alone treated group and control group. Myostatin, AcirIib and FstL3 gene expression with ALA-treated group might increase in epididymal fat tissue relation to decreasing IL-15, which inhibits fat deposition via a direct action on adipose tissue in rodents and inhibit or oppose TNF-a mediated pathway in both skeletal muscle and adipose tissue. This present data suggest that ALA had better effect in adipose tissue as energy expenditure and metabolic actions, myostatin signaling may play a role in the response of adipocytes to diabetes.

P332

Effects of food, hormones and autonomic nervous activity on rhythmic expression of clock genes and metabolic genes in rat white adipose tissue

R van der Spek1, L Kervezee1, S La Fleur1, E Fliers2 & A Kalsbeek1,2

1Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2Netherlands Institute for Neuroscience, Hypothalamic Integration Mechanisms, Amsterdam, The Netherlands.

Background

Shift workers and rodents with clock gene mutations show increased risk of metabolic syndrome and type 2 diabetes (T2DM). Conversely, obesity and T2DM are related to circadian disturbances in humans and rodents. The circadian release of adipokines from white adipose tissue (WAT) plays a pivotal role in energy metabolism. Its regulatory mechanism is unclear at present.

Aim

To determine the daily expression patterns of genes involved in circadian and metabolic pathways in different compartments of rat WAT. Subsequently, to investigate effects of scheduled feeding on these expression patterns.

Method

Experiment 1: 64 male Wistar rats were killed at 8 timepoints during the 12 h light:12 h darkness cycle. Blood was collected, perirenal(prWAT),
subcutaneous (sWAT), epididymal (eWAT) and mesenteric WAT (mWAT) were dissected and RT-qPCR was performed.

Experiment 2: rats (n=9 per ZT) were entrained to a six-meals-a-day feeding schedule. Each meal consisted of a 10 min feeding opportunity once every 4 h. Animals remained on this schedule for 4 weeks before they were killed at ZT2 and ZT14. Controls were fed ad libitum (n=3 per ZT). Blood was collected, prWAT and sWAT were dissected and RT-qPCR was performed.

Results
Experiment 1: in intact rats, circadian genes as well as part of the metabolic genes, showed distinct day/night rhythms in prWAT and sWAT. Only minor differences between prWAT and sWAT were found.

Experiment 2: day/night rhythms of most circadian genes were attenuated in absence of the day/night rhythm in feeding activity. In metabolic genes no significant effect of feeding regimen was found. Overall, effects were more pronounced in prWAT as compared to sWAT.

Conclusion
The clock gene rhythm amplitude in prWAT is partly dependent on rhythmic food intake. Additionally, hormones and nervous input likely contribute to fine-tuning of the rhythmic expression of clock- and metabolic genes in WAT and are subject of our future studies.

P333
Investigating the role of FTO in obesity: dysregulation of satiety signalling
F McMurray, C Church & R D Cox
MRC Harwell, Harwell, UK.

In 2007 a genome wide association study linked SNPs in intron 1 of FTO with an increased body mass index. Individuals with the ‘risk’ allele are on average 3 kg heavier than those with the ‘protective’ allele. Furthermore, those with the ‘risk’ allele have demonstrated greater energy intake. Mouse models of FTO have been generated including a conditional overexpression allele of FTO, which has 2 additional copies of FTO (FTO-4). These mice have increased body weight when globally expressed, which suggests that the FTO SNPs may lead to weight gain by increasing the activity and/or expression levels of FTO.

FTO-4 mice are hyperphagic. To investigate the cause, hormones, which are crucial for control of food intake and satiety, will be analysed.

Male 6 weeks old FTO-4 and wild-type mice fed on high fat diet were acclimatised to 16 h overnight fasting for 3 weeks. In subsequent weeks after fasting blood samples, food intake and body weight, fat and lean mass data and finally tissues were collected. Analysis of blood and tissue samples was then performed.

Significant dysregulation of specific hormones can be seen. Active ghrelin levels were either significantly higher in FTO-4 mice following refeeding or significantly lower before feeding began. Levels of leptin were significantly higher in FTO-4 mice (P=0.006) than in wild-types following refeeding suggesting resistance to leptin’s anorexigenic effects. Levels of NPY, an orexigenic peptide YY (PYY) was measured at the same time points. The anorexigenic peptide YY (PYY) was measured at the same time points.

Conclusion
Design
We measured plasma AEA and 2-AG levels in 12 normal weight (10 F, age: 39.1 ± 3.7 years, body mass index (BMI): 21.0 ± 0.6 kg/m², waist circumference (WC): 73.8 ± 2.9 cm) and 12 insulin-resistant obese subjects (8 F, age: 37.4 ± 3.4 years, BMI: 42.0 ± 1.4 kg/m², WC: 125.0 ± 4.5 cm) 1 h before, immediately before and 1 h after the consumption of a balanced meal. The anorexigenic peptide YY (PYY) was measured at the same time points.

Results
Basal plasma AEA and 2-AG levels were increased in obese and positively correlated with BMI, WC and insulin for AEA. Before the meal, AEA similarly and significantly increased in both groups. After the meal, AEA decreased significantly in normal weight but not in obese subjects. 2-AG levels did not change over the meal. Post-prandial AEA change negatively correlated with WC and explained 20.7% of the variance observed for waist (r²=0.207, P=0.04). Likewise, post-prandial PYY change inversely correlated with WC and explained 21.3% of waist variance (r²=0.213, P=0.04). Post-prandial AEA and PYY changes were not correlated (r²=0.242, P=0.30). A multiple regression analysis showed that post-prandial AEA and PYY changes explained 34% of the waist variance (r²=0.382, P<0.03), with only 8.2% of the variance commonly explained.

Conclusion
The pre-prandial peak of AEA suggests a role for this endocannabinoid in the initiation of the meal. The post-prandial changes of both the orexigenic AEA and the anorexigenic PYY are blunted in obese subjects and inversely and independently correlate with WC.

P334
Synergistic post-prandial deregulation of orexigenic and anorexigenic systems in obesity
B Gatta-Cherifi1,2, I Mattias1,3, M Vallée1,3, A Tabarini1,2, G Marsicano1,3, P V Piazza2,3 & D Cota1,3
1Groups ‘Energy Balance and Obesity’, Endocannabinoids and Neuroadaptation, ‘Physiopathology of Addiction’, INSERM U862, Neurocentre Magendie, 33077 Bordeaux, Bordeaux, France; 2Endocrinology Department, Haut-Lévêque Hospital, Pessac, France; 3Université Bordeaux 2, Bordeaux, France.

Introduction
Obese humans have increased plasma levels of endocannabinoids like anandamide (AEA) and 2-arachydonoyl-glycerol (2-AG). However, it is unknown whether these orexigenic signals have a role in human eating behavior.

Endocrine Abstracts (2011) Vol 26
P336

Therapy with exenatide in obese and morbidly obese type 2 diabetic patients: comparative analysis
M Dieguez Felechosa, C Tuson Rovira, C Sanchez Ragnarsson, F Casal Alvarez, N Valdés Gallego, L Manjón Miguélez, J Prieto Santiago
1Hospital de Cabueñes, Gijón, Spain; 2Hospital Universitario Central de Asturias, Oviedo, Spain.

Aim
To compare the effectiveness and tolerability of Exenatide twice daily treatment of obese and morbidly obese type 2 diabetic (T2D) patients.

Material and methods
To analyze data of obese and severe obese T2D patients initiated on Exenatide in our Endocrine clinics who complete one year of treatment. We separate patients in two groups: group A (BMI < 40 kg/m²) and group B (BMI ≥ 40 kg/m²). We did not include any modifications in previous lifestyle plans.

Results
We included 42 patients, 18 in group A (10 women and 8 men, mean ± s.d. age 57 ± 10 years, 9.2 ± 4 years of diabetes evolution) and 24 in group B (20 women and 4 men, mean ± s.d. age 61 ± 9 years, 5.4 ± 4 years of diabetes evolution). At baseline, HbAlc was 7.2 ± 1.6 and weight 92.8 ± 12.8 kg (BMI 36.5 ± 2.8 kg/m²) vs 111 ± 14 kg (BMI 44.4 ± 3 kg/m²) in group A and B respectively.

After 12 months of treatment, mean HbAlc reduction was 0.9 ± 2% in group A and 0.6 ± 2.4% in group B, mean weight loss 5.9 ± 2.6 kg (BMI reduction 2.3 ± 2.8 kg/m²) in group A and 10 ± 7.8 (BMI 3.6 ± 3 kg/m²) in group B, being all of them statistical significant (P < 0.01 Wilcoxon test). Comparing HbAlc, weight and BMI mean reductions of two groups we have not assessed significant differences (P > 0.05 Mann-Whitney U test).

Adverse events were registered in 9 patients (50%) in group A and in 4 patients (16.7%) in group B (P < 0.01 χ² test), with similar withdrawal rates (22.2 vs 21.7%).

Conclusions
Exenatide treatment significantly reduces HbAlc and weight in our population of obese T2D patients. We have not observed any significant difference in Exenatide efficacy between obese and severe obese T2D patients. Morbidly obese patients showed better Exenatide tolerance profile.

P337

Vitamin D and obesity
I Kostoglou-Athanassiou, A Chronaiou, V Triantí, S Tagara, A Michou, A Liakopoulou, T Terzi & A Karfi
Department of Endocrinology, Red Cross Hospital, Athens, Greece.

Low vitamin D levels have been found in patients with diabetes mellitus type 2 and have been correlated with poor glycemic control. There are observations suggesting that vitamin D levels may be low in obesity.

The aim was to study vitamin D levels in obese individuals.

The levels of 25(OH)D3 were measured in 30 obese individuals aged 42.67 years (mean), range 27-64, BMI 35.49 (mean), range 30-46 and 37 control subjects, aged 58.3 years (mean), range 33-83, BMI 24.9, range 21-29. The levels of 25(OH)D3 were measured by RIA.

Vitamin D levels were lower in the obese patients than the control subjects, levels being 21.87 ± 12.36 ng/ml (mean ± s.d.) in the obese patients as compared to 38.42 ± 15.31 ng/ml in the control group, P < 0.05 (Student’s t test).

It appears that vitamin D levels may be low in obesity. The aetiology of low vitamin D levels in obesity is still obscure. Vitamin D may be stored in the fat and thus its real levels within the body may be normal, low levels being detected only in the blood. Alternatively, vitamin D may be destroyed in obesity, as a result of increased oxidative reactions occurring in the context of obesity. Thus, low vitamin D levels may be another pathophysiological mechanism resulting in increased morbidity in the obese.

P338

Glimepiride improves insulin sensitivity in oxidative skeletal muscle of obese rats: possible association between GLUT4 and SUR2A expressions
M F S F M Felipe dos Santos Ferreira Marques, R C T M Cristina Tieko Mori, M M O Mitiko Okamoto & U F M Fabres Machado
University of São Paulo, São Paulo, Brazil.

Studies have demonstrated that ATP-sensitive potassium channel (KATP) subunits SUR2A (sulfonylurea receptor) and Kir6.2 are involved in glucose uptake into skeletal muscle. It is known that the glucose transporter 4 (GLUT4) expression is highest in oxidative type I fibers, pointing out the important role of oxidative muscles as glucose uptakers. Considering these aspects the aim of this study was to investigate whether KATP channel can influence glucose uptake in oxidative muscle soleus by regulating GLUT4 expression. Insulin resistance was induced in male Wistar rats by inducing obesity with monosodium glutamate (MSG) (4 mg/kg per day). At the age of 3 months, half control and MSG-treated animals started receiving 0.1 mg/kg per day of glimepiride in the drinking water, and distributed in 4 groups: control rats (C), control rats treated with glimepiride (OG), MSG-obese rats (O) and MSG-obese rats treated with glimepiride (OG). Animals were submitted to insulin tolerance test (ITT) and samples of soleus muscle were excised for quantification of SUR2A, Kir6.2 and GLUT4 mRNA expression and GLUT4 protein. In ITT, O rats showed 33% decrease in glucose decay constant (kITT in response to insulin (P < 0.05 versus C and OG) and the glimepiride treatment made the kITT value return to the control level. OG rats presented a ~48% increase in SUR2A mRNA content in comparison to O and C rats (P < 0.01). O rats showed 16% increase in GLUT4 mRNA content (P < 0.01 versus C), without any increase in GLUT4 protein. After glimepiride treatment, OG rats increased GLUT4 mRNA (19%, P < 0.01 versus C) and protein (159%, P < 0.01 versus C; and 78%, P < 0.05 versus O). Obesity or glimepiride treatment did not alter Kir6.2 mRNA content. We conclude that the glimepiride increased the GLUT4 expression in soleus of the insulin resistant animals which could be associated to SUR2A genes expression, playing an important role in the maintenance of the glycemic homeostasis.

P339

The relationship between adiposity and carbohydrate metabolism, by age and gender in Vlora, a city in Albania
Yllka Bulushi1,2, Gliodiana Sinimi1,2 & Ljujan Rumbullaku1,2
1University of Vlora, Vlora, Albania; 2University of Tirana, Tirana, Albania.

Objective study was to determine the prevalence of overweight, obesity, type 2 diabetes.

Methods
The study in hospital of Vlora was carried out between January 2008 and December of 2009. The total study involved 284 patients, 167 women and 137 men, mean age 40–70 years whose height and body weight were evaluated. They were diagnosed with type 2 diabetes and were tested in addition to anthropometric evaluations.

Each survey comprised a general practitioner, a nurse and a medical secretary.

Body weight and height were measured.

Body mass index (BMI) was calculated as weight (in kilograms) divided by the square of height (in meters).

All statistical analyses were performed for women and men separately.

Results
The prevalence of diabetes showed a steady increase up to the age group 60–69 years, after which the prevalence fell. Overall, the overweight rate was 34.2, 33.5% in women and 36.3% in men; obesity rate was 23.7, 32.4% in women and 14.1% in men. The prevalence of obesity showed steady increase up to the age group 60–69 years in men and 50–59 years in women.

Conclusion
We have reported for the first time the prevalence of overweight, obesity, and type 2 diabetes and their association with each other and with age and gender in a hospital of Vlora, a city in Albania.

Endocrine Abstracts (2011) Vol 26
P340

Long term low intensity recreational physical exercise attenuates colonic inflammation in rats: the role of heme oxygenase system
Z Szalai1, A M Berkó1, A Pósa1, R Szabo1, K Orbán2, A Király2, F László1,1, Cs Varga1
1Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Csongrád, Hungary; 2NIST Physical Education and Sport Sciences, Gyula Juhász Faculty of Education, University of Szeged, Szeged, Csongrád, Hungary.

Introduction
Obesity caused health problems are increasing. Metabolic syndrome including obesity with insulin resistance, hypertension, and high blood lipid levels increases the risks of cardiovascular and inflammatory diseases. Many studies have reported that heme oxygenase (HO) induces reduced insulin resistance and severity of inflammatory bowel disease. We investigate the anti-inflammatory effect, one among many positive effects, of regular recreational physical activity in rat colitis model provoked by triminobenzene sulphanic acid (TNBS).

Methods
After 6 weeks self-administered physical activity (running wheel) male Wistar rats were treated with TNBS (10 mg). 72 h after TNBS challenge we measured colonic inflammatory parameters and HO activity.

Results
The colonic inflammatory damage were significantly decreased by physical activity (extent of lesion: from 49.7±0.9 to 38.4±4.4%; severity of mucosal damage: from 7.3±0.1 to 6.1±0.4; n=10–12, P<0.05). The regular physical activity enhanced HO activity in the running control group compared to the sedentary control group (from 1.06±0.16 to 5.48±0.29 nmol bilirubin/h per mg protein; n=10–12, P<0.001). The TNBS treatment increased the HO activity both in the non-running sedentary control and running groups.

Conclusion
Long lasting recreational physical activity improves body’s defense mechanisms. Physical activity-induced increasing activation of HO system may play role of these mechanisms including colonic inflammation.

This work is supported by the SROP 4.2.1/B-09/1-KNNOV-210-005 and SROP 4.2.2.-08/1-2008-0006 research grants.

P347

Monitoring the efficacy of long term low intensity physical exercise programmes by the laboratory and hormone profile of obesity
A M Berkó1, G K Kis1, P Szabics2, B Kiss3, K Orbán1, E Seres1, Cs Varga1 & F László1,2
1Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Csongrád, Hungary; 2Institute of Physical Education and Sport Sciences, Gyula Juhász Faculty of Education, University of Szeged, Szeged, Csongrad, Hungary; 3Clinical Chemistry Laboratory, Faculty of Medicine, University of Szeged, Szeged, Csongrád, Hungary.

Introduction
In the human, obesity is one of the leading health problems as declared by the World Health Organization. Obesity is frequently associated with diabetes, hypertension and hyperlipaemia, these acts together as metabolic syndrome (MS). The risk of cardiovascular diseases is 5 to 10 times higher in MS. Lack of daily exercise is a good reason to evolve MS. Several hormones take part in the development of MS. Leptin and insulin, which are produced by the adipose tissue and the pancreas, and in addition the developed resistance to them play key role in the development of MS. We investigated the actions of recreational type of physical exercise on the levels of insulin and leptin in association with glucose- and lipid-metabolism parameters of MS.

Design
One hundred and eighty-five volunteers participated in a 5-month-long, low intensity, recreational type of aerobic physical activity program. We measured the levels of serum insulin, leptin, cholesterol, triglyceride, glucose and haemoglobin Alc (HBA1c) in 4 BMI categories (20–25, 25–30, 30–35, 35–<) at the beginning (day 0) in the middle (day 50) and at the end (day 150) of the program.

Results
We found decrease of body weight (88.6 kg ±2.2 to 81.0 ±2.0 kg) in the high BMI groups (30–<), where body fat content (from 42.7±1.0 to 38.5±1.0%), cholesterol (from 6.2±4.0 to 4.6±4.0 mmol/l), triglyceride (from 1.5±0.1 to 1.0±0.1 mmol/l), HBA1c (from 6.4±0.1 to 6.5±0.05%), leptin (from 35 595±4 400 to 17 319±1816 pg/ml) and insulin (from 7.6±1.6 to 3.0±0.4 μU/ml) levels were all decreased (at a minimum of P<0.05 level), while the decrease in glucose level was more moderate (from 5.7±0.4 to 4.9±0.1 mmol/l).

Conclusions
Long term recreational physical activity program decreases insulin and leptin resistance. Monitoring of these and other obesity associated hormones seems to be useful to follow up the efficacy of physical exercise programmes.

P344

3-iodothyronamine metabolism and metabolic effects in rat white adipocytes
M E Manni1, E Bigagli1, A Saba2, M Marchini2, R Zucchi2 & L Raimondi1
1University of Florence, Florence, Italy; 2University of Pisa, Pisa, Italy.

Introduction
3-iodothyronamine (T1AM) is a novel thyroid hormone derivative, which has been detected in rat and human tissues. In vivo, T1AM has been reported to produce several functional effects, including the switch of fuel utilization from carbohydrates to lipids. In the present work we used rat white adipocytes to investigate T1AM uptake, metabolism, and metabolic effects.

Methods
Rat white adipocytes were incubated with exogenous T1AM. The concentrations of T1AM, thyronamine, 3-iodothyroacetic acid and thyroacetic acid were assayed radiochemically using [3H]-2-D-dideoxyglucose (1 microM; 1 mCi/ml) and [14C]-palmitic acid (100 μCi/ml) respectively. Type A and type B
Brain Derived Neurotrophic Factor (BDNF) plays a fundamental role in regulation of metabolism and energy homeostasis. Low BDNF levels have been identified as possible biological causes for development of obesity and BDNF administration has been shown to induce weight loss and to improve insulin sensitivity in diabetic animal models. Acute exercise is known to induce a transient increase of peripheral BDNF but no information is yet available regarding the exercise-induced modulation of BDNF in obesity.

Methods
We studied the BDNF responses to 30 minutes exercise on cyclo-ergometer at a self-selected intensity in 12 obese healthy subjects (OS) (6males; BMI 33.9 ± 1.6 kg/m²) and 13 lean controls (LC) (6males; BMI 21.6 ± 0.5 kg/m²).

Results
Blood samples were collected every 15 min: before, during exercise and for 90 minutes thereafter. Heart rate (HR) was monitored and serum BDNF concentration was measured with an ELISA.

All the subjects concluded the 30 min of exercise at an average peak intensity of 42.6 W (85.2 ± 10.8% of subjects’ HRmax.) that were comparable between groups (P>0.05).

Exercise increased BDNF significantly in both OS (22.8 ± 6.3 (30 min) and 21.4 ± 6.2 (120 min); (P<0.01)) and LC (20.5 ± 7.3 ng/ml (baseline) vs 27.8 ± 9.9 (30 min) and 19.8 ± 6.8 (120 min); (P<0.01)). The BDNF response was comparable between both groups (P>0.05).

Conclusions
We show that exercise increases in BDNF levels in lean subjects and that this effect was preserved in obesity.

P344
The modulation of brain derived neurotrophic factor (bdnf) during exercise in obesity
A M Arafat1, A Brunelli2, H Budde3, A Adamidou1, J Spranger1, M Möhlig1 & A F H Pfeiffer1
1Charité-University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany; 2University of Roma ‘Foro Italico’, Rome, Italy; 3Institute of Sport Science, Humboldt University Berlin, Berlin, Germany.

Objectives
Brain Derived Neurotrophic Factor (BDNF) plays a fundamental role in regulation of metabolism and energy homeostasis. Low BDNF levels have been identified as possible biological causes for development of obesity and BDNF administration has been shown to induce weight loss and to improve insulin sensitivity in diabetic animal models. Acute exercise is known to induce a transient increase of peripheral BDNF but no information is yet available regarding the exercise-induced modulation of BDNF in obesity.

Methods
We studied the BDNF responses to 30 minutes exercise on cyclo-ergometer at a self-selected intensity in 12 obese healthy subjects (OS) (6males; BMI 33.9 ± 1.6 kg/m²) and 13 lean controls (LC) (6males; BMI 21.6 ± 0.5 kg/m²).

Results
Blood samples were collected every 15 min: before, during exercise and for 90 minutes thereafter. Heart rate (HR) was monitored and serum BDNF concentration was measured with an ELISA.

All the subjects concluded the 30 min of exercise at an average peak intensity of 42.6 W (85.2 ± 10.8% of subjects’ HRmax.) that were comparable between groups (P>0.05).

Exercise increased BDNF significantly in both OS (22.8 ± 6.3 (30 min) and 21.4 ± 6.2 (120 min); (P<0.01)) and LC (20.5 ± 7.3 ng/ml (baseline) vs 27.8 ± 9.9 (30 min) and 19.8 ± 6.8 (120 min); (P<0.01)). The BDNF response was comparable between both groups (P>0.05).

Conclusions
We show that exercise increases in BDNF levels in lean subjects and that this effect was preserved in obesity.

P346
AM251, a CB1 receptor antagonist, increases GLUT4 expression in adipocytes
D T Furuya, A C Poletto, H S Freitas & U F Machado
University of Sao Paulo, Sao Paulo, Brazil.

Evidences have suggested that the endocannabinoid system is overactive in obesity, resulting in enhanced endocannabinoid levels in both circulation and visceral adipose tissue. The cannabinoid CB1 receptor is expressed in the adipose tissue besides the brain. Few studies in vitro suggest that CB1 activation increases glucose uptake in adipocytes. The objective of the present study was to investigate the CB1 receptor modulation on glucose transporter GLUT4 expression, which is encoded by the SLC2A4 gene, and the related mechanisms. For this, 3T3-L1 adipocytes were incubated in the presence of a selective antagonist of CB1 receptor, AM251 (1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide). After 2, 4 or 24 h, cells were harvest to evaluate GLUT4 mRNA (real time PCR) and protein (western blotting), and NFkappaB activation specifically on the promoter of SLC2A4 gene (EMSA).

Acute and chronic incubation for 4 or 24 h with AM 251 expressively increased GLUT4 protein content (P<0.0001) but did not altered GLUT4 mRNA expression. Increased GLUT4 mRNA expression was only observed after 2 h of AM 251 treatment (P<0.001). Considering the participation of NF-kappaB in the SLC2A4 gene expression, AM251 was able to increase NF-kappaB activation in adipocytes only after 24 h incubation. In conclusion, the present data shows that the CB1 receptor inhibition markedly increases GLUT4 expression in adipocytes. Evidences point out to an important participation of the inflammatory transcriptional factor NFkappaB on the modulation of the SLC2A4 gene expression by CB1 receptor. FAPESP (08/01944-4 and 07/50554-1).

P347
Serum homocysteine levels in patients with nonalcoholic fatty liver disease
S A Polyzos1, J Kountouras1, K Patsioura2, E Katsiki2, E Zafeiriadou1, G Dereti2, C Zavos2, E Gavala2, V Mane2 & A Slavakis2
1Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece; 2Department of Pathology, Ippokration Hospital, Thessaloniki, Greece; 3Department of Radiology, Ippokration Hospital, Thessaloniki, Greece; 4Department of Neurology, Papageorgiou Hospital, Thessaloniki, Greece; 5Department of Biochemistry, Ippokration Hospital, Thessaloniki, Greece.

Introduction
High serum homocysteine (Hcy) has been associated with insulin resistance (IR) syndrome and cardiovascular risk, although controversy exists. Nonalcoholic fatty liver disease (NAFLD) is regarded as the hepatic component of IR syndrome, but data on Hcy are limited. The aim of this cross-sectional study was to evaluate serum Hcy levels in patients with NAFLD.

Methods
We studied the hormonal and metabolic responses to 30 min exercise on cyclo-ergometer at a self-selected intensity in 12 obese healthy subjects (OS) (6males; BMI 33.9 ± 1.6 kg/m²) and 13 lean controls (LC) (6males; BMI 21.6 ± 0.5 kg/m²). Blood samples were collected every 15 min: before, during exercise and for 90 minutes thereafter. Heart rate (HR) was monitored and plasma MR-proANP₃₋₉₀ was measured using a chemiluminescence assay.

Results
All the subjects concluded the 30 minutes of exercise at an average peak intensity of 138.4 ± 42.6 W (85.2 ± 10.8% of subjects’ HRmax.) that were comparable between groups (P>0.05).

Exercise significantly increased ANP levels in both study groups (P<0.01). However, the ANP response was more pronounced in LC as compared to OS (P<0.01).

Conclusions
This study demonstrates that the ANP responsiveness to exercise is reduced in obesity. The mechanisms underlying differential regulation of ANP in obesity and the role of ANP in mediating the exercise-induced lipolysis needs further investigations.
Methods

Thirty-one consecutive patients (54 ± 11 years, 8 males) with biopsy-proven NAFLD, 15 of whom with simple nonalcoholic fatty liver (NAFL) and 16 with nonalcoholic steatohepatitis (NASH) according to NAFLD activity score (NAS) histologic score, were recruited. Twenty-two healthy controls (52 ± 9 years, 5 males) matched for gender, age, and body mass index (BMI) served as controls. Blood samples for Hcy, folate, vitamin B12, insulin and standard biochemical tests were obtained after overnight fasting. Homeostatic model of assessment-insulin resistance (HOMA-IR) was calculated.

Results

The BMI of NAFLD patients was 33.1 ± 5.3 kg/m². There was no difference in mean serum Hcy levels between controls and NAFLD patients (12.6 ± 2.6 vs 13.5 ± 2.6 mmol/l, respectively; P = 0.432). Serum folate and vitamin B12 were also similar between the study groups. As expected, NAFLD patients had higher ALT (P < 0.001), γ-gt (P = 0.001), glucose (P = 0.001), insulin (P = 0.002) and HOMA-IR (P = 0.001). However, NASH patients had lower mean serum Hcy levels compared with NAFL patients (14.7 ± 2.1 vs 12.3 ± 2.5 mmol/l, P = 0.006). Mean age, BMI, serum folate, vitamin B12 ALT, γgt, glucose, insulin and HOMA-IR did not differ between NAFL and NASH patients. In multiple logistic regression analysis, Hcy independently predicted NASH (P = 0.049) after adjustment for age, BMI and HOMA-IR.

Conclusions

Our data suggest that serum Hcy levels are similar between NAFLD patients and controls, but decreased in NASH compared with NAFL patients and can independently predict NASH. Serum Hcy could probably represent another non-invasive marker for the assessment of NAFLD.

P348

Body mass index, obesity and hyperuricemia in postmenopausal women

V Povoroznyuk & G Dubetskia

Institute of Gerontology AMS of Ukraine, Kyiv, Ukraine.

Aim of research

To determine uric acid level in blood serum and incidents of hyperuricemia in postmenopausal women and their relation with body mass index (BMI).

Object of research

Patients of clinic by the physiology and pathology of bone and joint disease department and Ukrainian medical-scientific center of osteoporosis: postmenopausal women (n = 134). They were divided in the following groups depending on BMI: I group (BMI = 20.0–24.9) – normal weight, II group (BMI = 25.0–29.9) – overweight, III group (BMI = 30.0–34.9) – class I obesity, IV group – class II obesity (BMI = 35.0–39.9). Average age of examined patients was 64.3 ± 8.8 years.

Methods of research

Retrospective analysis of patients’ case histories. Patients were hospitalized to the clinic of physiology and pathology of bone and joint diseases, Institute of Gerontology AMS of Ukraine. Uric acid level in blood plasma was determined by uricase-peroxidase method, statistic analysis – by Statistica 6.0.

Results

Uric acid level among women during postmenopausal period depends on body mass index. The higher level of uric acid were found in patients with obesity of II class. In the I group it was 285.0 ± 13.4, in II group – 285.2 ± 13.5; in III group – 281.7 ± 8.3, in IV group – 329.7 ± 17.7. Incidence of hyperuricemia among women in the I group was 12.9%, in II group – 23.5%; in III group – 18.6%, in IV group – 39.0% (differences between I and IV groups was significantly (P = 0.005).

Conclusions

It was determined that uric acid level among women during postmenopausal period depending on body mass index. The higher level of uric acid and incidence of hyperuricemia were found in women with obesity of II class in comparison with women who have normal body mass index.

Steroid metabolism

P349

Beneficial effects of testosterone supplementation on prostatitis-like alterations in an animal model of metabolic syndrome

A Morelli1, S Filippi1, L Vignozzi1, P Comeglio1, I Cellai1, G B Vannelli 1, M Marchetta1, A Morelli1, E Maneschi1, E Sarchielli, E Maneschi, I Cellai, G B Vannelli & M Maggi

University of Florence, Florence, Italy.

Introduction

Adipose tissue dysfunction is associated to metabolic syndrome (MetS), a clustering of cardio-metabolic risk factors, including insulin resistance, adipocyte dysfunction and proinflammatory cytokine secretion. This can promote the development of MetS-related prostatitis-like alterations.

Purpose

To determine uric acid level in blood serum and incidents of hyperuricemia in postmenopausal women.

Methods

We evaluated the differentiation capacity of preadipocytes (rPAD) obtained from visceral fat of the following rabbit groups: HFD (rPAD-HFD), T-supplemented HFD-rabbits (rPAD-T), standard diet (rPADcontrol) and HFD treated with INT-747 (rPAD-I), an agonist of the nuclear receptor FXR which previously showed comparable to that of rPADcontrol.

Results

Uric acid level among women during postmenopausal period depends on body mass index. The higher level of uric acid were found in patients with obesity of II class. In the I group it was 285.0 ± 13.4, in II group – 285.2 ± 13.5; in III group – 281.7 ± 8.3, in IV group – 329.7 ± 17.7. Incidence of hyperuricemia among women in the I group was 12.9%, in II group – 23.5%; in III group – 18.6%, in IV group – 39.0% (differences between I and IV groups was significantly (P = 0.005).

Conclusions

It was determined that uric acid level among women during postmenopausal period depending on body mass index. The higher level of uric acid and incidence of hyperuricemia were found in women with obesity of II class in comparison with women who have normal body mass index.

P350

Testosterone supplementation improves adipose tissue function in an animal model of metabolic syndrome

A Morelli1, E Maneschi1, L Vignozzi1, S Filippi1, M Marchetta1, B Mazzanti1, A Calcagno2, P Comeglio1, I Cellai1, G B Vannelli1 & M Maggi1

1University of Florence, Florence, Italy; 2University of Padoa, Padoa, Italy.

Introduction

Adipose tissue dysfunction is associated to metabolic syndrome (MetS), a clustering of cardio-metabolic risk factors, including insulin resistance, adipocyte dysfunction and proinflammatory cytokine secretion. This can promote the development of MetS-related prostatitis-like alterations.

Methods

We evaluated the differentiation capacity of preadipocytes (rPAD) obtained from visceral fat of the following rabbit groups: HFD (rPAD-HFD), T-supplemented HFD-rabbits (rPAD-T), standard diet (rPADcontrol) and HFD treated with INT-747 (rPAD-I), an agonist of the nuclear receptor FXR which previously showed comparable to that of rPADcontrol.

Results

Histomorphometric analysis of visceral fat sections from all groups evidenced that adipocyte size was significantly increased in HFD-rabbit compared to control, indicating adipocyte dysfunction. Accordingly, rPAD-HFD showed a reduced capacity to accumulate triglyceride when exposed to DIM (84% over untreated cells) in comparison with rPADcontrol (318%). Moreover, glucose uptake in response to insulin was also reduced in rPAD-HFD. Interestingly, visceral adipocyte size was normalized in both T-and INT747-treated HFD rabbits. Functionally, rPAD-T and rPAD-I showed a significantly reduced glucose uptake ability comparable to that of rPADcontrol.

Conclusion

Overall, our results indicate that testosterone supplementation in the animal model of MetS may positively affect adipose tissue function through the restoration of adipocyte commitment. This could reflect the ability of T in counteracting metabolic alterations most likely restoring adiponectin and insulin sensitivity in experimental MetS.
Evaluation of a method to measure long term cortisol levels in health and disease
L Manenschijn, J W Koper, E L T van den Akker, R A Feelders, S W J Lamberts & E F C van Rossum
Erasmus MC, Rotterdam, The Netherlands.

Introduction
Elevated levels of cortisol are known to induce a wide range of pathology, e.g., abdominal obesity, type 2 diabetes and cardiovascular disease. Measuring serum and saliva cortisol is limited to one time point. Measurement of cortisol in scalp hair is a recently developed method to measure long term cortisol levels and might reflect cortisol exposure in patients with hyper- or hypo-cortisolism and in healthy persons. Our aims were to explore this measurement of cortisol by determining factors influencing hair cortisol levels in healthy controls. We also studied whether hair cortisol levels correspond to features of cortisol exposure in healthy persons and clinical course in patients with hyper- or hypo-cortisolism.

Methods
Hair samples were collected from 192 healthy individuals, 10 patients with Cushing’s syndrome (CS) and two patients with Addison’s disease (AD). Cortisol was extracted using methanol and cortisol levels were measured using a salivary ELISA kit. Measurements of waist and hip circumference were performed in 46 healthy subjects. A questionnaire was used to collect data concerning hair features.

Results
Cortisol levels were slightly influenced by hair treatment, but not by other factors such as gender, hair color, frequency of hair wash or hair products. In long hair, cortisol levels showed variation over time, without an overall washout effect. In patients with AD and CS, cortisol levels in hair correlated with clinical course. In healthy individuals hair cortisol correlated positively with WHR (r = 0.506, P < 0.001) and waist circumference (r = 0.360, P = 0.01).

Conclusions
Hair cortisol concentrations seem to be slightly influenced by hair treatment. No washout effect of cortisol in distal hair segments was observed and hair cortisol levels correspond with clinical course in patients with AD and CS. This suggests that cortisol in scalp hair reflects cortisol exposure, which is supported by the positive correlation between hair cortisol and abdominal fat.

Effect of smoking cessation on steroid balance in postmenopausal women
Hana Hruskovicova¹, Michaela Duskova¹, Katerina Simunkova¹,2, Martin Hill¹, Hana Pospisilova¹, Eva Kralikova¹,2, Karel Vondra¹ & Luboslav Starka¹
1Institute of Endocrinology, Prague, Czech Republic; 2Third Medical Department, First Faculty of Medicine, Charles University, General Faculty Hospital, Prague, Czech Republic; 3The Center for Tobacco Dependence, Department, First Faculty of Medicine, Charles University, General Faculty Hospital, Prague, Czech Republic.

Introduction
Cigarette smoking is one of the most serious substance abuse problems. It is generally accepted that nicotine and other chemicals in tobacco smoke alter endocrine function in women, induce changes in female hormonal balance and likely contributes to reported associations of smoking with adverse reproductive outcomes, including menstrual dysfunction, infertility, and earlier menopause. Studies on the effects of smoking and smoking cessation on female sex hormones have concentrated mainly on premenopausal women. In our study, we monitor changes of hormonal levels in postmenopausal women during smoking cessation.

Methods
We examined 60 postmenopausal women (average age 57.7 years, average BMI 26), before initiating of smoking cessation and after 6, 12, 24 and 48 weeks of abstinence. In the data analysis, we included seven women (average age 63.3 years), who got through. A broad spectrum of steroid metabolites, LH, FSH and SHBG, also basic anthropometric data were measured using GC–MS or immunoanalysis. Repeated measures ANOVA model was used for evaluation of the data. The local Ethics Committee approved the study, and all patients signed an informed consent form before taking part in the study.

Results
We found increasing levels of androgens (testosterone, androsterone) during smoking cessation, increasing of DHEA was insignificant. Conjugated to nonconjugated 20alpha pregnanolon ratio was significantly decreasing. Changes in the levels of other C21 steroids were not significant.

Conclusion
Smoking causes higher androgen levels in women, our results indicate that smoking discontinuation leads to their further increase.

The study was supported by Grant No. NS 510125-3 of the IGA MZCR and GAUK.
in 96-well plate format. Serum (500 µl) sample volume is needed. Two different elution steps are necessary (first fraction: all steroids except DHEAS, second fraction: DHEAS) for highly pure extraction fractions resulting in minimal matrix effects and improved accuracy. As the result there are two subsequent LC-MS/MS runs with a total run time of 22 min.

Validation data of the assay for human serum will be presented including inter-laboratory comparisons demonstrating the precision, accuracy, stability, and reproducibility of the newly developed standardized assay.

P355
Salivary cortisol and testosterone: a comparison of salivary collection methods in healthy controls
E Van Caenegem1, K Wierckx1, T Fiers2, H Segers2, E Vandensypel2, J M Kaufman1 & G T Sjoen1
1Department of Endocrinology, Ghent University Hospital, Ghent, Belgium; 2Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium.

Context
In population and psychosocial studies, saliva becomes increasingly popular, mainly due to its non-invasive collection methods and availability of free hormone fractions. However, few studies have evaluated the impact of collection devices on steroid hormone analysis; and none with the currently used methods.

Objective
The aim of this pilot study was to minimize pre-analytical errors based on sample collection methods.

Methods
We tested two saliva collection methods: chewing on a cotton swab (Salivette, Sarstedt) and passive drooling. Thirty healthy males with a median age of 27 years (range 19–65 years) participated. Morning saliva and serum samples were simultaneously collected after overnight fasting. Serum and salivary cortisol, serum total testosterone and SHBG were analyzed by electrochemiluminescent immunosay (ECLIA, Roche Modular) and transcortin by aRIA. Serum free cortisol and testosterone were calculated. Salivary testosterone was determined using liquid chromatography–mass spectrometry.

Results
Strong positive correlations between the cotton-based and the passive drooling collection method were observed for cortisol as well as testosterone (respectively \( r = 0.70 \) and \( r = 0.88 \)). For cortisol, we observed a mean positive bias of 65% for passive drooling versus Salivette. In addition, cortisol determined on passive drooling samples correlated much worse with calculated free cortisol than cortisol analyzed on the cotton samples (respectively \( r = 0.34 \) versus \( r = 0.70 \)). However, for testosterone passive drooling correlated well with the calculated free fraction \( (r = 0.66) \). A positive bias of 21% for testosterone collected by passive drooling versus Salivette was observed. In contrast to earlier reports, we found no artfactually high testosterone results with the cotton-based collection method.

Conclusion
Our findings have important implications for the use and potential misuse of saliva collecting methods. Cotton swabs and passive drooling both seem adequate parameters in men with AD. Distribution of common polymorphisms of SHR genes does not differ between patients and controls. We confirmed the positive association of estrogen levels with the CAG repeat length. The ESR2 Alu may adversely affect adiposity parameters in men with AD.

P356
Hormonal parameters and sex hormone receptor gene polymorphisms in males with autoimmune diseases
Charalampous Doukas1, Katerina Saltiki1,2, Konstantinos Terzidis1,2, Aimilios Mantiou3, Lilou Sarika3, Andriana Cimponeriu3, Petros Sfikakis3 & Maria Alevizaki1,2
1Endocrine Unit, Department of Medical Therapeutics, Alexandroupolis Hospital, Athens University School of Medicine, Athens, Greece; 2Department of Endocrinology and Metabolism ‘Evgenidion’ Hospital, Athens University School of Medicine, Athens, Greece; 3Department of B’ Medical Propaedeutics, Laiko Hospital, Athens University School of Medicine, Athens, Greece.

Introduction
Autoimmune disease (AD) is more common in women than in men. Sex hormones may play a role. Sex hormone receptors (SHR) are expressed in cells of the autoimmune system. We investigated the possible role of hormonal parameters and of common gene polymorphisms of the estrogen receptor alpha (ESR1), beta (ESR2) and androgen receptor (AR) in the presence of AD in men.

Methods
In a prospective study, 227 men were studied; 125 had at least one AD: Hashimoto’s (n = 65), Graves‘ (n = 12), STE (n = 10), RA (n = 38), 152 were controls. Estradiol, testosterone, SHBG, insulin, glucose and lipid levels were measured after discontinuation for ≥ 1 month of any corticosteroid therapy. Molecular analysis of the PvuII ESR1, Alu ESR2 and the number of the AR CAG repeats (iCAG/n) was performed.

Results
The frequency of ESR1 PvuII and ESR2 Alu did not differ between patients with AD and controls (allele frequency 52.2%, 40.2% in AD; 51.0% and 46.4% in control). The distribution of (iCAG/n) did not differ between the two groups: (AD: (CAG/n) 16–30, mean 21.38, control: 9–30, mean 20.7). Men with AD had higher estradiol levels (AD 31.32 ± 12.1; control 20.37 ± 7.9, \( p < 0.001 \)). No other significant differences in hormone, biochemical and clinical parameters were found. In AD group the (CAG/n) was positively associated with estrogen \( (r = 0.39, \ p = 0.002) \). AluI carriers had lower SHBG levels (27.20 vs 39.49, \( p = 0.001) \), higher waist perimeter, BMI and weight compared to non carriers (99.09 vs 91.58 cm, \( p = 0.025 \), 27.36 vs 24.55, \( p = 0.008 \) and 83.86 vs 75.21 kg, \( p = 0.006 \) respectively).

Conclusions
Higher estradiol levels may play a role in the appearance of AD in men. Distribution of common polymorphisms of SHR genes does not differ between patients and controls. We confirmed the positive association of estrogen levels with the CAG repeat length. The ESR2 Alu may adversely affect adiposity parameters in men with AD.

P357
Inhibitory effect of glucocorticoids on GLUT4 expression in visceral adipose tissue may be determined by increased 11b-hydroxysteroid dehydrogenase 1 (11b-HSD1) expression
R C T Mori, R S Campello & U F Machado
Institute of Biomedical Sciences, Sao Paulo, SP, Brazil.

Local glucocorticoids action depends on 11b-hydroxysteroid dehydrogenase (11b-HSD) enzymes. Adipose tissues mainly express the 11b-HSD1, which activates inactive cortisone. Altered 11b-HSD1 and GLUT4 expressions have been reported in obesity. GLUT4 participates in the genesis and maintenance of insulin resistance/obesity, and could also be involved in the insulin resistant state observed in hypercortisolism. The aim of this study was to investigate the 11b-HSD1 and GLUT4 expressions in visceral (VAT) and subcutaneous (SAT) adipose tissues of insulin resistant, hypercortisocorticosteron MSG-obese rats, considering the tissue-specific action of glucocorticoids.

Methods
Male Wistar rats (C) were rendered obese (O), by neonatal treatment with monosodium glutamate (4 mg/g per day). Insulin tolerance tests (ITT), plasma insulin and corticosterone confirmed the obesity features. GLUT4 and 11b-HSD1 mRNAs were analyzed in VAT and SAT, by northern blotting and RT-PCR respectively. Sterol regulatory element binding protein-1c (SREBP-1c) expression and binding activity were also investigated.

Results
Obese rats were hyperinsulinemic \( (O = 61.4±5.0 \mu U/\text{mL}, P < 0.05 \text{ vs } C = 40.1±5.5 \mu U/\text{mL}) \), hypercorticosteronemic \( (O = 168.3±9.5 \text{ ng/mL}, P < 0.001 \text{ vs } C = 80.3±9.8 \text{ ng/mL}) \) and insulin resistant (\( \text{KITT}=3.42\%\text{min}, P < 0.01 \text{ vs } C = 5.06\%\text{min}) \). GLUT4 mRNA was decreased in obese VAT \( (O = 80.9±3.8 \text{ UA}, P < 0.01 \text{ vs } C = 100.2±4.2 \text{ UA}) \), where 11b-HSD1 mRNA was increased \( (O = 142.5±6.9 \text{ UA}, P < 0.01 \text{ vs } C = 100.5±5.8 \text{ UA}) \). On the contrary, in obese SAT GLUT4 mRNA was increased \( (O = 122.1±9.4 \text{ UA}, P < 0.05 \text{ vs } C = 100.0±5 \text{ UA}) \) while 11b-HSD1 was decreased \( (O = 78.0±7.5 \text{ UA}, P < 0.05 \text{ vs } C = 100.0±5.2 \text{ UA}) \). SREBP-1c binding activity to GLUT4 promoter sequence was unaltered. However, SREBP-1c expression was significantly lower in obese VAT \( (O = 82.0±4.0 \text{ UA}, P < 0.05 \text{ vs } C = 100.0±4.4), \) remaining unchanged in obese SAT \( (O = 94.8±3.2 \text{ UA}, P < 0.05 \text{ vs } C = 100.0±6.3 \text{ UA}) \).

Conclusion
Data suggest an inhibitory effect of glucocorticoids on GLUT4 gene expression in VAT, determined by a higher expression of the 11b-HSD1 enzyme. This effect may involve mechanisms at transcriptional level, since the expression of SREBP-1c, a transcriptional factor known to increase GLUT4 gene transcription, was shown to be decreased in VAT. Financial support: 07/59722-4.
P358
Chronic effect of 17\beta estradiol on GLUT4 expression in 3T3-L1 adipocytes
R S Campello, A C Poletto, D T Furuya, R C T Mori & U F Machado
University of São Paulo, São Paulo, Brazil.

Introduction
Insulin resistance results from a combination of genetic and environmental factors and it may be considered the primary cause of the development of metabolic disorders, such as type 2 diabetes mellitus. It is characterized by a reduced ability of insulin sensitivity tissues to respond to normal levels of the hormone. In these tissues, glucose transport stimulated by insulin occurs through the glucose transporter 4 and alterations in its expression are related to changes in insulin sensitivity. It is known estradiol (E2) modulates insulin sensitivity and previous studies in skeletal muscle revealed it also participates in the GLUT4 regulation. Thus, the aim of this study was to investigate the effect of 17\beta Estradiol on GLUT4 expression in 3T3-L1 adipocytes.

Methods
3T3-L1 cells were treated with increasing doses of 17\beta Estradiol (0, 0.1, 1, 10 and 100 nM), for different periods of time (12, 24 and 48 h). After treatment, GLUT4 protein content was quantified by western blotting and mRNA expression by real time-PCR.

Results
GLUT4 protein content increased significantly (19–56%) after 24 h of E2 treatment, in all of the concentrations analyzed, as compared to control (0 nM). Furthermore, after 48 h of treatment, cells exposed to E2 (0.1 nM) also presented a significantly increase (16%) in GLUT4 protein content, comparing to the other doses. GLUT4 mRNA content increased significantly (20–30%) after 12 h of treatment in intermediate doses (1 and 10 nM), as compared to control (0 nM). However, after 24 or 48 h, no significant difference was observed in GLUT4 mRNA content in any of the doses evaluated.

Conclusion
Results suggested a time and dose dependent E2 effect on GLUT4 expression in 3T3-L1 adipocytes, in addition to a possible post-transcriptional modulation in the presence of the hormone.

Funding
FAPESP 2009/02217-1.

Nuclear receptors
P359
Oleic and linoleic fatty acids reduce the SLC2A4 gene expression: the involvement of the NFkappaB and HIF-1a transcriptional factors
A C Poletto, D T Furuya, R A dos Santos, G F Anhé, A D Silva, R S Campello & U F Machado
University of Sao Paulo, Sao Paulo, Brazil.

Introduction
High circulating levels of some but not all unsaturated fatty acids (UFAs) can be justified lifelong control. The treatment with OFA and LFA reduce the SLC2A4 gene expression in L6 muscle cells. The present findings suggest that NFkappaB, but not HIF-1a, may be involved in this modulation.

Funding
FAPESP 07/56091-3.

Adrenal medulla
P360
Pheochromocytoma: a complex case
F Fonseca¹, A Cordero², J Oliveira³, J Coutinho⁴ & A Agapito⁵
¹Curry Cabral Hospital, Lisboa, Portugal; ²Santa Luzia Hospital, Elvas, Portugal.

Introduction
Pheochromocytoma is an uncommon tumor. Non-classical forms can make diagnosis difficult and delay correct management strategies.

Case report
A 20-years old caucasian male presented to the emergency room with unproductive cough, fever and tiredness for 7 days. He was eupneic, afebrile, BP 176/115 mmHg, 104 bpm with inspiratory crepitations in the left lung base. Leucocyte–14.1×10³/l (N 70%); platelets – 659×10³/l; CRP – 6.9 mg/dl. Normal renal and hepatic function tests and no biochemical markers of myocardial ischaemia. X-ray: cardiomegaly, opacities in both lungs. Echocardiogram: dilated ventricles, LHV and LVEF 37%. Diagnosed as bilateral pneumonia, dilated myocardopathy and hypertension. On day 4, acute right limb ischaemia, hemodynamic instability, high fever and rapid deterioration of renal function. CT scan: 7 cm left adrenal tumor, aortic enlarged lymph nodes, right kidney hypodensity suggesting embolism. Pheochromocytoma was confirmed by urinary epinephrine 202 µg/day (<27) norepinephrine 311 (<97), and 131MBIG hyperfixation. After phenoxibenzamine he underwent left adrenalectomy and loco-regional lymphadenectomy. Three days later a left nephrectomy was necessary due to irreversible ischaemia. Abdominal hematoma and accentuation of thrombocytosis supervene. Hystology: pheochromocytoma (’unknown behaviour’). One month later, he developed hypercalcemia 11.9 mg/dl, PTH < 3 pg/ml, with normal PTHrp and chromogranin A. Thrombocytosis and hypercalcemia both subsided in the next 3 months. No gene mutations were found. After 30 months the patient is asymptomatic.

Conclusions
Dilated myocardopathy with heart failure in a young hypertensive patient should lead to consider pheochromocytoma. Occulsive arterial phenomena and hypercalcemia made this case even more complex. Tumor size and histology justifies lifelong control.

P361
Head and neck paragangliomas: genetic spectrum and clinical variability in 101 consecutive patients
Valentina Piccioni¹, Elena Rapizzì¹, Alessandra Baccà², Giuseppe Di Trapani¹, Raffaele Pulì¹, Valentino Giacchi¹, Benedetta Zampetti¹, Letizia Camù³, Antongiulio Faggianò², Luca Deiana³, Stefano Mariotti³, Maria Rosaria Ambrosio³, Maria Chiara Zatelli³, Gabriele Parenti³, Annamaria Colao³, Carlo Pratesi³, Gianpaolo Bernini³, Tonino Ercolino³ & Massimo Mannelli³
¹University of Florence, Florence, Italy; ²University of Pisa, Pisa, Italy; ³Clinica Piacenza, Piacenza, Italy; ⁴University of Ferrara, Ferrara, Italy; ⁵Careggi Hospital-AOU, Florence, Italy; ⁶University of Naples, Naples, Italy; ⁷University of Cagliari, Cagliari, Italy.

Purpose
To genotype patients with head-neck paragangliomas (HNPGL) and evaluate the percentage and types of germ-line mutations in patients classified according to family history (FH) and clinical presentation.

Endocrine Abstracts (2011) Vol 26
In total, 101 consecutive patients with HNPGL were examined for mutations in SDHB, SDHC, SDHD, SDHAF2 and VHL genes by PCR/sequencing. According to a careful FH, clinical, laboratory (including metanephrines) and instrumental examinations patients were divided in three groups: a) with a positive FH for HNPGL; b) with a negative FH and multiple/recurrent HNPGL; c) with negative FH and single HNPGL.

Results

Group a) included 33 patients (8 index cases, 25 affected relatives) resulted SDHD mutation carriers; seven presented a single HNPGL, 26 presented HNPGL which were multiple (18 patients) or associated with a secreting paraganglioma (sPGL) (eight patients).

All the 16 patients (100%) of group b) resulted SDHD mutation carriers. Four patients presented also a sPGL. Among the 52 patients of group c) 9 (17.3%) presented germ-line mutations (two SDHB, three SDHD, two VHL, two SDHAF2). Of the two SDHAF2 mutations one is missense and the other one was in SDHB. SDH mutations were found in 7 patients with a sPGL.

A positive FH or the presence of multiple/recurrent HNPGL are strong predictors for germ-line mutations, which are also present in 17.3% of patients clinically classified as sporadic.

By far, the most frequently mutated gene is SDHD but other, including SDHB, SDHAF2 and VHL, may be affected. In SDHD mutation carriers the risk of an associated sPGL is significantly higher for nonsense, frame-shift or insertion/deletion than for missense mutations.

P363

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors

M C De Martino1,2, R A Feelders1, P M van Koetsveld2, R De Kruijer3, J A M J L Janssen1, D Sprij-Mooij2, S W J Lamberts1, W W de Herder1, Annamaria Colao3, Rosario Pivonello4 & Leo Hofland1

1Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; 2Department of Endocrinology, Federico II University, Naples, Italy; 3Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.

The pathogenesis of pheochromocytomas (pheo) is poorly understood and malignant pheo need new treatment options. mTOR inhibitors, as sirolimus (S) and everolimus (E), are new promising antineoplastic drugs.

Aim

To evaluate whether the IGF/mTOR pathways have a role in the pathogenesis and whether S and E may have antiproliferative effects in pheo.

In 24 human pheo and two normal adrenal medulla (NM), we evaluated the mRNA expression of: IGF-I, IGFI, IGII, IGF-I receptor (IGFIR), insulin receptor (IR) A; IRB, IGFBP2, IGFBP3 and p70S6K (qPCR). We tested the dose- and time-dependent effects of S and E on cell growth in the PC12 rat pheo cell line.

In pheo, we observed a high expression of IGFI mRNA and an increased IRB/IRIR ratio. The IRBIR mRNA levels and the IRA/IRIR ratio were higher in pheo than in NM. The mRNA levels of mTOR, IGFIIR, IRB and 6 were lower in pheo than in NM. S and E were able to suppress PC12 growth in a dose and time-dependent manner, but S was more potent than E.

The results of the current study suggest a role of the IGF system in the pathogenesis of pheo. mTOR inhibitors can inhibit the in vitro cell proliferation of rat pheo cells, suggesting that mTOR inhibitors and/or other compounds targeting the IGF system may have a role in the inhibition of malignant pheo.

P364

Unusual mutation spectrum in Hungarian patients with apparently sporadic pheochromocytomas

N L Lendvai1, I S Szabó2, M T Tóth1, E F Förízs2, E S Sólyom2, G B Bekó4, P I Igaz1, K R Raczi3 & A P Patocs1,4,5

1Department of Internal Medicine, Semmelweis University, Budapest, Hungary; 2Department of Internal Medicine, Józsa F Hospital, Nyíregyháza, Hungary; 3Pediatric Department, BAZ County Hospital, Miskolc, Hungary; 4Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary; 5Molecular Medicine Research Group, Hungarian Academy of Sciences, Budapest, Hungary.

Background

Pheochromocytomas (Pheo) and paragangliomas (PGL) are rare, mostly benign tumors. Most of these tumors are sporadic but a significant percentage can be found as components of hereditary tumor syndromes caused by germline mutations of the VHL, RET, NF1, SDHD, SDHC, SDHB and the recently identified SDHAF2 genes. Germline mutations of these genes can be also found in several cases with apparently sporadic Pheo/PGL.

Aim

The aim of our study was to analyze the prevalence of germline mutations in patients with apparently sporadic Pheo/PGL.

Materials and methods

Mutations analysis of the RET, VHL, SDHC, SDHB, SDHD and SDHAF2 genes were performed in 69 patients (27 male/female, age: 38.2 (14–72) mean range, years) with apparently sporadic Pheo/PGL consecutively admitted for evaluation. Patients were clinically evaluated and genetic analysis was performed using PCR, direct DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) of the VHL gene.

Results

Of the 69 patients 14 patients (20.2%) had pathogenic germline mutation. Six patients had mutation of the RET protooncogen (Cys617Tyr, Cys634Tyr, Cys634Thr, Cys634Arg and in two unrelated cases Ser649Leu), five patients showed VHL gene (Pro63Leu, Arg79Gly, Tyr156Cys and in two unrelated patients Arg167Gln), one patient SDHD gene (c.147–148insA) and two patients SDHB gene mutations (Cys243Tyr and Cys253Tyr). Of the 14 mutation carriers four patients (one with VHL and three with RET mutation) were older than 40 years at the time of diagnosis of Pheo/PGL.
Conclusion
The prevalence of disease-causing mutations among Hungarian patients with apparently sporadic Pheo/PGL is similar to those reported in the literature. However, Cys634Tyr mutation of the RET gene classified as a mutation causing mild phenotype has not been previously associated with Pheo. Both Arg79Gly of the VHL gene and Cys243Tyr of the SDHB gene are novel disease-causing mutations. In addition, our results suggest that complex genetic testing is useful not only in younger but also in older cases.

P365
Pheochromocytoma occurs in Saudi patients with MEN 2A
Tarig Nasser1, Abdullah Karawagh1 & Faiza Qari1,2
1KSU/KAMC, Jeddah, Saudi Arabia; 2KAU, Jeddah, Saudi Arabia.

Objective
To evaluate pheochromocytoma that occurs in Saudi patients with MEN 2A

Patients and methods
Of 44 patients belonging to 5 MEN 2A families, 14 (31.8%) presented with pheochromocytoma. The following variables have been studied: clinical and diagnostic data (age, mutation, clinical features, and laboratory studies included measurements of 24-h urinary catecholamines, epinephrine, metanephrine, norepinephrine, dopamine, vanillylmandelic acid, and plasma metanephrine, norepinephrine, and epinephrine). Laboratory studies were considered abnormal in cases where these values were elevated. Tumor location and dimensions were obtained from computerized tomography (CT) scan and iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy results. The means of diagnostic, clinical, or genetic screening were also studied as well as surgical treatment and follow-up and recurrence. The mean follow-up time was 7 years (range: 12–108 months).

Results
The mean age of the 14 patients was 33.5 years (range: 12–52 years); 10 were women. Most (71.4%) mutations were found in exon 11. The most frequent mutations were Cys634Tyr (in eight cases (57.1%)) and Cys634Arg (in three (21.4%). The diagnosis of pheochromocytoma was made after the diagnosis of MTC in seven cases (50%), simultaneously in five (35.7%), and prior in the two remaining cases (14.3%). At the time of diagnosis eight patients (57.1%) were asymptomatic and six (42.9%) had clinical features related to pheochromocytoma. The most useful isolated laboratory studies were measurements of plasma metanephrines. The combination of CT scan and MIBG diagnosed 100% of cases. The pheochromocytoma was bilateral in two cases. The most commonly used medication for preoperative treatment was phenoxybenzamine, which was utilized in 11 patients (78.6%) and carvedilol blockade for 2–3 weeks. Surgery was uneventful in all cases. After surgery, all cases showed a normalisation of catecholamine levels, for plasma metanephrines (21.32 ± 18.41 pg/ml), P = 0.001, normetanephrines (67.79 ± 48.82 pg/ml), P < 0.001 and chromogranin A (95.83 ± 81.28 ng/ml), P < 0.001. The lipid profile showed an improvement in cholesterol levels after surgery (187.82 ± 44.14, P = 0.01, in nine cases being improved but in two worsened. In addition, three of the cases with normal preoperative values presented an increased cholesterol post surgery. Triglyceride levels decreased but did not reach statistical significance (109.5 ± 41.02 P = NS). Tumour diameter was strongly correlated with metanephrine and normetanephrine (P < 0.001) values.

Conclusion
In pheochromocytoma, tumour removal improves also the hypercholesterolaemia. Definitive metabolic treatment should be decided at 3 months after surgery.

P366
Impact of surgery upon lipid profile in a case series of pheochromocytoma
Corin Badiu1, Simona Jercalau1, Vadim Gavan1, Ruxandra Dobrescu1, Victor Tomulescu1,2, Mircea Beuran2 & Ana Maria Stefanescu1
1National Institute of Endocrinology, Bucharest, Romania; 2University of Medicine and Pharmacy, Bucharest, Romania.

In pheochromocytoma, intense lypolitic activity may lead to altered lipid profile, which can reverse after tumour removal.

Aim
In this study, we evaluated before and at 3 months after surgery for a catecholamine secreting tumour, a group of 19 patients diagnosed with pheochromocytoma (17) or paraganglioma (2). Patients and methods
13 women and 6 men, aged 53.68 ± 12.75 years (36–75), presented with a clinical picture of paroxistic high blood pressure and decrease of body weight, associated with other signs suggesting excess of catecholamines in 16/19, three cases being oligosymptomatic. The initial evaluation confirmed excess of plasma metanephrines (736.11 ± 886.51 pg/ml), normetanephrines (2423.26 ± 1907.6 pg/ml) and chromogranin A (790.44 ± 697.85 ng/ml).

Results
Lipid profile was evaluated by total plasma cholesterol (220.27 ± 50.39) and triglycerides (135.11 ± 74.84 mg/dl), being abnormal for total cholesterol in 11/19 cases. A CT scan detailed the tumour, with tumour diameters of 68 ± 20 mm (110–40 mm), the local invasion and allowed surgical approach. The patients were prepared for surgery using alpha (phenoxynbenzamine) and alpha-beta (carvedilol) blockade for 2–3 weeks. Surgery was uneventful in all cases. After surgery, all cases showed a normalisation of catecholamine levels, for plasma metanephrines (21.32 ± 18.41 pg/ml), P = 0.001, normetanephrines (67.79 ± 48.82 pg/ml), P < 0.001 and chromogranin A (95.83 ± 81.28 ng/ml), P < 0.001. The lipid profile showed an improvement in cholesterol levels after surgery (187.82 ± 44.14, P = 0.01, in nine cases being improved but in two worsened. In addition, three of the cases with normal preoperative values presented an increased cholesterol post surgery. Triglyceride levels decreased but did not reach statistical significance (109.5 ± 41.02 P = NS). Tumour diameter was strongly correlated with metanephrine and normetanephrine (P < 0.001) values.

Conclusion
Definitive metabolic treatment should be decided at 3 months after surgery.

Signal transduction
P367
Transmembrane potential (Δψm) slight changes in non-excitable individual cells at short-term hormone action
N S Kavo, M Yu Maluyakina, I A Borovoy & N L Pogrebnia
Institute for Scintillation Materials NAS of Ukraine, Kharkov, Ukraine.

Early events in activated by adrenaline (10-6 M) and phenylephrine (10-5M) single hepatocytes of rat have been investigated by quantitative image microfluorometry and microspectrofluorometry. Membrane potential-sensitive cationic DiOC6(3) and anionic SgSC4 probes have been used for image analysis and transmembrane potential (Δψm) estimation in real-time studies. Fluorescence spectra resulting from the accumulation of dyes in single cells were recorded. A special data acquisition program allowed measuring fluorescent cell parameters. Based on the mean fluorescence intensity the magnitude of Δψm was calculated by Nerst equation adapted for lipophilic cationic probes. DiOC6(3) has revealed that both hormones induced bidbach hyperpolarization of hepatocytes membrane with alpha-agonist phenylephrine causing a higher amplitude of Δψm changes.

The first increase of Δψm, between 2 and 5 min (ΔΔψm = −8.6±4.2 mV) after the Ca2+-mobilizing hormone addition evidently depends on Na+/K+-ATPase activation. The second peak of hyperpolarization (ΔΔψm = −13.2±3.2 mV) between 25 and 30 min, after a transient decrease of Δψm (ΔΔψm = 10.9±4.3 mV) at 15 min of experiment, probably is mediated by phenylephrine stimulating action on K+-channels.

Δψm-chelating with EDTA didn’t influence the curve character; however it slightly decreased the hormonal effect on the second peak amplitude.

Modulation of PLD-dependent signal transduction pathway by 0.4% butanol had a weak influence on the first increase of Δψm, but it abolished the second phase of hyperpolarization. It points to PLD involvement in the mediated by K+-channels Δψm fluctuations in response to phenylephrine.

Based on SgSC4 fluorescent parameters estimation of Δψm relative changes showed the same character of time dependence curve with two phase of hyperpolarization. Synchronous fluctuation of this parameter determined by oppositely charged probes demonstrates that quantitative microfluorometry allows estimation of slight Δψm changes in non-excitable individual cells at short-term hormone action.
P368

Research resource for analysing functional data of glycoprotein hormone receptors: novel tools to gain deeper insights into molecular mechanisms

A Kreuchwig1, G Klein1a,2, F Kreuchwig3, C L Worth1,3 & G Krause1
1Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany; 2Institut für Experimentelle Pädiatrische Endokrinologie, Charité Universitätsmedizin, Berlin, Germany; 3Institut für Physiologie, Charité Universitätsmedizin, Berlin, Germany.

The sequence–structure–function-analysis of glycoprotein hormone receptors (SSFA-GPHR) database provides a comprehensive set of mutation data for the glycoprotein hormone receptors (covering the lutropin – (LHCR), the follitropin (FSHR) and the thyrotropin receptor (TSHR)). Numerous databases present functional information along with pooled data from various public resources, but tools to analyse the molecular effects of genetic variations are as yet poorly provided. Besides extending the dataset (> 1100 mutations), the database has been completely redesigned and several novel features and analysis tools have been added. These tools allow the focused extraction of semi-quantitative mutant data from the GPHR subtypes and different experimental approaches. Functional data of the GPHRs are now linked interactively at the web interface with protein structure data and novel tools for data search and visualization are provided. A user defined 2D-search option, where snake plots highlights the requested mutated residue(s) in a two dimensional representation of the sequence of interest and hyperlinks them to the mutation information. A 3D-search serves as interactive picking option of any residue position of interest on a 3D structure and provides information about functional effects of available genetic variations that can be mapped onto the structure. The new receptor morphing simulation tool permits tracing of potential structural changes from the basal to an activated receptor conformation for any individual wild type residue and provides clues to the local structural environment, including potentially relocated spatial counterpart residues. Furthermore, double and triple mutations are newly included to allow the analysis of their functional effects related to their spatial interrelationship in structures or homology models. These new tools can be used to identify interacting residues as counterparts and to evaluate potential mechanisms of molecular malfunction caused by specific mutations and give thereby deeper insights in the mechanisms of hormone binding, signal transduction and signaling regulation of GPHRs.

P369

Different and common transmembrane activation mechanisms between glycoprotein hormone receptors and other G-protein coupled receptors

I Hoyer1, G Klein1a,2, A K Haas1, A Kreuchwig3, P Grzesik2, C L Worth1,3, R Schuelein & G Krause1
1Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany; 2Institute of Physiology, Charité Universitätsmedizin, Berlin, Germany; 3Institute of Physiology, Charité Universitätsmedizin, Berlin, Germany.

The aim of our study is to identify signalling sensitive residue positions of the glycoprotein hormone receptors (GPHR), especially the thyrotropin receptor (TSHR) on the transmembrane helices (TMH) 5 and 6, knowing to be involved in GPCR activation. We performed modelling driven site-directed mutagenesis to pinpoint residues that are responsible for stabilization of active and inactive conformations of the TSHR.

We highlight two amino acids that are highly conserved in other family A GPCRs but are different in the GPHRs. Proline at position 5.50 causes a conformational-twist in TMH5 at all available GPCR X-ray structures. This proline is replaced in GPHRs by an alanine. However, mutation of alanine to proline at position 5.50 (TSHR-A593P) results in a 20-fold decreased cell surface expression and a folding defect of TSHR. This implies structural consequences because of different interactions between TMH5 and neighbouring helices 3, 4, and 6 in the TSHR compared to other GPCRs. Our results favour for TSHR and homologous FSHR and LHCR rather a regular alpha-helix conformation than a proline-twisted conformation of TMH5.

Position 6.48 that is highly conserved in other family A GPCRs by a tryptophan known as a ‘toggle switch’ is replaced in GPHR by a methionine. Substitution of this methionine by tryptophan (TSHR-M637W) results in constitutive activation and indicates an alternative micro-switch at TSHR position 6.48.

Our functional data highlight the importance of hydrophobic amino acids at the TMH5 and 6 interface between TMH5 and 6. We confirmed this hypothesis by a statistical analysis of residue properties between the TMHs of a vast number of family A GPCR sequences. We revealed that interacting polar residues between TMH3, 2, 3, 6 and 7 likely constrain the inactive conformation, whereas their release plus the formation of hydrophobic interactions between TMH5 and 6 may constrain the active state conformation of GPCRs and also of GPHRs.

P370

Distribution of 3-iodothyronamine and trace amine-associated receptors in mouse

G Chiellini, P Erba, V Carnicelli, S Ghelardoni, S Frascarelli & R Zacchi University of Pisa, Pisa, Italy.

Introduction

3-Iodothyronamine (T1AM) is a novel endogenous relative of thyroid hormone able to interact with specific G protein-coupled receptors, known as trace amine-associated receptors (TAAR). Metabolic, endocrine and cardiac effects of exogenous T1AM have been reported.

Methods

We synthesized radiolabelled T1AM, [125I]-T1AM, and explored its distribution in different mouse organs after injection in the tail vein. The specificity of [125I]-T1AM was checked in parallel experiments, in which a 100-fold excess of unlabeled T1AM was injected 5 min before the radioligand. We also performed an in vivo evaluation of T1AM expression by quantitative real-time PCR, using specific primers for the nine known TAAR subtypes.

Results

[125I]-T1AM preferentially distributed to the gastrointestinal tract, liver and kidney: in particular at 30 min the highest levels of radioactivity (expressed as percentage of injected dose per g wet weight) were detected in gallbladder, stomach, intestine, liver and kidney (23.3, 8.6, 7.4, 6.1 and 7.2 respectively) and at 60 min top values were still present in gallbladder, liver and kidney (14.7, 6.1 and 6.5 respectively). At 24 h however the highest residual concentration was detected in liver and adipose tissue (1.2 and 0.5 respectively). T1AM expression investigations showed that in most tissues TAARs were expressed only at trace amounts (<10 copies per μg mRNA). Higher expression was detected in stomach and tests for TAAR1 (83 and 55 copies per μg mRNA) and in small bowel, spleen and tests for TAAR8 (16, 19 and 12 copies per microg mRNA). Notably, T1AM expression was negligible in liver and kidney.

Conclusions

Exogenous [125I]-T1AM is preferentially taken up by the liver, kidney and gastrointestinal tract. TAAR binding seems unable to account for T1AM distribution suggesting that T1AM binds to different targets, particularly in liver and kidney.

Thyroid (non cancer)

P371

Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy: a single-blinded, randomized controlled clinical trial

Gouda Ellabban

Department of General Surgery, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Aim

We aimed to test the hypothesis that the minimally invasive video-assisted thyroidectomy (MIVAT) affords comparable safety and efficacy as to the open conventional surgery in patients with unilateral thyroid nodules or follicular lesions in terms of cosmetic results, intraoperative and postoperative complications, postoperative pain, and hospital stay.

Methods

This was a single-blinded randomized controlled trial comparing the MIVAT with conventional thyroidectomy. The primary endpoints of the study were measurement of postoperative pain after 24 and 48 h from operation and cosmetic outcome 3 months postoperatively. The secondary outcome measures were operative time, incidence of recurrent laryngeal nerve injury, length of incision, and hospital stay.

Results

Operative time was less with open thyroidectomy than with MIVAT, while MIVAT was associated with less pain 24 h postoperatively. Pain score depicted statistically significant differences in favor of the MIVAT after 24 h. MIVAT was associated with less scarring and more satisfaction with cosmetic results. There was no difference between both procedures for presence of transient recurrent laryngeal nerve palsy and hypoparathyroidism.

Conclusion

MIVAT is a safe procedure that produces outcomes similar to those of open thyroidectomy, and is superior in terms of immediate postoperative pain and cosmetic results.
Complications after thyroidectomy: a 10 years experience in a District General Hospital
S Jafferbhoy & N I Ramus
Musgrove Park Hospital, Somerset, UK.

Background
Patients undergoing thyroid surgery are consented for a 1% risk of permanent hypocalcaemia and voice changes. These complications are considered to be permanent if they persist for more than 6 months. The aim of this study is to determine the incidence of complications in patients undergoing thyroid surgery in our hospital.

Methods
From January 1999 to March 2009, all patients who underwent thyroid surgery under the care of one surgeon were identified from the database. Data on the surgical procedure, indication, final histology and follow-up were recorded from case notes.

Results
Data were recorded on 559 patients who underwent surgery during this period, 498 for benign thyroid disease and 61 for malignancy. Thirty-five patients (6.3%) with benign pathology and 20 (32.8%) with thyroid malignancy had postoperative complications ($P = 0.0001$). Two patients (0.4%) in benign group and one patient (1.64%) with malignancy had permanent hoarseness. Permanent hypocalcaemia was noted in five patients (1.0%) in benign group and one patient (1.64%) in malignant group. The overall incidence of permanent hoarseness and hypocalcaemia was 0.54 and 1.07% respectively.

The incidence was higher in patients over the age of 60 years (17/284, $P = 0.004$) and in those having completion thyroidectomy (13/50 versus 42/509, $P = 0.004$). Multivariate logistic regression revealed only thyroid malignancy to be significantly associated with postoperative complications ($P < 0.0001$).

Conclusion
The incidence of permanent complications in thyroid surgery is low, patients with thyroid malignancy being at a higher risk. Thyroid surgery appears to be safe in the hands of a general surgeon with a subspecialist interest.

Acoustic radiation force impulse (ARFI)-imaging involves the mechanical excitation of tissue using short-duration acoustic pulses to generate localized displacements in tissue. The displacements result in shear-wave propagation which is tracked using ultrasonic, correlation-based methods and recorded in m/s. Inclusion criteria were: nodules ≥1 cm, non-functioning or hypo-functioning on radionuclide scanning, and cytological/histological assessment. All patients received conventional ultrasound, real-time elastography (RTE) and ARFI-imaging.

Results
Sixty nodules in 55 patients were available for analysis. Fifty-seven nodules were benign on cytology/histology, and three nodules were papillary carcinoma. The median velocity of ARFI-imaging in the healthy nodule-free thyroid gland, as well as in benign and malignant thyroid nodules was 1.98 m/s (range: 1.20–3.63 m/s), 2.02 m/s (range: 0.92–3.97 m/s), and 4.30 m/s (range: 2.40–5.40 m/s) respectively. While no significant difference in median velocity was found between healthy thyroid tissue and benign thyroid nodules, a significant difference was found between malignant thyroid nodules on the one hand and healthy thyroid tissue ($P = 0.018$) or benign thyroid nodules ($P = 0.014$) on the other hand. A specificity of ARFI-imaging of 91% could be achieved using a cut-off of 3.1 m/s. This was comparable to the specificity of RTE with 91% in the present study.

Conclusions
ARFI can be performed in the thyroid tissue with reliable results. This novel quantitative elastography-method can be performed with high specificity in the diagnostic work-up of thyroid nodules. Larger studies are awaited.

The influence of cure of subclinical hyperthyroidism on left ventricular walls thickness and mass index
G Kaminski1, K Makowski1, M Ruchala1, E Szczepanek2 & T Bednarczuk2
1Military Institute of Medicine, Warsaw, Poland; 2Poznan University of Medical Sciences, Poznan, Poland; 3Medical University of Warsaw, Warsaw, Poland.

Introduction
Subclinical hyperthyroidism (SH) affects about 1% of world human population at least. The diagnosis of this disease leans on the laboratory criteria only: decreased of TSH and normal FT3 and FT4 concentrations. SH increases mortality mostly due to cardiovascular diseases including overload of the heart and ventricular arrhythmia. These symptoms are anticipated by increasing of left ventricular walls thickness and its mass index.

Aim
To estimate an influence of cure of SH on left ventricular walls thickness: interventricular septum diameter (IVSd), posterior wall diameter (PWD) and left ventricular mass index (LVMI) measured by echocardiography. And also to find the correlations between these parameters and TSH, FT3, and FT4 concentrations.

Methods
Forty-four patients (37 women, 7 men) aged 45.9 ± 9.8 months of history of only autonomous endogenous SH (TSH = 0.16 ± 0.31 mIU/l), were examined with echo twice: before and after 9 months of TSH normalization (SH = 1.32 ± 0.1 mIU/l) with radiodiode treatment (dose 12.1 ± 5.7 mCi). The average time between examinations was 12.5 ± 6 months. The Local Ethical Committee approval has been obtained.

Results
The cure of SH caused decrease of IVSd ($P < 0.00001$), PWD ($P < 0.00001$), LVMI ($P < 0.0001$), During SH the level of FT3 was positively correlated with IVSd ($P = 0.045$) and PWD ($P = 0.038$).

Conclusions
1. Cure of autonomous subclinical hyperthyroidism with radiodiode decreases left ventricular walls thickness and its mass index. 2. These results can indicate
decrease of heart after load and the risk of ventricular arrhythmia. iii) In autonomous subclinical hyperthyroidism, the level of FT3 positively correlates with diameter of interventricular septum and left ventricular posterior wall. iv) Above findings support the decision to treat endogenous subclinical hyperthyroidism especially in patients with cardiovascular risk.

P376
The use of lithium and perchlorate therapy in special cases of hyperthyroidism
I Z Kun, Zs Szanto, T Bartok, C C Pop Radu & I Pascaru
University of Medicine and Pharmacy, Targu Mures, Mures County, Romania.

Objective
To study the efficacy of lithium and perchlorate in special cases of hyperthyroidism: thiouamide-resistant or iodine-induced thyrotoxicosis/thyrotic pre-crisis, hematological adverse effects of methimazole, leukopenia of other cases.

Material and methods
Twenty-seven hyperthyroid patients received lithium carbonate and/or potassium perchlorate, majority after methimazole-therapy (associated with folic acid in leukopenia). We followed the clinical course, TSH, FT3, FT4, and hemogram during therapy.

Results
Thyrotoxic pre-crisis appeared in 14.8% and moderate overt hyperthyroidism in 8.5% of patients (majority due to autoimmune thyroid diseases). Methimazole-induced leukopenia in 18 cases: in 14 the initial high doses (30–60 mg/day), in 4 in the chronic treatment. In four subjects interferon provoked leukopenia. Methimazole-therapy was insufficient in 3 and caused allergy in 2 cases. We introduced lithium carbonate in 250–1000 mg daily doses, and the leukocyte count began to rise on the second day, with normalization on fifth day. Lithium-therapy (perchlorate in 4 cases) normalized thyroid function on the 3–4th week in 8 cases, and reduced the plasma levels of thyroid hormones with about 38.8% in 19 patients. Four subjects underwent thyroidecomy after euthyroid status was reached; 6 continued lithium-therapy with lower doses, and 9 patients received gradually reduced doses of lithium and methimazole (5–15 mg/day) necessary to keep thyroid function and bloodcount normal. Lithium was ceased due to adverse effects in 6 cases (3 gastrointestinal, 3 psychical): we lost the contact with 2 patients. Mean duration of treatment was 4.4 months for lithium and 1.1 month for perchlorate.

Conclusion
Lithium/perchlorate with or without small doses of thiouamide may be a therapeutic option when thionamides alone are insufficient or not tolerated: they improve both the hyperthyroid state and the hematological disorders. Lithium provoked gastrointestinal and psychic complications, while the short-term perchlorate therapy did not cause any side effects.

P377
Comprehensive symptom profile in patients with nontoxic goiters: practicability and sensitivity of the new symptom assessment tool CSP-ThsSF22
A Novik, P Vetoshv, T Ionova, S Von & G Gorodokin
1Qol Research Unit, Pirogov Medical Surgical Center, Moscow, Russian Federation; 2Endocrine Surgery Department, Pirogov Medical Surgical Center, Moscow, Russian Federation; 3Multinational Center for Quality of Life Research, Saint-Petersburg, Russian Federation; 4New Jersey Center for Quality of Life and Health Outcome Research, Saddle River, New Jersey, USA.

The value of patient-reported outcomes in treatment efficacy assessment of thyroid disorders is of great importance. Recently, a new tool, Comprehensive Symptom Profile (CSP-ThsSF22), has been developed to assess symptoms specific for patients with nontoxic goiters. We aimed to test practicability and sensitivity of CSP-ThsSF22 in patients with euthyroid goiter undergoing thyroidectomy. A total of 78 patients with uninodular/multinodular euthyroid goiter were enrolled in this study (mean age 48.0, male/female – 14/64). All the patients underwent thyroidectomy. Patients filled out CSP-ThsSF22 before surgery and at different time-points thereafter. CSP-ThsSF22 is developed to assess the severity of 22 symptoms specific for patients with euthyroid or hypothyroid goiter. Wilcoxon’s matched pairs test was used to compare symptom severity at different time-points. The prevalence of moderate-to-severe symptoms was studied using χ2 test or Fisher’s exact test. Practicability of CSP-ThsSF22 was shown: patients needed 5–7 min to answer it; the proportion of missing values was < 1.5% for all questions; the questionnaire found high acceptance reflected by no refusals. Usefulness of CSP-ThsSF22 to distinguish patients in terms of severity and number of symptoms experienced was demonstrated. The information obtained was used by the surgeons at follow-up. After thyroidectomy, reduction in the vast majority of symptoms was observed. At 3 months after surgery, the severity of 11 out of 22 symptoms decreased significantly (P < 0.05). Remarkable decrease in the prevalence of moderate-to-severe symptoms after surgery was shown (P < 0.05). CSP-ThsSF22 is a sensitive and practical tool to assess symptom profile and severity in patients with nontoxic goiter. Comprehensive symptom monitoring is strongly recommended to clearly determine treatment outcomes in patients with euthyroid goiter undergoing thyroidectomy.

P378
Selenium treatment in chronic autoimmune thyroid diseases
I Z Kun, Zs Szanto & I Kun
University of Medicine and Pharmacy, Targu Mures, Romania.

Objective
To evaluate the effect of selenium on autoimmune thyroid diseases through ATPO-titers.

Material and methods
Selenium (0.1–0.2 mg/day) was associated with folic acid in Hashitoxicosis and 3 cases with active Graves’ disease, while two female patients were euthyroid without any treatment. Initial ATPO-levels were between 185 and 2000 U/ml with mean value of 802 U/ml. We followed the thyroid function and ATPO-values usually after 2–6 months of selenium administration.

Results
Ten hyper-thyroid patients had Hashimoto’s thyroiditis, 6 were diagnosed with Hashitoxicosis and 3 with active Graves’ disease, while 2 female patients were euthyroid without any treatment. Initial ATPO-levels were between 185 and 2000 U/ml with mean value of 802 U/ml. We observed considerable individual differences in the response to selenium treatment. It seems that the effect of selenium was stronger in patients having high initial ATPO-levels compared to those with moderately increased titers. The response was also influenced by the duration of selenium administration.

Conclusion
Selenium was effective in patients with Hashimoto’s thyroiditis and Hashitoxicosis, while the effect of selenium was not significant in patients with active Graves’ disease.
goiter. Wilcoxon’s matched pairs test was used to compare symptom severity at different time-points. The prevalence of moderate-to-severe symptoms was studied using χ² test or Fisher’s exact test. Practicability of the CSP-ThyroidSF27 was shown: patients needed 5–7 min to answer it; the proportion of missing values was <2% for all questions; the questionnaire found high acceptance reflected by no refusals. Usefulness of the CSP-ThyroidSF27 to distinguish patients in terms of severity and number of symptoms experienced was demonstrated. The information obtained was used by the surgeons at follow-up. After thyroidectomy, reduction in the prevalence of moderate-to-severe symptoms after surgery was shown (P < 0.05). The CSP-ThyroidSF27 is a sensitive and practical tool to assess symptom profile and severity in patients with toxic goiters. Comprehensive symptom monitoring is recommended to clearly determine treatment outcomes in patients with toxic goiters undergoing thyroidectomy.

A case of Riedel’s thyroiditis
Tufan Eliepek¹, Bilent Bilir², Betül Etkiz Bilir³, Sibel Gülükden³
¹General Surgery Department, Edirne State Hospital, Edirne, Turkey;
²Internal Medicine Department, Edirne State Hospital, Edirne, Turkey;
³Endocrinology Department, Trakya University Medical Faculty, Edirne, Turkey;
4Pathology Department, Trakya University Medical Faculty, Edirne, Turkey.

Introduction
Riedel’s thyroiditis (RT) is a rare and chronic fibro-inflammatory disease firstly described by Riedel in 1896. It is characterized by a dense fibrosis that replaces normal thyroid parenchyma. The fibrotic process invades adjacent structures of the neck and extends beyond the thyroid capsule, which differentiates RT from other inflammatory or fibrotic disorders of the thyroid. The overall incidence in outpatients is 1.06 per 100,000. We presented here a case of Riedel’s thyroiditis, which is operated for a suspicion of thyroid malignancy.

Case report
A 48-year-old woman was admitted to the hospital with shortness of breath and swelling in the neck. Her thyroid was firm and multiple nodules were palpated. She was euthyroid. Anti-TPO and anti-Tg antibody levels were in normal ranges.

A 48-year-old woman was admitted to the hospital with shortness of breath and swelling in the neck. Her thyroid was firm and multiple nodules were palpated. She was euthyroid. Anti-TPO and anti-Tg antibody levels were in normal ranges. In her thyroid ultrasonography, right lobe’s dimensions were increased. There were hypoechoic areas with irregular margins with dimensions of 9 mm at left upper pole, 23 × 15 mm at right middle pole and 9 × 9 mm at left lower pole, which were totally interpreted as thyroiditis. Multinodular hyperplasia with hypoechogenicity in the nodules of right lobe was obtained in the thyroid scintigraphy. In the fine-needle aspiration biopsy, there were no atypical cells. Surgery was performed to exclude malignancy and to relieve the patient’s complaints. On pathological examination, Riedel’s thyroiditis was diagnosed.

Conclusion
The main diagnostic modality in Riedel’s thyroiditis is pathological examination. The criteria most commonly used to diagnose Riedel’s thyroiditis is gross description of visible fibroinflammatory process involving all or a portion of the thyroid gland, gross or histological evidence of extension into adjacent structures, absence of granulomatous reaction and neoplasm. It may occur in a multinodular thyroid gland, gross or histological evidence of extension into adjacent structures, which were totally interpreted as thyroiditis. Multinodular hyperplasia with hypoechogenicity in the nodules of right lobe was obtained in the thyroid scintigraphy. In the fine-needle aspiration biopsy, there were no atypical cells. Surgery was performed to exclude malignancy and to relieve the patient’s complaints. On pathological examination, Riedel’s thyroiditis was diagnosed.

Evolution of thyroid function and antibodies in Hashimoto thyroiditis after 10 years observation. Study on 1000 patients
Dan Peretianu¹, Mara Carsoțe², Catalina Poiana³ & Cristina Daniela Stâicu³
¹Societatea Civila Medicala ‘Povernei’, Bucharest, Romania; ²Institute of Endocrinology, Bucharest, Romania.

Material and methods
A. Hashimoto thyroiditis (HT) diagnosis: i) antithyroperoxidase antibodies (ATPO) criteria; cut-off > 34 IU/ml. ii) If ATPO = normal (N), HT was considered only antithryoglobulin antibodies (ATG) were > 50 IU/ml and ultrasonography was pattern 1 (pseudonodular, intense hypoechochogenic, inhomogeneous – Peretianu, Endocrine Abstracts, 2007, 14, P340; 2008, 16, P772; 2009, 20, P79).

Study
Retrospective, cohort.

Results
A. At the diagnostic moment (DiMo). i) Function: euthyroid (EUT): 460 (46%), hypothyroid (HOT): 397 (39%), hyperthyroid: 143 (15%) – from these: 95 (66%) were with ATPO high, even no thyroid was detected. 28 with ATPO = N. iii) 26 (33%) HT with TRAB were EUT/HOT. iv) Amiodarone association: 14 (1.4%): 6 EUT, 4 HOT, 2 HT. B. Follow-up. i) Function: a. 15 (3.25%) with EUT became HOT after 0.2–5 years (average: 2.16, s.d.: 1.72), b. 100% HOT remained HOT. c. HT without treatment at 3 years become EUT in only 3, HOT in only 1. ii) ATPO: a. Evolutive type: undulatory: 118 (45%), increasing: 23 (56%). b. Linear correlation with thyroid hormone/ TSH: none; r = 0.5/0.17, P = 0.9 (NS).

Discussion
i) Ultrasound thyroid patterns. ii) ATPO histogramme by intervals. iii) Most common association in HT was GBD (see also Poiana, Endocrine Abstracts, 2008, 16, P782).

Measurements and functional significance of TSHR gene mutations in pediatric patients
Stefania Monal, Flavia Prodani, Alice Monzani, Simonetta Bellone, Stefania Riccomagno, Gillian Walker, Letizia Trovato, Marta Roccio, Patrizia Agretti & Gianni Bona
¹University of Piemonte Orientale, Novara, Italy; ²University of Pisa, Pisa, Italy.

TSH receptor (TSHR) is a G-protein-coupled seven-transmembrane domain receptor located in the basolateral membrane of thyroid follicular cells. The activated receptor couples to two major signal transduction pathways: the Gs/adenylate cyclase and the Gq/11/phospholipase C signalling. Many loss of function mutations have been identified in this gene leading to a wide spectrum of thyroid abnormalities, ranging from hyperthyrotropinemia and TSH resistance to severe hypothyroidism. We identified in one child a non-sense mutation in exon 10 for the substitution of tryptophan at position 520 with a stop codon (W520X).

Because the mutated receptor loses its C-terminal portion necessary for the cellular signalling, the functional significance of this variation was assessed in vitro.

Methods
Molecular analysis of TSHR gene was performed in 112 pediatric patients (M/F: 56/56, age range: 1–18 years) showing elevated serum TSH levels and normal thyroid hormones and in 112 healthy subjects. W520X mutation was introduced into the pSVL vector by mutagenesis. Wild-type and mutated vectors were expressed in CHO cells and cAMP assay, inositol phosphate (PI) assay and immunofluorescence analysis were performed.

Results
We identified in exon 9 the new synonymous variation D232D and the intronic substitution AGG at position IVS9+1 bp. Both were found in heterozygous state and were not present in our group of controls. We observed that CHO cells expressing the W520X mutated receptor showed a lower cAMP and PI production with respect to wild-type receptor. Moreover, a reduced expression of mutated receptor on the cell surface was observed.

Conclusion
Our data demonstrate that the premature stop codon introduced by the W520X mutation causes a reduction of TSHR expression at the cell surface. This reduces TSHR signalling pathway, thus being responsible of the hormonal pattern of subclinical hypothyroidism observed in our child.

Endocrine Abstracts (2011) Vol 26

Hashimoto’s thyroiditis is not associated with breast cancer more than other thyroid condition or more than general population
Mara Carsoțe¹, Catalina Poiana¹, Cristina Daniela Stâicu² & Dan Peretianu¹
¹Institute of Endocrinology, Bucharest, Romania; ²Societatea Civila Medicala ‘Povernei’, Bucharest, Romania.

Premises
Numerous recent medical journals and communications insist on the high prevalence of Hashimoto’s thyroiditis (HT) associated with breast cancer in women (see www.ncbi.nlm.nih.gov/ key words: breast cancer, thyroiditis, #91).
Objective
We proposed to present data from our casuistry related to HT (over 2000 patients and control, including men), observed during last 10 years.

Materials and methods
A. Patients: 950 consecutive women with HT, compared with 860 women with other thyroid diseases or normal thyroid, as controls, were investigated for breast cancer. B. All the patients had: i) ATPO analysis, for inclusion or exclusion of HT diagnostic; ii) thyroid ultrasound; iii) FT4 and TSH; iv) breast specific investigations (ultrasound and/or mammography). C. Statistical analysis was done by χ²-test.

Results
Breast cancer was registered in only 19 women (prevalence 1.05%): 11 with HT (prevalence 1.16%), 8 with other thyroid diagnostics (prevalence 0.93%).

Breast cancer in HT seems to be more than in general population.

Breast cancer prevalence in general population is around 0.85% (see, for USA, seer.cancer.gov/statfacts/html/breast). Breast cancer in HT seems to be more than in general population: 1.05 vs 0.85%.

Discussion
Breast cancer prevalence in general population is around 0.85% (see, for USA, seer.cancer.gov/statfacts/html/breast). Breast cancer in HT seems to be more than in general population: 1.05 vs 0.85%.

Conclusion
i) Women with Hashimoto’s thyroiditis did not associated more breast cancer than other women with other thyroid clinical conditions. ii) Breast cancer in women with Hashimoto thyroiditis in no more prevalent than breast cancer in general population. iii) Breast cancer in women with Hashimoto thyroiditis and other thyroid clinical condition in no more prevalent than breast cancer in general population.

P384
Occurrence and prognostic impact of hypothyroidism in chronic heart failure
V Triggiani1, M Iacoviello2, F Monzani3, V A Giagulli1, E Tafaro1, P Guida2, E Guastamacchia1 & S Favale3
1Endocrinology and Metabolic Diseases, University of Bari, Bari, Italy; 2Cardiology, University of Bari, Bari, Italy; 3Internal Medicine, University of Pisa, Pisa, Italy.

The aim of this study was to define the occurrence of hypothyroidism and its impact on CHF progression. Four hundred and twenty-two consecutive outpatients (326 males, aged 65 ± 12 years) with CHF in stable condition and conventional therapy were evaluated. Thyroid status was checked at least every 4 months. The progression of heart failure was defined as death, urgent heart transplantation, or hospitalisation due to worsening HF.

Results
A total of 51 patients (12%) had a previous diagnosis of hypothyroidism while 21 (5%) were newly diagnosed at the enrolment (prevalence of hypothyroidism at the first evaluation: 17%; 33% in females vs 13% in males; P < 0.001). During follow-up (median 28 months) hypothyroidism occurred in further 19 patients (incidence rate: 26/1000/year) and it was mainly attributable to amiodarone therapy. In patients affected by hypothyroidism a significantly greater occurrence of heart failure progression was observed (Fig. 1A/B).

P386
Serum lipid oxidation and paraoxonase enzyme activity in subclinical thyrotoxicosis
Mehrdad Solati1, Ladan Atai2 & Feriedoun Aazizi2
1Hormozgan University of Medical Sciences, Bandar Abbas, Islamic Republic of Iran; 2Shahed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

Changes in serum lipid and lipoprotein concentrations occur frequently in disorders of thyroid function. LDL-C oxidation susceptibility is higher in these patients than in normal population. This study aims at assessing lipids, lipoproteins, lipid oxidations and serum paraoxonase activity in patients with subclinical hyperthyroidism. Forty patients were compared with an age and sex matched control group. A fasting blood sample was obtained and serum total cholesterol, triglycerides, lipid oxidation parameters, and paraoxonase activity were measured. In patients with subclinical hyperthyroidism, significantly lower serum paraoxonase activity (52 ± 26 vs 76 ± 35 IU/ml, P < 0.001), triglycerides, LDL, Total cholesterol, Total antioxidant capacity, B-carotene, Vitamin A and E were found. The results show significant changes of lipid levels in subclinical thyrotoxicosis. In addition, significant reduction in serum paraoxonase activity was observed in these patients, this can be due to the hypermetabolic state in the patients with subclinical thyrotoxicosis.

P384
Occurrence and prognostic impact of hypothyroidism in chronic heart failure
V Triggiani1, M Iacoviello2, F Monzani3, V A Giagulli1, E Tafaro1, P Guida2, E Guastamacchia1 & S Favale3
1Endocrinology and Metabolic Diseases, University of Bari, Bari, Italy; 2Cardiology, University of Bari, Bari, Italy; 3Internal Medicine, University of Pisa, Pisa, Italy.

The aim of this study was to define the occurrence of hypothyroidism and its impact on CHF progression. Four hundred and twenty-two consecutive outpatients (326 males, aged 65 ± 12 years) with CHF in stable condition and conventional therapy were evaluated. Thyroid status was checked at least every 4 months. The progression of heart failure was defined as death, urgent heart transplantation, or hospitalisation due to worsening HF.

Results
A total of 51 patients (12%) had a previous diagnosis of hypothyroidism while 21 (5%) were newly diagnosed at the enrolment (prevalence of hypothyroidism at the first evaluation: 17%; 33% in females vs 13% in males; P < 0.001). During follow-up (median 28 months) hypothyroidism occurred in further 19 patients (incidence rate: 26/1000/year) and it was mainly attributable to amiodarone therapy. In patients affected by hypothyroidism a significantly greater occurrence of heart failure progression was observed (Fig. 1A/B).

P386
Serum lipid oxidation and paraoxonase enzyme activity in subclinical thyrotoxicosis
Mehrdad Solati1, Ladan Atai2 & Feriedoun Aazizi2
1Hormozgan University of Medical Sciences, Bandar Abbas, Islamic Republic of Iran; 2Shahed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

Changes in serum lipid and lipoprotein concentrations occur frequently in disorders of thyroid function. LDL-C oxidation susceptibility is higher in these patients than in normal population. This study aims at assessing lipids, lipoproteins, lipid oxidations and serum paraoxonase activity in patients with subclinical hyperthyroidism. Forty patients were compared with an age and sex matched control group. A fasting blood sample was obtained and serum total cholesterol, triglycerides, lipid oxidation parameters, and paraoxonase activity were measured. In patients with subclinical hyperthyroidism, significantly lower serum paraoxonase activity (52 ± 26 vs 76 ± 35 IU/ml, P < 0.001), triglycerides, LDL, Total cholesterol, Total antioxidant capacity, B-carotene, Vitamin A and E were found. The results show significant changes of lipid levels in subclinical thyrotoxicosis. In addition, significant reduction in serum paraoxonase activity was observed in these patients, this can be due to the hypermetabolic state in the patients with subclinical thyrotoxicosis.
Conclusions
Depression or anxiety, not being a smoker and hypercholesterolemia are the variables independently associated with undiagnosed subclinical hypothyroidism.

P387

Current results on urinary iodide excretion in pregnant women on the day of childbirth in Germany
R Hampel1, S Körber2, Ch Zingler2, O Niederstrasser3, H Below3 & V Briese4
1Internal Medicine Clinic II, Division of Endocrinology and Metabolic Diseases, University of Rostock, Rostock, Germany; 2Women’s Hospital, University of Rostock, Rostock, Germany; 3Institute for Hygiene and Environmental Medicine, University of Greifswald, Greifswald, Germany; 4Institute of Clinical Chemistry and Laboratory Medicine, University of Rostock, Rostock, Germany.

Objectives
Recent Germany-wide studies have shown that urinary iodide excretion in schoolchildren as well as in adults meet WHO targets. No current results for pregnant women in Germany are available. Methods: We investigated urinary iodide excretion in 1003 pregnant women on the day of childbirth in the greater Rostock area. Iodide was measured by cerasertene method modified by Lorenz. Results: Iodine contamination occurred in 168 women after caesarean section due to the use of the skin disinfectant povidone-iodine (Braunol). These women were excluded from analysis. In the remaining sample population of 714 women that had a spontaneous vaginal delivery, the median urinary iodide excretion was 91% compared to 86% in the group of women that used iodized table salt. Iodide excretion in pregnant women in Germany are available. No current results for pregnant women in Germany are available. Conclusions: These data suggest that the variation within iodine excretion and/or effectiveness of treatment in EOP.

P388

Tear cytokines in endocrine ophthalmopathy (EOP)
T Koszegi1, A Nagy1, E Mezosi2, E Gyorgy1, A Lajdry3 & G L Kovacs1
1Institute of Laboratory Medicine, University of Pécs, Pécs, Hungary; 2Department of Ophthalmology, University of Pécs, Pécs, Hungary; 3First Department of Medicine, University of Pécs, Pécs, Hungary.

Introduction
Human tear is rich in cytokines, i.e. in healthy individuals it exhibits a higher ratio of cytokines to total proteins than that in the serum of the same individual. EOP related to Graves-Basedow disease is thought to develop due to elevation of tear cytokines and isocratic separation by ion chromatography) and the serum thiocyanate concentration (pyridine/barbituric acid method).

Results
Iodine contamination occurred in 168 women after caesarean section due to the use of the skin disinfectant povidone-iodine (Braunol). These women were excluded from analysis. In the remaining sample population of 714 women that had a spontaneous vaginal delivery, the median urinary iodide excretion was 103.3 μg/l. Relative iodine excretion distribution: 46% >100 μg/l, 32% 50-99 μg/l, 12% 20-49 μg/l, 10% >20 μg/l. Median urinary iodide excretion in women using iodized table salt (91%) was 104 μg/l and 102.8 μg/l in women that did not use iodized table salt. Iodide excretion relative to iodine supplement intake; no intake ~ 92.3 μg/l; 100 μg per day ~ 95.8 μg/l; 200 μg per day ~ 112.9 μg/l. The values for thiocyanate (5.08 mg SCN−/l) and nitrate (44.22 mg NO3/ ml) were below the respective goitrogenic threshold and correlated with neither urinary iodide excretion nor thyroid volume obtained by sonography.

Conclusions
In Germany, women during pregnancy and in early puerperium remain with free iodine and products of conception. These data suggest that the variation within iodine excretion and/or thyroid volume obtained by sonography.

P389

The CT60 and Jo31 polymorphisms of CTLA-4 gene are associated with disease progression in Graves’ disease
J Daroszewski1, E Pawlak-Adamska2, M Bolanowski1 & I Frydecka3
1Department of Endocrinology, Diabetology, and Isotope Therapy Medical University, Wroclaw, Poland; 2Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland; 3Department of Hematology, Blood Neoplastic Diseases, and Bone Marrow Transplantation, Medical University, Wroclaw, Poland.

Introduction
Both genetic and environmental factors contribute to clinical manifestation of Graves’ disease including the response to medical therapy. CT60 gene is an important inhibitor of T-cell activation and its polymorphisms may influence the course of the disease.

Conclusions
We investigated the association between CT60 gene polymorphisms: c.49A>G, c.319C>T, g.*642AT(8_33), CT60, and Jo31 and the response to pharmacological therapy.

Materials
One hundred and seventy-two unrelated GD patients were genotyped and categorized into two groups: 96 patients responded to medical treatment and 76 subjects required surgical or 131I therapy because of a relapse.

Methods
The polymorphisms g.319C>T (rs5742909) in the promoter region, c.49A>G (rs231775) in exon 1, and CT60 (g.*6230G>A, rs3087243) in the 3’UTR of the CTLA-4 gene were examined by PCR-restriction fragment length polymorphism (PCR-RFLP) using TruI, BstXI, and TaqI enzymes. The Jo31 (g.*10223G>T, rs11571302) polymorphism in the 3’UTR region of the CTLA-4 gene was genotyped using PCR amplification followed by minisequencing using the commercial kit SNAPshot. The CTLA-4 3’UTR containing an (AT)n repeat was studied by PCR and fluorescence based technique.

Results
CT60(G) allele (genotype [GG] or [GT]) carriers were 4.51-fold more prone to disease progression (P=0.01, 95% CI: 1.25–16.20), CT60(G) allele and [GG] genotype increased risk of disease progression (P=0.002, OR =2.05, 95% CI: 1.29–3.27 and P=0.001, OR =2.24, 95% CI: 1.21–4.15, respectively). Also presence of one or two Jo31(G) allele was associated with relapse ([G] allele: P=0.008, OR =1.82, 95% CI: 1.17–2.83 and [GG] genotype: P=0.02, OR =2.07, 95% CI: 1.10–3.89, respectively). The CT60 and Jo31 markers were subjected to multivariate analysis. It appeared that only the CT60 polymorphic marker is an independent risk factor for disease progression (P=0.02, OR =4.51, 95% CI: 1.24–16.30).

Conclusion
These data suggest that the variation within CT60-A gene may discriminate Graves’ disease patients with different clinical manifestation and help to identify subjects at risk of a relapse.

P390

Hyperthyroidism in pregnancy: therapeutic decisions
Eduard Circo & Mihaela Seceleanu
‘Ovidius’ University, Constanza, CT, Romania.

Objectives
Hyperthyroidism in pregnancy presents a challenge for medical doctor, patient and products of conception.
Aim of the study
To specify the peculiarities of expression of hyperthyroidism in pregnant women, diagnosis, monitoring, treatment, prognosis of pregnancy and effect on the fetus.

Materials and methods
The study included a total of 27 women with hyperthyroidism of which 15 (group A) had thyrotoxicosis before conception and 12 (group B) were diagnosed during pregnancy. All pregnant women with thyrotoxicosis received treatment with propylthiouracil in average dose: 200 mg/day (n = 5, 26.31%), those in maintained remission during pregnancy received 50 mg/day (n = 14, 73.68%).

Results
Dosage anti TSH-receptor antibodies (TRAb) revealed pathological values in a number of 9 (69%) including 4 pregnant women with ophthalmopathy. Of the 27 pregnancies studied initially remained in development a number of 19 (70.37%), three cases with known hyperthyroidism did not want pregnancy preferred therapeutic abortion, all presenting also ophthalmopathy; three cases had suffered spontaneous abortion in weeks 13, 17 and 19 respectively; for two cases it was decided to practice therapeutic abortion in week 16 and 21 due to heart rhythm abnormalities correlated with persistent thyrotoxicosis with increased necessary for propylthiouracil and beta-blocker. In pregnant women who completed pregnancy were found two birth before term. For patients with ophthalmopathy remaining pregnant (n = 4) were not found symptoms and signs of progressive disease, correlated with serum levels of thyroid hormones and TRAb in remission. Mentioned one case with esophageal atresia in a female infant whose mother received propylthiouracil monotherapy 200 mg/day initiated within 16 weeks of pregnancy.

Conclusions
Hyperthyroidism in pregnant woman poses problems of diagnosis and monitoring due to maternal-fetal risk. Abortion rate is generally high both in terms of the decision, therapeutic and pathological. After the first trimester there is often an ‘improvement’ of clinical symptoms and autoimmune process: ophthalmopathy evolution; incidence of pathological TRAb serum levels.

P391
The association between serum TSH levels and hypertension in 12 353 children and adolescents
T Itermann 1,2, M Thamm 1, H Wallaschofski 1, R Retti 1 & H Völkle 1
1University of Greifswald, Greifswald, Germany; 2Erasmus University, Rotterdam, The Netherlands; 3Robert Koch Institute, Berlin, Germany.

Objective
Although subclinical thyroid dysfunction is associated with cardiac endpoints such as endothelial dysfunction, left ventricular hypertrophy, thickened artery walls or atrial fibrillation, it is currently under debate whether subclinical hyper- or hypothyroidism as well as thyroid function within the reference range are associated with an increased risk of hypertension. So far no study investigated the association between thyroid function and blood pressure in children and adolescents. Thus, we investigated the association between serum TSH levels and hypertension in a large-scale population-based study conducted in children and adolescents aged 3–17 years.

Material and methods
Data from 6528 children and 6134 adolescents of the ‘Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland’ (KiGGS) were analyzed. Two readings of systolic, and diastolic pressure were taken in an upright position after 5 min of rest. Hypertension was defined as a systolic blood pressure > 120 mmHg or a diastolic blood pressure > 80 mmHg. Serum TSH levels were measured with the ECLIA method on an Elecsys E2010. Decreased and increased serum TSH levels were defined according to age-specific reference limits for the assay used. Continuous as well as categorized serum TSH levels were associated with hypertension by multivariable logistic regression.

Results
Serum TSH levels were significantly associated with hypertension in adolescents (odds ratio (OR) = 1.19; P < 0.001) and in children (OR = 1.12; P = 0.045). Decreased and increased serum TSH levels were not associated with hypertension in adolescents and children.

Conclusion
In conclusion, we demonstrate a weak relationship between serum TSH levels and hypertension in adolescents and children. The conflicting results compared to studies conducted in adults might be related to lower prevalences of thyroid diseases and intake of medication in our population. Furthermore, previous studies might have had not sufficient power to detect a weak association between serum TSH levels and hypertension.

P392
Increased TSH response and regulatory CD4+CD25+CD127low Foxp3+ T cells in patients with chronic hepatitis C virus infection developing interferon-induced thyroiditis
B Soldilleva, N Alonso, M Martinez-Arconada, T Julian, R Planas, R Pujol-Borrell, E M Martinez-Caceres & A Sannarri
Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.

Introduction
Interferon-α (IFN-α) exerts different immune effects and is used in current therapy for chronic hepatitis C virus (HCV) infection. One of the side-effects of IFN-α therapy is interferon-induced thyroiditis (IT). The role of lymphocyte subpopulations in IT remains to be defined.

Objective
This study was conducted to assess different peripheral blood lymphocyte subpopulations, mainly regulatory CD4+CD25+CD127low Foxp3+ T cells (Tregs), in patients with chronic HCV infection who developed IT.

Patients and methods
From 120 patients with HCV who started antiviral treatment, those who developed IIT (IIT patients) were selected and compared with patients who did not develop IIT (Co-HCV). Peripheral blood mononuclear cells (PBMC) were obtained before treatment (BT), mid-treatment (MT), end of treatment (ET), 24 weeks post-treatment (PT) and at appearance of IIT (TT).

Results
Eleven patients developed IIT: 3 Hashimoto’s thyroiditis, 1 Graves’ disease, 1 positive antithyroid antibodies, 1 non-autoimmune hypothyroidism and 5 destructive thyroiditis. During combined antiviral treatment, a significant increase in CD8+ lymphocytes and in Tregs was observed in both groups. A significant decrease in CD3−, CD19+ and NKT lymphocyte subpopulations was also observed (all P < 0.05). However, no changes were observed in the percentage of CD4+CD25+Foxp3+ and iNKT lymphocytes. Th1/Th2 balance and Bcl2 expression on B cells when BT was compared with ET. At the appearance of IIT (TT), IIT patients had a higher TH1 response (CCR5+CCR7−) (P < 0.01) and a higher Tregs percentage (P < 0.05) than Co-HCV.

Conclusions
Our results point to the immunomodulatory effects of IFN-α on different lymphocyte subpopulations and a possible role of TH1 response and Tregs in HCV patients who developed IIT.

P393
Study of the relation between subclinical hypothyroidism and diabetic complications
H Kameda 1, S Nagai 1, C Shimizu 1,2, H Nomoto 1, A Hirai 1, K Kimachi 1, K Y Cho 1, A Nakagaki 1, T Sawada 1, T Kondo 1, H Miyoshi 1 & T Koike 1
1Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan; 2Department of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.

Introduction
There were some studies on the relation between subclinical hypothyroidism and atherosclerosis, but few studies between thyroid function and diabetic microangiopathy. This study was aimed at investigating the influence of subclinical hypothyroidism on diabetic complications in Japanese population.

Description of methods/design
We retrospectively surveyed a total of 106 type 2 diabetic patients with regard to thyroid function and microvascular complications. The patients were divided into two subgroups of subclinical hypothyroidism group (SCH group; TSH ≥ 3 μU/mL), and euthyroid group (TSH < 3 μU/mL). There were 16 patients of SCH group and 90 patients of euthyroid group.

Results
In the SCH group and euthyroid group, those with preproliferative and proliferative retinopathy were 5 (31.2%) and 10 patients (11.1%), overt nephropathy were 5 (31.2%) and 10 patients (11.1%), respectively. Those who had neuropathy were each 14 patients (87.5%) and 46 patients (51.1%), respectively. The trends for the three diabetic complications were all significantly higher in the SCH group than euthyroid group (P = 0.015, 0.015, 0.007). Serum TSH level was associated with greater prevalence of diabetic retinopathy in multiple logistic-regression analysis after an adjustment for age, duration of diabetes, HbA1c (OR 1.54, P = 0.037).

Conclusion
Subclinical hypothyroidism contributes to development of diabetic microangiopathy.

Endocrine Abstracts (2011) Vol 26
Melatonin drug use in complex treatment of hypothyroidism manifest Amongal Mansharipova, Gulnar Moldabek & Zhangentkhan Ablayaliy Uzbekistan Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.

Aim
The aim of the study was to evaluate the clinical efficacy of melatonin in patients with hypothyroidism.

Materials and methods
In study were taken 51 patients from 25 to 63 years to manifest hypothyroidism (on a background of autoimmune thyroiditis), with anxiety-depressive syndrome and sleep disturbance. Thyroid hormones were determined by ELISA (VectorBest Russia) Anxiety-depressive syndrome in patients with hypothyroidism were analyzed on hospital Anxiety and Depression Scale HADS. Patients were divided into 2 groups. First group with manifest hypothyroidism (25 patients) received standard replacement therapy with l-thyroxine and symptomatic therapy for 1 month. Second group with manifest hypothyroidism (26 patients) along with l-thyroxine and symptomatic therapy additionally received melatonin (15 mg/night) Statistical analysis was done by SPSS, to analyze the reliability of the Student T criteria.

Results
Thyroid hormones levels in the blood of patients with hypothyroidism group 1 and 2 before treatment showed no differences. With combination therapy of melatonin in group 2, serum TSH fell from the baseline to 82.2±1.5%, the level of free serum T4 increased from baseline to 85.2±2.5%, which differ from that of patients of group 1 after treatment. After the treatment, noted that in both groups there is significant reduction in anxiety, P<0.05, especially subclinical anxiety (P<0.05). Found that only after treatment of melatonin in the treatment of hypothyroidism is significantly reduced depressive states with 10.9±0.9 points to 6.9±0.5 points (P<0.05), with significantly reduced subclinical depression. Conclusion
The inclusion of melatonin in the standard therapy for symptomatic hypothyroidism showed that the drug can affect the pituitary-thyroid system, removing anxiety and depression.

Epidemiologic study of iodine deficiency in 6 regions of the Republic of Uzbekistan S I Ismailov, L B Nugmanova & B Kh Babakhanov The Center of the Scientific and Clinical Study of Endocrinology, Tashkent, Uzbekistan.

Introduction
Iodine deficiency disorders are considered as the most widespread non infectious diseases of the humanity. Uzbekistan is in the zone of the severe iodine deficiency (ID). According to epidemiologic studies performed in 1998 endemic goiter (EG) prevalence was 80% whereas urinary iodine was < 10 µg/l In May, 2007 Uzbek government legislated the Salt Iodization Law and in 2009 ID evaluation was performed in the Uzbekistan using sentinel approach.

Materials and methods
As recommended by World Health Organization we performed epidemiologic studies using sentinel method in six regions of the country, i.e. examination of children from 3 rural public schools and 3 urban public schools (randomized design). We collected 180 urinary samples and 180 salt samples on the level of households’ iodized salt consumption (HISC) from schoolchildren aged 6-12 years-old from each region. Both total urinary samples number and salt samples on the level of HISC constituted 6480 samples for each group. EG evaluation was performed among schoolchildren aged 6-15 years-old where total number of children constituted 19 212 children in 6 regions of the country (Namangan, Syrdarya, Dzijazak, Surkhandarya, Andijan and Republic of Karakalpakstan).

Results
Urinary iodine measurements in evaluated regions demonstrated ID in 39.0% of schoolchildren while HISC constituted 61.0%. Of 19 212 children aged 6-15 years-old 9626 (47.6%) had EG. Normal level of HISC registered in 52.0% of schoolchildren whereas 42.0% of children had insufficient salt consumption as 6.0% of evaluated salt was not iodized.

Conclusion
According to our results we consider that the iodine deficiency situation remains as severe in the Republic of Uzbekistan, although, in comparison with the 1998 data there is a positive trend as the endemic goiter prevalence.

Thyroid status and health-related quality of life in the LifeLines-cohort E J Klaver, R Stienstra, M M van der Klaauw, I P Kema & B H R Wollenbuttel Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background
Thyroid disorders are prevalent in western society, yet many subjects experience limited symptoms at diagnosis, especially in hypothyroidism. Design
In order to compare the health-related quality of life (HR-QOL) of subjects with suppressed TSH-levels (TSH <0.5 mU/l) or elevated TSH-levels (TSH >10 mU/l) to subjects with normal TSH-levels (TSH 0.5–4 mU/l), a cross-sectional study was performed within the Dutch adult population who participated in the LifeLines-cohort from December 2009 until August 2010. We measured thyroid hormone status (serum TSH, free T4 and free T3, Roche Modular) and HR-QOL (RAND-36 item Health Survey) in 9491 Caucasian participants, 3993 men and 5498 women (median age 45, range 18-88 years), without current or former use of thyroid medication.

Results
Suppressed TSH-levels (<0.5 mU/l) were found in 114 participants (1.2%), while 70 participants (0.7%) had TSH>10 mU/l. No relationship between increasing TSH-levels or reduced HR-QOL and ageing could be found. Men had a higher HR-QOL than women (P<0.001) except for the domain ‘general health’ (P=0.692). None of the domains of the RAND-36 was significantly reduced in men with suppressed or elevated TSH-levels (P>0.05) compared to euthyroid men. Only the domains ‘physical functioning’ and ‘general health’ were significantly reduced in women with suppressed TSH-levels versus euthyroid women (P=0.013 and P=0.036 respectively). Women with TSH > 10 mU/l had similar HR-QOL compared to euthyroid women (P>0.05). In both men and women no significant differences could be observed between HR-QOL and subjects with decreased, normal or elevated FT3-levels (P>0.05).

Conclusions
HR-QOL of subjects with suppressed TSH-levels or elevated TSH-levels is not significantly reduced compared to subjects with normal TSH-levels.

P394
P395
P396
P397
P398
Subclinical hypothyroidism and thyroid autoimmunity: risk factors for coronary heart disease?
Z Milicevic1 & J Ciric2
1Laboratory for Molecular Biology and Endocrinology, Institute for Nuclear Sciences Vinca, Belgrade, Serbia; 2Clinical Department of Endocrinology, Diabetes and Metabolic Disease, Clinical Centre, Belgrade, Serbia.

It has been claimed that an increased level of thyroid autoantibodies in serum is associated with a higher risk for coronary heart disease (CHD). We explored whether this risk was mediated by subclinical hypothyroidism and hypercholesterolemia. We evaluated 945 consecutive hospital patients (mean age 59 years) according to strict electrocardiographic and clinical criteria for the presence of CHD. Serum cholesterol, LDL and HDL cholesterol and sensitive TSH were measured in all patients. In 245 patients antithyroglobulin and thyroid peroxidase antibodies were also determined. Patients were divided into group I (normal TSH, i.e. below 4 mU/l), group II (borderline TSH, i.e. 4.0 to 5.9 mU/l) and group III (high TSH, i.e. 6.0 mU/l or more). There were 398, 45 and 22 women and 410, 50 and 20 men in group I, II and III respectively. Patients of group III were randomly age- and sex-matched with patients of group I and II combined as controls. Alternately the groups II and III were randomly age- and sex-matched with group I as controls. Both procedures gave on identical prevalence of CHD in control and index groups in both sexes. Cholesterol was significantly lower in group III compared to matched controls. The prevalence of thyroid antibodies was 8.3, 14.3 and 48% in women and 4.5, 2 and 4.8% in men of group I, II and III respectively. In women with antibodies mean cholesterol was lower than in age-matched controls without antibodies (P < 0.05) irrespective of whether they belonged to group I, II or III and the presence of antibodies was not associated with the prevalence of CHD. In men the prevalence of antibodies was too low to permit analysis of their contribution to CHD. We conclude that neither subclinical hypothyroidism nor thyroid antibodies are risk factors for CHD.

P399
Faster response to cholestyramine added in treatment of patients with hyperthyroidism
I E Bonapart, A Boumpaki & A Stamataki
Venizeleio-Pananeio Hospital, Heraklion, Crete, Greece.

Introduction
Faster decline in serum thyroid hormone levels in hyperthyroidism is seen adding cholestyramine at conventional treatment in some studies (1.2).

Design/methods
Retrospective controlled study. Follow-up: ± 3 weeks.

Patients with hyperthyroidism: 17 treated with antithyroid drugs (mean dose 35 mg/day) combined with cholestyramine (mean dose 12 g/day).

Control group: 23 only treated with antithyroid drugs (mean dose 20 mg/day).

Patients with Quervain disease: 5 treated with cholestyramine (mean dose 12 g/day).

Control group: 5 without therapy.

FT4 and FT3 levels before and after follow-up period were compared. Statistical analysis: Student’s t-test.

Results
Patients with hyperthyroidism: cholestyramine vs control group showed decline: FT4: 61 vs 20%, P < 0.01 and FT3: 72 vs 48%, P < 0.02. Patients with severe hyperthyroidism were all treated with cholestyramine and higher doses of antithyroid drugs. Subgroup analysis in mild hyperthyroidism and equal dose of medication (5 versus control 6 patients) showed: FT4: 48 vs 19%, P < 0.05 and FT3: 57 vs 25%, P < 0.02. Patients with Quervain disease: cholestyramine versus control group showed: FT4: 51 vs 41%, P < 0.3 and FT3: 54 vs 11%, P < 0.05.

Discussion
Cholestyramine added in treatment of hyperthyroidism shows faster decline in thyroid hormone levels during the first weeks. In this study, the effect is less in mild hyperthyroidism, probably because of smaller increase in T4-concentration in bile and faeces, but seems more pronounced in severe hyperthyroidism.

Conclusion
Cholestyramine is an option as adjunctive therapy especially in severe hyperthyroidism, obtaining faster decline in thyroid hormone levels.

P400
The expression of keratin 34E12 in ectopic thymus tissue
R Cornea1, M Cornianu1, E Lazar2, A Dema3, S Tăban1, A Muresan1, C Lazureanu4 & I Gola
1Pathology Department, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania; 2Endocrinology Department, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania.

Introduction
The ectopic thymus tissue (ETT) represents a migration and descending deficiency of the organ during embryogenesis. HMWK have a strong positive reaction in normal anatomical localized thymus and thymomas. A similar reaction pattern is seen in thyroid solid cell nests (SCNs) suggesting that these cells share a common origin with thymic tissue. Moreover, can be very helpful in differentiate CASTLE from other thyroid tumors.

Our aim was to investigate the expression of CK34E12 in the normal ectopic thymic tissue which was not yet described.

Materials and methods
We analyzed 5 cases of ETT, from female patients with age between 14 and 49 years, 2 intrathyroidal and 3 adjacent to thyroid and parathyroid. The tissue was incidentally discovered in patients with diverse thyroid and parathyroid pathology.

Slides of paraffin-embedded specimens were HE stained and the immunohistochemical investigation used monoclonal antibodies against HMWK, clone 34E12 (Dako).

Results
The thymic tissue was microscopically identified inside and adjacent to thyroid and parathyroid. In one case, within the thyroid were identified areas of SCNs. Also in one case ETT had the appearance of partial involution. In the intrathyroidal ETT, we observed an intense positive reaction for CK 34E12 with strong, granular pattern, in the epithelial cells of the subcapsular region, medullar areas and Hassall corpuscles. In the ETT adjacent to thyroid the intensity of reaction was smaller. The lower intensity was seen in the partial involution thymus.

Conclusions
Our results suggest that might be difference of CK34E12 expression in the ectopic cervical thymic tissue according with the location and age.
Conclusions

Mann–Whitney test) in mild ophthalmopathy group, as compared to moderate–smoking (Z-test). The diagnosis of thyrotoxicosis was established on clinical criteria, hormonal data (TSH, FT3 and FT4) and immunological data (TSH receptor antibodies). The evaluation of the ophthalmopathy comprised exophthalmometry, clinical activity score (CAS) and severity criteria.

Results

In 72 cases, thyrotoxicosis developed concomitantly with orbitopathy, 25 patients presented fist the thyrotoxicosis and in one case the eye disease was diagnosed 2 years before thyrotoxicosis. At admission, the evaluation of thyroid function during ophthalmologic assessment, showed 22 cases with subclinical hyperthyroidism, 15 euthyroid patients, 3 with subclinical hypothyroidism, the remaining presenting overt thyrotoxicosis (59.1%).

CAS values were comparable in euthyroid and dysthyroid groups (3.6 ± 2.0 vs 3.2 ± 1.85, P = 0.47, t-test).

According to EUGOGO severity criteria, the ophthalmopathy was classified as follows: 73 mild forms (9 men, 64 women), 20 moderate (4 men, 16 women) and 5 severe forms (1 man, 4 women).

Based on clinical activity score, the patients were divided into active ophthalmopathy group (31 cases) and inactive eye disease group (67 cases).

There were no statistically significant differences regarding age (P = 0.08, t-test), smoking (P = 0.07, Fisher’s exact test) or thyrotoxicosis severity (P = 0.40, Mann-Whitney test) in mild ophthalmopathy group, as compared to moderate–severe group.

Conclusions

The studied Graves’ cases were dominated by mild ophthalmopathy forms. Thyroid ophthalmopathy (CAS, severity) does not correlate with thyrotoxicosis onset.

Thyroid nodules in children: review of 67 patients

São João Hospital, Porto, Portugal.

Introduction

Thyroid nodules in children and adolescents are less prevalent, but entail greater risk of malignancy than in adults. Most are asymptomatic because they are associated with normal thyroid function, but their prevalence is increasing due to the incidental diagnosis by neck ultrasound.

Aims

To evaluate the characteristics of a pediatric population with thyroid nodules submitted to fine-needle aspiration (FNA) biopsy.

Methods

We evaluated 67 children and adolescents followed in the Pediatric Endocrinology consultation of Hospital de São João-EPE because of thyroid nodules. We determined the demographic parameters of patients, thyroid function, nodules’ size by neck ultrasound, the result of FNA and histology (in patients who underwent surgery).

Results

Fifty-six patients were females (83.6%). Overall they had mean age of 14.6 ± 3.7 years (4–18 years) and thyroid nodules mean size was 11.2 ± 5.2 mm (9–21 mm). Thyroid function was normal in 60 patients (89.55%), with the remaining having hypothyroidism. Mean TSH was 2.3 ± 1.1 μIU/ml (N: 0.35–4.94) and free T4 was 1.15 ± 0.16 ng/dl (0.7–1.48), after exclusion of patients with hypothyroidism. FNA revealed lymphocytic thyroiditis in 14 patients (20.9%), papillary carcinoma in 5 patients (7.46%) and follicular tumor in 8 patients (11.94%). In the latter case, histology showed that 4 were follicular adenomas (50.0%), 3 were follicular variant of papillary carcinomas (37.5%) and 1 was follicular carcinoma (12.5%). Two of the patients whose FNA showed benign lesions underwent thyroidectomy for multinodular goiter and its histology showed that they were adenomatous goiters. Malignancy was confirmed in a total of 9 patients (13.4%).

Conclusions

The prevalence of malignancy in our sample was high, which is consistent with previous studies.

The etiologic profile of thyromegaly in children in the south west of Romania between 2005 and 2010

Margineanu Otilia1, Varces Flore2, Simedrea Ioan1, Dora Andor3, Tamara Marcovici1 & Rodica Ilie1
1 1.85, Z-test).

1. In our region the etiologic profile is quite various. 2. The treatment depends on the etiology and thyroid function. 3. The response of the treatment in childhood is satisfied.

Awareness of secondary hypothyroidism in GH deficient hypopituitary adults has improved their lipid status

M-L Hartoft-Nielsen1, M Klose1, O Klefer1, V Gavan2, Å K Rasmussen1 & U Feldt-Rasmussen1
1Department of Endocrinology, Rigshospitalet, University Hospital of Copenhagen, PE-2131 Copenhagen, Denmark; 2Department of Thyroid Related Disorders, National Institute of Endocrinology ‘C.I. Parhon’, Bucharest, Romania.

Introduction

To evaluate if improved thyroid status in patients with hypopituitarism would improve cardiovascular risk markers.

Patients and methods

A total of 85 hypopituitary patients (45 women) with GH deficiency; 7 had isolated GH deficiency, 25, 16 and 22 patients had 1, 2 and 3 additional deficits respectively. Fifteen patients had panhypopituitarism. Biochemical and body composition assessment was performed at baseline (when patients were GH

P402

Clinical aspects in Graves’ disease associated with infiltrative orbitopathy

M Balas1, I Golu1, M Vlad1, C Gurban1 & I Zosin1
1Department of Endocrinology, University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania; 2Department of Biochemistry, University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania.

Aim

The aim of the study was to present some epidemiological data about Graves’ ophthalmopathy in a tertiary centre.

Material and method

The retrospective study included 98 patients with Graves’ disease associated with infiltrative ophthalmopathy, evaluated in our Department of Endocrinology in the period 2008–July 2010.

The mean age of the group was 45.2 ± 12.4 years, with a female/male ratio = 84/14.

The prevalence of malignancy in our sample was high, which is consistent with previous studies.

P404

The etiologic profile of thyromegaly in children in the south west of Romania between 2005 and 2010

Margineanu Otilia1, Varces Flore2, Simedrea Ioan1, Dora Andor3, Tamara Marcovici1 & Rodica Ilie1
1 1.85, Z-test).

1. In our region the etiologic profile is quite various. 2. The treatment depends on the etiology and thyroid function. 3. The response of the treatment in childhood is satisfied.

Awareness of secondary hypothyroidism in GH deficient hypopituitary adults has improved their lipid status

M-L Hartoft-Nielsen1, M Klose1, O Klefer1, V Gavan2, Å K Rasmussen1 & U Feldt-Rasmussen1
1Department of Endocrinology, Rigshospitalet, University Hospital of Copenhagen, PE-2131 Copenhagen, Denmark; 2Department of Thyroid Related Disorders, National Institute of Endocrinology ‘C.I. Parhon’, Bucharest, Romania.

Introduction

To evaluate if improved thyroid status in patients with hypopituitarism would improve cardiovascular risk markers.

Patients and methods

A total of 85 hypopituitar patients (45 women) with GH deficiency; 7 had isolated GH deficiency, 25, 16 and 22 patients had 1, 2 and 3 additional deficits respectively. Fifteen patients had panhypopituitarism. Biochemical and body composition assessment was performed at baseline (when patients were GH

P403

Thyroid nodules in children: review of 67 patients

São João Hospital, Porto, Portugal.

Introduction

Thyroid nodules in children and adolescents are less prevalent, but entail greater risk of malignancy than in adults. Most are asymptomatic because they are associated with normal thyroid function, but their prevalence is increasing due to the incidental diagnosis by neck ultrasound.

Aims

To evaluate the characteristics of a pediatric population with thyroid nodules submitted to fine-needle aspiration (FNA) biopsy.

Methods

We evaluated 67 children and adolescents followed in the Pediatric Endocrinology consultation of Hospital de São João-EPE because of thyroid nodules. We determined the demographic parameters of patients, thyroid function, nodules’ size by neck ultrasound, the result of FNA and histology (in patients who underwent surgery).

Results

Fifty-six patients were females (83.6%). Overall they had mean age of 14.6 ± 3.7 years (4–18 years) and thyroid nodules mean size was 11.2 ± 5.2 mm (9–21 mm). Thyroid function was normal in 60 patients (89.55%), with the remaining having hypothyroidism. Mean TSH was 2.3 ± 1.1 μIU/ml (N: 0.35–4.94) and free T4 was 1.15 ± 0.16 ng/dl (0.7–1.48), after exclusion of patients with hypothyroidism. FNA revealed lymphocytic thyroiditis in 14 patients (20.9%), papillary carcinoma in 5 patients (7.46%) and follicular tumor in 8 patients (11.94%). In the latter case, histology showed that 4 were follicular adenomas (50.0%), 3 were follicular variant of papillary carcinomas (37.5%) and 1 was follicular carcinoma (12.5%). Two of the patients whose FNA showed benign lesions underwent thyroidectomy for multinodular goiter and its histology showed that they were adenomatous goiters. Malignancy was confirmed in a total of 9 patients (13.4%).

Conclusions

The prevalence of malignancy in our sample was high, which is consistent with previous studies.
naive), and at follow-up (median 4.7 years (3.0–5.5) after initiation of GH replacement. Patients were divided into TSH sufficient (TSHsuff) (not on levothyroxine and free T₄ > 12 (n=23)), and TSH deficient (TSHdef), that were further divided into tertiles according to baseline free T₄.

**Results**

Baseline free T₄ was negatively associated to BMI (P=0.003) and total fat mass (P=0.01). TSHdef patients with lowest tertile free T₄ had higher total P=0.05) and LDL cholesterol (P=0.05) and triglycerides (P<0.01) compared to TSHsuff patients, also after adjustment for gender, age, BMI and IGF₁. At follow-up 9 patients initially defined as TSHdef had initiated levothyroxine treatment. 53 patients were on GH replacement throughout the follow-up period. The remaining 51 patients were off GH for a median period of 6 months (range 0–180 months), with further adjustment for change in IGF₁ (P=0.02).

**Conclusion**

After ~5 years of GH replacement also the secondary hypothyroidism was better adjusted with an improvement of the lipids of a higher magnitude than seen after GH replacement alone.

---

**P406**

**Cytological evaluation of pyramidal lobe and thyroglossal duct cysts**

Ayten Öguz, Hursiyie Basir, Dilek Tuzun, Alper Uşlagülları, Ali A Tam, Reşitn Ersoy, Gulpınar Guler & Bekir Cağır

Atatürk Education and Research Hospital, Bilkent, Ankara, Turkey.

**Aim**

Thyroid pyramidal lobe and thyroglossal duct cysts were reported to be associated with increased risk of thyroid cancer. In this study, we aimed to evaluate ultrasoundography (US) guided fine needle aspiration biopsy (FNAB) cytology results of pyramidal lobe and thyroglossal duct cysts.

**Material and methods**

Patients with pyramidal lobe and thyroglossal duct cysts detected in US were included. Thyroid functions, thyroid autoantibodies, Tc 99m thyroid scintigraphy and US guided FNAB cytology results were evaluated.

**Results**

There were 79 (97.5%) female and 2 (2.5%) male patients with a mean age of 52.0±12.3 (20-82). Thyroglossal duct remnant was observed in 26 (32.1%) and pyramidal lobe in 55 (67.9%) patients. There were 74 (91.4%) patients with a previous history of thyroidectomy and all were histopathologically benign. In 7 patients, there was not a history of thyroid operation. FNAB results of all thyroglossal duct and pyramidal lobe were benign.

**Conclusion**

Pyramidal lobe is an embryological remnant of thyroglossal duct and its incidence varies between 15 and 75% in surgical and autopsy series. It was reported that this tissue becomes hypertrophic under the influence of increased thyrotropin in thyrotoxic patients. Thyroglossal duct cysts develop in front of the neck. Increased risk of occult malignancy risk was reported in solid lesions, particularly when they include ectopic thyroid tissue. In our series, we did not observe any malignant cytology result.

---

**P407**

**The outcome of radiiodine therapy after 10 years in patients with toxic nodular goiter**

Saeid Abdelrazek¹, Franciszek Rogowski¹, Malgorzata Szorc² & Malgorzata Mojsak¹

¹Department of Nuclear Medicine, Medical University of Białystok, Białystok, Poland; ²Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland.

We studied 20 patients with non toxic nodular goiter, aged 42–79 years, 12 females and 8 males. All the patients complained of some symptoms of hyperthyroidism (palpitation, hot intolerance, sweating, tiredness and tachycardia). In all the patients serum TSH was in the lower normal range, serum levels of fT₃, fT₄, and TSH were evaluated before and monthly up to 12 months after RT. Thyroid ultrasound, and thyroid scan with thyroid RAU were done before and after 12 months of radioiodine therapy. The activity dose was calculated by Marinelli’s formula and was ranged between 280 and 800 MBq. The absorbed dose ranged between 180 and 260 Gy and was proportional to thyroid volume.

**Results**

After 12 months of radioiodine therapy a mean thyroid volume reduction of 46% was achieved in all the patients, euthyroidism persist in 95% of patients, and hypothyroidism develop in one patient (5%). All patients were highly satisfied; all the symptoms relieved and exercise tolerance improved.

**Conclusions**

The hot nodules may contribute to the symptoms complained by the patients, and this was confirmed when all the symptoms relieved after radioiodine therapy. Radioiodine is non-invasive, safe and cost effective method of therapy for reduction of goiter and should be used as first choice in every patient with non-toxic nodular goiter (>40 ml) with and without symptoms. The reduction of thyroid volume with low percent of hypothyroidism were due to accurate measurement of administered activity, and relatively high effective half-life.
P409
The induction of hyperthyroidism in patient with non-toxic goiter after radioiodine therapy: a case report
Saeid Abdelfazek & Franciszek Rogowski
Department of Nuclear Medicine, Medical University of Białystok, Białystok, Poland.

A 44-year-old female, with non-toxic goiter was referred to our Department for thyroid volume reduction. Serum levels of FT₃, FT₄, and TSH were within normal range, high resolution ultrasonography showed enlarged thyroid glands (50 ml), with 2 nodules one in the left lobe and one in the right lobe. Malignancy was ruled out by ultrasound-guided fine-needle aspiration biopsy. Thyroid radioiodine scintigraphy showed homogenous and diffuse uptake in both lobes with small reduction in the thyroid volume. RAIU after 24 and 48 h was 53 and 48% respectively. The patient received more doses of antithyroid drugs to control the hyperthyroidism, after 6 months of radioiodine therapy the patient was in subclinical hyperthyroid state, thyroid scintigraphy showed homogenous and diffuse uptake in both lobes with small reduction in the thyroid volume. TSH receptor antibodies increased, anti thyroglobulin antibodies and anti peroxidase antibodies were within normal range. The patient underwent an antithyroid surgery. She underwent an uncomplicated total thyroidectomy.

Case 2: 32 years old female admitted acutely with large toxic retrosternal goitre, day 8 and she underwent uneventful total thyroidectomy with good recovery. Thyroid surgery. She was treated with Lithium 1200 mg dose in addition to her antithyroid therapy. She was treated with Lithium 1200 mg dose in addition to her antithyroid treatment.

P410
Lithium in the acute preoperative preparation of thyrotoxicosis: a case series
S Dampetla & M Malik
Scunthorpe General Hospital, Scunthorpe, UK.

Introduction
Thionamides are the first line treatment in the management of thyrotoxicosis, however, in many cases it is difficult to lower thyroid hormone levels to normal and administer it in a short space of time. The rapidity of this action is important in the recent period due to thyroid hormone excess in thyrotoxic patients. Lithium is a monovalent cation that inhibits thyroid iodine uptake and hormone release with maximum effect in 3–5 days making it a suitable adjuvant agent to conventional preoperative antithyroid treatment.

We here report a series of three cases where lithium was used successfully as an adjuvant agent in the acute preoperative preparation of hyperthyroidism prior to emergency thyroid surgery.

Case 1: 28 years female with young family and severe symptomatic Graves hyperthyroidism resistant to high doses of carbimazole was admitted for primary thyroid surgery. She was treated with Lithium 1200 mg dose in addition to her current carbimazole treatment, T₃ and steroids. T₃ levels were down by 78% on day 8 and she underwent uneventful total thyroidectomy with good recovery. T₄ levels were down by 70% and 51%. She underwent an uncomplicated total thyroidectomy.

Case 3: 51 years female admitted with Graves’s thyrotoxicosis and progressive opthalmopathy resistant to high dose carbimazole and oral steroids. Lithium was added at a dose of 800 mg od by day six T₄ was down by 70.9% and subsequently underwent a successful total thyroidectomy.

Conclusion
Our series demonstrates that lithium is an effective and safe agent for the acute preoperative preparation of thyrotoxic patients.

P411
Thyroid peroxidase antibodies in euthyroid children: is long term follow up required?
K Tharian, C Evans & J T Warner
1Children’s Hospital for Wales, Cardiff, UK; 2University Hospital of Wales, Cardiff, UK.

Introduction
The presence of thyroid peroxidase (TPO) antibodies in euthyroid children poses a potential risk for the development of autoimmune hypothyroidism. Little is known about the ontogeny of this process. This retrospective study aims to estimate the risk of developing hypothyroidism in euthyroid children with raised TPO antibodies and provide a guideline for follow up.

Methods
Children 0–16 years with raised TPO antibodies (1996–2005) were identified from the biochemistry database of a University Hospital. In those that were euthyroid on initial screen, follow up clinical details and thyroid function tests were obtained from case records.

Results
Two hundred and eight children were identified with raised TPO antibodies, 164 had concurrent TFT results. 104 were excluded as they either had frank hypothyroidism, compensated hypothyroidism or thyrotoxicosis, leaving 60 euthyroid children (19 males, 41 females). 560 had no further follow up results. Within 2 years 25% (4) had developed hypothyroidism requiring treatment. By 5 years a further 2 children had developed hypothyroidism (one had type 1 diabetes (TIDDM) and the other Down syndrome). At 10 years another two children were being treated, one with T1DM and one with both T1DM and Down syndrome.

Conclusion
Risk of hypothyroidism in healthy euthyroid children with raised TPO antibodies is minimal after the first 2 years. Therefore a suggested policy of follow up with TFT at 3–6 months and then annually up to 2 years before discharge back to primary care would seem appropriate. However, children with chronic conditions like Down’s syndrome and autoimmune illnesses like T1DM need periodic monitoring.

P412
Increasing saturation with thyroid hormones is associated with haemostatic system activation
J Horacek, J Maly, I Svilias, M Zidkova, Z Pavlikova, M Pecka, E Malirova & J Vizda
1Department of Internal Medicine, Faculty of Medicine and University Hospital Hradec Královy, Charles University Prague, Hradec Královy, Czech Republic; 2Department of Nuclear Medicine, Faculty of Medicine and University Hospital Hradec Královy, Charles University Prague, Hradec Královy, Czech Republic.

While increasing levels of thyroid hormone may be a risk factor for venous thromboembolism (van Zaane et al. Blood 2010 115(22) 4344–4349), there is a relatively lack of detailed data on the effect of thyroid hormones on haemostatic system. We analyzed multiple markers of haemostasis in a cohort of patients shifting from severe hypothyroidism to mild hyperthyroidism during their differentiated thyroid cancer treatment.

In 94 patients following total thyroidectomy for cancer, selected tests were performed on two occasions: i) before the radioiodine remnant ablation, in hypothyroidism (TSH, median 92.2 mIU/l; interquartile range 72.2–135.9), and ii) 6–8 weeks later on levothyroxine treatment, with low-normal to suppressed TSH (0.29 mIU/l; 0.11–0.82).

While the values for D-dimer (medians, 0.34 and 0.32 mg/l, respectively), antithrombin (100 and 109.5%), and tissue plasminogen activator (2.9 and 2.8 µg/l) were not changed during levothyroxine treatment, other markers, i.e. fibrinogen (3.5 and 3.9 g/l), Wilcoxon P < 0.001), plasminogen activator inhibitor 1 (6.8 and 13.2 µg/l; P < 0.001), von Willebrand factor (95.141%; P < 0.001) and factor VIII (105.184%; P < 0.001) were increased significantly, suggesting a shift towards pro-coagulation activities in the haemostatic balance. Also, the activation times of primary haemostasis (i.e. platelet adhesion and aggregation), evaluated by the PFA-100 System after stimulation with collagen and epinephrine (136 and 116 s; P = 0.002) or with collagen and ADP (89 and 82 s; P = 0.017), were significantly shortened.

Increasing saturation with thyroid hormones is thus associated with multiple changes in haemostatic balance, suggestive of haemostatic system activation.

Endocrine Abstracts (2011) Vol 26
**P413**

**Sclerosing Hashimoto’s thyroiditis: a case presentation**

F Talbot1, S Krishnan1, A Mathews1, A Marker2, P Jani3 & K Chatterjee4  
1Hinchinbrooke Healthcare NHS Trust, Cambridgeshire, UK; 2Cambridge University Hospitals, Cambridge, UK.

**Introduction**

Autoimmune thyroiditis is rarely painful. A tender goitre usually indicates viral thyroiditis. Here, we present a case of a persistent painful goitre due to sclerosing-type Hashimoto’s thyroiditis.

**Case presentation**

Our patient is a 27-year-old mother, with no significant past medical history. She was diagnosed with autoimmune hypothyroidism in October 2005 when 4 months post-partum. At diagnosis her anti-TPO titre was 2041 U/ml, and she was asymptomatic. She was managed in the community until January 2009 when she presented with exquisite thyroid tenderness and dysphagia. A diagnosis of viral thyroiditis was made and managed with analgesia and steroids. Her anti-TPO titre was 3754 U/ml, and inflammatory markers raised (CRP 125). An ultrasound revealed a diffusely enlarged gland, with no evidence of abscess, nodules or lymphadenopathy. The nuclear medicine scan showed diffusely low uptake at 0.4%, consistent with thyroiditis.

Six months later despite a prolonged course of steroids the pain persisted and her anti-TPO titre was >6500 U/ml. In view of ongoing pain she was referred to the surgeons for biopsy, and consideration of a total thyroidectomy. The biopsy demonstrated small islands of follicles separated by dense fibrous stroma, with an intense chronic lymphocytic infiltrate (polyclonal B and T cells) and an intact basement membrane. The staining demonstrated that 57% of the IgG positive cells were positive for IgG3. This is in keeping with fibrosing-type Hashimoto’s thyroiditis, and she underwent a total thyroidectomy for symptom relief.

**Conclusion**

We present a case of a rare sclerosing-type of Hashimoto’s thyroiditis. Thyroid pain is rarely associated with autoimmune hypothyroidism. We conclude that ongoing pain is an indication for consideration of thyroid biopsy. Sclerosing-type Hashimotos may require thyroidectomy for pain relief.

**P414**

**Does levothyroxine plus thyrostatic drug titrated individually offer better control of hyperthyroidism than thyrostatic alone?**

Vukic Lovrencic and Lea Sokolic  
University Hospitals, Cambridgeshire, UK.

**Results**

For once.

**Conclusion**

Authors conclude that addition of levothyroxine is inevitable in cases of discordant levels of thyroxine and triiodothyronine, when decreased thyroxine is accompanied by normal or even slightly elevated triiodothyronine irrespective of TSH values.

**P415**

**Free T4 results in neonates: large differences between Immulite/VISTA and Vitros ECI**

F Weerkamp & R W Wulkan  
Maasstad Hospital, Rotterdam, The Netherlands.

**Introduction**

Thyroxine is essential for growth and brain development in neonates. Early detection of hypothyroidism by measurement of free T4 (fT4) is therefore paramount. Moreover, the initial monitoring of Thyrox suppletion requires accurate fT4 measurements.

**Methods**

In the Maasstad Hospital FT4 has been measured with the Immulite 2500 and from 2010 onward with the Dimension VISTA. Both instruments show good agreement when tested with adult samples. Samples of neonates are measured in our hospital and in addition are sent to the university hospital of Rotterdam for measurement with the Vitros ECI. We compared the Vitros FT4 results with the measurements in our hospital.

**Results**

In all patients, FT4 results were lower than measured by the Vitros. We found an age dependent, very variable difference (range 0.4–28.5 pmol/l) between methods. In neonates 2–5 days of age the difference was larger than in cord blood and decreased with age. The differences between patient results obtained with VISTA/Immulite and FT4/Vitros ECI were explained by variations from external quality control surveys. Neither could they be explained by variations in TBG concentration: TBG is not increased in young neonates. Illustrative is a difference of 14 pmol/l in FT4 results, found in an 8 days old, TBG deficient neonate.

**Conclusion**

Although an explanation of our observation is still missing, it is important for pediatricians to be aware of the fact that neonatal FT4 results can be very method dependent. In our hospital, this could potentially lead to overtreatment with T4. The phenomenon is largely unknown in our country.

**P416**

**N-terminal pro B type natriuretic peptide levels in thyroid dysfunctions**

Husniye Baser, Salih Baser, Nazli Gulsoy Kirnap, Murat Sakaci & Gul Gursoy

Department of Internal Medicine 3, Ankara Education and Research Hospital, Ankara, Turkey.

**Introduction**

Aminoterminal pro B type natriuretic peptide (NT-pro BNP) is the inactive degradation product of pro BNP. Thyroid diseases are known to have effect on NT-pro BNP levels. In this study, we aimed to determine possible changes in NT-pro BNP levels in patients with thyroid dysfunctions.

**Material and method**

Fifteen patients with hyperthyroidism, 8 with subclinical hyperthyroidism, 12 with hypothyroidism, 15 with subclinical hypothyroidism and 35 healthy controls were included in the study. The patients were evaluated for cardiac disease by physical examination, electrocardiography, and echocardiography. Those with systemic diseases were excluded from the study. Serum samples were taken for free triiodothyronine (FT3), free thyroxine (FT4), TSH, NT-pro BNP before and after achievement of euthyroidism in patients. Control subjects were tested for once.

**Results**

Baseline mean NT-pro BNP level of hyperthyroid group was significantly higher than the control group (101.8 ± 63.0 vs 41.40 ± 23.66 pg/ml, P < 0.001). In hyperthyroid, subclinical hypothyroid, subclinical hyperthyroid and control groups mean NT-pro BNP levels were similar. Mean NT-pro BNP significantly decreased after achievement of euthyroidism in hyperthyroid group (49.0 ± 20.0 pg/ml, P = 0.002). In hyperthyroid group, NT-pro BNP levels significantly increased after achievement of euthyroidism (52.75 ± 37.99 vs 79.00 ± 57.96, P = 0.015). There was no significant change in NT-pro BNP levels after treatment in subclinical hypothyroidism and hypothyroidism. Basal NT-pro BNP level was positively correlated with heart rate in hyperthyroid group (r: 0.569, P = 0.027) and it was negatively correlated with heart rate in hypothyroid group (r: −0.616, P = 0.033).

**Conclusion**

Studies to date suggest that thyroid hormone is one of the important factors that regulate serum NT-pro BNP level. In hyperthyroidism, NT-pro BNP levels reach the levels observed in severe heart failure. Thus, in patients without severe cardiac dysfunction, elevated NT-pro BNP level may be suggestive for hyperthyroidism.
The efficacy of real-time ultrasound elastography in evaluation of thyroid nodules

M Gietka-Czernel, M Kochman, K Bujalska, E Stachlewiska-Nasfeter

1Medical Centre of Postgraduate Medicine, Warsaw, Poland; 2Head and Neck Cancer Department, Institute of Oncology, Warsaw, Poland.

Introduction

Real-time elastography (RTE) is a noninvasive ultrasound method of estimation of tissue stiffness by measuring the degree of local tissue displacement after a small compression. Recent data has shown that it is able to differentiate benign and malignant tumors. The aim of the study was to evaluate the diagnostic accuracy of RTE in the diagnosis of malignant and benign thyroid nodules.

Methods

A total of 75 thyroid nodules in 54 patients: 44 females and 10 males aged 28–77 years were examined using conventional ultrasonography (US), fine-flow CD imaging and RTE. Thyroid US and RTE were performed by 3 examiners using a real-time Hitachi Hivision Preirus machine with linear transducer of 5–12 MHz. All nodules underwent fine-needle aspiration biopsy (FNAB) and patients with malignant and suspicious cytological results were referred to surgery. The final diagnosis was based on FNAB results in patients with benign cytology and on the histopathology reading in those who underwent surgery. The elasticity score (ES) from 1 to 5 was determined for each nodule according to Ueno classification.

Results

Elasticity score (ES) 4 or 5 was found in 19/22 (86.5%) thyroid cancers and in only 1/34 (3%) benign nodule. This was strongly indicative of malignancy (P<0.0001) with sensitivity 86%, specificity 97%, positive predictive value (PPV) 95% and negative predictive value (NPV) 91%. Among 9 suspicious nodules 3 appeared to be malignant (1 oxyphillic cell type carcinoma, 2 papillary carcinomas) and 6 were benign. All malignant nodules had ES 4 and benign ones had ES 2 or 3.

Conclusions

RTE is a highly sensitive and specific method of diagnosing thyroid nodules. This technique can be employed in selecting thyroid nodules for the fine-needle aspiration biopsy.

Analysis of T regulatory cells in young patients with dynamic of Graves’ disease and Hashimoto’s thyroiditis

A Bosowski, M Moniuszko, M Dabrowska, M Mrugacz, B Sawicka

1Medical University in Białystok, Białystok, Poland; 2Department of Allergology and Internal Medicine, Białystok, Poland; 3Department of Hematology Diagnostic, Białystok, Poland; 4Department of Pediatric Ophthalmology, Białystok, Poland; 5Division of Cardiology, Internal Affairs and Administration Ministry Hospital, Białystok, Poland.

Autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune disorder. Genetic background, environmental and endogenous factors are play important roles in determining the activation of immune cells or the efficacy of the immunoregulatory pathways. In recent years underlined the immunomodulatory role of T lymphocytes with expression of CD4+CD25+ (Tregs) in regulation mechanisms of peripheral immune tolerance. The aim of the study was to estimate the expression of CD4+CD25high, CD4+CD25+CD127low and CD4+FoxP3+ T cells in patients with Graves’ disease (GD) (n=20, mean age 16.3 years old), in patients with Hashimoto’s thyroiditis (HT) (n=20, mean age 15.8 years old) in comparison with sex- and age-matched healthy control subjects (n=20, mean age 15.9 years old). The expression of the immune cells populations were analyzed by the four-color flow cytometry using a FACSCalibur (BD Biosciences) cytometer.

In untreated patients with Graves’ disease and HT we observed a significant decrease of CD4+FoxP3 (P<0.001, P<0.01) and CD4+CD25high (P<0.01, P<0.048) T lymphocytes in comparison to the healthy control subjects. The analysis of CD4+CD25+CD127low T cells in the peripheral blood revealed comparable percentages of these cells in patients with thyroid autoimmune diseases to the controls. In untreated Graves’ patients negative correlation between percentage of CD4+CD25+ T cells and serum level of anti-TSH-R (P<0.017) antibodies was found, while no such correlation were detected in relation to CD4+CD25+CD127low or CD4+FoxP3 T cell.

We conclude that the defective function and the reduction number of Treg cells with expression of CD4+CD25high and CD4+FoxP3 could be responsible for loss immune tolerance and development of autoimmune process in thyroid disorders.
**P421**

**Effects of thyroxin on pituitary and plasma GH levels in thyroidectomized: diabetic rats**

Z Milicev1,2 & J Ciric1,2

1 Laboratory for Molecular Biology and Endocrinology, Institute for Nuclear Sciences Vinca, Belgrade, Serbia; 2 Clinic of Endocrinology, Diabetes and Metabolic Disease, Clinical Center, Belgrade, Serbia.

The effects of thyroid hormone deprivation and restitution on growth rate and pituitary and plasma GH levels have been studied in control and streptozotocin (STZ) – diabetic rats. GH was measured by a specific RIA using the NIAMDD rat-GH kit. Male Wistar rats which had been surgically thyroidectomized for 30 days and which had stopped growing were injected i.p. with either saline or STZ (4 mg/100 g b.wt). Eight days after saline or STZ, groups of thyroidectomized control (Thx-C) and thyroidectomized diabetic (Thx-D) rats were injected twice daily at 9 a.m. and 5 p.m. for 7 days with either saline or l-thyroxin (T4). 0.25, 0.5, or 1.0 μg/100 g b.wt/1m.

**Table 1**

<table>
<thead>
<tr>
<th>Data: mean ± s.e.</th>
<th>Δ b.wt g/7 days</th>
<th>Pituitary GH (μg/ml)</th>
<th>Plasma GH (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thx-D + saline</td>
<td>–2.0 ± 0.9</td>
<td>1.6 ± 0.8</td>
<td>5.3 ± 2.3</td>
</tr>
<tr>
<td>Thx-D + 0.5 μg T4</td>
<td>1.1 ± 0.8</td>
<td>2.0 ± 0.9</td>
<td>9.3 ± 2.5</td>
</tr>
<tr>
<td>Thx-D + 1 μg T4</td>
<td>2.3 ± 1.3</td>
<td>9.4 ± 4.5</td>
<td>10.5 ± 7.5</td>
</tr>
<tr>
<td>Thx-D + 2 μg T4</td>
<td>6.4 ± 2.5</td>
<td>23.5 ± 10.2</td>
<td>20.8 ± 13.9</td>
</tr>
<tr>
<td>Thx-C + saline</td>
<td>–1.3 ± 1.1</td>
<td>1.6 ± 1.3</td>
<td>7.2 ± 2.9</td>
</tr>
<tr>
<td>Thx-C + 0.5 μg T4</td>
<td>11.6 ± 3.2</td>
<td>30.8 ± 9.3</td>
<td>38.4 ± 10.5</td>
</tr>
<tr>
<td>Thx-C + 1 μg T4</td>
<td>17.9 ± 4.3</td>
<td>50.8 ± 19.2</td>
<td>46.8 ± 17.5</td>
</tr>
<tr>
<td>Thx-C + 2 μg T4</td>
<td>21.3 ± 5.6</td>
<td>60.4 ± 14.9</td>
<td>41.4 ± 14.1</td>
</tr>
</tbody>
</table>

Present data show that when thyroid hormones are replaced in intensely hyperplastic control and diabetic rats both the pituitary GH concentration and the circulating GH levels increase. However, our data show that for comparable doses, T4 is less efficient on restoring the pituitary and plasma GH levels in the Thx-D than in Thx-C. Thus, it appears that normal insulin levels are required for biological action of thyroid hormones, at least on pituitary GH synthesis.

**P422**

**The incidence of thyroid nodules in autoimmune thyroiditis in one endemic area**

Mihaela Stanciu, Florina Popa, Alina Pascu & Ioan Gheorghe Totolian

Clinical County Hospital, University Lucian Blaga, Sibiu, Romania.

Introduction

The coexistence of thyroid nodules and autoimmune thyroid disease (ATD) has been widely reported. The aim of our study was to retrospectively evaluate the coexistence of thyroid nodules and autoimmune thyroid disease (ATD) in University County Hospital in last 2 years (2008–2010). We recorded clinical, ultrasonographic, histopathological and laboratory features of these patients.

Material and methods

We retrospectively analysed data from 600 patients (25–79 years) with autoimmune thyroiditis in University County Hospital in last 2 years (2008–2010). We recorded clinical, ultrasonographic, histopathological and laboratory features of these patients.

Results

The frequency of thyroid nodules was statistically significantly higher at women (95%) than in men (5%), with a maximum for the group with age between 40 and 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%). Our study show a incidence of nodules about 39.47% from total patients. The ultrasonographyc thyroid volume was higher than normal value in 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%) than in men (5%), with a maximum for the group with age between 40 and 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%). Our study show a incidence of nodules about 39.47% from total patients. The ultrasonographyc thyroid volume was higher than normal value in 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%) than in men (5%), with a maximum for the group with age between 40 and 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%) than in men (5%), with a maximum for the group with age between 40 and 60 years. The incidence of thyroid nodules was higher at patients from urban residence (61.9%) than in men (5%), with a maximum for the group with age between 40 and 60 years.

Conclusions

The incidence of thyroid nodules in patients with ATD was high. So, in Sibiu county is important to evaluate completely the nodular goite, based on the fact this area is known as one with mild iodine deficiency.

**P423**

**The regulatory role of neuroprotective nerve growth factor in Graves’ ophthalmopathy**

Ikiko Molnar1 & Agota Bokk 2

1 EndoMed, Debrecen, Hungary; 2 Genzyme Europe BV, Budapest, Hungary.

Nerve growth factor (NGF) belongs to the neurotrophic family and maintains the normal function of peripheral sympathetic and sensory neurons. NGF can synthesize locally in the neuronal and nonneuronal tissues. The main cell sources of NGF restrict to bone-marrow derived cells (lymphocytes, mast cells, eosinophils, monocytes, macrophages) as well as to structural cells (fibroblasts, epithelial cells, smooth muscle cells, adipocytes, keratinocytes). The sympathoadrenal activity initiated NGF-liberation is linked to the hormone-releases from the anterior pituitary. NGF plays a potent role in the highly sympathetic innervated organs such as in glands, adipose tissues and orbits, where it participates in the development of retina, corneal and conjunctival epithelium, lens, iris, ciliary bodies and optic nerves. NGF can induce a local inflammation with the liberation of cytokines, chemokines, active peptides and influence the cell survival and apoptosis processes via its two classes of receptors, tyrosine kinase A and p75. Maintaining the integrity of the sympathetic innervation, NGF contributes to tissue reparative responses.

Graves’ ophthalmopathy represents a complexity of endocrine, autoimmune and inflammatory events with an increased sympathoadrenal activity. We investigated the serum NGF levels in the patients with Graves’ disease (n=95). Hashimoto’s thyroiditis (n=19), toxic nodular goitre (n=17) and controls (n=20). Our findings demonstrated elevated NGF levels in Graves’ hyperthyroidism in comparison with Graves’ euthyroidism (1831.29 ± 39.32 vs 1649.33 ± 75.63 pg/ml, P<0.023). The presence of TSH receptor autoantibodies (P<0.009) and the levels of FT3, (P<0.01) gave a strict association with the elevation of NGF. Surprising, hyperthyroid Graves’ patients with ophthalmopathy showed lower NGF levels than those who had no eye symptoms (1910.47 ± 55.62 vs 1744.65 ± 51.98 pg/ml, P<0.036).

The results support, that the lower serum NGF due to a failed neuroprotectiveactivity may contribute to the onset of ophthalmopathy.
P425
Changes in urinary iodine status following 10-year voluntary salt iodization in Latvia
I Konrade1,2, M Makreca2, M Dambrova2, L Neimane1, I Strele1,
U Gruntmanis2, A Lejnieks1,2 & V Piragš1
1Riga Stradins University, Riga, Latvia; 2Latvian Institute of Organic
Synthesis, Riga, Latvia; 3Southwestern Medical Center, University of
Texas, Dallas, Texas, USA; 4Faculty of Medicine, University of Latvia,
Riga, Latvia; 5Riga East Clinical Hospital, Riga, Latvia.

Background
Previous nation-wide survey on iodine deficiency disorders (IDD) in Latvia
showed a mild iodine deficiency in 587 schoolchildren (median UI – 59 µg/l).
At the time less than 1% of all edible salt was iodized. Despite of the results of
National IDD Elimination Committee study, all preventive measures were limited
to production of leaflets promoting voluntary iodine salt consumption and
convincing industry to use iodized salt. In order to perform a 10-year follow-up
study we performed a survey with similar design in the same regions of Latvia.

Study design and methods
We conducted a cross-sectional school-based 20-cluster survey of children aged
9–12 in randomly selected 24 schools in all regions of Latvia. In total 508 samples
of urine and questionnaires on diet, consumption of iodized salt were collected.
UIE was measured by ammonium persulphate method.

Results
Self-reported prevalence of regular iodized salt consumption was 52.5%.
The median creatinine-standardized UI concentration in Latvian schoolchildren
was 129.7 (IQR 90.76) µg/l. Frequency distribution of UI values showed that
68.5% (95% CI: 64.3–72.4) of samples had normal levels (≥ 100 µg/l) of iodine
in urine, while 27.8% (95% CI: 24.0–31.8) of schoolchildren had mild
(50–99 µg/l), 3.3% (95% CI: 2.1–5.3) moderate (20–49 µg/l) and 0.4% severe
(<20 µg/l) decrease in urinary iodine concentrations. Socioeconomic status
of parents or self-reported iodized salt consumption was not associated with iodine
status.

Conclusion
Ten-year follow-up indicated an impressive increase in self-reported prevalence
of regular iodized salt consumption and urinary iodine excretion among
schoolchildren. It shows that iodine deficiency could be effectively eliminated
even without Universal Salt Iodization programme in the same regions of Latvia.

P426
Triiodothyronine stimulates cystatin C production and glucose transport in bone cells
Ch Schmid, C Ghirlanda & C Zwimpfer
University Hospital of Zurich, Zurich, Switzerland.

Background
Thyroid hormones increase both serum levels of cystatin C and renal glomerular
filtration rate (reflected by lower serum creatinine); the latter is considered
the main determinant of cystatin C levels. A potential explanation for this apparently
discrepant finding is an increased production, rather than a decreased clearance,
of cystatin C. To study the principle of ultrasound- elastography - that compression of
the examined tissue induces a smaller strain in hard tissues than in
soft ones. Until now elastography has been applied to study the hardness and
elasticity of thyroid nodules, aiming to differentiate malignant from benign ones.

Methods
We decided to study if ultrasound elastography by Acoustic Radiation Force
Impulse (ARFI) can offer information about the stiffness of thyroid gland
parenchyma in patients with chronic thyroid pathology, Graves’ disease
and chronic autoimmune thyroiditis (CAT).

Results
We studied 51 patients, 29 with Graves’ disease and 22 with CAT (diagnosed
by specific tests), and 23 healthy volunteers. For all subjects, 10 elastography
determinations were performed in the right thyroid lobe (RTL) and 10 in the left
thyroid lobe (LTL). The measurements were performed with a Siemens Acuson
S2000 ultrasound system, using a convex probe 2–6 MHZ. The values were
expressed in meters/second (m/s) and the median was calculated. We calculated a
mean value between ARFI from RTL and LTL. The t-test was used to compare the
ARFI values.

Conclusion
We found a statistically significant difference between subjects without thyroid
pathology (healthy volunteers) and those with autoimmune thyroid diseases
(2.07 ± 0.44 vs 2.68 ± 0.50 m/s) (P<0.001). Thyroid stiffness was statistically
significant higher in patients with Graves’ disease versus those with CAT (2.82
±0.47 vs 2.49±0.48 m/s) (P=0.02). In cases with CAT, we obtained a
significant difference between ARFI values in the two thyroid lobes.
Explanations for this difference could be the distribution of fibrosis in the thyroid
gland and the differences regarding vascularization and thyroid volume.

P427
Acoustic radiation force impulse elastography (ARFI) in patients with autoimmune
thyroid disease
M Vladi1, I Zosin1, M Babals1, I Sporea2, S Bota1, A Popescu2, A Popa1 & S Radu1
1Clinic of Endocrinology, ‘Victor Babeș’ University of Medicine and
Pharmacy, Timisoara, Romania; 2Department of Gastroenterology
and Hepatology, ‘Victor Babeș’ University of Medicine and Pharmacy,
Timisoara, Romania.

Introduction
Elastography is a new dynamic technique that uses ultrasonography for the
assessment of tissue stiffness. The principle of ultrasound-elastography -
that compression of the examined tissue induces a smaller strain in hard tissues than in
soft ones. Until now elastography has been applied to study the hardness and
elasticity of thyroid gland parenchyma in patients with chronic thyroid pathology, Graves’ disease
and chronic autoimmune thyroiditis (CAT).

Methods
We studied 51 patients, 29 with Graves’ disease and 22 with CAT (diagnosed
by specific tests), and 23 healthy volunteers. For all subjects, 10 elastography
determinations were performed in the right thyroid lobe (RTL) and 10 in the left
thyroid lobe (LTL). The measurements were performed with a Siemens Acuson
S2000 ultrasound system, using a convex probe 2–6 MHZ. The values were
expressed in meters/second (m/s) and the median was calculated. We calculated a
mean value between ARFI from RTL and LTL. The t-test was used to compare the
ARFI values.

Results
We found a statistically significant difference between subjects without thyroid
pathology (healthy volunteers) and those with autoimmune thyroid diseases
(2.07 ± 0.44 vs 2.68 ± 0.50 m/s) (P<0.001). Thyroid stiffness was statistically
significant higher in patients with Graves’ disease versus those with CAT (2.82
±0.47 vs 2.49±0.48 m/s) (P=0.02). In cases with CAT, we obtained a
significant difference between ARFI values in the two thyroid lobes.
Explanations for this difference could be the distribution of fibrosis in the thyroid
gland and the differences regarding vascularization and thyroid volume.

Conclusion
ARFI seems to be a useful method to predict accurately enough the presence of
autoimmune thyroid diseases (AUCROC = 0.80).
Results
PI-PCNA was higher in thyroid nodules than in normal surrounding thyroid tissue, with statistically significant values for FA (14.3 vs 3.8%; P < 0.029) and for AN (8.3 vs 1.24%; P = 0.001). Mean PI-Ki67 in nodules versus surrounding tissue was 1.64 vs 1.10% in FA (P < 0.35) and 1.07 vs 0.51% in AN (P < 0.05). We also noted: (1) significantly higher PI-PCNA values (P < 0.01) in FA (14.03%) than in AN (8.36%), as compared to statistically insignificant values for Ki-67 (1.64 vs 1.07%; P = 0.05); (2) increased proliferation rate (P < 0.01) in thyroid nodules with aspects of lymphocytic thyroiditis (LT). PI-Ki67 was 1.21% as compared to nodules without LT (PI-Ki67 was 0.12%); (3) a mean PI-PCNA of 8.5% and PI-Ki-67 of 4.61% in toxic thyroid nodules (TTN) versus 3.01% and 1.5% in normal surrounding thyroid, respectively.

Conclusions
The clinical expression of SCN is the consequence of increased thyrocyte proliferation in the nodules; the increased proliferative potential of TTN thyrocytes is a common feature of nodules, independent of their histopathological characteristics.

P429
The effect of age on thyroid function and diagnostic significance of TRH test in elderly people
S P P Popovic-Pjejcic1 & A P Pejicic2
1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center, Banja Luka, Bosnia and Herzegovina; 2Medical Faculty, University of Vienna, Vienna, Austria.

The effect of age on thyroid function and hypothalamic–pituitary–thyroid axis have been studied. The objective of the study was to examine: correlation between triiodothyronine (T3) and thyroxine (T4) hormone levels, thyroid antibodies and thyroglobulin levels and old age; capability of TSH and prolactin (PRL) response to TRH, in TRH test depending on age and gender of the examinees. We have tested 125 subjects, classified in 4 group. First, control group comprised of 42 health adults aged 20–40 years, 22 females and 20 males. The next three groups comprised of 83 healthy elderly persons, aged 40-70 years, 34 males and 49 females. All the patients had total T3 and T4, free T3 and T4, thyroid antibodies and thyroglobulin, TSH and PRL basal and after TRH stimulation determined. The results showed that with ageing, there was significant decrease of total and free T4 values and slightly lesser intensity of T3 in the male group, while in the female group, it was noted a mild increase of the total hormones values, but within the normal euthyroid values with no changes in free hormone values. A significant fall of thyroglobulin antibodies with ageing was observed in the group of males and a considerable increase of thyroglobulin was shown in the group of females. Basal values of TSH and PRL remained within their normal values with ageing in both groups of examinees. Diminished sensibility in TSH response to the negative recurrent relation with the thyroid hormones, i.e. certain resistance of adenohypophysis to thyroid hormones was noted with ageing. TSH and PRL response in TRH test was diminished with ageing in the female group of examinees. It may be concluded that, despite of euthyroid status, TSH and PRL response has been changed in elderly examinees, more in women than men. The results also show difficulties in evaluating thyroid gland function in elderly examinees and TRH test limitations as diagnostic tool. In interpreting of the result of thyroid gland function tests, it is certainly necessary to take into consideration the age and gender of examinee. There is a need for a review of our strategy in thyroid gland function testing in elderly population.

P430
Improved prognosis in myxedema coma: happy ending of an old story: case report

Introduction
Myxedema coma (MC) is a rare life-threatening form of hypothyroidism most often seen in patients with incompletely treated or unknown hypothyroidism exposed to stressful conditions (surgery, infections, hyperthermia, trauma).

Case report
We report the case of a 58-years-old woman hospitalized for coma in a peripheral hospital after a severe respiratory infection. Two days after, patient’s condition was worsening and she was transferred to a University Hospital, where myxedema coma was suspected (history of untreated autoimmune hypothyroidism, apparently normal temperature – 36 °C despite the infection, bradycardia, hypotension, hyperventilation, hypopresoria, generalized edema). Biological findings showed respiratory acidosis without hypotenraemia or other abnormalities. Very low FT4 (<1 pmol/l) with high TSH (32 μIU/ml) confirmed MC. Intensive therapy (fluid replacement, dopamine, orotracheal intubation with oxygenotherapy) and hormonal therapy: 400 μg thyroxine by nasogastric tube, concurrent with hydrocortisone (HIC) 100 mg/6 h, improved patient’s status. Coma became superficial and 4 days after, having spontaneous respiration, normal gasometria and hemodynamic data, she was transferred in the Department of Endocrinology. Treatment included oral l-thyroxine (100 μg/day), HIC, antibiotics. Edematous syndrome and cognitive function improved, although some confusional features persisted (Hashimoto’s encephalopathy).

Discussion
Owing to the rarity of myxedema coma there are very few studies evaluating the efficacy of treatment and the evolution. Knowing its severe prognosis, it is important to promptly treat the patients with myxedema coma, even when the diagnostic is not certain. Nowadays the mortality rate decreased from 80% to 20-40% thanks to improved diagnostic testing, advances in intensive care, and increased awareness of physicians. Our happy ending story illustrates this improvement.

P431
The immunohistochemical demonstration of parafollicular cells and evaluation of calcium-phosphate balance in patients with thyroid hemiagenesis
Ewelina Szczepanek1, Marek Ruchala1, Patrycja Sujka-Kordowska2, Maciej Zabel1, Maciej Biczysko1 & Jerzy Sowinski1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland; 2Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland; 3Department of General, Gastroenterological and Endocrine Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Introduction
Thyroid hemiagenesis (TH) is characterised by congenital absence of one thyroid lobe. Aim
To assess possible association between TH and concomitant alterations of other structures derived from pharyngeal apparatus, which might potentially impact calcium-phosphate balance. Materials and methods
Studied group: 20 patients with TH. Control group: 20 subjects with bilobed thyroid, matched for age and gender. Serum concentrations of total calcium, parathormon and calcitonin were measured. Additionally, an immunohistochemical expression of calcitonin, chromogranin A (chA), somatostatin, neuron-specific enolase (NSE) and calcitonin gene-related peptide (CGRP) was evaluated in surgical specimens from patients with TH and subjects with normal thyroid. Results
There were no significant differences between concentrations of total calcium, parathormon and calcitonin between patients with TH and subjects with bilobed thyroid (total calcium: 9.62 ± 0.8 mg/dl in TH vs 9.88 ± 0.6 mg/dl in controls, P = 0.331; parathormon: 40.99 ± 16.8 pg/ml in TH vs 42.96 ± 14.4 pg/ml in controls, P = 0.978; calcitonin: 6.84 ± 3.8 pg/ml in TH vs 8.54 ± 6.3 pg/ml in controls, P = 0.408). Positive staining for calcitonin was demonstrated in 3/8 (37.5%) of thyroid sections from patients with TH, while only in 2/3 (6.06%) of sections from control patients (P < 0.005). All sections from patients with TH positive for calcitonin, also expressed chA, NSE and CGRP. Two sections from control subjects, positive for calcitonin, presented additionally positive reaction for chA and one of them also for NSE. None of them however, presented positive staining for CGRP and somatostatin. Out of three TH sections, in one hyperplasia of parafollicular cells of medium grade and of high grade in another one could be detected, in comparison to control sections, where hyperplasia of C-cells of low and medium grade was observed.

Conclusions
The study provides first immunohistochemical demonstration of the presence of parafollicular cells in subjects with TH. TH was associated with slightly enhanced C-cells hyperplasia in comparison to control specimens, what might indicate compensative proliferation of parafollicular cells. However, calcium-phosphate balance seems not significantly affected.
The influence of radioiodine therapy on ophthalmologic symptoms and their relation to urine cotinine level in patients with Graves’ disease

P432

The aim of the study is to present cases of patients with toxic nodular goitre who developed autoimmune hyperthyroidism after initial 131I dose, and results of treatment with second 131I dose or thyrostatics. Four patients with toxic nodular goitre received therapeutic dose of 131I. Thyroid function was assessed by measuring FT3, FT4, TSH, TSHRAb levels. Male aged 44 received 131I treatment (after 6 months) again due to hyperthyroidism. TSHRAb was increased to 3.3 U/l. Three months after administering second 131I dose, hypothyroidism was diagnosed (TSH 46.74 mIU/l) and substitute treatment was added. Female aged 40 (TSHRAb <0.3 U/l before 131I) euthyroidism after 3 months of 131I therapy; recurrence of hyperthyroidism and an increase in TSHRAb to 5.8 U/l after another 3 months. After administering thyrostatics for 6 months, euthyroidism was achieved. TSHRAb decreased to 0.9 U/l. Female aged 57 (TSHRAb <0.3 U/l before 131I); increase in FT3, FT4 and TSHRAb to 5.8 U/l after 3 months of 131I therapy. After administering thyrostatics for 3 months, euthyroidism was achieved. TSHRAb decreased to <0.03 U/l. Female aged 53 (TSHRAb < 0.3 U/l); after 3 months of 131I therapy, thyroid function tended to be normal (TSH=0.34 mIU/l); after 6 months there was recurrence of hyperthyroidism with increase of TSHRAb to 1.9 and 4.0 U/l after another 3 months. When patient was treated with thyrostatics, her thyroid function tended to be normal. Conclusion Although insignificant number of patients makes it impossible to analyse results of treatment of autoimmune hyperthyroidism (second 131I dose versus thyrostatics), it seems that treating patients with thyrostatics before administering possible second dose of radioiodine is justified.

Autoimmune hyperthyroidism triggered by 131I treatment for toxic nodular goitre: treatment with a second dose of 131I versus thyrostatics

P434

The transformation of toxic nodular goitre into autoimmune hyperthyroidism with development of thyrotopin receptor antibodies (TSHRAb) as effect of 131I therapy is rarely investigated. The aim of the study is to present cases of patients with toxic nodular goitre who developed autoimmune hyperthyroidism after initial 131I dose, and results of treatment with second 131I dose or thyrostatics.

All the patients were examined for the presence of anti-TSH receptor by RIA (Cisbio) and the cut off for positivity was >1.0 U/ml. As control we took a group of normal subject and with Hashimoto hypothyroidism. Results With a cut off point of TRAb ≥ 1 U/l the TRAb antibodies were positive in 90.7% of patients with Graves’ disease before treatment with an average level 8.89 U/l ± 13.71 s.d. with a range 1.1–105. In those without Graves’ disease, TRAb were positive in 1.6% one patient with autoimmune thyroiditis and undetectable in euthyroid and multinodular toxic goiter and normal controls. Conclusion In this study, we conclude that TRAb assay is of great interest in confirming the diagnosis. Using these assays in clinical routine is helpful in the differential diagnosis of hyperthyroidism, since the presence of antibodies confirms GD, while their absence indicates a non autoimmune origin of hyperthyroidism.
Aim
The aim of this study was to define the diagnostic cut-off point of TRAb at which we could indentify patients with active GO.

Methods
We studied 124 females and 46 males with GD who were on treatment with antithyroid drugs and were euthyroid for at least 3 months. Disease duration varied from 6 to 72 months. According to the Clinical Activity Score (CAS); 50 patients had active and 120 non-active GO. Serum FT3, FT4 (AxSYM Abbott), TSH (electrochemiluminescence (ECL) method on Elecsys 2010 Roche), TRAb (DYNONEst TRAb Human kit Brahms Ria kit), anti-TPO and anti-Tg (ECL Elecsys 2010 Roche) were measured in all patients.

Results
Patients with active GO had significantly higher TRAb levels compared to patients with non-active GO (P<0.001) while no difference was found for anti-TPO and anti-Tg levels. Area under the sensitivity (true positives) versus 1-specificity (false positives) curve for TRAb±±,SEM was 0.85±±0.032 and the corresponding 95% confidence interval ranged from 0.79 to 0.91 indicating that TRAb is a useful marker in GO activity assessment. TRAb values higher than 4.7 IU/l (sensitivity 74%, specificity 74.2% and efficiency 74%) can discriminate patients with active GO.

Conclusion
In patients with GO, a TRAb cut-off value of 4.7 IU/l could be applied for anti-inflammatory treatment decisions during the course of the disease.

P436
Postpartum follow-up of women positively screened for thyroid disease in pregnancy: the necessity of a better care
E Potlikova1, J Jiskra1, Z Telicka1, J Bartakova1, D Springer2 & Z Limanova1
1Third Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 2Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic.

Introduction
The utility of screening for antibodies against thyroperoxidase (TPOAb) in early pregnancy remains controversial. The aim of our retrospective follow-up study was to examine the thyroid function of initially euthyroid TPOAb+ women at a longer period after delivery.

Methods
We invited 822 women screened positive for thyroid disorders in the first trimester of pregnancy (9th–12th gestational week) for follow-up. This included measurement of TSH, free thyroxine (FT4), TPOAb and filling of a detailed questionnaire regarding family and personal history.

Results
One hundred eighty-nine (23%) of invited women joined the study. Of these, 100 were TPOAb+ and initially euthyroid in pregnancy. Only 49% of all TPOAb+ women had a positive family history for thyroid disorders. Median time between delivery and follow-up reached 22 months. At follow-up, 13% of the initially euthyroid TPOAb+ women had TSH below 0.3 mU/l, 15% had TSH between 4 and 10 mU/l, and 8% had TSH above 10 mU/l. Serum levels of TPOAb in pregnancy were not linked to the development of thyroid dysfunction. Thirty-five percent of those women who were never treated for thyroid disorders developed thyroid dysfunction at the follow-up. Surprisingly, 29% of women who were currently treated for thyroid disease had TSH outside of the normal range at the time of follow-up.

Conclusion
Thirty-six percent of TPOAb+ women euthyroid in early pregnancy have TSH outside of the normal range at 22 months after delivery. The follow-up and treatment of these women is insufficient. TPOAb+ women after delivery should be closely monitored even if they are euthyroid during pregnancy.

Supported by the Grant of The Czech Health Ministry IGA 10662-3.

P437
CTLA4 exon1 A49G polymorphism in Slovak patients with rheumatoid arthritis and autoimmune thyroid disease
Ivica Lazurova, Karol Benhatchi, Ivana Jochanovová & Viera Habalová
Medical Faculty, University Košice, Košice, Slovakia.

Autoimmune thyroid diseases (AITD), such as Hashimoto’s thyroiditis (HT) and Grave’s disease (GD) frequently form overlap syndromes with rheumatoid arthritis (RA). Among genetic factors, the role of the HLA antigens and CTLA4 gene polymorphisms in the formation of such overlap syndromes has been suggested.

Objective
Aim of this study was to investigate the allel and genotypes frequency of the CTLA4 exon1 A49G polymorphism in Slovak patients with RA, HT and both (RA±±HT) and to compare it with healthy controls.

Subjects and methods
Homogeneous groups of 57 unrelated adults with RA, 57 patients with HT, 34 patients with both RA and HT, and 51 randomly selected normal adults without any history of autoimmune disease were studied. All of them were ethnic Slovak living in the same geographical area. The CTLA4 exon1 A49G polymorphism was genotyped by using small amplicon melting analysis after real-time PCR.

Results
The CTLA4 A49G genotype and G allele frequency in the group with RA was not significantly higher in comparison with controls (10.53 vs 9.8%, OR 1.39, P=0.62 for GG genotype, 39.47 vs 34.31% OR 1.25 for G allele). The frequency of GG genotype was slightly but not significantly higher in patients with HT as compared with control group (19.3 vs 9.8%, OR 2.27, P=0.17). However the frequency of GG genotype and G allele in patients with the coexistence of RA and HT was significantly higher than that in control group (29.41 vs 9.8%, OR 4.49, P=0.02 for GG genotype, 51.47 vs 34.31%, OR 2.02 for G allele, P=0.03).

Conclusion
Our results show that patients with RA who are carriers of GG genotype of CTLA-4 A49G gene polymorphism may be susceptible to develop HT.

P438
An unusual organ involvement in Werner syndrome: thyroid atrophy
Mustafa Altay, Mehmet Colbay, Fusun Balois Toruner, Mujde Akturk, Erkam Sancar, Nuri Cakir & Metin Arslan
Gazi University Medical Faculty, Ankara, Turkey.

Introduction
Werner syndrome (WS) is an autosomal recessive disease characterized by premature aging, skin changes, gray hair, alopecia, muscle atrophy, osteoporosis, and cataracts and has a high frequency of association with rare neoplasms. In addition, some endocrinological abnormalities were manifested in this rare disease, such as hypogonadism, diabetes mellitus, hyperlipidemia. Atrophic changes of organs and systems such as skin, brain and genital organs were reported. However, as our knowledge, thyroid atrophy has not been reported in literature, yet. Here, we present a case with thyroid atrophy in WS.

Case
Nineteen-year-old female patient had been diagnosed with WS for 2 years. She had type 2 diabetes mellitus, osteopenia, hyperlipidemia, cataract, gray hair, and skin atrophy. She had been treated with insulin aspart and glargine, metformin, gemfibrozil, calcium and vitamin D. At the time of routine outpatient clinic control, her glucose was unregulated and she was hospitalized for regulation of the blood glucose. Her laboratory tests were as follows: glucose 245 mg/dl, Hba1c 7.9%, TSH: 2.3 μIU/ml (0.6–4.8), FT3 3 pg/ml (2.3–4.2), FT4 0.71 ng/dl (0.74–1.52), anti-T 50.7 (0–64) U/ml, anti-TPO 33.7 U/ml (0–57), TG 73 (16–200) mg/dl. Thereafter, thyroid ultrasonography was performed and bilateral parenchymal heterogeneity and very low thyroid volume were detected (right lobe dimensions were 19×10×8 mm, volume was 1 cm3 and left lobe dimensions were 19×10×7 mm, volume was 0.6 cm3). FNA biopsy of both lobes was performed. Decreased follicular epithelium cells were detected in specimens and there was not any thyroiditis signs. Because of having no symptoms and signs of hypothyroidism she was followed up without treatment.

Conclusion
In conclusion, we suggest that thyroid tests and ultrasonography should be performed in all patients with WS.

P439
Thyroid pathology in patients with type 1 diabetes mellitus
J Idrizcanu, M Graur, C Preda, I Vasiliiu, R Balcan, M C Ungureanu, C Cristea & C Vulpoi
University of Medicine and Pharmacy ‘Gr. T. Popa’, Iasi, Romania.

Introduction
The association of type 1 diabetes mellitus (DM1) with thyroid diseases is well known, especially in the field of polyglandular autoimmune diseases. Thyroid
status can influence the necessity of insulin – decreased in hypothyroidism and higher in hyperthyroidism. We wanted to evaluate the prevalence of thyroid pathology in patients with DM1.

Patients and methods
Cross-sectional study including 66 patients with DM1 (23 men, 43 women) aged between 20 and 65 years and 50 healthy volunteers age and sex matched (group B), evaluated biologically (TSH, fT4, anti-thyroidperoxidase antibody – TPO) and morphologically (thyroid ultrasonography).

Results
Autoimmune thyroiditis (AIT) was significantly more frequent in DM1 group (56 vs 16%, P = 0.006), as well as thyroid hypoechogenicity (48.5 vs 26%, P = 0.017). We found a good correlation between thyroid hypoechogenicity and autoimmunity (r² = 0.417, P = 0.006). Hypothyroidism was confirmed in 12 cases (18.2%; 9 overt and 3 subclinical), more frequent in those with AIT (27 vs 6.9%, P = 0.001), and in only 3 cases (6%) in control group. None of our subjects had hyperthyroidism.

Discussion
Thyroid autoimmunity and dysfunctions are more frequent in DM1 patients than in general population. Hypothyroidism is associated with diminished insulin necessity, with higher requirement once TSH normalised, which impose rigorous glycaemic control. Owing to the good correlation between thyroid hypoechogenicity and TPO levels, thyroid us may be a useful tool in assessment thyroid status.

Conclusion
Screening of thyroid diseases should be systematic in DM1 patients in order to detect unknown thyroid dysfunctions.

P440
Goiter and epidemiology of autoimmune thyroiditis
I Kostoglou-Athanassiou, A Michou, S Tagara, A Chroniou, A Liakopoulou, E Xanthakou, T Terzi & A Karfi
Department of Endocrinology, Red Cross Hospital, Athens, Greece.

Thyroid disease epidemiology has changed recently. This change may be related to the iodine sufficiency currently in Athens, and differences in iodine intake in Greece. The progression of multinodular goiter to hyperthyroidism was frequently observed. Nowadays, the development of autoimmune thyroiditis is frequently observed in patients with simple or nodular goiter. This development may be related to the proinflammatory action of iodine, iodine being nowadays adequate in the environment.

The aim was the long term follow up of patients with simple or micronodular goiter in the area of Athens. We studied 87 patients, 80 female and 7 male, aged 40–70 years, with simple goiter, micronodular goiter or nodular goiter. All of them had undetectable antithyroid antibodies at presentation. We followed up these patients for 5–8 years. During follow up 24 patients developed detectable antithyroid antibodies, in 2 of them only antithyroglobulin antibodies being detected. In 18 of them a progressive increase of the antibodies was observed. 1 patient female developing hypothyroidism due to autoimmune thyroiditis. Within the group of the patients with detectable antithyroid antibodies 5 had a positive family history for autoimmune thyroid disease. During long term follow up patients with goiter appear to develop antithyroid antibodies, progression to autoimmune hypothyroidism being however infrequent. This development may be related to the iodine sufficiency currently observed in modern Greece, particularly in the area of Athens.

P441
Thyroid-associated ophthalmopathy (TAO) in association with another disorders
Cristina Corina Pop Radu1,2, Jozsef Balazs1, Camelia Gliga1,2, Anisie Nasalean1, Ionela Pacsanu1,2 & Imre Kun1,2
1Department of Endocrinology, County Clinical Hospital, Targu Mures, Mures, Romania; 2University of Medicine and Pharmacy, Targu Mures, Mures, Romania.

Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune process that is strongly associated with thyroid dysfunction. Patients with TAO may present eyelid retraction, proptosis, chemosis, peri orbital oedema and altered ocular motility with significant functional and cosmetic consequences. There is the possibility of coexistence of two or more autoimmune diseases affecting the eye due to the cross-reactivity to common antigens from the eye muscles.

The aim of this study was to evaluate association of TAO with other autoimmune and non-autoimmune diseases and reveal some problems in differential diagnosis of TAO. This study was retrospective and performed on patients diagnosed with TAO in Endocrinology Clinic from Tg-Mures, Romania (January 2000–December 2010). We found 238 patients with TAO with ages between 14 and 75 years, with a peak for women at 40–49 years and 50–59 years for men. Female/male ratio was 4.4/1. 83.19% (meaning 198 patients) were found with hyperthyroidism, 10.09% (24 patients) presented hypothyroidism and 6.72% (16 patients) presented euthyroidism. One hundred and seventy-two patients presented asymptomatic exophthalmos and 56 of them – symmetric. One hundred and fifty-eight patients (66.4%) presented associated pathology. We found TAO associated with: multiple sclerosis (2 cases), rheumatoid arthritis (2 cases), psoriasis (2 cases), Marine-Lenhart Syndrome (4 cases), glaucoma (3 cases), ovarian cysts (2 cases), premature ovarian failure (2 cases), systemic lupus erythematosus (4 cases), mastiata gravis (3 cases), vitiligo (6 cases), breast tumor (4 cases), obesity (7 cases), chronic hepatitis (7 cases), diabetes mellitus (8 cases), dysthyrnia (18 cases), anaemia (34 cases), hypertension (36 cases).

We also found TAO after Amiodarone treatment (6 cases), TAO during early pregnancy (8 cases). Patients with TAO might have higher risk of developing another diseases, especially autoimmune diseases and this possibility may be due to immunological cross-reactivity against common autoimmune targets, as well as to a common genetic background.

P442
Evaluation of thyroid function test remission and relapse after low dose anti-thyroid drug therapy of Graves’ disease, interim report of a long term retrospective study
H R Razafshan1,2, M Steinmaier1, F Fitz1, A R Maleki1,2, I Wolf1, C Reichl1, M Beheshti1 & W Langsteiger1
1Department of Nuclear Medicine and Endocrinology, PET-CT Center Linz, St Vincent’s Hospital, Linz, Austria; 2Department of Endocrinology, Goleston University of Medical Sciences, Gorgan, Islamic Republic of Iran.

Introduction
Optimal anti-thyroid regimen for management of Graves’ disease is still a matter of controversy. The aim of this study is determination of remission rate and long-term relapse rate after low-dose anti-thyroid drug therapy.

Method
This study is a long-term retrospective study. We selected 100 patients with the diagnosis of Graves’ disease that admitted to our endocrinology clinic from January 2000 until December 2010. All of patients were treated with anti-thyroid drugs at the initial dose of 20 mg/day of Methimazole then, doses were gradually decreased or changed 25 mg/day and discontinued when the patients were able to maintain euthyroid (normal fT4 fT3 and TSH). We recorded fT4, fT3, TSH measurements before starting drugs and then at 1, 2, 3, 6, 9, 12 months and 1, 2 and 5 years after starting of treatment to evaluate the remission and relapse rates.

Results
From all 100 Graves’ patients 85% were female and mean age was 53.5 years. 79% had diffuse goiter Graves’ disease and 21% had additional thyroid nodule.

Percentage of patients with normal TSH was 20, 26.4, 51.6, 51.8, 65.4, and 81.3% after 3 months, 6 months, 1 year, 2 years, 5 years and 10 years respectively. Percentage of patients with normal free T4 was 79, 82.8, 88.9, 89.7, 90 and 98.2% after mentioned time intervals respectively. Also 72.1, 84, 90.1, 82.8, 88.5, 93.1% of patients have normal free T3 after mentioned time intervals respectively. We had 60.6 and 94.4% of complete remission after 1 and 2 years anti-thyroid drug therapy.

Conclusion
Our study shows the effectiveness of low-dose anti-thyroid drug therapy in patients with Graves’ disease. So regarding lower side effects, we recommend low-dose anti-thyroid regimen for initial treatment of Graves’ hyperthyroidism.
Long-term follow-up of thyroid autoimmunity biomarkers in Graves’ disease treated with low dose anti-thyroid medications (interim report)
H R Bazrafshan1,2, F Fitz3, M Steimmel4, S Haim5, C Reichl5, M Beheshti1, W Langsteiner1 & L Klesov1
1Department of Nuclear Medicine and Endocrinology, PET-CT Center Linz, St Vincent’s Hospital, Linz, Austria; 2Department of Endocrinology, Golestan University of Medical Sciences, Gorgan, Islamic Republic of Iran.

Background
There are remarkable debates on the pathogenic mechanisms of Graves’ disease (GD). We prospectively followed up the serum levels of different autoimmunity indices in patients with GD in order to elucidate their pattern of alteration with time.

Methods
A total of 119 consecutive patients with GD were treated using low dose anti-thyroid medications at the initial dose of 20 mg/day of methimazole (MMI). Then, the dose was gradually decreased, when the patients were able to the minimum maintenance dosage of 5 mg MMI or 25 mg PTU and finally discontinued in euthyroid patients after one year. During the treatment and also after the discontinuation of the drugs, the thyroid hormones (FT3, FT4, and TSH) and thyroid auto-antibodies (anti-TPO, anti-TSHRab and anti-Tg) were measured routinely every 4 weeks for the first 3 months and every 3 months. Follow-up period was up to 10 years.

Results
The mean reductions of anti-TPO, anti-TSHRab and anti-Tg during the follow-up period were 6, 35.8 and 59.6%, respectively. Euthyroid status was achieved in 25.3, 26.1, 37, 45.4, 51.3, 52.9 and 47.9% in 3rd, 6th, 9th, 12st, 24nd, 60th and 120th month follow-ups, respectively. No significant correlation was found between the reductions in serum concentrations of anti-TSHRab and anti-TPO as well as anti-TSHRab and anti-Tg and also anti-TPO and anti-Tg.

Conclusion
Low dose anti-thyroid medications reduce the serum concentrations of thyroid autoimmunity biomarkers during years, which can be considered as an indirect evidence for their immunosuppressive effects. Unparallel pattern of reduction of these thyroid auto-antibodies suggest the presence of different pathologic mechanisms and independent autoimmunity routes for GD.

Regulation of visceral adipose tissue-derived serine protease inhibitor in overt and subclinical hypothyroid patients
Nese Cinar, Nese Ersöz Gulcelik, Kadriye Aydin, Safak Akin, Aydan Usman & Alper Gurlek
Hacettepe University School of Medicine, Ankara, Turkey.

Introduction
Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a novel adipocytokine which might exert an insulin-sensitizing effect. It is thought that vaspin mRNA expression may be a marker for obesity and insulin resistance. Given the fact that subclinical and overt hypothyroidism are known risk factors for insulin resistance, we aimed to assess the regulation of vaspin by thyroid hormones in humans.

Methods
We enrolled 32 overt hypothyroid, 42 subclinical hypothyroid and 37 euthyroid patients in the study. We evaluated the body mass index (BMI), fasting glucose, lipid profile, TSH, free T3, free T4, fasting insulin and vaspin levels. Vaspin levels were determined by ELISA (ng/ml). We calculated the HOMA-IR index. We evaluated the change in vaspin levels in overt hypothyroid patients after replacement of thyroid hormones.

Results
Overt hypothyroid patients were significantly older (P<0.05) and had higher BMI values (P<0.05) than subclinical and euthyroid patients. A significant difference in fasting glucose, triglyceride, HDL, LDL levels was found between the groups (P<0.05). However there was no significant difference in total cholesterol, insulin levels and HOMA-IR (P>0.05). Vaspin levels were not different between the groups (mean of vaspin levels in overt, subclinical and euthyroid patients respectively 1.13±0.8, 1.32±1.08, 1.03±0.76 ng/ml P>0.05). No significant association was observed between vaspin levels and BMI, fasting glucose, insulin and HOMA-IR (P>0.05). After replacement of thyroid hormones in overt thyroid patients, there was no significant change in serum vaspin levels (before and after treatment respectively, 1.23±0.94; 1.23 ±0.07 ng/ml P>0.05).

Vitamin D levels are associated with serum TSH levels but not with thyroid autoantibodies
Mehmet Colbay, Mustafa Altay, Mujuje Akturk, Ilhan Yetkin & Metin Arslan
Endocrinology and Metabolism Department, Gazi University Hospital, Ankara, Turkey.

Introduction
Hashimoto’s thyroiditis (HT) is common autoimmune thyroid disorder and is predominantly the clinical expression of cell-mediated immunity leading to destruction of thyroid cells. Vitamin D plays a role in the regulation of immunity and cell proliferation. So, do the serum levels of vitamin D reduced in HT? Methods We examined the medical records of the ‘Thyroid Policlinic’ patients with or without HT. Vitamin D, thyroid autoantibodies and TSH levels that evaluated in winter month’s interval (January–March 2010), were assessed.

Results
Totally, 319 patients (196 with HT, 123 without HT and 25 male) medical records were reviewed. Their demographic and clinical characteristics were shown in Table 1. There were no differences between ages, vitamin D and TSH levels except for the autoantibodies. But there was a significant negative correlation between the vitamin D levels and TSH levels (P<0.001).
P447  
Evaluation of thyroid surgery: 10 years of experience in a Military Hospital  
Mafalda Marcelino, Carlos Lopes, Raquel Carvalho, Paulo Guerra, Dolores Passos, Helena Vilar, Luís Lopes & João Castro  
Military University Hospital, Lisbon, Portugal.

Introduction  
Thyroid surgery is nowadays associated with low morbidity and extremely low mortality. A consistent association has been observed between high surgical volume and better outcomes. Patients who undergo surgery by a skilled surgeon have fewer complications. On the other hand, different surgical techniques have been associated with different outcomes. Since 1997, thyroid diseases are treated in our department by a multidisciplinary team.

Objective  
To access the results of thyroid surgery in our hospital, over the last 10 years.

Methods  
We studied retrospectively the patient’s medical files that underwent thyroid surgery from 1999 to 2010. Statistic tests were used to analyze the different variables.

Results  
A total of 240 patients underwent thyroid surgery over the 10-year study period. The mean age of the patients was 54 years and 76% were females. Pre-operative diagnosis was thyroid nodular disease in 83.3% (13.9% toxic multinodular goiter and 12.5% substernal goiter), papillary carcinoma in 6.7% and follicular neoplasm in 5.8%. 4.2% of the patients had associated with total thyroidectomy.

Six percent of patients had permanent complications (total thyroidectomy 6.4% and lobectomy 3.4%). Permanent hypoparathyroidism occurred in 4.2% of cases, always associated with total thyroidectomy.

Conclusions  
Benign thyroid disease is the main surgical diagnostic indication in our hospital. Lobectomy is associated with better outcomes. Our complications rates are slightly higher than international reference centres.

P448  
Fine needle aspiration biopsy in thyroid nodular disease: 10 years of experience in a Military University Hospital  
Mafalda Marcelino, Saudade André, Luísa Figueiredo, Dolores Passos, Helena Vilar, Luís Lopes & João Castro  
Military University Hospital, Lisbon, Portugal.

Introduction  
Fine needle aspiration biopsy (FNAB) plays an essential role in the evaluation of thyroid nodular disease (TND). It reduces the rate of unnecessary thyroid surgery for patients with benign nodules, and allows the choice of the appropriate surgery. In our department, 2124 FNAB were performed in 10 years. 60% of them are now ultrasound guided (UGFNAB).

Objective  
To access the accuracy of FNAB in our hospital.

Methods  
Retrospective study of 204 patient’s medical files who underwent FNAB and who were submitted to surgery, between 1999 and 2010. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of FNAB (without UG and UG) were examined based on cytologic histologic correlation. All statistical evaluation was made using an SPSS software. A P value <5% was considered statistically significant. Classification of cytological results were adapted from Bethesda system.

Results  
Cytological results were benign in 78% of the cases. From the remaining, 8.6% were malignant and 13.4% were follicular neoplasms. Histological results were benign in 86.7% and malignant in 13.3%, being 9.1% papillary carcinomas. After the evaluation of cytologic histologic correlation, there were 79.4% of true-negatives, 15.7% of true-positives, 3.4% of false-negatives and 1.5% of false-positives. All the false-negatives (7) correlates with large nodules (6) or with non dominant nodule in histology (not analyzed by FNAB). The sensitivity was 95.9%, the specificity was 91.4%, the negative predictive value was 82.1% and the positive predictive value was 98.2%. The comparison of FNAB without UG or UGFNAB demonstrates a false predictive value of 64.7 vs 100% and a positive predictive value of 100 vs 88.9% There were no unsatisfactory samples.

Conclusions  
The results show a good accuracy of FNA in our hospital, with a high sensibility and specificity. Our results are similar to the published data.

P449  
Routine serum calcitonin measurement in screening of medullary thyroid carcinoma (MTC) in Gohierri county  
J Martí & M M Galar  
Hospital Zumarraga, Zumarraga, Guipuzcoa, Spain.

Introduction  
The utility of serum calcitonin has been evaluated in a series of prospective, nonrandomized studies suggest that the use of routine serum calcitonin for screening may detect C-cell hyperplasia and medullary thyroid cancer at an earlier stage and overall survival may be improved. An earlier study estimated that routine measurement of plasma calcitonin in thyroid nodule patients would yield an additional 2.2 life-years per positive patient.

Aim  
To determine the usefulness in our county of the determination of calcitonin in patients with thyroid nodules disease, to exclude the presence of MTC.

Patients and methods  
The study included 434 patients seen in our Department between 2006 and 2009 for nodular thyroid disease, who were screened for MTC by serum CT measurement. The clinical diagnosis, as assessed by clinical examination, thyroid ultrasound, and thyroid function tests, included single nodules, non-toxic multinodular goiter, autonomous functioning thyroid nodules. Fine needle aspiration was performed as a routine procedure. The cost of calcitonin determination was 15, per sample. Patients with impaired renal function, protons pump inhibitor treatment were been excluded. None of patient had had family with MCT.

Results  
We studied 434 patients, 71 men and 361 women (60.29 ± 15.3 years), with multinodular goiter (76.3%) and uniodular (22.7%). They were analyzed a 595 samples of calcitonin, which was normal in all patients (<8 pg/ml). The global cost of calcitonin determination for 4 year was 8925 euros. Surgical proceeding was been performed in 76 patients (compressive goiter, cytology suspicious of malignancy), the diagnosis was 4 papillary carcinoma and benign nodular lesion to the rest of patients, no MCT was found.

Conclusion  
In our study, the analysis of calcitonin was normal in all patients, despite in our study we have not found any MCT we believe that calcitonin measurement is an useful test with low cost in early diagnosis of MCT.

P450  
Coexistence of hyperparathyroidism with papillary thyroid microcarcinoma  
M R Diaconescu, M Glod, I Costea & S Diaconescu  
‘Gr T Popa’ University of Medicine and Pharmacy, Iasi, Romania.

Background  
Concomitant occurrence of primary (PHP) or renal (RHP) hyperparathyroidism and papillary thyroid microcarcinoma (PTMC) is rarely described in literature.
Patients and methods
Between 1986 and 2010 sixtythree subjects underwent operations for PHTp (n=20) or RHTp (n=43) in our clinic. In three cases (4.7%) a synchronous PTMC was intraoperatively discovered.

Results
First case, female – 56 years old presented with recurrent hyperparathyroidism 6 years after an 'extra muro's' extirpation of a right sided inferior adenoma. At operation multiple gray-tan micronodules of 2–5 mm was discovered on the thyroid surface. Biopsy revealed benign parathyroid tissue leading to a diagnosis of parathyromatosis. A right thyroid lobectomy was done. At the paraffine examination a minute foci of PTMC was identified. Any postoperative therapy was recommended. At two years postoperatively she presents a symptomless course.

In two cases of RHTp, one male and one female of 48 and 50 years respectively, in both of whom a near-total parathyroidectomy together with a Dunhill operation was done due to the presence of a bilateral nodular goitre and also of a hard nodule of 5 mm in diameter.

Pathology precise existence of a PTMC classified as PT1. The patients were guided to complementary therapy and both are alive without recurrences at 7 and 4 years respectively.

Discussions and conclusions
Coexistence between PHTp or RHTp with PTMC is coincidental but can be encountered in endemic goitre areas. The diagnosis of these lesions is rarely affirmed before surgery being established by serendipity or better by a careful intra- or postoperative exploration. Surgical treatment must be adapted to the slowly lesion: thyroid carcinoma.

P451
Recombinant tsh-stimulated thyroglobulin measurements in patients with differentiated thyroid carcinoma with basal thyroglobulin <1 ng/ml
A Vieira, F Carrilho, C Ribeiro, M Melo, M Alves, S Gouveia, J Saravia & M Carvalheiro
Endocrinology, Diabetes and Metabolism Department, Coimbra’s University Hospital, EPE, Coimbra, Portugal.

Introduction
A value of thyroglobulin (Tg) undetectable under treatment with levothyroxine (LT) does not exclude residual/metastatic disease; this can be found in 18–35% of patients after recombinant TSH-stimulated Tg (sTg) measurements.

Objective
Evaluating the role of recombinant TSH-stimulated thyroglobulin (sTg) measurements in patients with differentiated thyroid carcinoma, treated with suppressive LT doses, with basal Tg (bTg) <1 ng/ml.

Methods
Retrospective evaluation of patients with differentiated thyroid carcinoma with bTg <1 ng/ml submitted to sTg measurements between 01/01/2008–31/12/2009. Patients were divided into two groups: bTg <0.2 ng/ml (group 1); bTg between 0.2–1 ng/ml (group 2). Patients with anti-Tg were excluded. Limit of detectable Tg in our institution 0.2 ng/ml.

Results
n = 96; 80.2% Õ; diagnosis age = 41.8 ± 13.4year; 78.1% papillary (10.4% microcarcinomas), 11.5% follicular. Abative radiodine dose = 97.1 ± 29.3 mCi. 73 patients belonged to group 1 and 23 to group 2. There was no statistically significant relationship between these groups with respect to gender, diagnosis age, presence of nodal metastasis, stage or radioiodine dose. All patients of group 2 had papillary carcinoma.

Table 1

<table>
<thead>
<tr>
<th>Patients number with sTg &lt; 2 ng/ml</th>
<th>P</th>
<th>Mean sTg (ng/ml)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>60</td>
<td>0.000</td>
<td>0.61</td>
</tr>
<tr>
<td>Group 2</td>
<td>36</td>
<td>0.024</td>
<td>2.57</td>
</tr>
</tbody>
</table>

There was no statistically significant relationship between sTg ≥2 ng/ml and gender, diagnosis age, histology, presence of nodal metastases or radioiodine dose. 31.3% of patients with sTg ≥2 ng/ml belong to stage IV while in the group with sTg <2 ng/ml only 9.3% belong to this stage (P=0.050). There was a positive correlation between bTg and sTg (r = 0.329, P=0.001). There was no statistically significant relationship between sTg and gender, diagnosis age, histology, presence of nodal metastasis, stage or iodine dose.

Conclusions
In Group 1, 91.9% with bTg <0.2 ng/ml kept sTg within normal range. In this group, 83.3% with sTg ≥2 ng/ml had multifocal disease. In Group 2, 56.5% had sTg <2 ng/ml; 60% of this group with sTg ≥2 ng/ml showed capsule’s invasion. In 50% of patients with sTg ≥2 ng/ml was detected locoregional disease. There was no distant metastasis.

P452
Thyroid disease in patients with type-1 neurofibromatosis: an underestimated issue?
C Diziozi, A Guidi, A Luberto, E Taliani, B Madeo, V Rochira & C Carani
Chair of Endocrinology, Department of Medicine, Endocrinology and Metabolism, Geriatrics, University of Modena and Reggio Emilia, Modena, Italy.

Introduction
In type-1 neurofibromatosis (NF-1) there is an increased risk of endocrine tumors, especially pheochromocytomas, whereas thyroid carcinomas seem to be extremely rare, with few cases reported in literature.

Subjects and methods
In order to investigate the frequency of hypercalcitoninaemia and medullary thyroid cancer (MTC) in patients with NF-1, we evaluated the thyroid gland morphology and function in 17 patients with NF-1 by i) neck US, ii) Fine Needle Aspiration (FNA) biopsy of the nodules detected at US and the measurement of calcitonin (CT) in wash-out fluid from FNA (CT-FNA), iii) serum CT at basal level and after stimulation with pentagastatin (CT-Pg) and iv) thyroid function.

Results
i) 10/17 (58.8%) had nodular goiter and ii) on the basis of cytology at FNA, 3/10 underwent total thyroidectomy with histological confirmation of malignancy in 2/10 patients (1 papillary thyroid cancer and 1 infiltrative squamous carcinoma); iii) only 1/17 presented an increased in basal CT with pathologically increased CT-Pg (>100 pg/ml) with an histological finding of C-cell Hyperplasia after thyroidectomy; iv) of the 16 remaining patients, CT-Pg was normal in 10 patients (<50 pg/ml), while 6 patients had a borderline response (50<CT-Pg<100 pg/ml) (Elisei et al. Journal of Clinical Endocrinology and Metabolism 2004); v) of the 6 patients with CT-Pg<100 pg/ml, 5 had thyroid nodules and 2 had notably increased CT-FNA levels (745 and 789 pg/ml respectively); vi) thyroid function was normal in all patients.

Discussion
The finding of goiter in 60% of NF-1 patients, of thyroid cancer in 11 and 40% of borderline/high CT-Pg suggest that an accurate study of thyroid gland in patients with NF-1 is mandatory and that thyroid diseases may be underestimated in the context of NF-1.

P453
Papillary thyroid microcarcinoma: size and metastatic behavior
O Demiduk, I Avetisian, P Malyarevsky, S Tsimbulak, A Dinets
Kyiv City Teaching Endocrinological Center, Kyiv, Ukraine.

Introduction
Papillary thyroid microcarcinoma (PTMC) is defined as a papillary thyroid cancer measuring 10 mm or less in greatest dimension. Diagnosis of PTMC could be established during the surgery for benign thyroid lesions and after fine needle aspiration biopsy. Despite the small size, PTMC could be highly aggressive tumor showing metastases and elevated invasiveness. However, correlation between tumor size and risk of lymph-node metastases remains unclear.

The aim of the study was to investigate and correlate local lymph-node metastases and multifocality as factors of tumor aggressiveness in patients with different sizes of PTMC.

Materials and methods
1408 patients operated on for PTMC during 1986–2009 in Kyiv City Teaching Endocrinological Center were identified for study. Three groups were established according to size of primary tumor. There were patients with size of PTMC less than 3 mm in maximum diameter in group 1 (n=197), 3–5 mm in group 2 (n=297), and 5–10 mm in group 3 (n=914) respectively. Such clinicopathological features as local lymph-node metastases and multifocality were compared between groups.

Results
The statistically significant frequency of local lymph-node metastases was higher in group 3 (30.0%) compared to group 2 (30.0%) and group 1 (0%), P<0.01. Multifocality was higher in group 3 (24.5%) and group 2 (21.5%) compared to group 1 (10.7%), P<0.01. There was no statistical significant difference for multifocality in group 3 compared to group 2.
Conclusions
Our finding suggest that patients with size of PTMC between 5 to 10 mm (group 3) may have a higher risk of lymph-node metastases compared to those who have smaller sizes of PTMC. Long-time follow-up study is ongoing in order to determine consequences for patients’ outcome.

P455
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells
H H G Verbeek1,2, M M Alves1, J W B deGroot1, T P Links1 & R M W Hoëstra2
1Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands; 4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands.

Introduction
Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease but since RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK-inhibitor might be promising. Several TK-inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most effective and if there is any specificity for particular RET mutations. We aimed to compare the effect of four TK inhibitors (axitinib, sunitinib, vandetanib and XL184) on cell proliferation, RET expression and autophosphorylation, and ERK activation in cell lines expressing a MEN2A (MTC-TT), a MEN2B (MZ-CRC-1) mutation, and a RET/PTC (TPC-1) rearrangement.

Results
XL184 and vandetanib, most effectively inhibited cell proliferation, RET autophosphorylation in combination with a reduction of RET expression, and ERK phosphorylation in MTC-TT and MZ-CRC-1 respectively. TPC-1 cells showed a decrease in RET autophosphorylation after treatment with XL184, but no effect was observed on ERK activation.

Conclusion
There is indeed specificity for different RET mutations, with XL184 being the most potent inhibitor in MEN2A and PTC, and vandetanib the most effective in MEN2B in vitro. No TK inhibitor was superior for all the cell lines tested, indicating that mutation-specific therapies could be beneficial in treating MTC and PTC.

P456
Thr300Ala ATG16L1 polymorphism influences susceptibility to and the prognosis of epithelial cell derived thyroid carcinoma
A Huijbers1, T S Plantinga1, M Oosting1, L A B Joosten1, K K H Aben1,2, M G Netea1, A R M M Hermus1 & R T Netea-Maier1
1Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2Comprehensive Cancer Centre East, Nijmegen, The Netherlands.

Background
Loss of autophagy protein ATG16L1 enhances endotoxin-induced interleukin 1β (IL1β) production. IL1β has been found to have antineoplastic effects in thyroid malignancies. We hypothesized that a missense polymorphism in ATG16L1 autophagy gene (Thr300Ala) results in changes in the function of the molecule and influences susceptibility to and prognosis of epithelial cell derived thyroid carcinoma (TC).

Objective
i) To assess the functional differences between the 300Thr (A) and 300Ala (G) allele of ATG16L1; and ii) to assess whether ATG16L1 Thr300Ala polymorphism influences the susceptibility to and the prognosis of TC.

Patients and methods
The ATG16L1 genotype was analyzed by PCR in 139 TC patients and 136 healthy controls. In the control group peripheral blood mononuclear cells were stimulated with the NOD2 ligand muramyl dipeptide (MDP). The ATG16L1 function was assessed by measuring IL1β 24 h later. Within the patients group we analyzed the genotype-phenotype associations.

Results
MDP-stimulated IL1β production was significantly higher in individuals bearing the GG/GA allele compared to those bearing AA allele, supporting a gene-dosage effect of the 300Ala variant on the function of the molecule. The difference in genotype frequencies between the patients and control groups were analyzed in a gene dosage dependant model using logistic regression and in a dominant model using χ² analysis. The G allele of ATG16L1 is associated with decreased risk for TC (OR=0.46, P=0.041 in the gene dose dependent model, and OR=0.51, P=0.025 in a dominant model). Furthermore, patients carrying the AG/GG genotype had a higher chance of successful 131I ablation (P=0.017) and required a lower cumulative 131I dose to achieve remission (P=0.014) than patients carrying the AA genotype.

Conclusions
The Thr300Ala ATG16L1 polymorphism has important functional consequences, with significantly higher IL1β release in individuals bearing the 300Ala variant. The 300Ala allele was associated with both a lower susceptibility for TC and lower 131I dose required to achieve remission.

P457
Reversine, an anti-cancer candidate, induces cell cycle arrest and apoptosis in human thyroid cancer
Ying-Ray Lee1, Shih-Chen Hua2, Shu-Hsin Chen1, Chieh-Hsiang Lu3, Hui-I Yu4, Hau-Ren Chen5 & Tien-Chun Chang4
1Department of Medical Research, Chiayi Christian Hospital, Chiayi City, Taiwan; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Chiayi Christian Hospital, Chiayi City, Taiwan; 3Division of Life Science, Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan; 4Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.

Thyroid cancer is the most prevalent cancer among endocrine malignancies. Surgical resection combined with radioactive iodine therapy has been proved
P458

Intraindividual comparison of serum calcitonin levels after calcium versus pentagastrin stimulation

R Hampel1, J Laue1, Ch Zingler2, B Klar3

1 Internal Medicine Clinic II, Division of Endocrinology and Metabolic Diseases, University of Rostock, Rostock, Germany. 2 Institute of Clinical Chemistry and Laboratory Medicine, University of Rostock, Rostock, Germany.

Objectives

The aim of the study was to compare serum calcitonin levels after calcium versus pentagastrin stimulation in healthy individuals and in patients with medullary thyroid carcinoma (MTC).

Methods

The study enrolled 44 healthy individuals and 27 patients with MTC.

Time of measurement: baseline, 2, 5 and 10 min after injection of:
- Calcium 2.0 mg/kg body mass i.v. (10% Calcium Gluconate, Braun Melsungen AG, Germany). Injection speed 10 ml/min.
- Pentagastrin 0.5 µg/kg body mass i.v. (Pentagastrin Injection BP, Cambridge Laboratories, Wallsend, UK). Injection speed 10 s.

After stimulation there was a washout period of at least two weeks before the pentagastrin stimulation.


Results

Mean calcitonin levels (pg/ml) in healthy individuals after calcium injection were significantly different from basal levels: 1.2/19.5*/16.4*/10.2* vs 1.8 (*P < 0.01). After pentagastrin injection: 1.3/4.5/4.0/2.4 (*P < 0.01) vs 1.8 (*P < 0.01). There was no difference in terms of multicentricity, capsule and vascular invasion, extrathyroidal involvement and lymph node invasion.

Conclusion

FVPTC tends to have more benign features in US and less malignant results in cytology. Higher tumor size in FVPTC compared to CPTC might be explained by the recognition of clinical importance of these lesions after reaching particular sizes due to benign US features.

P460

Serum 25-OH Vitamin D levels in patients with benign and malignant thyroid nodules

Didem Ozdemir1, Husniye Basar, Fevzi Balkan, Dilek Arpaci, Reyhan Ersoy & Bekir Cakir

Department of Endocrinology and Metabolism, Ataturk Education and Research Hospital, Ankara, Turkey.

Introduction

Increased exposure to sunlight and high serum levels of Vitamin D were reported to relate with decreased risk of various cancer types, such as prostate, breast and colon. Vitamin D receptor and 1α-hydroxylase expression were shown in papillary thyroid carcinoma. In this study, we aimed to evaluate serum 25-OH Vitamin D levels in patients with benign and malignant thyroid nodules.

Methods

Patients admitted to our thyroid clinic were recruited for the study. Thyroid ultrasonography and serum 25-OH vitamin D measurement were done in all patients and controls. Because serum 25-OH vitamin D levels may change with seasons, blood samples were taken in April–May 2009 and 2010. Results were compared in patients with histopathologically proven thyroid papillary cancer.
patients with histopathologically or cytologically proven benign thyroid nodules and patients without thyroid nodules. Patients with diseases related to bone metabolism and thyroid dysfunctions were excluded.

Results
There were 31 patients with histopathologically proven papillary thyroid cancer, 128 patients with cytologically or histopathologically proven benign nodules and 269 patients without any nodule. Of 428 subjects, 360 (84.1%) were female and 68 (15.9%) were male and sex distribution were similar in three groups (P = 0.079). Mean serum 25-OH vitamin D levels were 16.91 ± 10.42, 16.35 ± 9.02 and 17.19 ± 10.74 μl/mol in malignant, benign and control groups, respectively (P = 0.746). Including all subjects, although mean serum vitamin D levels were higher in males compared to females, the difference did not reach statistical significance.

Conclusion
Serum 25-OH vitamin D levels, here in this study, were shown not to differ in patients with benign nodules, malignant nodules and patients without nodules. Possible effect of vitamin D metabolism and receptors on thyroid papillary cancer that was suggested in previous in vitro and in vivo studies seems to be independent from serum 25-OH vitamin D levels.

Role of 99mTc HYNIC Octreotide in the follow-up of thyroid cancer patients that after surgery and 131I therapy present raised thyroglobulin levels and negative 131I whole body scan

P461

Introduction
Patients bearing thyroid cancer that have already gone into surgery and 131I therapy in the follow-up have high thyroglobulin levels and negative 131I whole body scan represent a diagnostic and therapeutic challenge. 99mTc HYNIC Octreotide recognizes somatostatin receptors that are expressed in thyroid cancer. The objective of this paper is to evaluate these patients by means of 99mTc HYNIC Octreotide and to correlate the results with other imaging methods.

Materials and methods
99mTc HYNIC Octreotide scintigraphy was performed to 20 patients bearing differentiated thyroid cancer (16 papillary and 4 follicular) postthyroidectomized with raised thyroglobulins (2.5 to 114 ng/ml mean 15.7 ng/ml) and negative whole body scans (18 women and 2 men, age 18–72 years). Studies were performed after obtaining informed consent. Images started 2, 4 and 24 h after the injection of 900 MBq of 99mTc-HYNIC Octreotide, performing a whole-body scan followed by a SPECT acquisition of the region of interest. A double detector gamma camera equipped with LEHR collimators (Mediso Nucline Spirit DH-V, Hungary) was used. Three-dimensional images were co-registered with CT scans in order to define better the abnormal 99mTc HYNIC Octreotide uptake using software fusion imaging.

Results
99mTc HYNIC Octreotide allowed us to detect abnormal areas in 17 patients, being 3 negatives. We could correlate these results with computed tomography in 12 of them. We found morphologic alterations that corresponded to the abnormal 99mTc HYNIC Octreotide uptake in 7. In the remaining 5 we didn’t find an anatomic alteration. In all cases, SPECT-CT fusion images allowed a better diagnostic confidence by providing anatomic correlation.

Conclusions
These preliminary results highlight the role of 99mTc HYNIC Occreotide as a potential radiopharmaceutical method that could aid in the diagnosis of these thyroid cancer patients. Also this information can be used to plan radio-guided surgery or radioiodine therapy with 177Lu somatostatin analogues.

Comparison of clinical and histopathological characteristics of thyroid papillary microcarcinoma and papillary thyroid carcinoma

P463

Introduction
Papillary thyroid carcinoma (PTC) is most frequent endocrine cancer on the other hand papillary microcarcinoma can be seen increasing frequency in recent years. In this study we compare clinical and histopathological characteristics of thyroid papillary microcarcinoma and papillary thyroid carcinoma retrospectively. Eighty one PTC and 38 PMC total 119 patients followed between 2005 and 2009 were enrolled study. Average follow-up time is 35 months in PTC and 36 months in PMC. Age, sex, background, tumour variants, pathological features, surgical procedure and postoperative surgical complications were collected and analysed from archive records. There were no significant difference between PTC and PMC patients for prognostic factors like capsul invasion, vascular invasion, lymph node metastasis, distant metastasis, bilaterality, multicentricity, age, sex and tumour variants (P > 0.05). Lymph node metastasis was more frequent in bilateral and multicentric tumours (P < 0.05).

As a result we found no significant difference between PTC and PMC for poor prognostic factors like capsul invasion, vascular invasion, lymph node metastasis, distant metastasis, bilaterality and multicentricity. According to these findings follow-up and therapy for PMC is processed like PTC.
P464
Both Follicular and Papillary neoplasms in a patient with Hashimoto’s thyroiditis: complete coincidence?
U Mousa & N B Tutuncu
Baskent University, Ankara, Turkey.

Even though it is unusual, many cases presenting with combinations of thyroid carcinomas have been reported. Concurrent occurrences of medullary – papillary carcinoma, follicular – papillary – medullary carcinoma, follicular – anaplastic – papillary carcinoma, papillary – follicular carcinoma have been presented. The cases reported up to now had no thyroid autonomy. We present a case with known Hashimoto’s thyroiditis having a combination of papillary and follicular carcinoma.

A 49 year old female patient presented to the Endocrinology department with known type 2 diabetes and hypothyroidism. She was on levothyroxine 50 μg/day and glimepiride 3 mg/day. Physical examination of the thyroid gland revealed suspicious nodules on both lobes and ultrasonography was performed at the Endocrinology department. Multiple nodules were viewed in both lobes coalescent in character with maximum diameters ranging from 15 to 40 mm respectively. She received 100 millicuries of radioactive iodide treatment two months after the surgery. Posttreatment scan showed no pathological activity or residual tissue. She is still under levothyroxine suppression therapy and is under remission for two years with normal thyroglobulin levels and negative whole body iodide scans.

Patients with combinations of thyroid carcinomas have been discussed in the literature. Complex genetic mechanisms theories have been proposed like ‘stem cell theory’, ‘divergent differentiation theory’, ‘field effect theory’, ‘hostage therapy’ and ‘collision theory’. The last theory states that these events are of complete coincidence. Whether Hashimoto’s thyroiditis contributes to our case is of complete controversy. More cases are needed to be able to explain the exact pathogenesis.

P465
Association between thyroid autoimmunity and papillary thyroid carcinoma: recent confirmations from a prospective study
F Boi1, A Borghero1, M L Lui1, S Casula1, I Maurelli1, P G Calò3, A Nicolosi3 & S Mariotti2
1Endocrinology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy; 2Department of Citomorphology, University of Cagliari, Cagliari, Italy; 3Surgery Unit, University of Cagliari, Cagliari, Italy.

Introduction
The association between autoimmune thyroid diseases and papillary thyroid carcinoma (PTC) is still controversial and it is based only on retrospective analyses.

Objective
Aim of the present research was to evaluate this association in a prospective study of unselected consecutive thyroid nodules (TN) submitted to fine-needle aspiration cytology (FNAC), anti-thyroid autoantibodies (ATA) measurement and histological analyses of surgical samples.

Subjects and methods
One hundred and ninety-six patients (252 nodules) with TN were studied. 106 patients (142 TN) had undetectable ATA (ATA−), while 90 (110 TN) were ATA positive (ATA+), including 78 (93 TN) with definite autoimmune thyroid disease (AITD) and ‘collusion theory’ and ‘collision theory’. The last theory states that these events are of complete coincidence. Whether Hashimoto’s thyroiditis contributes to our case is of complete controversy. More cases are needed to be able to explain the exact pathogenesis.

Conclusions
To our knowledge this is the first prospective study, carried out on a unselected series of consecutive thyroid nodules, confirming the significant association between AITD and PTC, described only in retrospective analyses.

P466
Primary malignant thyroid teratoma combined with papillary thyroid carcinoma in a female patient with Hashimoto thyroiditis
C T Tsentidis1, V M Vasilamatzis2, P S Pinis1, M K Karayanni1, C V Vasilopoulos4 & A Argyropoulos2
1Nicaea General Hospital, Piraeus, Greece; 2General Hospital ‘Euangelismos’, Athens, Greece.

Introduction
Primary malignant thyroid teratoma is a rare neoplasm. Even rarer is the concomitance of the mentioned tumor and papillary thyroid cancer.

Case report
We report a case of a 44-year-old woman diagnosed with Hashimoto thyroiditis and multinodular, non-toxic goiter since 2004. The two larger, initially non palpable nodules were located in right thyroid lobe, 16 and 12 mm in diameter respectively. Under suppressive thyroxine therapy the diameter of the two nodules constantly increased (205–20 and 12 mm, 2006–23 and 12.6 mm, 2007–25 and 15 mm, 2008–30 and 22 mm). The nodules were palpable in physical examination since 2007. Two FNA biopsies of the described nodules on 1/2005 and 12/2006 revealed benign/reactive cytology, without any indication of malignancy. Due to continuous nodule enlargement, thyroidectomy was suggested and performed on 12/2008. Histopathological evaluation of the resected thyroid gland (subtotal thyroidectomy) revealed chronic thyroiditis and i) lesion of malignant teratoma (~2.5 cm) with primitive mesenchymal, neuroectodermal and epithelial tissue from grade 1 to grade 3 and ii) lesion (~1 cm) of papillary thyroid carcinoma (collision tumors) of follicular variant cells, evading thyroid capsule. After thorough whole body radiological evaluation, no site of possible primary neoplasm was recognized and the diagnosis of primary malignant thyroid teratoma was set. Three sessions of adjuvant chemotherapy, based on cis-platinum, followed the surgical resection for the stage 1 teratoma and RAI therapy with 70 mCi131I for the stage I papillary thyroid cancer. Further periodic laboratory and radiologic evaluation support disease remission. Two years after subtotal thyroidectomy and 1.5 years after adjuvant therapy completion, there is no sign of regional or distal tumor relapse.

Conclusion
Concomitant primary malignant thyroid teratoma with papillary thyroid cancer is an extremely rare, if not the unique, case. Early diagnosis is critical for successful therapy. Complex cancer cases like this demand multidisciplinary approach, in order to achieve maximal patient survival.

P467
Differences between incidental and preoperatively diagnosed papillary thyroid microcarcinomas. Review of the last decade
M Paja1, A Oleaga2, A Ugalde3, A Expo'sito3, C Moreno1, M Sánchez-Goitia1, A J Izuzquiza1 & J R Elorza1
1Endocrinology, Hospital de Basurto, Bilbao, Spain; 2Pathology, Hospital de Basurto, Bilbao, Spain; 3Endocrine Surgery, Hospital de Basurto, Bilbao, Spain.

Increasing incidence of papillary thyroid microcarcinoma (PTMC) is due to accurate histological study of surgical specimens (incidental, INC) or to improved preoperative diagnostic techniques (preoperatively diagnosed, PD). We evaluate the differences between both groups of PTMC from 2000 to 2009.

We reviewed data of patients diagnosed of PTMC (<10 mm) during the last decade with complete follow-up since surgery. Demographic data, tumour size, histological features (variant, extra capsular involvement (ECI), number of foci), lymph node disease (LND), treatment and clinical course were recorded.

Eighty-seven patients included 50 INC and 37 PD; 29 between 2000 and 2004 (18 INC, 62%) and 58 between 2005 and 2009 (32 INC, 55%). Main features are showed:
The incidence of PTMC shows an increasing trend in our series. INC tumours occur in older patients, are more frequently unifocal, without ECI and without LND, but they can display a high risk stage and require treatment as PD and larger tumours.

P468
A diagnostic value of elastosonographically determined strain index in the differential diagnosis of benign and malignant thyroid nodules
Bekir Cakir, Cevdet Aydin, Birol Korukluoglu, Didem Ozdemir, Cagatay I Sisman, Dilek Tuzun, Ayten Oguz, Gulnur Guler, Guven Gunev, Ahmet Kusdemir, Yavuz S Sanisoglu & Reyhan Ersoy
Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

Aim
In this study, we aimed to determine the strain index (SI) as well as the ES scoring of thyroid nodules, and establish the role for these parameters in the differential diagnosis of thyroid nodules using histopathological analysis as a reference standard.

Material and method
Real-time ES in transverse axis (TA) and longitudinal axis (LA) was performed in 391 nodules of 292 patients. ES scoring was made for all the nodules. SI in TA and LA was calculated for 4 times in each nodule and mean values were determined. The results were compared with final histopathological diagnosis.

Results
In histopathological examination, 125 (31.97%) of 391 nodules were malignant and 266 (68.03%) were benign. Of these histopathologically benign nodules, 189 (47.10%) were also in probably benign group according to elastosonographic scoring (score 1, 2, 3), while 77 (20.95%) were in probably malignant group (score 4, 5). Among 125 histopathologically malignant nodules, 52 (41.60%) were in probably benign and 77 (60.40%) in probably malignant group according to elastosonographic scoring. There was a significant relation between scoring and histopathological findings (p = 0.001). Accordingly, sensitivity, specificity and specificity of SI scoring were 58.4 and 71.0%, respectively. ROC analysis value obtained for strain ratios in TA (AUC: 66.0%). Thus, ROC analysis evaluated was applied only for SI in LA. The optimal SI cut-off value in LA was 4.480 (AUC 77.6, Sp: 35.7%). Since sample sizes of follicular and hurthle cell carcinomas were small, we did not make any analysis for these nodules.

Conclusion
SI measurement using ES may be a valuable method with high sensitivity in PTMC and PTC variants, however further studies with larger sample sizes are required to conclude about follicular and hurthle cell carcinomas.

P470
An uncommon thyroidal entity: hyalinizing trabecular adenoma
Ozen Oz Gul1, Soner Cander1, O K Unal1, O Saraydaroglu2, C Ersay1, E Erturk1, E Tuncel1 & S Imanoglu1
1Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa, Turkey; 2Department of Pathology, Uludag University Medical School, Bursa, Turkey.

Introduction
Hyalinizing trabecular adenomas (HTA) of the thyroid are an unusual disorder. HTA can be present as a thyroid nodule or incidental finding in a thyroidectomy specimen. Most behave as benign neoplasms, but their cytological features can be similar to those of papillary thyroid carcinoma.

Case report
A 68 year old woman admitted to our institution with a solitary thyroid nodule. Her serum free thyroxine (t4), free triiodothyronine (t3) and TSH levels are 1.03 ng/dl, 2.79 pg/ml, and 0.364 uIU/ml. Ultrasonography of the thyroid gland showed a 1.7 cm sized, regularly marginated, hypochoic, calcified thyroid nodule. Fine needle aspiration biopsy of the thyroid nodule revealed suspicious for papillary carcinoma (PTC). Thyroid scan is showed a cold thyroid nodule in the right lobe. Total thyroidectomy were performed. The final pathology was 1.1 cm sized hyalinizing trabecular adenoma. Histologically, the tumor showed tumor cells arranged in trabeculae and a prominent hyaline stroma. The neoplastic cells were focally immunoreactive for thyroglobulin and negative for calcitonin and chromogranin. After surgery i-thyroxine replacement therapy was started. Two years after thyroidectomy, the patient is alive and free of disease.

Conclusion
Ultrasonographic features of HTA similar to malignt thyroid lesions are frequently misdiagnosed as papillary carcinoma on fine-nadle aspiration cytology. The most recent and controversial debate surrounding HTA concerns its potentially malignant behavior and the possible relationship to PTC. Although cases of malignant HTT have been recorded, HTT should be considered a benign neoplasm or, at most, a neoplasm of extremely low malignant potential. In this report we present and discuss an unusual case of a patient who had a hyalinizing trabecular adenoma.

P469
Diagnostic value of elastosonographically determined strain indexes in differentiated thyroid carcinomas
Bekir Cakir, Birol Korukluoglu, Cevdet Aydin, Dilek Tuzun, Cagatay I Sisman, Ayten Oguz, Didem Ozdemir, Gulnur Guler, Guven Gunev, Ahmet Kusdemir, Yavuz S Sanisoglu & Reyhan Ersay
Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

Aim
We aimed to determine strain index (SI) values using Elastosonography (ES) in histopathologically confirmed differentiated thyroid carcinomas (DTC) path investigate the role of these values for the differential diagnosis of nodular thyroid diseases.

Material and method
ES in longitudinal axis (LA) was performed in 391 thyroid nodules of 292 patients. ES scores of thyroid nodules were determined and SI in LA for each nodule was calculated. The findings were compared with histopathological results.

Results
Histopathologically, of 391 nodules, 125 (31.97%) were malignant and 266 (68.03%) were benign. Among 125 malignant nodules, 100 were papillary thyroid carcinoma (PTC) (70 classical, 24 follicular variant, 3 solid trabecular variant, 2 column variant, 1 oncocyctic variant), 15 were follicular carcinoma, 9 were hurthle cell carcinoma and 1 was medullary carcinoma. When we compared SI of 100 nodules with PTC/PTC variants and 266 benign nodules, we found that SI cut-off value for 90% sensitivity (Sn) was 5.885 (AUC 77.6, P<0.001). In hypoechogenic nodules with ES score of 4–5, irregular margins and type I vascularization pattern, SI cut-off value for 90% Sn was 7.020 (Sp: 50%, AUC 72.4, P=0.011). Data of 70 nodules with classical PTC was compared with data of benign nodules and SI cut-off value for 90% Sn was calculated as 7.885 (AUC 79.2, P<0.001). The optimal SI cut-off value in 30 nodules with variant PTC was 14.785 (Sn:73.3%, sp:66.2%, PPV:19.6%, NPV:95.7%). In these nodules, SI cut-off value for 90% Sn in LA was 4.480 (Sp:35.7%). Since sample sizes of follicular and hurthle cell carcinomas were small, we did not make any analysis for these nodules.

Conclusion
SI measurement using ES may be a valuable method with high sensitivity in PTC and PTC variants, however further studies with larger sample sizes are required to conclude about follicular and hurthle cell carcinomas.

P471
Differentiated thyroid cancer: primary tumor size and clinicopathologic features
R Rangel, A Afonso, L Matos, F Fonseca, L Cortez, T Sabino, J Coutinho & A Agapito
Curry Cabral Hospital, Lisbon, Portugal.

Introduction
Several recent studies have reported an increase in the incidence of thyroid cancer during the last decades. The delineation between low-risk and high-risk tumor
size is not well defined. The purpose of this study was to evaluate the relationship between the primary tumor size of differentiated thyroid cancer and clinicopathological data.

Methods
We have analysed all records of all patients submitted to thyroidectomy at our hospital between 2005 and 2010, with the histologic result of differentiated thyroid cancer. Were studied 64 case reports considered and considered medical data such as age, gender, tumor size, solitary/multiple nodularity, presence/absence of chronic thyroiditis, of compressive symptoms and of microcalcifications, cytological, histologic and neoplastic stage classification.

Results
The studied population (58 females, 8 males) was characterized by a mean age of 49.2 ± 15.9 years old. Mean tumor size was 2.7 ± 1.3 cm; it was significantly associated with the presence of compressive symptoms (P = 0.011). Solitary tumoral nodules were significantly larger than neoplastic nodules associated with multinodules (P = 0.037). In addition, the tumor size was significantly smaller in patients with previous malignant cytological result (P = 0.002). There was a significant association between tumor size and the neoplastic stage of the disease (P = 0.014).

Conclusion
Lesion size of differentiated thyroid cancer influences the occurrence of compressive symptoms. Tumor size of differentiated thyroid cancer is greater in solitary nodules, in patients with previous non malignant cytological result, and in more aggressive stages of the disease.

P472
Incidental papillary thyroid microcarcinoma: a retrospective study
R Rangel, A Alfonso, I Mato, F Fonseca, I Cortez, P Tavares & A Agapito
Curry Cabral Hospital, Lisbon, Portugal.

Introduction
Recent data reveal that in the last 25 years it has been a 2.4 fold increase in thyroid cancer, with concomitant rise in thyroid microcarcinoma cases. The main purpose of this study was to analyse the surgical indications that leads to incidentally noted papillary microcarcinoma diagnosis.

Methods
We analysed clinicopathologic data of nineteen cases of incidentally found papillary thyroid microcarcinoma, from 1244 thyroid surgeries realized in our institution between 2005 and 2010.

Results
The mean age was 53.8 ± 9.2 years old. Female to male ratio was 3:1. Mean tumor size was 5.7 ± 3.01 mm. Hashimoto thyroiditis was detected in 4 cases. Multinodular nontoxic goiter was the endocrinological reason of consultation in 63%. The surgical induction was the increase of nodule volume in 43% of the cases, indeterminate cytology report in 21%, nodule diameter > 4 cm in 21%. Graves disease and multinodular toxic goiter in 5% each. Total thyroidectomy was primary realized in 13 cases and completed in 2 with multilocular disease.

Conclusions
The main surgical indication behind the incidental papillary microcarcinoma is the increase of nodule volume.

P473
Clinicopathologic significance of BRAF mutation in papillary thyroid carcinoma
J Satzic, Y Campos, O Llamazares, I L Orradre, A Vicente, A Marco, S Aso & J Lopez
Complejo Hospitalario de Toledo, Hospital Virgen de la Salud, Toledo, Spain.

Background
Thyroid carcinoma is the most common endocrine malignancy. BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid carcinomas (PTC). There are some discrepancies regarding the overall frequency of the mutation, its prevalence in PTC-variants and its relationship with clinicopathological parameters of poor outcome.

Aims
To investigate the relationship of clinicopathological features of PTC with BRAF mutation with particular reference to histological subtype.

Patients and methods
We analysed 97 patients (77.3% female, mean follow up 33.9 ± 26.7 months) with pathological diagnosis of PTC. DNA was extracted from tissues blocks or fresh tissue and BRAF (V600E) mutations were detected by PCR and sequencing. Uniariate (χ² and Student’s t test) and multivariate analysis were realised.

Results
BRAF (V600E) was detected in 45.4% of the study group. The prevalence of mutation was found in 54.4% of classical PTC, 22.2% of follicular variant and 30.8% of microcarcinomas (P < 0.05).

BRAF (V600E) mutation was associated with male sex (P < 0.05), extrathyroidal extension (P < 0.05) and with tumours of greater size or locally invasive (T1 + T2 versus T3) (P < 0.05). There were no associations with age, tumour size, multicientricity or lymph node metastasis. BRAF (V600E) was negatively associated with the presence of distant metastasis in our group (P < 0.05).

Conclusions
Our data suggest that BRAF (V600E) mutation is associated with some histological subtypes of PTC and with cancers with locally invasive growth.

The small number of cases in this report could explain the insufficient statistical significance in multivariate analysis.

P474
Diagnostic performance and concordance analysis between ultrasonographic findings suggestive of malignancy and fine-needle aspiration (FNA) in euthyroid nodules
H Vargas-Uricoechea 1,2, I Meza Cabrera 1,2 & G Omezc Astaiza 1,2
1University of Cauca, Popayán-Cauca, Colombia; 2Hospital Universitario San José, Popayán-Cauca, Colombia.

Introduction
In population, thyroid nodule incidence is 1 to 30%; malignancy incidence is 1–20% up to different series, which make us to realize diagnostic methods with variable sensibility and specificity, taking as point of reference, the cytological analysis.

Materials and methods
Fifty consecutive patients (44 women, 6 men) with thyroid nodule, performed neck ultrasonography (ALOKA SSD3500 equipment); material of FNA was processed according to international protocols (Koss-Papanicolau), the evaluated ultrasonographic findings were: solitary nodule, microcalcifications, solid structure, hiperhencogenicy, irregular margins, perinodular halo and intranodular vascular spots; it was analyzed Sensibility (S), Specificity (E), Predictive Values (PPV, NPV), Likelihood Ratio (LR+) and concordance (kappa index), with cytological report as gold standard which was categorized as positive or negative for malignancy, for the samples reported as ‘unsatisfactory or undetermined’, the FNA was performed until the result was positive or negative (3X maximum).

Results
The mayor performance for malignancy diagnostic was the presence of microcalcifications, S: 85.7% (95% CI: 42.01–99.25); E: 91.7% (95% CI: 71.53–98.54%); PPV: 75%; NPV: 95.7%; LR+ =10.29%, kappa=0.737. The presence of solitary nodule showed S: 100%; E: 66.67% (95% CI: 44.69–83.57%), NPV: 100%, PPV: 46.78%; LR+: 3.0; LR–: 0.475. When unite this ultrasonographic variables: uninodeular, solid structure, hiperhencogenicy, microcalcifications, irregular margins, perinodular halo, intranodular vascular spots, all together show S: 100%; E: 70.83% (95%CI: 48.75–86.56%); PPV: 50% (95% CI: 24.04–75.96%); NPV: 100%, LR+: 3.43; kappa=0.737.

Conclusion
Ultrasonographic findings such as microcalcifications and solitary nodule have the most diagnostic performance for malignancy in thyroid nodule, however with other findings like solid structure, hiperhencogenicy, irregular margins, perinodular halo, intranodular vascular spots, all together increase the diagnostic performance for malignancy in patients with thyroid nodules.
malignancy. Since the prevalence of IC reported in the literature is extremely variable (4.6–17%), mostly due to the limited number of cases, we aimed to study the features of IC in our large series. We retrospectively evaluated 1955 patients who consecutively underwent total thyroidectomy for non malignant diseases from 1998 to 2010 in our Endocrine Surgery Centre. The pre-surgical diagnoses were of uni-multinodular goiter, toxic adenoma or Graves’ disease. Moreover, 211 patients had a preoperative cytological diagnosis of micro-follicular lesion (64/211, 30%) and toxic adenoma (4/17, 23%), compared to patients with Graves’ disease (25/258, 9.7%), with uni-or multinodular non-toxic goiter (142/123, 11.5%) or with toxic multinodular goiter (16/231, 7%). The TNM staging was pT1N0N0 in 75% of cases (81% were microcarcinomas ≤1 cm) and pT2N0N0 in 6.8% of patients. An extra-thyroidal invasion (pT3-T4N0N0) was found in 10.7% of tumors, and lymph node metastases (pT1-T4N1) were diagnosed in 6.3% of patients. In conclusion, in a large series of patients submitted to thyroidectomy for benign diseases, a high prevalence (12.8%) of IC was found. Although most of the tumors were small and intra-thyroidal, a significant proportion of carcinomas showed extra-thyroidal invasion or lymph node involvement. Thus, present data indicate the need to perform an accurate preoperative evaluation in patients with benign diseases regardless of the association with thyroid autoimmune or hyperfunction.

P476
Failure to supress TSH level in a thyroid cancer patient; a case report
Arzu Gedik1, Merve Yilmaz2, Tugba Gunus1, Mehmet Calan2, Mujde Soyturk2 & Abdurrahman Comlekci1
1Endocrinology Department, Medical Faculty, Dokuz Eylul University, Izmir, Turkey; 2Gastroenterology Department, Medical Faculty, Dokuz Eylul University, Izmir, Turkey.

TSH supression therapy with thyroid hormone is a mainstay of thyroid cancer treatment. Effectiveness of thyroid hormone therapy may be disrupted by nonadherence of the patient, interfering drugs, foods and intestinal disorders. We here present a case of papillary thyroid cancer with unsuccessful supression therapy. Case A 38 year old woman, underwent total thyroidectomy for euthyroid multinodular goitre, with a pathological diagnosis of papillary thyroid carcinoma was referred to our clinic for further evaluation. She received radioiodine ablative treatment and was started TSH supression therapy. Her past medical and family history were unremarkable. On physical examination, a blood pressure of 100/60 mmHg, heart rate of 72 beats/min, thyroidectomy scar, normal reflexes were recorded. Laboratory evaluation revealed: hemoglobin:11.6 g/dl (12–16), MCV:79.9 FL (80–95), calcium:8.8 mg/dl (8.4–10.2), albumin: 4.6 g/l (3.5–5), TSH: <75 IU/ml (0.4–5), free T4: 0.6 ng/dl (0.8–1.9), anti-thyroid peroxidase antibody: <10 IU/ml (0–50), anti-thyroglobuline antibody: <20 IU/ml (0–50). During follow up, the optimum TSH supression could not be achieved despite the progressive increments in thyroid hormone dose (Levothyroxine sodium, 350 μg/day; levothiouridiolone sodium, 150 μg/day). She had no compliance problems and told about mild diarrheal episodes when asked for malabsorptive symptoms. Antendomysium and antiglutadin antibodies were negative. Endoscopic biopsy of the small intestine revealed intraepithelial lymphocytes and focal villous atrophy characteristic for celiac disease. Gluten free diet was started, her diarrheal episodes were relieved and her TSH level fell to target supression levels. Conclusion Oral thyroid hormone treatment is a relatively vulnerable therapy which is easily affected by ingested substances or medications. In a patient with unsuccessful thyroid hormone replacement or supression therapy, with no adherence problems and interfering substances or drugs, malabsorption should come into mind and be evaluated.

P477
Long term follow-up and outcome in thyroid papillary microcarcinoma
B Vlassopoulou1, A Vryonidou2, D Ioannidou3, A Koleti4, N Klonaris2,2, C Katsouilis5, Ch Vasilopoulos6 & I Tzavara6
1Department of Endocrinology and Metabolism-Diabetes Centre, Evangelismos Hospital, Athens, Greece; 2Department of Endocrinology, Diabetes and Metabolism, Red Cross Hospital, Athens, Greece; 3Department of Endocrinology, Diabetes and Metabolism, ‘Amalia Fleming’ General Hospital, Athens, Greece.

Background and patients The clinical significance and management of papillary thyroid microcarcinoma (PTMC) is widely debated. The objective of this study was to assess the clinical presentation, tumor characteristics and the outcome of the disease in patients with PTMC. In this retrospective study we evaluated 286 patients who were followed for a minimum of three years. Results Of the 286 patients with a mean age 48.9 years, 226 (79%) were females. Two hundred and sixty one patients (91.2%) underwent a near total and 25 patients an incomplete thyroidectomy. PTMC was discovered incidentally in 248 (86.7%) patients undergoing surgery for other pathology not related to thyroid malignancy, while 38 patients were operated for suspicious FNAB or positive lymph nodes. Unifocal disease was detected in 182 (63.6%) patients; with 92 having a focus of 1-5 mm and the remaining a focus of 6-10 mm. Multifocal disease was detected in 104 (36.3%) patients. From these patients, none had distant metastases; however, loco-regional extension and lymph-node involvement were detected in 13 and 29 patients respectively. Two hundred twenty six (79%) patients underwent radioactive iodine ablation for worrisome histological subtypes, thyroid capsule invasion, multifocality or thyroid remnants. The mean follow-up was 8.19 years. Disease recurrence was observed in only one patient (with lobectomy and radiiodine ablation), 20 years after the initial diagnosis. Six patients had persistent disease during the follow-up period, all of whom had undergone near-total thyroidectomy and remnant ablation. The remaining 279 (97.5%) patients were disease free. Conclusions PTMC appears to have a benign course in the majority of patients initially treated with near-total thyroidectomy and therefore, according to the revised ATA thyroid cancer guidelines, additional radiiodine ablation is not justified. However, an aggressive subtype of PTMC seems to exist. More prospective studies or probably molecular markers are needed, in order to identify this subtype.

P478
Incidentally discovered thyroid carcinomas. An experience of a centre through 18 years
Aitzol Lizarraga, Miguel Paja, Maider Sanchez, Borja Barrios, Josu Perez & Vanessa Arosa
Hospital de Basurto, Bilbao, Bizkaia, Spain.

Incidental thyroid carcinoma includes thyroid carcinomas detected after surgery in patients whose thyroid has been correctly studied with no data of malignancy. Lately, the widely spread use of image techniques and thorough search of thyroid nodular complaints, have lead to a growing number of thyroid carcinomas. But still there are some of these incidentally discovered after thyroidectomy. We report 98 cases of thyroid carcinomas incidentally found from a series of 360 thyroid carcinomas (27.2%), diagnosed since 1992. Demographic data, thyroidectomy criteria, histopathology, tumour size, multicentric cases, extension, radioiodine treatment and follow up data were collected. Our results show a mainly female cohort (81.6%), with ages ranging from 21 to 81 years (mean 51.29 and median 31). First 3 cases detected in 1994 and ever since the number has been increasing (14 cases in 2008, 11 in 2009 and 11 in 2010). The criteria for thyroidectomy was nodule size with being cytology (87.7%), associated hyperparathyroidism (6.2%) and hyperhyroidism (3%). Hystopathology result was Papillary thyroid carcinomas (PTC) in 96%. Mean tumour size was 13.5 mm and median of 7 mm, ranging from 1 to 75 mm. Multicentric cases were found in 27.5%. Extra thyroid extension was recorded in 15.3% cases. Radioiodine treatment (131I) was used in 80.8% of PTC. During the years of follow up there has been only one death. Incidental tumours are more common in women of young mean age. PTC of small size, non multicentric and not extended out of the thyroid is the main outcome after thyroidectomy. Most of them underwent 131I treatment. Due to the described features the general prognosis of these cases is good. Careful hystopathologic analysis and standard treatment and follow up is our basic approach. Probably 131I shows overused in our series since retrospectively it was more used in the past.
P479

Evaluation of safety and tolerability of calcitonin stimulation using high-dose calcium in patients with medullary thyroid carcinoma (MTC)
Aldona Kowalska, Iwona Paliya, Danuta Gasior-Perczak, Anna Sluszniai & Stanisław Gozdzi
Holycross Cancer Centre, Kielce, Poland.

The pentagastrin-stimulated calcitonin test is known and widely used in monitoring patients with MTC. Given the problems of pentagastrin availability other diagnostic tests are being tried. The goal of the study was the evaluation of safety and tolerance of high-dose calcium to stimulate calcitonin in MTC patients.

Materials
The study included 41 patients after surgery for medullary thyroid cancer who were under observation. Patients underwent calcitonin stimulation using high-dose calcium while observing tolerance and undesired side effects. Six months earlier the same patients underwent calcitonin stimulation using pentagastrin. Patients compared the tolerability of the two tests.

Results
Undesired side effects occurred in 37 (90%) of 41 patients. The most frequently reported side effects by patients were: feeling heat 35/37, metallic taste 10/37, flushing of face 8/37, sweating 5/37, nausea 5/37, facial paresthesia 4/37, dizziness 1/37, and weakness 1/37. Symptoms occurs in the first or second minute of administering of calcium. Symptoms resolved after 1 to 5 min until the completion of injection. Patients assessment comparing tests using pentagastrin and calcium rated the calcium test: more tolerable 30/41, equally tolerated 10/41, worse tolerated 1/41.

Conclusions
The calcitonin stimulation test using high-dose calcium is safe and well tolerated. Although side effects occurred frequently (90% of patients), most were mild and transient.

P480

Comparison of calcitonin stimulation tests with pentagastrin (Pg) and high-dose calcium in patients with medullary thyroid carcinoma (MTC)
Aldona Kowalska, Iwona Paliya, Danuta Gasior-Perczak, Anna Sluszniai & Stanisław Gozdzi
Holycross Cancer Centre, Kielce, Poland.

Introduction
The Pg calcitonin stimulation test is widely used in monitoring patients with MTC. In view of accessibility problems of Pg it is necessary to use high doses of calcium as the calcitonin stimulant.

Objective
The aim of the study was the comparison of calcitonin concentrations after Pg and calcium stimulation, respectively.

Materials
The study was performed in 31 patients under observation after deemed surgically cured of MTC.

Method
In patients calcitonin secretion stimulation tests were performed first with Pg, and after 6 months with high-dose calcium. Recorded data were analyzed.

Results
i) Baseline calcitonin concentration using Pg was 6,187 (±1,0468), and using calcium was 6,389 (±1,3148).
ii) Pg stimulated calcitonin concentration
   • Mean calcitonin concentration after 3 min was 7.217 (±3,2741).
   • Mean calcitonin concentration after 5 min was 6.992 (±2,4282). No statistically significant increase in calcitonin concentration was found after Pg.
iii) Calcium stimulated calcitonin concentration
   • Mean calcitonin concentration after 3 min was 9.247 (±10,4396).
   • Mean calcitonin concentration after 5 min was 8.122 (±7,7745). No statistically significant increase in calcitonin concentration was found after calcium.
iv) Comparison of calcitonin concentrations stimulated with Pg and calcium. No statistically significant difference was observed at 3 and 5 min between Pg and calcium stimulation of calcitonin.

Conclusions
Calcitonin stimulation tests with Pg and calcium were comparable in patients with deemed surgically cured MTC.

P481

The value of CK19, Ki-67 and p53 expression in the diagnosis of thyroid follicular neoplasms
Mariusz Cornianu, Alis Dema, Sorina Taban, Ioana Golu, Anca Muresan, Remus Cornea, Elena Lazar & Alexandru Faur
UMF ‘Victor Babes’, Timisoara, Timis, Romania.

Introduction
Cytokeratin-19 (CK19), p53 and Ki-67 are some of the proposed markers for differentiating benign from malignant thyroid tumors.

Material and method
We evaluated the tissue expression of the three markers in 60 thyroid lesions including: 8 cases of nodular hyperplasia (NH), 16 follicular adenomas (FA), 26 papillary carcinomas (PC) and 10 follicular carcinomas (FC). Tissue sections fixed in formalin and embedded in paraffin were immunohistochemically (IHC) stained (LSAB technique, visualization with DAB) using monoclonal antibodies anti-Ck19 (clone RCK 108), anti-Ki67 (clone MIB-1) and anti-p53 (clone DO-7); the data were statistically analyzed using the unpaired T-test.

Results
CK19 was significantly expressed only in PC (P<0.001). For p53 and Ki-67 the results of statistical analysis were not significant for the compared pairs.

Conclusions
CK19 is useful in differentiating the follicular variant of PC from FC and PC from the papillary aspects in NH. Immunoreactivity of p53 and Ki-67 was not proven to be useful in differentiating PC from NH, the results being statistically insignificant.

P482

Does preoperative fine-needle aspiration decreases the thyroideectomy rates?
S Cander1, Ö Saraydaroglu2, OK Unal1, Ö Oz Gülı1, A Akkurt1, E Ertünk1 & S Imanoglu1
1Department of Endocrinology and Metabolism, Uludag University, Bursa, Turkey; 2Department of Pathology, Uludag University, Bursa, Turkey.

Introduction
Fine-needle aspiration (FNA) biopsy of thyroid nodules is minimally invasive and safe. The clinical importance of the thyroid nodule evaluation is primarily related to the need to exclude thyroid cancer. We aimed to investigate the relationship between preoperative FNA cytology and results of thyroideectomy in this study.

Materials and Methods
Histopathologic examination reports of 302 patients undergoing thyroideectomy and preoperative FNA cytological reports of 125 patients were included in the study. The results of FNAs were classified as benign, suspicious, malignant and inadequate, postoperative histopathologic results were classified as benign or malignant. Suspicious and malignant cytology were evaluated in same group in terms of surgical indication. The results were compared in patients with and without preoperative FNA.

Results
FNA cytology results were found benign 55.2%, suspicious 19.2%, malignant 10.4% and inadequate 15.2%. After the removal inadequate group, malignant-suspicious and benign results were 34.9 and 65.1% respectively. Malignant disease frequencies was 24.6 and 17.5% for patients with and without preoperative FNA. Benign and malignant disease rates were not statistically significant in both groups. Malignant disease was found 84.6% of patients with malignant cytology, there with suspicious in 37.5 and 8.7% of benign ones. Malignant disease rates was observed 54 and 17.5% as a result of suspicious/malignant cytology and without FNA patients respectively (P<0.01).

Conclusion
The main surgical indication of thyroid nodules is evidence or suspicion of malignancy. We concluded that preoperative FNA significantly reduced (82.5 and 46%) operations performed for benign disease, when patients with malign or suspicious cytology compared to without FNA group. We think that, FNA decreases the risk of unnecessary surgery when performed to determine the indications for thyroideectomy.
Malignancy rate is different in dominant nodule and non-dominant nodule by fine needle thyroid aspiration

Omer Yazgan,1 Fahri Halid Besir,1 Yusuf Aydin2, Sibel Yazgan1, Melih Engin Erkan3, Burhan Yazici3, Ramazan Buyukkaya1 & Omer Orhanc

1Faculty of Medicine, Radiodiagnostic Department, Duzce University, Duzce, Turkey; 2Faculty of Medicine, Endocrinology and Metabolism Department, Duzce University, Duzce, Turkey; 3Faculty of Medicine, Nuclear Medicine Department, Duzce University, Duzce, Turkey.

Objective
Thyroid fine-needle aspiration biopsy (FNAB) is the golden standard for approaching thyroid nodule’s malignancy. It is recommended to carry out an FNAB from the dominant nodule in multi nodular goiter. In our study, we compared the FNAB results that we carried out from dominant nodule and any other nodule which have features that may be malignant to US. Besides, the relationship between the results of cytology and US features of nodules has been analyzed.

Material and methods
One hundred and ninety-seven cases diagnosed MNG were analyzed between 2009–2010. These cases followed by applying to endocrinology polyclinic were carried out FNAB from both dominant nodule and non-dominant nodule. Whole cystic nodules, nodules with peripheral calcification and nodules that its FNAB result has poor material were not used in the study and 171 cases were used. As a malignancy criterion at US, including hypo echoic pattern, solid structure, micro calcification features of nodule and not having peripheral halo feature of nodule were used. In statistical analyze, P < 0.05 was accepted as significant.

Results
While malignancy rate was found 1.8% in dominant nodules, in non-dominant nodules malignancy rate was found 0.6% (total malignancy rate: 2.4%). In the cytological analyze of non-dominant nodules, malignancy rate was found significantly high (P < 0.001) which those including micro calcification. In nodules not having peripheral halo, malignancy rate was also found significantly high (P = 0.048). It was not determined statistically significant relation between malignancy and, hypo echoic pattern, solid structure as US features of nodules.

Conclusions
According to our data, the last UICC/TNM classification did not provide better prognostic information for low and intermediate risk patients, however further studies with a longer follow-up and a larger number of patients are needed to confirm these findings.

Very low-risk papillary thyroid carcinoma: where to set the limits?


Instituto Português de Oncologia de Coimbra FG EPE, Coimbra, Portugal.

Currently there is no widely accepted definition of very low-risk papillary thyroid carcinoma (PTC). Although unifocal microcarcinomas without extrathyroidal extension and no local or distant metastases have been recognized as having an excellent overall prognosis the threshold for such a favourable clinical behaviour remains controversial. The study aim was to identify the clinicopathological characteristics of T1 tumours (≤2 cm) presenting a very low-risk of mortality or recurrence. We retrospectively reviewed the medical data of 258 patients with PTC presenting the following characteristics: TI N0 M0 disease, no history of head-neck irradiation, all macroscopic tumour had been resected and the tumour did not have aggressive histological subtype. Periodic follow-up included clinical and ultrasound examination and serum Tg, TSH and antithyroglobulin antibodies measurements. Other imaging modalities were used as required. There were 226 (87.6%) female patients. Mean age at diagnosis was 48.0 years (range, 22-79 years). One hundred ten patients were classified as T1b. The majority of the patients (93.4%) were treated with total or near-total thyroidectomy. Forty-nine patients (18.9%) underwent a variety of cervical lymph node dissections. Radioiodine ablation therapy was administered to 111 patients (43.0%). Patients were followed for a median of 8.2 years after thyroidectomy. Residual/recurrent disease in regional lymph nodes was identified in six patients (2.3%). There was no disease-specific mortality and none of the patients developed distant metastases during follow-up. All patients were considered free of disease at the last follow-up. This study shows that it is possible with a simple set of criteria to accurately identify a subgroup of T1N0M0 PTC patients with very low-risk of recurrence. Our results may suggest that these very low-risk patients may be effectively treated with a conservative management strategy in terms of surgical treatment (extent of thyroidectomy and prophylactic lymph node dissections), radioiodine ablation therapy and levotyroxine therapy.

Very low-risk papillary thyroid carcinoma: where to set the limits?


Instituto Português de Oncologia de Coimbra FG EPE, Coimbra, Portugal.

Currently there is no widely accepted definition of very low-risk papillary thyroid carcinoma (PTC). Although unifocal microcarcinomas without extrathyroidal extension and no local or distant metastases have been recognized as having an excellent overall prognosis the threshold for such a favourable clinical behaviour remains controversial. The study aim was to identify the clinicopathological characteristics of T1 tumours (≤2 cm) presenting a very low-risk of mortality or recurrence. We retrospectively reviewed the medical data of 258 patients with PTC presenting the following characteristics: TI N0 M0 disease, no history of head-neck irradiation, all macroscopic tumour had been resected and the tumour did not have aggressive histological subtype. Periodic follow-up included clinical and ultrasound examination and serum Tg, TSH and antithyroglobulin antibodies measurements. Other imaging modalities were used as required. There were 226 (87.6%) female patients. Mean age at diagnosis was 48.0 years (range, 22-79 years). One hundred ten patients were classified as T1b. The majority of the patients (93.4%) were treated with total or near-total thyroidectomy. Forty-nine patients (18.9%) underwent a variety of cervical lymph node dissections. Radioiodine ablation therapy was administered to 111 patients (43.0%). Patients were followed for a median of 8.2 years after thyroidectomy. Residual/recurrent disease in regional lymph nodes was identified in six patients (2.3%). There was no disease-specific mortality and none of the patients developed distant metastases during follow-up. All patients were considered free of disease at the last follow-up. This study shows that it is possible with a simple set of criteria to accurately identify a subgroup of T1N0M0 PTC patients with very low-risk of recurrence. Our results may suggest that these very low-risk patients may be effectively treated with a conservative management strategy in terms of surgical treatment (extent of thyroidectomy and prophylactic lymph node dissections), radioiodine ablation therapy and levotyroxine therapy.
P487
Synchronous thyroid and gastric diffuse large B cell lymphoma
Mustafa Altay, Fusun Balos Toruner, Fatih Karakaya, Nuri Cakir & Metin Arslan
Gazi University Medical Faculty, Ankara, Turkey.

Introduction
Thyroid lymphoma is a rare disease. Furthermore, coincidence of extrathyroidal lymphoma is very rare.

Case
A 69 years-old woman patient was admitted to the hospital with dyspnea, hoarse voice and swelling of throat for a month. In her history, she had been diagnosed as gastric lymphoma 6 years ago, while she was being investigated for upper gastrointestinal bleeding. Six cures of chemotherapy has been applied. She was not on follow up. In physical examination, she looked cachectic and dyspneic. Thyroid was enlarged diffusely and multiple nodules were palpated. Trachea was shifted and pressed by the thyroid. Laboratory tests were as follows: Hgb: 10.1 g/dl; TSH: 0.8 μU/ml (0.6–4.8), T4: 1.1 ng/dl (0.74–1.52), T3: 1.3 pg/ml (2.3–4.2), anti-TPO: 133 U/ml (0–57), anti-T: 130 U/ml (0–64), Tg: 155 (1.6–59.9) ng/ml. Thyroid ultrasonography revealed chronic thyroiditis and multinodular goitre. FNA biopsy was performed to the nodules and diffuse large B cell lymphoma (CD 20 was positive, CD3 and CD30 were negative) was detected. Also, diffuse large B cell lymphoma was revealed at the endoscopic gastric biopsy specimen, too (CD 20 and bcl-6 were positive and Ki-67 proliferation index was 99%). At radiological evaluation for the staging of disease, subcarinal and parastrachal lymphadenopathies and multiple nodules in each of the lungs were detected. Because her performances status was poor, bronchoscopy could not be applied. After several days, her performance status worsened and she died.

Conclusion
In this case report, we purposed to remind that thyroid nodules which were developed on the base of chronic thyroiditis should be immediately evaluated for lymphoma, especially in cases which gastric or another organ lymphoma had been detected synchronously.

P488
Radioiodine therapy and age at menopause in women with differentiated thyroid cancer
T Martins, T Azevedo, M Martinho, S Oliveira, J Neto & F Rodrigues
Oncology Institute of Coimbra, Coimbra, Portugal.

Introduction
Radioiodine (¹³¹I) is widely used in the treatment of patients with thyroid cancer. This therapy is associated with some adverse effects including possible impairment of ovarian function and earlier menopause.

Objective
The aim of this study was to evaluate female fertility after treatment with ¹³¹I of differentiated thyroid cancer (DTC).

Methods
We retrospectively analysed 250 women with DTC treated with ¹³¹I. We selected those who had received the first ¹³¹I before or at the age of 45 and who still presented regular menses on this occasion. Hysterectomized patients and those submitted to external pelvic radiotherapy or chemotherapy before menopause were excluded. Only 33 women filled these criteria. The control group consist of 64 women with multinodular goiter (MNG) in whom we applied the same criteria.

Results
The age at menopause was 49.3 ± 3.8 years in the group of women with DTC and 49.41 ± 3.8 years in the group with MNG (P = ns). We didn’t find any difference between the age at menopause and the number of therapies. We found a marginally significant correlation (R² = 0.116; P = 0.05) between the cumulative dose of ¹³¹I and the age at menopause.

Conclusion
In our study the age at menopause was similar between the 2 groups. We verified a correlation between the cumulative dose of ¹³¹I and age at menopause: higher doses were associated with earlier menopause.

P489
Value of sonographic index point and resistivity index in the diagnosis of the malignant potential of nodular thyroid disease
V Jain¹, J N Toppo², K Masih³ & J J Jacob⁴
¹Department of Radiology, Christian Medical College and Hospital, Ludhiana, Punjab, India; ²Department of Pathology, Christian Medical College and Hospital, Ludhiana, Punjab, India; ³Endocrine Unit, Department of Medicine, Christian Medical College and Hospital, Ludhiana, Punjab, India.

Objective
To assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of sonographic index point and resistivity index in predicting the risk for malignancy in thyroid nodules.

Methods
Fifty consecutive patients undergoing thyroid ultrasound for clinical nodular thyroid diseases prior to planned surgery were recruited for the study. Sonographic index point was calculated for each nodule using morphological characteristics (margins, shape, echogenicity, echostructure and nature of calcification) as a score. Spectral analysis was performed from the region showing maximum colour flow on 1 to 3 arteries of greater calibre in each nodule. Resistivity index (RI) was recorded as an average of indices obtained.

Results
There were 16 (5M/11F) malignant lesions and 34 benign lesions (4M/30F) among the study patients. The sonographic index points for malignant nodules were in the range of 3–8 and for benign lesions 1–7. The sonographic index point at a cut off value of > 2 had a sensitivity of 93.7%, specificity of 75.3%, PPV of 15.7% and NPV of 98.4% in differentiating malignant from benign nodule. Using resistivity index at a cut off value of 0.75 showed sensitivity of 81.5%, specificity 92.3%, PPV 95.6% and NPV of 70.5%. A combination of both the indices had a sensitivity of 89.2%, specificity of 92.3%, PPV of 97%, NPV of 75% and diagnostic accuracy of 90%.

Conclusions
Sonographic index point had high sensitivity and with a high negative predictive value for diagnosing malignant nodules despite poor specificity. In combination with the Resistivity index there was improvement in the specificity with some loss of sensitivity but with a diagnostic accuracy of over ninety percent.

P490
Retrospective analysis of predictive factors for recurrence during long term follow-up in papillary thyroid cancer patients who had remission after primary treatment
Özlem Soylük, Harika Boztepe, Ferihan Aral & Nese Colak
Division of Endocrinology and Metabolism, Istanbul Medical Faculty, Department of Internal Medicine, Istanbul, Turkey.

The aim of our study is to detect parameters which may predict recurrences during long-term follow-up in papillary thyroid cancer patients who achieved remission after primary treatment. The data of 492 patients who achieved selected remission criteria after primary treatment were recorded. Remission criteria were for anti-thyroglobulin (antiTg)-negative patients: no uptake in first iodine-131 whole body scan (WBS) after primary treatment and stimulated thyroglobulin (Tg) level < 2 ng/ml when TSH > 30 μU/ml. Recurrence was detected in 12 of 492 patients (2.4%). Tumor size, stimulated Tg concentrations and frequency of antiTg positivity at first WBS and duration of follow up were significantly higher in patients with recurrence compared with remaining patients (P: 0.024, 0.013, 0.01, 0.002 respectively). Patients with stimulated Tg ≥ 0.25 ng/ml at first WBS had significantly higher frequency of recurrence compared with patients having Tg < 0.25 (P: 0.009). Cox regression and Kaplan-Meier survival analyses indicated that lymph node metastasis at initial presentation was the only parameter significantly related to recurrences during follow-up (P: 0.011, 0.01 respectively). We conclude that patients with lymph node metastases at presentation and relatively higher (>) 0.25 ng/ml Tg and anti-Tg positivity at first WBS have higher risk for recurrence.
**Factors connected with the female sex – association with differentiated thyroid cancer**

E P M Przybylak-Mazurek, A H D Hubalewska-Dydejczyk, A F Fedorowicz & D P Pach

Medical College of Jagiellonian University in Krakow, Krakow, Poland.

Differentiated thyroid cancer (DTC) is more frequent in women than in men. The aim of the study was to analyze whether factors connected with the female sex could increase the risk of DTC.

**Material and methods**

Ninety nine patients with a mean age ± s.d. of 40.5 ± 5.9 years with DTC and 51 healthy women with a mean age of 36.52 ± 8.3 years were examined. Gynecological and obstetric histories were taken and serum estradiol and progesterone levels were analyzed in all women.

**Results**

Patients with DTC had more frequent menstrual cycle disturbances, used hormone-containing medicines more frequently, were multiparous more frequently, had spontaneous miscarriages more frequently, and their duration of lactation was significantly shorter than in controls. The mean serum estradiol level ± s.d. in women with DTC was significantly higher than in the controls, in the follicular phase 193.74 ± 66.31 vs 157.63 ± 42.88 pmol/l and in the luteal phase 519 ± 176.9 vs 369 ± 71.49 pmol/l. The mean serum progesterone level ± s.d. was higher in the controls than in DTC patients in the follicular phase: 2.11 ± 0.70 vs 1.38 ± 0.56 nmol/l, in the luteal phase 20.95 ± 17.46 vs 17.31 ± 12.28 nmol/l.

**Conclusions**

The results of these studies imply that multiparity and gynecological or obstetric disorders connected with excessive activity in endogenous or exogenous estrogens were more frequently observed in patients with differentiated thyroid cancer than in healthy ones. The female sex hormones probably intensify the actions of other carcinogens as well.

---

**Bone/calcium/Vitamin D**

**P491**

Does vitamin D replacement therapy improve insulin sensitivity in elderly?

Ilkin Naharci1, Nurı Karadurmus2, Ergun Bozoglu3, Turker Turker4, Huseyin Doruk3 & Muhittin Serdar4

1Division of Geriatrics, Gulhane Medical Faculty Training Hospital, Department of Internal Medicine, Ankara, Turkey; 2Gulhane Medical Faculty Training Hospital, Department of Internal Medicine, Ankara, Turkey; 3Gulhane Medical Faculty Training Hospital, Department of Epidemiology, Ankara, Turkey; 4Gulhane Medical Faculty Training Hospital, Department of Medical Biochemistry, Ankara, Turkey.

**Introduction**

Vitamin D has a potentially beneficial role in insulin resistance, but there is a lack of evidence in elderly. We report preliminary results of an ongoing study that investigated the effect vitamin D replacement treatment (12 weeks) on insulin resistance and metabolic parameters in elderly people with normal glucose tolerance.

**Methods/design**

The study’s eligibility criteria were body mass index < 30.0 kg/m², creatinine levels < 1.2 mg/dl, no evidence of prediabetes and diabetes, no self-reported use of hypoglycemic drugs, and fasting serum glucose < 100 mg/dl. Eighty-six participants (aged ≥65 years) were eligible for the present investigation. Serum concentrations of 25(OH)D were categorized as deficient (group I < 20 ng/ml), insufficient (group II, 20 to 30 ng/ml), or normal (group III, > 30 ng/ml) vitamin status, respectively. Group I was treated initially with 300 000 international units of vitamin D3 ampoule orally once for six weeks, and then 880 IU of vitamin D3 status, respectively. Group I was treated initially with 300 000 international units of vitamin D3 ampoule orally once for six weeks, and then 880 IU of vitamin D3.

**Results**

There were no significant differences in all baseline parameters except vitamin D levels among three groups. After 12 weeks of vitamin D replacement therapy, 95.3% of all subjects had 25(OH)D levels within the normal range with a mean level of 34.3 ± 13.3 ng/ml. There was a significant reduction in HOMA-IR scores in group I (P < 0.001), but not in group II (P = 0.074) and group III (P = 0.123).

**Conclusion**

We found that supplementation in vitamin D deficient subjects may modify insulin sensitivity in elderly.

---

**P493**

Increased circulating levels of FGF23 an adaptive response in primary hyperparathyroidism?

J E Wittenveen, A H van Lierop, S E Papapoulos & N A T Hamdy

Leiden University Medical Center, Leiden, The Netherlands.

**Introduction**

Fibroblast growth factor 23 (FGF23) and PTH have been identified as major players in the bone-parathyroid-kidney axis controlling phosphate homeostasis. In patients with primary hyperparathyroidism (PHPT) data on the relationship between PTH and FGF23 are scarce and not always concordant.

**Objective**

The aim of our study was to evaluate whether the relationship between PTH and FGF23 was altered in patients with primary hyperparathyroidism and whether, if present, this alteration was sustained after cure following successful parathyroidecemy.

**Patients and methods**

We identified 22 patients with primary hyperparathyroidism (PHPT) and 24 patients with long-term cure after successful Ptx (EuPTH). All patients underwent biochemical evaluation of renal function, parathyroid status, vitamin D status, bone turnover markers and serum intact FGF23 levels.

**Results**

Mean serum FGF23 concentration was significantly higher in EuPTH patients (50.4 ± 27.2 vs 33.1 ± 12.5 pg/ml, P = 0.011). FGF23 levels significantly correlated with PTH levels (r = 0.362, P = 0.013), even after correction for 1,25(OH)2D levels (r = 0.422, P = 0.01). FGF23 levels showed a significant negative correlation with 1,25(OH)2D, which was more pronounced in PHPT than in EuPTH patients (r = -0.780, P = 0.000 vs r = -0.519, P = 0.023).

**Conclusion**

Our findings suggest that in PHPT, increased PTH levels can directly stimulate FGF23 production and that this increase is reversible when eucaparathyroidism is achieved. Based on the greater negative relationship between FGF23 and 1,25(OH)2D in PHPT patients, we propose that the PTH-induced increase in FGF23 levels may be an adaptive mechanism to prevent the potential deleterious effects of 1,25(OH)2D on phosphate homeostasis.

---

**P494**

Effects of ibandronate versus risendronate on hip bone density in the osteoporotic elderly

Ilkin Naharci1, Ahmet Turan Isık3, Ergun Bozoglu4, Ozdes Emer2, Turker Turker5, Metin Uyanık6, Muhittin Serdar7 & Huseyin Doruk1

1Division of Geriatrics, Gulhane Medical Faculty Training Hospital, Department of Internal Medicine, Ankara, Turkey; 2Gulhane Medical Faculty Training Hospital, Department of Nuclear Medicine, Ankara, Turkey; 3Gulhane Medical Faculty Training Hospital, Department of Medical Biochemistry, Ankara, Turkey.

**Introduction**

The aim of this study was to investigate whether monthly ibandronate improves hip bone mineral density (BMD) to the same degree as weekly risendronate in osteoporotic elderly.

**Material and methods**

Eighty-one older adults with osteoporosis, age ranging from 65 to 95 years (mean: 77.5 years) were completed the study. Patients were treated either ibandronate 150 mg once monthly (n = 56) and risendronate 35 mg once weekly (n = 25). Changes in BMD at the total hip, neck, and trochanter, changes in bone turnover markers, and safety were compared at 12 months.

**Results**

There were no significant differences in all baseline parameters for two groups. After treatment in the ibandronate group, BMD was significantly increased by 3.6%, 3.3%, and 3.7% at the total hip, neck, and trochanter, respectively, as compared with baseline (P < 0.001, for all comparisons). In the risendronate group, BMD was also significantly increased by 3.60, 3.24, and 3.78% at the total hip, neck, and trochanter, respectively.
Results

Group B have significantly higher hip bone mineral density, than group A
($\chi^2 = 10.17$, $P = 0.0014$, $\chi^2 = 7.76$, $P = 0.0048$). There was no significant
difference between two groups in bone mineral density of lumbar spine
$\chi^2 = 0.03$, $P = 0.8558$ with correction for continuity $\chi^2 = 0.1$, $P = 0.9186$).

Conclusion

Postmenopausal women with BMI 25–30 kg/m$^2$ have higher hip bone mineral
density, alto overweight has no influence on lumbar spine mineral density.

---

**P497**

Incidence of osteoporosis study in premature ovarian failure
I Bistrițeanu$^1$, M E Preda$^1$, M Bistrițeanu$^2$, M Popescu$^2$, B Bicu$^1$
& L Putineu$^3$

$^1$Department of Endocrinology, Emergency Hospital, Craiova, Romania;
$^2$Department of Endocrinology, University of Medicine and Pharmacy,
Craiova, Romania; $^3$Department of Gynaecology, Clinical Affections and
Geriatric Hospital’s, Craiova, Romania.

At patients with premature ovarian failure, follicular endowment is very low and
therefore is deficient ovarian hormonogenesis. As the number of follicles is lower,
the lifetime of the ovary is reduced, representing a clinical spectrum from total or
partial absence of pubertal sexualisation by early onset climacteric.

The disruption of ovarian hormones that control bone homeostasis, is disturb-training
report bone resorption with decreased bone mass and osteoporosis.

Method

The study was conducted on 48 patients whose age ranged between 20–38 years.
Investigations were focused on the study hormonology FSH, LH, PRL, oestradiol,
progesterone. Pelvic ultrasound was also performed utero-ovarian. At all patients
the bone mineral density (BMD) was assessed by dual X-ray absorptiometry
(DXA). As biochemical markers of bone turnover were studied and serum
Osteocalcin CrossLaps by ELISA.

Results

Hormonal dosages showed low levels of oestradiol and progesterone, but those of
gonadotrophic hormones (LH, FSH) were between 210–385 ml/ml (upper limit of
normal: 0.110 to 190 ml/ml). BMD measurement showed the presence of osteoporosis in 22 cases, representing 45.8% of all cases investigated. BMD is
correlated with biochemical markers of bone turnover.

Conclusion

i) A study of BMD and biochemical markers of bone turnover in premature
ovarian failure, it must be conducted regularly to identify patients who rapidly
lose bone mass and increased risk of osteoporosis.

ii) The estrogen-progesterone substitution represents the therapeutic attitude which is
the first choice for premature ovarian failure to prevent osteoporosis, and
metabolic complications of vesical.

iii) Patients with osteoporosis will be associated the antiresorption or
proformation medication to prevent fragility fractures.

---

**P498**

Bone markers of osteoblast/osteoclast activity in postmenopausal
osteoporosis

C Gurban$^1$, M Balas$^2$, S Gotia$^3$, L Gotia$^3$, D Drugarin$^4$ & I Zosin$^2$

$^1$Department of Biochemistry, University of Medicine and Pharmacy
Victor Babes’, Timisoara, Romania; $^2$Department of Endocrinology,
University of Medicine and Pharmacy ‘Victor Babes’, Timisoara, Romania;
$^3$Department of Physiology, University of Medicine and Pharmacy ‘Victor Babes’,
Timisoara, Romania; $^4$Department of Immunology, University of

Aim

The aim of this study was to assess the implications of TRACP-5b (bone tartrate-
resistant acid phosphatase isoform-5b), BAP (bone alkaline phosphatase) BGP
(bone Gla protein) and E2 estradiol) in bone remodelling process, in osteoporotic
postmenopausal women.

Material and method

The study comprised two groups of women with postmenopausal osteoporosis
(with different degrees of estrogenic deprivation): group I ($n=48$, estrogenic
depression $<15$ years) and group II ($n=26$, over 15 years of estrogenic
depression), compared to a control group ($n=20$, postmenopausal women

---

**P495**

Overweight and risk for osteoporosis

Snezana Polovina$^1$, Klara Tucic Nemet$^1$, Jelena Micic$^2$,
Kovijika Milenkovic Vulovic$^3$, Dusan Micic$^1$ & Dragan Micic$^5$

$^1$General Hospital Subotica, Subotica, Serbia; $^2$Medical Center
Cacak, Cacak, Serbia; $^3$Emergency Center, Clinical Center of Serbia,
Belgrade, Serbia; $^4$Clinic for gynecology and obstetrition, Clinical Center of
Serbia, Belgrade, Serbia; $^5$Clinical Center of Serbia, Belgrade, Serbia.

BMI over 30 kg/m$^2$ is associated with lowest risk for osteoporosis and hip fracture
in both sex. Increased body fat mass is followed with greater hip fracture risk,
independently of BMI.

Aim

Evaluate risk for osteoporosis in postmenopausal female with BMI 25–29.9 kg/m$^2$
and influence of body fat mass on mineral density of bone.

Material and methods

One hundred postmenopausal female, age 48–88 (62.8 ± 12.3), divided in two
groups: group A, BMI 20–24.9 kg/m$^2$ (N = 19) and group B, BMI 25–29.9 kg/m$^2$
(N = 81) and according of body fat mass on group A1 with < 30% fat mass (N = 4),
and B1 with more than 30% fat mass (N = 86). Mineral bone density (femoral
neck) percentage of body fat mass was measured by DEXA. Break point for osteoporosis was – 2.5 s.d.

Results

In group B bone mineral density was more than group A ($\chi^2 = 10.17$, $P = 0.0014$
with correction for continuation $\chi^2 = 7.96$, $P = 0.0048$). Between A1 and B1 there
was no difference according osteoporosis appearance ($\chi^2 = 0.42$, $P = 0.5176$
with correction for continuation $\chi^2 = 0.01$, $P = 0.9297$).

Conclusion

Postmenopausal female with BMI from 25 to 30 kg/m$^2$ have more mineral bone
density than normal weight female, and lower risk for osteoporosis. Percentage of body fat mass 30–51% in overweight post menopausal female has no influence
on bone mineral density.
without osteoporosis). Serum levels of the above mentioned bone markers were measured by ELISA technique.

Results
The levels of TRACP-5b were significantly higher in postmenopausal osteoporosis (group I: 4.21 ± 1.18 U/L, P < 0.001, group II: 4.57 ± 1.41 U/L, P < 0.0001) versus control group (2.45 ± 1.07 U/L), demonstrating osteoclastic activity.

BAP levels increased in postmenopausal osteoporosis (group I: 13.76 ± 0.6 μg/L, P < 0.001, respectively group II: 11.88 ± 0.38 μg/L, P < 0.0001) versus control group (8.68 ± 0.44 μg/L), showing osteoblastic activiation.

Serum BGP levels in postmenopausal osteoporosis were increased in group I (13.65 ± 0.87 ng/mL, P < 0.004) versus control group (12.62 ± 0.79 ng/mL, P < 0.004) attesting osteoblastic activation and decreased in group II (15.12 ± 1.55 ng/mL, P < 0.05) versus control group (16.22 ± 1.62 ng/mL), secondary to osteoblastic apoptosis stimulation.

Estradiol levels were significantly lower in both study groups as compared to control groups (group I: 10.23 ± 0.54 pmol/l, P < 0.004 and group II: 19.66 ± 1.25 pmol/l, P < 0.0002). Estradiol levels correlated with low bone mineral density (in group I: spine BMD = 0.639 ± 0.051 g/cm², P < 0.0003 and femoral BMD = 0.653 ± 0.042 g/cm², P < 0.0002; in group II: spine BMD = 0.563 ± 0.012 g/cm², P < 0.0002, respectively femoral BMD = 0.577 ± 0.015 g/cm², P = 0.0003) versus control group (spine BMD = 0.773 ± 0.141 g/cm² and femoral BMD = 0.785 ± 0.128 g/cm²).

Conclusion
This imbalance of bone markers reflects a decreased bone formation and an increased bone resorption. This will lead to bone demineralization and osteoporotic bone microfractures.

P500
Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density
M Piedra1, M T García-Unzueta3, A Berja1, J A Riancho2,4, C Valero2, B Paule1, B A Lavín1 & J A Amado1,4
1Endocrinology Service ‘Marqués de Valdecilla’ University Hospital, Santander, Spain; 2Internal Medicine Service ‘Marqués de Valdecilla’ University Hospital, Santander, Spain; 3Clinical Biochemistry Service ‘Marqués de Valdecilla’ University Hospital, Santander, Spain; 4University of Cantabria, Santander, Spain.

Background
Primary hyperparathyroidism (PHPT) affects mainly cortical bone. It is thought that PTH indirectly regulates the activity of osteoclasts by means of the osteoprotegerin/ligand of the receptor activator of nuclear factor-κB (OPG/RANKL) system. Several studies have confirmed that OPG and RANKL loci are determinants of bone mineral density (BMD) in the general population. The aim of this study is to analyze the relationship between fractures and BMD and the 163 A/G, 245 T/G and 1181 G/C SNPs of the OPG gene and the rs227438 SNP of the RANKL gene, in patients with sporadic PHPT.

Methods
We enrolled 298 Caucasian patients with PHPT and 328 healthy volunteers in a cross-sectional study. We analyzed anthropometric data, history of fractures or renal lithiasis, biochemical determinants including markers for bone remodelling, BMD measurements in the lumbar spine, total hip, femoral neck and distal radius, and genotyping for the SNPs to be studied.

Results
Significant lower BMD in the distal radius with similar PTH levels was found in the minor allele homozygotes (GG) compared to heterozygotes and major allele homozygotes in both OPG 163 A/G and OPG 245 T/G SNPs in those with PHPT but not in control subjects. We found no difference between genotypes of the OPG 1181 G/C SNP with regard to BMD in the PHPT subjects. However, we did find higher BMD in the lumbar spine in the CC than in the GG genotype group in the control subjects.

Conclusions
Our study provides the first evaluation of the relationship between SNPs of the OPG/RANK system and sporadic PHPT. Subjects with PHPT and GG genotype for the OPG 163 A/G and 245 T/G SNPs have lower BMD in the distal radius, and this association does not appear to be mediated by differences in PTH serum levels.

P499
Osteoporosis in the women with metabolic syndrome
Lali Kilasonia, Nino Rusia, Luba Lagvilava & Tamara Burchuladze
‘Medallia’ clinic, Tbilisi, Georgia.

Background
It is recognized worldwide that the endocrine diseases lead among the causes of secondary osteoporosis. Based on many studies there was established the frequency of osteoporosis during the thyroid disorders, diabetes mellitus, hyperinsulinemia. The most obscure in this line is the metabolic syndrome. The study of bone mineral density index during the metabolic syndrome is interesting from the aspect that until now the obesity has been considered to be the prevention of osteoporosis...

Objectives
The objective of the work was to study the bone mineral density in women with metabolic syndrome, detection of correlations between the bone metabolism and those criteria which accompany the metabolic syndrome.

Methods and materials
Ninety women with metabolic syndrome (MS) were studied, aged 25–50 (the average age 30.5–40.7). The diagnosis included the body mass index (BMI), fat distribution variants, obesity accompanying complications. All patients underwent the oral glucose meal, fasting blood sugar test, fasting immunoreactive insulin test and glucose loading insulin test. The patients were divided into 3 groups: 1st Group – 34 women with full MS diagnosis (30.7%), 2,27 apitients with MS diagnosis without carbohydrate metabolism disorder (39%). 3,29 patients with MS diagnosis without dislipidemia. All patients underwent the densitometric study by the dual energy X-ray absorption densitometers (Hologic Q-1000); the bone mineral density was measured in lumbar vertebrae, in the femoral neck, distal forearm area, using Tscore criterion.

Results
The results of the study appeared to be interesting not only for determination of the osteoporosis frequency during MS but for establishment of rhetoric relations between obesity and bone mineral density; out of 90 patients in 31 cases the low bone mineral density (T ≤ −2.5) was fixed mainly (35%) in the femoral neck – 11 patients, Ward’s triangle – 10 patients and in the distal forearm area – 20 patients. The osteoporotic syndrome (T ≤ −2.0) was revealed in 11 patients mainly in those skeleton fragments which are represented with the cortical bones. From the aspect of patient’s age the frequency of low bone density index was very surprising.

Conclusion
The more frequent low bone mineral density was revealed during MS with hyperinsulinemia. No correlation between the BMD index and dislipidemia quality was revealed. Obesity does not exclude the osteoporosis during MS and correlated with the gravity of syndrome.

P501
Vitamin D deficiency in Spain: a population-based cohort study
I Gonzalez-Molerio1, S Valdes1, S Morcillo1, V Perez-Velazquez1, P Botas2, E Delgado2, E Menendez2 & E Soriguera3
1Hospital Carlos Haya, Malaga, Spain; 2Hospital Central de Asturias, Oviedo, Spain.

Background
Vitamin D deficiency is common worldwide. No homogenous reference values have yet been established and no studies of values have been done in Spain involving a large number of participants.

Objective
To study the population concentrations of vitamin D in a representative sample of the Spanish population.

Subjects/methods
The study involved two cohorts from Spain, the Asturias Study and the Pizarras Study, which are two prospective, population-based studies involving 2260 participants. In 1262 subjects (age: 20–83 years) we studied 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), calcium, phosphorus and creatinine.

Results
The median population values of 25-hydroxyvitamin D and iPTH were 22.46 ng/ml and 42.29 pg/ml respectively. The values of 25-hydroxyvitamin D were significantly higher in summer and correlated with age (β = −0.05 ± 0.01, P = 0.0003), creatinine (β = 6.42 ± 1.17, P < 0.0001) and iPTH (β = −0.07 ± 0.01, P < 0.0001), but not with calcium, phosphorus or sex. The increase in iPTH with age was seen regardless of the vitamin D values and was greater in the older persons. The concentration of iPTH rose continuously with effect from 30 ng/ml. Values above 35 ng/ml were associated with a significantly lower concentration of iPTH.
Conclusions
One third (33.9%) of the Spanish population may be at risk for Vitamin D deficiency. 25-hydroxyvitamin D values above 30 ng/ml can safely discard "hyper PTH". The increase in iPTH concentration is greater in older persons for similar values of 25-hydroxyvitamin D.

P502
Serum testosterone and estradiol in relation to bone mineral density, muscle strength and body composition in elderly men
A A Hammadi 1, Z. A Hassan 1, F K Hamad 2, D M Abaza 1, K M Abdel Hammid 1 & M E K El Waeel 2
1 Ain Shams University, Cairo, Egypt; 2 Al Azhar University, Cairo, Egypt.

Objective
Sex steroids play an important role in the maintenance of bone health. However, there is limited information on the association between sex hormones and age-related bone loss in men. Our objective was to study the relationship between sex steroid levels and the changes accompanying aging process, including bone mineral density (BMD), muscle strength and body composition in elderly Egyptian men.

Methods
Free testosterone (FT), estradiol (E2) and sex hormone-binding globulin (SHBG) were measured in thirty elderly men, age range 60–73 years, and 15 young men (age range 30–36 years). Patients receiving hormonal ablation for prostate expressed and patients with chronic liver, renal disease or receiving corticosteroids were excluded. Sex steroid levels were correlated to BMD measured by DXA, lower limbs muscle strength calculated by isotonic Biodex dynamometry and body composition assessed by body fat analyzer.

Results
FT and E2 levels were significantly lower in elderly men compared to young group (P < 0.01), whereas SHBG significantly increased with age (P < 0.01). Peak torque values of both extensors and flexors were significantly lower in elderly men (P < 0.01). Low BMD was found in 90% of elderly men; osteopenia (60.5%) and osteoporosis (29.5%). E2 levels were associated positively with BMD at neck with muscle strength and lean mass; so older men with lower FT could be more significant negative correlation with lean mass and muscle strength (r = −0.833, P < 0.01).

Conclusions
FT is not associated with BMD in elderly men, however, FT has strong relation with muscle strength and lean mass; so older men with lower FT could be more liable to falls. Elderly men with low E2 are more likely to be osteoporotic as E2 is an important determinant of bone density changes in old age.

P503
Differential gene expression in Runx2 and osterix double heterozygotes during skeletal development
J E Baek 1,2, Y H Kim 1, W Y Baek 1,2, B de Crombrugghe 1, J Y Choi 1,2 & J E Kim 1,2
1 Kyungpook National University School of Medicine, Daegu, Republic of Korea; 2 Cell and Matrix Research Institute, Daegu, Republic of Korea; 3 Keimyung University School of Medicine, Daegu, Republic of Korea; 4 University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

The transcription factors Runx2 and osterix (Oxs), which are known as downstream genes in BMP2 pathway, are essential for osteoblast differentiation and bone formation. Runx2 expression is normal in Oxx null mice, but Oxs is not expressed in Runx2 null mice, indicating that Oxs acts as a downstream of Runx2. Here, we questioned whether or not both genes could be formed by BMP2-Runx2-Osx pathway or unknown their own gene axis. To answer this question, we first analyzed bone phenotype of Runx2;Oxx double heterozygotes which were generated by Runx2 and Oxs heterozygous mice. Compared to each Runx2 and Oxs heterozygous embryos, Runx2;Oxx double heterozygotes showed a reduction of the length of long bones including humerus and femur. Maxillary and palatine shelf, presphenoid bone, zygomatic bone, and tympanic ring were hypoplastic or missing. Severe inward bendings were observed in ribs and humerus. In histological analysis, the region of hypertrophic chondrocytes was expanded and the area of mineralized bone was reduced in Runx2;Oxx double heterozygotes. To further elucidate the difference of Runx2 and Oxx downstream target genes in skeletal development, DNA microarray analysis was conducted in calvaria of Runx2, Oxx, and Runx2;Oxx double heterozygotes. Many genes involved in cell cycle regulation, growth and apoptosis, immune response, extracellular matrix structure, skeletal development and morphogenesis were upregulated or downregulated in Runx2;Oxx double heterozygotes. Especially, among skeletal development related genes, matrilin 1 and 4, hyaluronan and proteoglycan link protein 1, aggrecan, epiphycan, Col1a1, Col9a1, and Sox9 were decreased, while JunD, peptidase inhibitor 16, elastin microfibril interactor 2, mast cell protease, dynein, and angiotensin II receptor were remarkably increased in Runx2;Oxx double heterozygotes. Taken together, differential gene expression profiles in Runx2;Oxx double heterozygotes provide the understanding of the correlation between Runx2 and Oxx in skeletal development (Grant support: RT04-01-01, KRF 2008-331-E00039).

P504
Sex-specific response of mammalian bone in vivo and in vitro to estrogens and androgens
D Somjen
Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 64239, Israel.

Rat and mice bones and their derived cell cultures in vitro respond sex-specifically to gonadal steroids (GS) by stimulating DNA synthesis (DNA) and the specific activity of creatine kinase (CK; a hormone receptor response marker). Similar results were demonstrated in cultured human male or female-derived bone cells (ObS); female ObS responded only to estradiol-17β (E2) whereas male ObS responded only to dihydrotestosterone (DHT) by stimulating DNA, CK, 1,25 vitamin D hydroxylase (1OHase) mRNA expression and production of 1,25(OH)2D3. Rat epiphyseal cartilage in vivo and its derived cell cultures in vitro responded to both hormones. The sex-specific response of ObS was modified by manipulating the endocrine environment in early development like gonadectomy, neonatally androgenization of female rats and androgen-receptor deficiency in male rats (Tfm). Rat bone marrow (BM) transplanted under the renal capsule formed bone ossicles responding to GS according to the donor gender. Rat demineralized tooth matrix particles (DTM) implanted under the skin induced bone formation responding to GS according to the host gender. Cultured femoral rat bone BM differentiated into ObS responding to GS according to the donor gender, losing sex-specificity after gonadectomy. Human ObS responded sex-specifically to GS via both genomic (DNA and CK) and non-genomic (intracellular Ca2+ concentration) binding sites. Male ObS although not responding to estrogens, expressed estrogen receptors suggesting involvement of post-receptor mechanism(s). The 'less differentiated' epiphyseal cartilage cells and the 'de-differentiated' ObS after gonadectomy lost sex-specific responses. In conclusion cultured ObS and bones in vivo respond sex-specifically to GS by different parameters.

P505
Insulin sensitivity and bone mineral density in primary hyperparathyroidism
L G Gianotti, F T Tatsone, M P Pellegriino, F C Cesario, C B Baffoni, G M Magro, C G Croce & G B Borretta
Division of Endocrinology and Metabolism, S. Croce and Carle Hospital, Cuneo, Italy.

Introduction
Recent data suggest a reciprocal influence between bone and energy metabolism. Mediators have been identified as osteocalcin (OC), which stimulates insulin (IRI) secretion and activity and IRI as bone anabolic factor. Primary hyperparathyroidism (PHPT) stimulates bone turnover, induces osteoporosis
and is associated with increased IRI resistance. A positive relationship between OC and IRI sensitivity has been found in PHPT, but no data exist on the relationship between IRI and bone mineral density (BMD).

Aim
To evaluate in a series of PHPT patients without known diabetes mellitus (DM), the relationship between IRI levels or sensitivity and BMD.

Subjects and methods
We studied 267 patients with PHPT (age, mean ± s.d., 58.5 ± 13.8 years; F:M 198/69; BMI 25.2 ± 4.6 kg/m²; PTH 228.4 ± 269.3 pg/ml; calcium 11.2 ± 1.2 mg/dl) without known DM. Fasting blood glucose and IRI as well as BMD at lumbar spine, femur and forearm were measured. IRI sensitivity was assessed by the quantitative insulin sensitivity check index (QUICKI).

Results
In univariate analysis a positive relationship between IRI levels and BMD (R=0.19, P<0.03) or T score (R=0.23, P<0.005) at femoral site was found, but not at lumbar spine nor at forearm. A negative relationship between QUICKI and BMD (R=-0.20, P<0.015) or T score (R=-0.23, P<0.004) at femoral site was found. In multivariate analysis, we found that age (β=−0.35, P<0.000004), BMI (β=0.39, P<0.000001), PTH (β=−0.18, P<0.013) and QUICKI (R=−0.15, P<0.048) exerted an independent effect (R²=0.29) on femoral T score.

Conclusions
Our data show a relationship between insulin levels and/or sensitivity and BMD at femur in PHPT, as found in other diseases associated with insulin resistance. This finding suggests a link between bone and energy metabolism in PHPT. However, the clinical influence of this relationship on the PHPT-related bone damage is to be established.

P506
Suspected parathyroid lesions and incidentally detected parathyroid adenomas during thyroid ultrasonography
Didem Ozdemir, Dilek Arpaci, Rıtıki Ucier, Nesilhan Cuhaci, Reyhan Ersoy & Bekir Çakır
Department of Endocrinology and Metabolism, Ataturk Education and Research Hospital, Ankara, Turkey.

Introduction
Although incidentalomas in endocrine glands such as pituitary, adrenal or thyroid are well defined, parathyroid incidentalomas is a rare concept. In this study, we aimed to determine the prevalence of suspicious parathyroid lesions and true parathyroid incidentalomas in patients referred for thyroid ultrasonography (US) and investigate the possible factors that might cause inadvertent suspicion of a parathyroid adenoma.

Methods
Patients suspected to have parathyroid lesions during thyroid US were recorded prospectively between August 2009 and January 2010. Patients referred for parathyroid US and patients with known high serum calcium or parathyroid hormone (PTH) levels were excluded. Suspected parathyroid lesions were defined as hypoechoic homogeneous solid lesions with regular margins located outside the thyroid lobe, most commonly inferior to the thyroid gland.

Results
Thyroid US was performed in 6528 patients during the study period. There were 78 patients (1.19%) (73 female and 5 male) with suspected parathyroid lesion and the mean age was 45.32 ± 12.59. The diagnosis of a true parathyroid adenoma was confirmed six (7.69%) patients. Mean serum calcium, phosphorus and PTH levels were 10.57 ± 2.48 mg/dl, 3.03 ± 0.52 mg/dl and 182.91 ± 46.62 pg/ml respectively in patients with true adenoma. Among 72 patients with false positive parathyroid lesion, antithyroid peroxidase antibody was positive in 50 (69.4%), antithyroglobulin antibody was positive in 46 (63.9%) and one of these antibodies were positive in 59 (81.9%) patients. Also, 46 (63.9%) of 72 patients had thyroid dysfunctions (43 hypothyroidism and 3 hyperthyroidism) and 59 (81.9%) had chronic thyroiditis ultrasonographically.

Conclusions
Parathyroid incidentaloma was detected in 0.09% of patients referred for thyroid US. Presence of clinically or ultrasonographically chronic thyroiditis seems to be the major factors related to inadvertent interpretation of a hypoechoic lesion as a parathyroid pathology during thyroid US. Most of these lesions are probably lymphadenopathies that may occur commonly in patients with chronic thyroiditis.

P507
Challenges and pitfalls in the management of persistent hyperparathyroidism: a case series
J E Witteveen, J Kiević, H Morreau, J A Romijn & N A T Handy
Leiden University Medical Center, Leiden, The Netherlands.

Introduction
Persistent hyperparathyroidism is reported to occur in 0-6% of cases after initial surgery for sporadic primary hyperparathyroidism (PHPT). The management of these cases is complex, however, with a poor cure rate despite repeated surgery. The aim of our study was to identify the challenges and pitfalls encountered in the management of a series of patients with persistent hyperparathyroidism after initial parathyroidectomy.

Patients and methods
Using the Leiden University Medical Center hospital records, we identified 20 patients with sporadic PHPT who had undergone 33 revision surgeries for persistent hyperparathyroidism. Clinical, operative and histology data were documented from the patients’ notes.

Results
The most common cause of persistent PHPT was a missed ectopic gland at initial surgery (33%), followed by missed multiglandular disease (15%). The least common cause was parathyromatosis (9%), with its risk increasing with repeated surgery. Pre-operative localization studies had poor sensitivity: US 18%, MRI 20%, Tc99m-MIBI-SPECT 25%, CT scan 30%. In contrast, selective venous sampling for PTH had a sensitivity of 50% and a specificity of 89%. The decrease in intraoperative PTH was significantly less marked (63±26% vs 89±11, P=0.003) and less rapid in patients in whom PHPT persisted compared to those who achieved cure. The risk of complications, particularly recurrent laryngeal nerve palsy, increased with each subsequent surgery: 20% after the first, 50% after the 2nd and 67% after the 3rd revision surgery.

Conclusion
Persistent PHPT represents a significant management challenge largely due to the poor predictive value of pre-operative localization studies and to increased risk of complications with each subsequent surgery. Intraoperative PTH decreases operating time and thus risk of complications. Cases of parathyromatosis are the most challenging, with decreased likelihood of cure after repeated surgery. The potential of calcimimetics in the management of these patients remains to be explored.

P508
The diseases which are associated with asymptomatic primary hyperparathyroidism as an aid and obstacle for early diagnosis of the disease, especially arterial hypertension and malignancy
Helena Síprová 1, Zdeňek Fryšák 2 & Kvetoslav Sirp 1
1. St. Anne Faculty Hospital in Brno, Brno, Czech Republic; 2. Palacky University, Faculty of Medicine, Olomouc, Czech Republic.

Best of all, the primary hyperparathyroidism (PHPT) should already be disclosed in the asymptomatic stage. The authors of this contribution are participating in a longitudinal study, which is focused on several aspects of asymptomatic PHPT. The study has been in progress in the Czech Republic at the two tertiary endocrinology centers. Previously we had attempted to verify the assumption that the presence of a chronic disease results in more frequent contact of the patient with the health-care establishment, and that more frequent visits to the consulting room increase the probability of a laboratory examination, and therefore also the earlier detection of PHPT. This time we were particularly interested in a 6-month period before diagnosis of asymptomatic PHPT was completed, wanted to know what the original disease was and whether the contact with the physician increased the likelihood of early diagnosis of PHPT in its asymptomatic stage. At the end of 2010 our cohort included 167 patients aged 20–87 years (median 63) who were followed-up for asymptomatic PHPT for 3–96 months (median 30). The most common concomitant illness was that of endocrine. Out of 118 probands 96 cases suffered from thyroid disease and 10 from pituitary respectively. Seventy-nine patients had cardiovascular disorders; out of them 61 were hypertensive. Twenty patients were followed-up because of malignancy. We were not able to confirm that repeated contact of patients with their physician resulted in earlier detection of PHPT. In 47 PHPT patients, the diagnosis was the result of the search for the cause of osteoporosis. Almost every endocrinologist checked the parathyroid hormone level as a part of endocrinological examination. Surprisingly late PHPT was diagnosed in patients with malignancies. Hyperparathyroidism has been probably a far more common disease than it was previously expected.
We have previously reported, that cultured female-derived human osteoblasts (hOBS) responded to DT56a (Femarelle). Since the skeletal protective effects of estrogens are not discernible in diabetic women, we sought to test the effects of DT56a on hOBS grown in high glucose concentration in the growth medium (HG) as compared to estradiol-17β (E2). We used the stimulation of creatine kinase specific activity (CK), and 3[H] thymidine incorporation into DNA (DNA synthesis), in response to E2 or DT56a as markers for treatment responsiveness. hOBS were isolated from premenopausal and postmenopausal women. Cells were grown either in normal glucose (NG) (4.5 g/l; 22 mM) or HG (9.0 g/l; 44 mM) for 7 days. HG slightly increased DNA synthesis in hOBS. In HG environment, the stimulation in response to E2 was decreased but not to DT56a in both age groups. Growing hOBS in HG resulted in increased expression of both ERα (alpha and beta) mRNA in hOBS from pre-menopausal but not in hOBS from post-menopausal women. Pre-treatment of hOBS with DT56a increased the expression of both ERα mRNA in hOBS from both age groups. Pre-treatment of hOBS with E2 increased expression of ERα mRNA in hOBS from pre-menopausal women but inhibited it in hOBS from post-menopausal women. Pre-treatment with E2 in hOBS from both age groups inhibited ERβ mRNA expression. Growing hOBS in HG led to decrease of intracellular binding of 3[H] E2 in cells from both age groups when compared by E2 but not by DT56a. This study shows that DT56a, contrary to E2, is active on hOBS even in HG environment and, contrary to E2, activates ER even in HG environment. These findings suggest that Femarelle (DT56a) may be used as an effective treatment for the hyperglycemic/diabetic postmenopausal women.

**Conclusion**

Based on our results, we conclude that DT56a (Femarelle), contrary to estradiol-17β, has a positive stimulatory effect on human derived female cultured cells in hyperglycemic conditions.
**P513**

**Influence of thyroid disease in diagnostic accuracy of Tc99m-sestamibi scintigraphy in patients with primary hyperparathyroidism (PHP)**

Nerea Egaña, Miguel Paja, Maria Teresa Gutierrez, Maria Luisa Rodriguez, Fernando Gotli, Estibaliz Ugarte & Javier Espiga
Hospital Baseruto, Bilbao, Spain.

Bilateral cervical exploration has been the gold standard in parathyroid surgery. Nowadays, the preoperative localization procedures have facilitated the minimally invasive surgery. This study aims to analyze the influence of thyroid disease in Tc99m-sestamibi scintigraphy (MIBI) results. A series of 154 patients with PHP who underwent parathyroidectomy was reviewed. Patients were divided into two groups: group 1 (G1, 58 patients) with thyroid diseases, and group 2 (G2, 96 patients) without goiter or thyroid nodules. Predictive positive value (PPV) of the MIBI was defined as true positive results (when the pathologic gland was correctly localized)/true positive + false positive (when no pathologic gland was found).

**Results**

There was no difference between two groups in sex, age and most of the preoperative biochemical parameters.

**Table 1**

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>9 (13.5%)</td>
<td>16 (16.7%)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>40 (64.5%)</td>
<td>80 (63.3%)</td>
</tr>
<tr>
<td>Age</td>
<td>63.1 ± 12</td>
<td>62.8 ± 14</td>
</tr>
<tr>
<td>SiO4 (sodium)</td>
<td>11.6 ± 1.9</td>
<td>11.6 ± 0.9</td>
</tr>
<tr>
<td>PTH</td>
<td>279.7 ± 266.5</td>
<td>236.7 ± 148.6</td>
</tr>
<tr>
<td>25-OHVD</td>
<td>21.3 ± 16.8</td>
<td>22.2 ± 14.7</td>
</tr>
<tr>
<td>Calcium</td>
<td>394.8 ± 156.4</td>
<td>401.6 ± 224.5</td>
</tr>
</tbody>
</table>

Histopathology showed 143 (93%) single adenomas (G1 = 51, G2 = 92), 3 carcinomas (two in G1), 5 hyperplastic (three in G1), and 3 double adenomas (two in G1). The PPV of MIBI in G1 was 65% (26/26 + 12) and in G2, 85% (69/69 + 12); \(P = 0.003\).

Since minimally invasive surgery is performed, the preoperative localization procedures have become very important, particularly MIBI. Because the presence of thyroid nodules reduces the sensitivity of MIBI, patients with HPT should rule out coexistent thyroid disease.

**P514**

**Secondary hyperparathyroidism in a patient with multiple myeloma**

I M R Mandac Rogulj, D R K Radic Kristo, S O K Ostojic Kolonic & A P P Planinic Petrica
University of Zagreb, Clinical Hospital Merkur, Zagreb, Croatia.

Multiple myeloma is a hematologic malignancy characterized by osteolytic bone destruction which follows the increased osteoclastic resorption of bone that is not accompanied by increased bone formation. This can lead to bone pain, diffuse osteopenia, focal lytic lesions, pathologic fractures, spinal cord compression, and hypercalcemia. In addition to bone lesions, hypercalcemia is evident because it is a major cause of morbidity and mortality in patients with multiple myeloma. Long-term monthly infusions of pamidronate as an adjunct to chemotherapy or as a maintenance therapy can reduce skeletal events and may improve the survival of patients.

Hypercalcemia is mainly caused by interleukin-6 and tumor necrosis factor. Myeloma cells activate genes that both stimulate bone resorption via osteoclast activation and prevent new bone creation by inhibiting osteoblasts. Pamidronate is a second-generation bisphosphonate, which inhibits bone resorption. Bisphosphonate bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Pamidronate does not interfere with bone mineralization at therapeutic doses.

A standard daily infusion dose of pamidronate for the treatment of hypercalcemia in patients with normal renal function is 60–90 mg over 2–4 h every 3–4 weeks for 2 years. Pamidronate appears to reduce calcium levels for prolonged periods of time, and hypercalcemia, which would increase PTH levels, might be an adverse complication. Some studies showed that intravenous pamidronate can aggravate secondary hyperparathyroidism, but for 2-year period, pamidronate is a safe and effective treatment for the correction of hypercalcemia. Here we present a female patient with multiple myeloma who has been receiving pamidronate for more than 5 years and developed secondary hyperparathyroidism.

**P515**

**Bone mineral density and its contributing factors in type 1 diabetic patients**

V Zhukouskaya1, C Eller-Vainicher1, A Shepelkevich1, Y Tolkachev3, S Kortiko2, E Cairlo1, P Beck-Peccoz1 & I Chiodini1

1University of Milan, Milan, Italy; 2Belarusian State Medical University, Minsk, Belarus; 3Republic Clinical Hospital of Medical Rehabilitation, Minsk, Belarus; 4Republican Medical Rehabilitation and Balneotreatment Centre, Minsk, Belarus.

**Aim**

To investigate factors associated with low bone mineral density (BMD) in type-1 diabetic (T1D) patients.

**Patients and methods**

One hundred and seventy-five eugonadal T1D patients (age 32.8 ± 8.4 years, diabetes duration 13.0 ± 5.4 years) were studied. Body mass index (BMI), daily insulin dose (ID), age at diagnosis (AgeD), presence of diabetic complications, glomerular filtration rate (GFR), HbA1c, and BMD at lumbar spine (LS) and femur (F) by dual X-ray absorptiometry (as Z-score) were determined. Patients were categorized on the basis of LS- and F-BMD ≤ (low BMD) or > 1.0.

**Results**

As compared with T1D patients without low LS-BMD, those with low LS-BMD (\(n = 46, 26.3\%\)) had lower BMI (22.3 ± 3.4 vs 24.3 ± 3.7 kg/m\(^2\), \(P = 0.005\)) and higher DID (0.9 ± 0.3 vs 0.7 ± 0.2 U/kg, \(P = 0.0001\)). As compared with T1D patients without low F-BMD, those with low F-BMD (\(n = 58, 33.1\%\)) had lower BMI (23.0 ± 3.3 vs 24.5 ± 3.8 kg/m\(^2\), \(P = 0.013\)); AgeD (17.3 ± 8.7 vs 21.0 ± 9.2 years, \(P = 0.013\)) and GFR (88.1 ± 31.3 vs 101.8 ± 31.3 ml/min, \(P = 0.007\)), and higher DID (0.8 ± 0.3 vs 0.7 ± 0.2 U/kg, \(P = 0.006\)) and HbA1c (8.6 ± 1.1 vs 8.2 ± 1.2%, \(P = 0.05\)). The diabetic complications were not associated with low BMD. The LS-BMD was independently associated with age (\(β = 0.193, P = 0.049\)), BMI (\(β = 0.187, P = 0.022\)), DID (\(β = -0.177, P = 0.025\)), while F-BMD with GFR (\(β = 0.170, P = 0.03\)). The cut-off values of these factors for predicting low BMD at any site were determined (age 33.5 years, BMI 23.5 kg/m\(^2\), GFR 0.67 U/kg, GFR 88.8 ml/min) and in each patient the presence/absence of each risk factor and a total risk factors' score for low BMD were calculated by summing the number of present risk factors. The RFSC of 0 showed a negative predictive value of 81.8% and the RFSC of 4 a positive predictive value of 63.4%, for low BMD respectively.

**Conclusion**

In T1D patients, low LS-BMD is associated with young age, low BMI and high DID, while low F-BMD with low GFR.

**P516**

**Hungry bone syndrome following parathyroidectomy**

Neslihan Soysal Atile, Betül Ekiz Bilir & Sibel Güldiken
Internal Medicine, Endocrinology Division, Trakya University Medical Faculty, Edirne, Turkey.

**Aim**

Hypocalcemia is a common problem after parathyroidectomy but is generally transient. In some cases the postoperative hypocalcemia is severe and prolonged despite normal or even elevated levels of parathyroid hormone (PTH). This phenomenon, called the hungry bone syndrome (HBS), occurs due to sudden withdrawal of PTH leading to a marked net increase in bone uptake of Ca, P, and Mg. We aimed to evaluate predictive factors for HBS development after parathyroidectomy.

**Material and method**

Forty-four patients who undergone surgical resection for parathyroid adenoma were evaluated retrospectively. Age, gender and preoperative serum levels of corrected Ca, iPTH, urea and creatinine were recorded. We accepted HBS diagnosis as the serum calcium concentration below normal limits for at least 1 week after parathyroidectomy.

**Results**

We divided the patients into two groups as HBS (\(n = 13\)) and non-HBS (\(n = 31\)). There was no difference between the groups in terms of age and gender. Serum Ca and ALP levels of groups were similar. Serum P, iPTH, urea and creatinine levels were higher in HBS group than non-HBS group (\(P < 0.05\), \(P < 0.01\), \(P < 0.05\), \(P < 0.05\) respectively). 6 of 13 (46.2%) patients with HBS had chronic renal failure (CRF), whereas CRF percentage was just 6% in non-HBS group (\(P < 0.01\)).

**Conclusion**

We suggest that CRF is an important risk factor for HBS development after parathyroidectomy.
P517
Genome-wide association in the Rotterdam study implicates the 16q24 locus as determinant of osteoporotic vertebral fractures
H L D W Oei, K Estrada, M C Castano-Betancourt, M van der Klift, J M Kerkhof, A Hofman, H A P Pols, L Stolk, J B van Meurs, M C Zillikens, A G Uitterlinden & F Rivadeneira
Erasmus MC, Rotterdam, The Netherlands.

Risk for vertebral fractures (VFx), the most common osteoporotic fractures, is a heritable complex trait. No genome-wide association studies (GWAS) searching for genetic susceptibility factors for VFx have been reported. We report here a GWAS for VFx in a population-based study of Dutch elderly. Thoracolumbar spine radiographs were scored for osteoporotic VFx using the McCloskey/Kanis method. Genetic data was available in 329 VFx cases and 2666 controls. We tested 2 543 887 imputed (HapMap CEU release 22, build 36) SNPs using a logistic regression model (MACH2DAT) adjusted for age, sex, and admixture principal components. At a genome-wide significant z-level (GWS) of 5 × 10⁻⁵, the design has 0.80 power to detect risk effect sizes (OR) of 1.7 to 2.4 for minor allele frequencies (MAF) of 0.20 to 0.05. A SNP on chromosome 16q24 (MAF=0.10) was associated at GWS level (P = 4.6 × 10⁻⁶) with an increased risk for VFx. Heterozygous carriers of the minor allele had 1.7-fold (95% CI: 1.3–2.2) and homozygous carriers 5.8-fold (95% CI: 2.6–12.6) increased risk compared to non-carriers. The VFx-associated SNP maps in a region previously found associated with lumbar spine BMD (LS-BMD) in a meta-analysis of 19 125 individuals, yet represents an independent signal from the reported BMD SNP (LD r²=0.002). The VFx-associated SNP was not associated with LS-BMD. FOXC2 is a strong candidate gene mapping ~200 kb upstream from the associated SNP. FOXC2 is a transcription factor essential for axial skeletonogenesis in mice, highly expressed in human bone tissue and involved in osteoblast differentiation through activation of canonical Wnt/β-catenin signals. Inactivating mutations affecting the FOX gene cluster cause severe vertebral malformations in humans. In conclusion, our findings implicate the 16q24 locus from the associated SNP. FOXC2 is a transcription factor essential for axial skeletonogenesis in mice, highly expressed in human bone tissue and involved in osteoblast differentiation through activation of canonical Wnt/β-catenin signals. Inactivating mutations affecting the FOX gene cluster cause severe vertebral malformations in humans. In conclusion, our findings implicate the 16q24 locus as a strong determinant for osteoporotic VFx. Pleiotropic effects of FOXC2 are potentially driving these associations with LS-BMD and VFx. Replication within the GEPOS/GENOMOS consortia is currently underway to confirm this finding.

P518
Bone turnover markers and the metabolic syndrome
S E Oros1, O Iană1, D Manda1, R I Rosca 1,2, O M Popa 1, S Vlăduţ1 & C Dumitrache1,2
1C.I. Pătron National Institute of Endocrinology, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Obesity was considered to be a protective condition against osteoporosis. New studies suggest that visceral obesity is associated with low BMD and a higher risk for fracture. Patients with diabetes mellitus, although they do not have a low BMD, have a higher fracture risk, probably due to the lower bone turn over.

Aim
The aim of the study was to evaluate bone metabolism in connection with hormonal profile in postmenopausal women with metabolic syndrome compared with matched controls without metabolic syndrome.

Subjects and methods
A number of 144 postmenopausal women were enrolled and 2 groups were formed (57 subjects with metabolic syndrome, 87 controls). Fasting blood samples were taken in order to determine the biochemical and hormonal status. SPSS version 15 was used for statistical analysis. Results were expressed as mean values ± S.D. and were considered to be statistically significant if the P value was ≤ 0.05.

Results
Significant higher mean values were found for BMI, waist circumference, blood pressure, glycemia, triglycerides and apolipoprotein B, white blood cells, lymphocytes, CRP (markers of the pro-inflammatory state), insulinemia and inflammation markers expressed by HOMA, GHBP (P < 0.01) and PTH (P = 0.01).

Postmenopausal women with metabolic syndrome had lower HDL-cholesterol, SHBG, IGFBP1 (P = 0.027) and 25OH vitamin D (P = 0.025) levels. Osteocalcin correlated positively with c-reactive proteins (P < 0.01), PTH (P = 0.025) and 25OH vitamin D (P = 0.005); PTH correlated positively with glycemia, uric acid and negatively with IGFBP3 (P = 0.048).

Conclusions
Postmenopausal women with metabolic syndrome have a modified hormonal status and different correlations between bone turn-over markers. Lower 25 OH vitamin levels, leading to higher PTH levels reinforce the importance of optimal vitamin D concentrations and its role in metabolic syndrome.

P519
Trace elements and bone mineral density in pre- and postmenopausal women
Homayoun Sheikhholeslami, Mahmood Gharbavi, Kamilla Kani & Sari Sheikhholeslami
Qazvin University of Medical Sciences, Qazvin, Islamic Republic of Iran.

Introduction
In postmenopausal women the rate of bone remodeling increases. Trace elements are known to influence bone metabolism. The aim of the study was to assess serum concentrations of some elements in pre- and postmenopausal women with and without osteopenia.

Methods
Serum concentrations of magnesium, copper, cadmium and vanadium were measured by inductively coupled plasma atomic emission spectroscopy in 51 postmenopausal women (19 women with osteopenia and 32 with normal bone mineral density) and 29 age- and BMI-matched premenopausal women (12 women with osteopenia and 17 with normal bone mineral density). The diagnosis of osteopenia was based on assessment of bone mineral density (BMD) at the spine and proximal femur by dual-energy X-ray absorptiometry.

Results
Mean concentration of vanadium was significantly higher in postmenopausal than in premenopausal women. In addition, magnesium, copper and cadmium concentrations in postmenopausal women were lower than in premenopausal women, but with no significant differences. There were no statistically significant differences observed between the osteopenic and normal pre- and postmenopausal women with respect to magnesium, copper, cadmium and vanadium levels. In premenopausal women the serum level of copper was positively correlated with the T-score at the femoral neck and with the BMI.

Conclusion
The consequences of changes in bone turnover can be detected by increased levels of bone biomedical markers. Vanadium accumulates in bone, though its role on bone quality is not clear. Serum vanadium level might be a marker of bone turnover and its serum level may reflect processes related to bone resorption. Copper plays an important role in bone development in part due to its role as cofactor for various enzymes (lysyl oxidase and superoxide dismutase) required for the synthesis or modification of bone matrix. The results of study provide more evidence of a correlation between copper status and osteopenia.

P520
Fahr’s syndrome in a patient with unknown hypoparathyroidism
Joana Nicolau Rama, Ana Espino Ibíñez, Carla Francisco Artigas, Rosmeri Rivera Irigoyen, Joséfini Olivares Alcolea, Luis Alberto Gómez Gómez, Irene Rodríguez Rodríguez & Lluis Masmiquel Comas
Hospital Son Llàtzer, Palma de Mallorca, Spain.

Introduction
Fahr’s syndrome is characterized by bilateral calcifications in basal ganglia, dentate nucleus and semiovale center. Its clinical manifestations are a rigid hypokinetic syndrome, mood disorders and cognitive impairment. The most frequent aetiology of this syndrome is, together with idiopathic causes and congenital infections, calcium deficiencies, mainly primary hypoparathyroidism, accounting for up to 80% of all cases.

Case report
A 57-year-old woman was admitted to the Neurology Unit for study of parkinsonian features that had worsened over the last 6 months. She had a medical history of dyslipidemia, 6-year-history of depressive syndrome. She reported no family history of interest. She related a progressive 6-month self-limiting walking disorder along with cramps and stiffness in lower limbs. On physical exam, the most important findings were: cogwheel rigidity and absence of reflexes; Chvostek and Trousseau signs were positive. Laboratory findings were: calcium 4.5 mg/dl, CK 693 IU/l (20–135), 25-OH vitamin D 32 ng/ml (20–54), PTH (P < 0.001) and PTH (P = 0.025) levels. Osteocalcin correlated positively with c-reactive proteins (P < 0.01), PTH (P = 0.025) and 25OH vitamin D (P = 0.005); PTH correlated positively with glycemia, uric acid and negatively with IGFBP3 (P = 0.048).

Conclusions
Postmenopausal women with metabolic syndrome have a modified hormonal status and different correlations between bone turn-over markers. Lower 25 OH vitamin levels, leading to higher PTH levels reinforce the importance of optimal vitamin D concentrations and its role in metabolic syndrome.

Endocrine Abstracts (2011) Vol 26
Huntington’s disease and viral infections. Calcium sensing receptor and antiparathyroid tissue antibodies were also negative. Chvostek and Trousseau became negative. Stiffness and cramps disappeared and electromyogram became normal; however, no changes in walking were seen. Six months later, the patient continued normocalcemic. No improvements in parkinsonian walking were seen despite normocalcemia and treatment with levodopa.

Conclusions
Primary hypoparathyroidism should be ruled out when diagnosing a Fahr’s syndrome. Restoring normocalcemia improves cramps and myoclonus; however, it has little effect on mood or parkinsonism.

Results
On breast mammography, benign calcification was observed in 21 patients (group A) and was not observed in 70 patients (group B). Lumbar bone mineral density was 0.832 ± 0.150 g/cm² on the average with benign calcification and 0.782 ± 0.141 g/cm² without benign calcification. There was not a significant difference between group A and B (P=0.169). Average age of patients of group A and B was 59.9 ± 6.1 years and 61.1 ± 5.8 years respectively, which had no significant difference (P=0.4). In addition, there was not a significant difference between group A and B for body weight, body mass index, waist circumference, smoking habits, alcohol drinking habits and physical activity index (P>0.05).

Conclusion
Lumbar bone mineral density with benign calcification on breast mammography was not statistically different compared to that without calcification. In the future there is a need for prospective, greater mass study.

P522
Relationship between benign calcification of breast and lumbar bone mineral density
H.J. Lee
Dongeui Medical Center, Busan, Republic of Korea.

Introduction
There are many reports that vascular and/or heart valve calcification is a good predictor for low bone mineral density. I investigated whether benign calcification of breast can also predict low bone mineral density.

Methods/design
I have reviewed and analyzed the records of 91 women with age more than 50 years old among patients examined bone mineral density and breast mammography from January through December 2010. The lowest value of lumbar bone mineral density was selected and analyzed, but femoral bone mineral density was not analyzed due to no routine examination and frequent omission.

P523
Vitamin D and bone metabolism in adult patients with cystic fibrosis
L. Vuolo1, V. Carnovale2, E. Guerra1, M. Rubino1, P. Contaldi1, F. Rengo2, A. Colao1 & C. Di Somma1
1Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica Universita Federico II, Napoli, Italy; 2Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche Universita Federico II, Napoli, Italy.

Objective
To evaluate Vitamin D levels and bone metabolism in adult patients with cystic fibrosis (CF).

Patients and methods
One hundred patients with CF (53 F, 47 M; age 29 ± 8 years) and 100 healthy controls were enrolled. Patients were assessed through clinical, and laboratory investigations. Evaluation of serum 25 hydroxy vitamin D (25OHD), vertebral fractures (quantitative morphometric analysis) and bone mineral density (BMD) at lumbar spine and total hip (dual energy X-ray absorptiometry) was done.

Results
Serum 25 OHD vitamin D was lower in patients than in controls (P<0.001). Vitamin D deficiency (< 10 ng/ml) was observed in 14%, vitamin D insufficiency (10-30 ng/ml) in 47% and normal value of vitamin D (30-100 ng/ml) in 39% of CF patients. Osteoporosis was found in 15%, while osteopenia in 28% of CF patients. Normal values of BMD was found in 57% of them. Furthermore, in 10 patients we evaluated vertebral fractures; the fractures were mild in two patients (20%), moderate in five (50%), and severe in two patients (20%). 25OHD vitamin D levels was not related to T and Z score at lumbar spine and femoral neck (P = 0.431; P = 0.487; P = 0.629; P = 0.849, respectively).

Conclusions
This study reports a high prevalence of vitamin D deficit and osteoporotic vertebral fractures in adult patients with CF, suggesting that complicated osteoporosis is an important comorbidity of CF patients. Adequate supplementation with vitamin D and treatment for osteoporosis could improve the quality of life of these patients.

P524
Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women
A. Markatseli1, E. Hatzi2, I. Bosba3, I. Georgiou2, A. Challa4, S. Tigas5 & A. Tsatsoulis6
1Department of Endocrinology, University of Ioannina, Ioannina, Greece; 2Laboratory of Human Reproductive Genetics, Department of Obstetrics and Gynecology, University of Ioannina, Ioannina, Greece; 3Laboratory of Child Health, Department of Pediatrics, University of Ioannina, Ioannina, Greece.

Wnt signaling through low-density lipoprotein receptor-related protein 5 (LRP5) is an important determinant of bone mass regulation. Polymorphisms in the LRP5 gene have been associated with either osteoporotic phenotypes or normal bone mineral density (BMD) variation.

Objective
To explore the influence of two LRP5 single nucleotide polymorphisms (SNPs) A1330V and V667M in BMD and serum levels of osteoprotegerin (OPG), receptor activator of nuclear factor-κB ligand (RANKL) and bone metabolic markers in a Greek female population.

Endocrine Abstracts (2011) Vol 26
P525
Efficacy of Alendronate treatment in women with postmenopausal osteoporosis: results after 3-year study
Lisinic Natalia, Florescu Alexandru, Loghin Andra Iulia & Galesanu Corina
University of Medicine and Pharmacy ‘Gr T Popa’, Iasi, Romania.

Introduction
In Romania, the prevalence of postmenopausal osteoporosis in urban centers was estimated by a study in 2007 to be 16.5%. Using alendronate we are increasing bone mineral density and reducing bone turn-over in women with postmenopausal osteoporosis.

Materials and methods
There were examined 55 postmenopausal women with osteoporosis (average age 62±4.5 years). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometer (HOLOGIC Delphi W; SN 7044909) on lumbar spine. Examination was performed before the onset of treatment and after a period of 1, 2 and 3 years of treatment. Alendronate was taken in a dose of 70 mg weekly. The patient also received 1000 mg of calcium and 800 IU Vit D daily.

Results
Alendronate (FOSAMAX) significantly increase BMD at lumbar spine after one year of therapy (1.9%) with further increase after two and three years of treatment (2.44 and 0.8%). In this study we had no serious side-effects or significant gastro-intestinal adverse effects. Also, no fractures were encountered during this period.

<table>
<thead>
<tr>
<th>Baseline</th>
<th>1 year</th>
<th>2 years</th>
<th>3 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMD (g/cm²)</td>
<td>0.723</td>
<td>0.737</td>
<td>0.756</td>
</tr>
<tr>
<td>%</td>
<td>1.9%</td>
<td>2.44%</td>
<td>0.8%</td>
</tr>
</tbody>
</table>

Conclusion
Our study suggest that alendronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis, but we need full support from the patient and long term-compliance.

P526
Bisphosphonates therapy in women with post-menopausal osteoporosis: comparative results
Galesanu Corina, Florescu Alexandru, Loghin Andra Iulia & Lisnic Natalia
University of Medicine and Pharmacy ‘Gr T Popa’, Iasi, Romania.

Aim
To evaluate the effect of risedronate vs ibandronate in treatment of systemic osteoporosis in postmenopausal women.

Materials and methods
We examined 57 postmenopausal women with systemic osteoporosis (average age 61±3.5 years). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometer (HOLOGIC Delphi W; SN 7044909) on lumbar spine. Examination was performed before the onset of treatment and after a period of 1, 2 and 3 years of treatment. Risedronate was taken in a dose of 55 mg weekly by 24 patients, while ibandronate 150 mg once a month by 33 patients. The women also received 1000 mg of calcium and 800 IU Vit D daily.

Results
After the first year of treatment, we observed an increase of 3.65% in BMD in risedronate group and a 4.7% in ibandronate group. The main difference came after 3 years of treatment, when, in the ibandronate group, we noticed a decrease in BMD by 4.25%, comparing with the other group (possible explanation – lack of compliance). In the third year there was an increase in both groups. No fractures were reported during this period.

<table>
<thead>
<tr>
<th>Baseline</th>
<th>1 year</th>
<th>2 years</th>
<th>3 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risedronate</td>
<td>BMD (g/cm²)</td>
<td>0.767</td>
<td>0.795</td>
</tr>
<tr>
<td>%</td>
<td>3.65%</td>
<td>0.76%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Ibandronate</td>
<td>BMD (g/cm²)</td>
<td>0.741</td>
<td>0.776</td>
</tr>
<tr>
<td>%</td>
<td>4.7%</td>
<td>4.25%</td>
<td>3.49%</td>
</tr>
</tbody>
</table>

Conclusion
Our experience shows that both risedronate and ibandronate are efficient against post-menopausal osteoporosis, with minimal side-effects.
Diabetes mellitus and the incidence of fracture
A A Gusova, M G Pavlova, G A Melnichenko, G M Kavalerovsky, L L Silin & N V Zaiteva
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.

Introduction and aim
Primary hyperparathyroidism (PHP) is the most frequent endocrine abnormality in MEN1 affecting about 100% of cases and inducing severe bone and kidney complications. Although surgery represents the only curative approach in MEN1 PHP, novel drugs are now available to effectively control PHP. The objective of this study was to show the recent changes in clinical presentation and therapeutic approach in MEN1-related PHP occurred in the last years.

Methods
The study population included 27 consecutive patients with MEN1-related PHP in follow-up between 1990 and 2010. The differences in clinical presentation of PHP and type and outcome of the therapeutic approaches for PHP between patients diagnosed before 2008 (13) and those diagnosed in 2008–2010 (14) were investigated.

Results
In the subgroup before 2008, 31% were asymptomatic, while 69% presented nephrolithiasis and/or osteoporosis; in the subgroup 2008–2010 64% were asymptomatic while 36% presented nephrolithiasis and/or osteoporosis. Total parathyroidectomy was performed in 31% of cases diagnosed before 2008 and was never performed in those diagnosed in 2008–2010, while partial parathyroidectomy was performed in 46% of patients diagnosed before 2008 and in 14% of those diagnosed in 2008–2010. Medical therapy consistent with cinacalcet was administered to 7 patients diagnosed before 2008 (54%), while it was administered to 12 patients diagnosed in 2008–2010 (86%).

In all of patients treated with cinacalcet, serum calcium levels were normalized and PTH levels significantly decreased. No patient treated with total parathyroidectomy relapsed, however, all of them developed hypoparathyroidism. All but one of the patients undergone partial parathyroidectomy relapsed after surgery.

Conclusions
Clinical presentation of PHP is recently changed in patients with PHP. Based on the attenuation in the severity of clinical manifestations and on availability of an effective medical therapy, the therapeutic management of these patients is suggested to switch from surgery to medical therapy.
inhibits lactation-induced adaptations in rat calcitriol synthesis and calcium transport

**P534**

**Dietary fructose inhibits lactation-induced adaptations in rat calcitriol synthesis and calcium transport**

V Douard1, T Suzuki2, Y Sabbagh3, S Shaposh4 & R P Ferraris1

1UMDNS, Newark, New Jersey, USA; 2Rutgers University, New Brunswick, New Jersey, USA; 3Genzyme Corporation, Framingham, Massachusetts, USA; 4University of Shizuoka, Shizuoka, Japan.

An adequate intestinal uptake of calcium is critical for the maintenance of calcium homeostasis during pregnancy and lactation. We previously found in rat models of end-stage renal disease that dietary fructose reduces intestinal calcium absorption and perturbs kidney morphology. Despite the dramatic rise in fructose consumption and the evidence of its deleterious effects for adult health, there is no information about fructose effects on maternal health and pregnancy outcomes.

We investigated the interactions between pregnancy/lactation and dietary fructose, to evaluate if fructose compromises intestinal calcium absorption and homeostasis and whether calcitriol (active form of vitamin D and one of the main regulators of calcium transport) mediates this effect. Three groups of pregnant rats and virgin controls were fed isocaloric 63% glucose, fructose or starch diets during gestation and lactation. Excessive fructose intake prevents lactation-induced increases in intestinal calcium transport, in intestinal expression of calcium transporting and binding proteins (TRPV6 and CaBP9k), and in calcitriol plasma level. The binding of VDR, the transcription factor mediating the activity of calcitriol to the promoters of TRPV6 and CaBP9k genes was also significantly reduced in dams fed fructose. Changes in calcitriol levels were tightly correlated with alterations in expression of the 1α-hydroxylase but not 24-hydroxylase, indicating that excessive fructose intake perturbs specifically the final step in calcitriol synthesis. Bone mineral density and content as well as mechanical strength decrease with lactation, and dietary fructose and glucose significantly exacerbate these effects. Thus, we showed that over-consumption of fructose during pregnancy and lactation impairs renal production of calcitriol which leads to a decrease in active intestinal calcium transport due to lowered expression of calcium transporters in duodenum. These results are all the more important since there is evidence that the current daily recommendations for vitamin D intake may be inadequate to ensure calcitriol sufficiency in humans.

---

**Endocrine Abstracts (2011) Vol 26**
After multiple regression EW was significantly associated with decreased mineralization at femoral neck and MELD score and ALP levels were significantly correlated with demineralization at lumbar spine. It was found a significant correlation between VitD levels, AST and ALT levels \((r=-0.36, \ r^2=0.60)\), but there wasn’t significant association between VitD and severity of hepatic or neurological disease.

**Conclusion**

Decreased bone mineralization in our WD population doesn’t seem to be associated with low VitD levels, but to the degree of hepatic and neurologic impairment. We didn’t find any correlation between VitD deficiency and severity of neurologic or hepatic disease. We advocate that the high rates of demineralization and VitD deficiency found are significant and it is therefore advisable to evaluate and treat these two issues in this population.

---

**P536**

**Total parathyroidectomy without autotransplantation in the surgical treatment of ‘refractory’ renal hyperparathyroidism**

Mihai Radu Diaconescu, Mihai Gild, Ioan Costea, Mirela Grigovorici & Smaranda Diaconescu

‘Gr T Popa’ University of Medicine and Pharmacy, Iasi, Romania.

**Background**

The optimal surgical technique in patients with refractory renal hyperparathyroidism (RHP) on hemodialysis for end stage renal disease is still a point of debate.

The high percentage of recurrences after standard surgical procedures, i.e., subtotal parathyroidectomy (SPtx) and total parathyroidectomy with autotransplantation (TPtx + AT) reactualised the practice of total parathyroidectomy (TPtx).

**Patients and methods**

Forty-three patients with RHP underwent surgery in the last 16 years period. There were 24 SPtx, 6 TPtx + AT, both procedures determining 6 recurrences (20.7%) so in the last years TPtx was performed in a series of 13 cases (7 males and 6 females, with median age 43.0 – range 22–63 years, and median dialysis time before PTx 8.2 – range 3–13 years. Parameter studies included demographics, preoperative and follow-up laboratory tests, surgical techniques, pathology results and postoperative immediate and medium term results.

**Results**

Main indications for TPtx were severe bone disease, soft tissue calcifications, neuromuscular phenomena, grossly elevated iPTH and sometimes hypercalcemia. TPtx was done in 12 patients, the 13th one suffering a completion PTx 1 year after outward exeresis of only two glands. Postoperatively the majority of symptoms markedly improved and the values of calcemia, phosphatemia, and alkaline phosphatase normalised together with low or no measurable level of iPTH. One patient required a reexploration for cervical hematoma but no one presented permanent hypocalcemia or recurrent hyperparathyroidism. Pathology revealed nodular hyperplasia in all the cases, a parathyroid carcinoma of one gland and also an incidentally thyroid papillary microcarcinoma in a completion thyroidectomy.

**Conclusions**

TPtx alone proves to be an equally safe and successful as another techniques currently used in the management of RHP eliminating the hyperparathyroidy status but being superior with regard of recurrences. The procedure is indicated especially in cases with aggressive, refractory forms of RHP without the prospect of renal transplantation.

---

**P537**

**The efficacy of four monthly 200 000 IU vitamin D supplementation to treat vitamin D deficiency in institutionalized elderly**

Veronica Mocanu, Magda Badescu, Roxana Costan, Florin Zugun, Raluca Haliga & Corina Galesanu

‘Gr. T. Popa’ University of Medicine and Pharmacy, Iasi, Romania.

**Introduction**

Vitamin D deficiency has been frequently observed in the elderly population. Improving vitamin D status may be an important modifiable risk factor to reduce fractures; however, adherence to daily supplementation is poor. We tested whether oral administration of an alcoholic solution of vitamin D3, 200 000 IU every 4 months in elderly could assure an optimal serum 25(OH)D concentration of 80–120 nmol/l.

**Method**

We enrolled 50 institutionalized elderly (70% women, age 72.7 ± 6.8 years; 30% men, age 72.1 ± 5.8 years) living in a nursing home for elderly people in Iasi, Romania (latitude: 47°N). Using a factorial design, we randomly allocated subjects to cholecalciferol therapy or placebo.

**Results**

At baseline, 25(OH)D levels were 25.5 ± 16 nmol/l and 60% of participants had of <25 nmol/l. Cholecalciferol treatment using an alcoholic solution of vitamin D3, 200 000 IU every 4 months did not succeed to rise 25(OH)D levels above 80 nmol/l. The 25(OH)D levels were 34 ± 12 nmol/l at 4 months, 45 ± 21 nmol/l at 8 months and 49 ± 19 nmol/l at 12 months. One patient required a reexploration for cervical hematoma but no one presented permanent hypocalcemia or recurrent hyperparathyroidism. Pathology revealed nodular hyperplasia in all the cases, a parathyroid carcinoma of one gland and also an incidentally thyroid papillary microcarcinoma in a completion thyroidectomy.

**Conclusion**

In elderly, the correction of low status of vitamin D3 require doses above 2000 IU/day. In our study, the oral administration of vitamin D3, 200 000 IU every 4 months (equivalent of oral doses of vitamin D3 2000 IU/day) may be a convenient way to maintain sufficient vitamin D status but failed to establish the optimal levels of serum 25(OH)D concentrations.

---

**P538**

**Recurrent primary hyperparathyroidism**

E Slotema, F Sebag & J F Henry

CHU Timone, Marseille, France.

Recurrent primary hyperparathyroidism (RPHTP) is defined as hypercalcemia occurring after 6 months of normocalcemia following initial operation. The aim of this study was to analyze our experience in RPHTP. Between 1980 and 2010 33 patients (1.2%) with primary hyperparathyroidism (HPT1) were reoperated in our tertiary referral centre for recurrence of disease: 24 adenomas, six subtotal parathyroidectomies, two total parathyroidectomies with autotransplantation and one negative exploration. Twenty-five patients had their first parathyroid intervention in our department.

Mean age at primary and secondary intervention was 50 and 63 years respectively. Mean time till recurrence was 12.8 years, not significantly different in uni- or multiglandular disease. In 22 patients contributing factors for recurrence could be identified: eight had a genetic compound (positive familial history, MEN-1 syndrome), eight had previous medical history of cervical radiotherapy, three cases of parathyroid carcinoma and three surgery itself (twice parathyreomatosisis, one devascularised but not-identified adenoma). In 11 patients no risk factor was identified of which five had a metaphrochosmic adenoma. Mean calcium was preoperatively 2.71 mmol/l and PTH 120 pg/ml and postoperatively 2.25 mmol/l with PTH 27.5 pg/ml. Positive findings on ultrasound and MIBI-scanitigraphy allowed for eighteen focussed surgical approaches. Morbidity following secondary intervention included one vocal cord palsey due to oncologic resection. Four patients (13%) were treated for temporary hypocalcemia and three patients (9.7%) had definitive hypoparathyroidism. Six patients were not cured, of which three patients died eventually from parathyroid carcinoma.

We may conclude that RPHTP is a rare disease. In 67% of the cases predisposing factors can be identified that should initiate prolonged follow-up of the patient. In contrast with persisting HPT1, recurrent HPT1 is rarely due to surgical failure.

---

**P539**

**Vitamin D and dark skin**


Department of Endocrinology, Red Cross Hospital, Athens, Greece.

Vitamin D is synthesized in the skin. Low vitamin D levels have been observed in African Americans. However, the relationship between vitamin D and skin color has not been completely evaluated.

The aim was to study the relationship between dark skin color and vitamin D levels in healthy individuals.

Vitamin D (25(OH)D) levels were measured in 15 dark skinned individuals. All subjects were immigrants, having migrated to Greece for financial reasons. They had migrated to Greece at least a year before the study, thus residing in Greece for at least a year before vitamin D measurement. Immigrants were from Egypt and the Middle East. However, they were not wearing the traditional clothes covering the whole body, having already adapted to the clothing of the western civilization.

Vitamin D, 25(OH)D levels were measured by RIA.

---

Endocrine Abstracts (2011) Vol 26
All individuals had low vitamin D levels, mean 25(OH)D levels being 13.6 ng/ml, range 11–17 ng/ml, s.d. 1.4.

Vitamin D was found to be low in all dark skinned individuals studied. Vitamin D deficiency observed in the immigrant population studied may be related either to dark skin color or to nutritional deficiency. Dark skin may protect the skin from the photon energy thus protecting it from carcinogenesis, preventing however vitamin D synthesis.

**Conclusion**

Furthermore oral therapy had better effect on serum 25(OH)D3 level in oral methods but the vitamin D level after treatment in oral method was higher than in injection one. ($P_{0.046}$).

**Results**

Duration of the ESRD was 8.76 ± 5.06 years. The ESRD was treated by hemodialysis in 65.82% cases. A total of 16 cases were submitted to kidney transplantation with a rejection rate of 5 cases. At the time of the PTX, 6 patients were with kidney transplantation. The medical therapy of SHPT was vitamin D and phosphate binders, calcimimetics were not used in this group. The increased parathyroid volume was evaluated by ultrasonography (sensitivity 92.45% versus pathology), in 159 patients. Tertiary HPT was diagnosed in 53 (27.04%) patients despite medical treatment. The evaluation was performed 24 h before and after surgery. Preoperative values were for PTH = 1721.84 ± 839.84 pg/ml, Ca = 9.94 ± 1.28 mg/dl and P = 6.38 ± 1.90 mg/dl; Ca x Ph product above 75 mg²/dl² was found in 23.97% (n = 47) cases. Surgery was performed by preserving all parathyroid glands but one which was dissected to a equivalent volume of a normal parathyroid. Autotransplantation consisted in placement of this remnant parathyroid in the jugular notch area, by keeping the vascular supply from the cervical vessels. PTX effect was the decrease of PTH values to 48.13 ± 58.18 pg/ml, calcium to 6.93 ± 1.29 mg/dl and phosphate to 4.90 ± 1.90 mg/dl, while the product Ca x Ph decreased in 195 cases under 75 mg²/dl². Postoperative evolution was uneventful in all cases, but the global prognosis is decided by the kidney disease.

**Conclusion**

Parathyroidectomy in ESRD is an important part of management in secondary or tertiary HPT, cervical autotransplantation being an useful surgical alternative.

---

**P540**

Comparison of oral versus intramuscular treatment of vitamin D deficiency or insufficiency

Seyed Adel Jahedi1,2, Mahan Shahrivari1,2, Mozdeh Zabihiyeganah1,2 & Majid Shahki1,2

1Islamic Azad University, Tehran Medical Branch, Tehran, Islamic Republic of Iran; 2Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

**Background**

Different dosing protocols have been used for vitamin D supplementation, but there has been a lack of comparative data among them. This clinical trial study was aimed to compare the efficacy of two different regimens of vitamin D supplements on serum 25(OH)D level, at the end of a 3 months therapy period.

**Design**

Eighty-four cases of vitamin D deficiency or insufficiency who did not meet exclusion criteria were randomized to two different vitamin D supplementation protocols as pearl 50,000 IU weekly for one month then monthly for 2 months or injection of 300,000 IU vitamin D during the 3 months for whom had insufficient level of vitamin D, while the deficient ones were under treatment of pearl 50,000 IU weekly for 2 months and one for another month or injection of 300,000 IU vitamin D during the 3 months. The primary outcome measure was the serum 25-hydroxyvitamin D (25(OH)D) concentration 3 months after onset of treatment.

**Results**

Pre-treatment level of vitamin D was not different meaningfully in oral and injection methods but the vitamin D level after treatment in oral method was higher than in injection one. ($P_{0.023}$). In addition, at the end of the treatment 23.8% (10) of the patients on oral therapy did not receive to sufficient level of vitamin D while in the injection methods but the vitamin D level after treatment in oral method was higher than in injection one. ($P_{0.046}$).

Furthermore oral therapy had better effect on serum 25(OH)D level in overweight persons ($P_{0.064}$).

**Conclusions**

Based on the results, we concluded, oral method had better effect on serum 25(OH)D level, 3 months after therapy than injection route.

---

**P542**

Pseudohypoparathyroidism and GNAS epigenetic alterations: quantitative analysis of methylation defects and correlation with clinical characteristics

F M Ellì1, A M Barbieri1, L de Sanctis2, V Bollati3, P Beck-Peccoz2, A Spada1 & G Mantovani1

1Department of Medical Sciences, Endocrinology and Diabetology Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 2Department of Pediatrics, Regina Margherita Children’s Hospital, University of Turin, Turin, Italy; 3Department of Environmental and Occupational Health, Center of Molecular and Genetic Epidemiology, Università degli Studi di Milano and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.

The two main subtypes of pseudohypoparathyroidism (PHP), PHP-Ia and -Ib, are caused by mutations in GNAS exons 1–13 and methylation defects in the imprinted GNAS cluster, respectively. PHP-Ia patients show Albright hereditary osteodystrophy (AHO) and resistance toward multiple hormones (PTH/TSH/GHRH/gonadotropins), whereas PHP-Ib patients classically display hormone resistance limited to PTH and TSH. Incoming data suggest that the two diseases share more genetic and clinical similarities than previously thought. In particular, methylation defects have been detected in a subset of patients with PHP and AHO, but the correlation between molecular findings and the severity of the disease has not been investigated yet.

In the present study, we included 30 patients with either classical PHP-Ib (N = 16) or PHP with different degrees of AHO (N = 14), all found to have broad GNAS methylation defects in the absence of mutations. Differential methylation of GNAS DMRs A/B, AS, XL, NESP was assessed using highly quantitative analysis based on PCR-pyrosequencing. The data obtained were correlated with the following clinical characteristics: age at diagnosis, endocrine function (PTH, TSH, FT4, calcium, phosphorus levels) and the presence or absence of AHO signs (short stature, brachydactyly, round face, ectopic ossifications, mental retardation).

No statistical difference was observed between the group of patients with classical PHP-Ib and the group with PHP plus AHO. In particular, the degree of the imprinting defect (percentage of methylation at each DMR expressed in respect with a pool of 20 normal subjects age- and gender-related) did not correlate with the onset of the disease, the severity of endocrine resistances, nor with the presence/absence of specific AHO signs.

In conclusion, similar molecular alterations may lead to a broad spectrum of diseases, from isolated PTH resistance to complete PHP-I, highlighting the need of an updated classification that takes into account the recent knowledge on the molecular basis underlying these defects.

---

**P541**

Outcomes of parathyroidectomy with autotransplantation in nephrogenic secondary hyperparathyroidism

Alina Georgescu1, Bogdan Stanescu1,2, Adrian Zagravu1,2, Gabriel Mircescu1,3 & Corin Badiu1,3

1National Institute of Endocrinology, Bucharest, Romania; 2C. Davila Hospital of Nephrology, Bucharest, Romania; 3University of Medicine and Pharmacy, Bucharest, Romania.

**Background**

One of the major complications developed by patients with end stage renal disease (ESRD) is secondary hyperparathyroidism (SHPT), due to hypocalcemia, hyperphosphatemia and 1,25(OH)2D deficiency with parathyroid hyperplasia and high PTH levels as earliest changes, which may require parathyroidectomy (PTX).

**Study design and objectives**

This study aimed to evaluate the indications, the particularities and outcomes post-PTX of patients suffering from secondary hyperparathyroidism due to chronic kidney disease (CKD).

**Patients and methods**

A total of 196 patients, 112 F (57.14%), aged 51.66 ± 11.27 (ranged 21–81 years) with hyperparathyroidism and ESRD underwent PTX with (194 patients) or without (2 patients) autotransplantation from 1999 to 2009.

**Results**

No statistical difference was observed between the group of patients with classical PHP-Ib and the group with PHP plus AHO. In particular, the degree of the imprinting defect (percentage of methylation at each DMR expressed in respect with a pool of 20 normal subjects age- and gender-related) did not correlate with the onset of the disease, the severity of endocrine resistances, nor with the presence/absence of specific AHO signs.

In conclusion, similar molecular alterations may lead to a broad spectrum of diseases, from isolated PTH resistance to complete PHP-Ia. Our study further confirms the existence of an overlap between molecular and clinical features of PHP-Ib, highlighting the need of an updated classification that takes into account the recent knowledge on the molecular basis underlying these defects.

**Endocrine Abstracts (2011) Vol 26**
**P543**

**Does total parathyroidectomy with autotransplantation simplify reinter-
ventions for persistent or recurrent secondary hyperparathyroidism?**

E Slotema & J F Henry

CHU Timone, Marseille, France.

Subtotal parathyroidectomy (SPX) and total parathyroidectomy with autotrans-
plantation (TPXAT) are adequate techniques in treatment of secondary 
hyperparathyroidism (HPT2) in hemodialysed patients with identical results. 
Reinterventions required for persistence or recurrence of HPT2 may seem easy 
after TPXAT: no redo-surgery in the cervical area and removal of grafts in the 
forearm under local anaesthesia. The aim of this study was to analyze our results 
of reiterative surgery in HPT2.

Between 1981 and 2010, 44 hemodialysed patients were reoperated for HPT2 in 
our tertiary referral centre. Twelve cases were excluded for missing data or an 
incomplete primary intervention. Five patients were operated initially elsewhere. 
Primary interventions consisted of 18 SPX and 14 TPXAT that were performed 
correctly. Male/female ratio was 3.5. Operative indication for reintervention was 
PTH-level > 500 pg/ml (mean: 967 pg/ml). Localization studies included cervical 
ultrasound and MIBI-scintigraphy, plus CT-scan or invasive PTH-gradient 
measurements if necessary.

Mean time to reinteervention was 60 and 111 months after SPX and TPXAT respectively (P < 0.05). After SPX two patients had persisting hypercalcemia caused by a mediastinal supernumerary gland and inadequate judgment of the 
parathyroid remnant size. Twelve patients had recurrence following SPX caused 
by remnant hyperplasia and four patients had a supernumerary gland (n = 4). 81% was 
cured after 1.1 reoperation without any postoperative morbidity. Following 
TPXAT, no occurrence and recurrence was caused by hyperplasia on 
parathyroid autografts (n = 11) and by supernumerary glands (n = 4).

Significantly more imaging studies were required for localization of pathological parathyroid tissue after TPXAT. 79% was cured after 2 (mean) reinterventions (P < 0.05).

In our experience reoperations for persistent or recurrent HPT2 were not easier to 
perform after TPXAT than after SPX.

---

**P544**

**Bone turnover markers and vitamin D status over a training year 
in female elite alpine skiers**

G Lombardi1, A Colombo2, M Freschi2, R Tavana2, H Schoenhuber2 & G Banti1

1IRCCS Istituto Ortopedico Galeazzi, Milano, Italy; 2F.I.S.I., Milano, Italy.

Introduction

The training year of elite athletes is characterized by different kind and intensities 
of workload implying different level of metabolic responses of the skeletal tissue, 
assessable by measuring serum levels biochemical markers.

Methods

Fourteen top-level female skiers, from the Italian Women’s Alpine Ski Team 
(slalom and giant slalom), were tested at the end of the relative rest period (T1), 
the semester recharge (T2) and the competitive season (T3). Anthropometric and 
clinical data (age, height, weight, BMI, body fat%, VO2max (lO2/min), 
counter-movement jump (h)) were recorded at each timepoint. Serum levels of 
bone-specific alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase 
(TRAP5b) activities and of osteocalcin (OC) and the carboxyterminal crosslinked 
peptide of type I collagen (b-CTx), were assayed together with the 
determination of 25(OH)D levels.

Results

No significant variation were found in anthropometric and clinical data over the 
training year. Formation markers, BAP activity (P < 0.01) and OC (P < 0.05) and 
the resorption marker TRAP5b activity (P < 0.05) significantly increased from T2 
and T3, while beta-CTx showed no significant decreases all over the study. The 
trends of all bone markers correlated each with each other at T2 versus T3. 25(OH)D 
levels increased from T1 to T2 and from T1 to T3 (P < 0.01) but its variations do 
not correlate with any of bone markers.

Discussion

The passage through T2 to T3 stimulated the whole bone metabolism, as 
consequence of the heavy mechanical stimulation during the highly demanding 
competitive period. These variations were completely independent from the 
corresponding changes of 25(OH)D. All athletes showed an insufficiency of vitamin 
D even though they exercised outdoor, mainly at latitudes in which sunlight exposure is adequate.

---

**P545**

**Some epidemiological aspects of primary hyperparathyroidism in 
Russia**

Liliya Rostomyan, Natalya Mokrysheva, Svetlana Mirnaya, 
Nataliya Kirdyankina & Liudmila Routhinokaya

Research Centre for Endocrinology, Moscow, Russian Federation.

Primary hyperparathyroidism (PHPT) is the third most frequent endocrine 
disorder and has a variable clinical presentation. Asymptomatic PHPT became the 
predominant form of the disease with increase of it’s incidence after the 
introduction of automated serum calcium measurement in North America and 
Europe. Data from Russia is lacking.

Aim

To present the clinical profile of PHPT in Russia.

Materials and methods

This retrospective study was conducted at endocrinology centers in 8 regions of 
Russia, which analyzed the clinical presentation, and treatment options in patients 

Results

Seven hundred and thirty-eight patients (F:M=8:1) with age ranging from 13 to 
83.4 years (mean 54.3) were included: 54% – from Moscow (n = 397), 11% – 
from Moscow region (n = 79) and 35% – from 53 regions of Russia (n = 262). 
33% of patients were in 50–59 years age-group. PHPT was diagnosed in woman 
more often in 50–59 years (23.8%) and 60–69 years (28.8%) age groups while in 
men it was irrespective of age. Symptomatic PHPT was the most common form 
(74.6%) and was revealed with osteoporosis in 56%, nephrolithiasis – in 45% 
and ulcer disease – in 18%. Our data showed an increase in the incidence of PHPT 
after 2005 compared with earlier period (from 4–29 per year to 93 in 2006) with 
peak in 2009 (n = 126) and a tendency to more frequent detection of mild PHPT 
in the last decade (from 15 to 41%). 64.9% of patients were treated surgically, 
17 patients undergone repeated parathyroid surgery. 28.3% received bisphos-
phonates, calcitonin and/or cinacalcet. 11.5% was observed without treatment.

Conclusions

PHPT still remains symptomatic disorder in our country most frequently with 
skeletal and renal manifestations. Although our data demonstrates marked 
changes in diagnostics of PHPT in the course of time, apparently many cases 
especially the mild forms of PHPT) are unrecognized.

---

**P546**

**Conservative therapy by cinacalcet for primary hyperparathyroidism management: first results of two center prospective study**

Peter Kentos1,2, Adriana Banárová1, Mikušák Pura1, Peter Vanaga1 & Mihoj Payer3

1Department of Endocrinology, National Institute of Endocrinology and 
Diabetology, Lubochna, Slovakia; 2First Department of Internal Medicine, 
Jesenius Faculty of Medicine, Martin, Slovakia; 3Fifth Department of 
Internal Medicine, Medical Faculty of Comenius University, Bratislava, 
Slovakia.

Introduction

Parathyroid hormone (PTH) secretion is regulated by the concentration of extracellular 
ionized calcium. The calcium sensing receptors (CaSR) of parathyroid chief cells play 
a central role in calcium homeostasis. Their activity is reduced by calcimimetics, the 
compounds that directly increase the sensitivity of CaSR to extracellular ionized 
calcium. Cinacalcet hydrochloride, an oral calcimimetic, is indicated in treatment of 
primary hyperparathyroidism (PH), for patients with failure of previous surgery, 
patients with serious comorbidity that makes surgery impossible, or patients who do 
not accept surgery or do not carry out the surgical criteria.

Aim

To assess the efficacy, tolerability and safety of cinacalcet in the patients with PH.

Patients and methods

Project is an ongoing prospective two center study in 33 patients (29 women) with 
PH, mean age 64.0 years (95% CI 55.4–74.6). Frome these, surgery was 
contraindicated in 16 patients, in 12 patients previous surgery failed, and 5 patients 
did not accept surgery. Serum concentrations of calcium, iPTH, phosphates were 
evaluated before and during the treatment.

Results and conclusion

All patients responded to cinacalcet. Applied doses of cinacalcet ranges from 15 to 
90 mg. Serum calcium was 2.80 mmol/l (95% CI 2.74–2.86) at baseline, iPTH 
concentration was 19.5 pmol/l (95% CI 15.6–28.4) and phosphatemia was 
0.83 mmol/l (95% CI 0.78–0.89). After 6 months, mean calcium concentration 
was 2.35 mmol/l (95% CI 2.27–2.44) (P < 0.001) and mean iPTH concentration 
was 14.5 (95% CI 11.4–17.7) (P < 0.001). The most common adverse event was 
nausea, which affected 5 patients. Cinacalcet effectively normalizes calcium 
concentration and significantly reduces (but not normalizes) iPTH concentration. 
Therapy is safe and well-tolerated.
The QUS fracture risk groups: unifactorial analyze regarding bone markers and DXA assessment
Mara Carsote¹, Corina Chirita², Valentin Radoi³, Cristina Ene², Adriana Gruiu¹, Gabriela Voicu¹, Catalina Poiana²,² & Mihai Cociulescu¹,³
¹Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ²CI Parhon National Institute of Endocrinology, Bucharest, Romania; ³Medlife, Bucharest, Romania;

Introduction

The quantitative ultrasound (QUS) is an useful tool in the evaluation of the fragility fracture risk.

Aim and study design

We performed the QUS fragility fracture risk groups (valided by the golden standard DXA) by a unifactorial analyze including the bone markers.

Method

The cut offs used were: SI ≥ 59U (high risk), SI < 59U (low risk), and medium risk with SI between 59 and 83U. The QUS analyze was performed by a heel GE Achilles Device. The statistical analyze used student t test. We studied 130 postmenopausal women who were not treated for osteoporosis.

Results

In a prospective study, the anamnesis, serum bone markers, DXA and QUS were performed. Low risk patients (n=48) and high risk (n=19), without age difference. 31.57% of the patients from the high risk group were diagnosed with osteoporosis versus 7.6% in the low risk category. The percent of the women with normal DXA was 21.05 vs 56.41%. The percent of the false positive patients (high risk at QUS and normal DXA) was 11.06%. The percent of the false negative patients with osteoporosis was 7.6%. In the high risk group, serum PTH, 25OH-D, osteocalcin, alkaline phosphatase were not significantly different from the group with low risk. In the high risk group, the BMI, total calcium, and Beta Cross Laps were statistically significant different from the low risk group. The percent of the patients with an already known fragility fracture was: 12.5% in the low risk group, versus 26.32% in the high risk group.

Conclusion

Bone markers as PTH, 25 OH D have no influence. The DXA assessment proved significant difference; the osteoporosis was almost 4 times more frequent in the high risk groups while the normal DXA was found two times more frequent in low risk patients (QUS) versus high risk patients.

Bone density in patients with ACTH-dependent and ACTH-independent Cushing syndrome
Peter Vanuga, Peter Kentoš & Mikuláš Pura
Department of Endocrinology, National Institute of Endocrinology and Diabetology, Lubochna, Slovakia

Background

The presence of functional ACTH receptors (MC2R) on osteoblasts and fact, that their activation lead to the proliferation of osteoblasts is consistent with the presence of receptors for another anterior pituitary hormones (FSH and TSH) on bone cells. Does ACTH directly regulate bone? Is it possible, that this is another hormone of a novel regulatory axis, pituitary-bone axis, in which hormones bypass traditional endocrine targets to regulate bone mass directly? Supraphysiological doses of glucocorticoids lead to different metabolic complications as well as to osteoporosis and osteonecrosis. However, osteonecrosis is not a cardinal feature of ACTH-producing adenomas.

Aim

To compare bone mineral density (BMD) in patients with ACTH-dependent and ACTH-independent Cushing syndrome (CS).

Patients and methods

Retrospective analysis of BMD by X-ray absorptiometry (Hologic Discovery) in patients with ACTH-dependent (n=15) and ACTH-independent (n=7) form of CS.

Results

Patients with ACTH-dependent (ACTH 92.7 µg/ml and ACTH-independent (ACTH 3.0 µg/ml) form of CS did not differ by their body height (165.1 vs 164.4 cm), body weight (80.6 vs 74.4 kg), BMI (29.6 vs 27.6 kg/m²), UFC (3.78 vs 3.54 µg/24 h), nor BMD at femoral neck (0.69 vs 0.73 g/cm², trochanter 0.61 vs 0.61 g/cm², inter 1.01 vs 0.99 g/cm², total 0.85 vs 0.85 g/cm²), neither at the lumbar spine (L1 0.82 vs 0.83 g/cm², L2 0.89 vs 0.93 g/cm², L3 0.91 vs 0.95 g/cm², L4 0.92 vs 0.97 g/cm², total 0.88 vs 0.91 g/cm²).

Conclusions

We did not find differences in BMD in patients with ACTH-dependent and ACTH-independent CS. However, the fact that low ACTH is associated with osteonecrosis and that ACTH administration reduces such necrosis in animal model, even despite methylprednisolone acetate, provides a rationale for the use of ACTH in humans to decrease the risk of osteonecrosis.

Effects of atorvastatin and rosuvastatin therapy on serum 25-hydroxyvitamin D levels: a comparative study
Canan Cicek Demir, Umut Mousa, Cuneyd Anil, Yusuf Bozkus, Asli Nar & Nesimcan Bascil Tutuncu
Department of Endocrinology and Metabolism, Baskent University, Ankara, Turkey.

Introduction

There is accumulating evidence on the favorable effects of some statins on bone and mineral metabolism. Although some studies have reported drop of serum 25-hydroxyvitamin D levels in subjects receiving statin therapy, comparative studies evaluating various statins in prospective randomized design is lacking. Our purpose is to compare the effects of variable doses of rosuvastatin and atorvastatin on serum 25-hydroxyvitamin D levels adjusted for seasons.

Methods

Hyperlipidemic patients who did not receive lipid lowering therapy before were included. They were randomly assigned to receive rosuvastatin 10 mg, rosuvastatin 20 mg, atorvastatin 10 mg and atorvastatin 20 mg. We planned to evaluate serum 25-hydroxyvitamin D, LDL-c, HLDL-c, triglyceride levels at baseline, 12, and 24 weeks of therapy. Preliminary results are reported.

Results

Seventy-six cases were recruited to the ongoing study till now. 16 hyperlipidemic men and women, 8 of whom received rosuvastatin 10–20 mg/day, and the remaining atorvastatin 10–20 mg/day completed the first twelve weeks. The mean basal lipid and 25-hydroxyvitamin D levels were similar in both groups (155.8 ± 23.4 mg/dl and 54.4 ± 20.9 UGF for atorvastain; 172.1 ± 46.8 mg/dl and 48.5 ± 13.4 UGF for rosuvastatin group, respectively) (mean ± stdev). LDL-c levels decreased significantly in both groups to a mean value of 85.5 and 100.9 mg/dl, respectively (P<0.01). No significant effects of atorvastatin and rosuvastatin were observed on 25-hydroxyvitamin D levels at the end of twelve weeks (65.8 ± 31.7 and 47.3 ± 31.7 UGF, respectively; P>0.05). There was no correlation between LDL-c and 25-hydroxyvitamin D level changes in both of the groups.

Conclusion

In contrast to some previous data, rosuvastatin and atorvastatin, two potent and widely prescribed statins, did not lead to a significant change in 25-hydroxyvitamin D levels. Long-term prospective studies are needed to evaluate the effects of statins on vitamin D levels.
The relation between metabolic syndrome and cognitive decline in elderly Turkish people
Sayid Shahi Zuhur, Berrin Karadag & Yuskel Altuntas
Endocrinology and Metabolism Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey.

Objective
To determine the relationship between metabolic syndrome (MS) and cognitive decline in people over 60 years age.

Methods
The age of the participants were between 60 and 89 years old (71.71 ± 6.58). According to NCEP ATP III criteria 93 had MS and 47 had not. Cognitive performance was determined with the use of standardized mini mental test and the mini mental scores (MMS) of the two groups were compared. Apart from the MS we investigated the relationship between MMS and age, gender, educational status, tobacco and alcohol use, the history of acute myocardial infarction (AMI) and stroke, medication use (antihypertensive, insulin, oral antidiabetic, statin) and body mass index (BMI) kg/m², depression, which is a cause of pseudodemencia, was also assessed with the use of geriatric depression scale (GDS).

Results
The MMS was low in 25 patients (26.9%) in the MS group, and in 7 subjects (14.9%) in the control group. We could not find difference between MMS's of two groups statistically. In this study the MMS was low in subjects with high fasting plasma glucose level, tobacco use, insulin use, advanced age and depression. The GDS’s of two groups were similar. There was not difference in the MMS’s between patients with high blood pressure, high triglyceride level, low HDL cholesterol level, history of AMI and stroke, low educational status, high BMI and in whom without them. We also could not find difference between MMS’s of the patients who use antihypertensives, oral antidiabetics and statins and in whom not using these medications.

Conclusion
The number of elderly people increases in Turkey, however, cognitive decline related to diseases also increases. The establishment of the risk factors, which affect the cognitive functions and prevention of them in elderly, would prevent the cognitive decline, one of the important causes of mortality and morbidity in today’s world.

Inflammation indices and insulin resistance in metabolic syndrome with and without coronary artery disease
Mojtaba Khademi, Marzieh Nikparvar, Shahram Zare & Mehrdad Solati
Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Background
Obesity, particularly abdominal obesity, is associated with resistance to the effects of insulin on peripheral glucose and fatty acid utilization, often leading to type 2 diabetes mellitus. Insulin resistance, the associated hyperinsulinemia and hyperglycemia, and adipocyte cytokines (adipokines) may also lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease (CVD). The aim of our study was to assess the association of insulin resistance and inflammatory markers with the occurrence and extent of CAD.

Methods
Plasma level of FBS, oral glucose tolerance test (OGTT), insulin, fibrinogen, TG, LDL-C, HDL-C, ESR, C-reactive protein (CRP), magnesium (Mg) and calcium (Ca) were measured. Measurements were made in samples obtained from 44 patients who had metabolic syndrome with coronary arteries diseases (cases), and 45 patients who had metabolic syndrome but without CAD (controls). Cases were patients with 3 of 5 criteria of metabolic syndrome whom had documented CAD (resent or old MI, positive angiography for CAD) and controls were the patients with metabolic syndrome but (same the cases) but with no evidence of ischemic heart disease (IHD) such as normal electrocardiogram, echocardiogram, exercise tolerance test and no sign and symptom of IHD.

Results
After adjustment for factors, high levels of hsCRP and fibrinogen were significantly related to an increased risk of coronary heart disease in cases group (P < 0.001). Although the insulin level, ESR and smoking were higher in cases group but these difference were not significant level of HDL in cases group was lower than control group but no significantly.

Conclusion
Elevated levels of inflammatory markers, particularly hsCRP and fibrinogen level indicate an increased risk of coronary heart disease.

Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome
Yuanyuan Bao1, Xiliang Shang2, Linuo Zhou1 & Renming Hu1
1Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Sports Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China.

Instruction
Previous studies have been shown that obese individuals have reduced natriuretic peptide levels. But conflicting data exist on the relation of natriuretic peptide levels to metabolic syndrome (MetS), metabolic risk factors in 469 patients free of heart failure.

Material and methods
Two hundred and thirty diagnosed MetS cases and 239 non-MetS cases were included in this study. Echocardiography examinations were performed and left ventricular mass index was calculated according to Devereux correction formula. NT-proBNP was measured by electrochemiluminescence. The log-transformed NT-proBNP levels were used for abnormal distribution. Multiple linear regression analysis was performed to assess the relationship between levels of NT-proBNP and metabolic components. There is a relationship between MetS and lower plasma glucose levels. But conflicting data exist on the relation of natriuretic peptide levels to metabolic syndrome (MetS), metabolic risk factors in 469 patients free of heart failure.

Results
Adjusted log NT-proBNP levels were lower in patients with high blood pressure, high triglyceride level, low HDL cholesterol level, history of AMI and stroke, low educational status, high BMI and in whom without them. We also could not find difference between MMS’s of the patients who use antihypertensives, oral antidiabetics and statins and in whom not using these medications.

Conclusion
The number of elderly people increases in Turkey, however, cognitive decline related to diseases also increases. The establishment of the risk factors, which affect the cognitive functions and prevention of them in elderly, would prevent the cognitive decline, one of the important causes of mortality and morbidity in today’s world.

Regulation of fuel metabolism during exercise in hypopituitarism with growth hormone-deficiency (GHD)
E R Christ, S Alleman, A Egger & C Stettler
University Hospital of Bern, Inselspital, Bern, Switzerland.

Introduction
Hypopituitary patients with GHD tend to have a reduced exercise capacity. GH is secreted during exercise, has a strong lipolytic action and has been shown to be positively correlated with exercise performance. We hypothesized that the lack of GH leads to a reduced systemic availability of free fatty acids (FFA) during exercise thereby affecting exercise performance.

Methods
Patients with GHD and matched sedentary control subjects (CS) were exposed to an increasing workload on a treadmill for the determination of VO2max. On a separate day, the patients and CS performed a 2-h exercise session on a treadmill (50-60% of the VO2max). Usual hydrocortone replacement therapy was administered prior to exercise as needed. Blood samples were taken at baseline and every 30 min during the exercise. Analysis of the samples included GH, catecholamines (noradrenaline, adrenaline) as well as glucose and FFA. Area under the curve (AUC) as well as peak concentrations of hormones and metabolites were analyzed.

Results
Ten patients with GHD (4 females, age: 42.5 ± 12.4 years, mean ± s.d.; BMI: 26.6 ± 3.8 kg/m²; waist: 89.3 ± 12.9 cm) and 10 CS matched for gender, age, BMI and waist (age: 42.8 ± 12.6 years; BMI: 25.2 ± 4.3 kg/m²; waist: 90.7 ± 19.1 cm) volunteered for the study. GHD patients tended to have a reduced VO2max compared with CS (GH: 36.3 ± 6.7 ml O2/kg per bodyweight; CS: 41.7 ± 6.0, P = 0.07). GH-AUC and GH peak concentrations were lower in GHD patients compared to CS (by a factor 1.5). AUC and peak concentrations of catecholamines were similar in patients and CS. FFA-AUC. Glucose-AUC and glucose peak concentrations were not significantly different between the two groups. GHD patients tended to have lower FFA peak-concentrations compared to sedentary controls (patients: 1.03 ± 0.39 nmol/l; CS: 1.51 ± 0.53, P = 0.054).

Conclusion
This study indicates that i) there is a tendency towards a reduced exercise capacity in GHD patients compared to matched control subjects and ii) systemic
availability of FFA may be slightly reduced whereas glucose availability is similar during exercise in GHD.

P554
Prevalence of androgen deficiency in males with metabolic syndrome: relation between hormonal and metabolic parameters
Antonio Becerra1,2, Gilberto Perez-Lopez1, Miriam Menacho3, Jose M Rodriguez-Molina1,4, M Jesus Lucio1, Nuria Aseно4 & Rosa Villar5
1Gender Unit, Department of Endocrinology, Hospital Universitario Ramon y Cajal, Madrid, Spain; 2University of Alcalá, Madrid, Spain; 2Department of Biochemistry, Hospital Universitario Ramon y Cajal, Madrid, Spain; 3Autonomous University, Madrid, Spain; 4Department of Endocrinology, Hospital Universitario de Fuenlabrada, Madrid, Spain.

Androgen deficiency in the aging male has become an actual topic due to the aging population and finding from different studies that shows a progressive decline of serum levels of age-related testosterone. These levels have been inversely related with markers of metabolic syndrome and cardiovascular disease. The aim of this observational study was to investigate the relation of androgenic testosterone and other sex hormones with different components of metabolic syndrome, as defined by the National Cholesterol Education Program (NCEP), in a Spanish middle-aged and elderly male population.

We studied 73 consecutive men with metabolic syndrome (criteria NCEP), aged between 40 and 70 years. The body weight, waist circumference and arterial pressure were measured, and fasting serum levels of glucose, insulin, lipid profile, total testosterone (TT), SHBG, dehydroepiandrosterone sulfate (DHEA-S) and estradiol were determined. The insulin resistance was calculated by use of the HOMA index. Our male population present an evident androgenic deficit (TT < 230 ng/dl) in 9/73 cases (12.3%) and a partial androgenic deficit (TT 230–345 ng/dl) in 34/73 cases (46.6%). We found an inversely significant correlation of values of TT with those HOMA index (r = -0.293, p < 0.05) and those waist circumference (r = -0.312, p < 0.05).

In conclusion, our findings show that patients with metabolic syndrome could present a relatively high prevalence of hyponogadism, so this abnormality must be investigated in this population. The decrease in androgens concentrations in men could be related with insulin resistance, and in consequence with the development of diabetes mellitus and cardiovascular disease.

P555
Polycystic ovary syndrome and their relationship with metabolic syndrome in female-to-male transsexuals
Antonio Becerra1,4, Gilberto Perez Lopez1, Miriam Menacho3, Jose Miguel Rodriguez Molina1,4, M Jesus Lucio1 & Nuria Aseño1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Endocrinology and Sexual Medicine Unit, University of Florence, Florence, Italy; 3Diabetes Section Geriatric Unit, University of Florence, Florence, Italy; 4Autonomous University, Madrid, Spain.

Objective
To determine the prevalence of polycystic ovary syndrome (PCOS) and hyperandrogenism and their relationships with metabolic syndrome (MS) parameters in female-to-male transsexuals (FMT).

Design and Methods
Seventy-seven FMT were assessed clinically and biochemically to hyperandrogenism, before the beginning of the treatment with testosterone. We also assessed cardiovascular risk factors and other parameters of MS.

Results
26.0% of the sample had overweight, and 19.5% were obese patients. The prevalence of hyperandrogenism was 49.35% and those of PCOS was 36.4 and 51.9% of patients had MS. By adjusting the parameters of MS and PCOS, for the body mass index (BMI), we observed that the higher BMI, regardless of the concentrations of free testosterone (FT), increases insulin resistance (HOMA-IR 2.43 vs 2.93 vs 3.85, p < 0.001). Of all patients, 27.3% had HDL-cholesterol below 50 mg/dl.

Conclusions
The general hyperandrogenism, and PCOS in particular, are highly prevalent in FMT. The high prevalence of PCOS appears to be related to body weight. The hyperandrogenism is associated with the development of MS, and other factors such as insulin resistance and decreased HDL-C, which globally increase the cardiovascular risk. These data suggest that gender dysphoria at least in FMT could be related to hyperandrogenism secondary to hyperadrenal axis activation and/or gonadal, although many studies assess these phenomena as the cause of these disorders.

P556
Is metabolic syndrome a useless category in subjects with high cardiovascular risk? Results from a cohort study in men with erectile dysfunction
Giovanni Corona1,2, Matteo Monami3, Giulia Rastrelli1, Alessandra Sforza2, Gianni Forti1, Edoardo Mannucci1 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Endocrinology Unit, Azienda Usl di Bologna, Ospedale Maggiore, Bologna, Italy; 3Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 4Endocrinology Unit, University of Florence, Florence, Italy.

Introduction
Although several studies have demonstrated that MetS is associated with a twofold increase in the risk of cardiovascular (CV) diseases, this risk does not appear to be greater than the sum of risks associated with each of its individual components. To determine the association of men with ED and individual components of MetS and their subsequent relationship to cardiovascular (CV) risk, and, more specifically whether the sum of the MetS components is greater than the individual components in predicting CV risk.

Methods
We longitudinally studied a consecutive series of 1687 (mean age 52.9 ± 12.8; range 17–88 years) patients attending our clinic for ED and evaluated different clinical and biochemical parameters. Information on MACE was obtained through the City of Florence Registry Office.

Results
One hundred and thirty-nine MACE, 15 of which were fatal, occurred during a mean follow-up of 4.3 ± 2.6 years. Subjects with MetS at baseline showed a higher incidence of MACE (HR = 1.77), after adjusting for age, however, the association disappeared in an alternative Cox model, adjusting both for age and for individual MetS components (HR = 1.525 (0.564–4.123); P = 0.408). The two most predictive MetS components of CV risk were low HDL cholesterol and high triglycerides. Exploring possible interactions between individual components of MetS and their effect on CV risk using two alternative approaches indicates that the effect of MetS components on CV risk is additive, but not synergistic. Among subjects with hypertension, after adjusting for age, elevated glycaemia and low HDL-cholesterol confer relevant additional risk, while in subjects with high triglycerides, hyperglycaemia increased the risk of incident MACE.

Conclusions
With regards to CV risk, the MetS construct seems to add little or nothing to the careful assessment of its components. Thus, there is no reason to recommend the use of MetS as a diagnostic category in patients with ED.

P557
Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction
Giovanni Corona1,2, Giulia Rastrelli1, Valentina Boddì1, Matteo Monami3, Alessandra Sforza2, Gianni Forti1, Edoardo Mannucci1 & Mario Maggi3
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Endocrinology Unit, Azienda Usl di Bologna, Ospedale Maggiore, Bologna, Italy; 3Diabetes Section Geriatric Unit, University of Florence, Florence, Italy.

Introduction
We previously reported that in subjects consulting for sexual dysfunction lower PRL plasma levels were associated with worse lipid and glycemic profile, as well as with a higher prevalence of metabolic syndrome and arteriogenic erectile dysfunction (ED). To assess possible associations between PRL levels and incident major cardiovascular events (MACE) in subjects with ED.

Methods
This is an observational prospective cohort study evaluating a consecutive series of 1687 patients attending our Andrological Unit for ED. Different clinical, biochemical and instrumental parameters were evaluated. Information on MACE was obtained through the City of Florence Registry Office.
Conclusions
In subjects at high risk for cardiovascular diseases, such as those with ED, a relatively high PRL plasma level is associated with an overall decreased chance of MACE, independently from other known risk factors.

P558
Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction
Giovanni Corona1,2, Giulia Rastrelli3, Matteo Monami1, Alessandra Sforza4, Gianni Forti4, Edoardo Mannucci1 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Endocrinology Unit, University of Florence, Florence, Italy; 3Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 4Endocrinology Unit, Azienda USL di Bologna, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy.

Introduction
Obesity is an independent cardiovascular (CV) risk factor. Testosterone (T) is inversely related to body mass index (BMI) in males. There is substantial evidence suggesting that low T could play a role as a moderator of CV mortality in men, and so this study is designed to assess the possible interaction between T and obesity in predicting major cardiovascular events (MACE) in a sample of subjects with erectile dysfunction.

Methods
This is an observational prospective cohort study involving a consecutive series of 1687 patients attending our Unit for erectile dysfunction. According to BMI, subjects were divided into normal weight (BMI = 18.5–24.9 kg/m²), overweight (BMI = 25.0–29.9 kg/m²) and obese (BMI ≥ 30.0 kg/m²). Hypogonadism was defined as total T below 10.4 nmol/l. Information on MACE was obtained through the City of Florence Registry Office.

Results
Among the patients studied, 39.8% had normal weight, whereas 44.1% and 16.1% were overweight or obese respectively. Unadjusted analysis in the whole sample showed that, while hypogonadism and obesity were significantly associated with an increased risk of MACE, their interaction term was associated with a protective effect. In a Cox regression model, adjusting for confounders, hypogonadism showed a significant increased risk of MACE in normal weight subjects, whereas it was associated with a reduced risk in obese patients.

Conclusions
Hypogonadism-associated CV risk depends on the characteristics of subjects. Further studies are advisable to clarify if low T in obese patients is a positive (consequence of a comorbid condition to save energy) or if it represents a pathogenetic issue of the same illness.

P559
Severe depressive symptoms and cardiovascular risk in subjects with erectile dysfunction
Elisa Bandini1, Alessandra Fisher2, Giovanni Corona3,4, Valdo Ricca2, Matteo Monami1, Gianni Forti1, Edoardo Mannucci1 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Psychiatry Unit, Department of Neurological and Psychiatric Sciences, Florence, Italy; 3Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 4Psychiatry Unit, Department of Neurological and Psychiatric Sciences, Florence, Italy; 5Diabetes Section, Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 6Endocrinology Unit, Azienda USL di Bologna, Ospedale Maggiore, Florence, Italy; 7Endocrinology Unit, University of Florence, Florence, Italy.

Introduction
Erectile dysfunction (ED) and mood depression are often associated and both are correlated with an increased risk of cardiovascular morbidity and mortality.

The aim of the present study is to explore biological and clinical correlates of depressive symptomatology in a sample of men consulting for sexual dysfunction and to verify possible associations between depressive symptoms and incidence of major adverse cardiovascular events (MACE).

Methods
A consecutive series of 2303 male patients attending the Outpatient Clinic for sexual dysfunction was retrospectively studied. A subset of the previous sample (N = 1687) was enrolled in a longitudinal study. All patients were investigated using a structured interview on erectile dysfunction (SIEDY), composed of three scales which explore organic, relational and intra-psychic components of ED. MHQ-D scoring from middlesex hospital questionnaire (MHQ) was used as a putative marker of depressive symptoms. Information on MACE was obtained through the City of Florence Registry Office.

Results
We found a positive relationship between MHQ-D score and a progressive impairment in obtaining an erection hard enough for penetration, even after adjusting for confounding factors. Moreover, we observed positive relationships between MHQ-D score and the three pathogenetic domains underlying ED. When the longitudinal subset was evaluated, during a mean follow-up of 4.3 ± 2.6 years, 139 MACE, 15 of which were fatal, were observed. Unadjusted incidence of MACE was significantly associated with baseline depressive symptoms. When the presence of severe depressive symptoms were introduced in a Cox regression model, along with the arteriogenic ED and partner’s hypoactive sexual desire, after adjusting for age, chronic diseases score, and SMHQ (a broader index of psychopathology), severe depressive symptomatology was independently associated with a higher incidence of MACE.

Conclusion
Depressive symptomatology constitutes an independent risk factor for cardiac morbidity and mortality in men with ED.

P560
Priapus is happier with Venus than with Bacchus
Giovanni Corona1,2, Valentina Boddi1, Matteo Monami3, Alessandra Fisher4, Elisa Bandini2, Gianni Forti1, Edoardo Mannucci3 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Endocrinology Unit, Azienda USL di Bologna, Ospedale Maggiore, Bologna, Italy; 3Diabetes Section Geriatric Unit, Department of Critical Care, University of Florence, Florence, Italy; 4Endocrinology Unit, University of Florence, Florence, Italy.

Introduction
The relationship between alcohol consumption and erectile function is still not completely clarified. Aims of the present study are to explore a number of biological and clinical correlates of alcohol consumption in a sample of men consulting for sexual dysfunction, and to verify possible associations between the incidence of major adverse cardiovascular events (MACEs).

Methods
A consecutive series of 1956 (mean age 55 ± 11.9 years old) attending our outpatient clinic for sexual dysfunction was retrospectively studied. A subset of the previous sample (N = 1687) was enrolled in a longitudinal study. Different clinical, biochemical, instrumental (penile Doppler ultrasound (PCDU)), and intrapsychic (Middlesex Hospital Questionnaire (MHQ)) were evaluated. We considered alcohol abuse more than 3 drinks/day.

Results
Among the patients studied 81% reported no or mild (<4 drinks/day) alcohol consumption whereas 14.3 and 3.9% declared a moderate (4–6 drinks/day) or severe (>6 drinks/day) alcohol abuse respectively. After adjustment for confounders, both moderate or severe alcohol abuse was associated with low perceived partner’s sexual desire, worse couple relationship, and smoking abuse. Furthermore, moderate and severe alcohol abuse was associated with low prolactin and thyroid-stimulating hormone levels, as well as an increase in triglycerides and total cholesterol levels. Penile blood flow was reduced in moderate and severe alcohol drinkers even after adjustment for confounders.

In the longitudinal study, after adjusting for confounding factors, any kind of alcohol abuse was independently associated with a higher incidence of MACE (hazard ratio = 2.043 (1.059–3.943); P = 0.0001).

Conclusions
Our findings demonstrate that, in subjects consulting for erectile dysfunction, severe alcohol consumption is associated with a worse sexual function and a higher incidence of MACE.
**P561**

**Young women with the polycystic ovary syndrome (PCOS) have evidence of endothelial dysfunction but not of altered arterial structure**

A Dunca1, R Ilie1, C Georgescu1, I Marian1, T Mocan1, B Man1, C Brad1 & G Hau1

1) Department of Endocrinology, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 2) Department of Internal Medicine, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 3) Department of Physiology, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 4) Clinical Laboratory, Emergency County Hospital Cluj, Cluj-Napoca, Romania.

**Aim**
The aim of our study was to assess the presence of endothelial dysfunction and of increased carotid intima-media thickness (IMT), two precocious markers of atherosclerosis in PCOS subjects. Simultaneously, their relationship with some metabolic, hormonal and anthropometric parameters was analyzed.

**Methods**
The study group consisted of 45 women with PCOS (age 23.1 ± 4.1 years, body mass index (BMI) = 28.4 ± 5.9 kg/m²). Thirty-two healthy age-matched women (23.0 ± 5.3 years and BMI = 25.8 ± 6.8 kg/m²) were included as controls. All women were evaluated clinically and biochemically. Serum insulin, total testosterone, sex hormone binding globulin and estradiol were measured using ELISA commercial kits. Intima-media thickness was assessed by high-resolution ultrasonography at the level of common carotid artery bilaterally, while endothelial dysfunction was investigated by both endothelin (ET)-1 levels determination and measurement of flow-mediated dilatation (FMD) of the brachial artery.

**Results**
ET-1 levels were significantly higher while the FMD was significantly lower in the PCOS women compared with the control women (P = 0.001). In contrast, no difference was observed between the two groups in carotid artery IMT. In the total study group, both ET-1 (correlation with TT: r = 0.439, P < 0.0001) and with the free androgenic index (FAI): r = 0.448, P < 0.0001) and brachial artery FMD (correlation with the FAI: r = -0.242, P = 0.046) were significantly associated with hyperandrogenemia markers. In multiple regression analyses for the total population, only PCOS presence represented an independent predictor of FMD levels (β = -0.406, P = 0.001).

**Conclusions**
Our data show that young, non-dyslipidemic, non-hypertensive and eu-glycaemic women with PCOS have altered endothelial function but not evidence of altered arterial structure and that increased androgen levels are linked to impaired endothelial function.

**P562**

**Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotrophic hypogonadism**

A Sonmez1, C Haymana1,2, B Bulut1, A Aydogdu1, S Tapang1,3, M Sert1,3, B Altun1,2, C Barcin1,2, A Tasliptina1, C Meric1, G Uckay1 & M Kutlu1

1) Gulhane School of Medicine Department of Endocrinology and Metabolism, Ankara, Turkey; 2) Gulhane School of Medicine Department of Internal Medicine, Ankara, Turkey; 3) Gulhane School of Medicine Department of Biochemistry, Ankara, Turkey; 4) Gulhane School of Medicine Department of Cardiology, Ankara, Turkey.

**Objective**
The relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far there has been no data about the presence of MS in young hypogonadal patients. Also there is controversial data about the metabolic effects of testosterone replacement therapy. We investigated the frequency of MS in treatment naïve, young men with congenital hypogonadal hypogonadism (CHH). We also searched for the effect of testosterone replacement on the metabolic profiles of this specific patient group.

**Design**
Retrospective analysis

**Methods**
A total number of 332 patients (age 21.68 ± 2.09 years) were enrolled. The control group was the 395 age and body mass index (BMI) matched healthy young men (age 21.39 ± 1.49 years). Standard regimen of testosterone esters (250 mg/3 weeks) were given to 208 patients.

**Results**
MS was more prevalent in CHH (P < 0.001) according to healthy controls. The patients had higher arterial blood pressure, waist circumference (WC), triglyceride (P < 0.001 for all), fasting glucose (P = 0.02), insulin (P = 0.004), HOMA-IR (P = 0.002) and lower HDL cholesterol (P < 0.001) levels. With a mean follow-up period of 5.63 ± 2.6 months, the BMI, WC (P < 0.001 for both), systolic blood pressures (P = 0.002) and triglyceride levels (P = 0.04) were increased and the total and HDL cholesterol levels were decreased (P = 0.02 and P < 0.001 respectively).

**Conclusions**
This study shows increased prevalence of MS and unfavorable effects of testosterone replacement in young patients with CHH. Long term follow up studies are warranted to investigate the cardiovascular safety of testosterone treatment in this specific population.

**P563**

**Determinants and outcome of amiodarone-associated thyroid dysfunction**

S Ahmed, I C Van Gelder, A C P Wiesfeld, D J Van Veldhuisen & T P Links

University Medical Center Groningen, Groningen, The Netherlands.

**Background**
Amiodarone is frequently associated with thyroid dysfunction. Identifying predictors for amiodarone-associated thyroid dysfunction and assessing treatment outcome may aid clinicians in daily practice.

**Patients and methods**
In our retrospective study, we included 303 consecutive patients with amiodarone therapy for cardiac arrhythmias (260 with atrial fibrillation and 43 with ventricular arrhythmias). Thyroid function tests were performed every 6 months.

**Results**
Mean age was 63 ± 12 years and 66% was male. After median follow-up of 3.3 (0.1–24) years, 23 (8%) patients developed amiodarone-associated thyrotoxicosis (incidence rate 1.9 per 100 person years) and 18 (6%) hypothyroidism (incidence 0.1–24) years, 23 (8%) patients developed amiodarone-associated thyrotoxicosis (incidence rate 1.1 per 100 person years). The only predictor for amiodarone-associated thyrotoxicosis was age < 62 years (HR = 2.4 (95% CI 1.0–5.7), P = 0.05). Predictors for amiodarone-associated hypothyroidism were thyroid stimulating hormone > 1.4 mU/l at baseline (HR = 5.1 (95% CI 1.1–22.4), P = 0.03), left ventricular ejection fraction < 45% (HR = 3.8 (95% CI 1.1–13.3), P = 0.04) and diabetes mellitus at baseline (HR = 5.3 (95% CI 1.1–10.3), P = 0.04). Gender was not a predictor for amiodarone-associated thyroid dysfunction. Five out of 23 (22%) patients with thyrotoxicosis exhibited spontaneous normalization of thyroid function on continuation of amiodarone therapy. Mean time to normalization in the total group was 6.2 ± 3.3 months, with no difference between continuing or discontinuing amiodarone (6.6 ± 3.8 versus 5.8 ± 2.8 months, P = 0.15).

**Conclusions**
During median follow-up of 3.3 years, the incidence of amiodarone-associated thyrotoxicosis was higher compared to hypothyroidism. Only general predictors for amiodarone-associated thyroid dysfunction were observed. Discontinuation of amiodarone did not influence treatment outcome.

**P564**

**Abstract withdrawn.**
Background

The presence of the metabolic syndrome (MS) increases cardiovascular morbidity and mortality but few data is available on the outcome in subjects with the MS and subclinical atherosclerosis.

Aim

We aimed to assess cardio- and cerebro-vascular events in subjects with MS and subclinical atherosclerosis.

Methods

We followed up for 5 years 339 subjects with asymptomatic carotid intima-media thickness >0.9 mm, of whom 130 had the MS, evaluating at baseline traditional cardiovascular risk factors (including male gender, older age, obesity, hypertension, diabetes, smoking, family history of cardiovascular diseases, dyslipidemia) and plasma levels of C-reactive protein and fibrinogen.

Results

Cardio- and cerebro-vascular events were registered in the 29% of subjects with the MS and in the 20% of those without it and the presence of more criteria for the diagnosis of the MS was significantly associated with vascular morbidity and mortality: with transient ischemic attack (P<0.0001), angina (P=0.0022), cardio- and cerebro-vascular death (P=0.0019) and the presence of any clinical event (P=0.0003). Further, we used logistic regression analysis to search for possible independent associations of any parameter evaluated at baseline with the occurrence of clinical events and we found a predictive role for elevated markers of inflammation (OR 3.8, 95% CI 2.6–12.5, P=0.0022), elevated fasting glucose (OR 2.1, 95% CI 1.2–4.0, P=0.0134) and elevated triglycerides (OR 1.4, 95% CI 1.1–2.9, P=0.0351).

Conclusions

These findings confirm a worst vascular outcome in subjects with more criteria for event (OR 2.1, 95% CI 1.2–4.0, P<0.0003), higher triglycerides, total and LDL cholesterol, uric acid, GHBP (P<0.034).

Apolipoprotein A correlated positively with HDL-cholesterol (P<0.001), apolipoprotein B (P=0.001) and negatively with estradiol (P=0.017), estrone (P=0.022), alkaline phosphatase, crosslaps (P=0.001) and osteocalcin (P=0.023).

Conclusion

Postmenopausal women have higher apolipoprotein B and surprisingly higher apolipoprotein A levels that correlate positively. Their correlations with the hormonal status point to changes due to aging and joint action regarding cardiovascular risk.
biomarkers. Obesity is a known risk factor for cardiovascular disease. Cross sectional data suggest however that plasma levels are reduced among obese. Therefore, the aim of the present study was to investigate the impact of weight loss and corresponding changes in body composition on plasma levels of A and B-type natriuretic peptides.

Methods and design
Fifty-two obese individuals 47 women, BMI 36.5 ± 6.6 kg/m²; age 62 ± 7 years (mean ± s.d.). Randomized to either intervention on a weight reduction program, using a low energy diet between 3.4 and 5 M/day, or to a control group which was offered diet counseling. Body composition measuring fat and fat free mass using whole body Dual energy X-ray (DEXA) scan, and plasma levels of NT-proBNP, MR-proANP and were measured at baseline and after 52 weeks.

Results
In the intervention group (n = 28), diet induced a substantial weight loss (BMI 31.6 ± 6.2 vs. 37.1 ± 6.1 kg/m²; P < 0.001) and loss in body fat (23.5 ± 15.5%; P < 0.001) after 52 weeks. Corresponding, plasma NT-proBNP (97 ± 55 vs. 55 ± 31 pg/ml; P < 0.001) and MR-proANP (74 ± 26 vs 59 ± 21 pmol/l; P < 0.001) levels increased. A modest weight loss (33.6 ± 5.5 vs. 35.8 ± 5.2 kg/m²; P = 0.001), and body fat (9.2 ± 11.0%; P < 0.05) was observed among controls (n = 24), with no changes in NT-proBNP or MR-proANP concentrations. The loss in total weight and in fat mass were significantly higher in the intervention as compared with the control group (P < 0.001), for both.

Conclusions
NT-proBNP and MR-proANP concentrations increases in circulating plasma during substantial weight loss, underlining the impact of BMI on plasma levels of A and B-type natriuretic peptides.

P569
α-Defensins are novel biomarkers of low grade inflammation with strong prognostic impact in patients with heart failure
C Kistorp1, H M Christensen1, J Frydych2, A Flyvbjerg2, P Hildebrandt3, M Schou1 & J Faber1
1Herlev University Hospital, Herlev, Denmark; 2Aarhus University Hospital, Aarhus, Denmark; 3Glostrup University Hospital, Glostrup, Denmark; 4Hillerød University Hospital, Hillerød, Denmark.

Introduction
α-Defensins are recently described peptides, which are part of the innate immune system. Increased circulating levels are observed in conditions associated with chronic low grade inflammation, such as ischemic heart disease and in diabetes mellitus (DM). Recently we reported adverse prognostic implications of high α-defensins in patients with type 1 DM. However, it is not clear whether this finding may be generalized to include other groups such as patients with chronic heart failure (CHF). Therefore the aims were to compare plasma levels of α-defensins in CHF patients and healthy controls, and to examine the predictive ability of α-defensins with respect to all-cause mortality and future cardiovascular outcome.

Methods and design
Prospective observational study, median follow-up of 2.6 years, the prognostic value of plasma α-defensins with respect to overall mortality and new ischemic events in 194 CHF patients and 98 age-matched healthy controls.

Results
α-Defensins levels were two times higher among patients with severe heart failure (NYHA class III/IV) than in patients in NYHA class I/II and healthy controls (P < 0.001). After adjustment for potential confounders including NT-proBNP, high α-defensins (> 540 ng/ml) corresponding to the optimal cut-off value, were associated with a twofold increased mortality risk hazard ratio (HR) being 2.1 (95% CI: 1.2–4.1; P = 0.029) and of new ischemic events HR: 1.86 (95% CI: 1.15–3.01; P = 0.001). The combination of high α-defensins and high NT-proBNP levels (above the respective median values) were associated with a threefold increase in mortality HR: 3.19 (95% CI: 1.68–6.06; P < 0.001), as compared to patients with low levels of both biomarkers.

Conclusion
α-Defensins are novel interesting biomarkers of chronic inflammation. In heart failure patients α-defensins provide incremental prognostic information to established clinical risk markers.

P570
B-type natriuretic peptide modulates the response to intravenous glucose in a placebo-controlled cross-over study in healthy volunteers
B Heinisch1, G Vila1, M Resl1, M Riedl1, A Lugner1, G Pacini2 & M Codi1
1Medical University of Vienna, Vienna, Vienna, Austria Institute of Biomedical Engineering, Padua, Italy.

B-type natriuretic peptide (BNP) is a hormone secreted from the heart in response to volume load and serves clinically as a reliable biomarker in the diagnosis of cardiac dysfunction and heart failure. As patients with heart failure present an increased risk for developing diabetes, we aimed to investigate the role of BNP on parameters of glucose metabolism in a placebo-controlled crossover study performed in 10 healthy volunteers (25 ± 1 years; BMI 23 ± 1 kg/m²; fasting glucose 83 ± 2 mg/dl). Participants received intravenously either placebo or 3 pmol/kg per minute BNP-32 for 4 h. One hour after beginning the BNP/placebo infusion, a 3 h intravenous glucose tolerance test (0.33 g/kg glucose +0.03 U/kg insulin at 20 min) was started. Plasma glucose, insulin and C-peptide were frequently measured and minimal model analysis was performed. BNP increased the glucose distribution volume (13 ± 1% BW vs. 11 ± 1%; P < 0.002), leading to an overall reduction of glucose concentrations (P < 0.001) especially during the initial 20 min of the test (P = 0.001). This was accompanied by a reduction of the initial C-peptide levels (4.3 ± 0.4 ng/ml vs. 4.9 ± 0.3, P = 0.015). On the other hand, BNP had no specific impact on beta cell function (129 ± 17 vs. 124 ± 11 pmolCP/mmolG30, insulin clearance (8.7 ± 1 vs. 8.3 ± 0.7 ml/min per kilogram) and insulin sensitivity (10 ± 0.9 vs. 9.2 × 106 min–1 μU/ml), all P > 0.6.

Intravenous administration of BNP increases glucose distribution volume lowering plasma glucose concentrations after fasting without affecting beta cell function and insulin sensitivity. These results speak for the concept that BNP does not worsen, but improves diabetes in patients with heart failure, and open otherwise new questions regarding BNP-induced differences in glucose availability and signaling in several organs/tissues.
**P572**

**Phosphate levels inversely correlate with aortic stiffness in patients with primary hyperparathyroidism**

Fanni Athanasosou1, Leonidas Papadopoulos2, Anastasia Vernour2, Konstantine Chaliaras3, Evelin Elihimious3, Theodore Athanasoulas1, Christs Papamichal6, Kimon Stamatopoulos4, Evangelos Terpos6, & Maria Alevizaki1

1Endocrine Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece; 2Vascular Laboratory, Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece; 3Department of Nuclear Medicine, Alexandra Hospital, Athens, Greece.

**Introduction**

Although data on the association of primary hyperparathyroidism (pHPT) with cardiovascular disease are accumulating, there is still controversy on this issue. Moreover, possible associations of aortic stiffness and central aortic pressures with pHPT and associated effective molecules have not been addressed.

**Methods**

Seventy patients with pHPT were consecutively recruited from the outpatients’ clinic of an academic department of endocrinology. In all patients, arterial stiffness was assessed by measurement of pulse wave velocity (PWV) between carotid and femoral arteries while reflected waves and central blood pressures were evaluated by pulse wave analysis. Laboratory evaluation included parathyroid hormone (PTH), 25(OH)2D, total calcium, phosphate and albumin levels.

**Results**

Phosphate levels but not calcium, PTH or vitamin D3 levels inversely correlated with PWV ($-0.244$, $P=0.046$) but not with reflected waves or central blood pressures. By multivariate analysis, among other risk factors, phosphate levels independently determined PWV ($P=0.032$).

**Conclusions**

In patients with pHPT, phosphate levels independently correlated with aortic stiffness as expressed by PWV. Further research is needed to assess the possible effect of low phosphate levels on atherosclerosis in pHPT.

---

**P573**

**Low sex hormone binding globulin – strong association with metabolic syndrome in patients with acute coronary syndrome**

J Payer, A B Banarova, T K Kolier & P J Jackuliak

5th Department of Internal Medicine, Medical Faculty of Comenius University, Bratislava, Slovakia.

**Objective**

Despite of conflicting data, reduced levels of endogenous sex hormones and especially sex hormone binding globulin (SHBG) seem to be associated with metabolic syndrome (MS). In this study we determined relationship between endogenous sex hormone levels and SHBG and components of metabolic syndrome in both sexes.

**Methods**

In 39 men (median age 70.2) with total testosterone level in the lowest quartile of normal range (median 12.8 mmol/l) and 29 postmenopausal women (median age 74.5, median estradiol 78.6 pmol/l) without hormone replacement therapy who were admitted with acute coronary syndrome we determined concentrations of endogenous sex hormones: total testosterone (TT), calculated free androgen index (FAI), estradiol (E) and SHBG. Using correlation analyze we determined their relationship to components of MS: waist circumference, serum concentration of triacylglycerides (TAG) and high density lipoproteins (HDL), diabetes mellitus, arterial hypertension and body mass index (BMI).

**Results**

In men low TT was associated with higher BMI ($P=0.0009$) and waist circumference ($P=0.017$), low SHBG was associated with higher BMI ($P=0.0014$), waist circumference ($P=0.0073$) and level of TAG ($P=0.03$). FAI did not have relationship to MS. In women low estradiol was associated with higher level of TAG ($P=0.02$). Lower TT was associated with higher BMI ($P=0.02$) and waist circumference ($P=0.03$) and low SHBG was associated with higher BMI ($P=0.05$), arterial hypertension ($P=0.006$) and TAG ($P=0.007$). FAI in women correlated negatively with BMI ($P=0.05$), waist circumference ($P=0.04$) and diabetes mellitus ($P=0.02$).

**Conclusions**

We confirmed inverse association between metabolic syndrome and endogenous sex hormones but especially SHBG. This supports the theory of possible nonmemonic action of sex steroids mediated by SHBG although the exact pathogenesis of this relationship is still not well understood.
and insulin resistance calculated by HOMA-IR. 18:2n-6 correlated directly with HbA1c ($P<0.05$), triglycerides ($P<0.05$), inversely with HDL-C ($P<0.05$), and directly with HOMA-IR ($P<0.05$). By multiple regression analysis 18:2n-6 was still independent predictor of HOMA-IR.

Conclusion
It looks like that n-6 PUFAs, particularly 18:2n-6, could contribute to insulin resistance in T2DM. Therefore, the treatment of insulin resistance in T2DM should include diet modification with reduce intake 18:2n-6 polyunsaturated fatty acid.

P576
Parathormone 1-84 in type 2 diabetic patients
M I Belovici & M Buyssaercht
University of Louvain, Bruxelles, Belgium.

Objective
Increasing evidence suggests a role for mineral metabolism in cardio-vascular disease risk. We aimed at determining in type 2 diabetes patients the relationship between serum levels of 1-84 parathormone (PTH1–84), 25-hydroxy-vitamin D (25(OH)D) or calcium and the glycated hemoglobin (HbA1c), insulin sensitivity or β-cells function, but also the relationship between these factors and coronary arterial disease confirmed by myocardial scintigraphy.

Research design and methods
Serum PTH1–84, 25(OH)D and calcium were determined in 60 adult patients with type 2 diabetes divided into two groups: group A-normal myocardial scintigraphy ($n=37$) and group B-positive scintigraphy ($n=23$). The groups were matched regarding age, HbA1c, body mass index, glomerular filtration rate and pharmacotherapy with either vitamin D, angiotensin-converting enzyme inhibitors, sartans or calcium channel blockers.

Results
All type 2 diabetic patients had normal levels of PTH 1–84 and calcium, but low levels of 25(OH)D. Serum PTH1–84 were significantly increased in group B (positive myocardial scintigraphy) versus group A (negative scintigraphy) (Table 1). We found a negative correlation between PTH1–84 and glycated hemoglobin HbA1c ($P=0.015$). There were no significant correlations between calcium, vitamin D or PTH1–84 and HOMA insulin-sensitivity or β-cells function (HOMA-B).

| Table 1 |
|-----------------|-----------------|-----------------|
| Group A | Group B | Value (B versus A) |
| Serum 1-84 PTH (16–81 pg/ml) | 21 (10–42) | 27 (17–47) | 0.01 |
| Serum 25(OH)D (30–100 ng/ml) | 11 (5–48) | 12.1 (5–31) | 0.58 |
| Serum total calcium (8.6–10 mg/dl) | 8.4 (9.4–10.2) | 8.9 (8.4–9.7) | 0.35 |

Conclusion
In type 2 diabetic patients higher levels of PTH1–84 were associated with pathological myocardial scintigraphy, suggesting a role for PTH1–84 in cardiovascular disease risk. Serum PTH and HbA1c were inversely correlated.

P577
Rhabdomyolysis associated with fenofibrate: a case report
Derya Oz, Öğün Hatipoglu, Pinar Alsarlan, Halife Kurt, Nuri Fidan, Bilgin Ozmen & Zelih Hekimsoy
Celal Bayar University Medical Faculty, Manisa, Turkey.

Rhabdomyolysis is a characterized by muscle necrosis and release of intracellular muscle constituents into the circulation. Most cases are associated with a predisposing factor such as high dose statin therapy, diabetes, old age, female gender, renal failure or hypothyroidism. An 80-year-old woman presented with severe and generalized muscle pain. Her medical history included hypertension, congestive heart failure, chronic atrial fibrillation and a thyroidectomy while an adolescent (unknown diagnosis). Recently she had been hospitalized due to newly diagnosed type 2 diabetes and treated with insulin. During her hospitalization, fenofibrate (267 mg) was added to her daily regimen, as her triglyceride, total cholesterol and HDL cholesterol levels were 561 mg/dl, 187 mg/dl, and 33 mg/dl respectively. Her other medications included furosemide, aspirin, spironolactone, ramipril, verapamil, warfarin tablets, and short- (aspart) and long-acting (detemir) analog insulin. Her physical examination was normal except for muscle tenderness. Upon hospitalization, creatinine, creatinine clearance, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatinine kinase and INR were 1.5 mg/dl, 28 ml/min, 377 IU/l (normal range (NR)=15–41), 136 IU/l (NR = 57–158), 7.081 IU/l (NR = 0.98–192), 10.466 IU/l (NR = 38–234) and 9.76 respectively. Serum creatinine values were similar to previous laboratory tests. To date, only a few cases of rhabdomyolysis due to fibrate treatment have been reported; its mechanism is unknown. The combination of statin and fibrate agents may increase the risk of rhabdomyolysis. Fenofibrate is highly (99%) bound to plasma proteins, Fenofibric acid is inactivated by UDP-glucuronyltransferase into fenofibric acid glucuronide and is excreted mainly in urine. When starting fibrate treatment, factors such as age, drug interactions, and renal function should be taken into account.
P579
Correlation of atherogenic dyslipidemia with other plaque instability biomarkers and outcome in non ST-segment elevation acute coronary syndromes (NSTE-ACS)

Elena Bobescu1,2, Alina Mihaela Pascu1-2, Mariana Radoi1-2, Georgeta Datcu1, Dan Dobrenatu1, Gheorghe Ioan Totoiana1, Mihaela Stanciu1 & Ovidiu Burtă6
1Transilvania University Brasov, Faculty of Medicine, Brasov, Romania; 2Clinical Emergency County Hospital Brasov, Brasov, Romania; 3Grigore T. Popa University of Medicine and Pharmacy Iasi, Iasi, Romania; 4University of Medicine and Pharmacy Targu Mures, Targu Mures, Romania; 5Lucian Blaga University Sibiu, Faculty of Medicine, Sibiu, Romania; 6Faculty of Medicine and Pharmacy Oradea, Oradea, Romania.

Introduction
Atheromatous plaque instability biomarkers are the most important predictors for the evolution with major acute cardiovascular events (MACE) in patients with NSTE-ACS.

Objective
To evaluate the impact of dyslipidemia, endothelial dysfunction, oxidative stress, platelet hyperactivity and hypercoagulable state and their inter-correlation on the outcome of NSTE-ACS.

Methods
Two hundred and forty patients with NSTE-ACS, 154 (64.17%) men, mean age 58.31 ± 8.92, were investigated for dyslipidemia (LDL-Cholesterol > 100 mg/dl), HDL-Cholesterol < 50 mg/dl (men) and < 40 mg/dl (women), oxidative stress [total antioxidant status (r = 0.36, P < 0.0001), low serum total antioxidant status (r = 0.69, P < 0.0001), hypercoagulable state (r = 0.63, P < 0.0001), and platelet hyperactivity (r = 0.53, P < 0.01)]. In patients with NSTE-ACS and MACE from our study group, a high LDL-Chol level (> 100 mg/dl) and a low LDL-Chol level (< 50 mg/dl in men and < 40 mg/dl in women) were both best correlated with a low total antioxidant status (r = 0.63, P < 0.0001; r = 0.54, P < 0.02).

Conclusion
In patients with NSTE-ACS from our study group atherogenic dyslipidemia was significantly correlated with endothelial dysfunction, oxidative stress and platelet hyperactivity biomarkers, and with MACE at 1-year follow-up. This work was supported by CNCSIS-UEFISCU, Project number NIH-ID 727/2008.

P580
Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography

A Tomashchuk1, S Pilz1-2, E Ritz2, T Grammer2, K Amrein1, B O Boehm1 & W Márz1,6
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria; 2Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; 3Department of Nephrology, University of Heidelberg, Heidelberg, Germany; 4Syntlab Centre of Laboratory Diagnostics, Heidelberg, Germany; 5Division of Endocrinology, Diabetes and Metabolism, Graduate School of Molecular Diabetology and Endocrinology, Ulm University, Ulm, Germany; 6Mannheim Institute of Public Health, Rupertus Carola University Heidelberg, Medical Faculty Mannheim, Mannheim, Germany.

Introduction
An increasing notion suggests that aldosterone contributes to the development and progression of atherosclerosis and cardiovascular disease. Experimental studies documented an upregulation of cellular adhesion molecules, which are involved in the pathogenesis of atherosclerosis, after administration of aldosterone. However, evidence for an association between circulating aldosterone levels and soluble cellular adhesion molecules in humans is sparse.

Methods
We investigated the relationship between plasma aldosterone concentration (PAC; median: 82.0 [51.0–129.0] pg/ml) and soluble cellular adhesion molecules in a large cohort of patients referred to coronary angiography. After exclusion of patients with ongoing oral contraceptive or hormone replacement therapy 1752 patients (mean age: 62.5 ± 10.8 years; 26.4% women) remained eligible for analyses.

Results
Age and gender adjusted partial correlation analyses revealed a positive association between PAC and soluble (s) selectin levels but not with sCAM1 and sVCAM1 respectively. In multivariate adjusted analyses of covariance (ANCOVA) sE- (P = 0.003), sL- (P = 0.027) and sP-selectin (P < 0.001) levels increased steadily from the first (reference) to the third gender-specific tertile of PAC. No significant variation across PAC tertiles was found for sCAM1 and sVCAM1 levels respectively. Finally, multivariate regression analyses revealed circulating aldosterone as an important predictor for soluble selectin levels.

Conclusion
Our findings in a large cohort of patients indicate that the upregulation of selectins might represent a novel mechanism of aldosterone mediated development and progression of atherosclerosis. Our findings warrants further interventional studies which should evaluate anti-atherosclerotic effects of aldosterone blocking treatment strategies in humans.

P581
Long term recreational physical exercise decreases angiina susceptibility and induces cardiovascular protective shifts in nitric oxide synthase, heme oxygenase and matrix metalloproteinase enzyme regulation in rats

R Szabó1, A Pósa1, Z Szalai1, P Szabics1-2, C S Varga1, A M BerkJ1, K Orbán2 & F László1,2
1Department of Physiology, Anatomy, Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Csongrad, Hungary; 2Institute of Physical Education and Sport, Gyula Juhász Faculty of Education, University of Szeged, Szeged, Csongrad, Hungary.

Introduction
Physical inactivity, i.e. sedentary life style increases circulatory disease risk. Carbon monoxide and nitric oxide produced by the heme oxygenase (HO) and by the constitutive nitric oxide synthase (cNOS) protect circulation. In contrast, the enhanced level of the matrix metalloproteinase (MMP) augments cardiovascular risks. We examined the actions of recreational physical exercise on the expression of these enzyme systems in conjunction with cardiovascular protection.

Design
Male Wistar rats were placed into cages installed with running wheels allowing them the self administration of physical exercise over 6 weeks. We studied i) the activity and expression of HO in the aorta and heart left ventricle (LV); ii) the activity and expression cNOS in the aorta and LV; iii) the plasma level of MMP-2 and MMP-9 respectively, and the angiina susceptibility (the heart assessed by lead II surface ECG following adrenaline plus phenolamine challenge).

Results
We found that physical exercise: i) increased LV and aortic HO activity (from 0.83 ± 0.21 to 5.35 ± 0.36 and from 0.73 ± 0.15 to 1.60 ± 1.13 nmol bilirubin/h/mg protein respectively; n = 12–15; P < 0.001) and LV HO-1 isoenzyme expression (from 106.3 ± 3.12 to 164.0 ± 16.47% n = 6–7; P < 0.05) and ii) increased LV and aortic cNOS activity (from 16.32 ± 3.71 to 59.11 ± 7.94 and from 105.38 ± 55.72 to 181.78 ± 30.39 pmol/min per milligram protein respectively; n = 9–15; P < 0.001) and LV endothelial NOS isoenzyme expression (from 109.15 ± 2.47 to 163.1 ± 10.67% n = 3; P < 0.05); and iii) decreased MMP-2 plasma level (64 KDa; from 1002.71 ± 37.50 to 679.73 ± 34.35 intensity × mm²; n = 12–13; P < 0.001); and iv) decreased heart ischaemia susceptibility (ST segment depression: from −0.14 ± 0.018 to −0.019 ± 0.019 mV; n = 11; P < 0.001).

Discussion
Long term recreational physical exercise protects the heart against angina, which might be associated with the up-regulation of the HO and NOS enzyme system, and the down-regulation of MMP-2 activation.

Grant supports
SRP 4.2.1./B-09-1/UNIVON-210-0005; SRP 4.2.2.-08/1-2008-0006; Bolyai Scholarship (Amiko Posa).
Heme-oxidogen mediates cardiovascular protection by oestrogen and raloxifene in menopause

A Posà1, 2, C S Varga1, 2, A M Berko1, M Veszelka1, R Szabò1, K Orbán2, 3, I Pavo3, 4, F László1, 4, 5
1Department of Physiology, Anatomy, Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Csongrad, Hungary; 2Institute of Physical Education and Sport, Gyula Juhász Faculty of Education, University of Szeged, Szeged, Csongrad, Hungary; 3Lilly Area Medical Center, Vienna, Austria.

Introduction
Selective oestrogen receptor modulators function as oestrogen receptor antagonist in the breast and gonads, while they have agonistic effects on the bone and the cardiovascular system. It is also known that endogenously produced carbon monoxide by the heme-oxidogen (HO) enzyme exerts beneficial actions in cardiovascular protection.

Design
Intact females, ovarietomized (OVX), raloxifene or oestradiol treated OVX Wistar rats were used. We studied i) the activity and expression of HO enzymes in the left ventricle (LV) and aorta ii) the ST segment depression (standard lead II surface ECG) provoked by the administration of adrenaline (1 µg/kg, i.v.) and 30 second later phenolamine (1 mg/kg, i.v.), iii) the increase of blood pressure in vivo and iv) heart perfusion ex vivo induced by arginine vasopressin (AVP).

Results
We found that OVX i) decreased in the LV HO activity from 2.65 ± 0.29 to 0.78 ± 0.12 nmol bilirubin/hr per milligram protein, n = 9-10; P < 0.05) and HO-1 expression (HO-1: from 93.14 ± 1.79 to 48.0 ± 2.76%; HO-1: from 22.4 ± 3.02 to 20.6 ± 3.98%), n = 9-10; P < 0.05) and in the aorta (HO activity from 7.67 ± 2.44 to 3.56X ± 3.11 nmol bilirubin/hr/mg protein, n = 8-10; P < 0.05); HO-2 from 22.95 ± 2.03 to 17.96 ± 2.32%; HO-2: from 83.50 ± 3.30 to 57.47 ± 3.25%; n = 12; P < 0.05), ii) increased the susceptibility of the heart towards ischemia (ST segment depression: from 0.51 ± 0.025 to 0.13 ± 0.037 mV, n = 10; P < 0.05), iii) increased the response of blood pressure and iv) decreased the heart perfusion to AVP. The oestrogen and raloxifene replacement restored the differences to the level observed in the ovary-intact females. Finally, HO inhibition by tin-protoporphyrine pre-treatment augmented the response of blood pressure, the ST depression and heart perfusion in all groups investigated.

Conclusion
Oestrogen improves cardiovascular defence in menopause, at least in part, by a HO-mediated pathway. In our system, raloxifene exerts oestrogen agonistic effect.

Grant supports

Clinical case reports

MGMT immunoreactivity in adamantinomatous craniofaryngiomas

Sayid Shafi Zuhur1, Ahmet Murat Musluman2, Canan Tanik3, Ozcan Karaman1, Feyza Yener Ozturk1, Hanife Ozkayalar3 & Yuksel Altuntas4
1Sisli Etfal Training and Research Hospital, Endocrinology and Metabolism Department, Istanbul, Turkey; 2Sisli Etfal Training and Research Hospital, Neurosurgery Department, Istanbul, Turkey; 3Sisli Etfal Training and Research Hospital, Pathology Department, Istanbul, Turkey.

Background
Currently, no effective medical treatment exists for recurrent and aggressive craniofaryngiomas that are resistant to conventional therapies, including repeat surgeries and adjuvant radiotherapy (RT). Temozolomide is an alkylating chemotherapeutic agent and is used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O6-methylguanine DNA methyltransferase (MGMT). Evidence supports that low MGMT immunoreactivity correlates with positive response to temozolomide

Purpose
We aimed to evaluate MGMT immunoreactivity in adamantinomatous craniofaryngiomas, in an effort to predict the likelihood of response to temozolomide.

Methods
Our material consisted of 23 adamantinomatous craniofaryngiomas operated at the Sisli Etfal Training and Research Hospital during the interval 1993–2009 and identified by histological examination. Immunostaining for MGMT was performed using the avidin–biotin–peroxidase complex method. MGMT immunoreactivity was evaluated microscopically and recorded as percentage of nuclear MGMT immunostaining.

Results
Of the 23 specimens evaluated, 22 (96%) demonstrated negative (<10%) and 1 (4%) demonstrated low (10%) MGMT immunorepression.

Conclusion
The data provided by the current study suggests all adamantinomatous craniofaryngiomas exhibit low MGMT immunoreactivity and could be treated with temozolomide. Our findings provide a ground for the assessment of TMZ’s efficacy in clinical trials as an alternative agent in this rare tumor subtype, if conventional therapy, including repeat surgeries and RT, fails.
Case
A 27-years-old female presented with loss of consciousness and headache during fasting. Neurological and physical examination was normal. Her laboratory findings were consistent with insulinoma and primary hyperparathyroidism. Prolonged fasting test was consistent with insulinoma. A 0.4 cm pituitary mass was found on MRI which was non-functional. TC 99 m sestamibi SPECT/CT demonstrated a lift lower parathyroid adenoma. There was not pancreatic mass on USG, CT and MRI. EUS demonstrated a 0.9 cm mass in distal pancreas. EUS guided FNAB was consistent with PNET. The patient underwent parathyroid adenomeectomy and thymectomy followed by distal pancreatectomy. Histopathological analysis of distal pancreas demonstrated three well-differentiated PNET. Immunohistochemical analysis was positive for glucagon and negative for insulin. Adenectomy was performed. The final histopathological diagnosis was consistent with insulinoma.

Conclusion
Very small number of the coexistent double small insulinoma along with a small glucagonoma in MEN-1 disease have been reported. However, insulinoma could be multifocal and could also be associated with glucagonoma, as in the present case. Small tumors could be missed easily on pathologic analysis, therefore, careful histopathological examination of pancreas should be made in cases of MEN-1 disease.

P588
Congenital adrenal hyperplasia and adrenal myelolipoma – incidental on causal relationship?
A Vieira, I Paiva, J Santos, M Alves, S Gouveia, J Saraiva, F Carrilho & M Carvalheiro
Endocrinology, Diabetes and Metabolism Department, Coimbra’s University Hospital, EPE, Coimbra, Portugal.

Introduction
There are fewer than 20 reported cases involving congenital adrenal hyperplasia (CAH) and myelolipoma. This is a rare benign tumor, often located on the adrenal, consisting of mature adipose and hematopoietic tissues. Its origin is unclear; the most accepted theory is the occurrence of blood capillaries reticuloendothelial cells metaplasia, in response to infection, stress or necrosis. In a small number of cases CAH hypersecretion coexists.

Case report
Woman 56 years, is referenced to endocrinology due to external genitalia virilization. She presented melanodermia, hirsutism, androgenic alopecia and obesity (BMI 34.5 kg/m²), hypertension (180/110 mmHg) and hirsutism (score 8), there was no chloromagaly, cutaneous bruising or striae. Laboratory tests showed normal ACTH, cortisol, S-DHEA and androstenedione but elevated total testosterone -1.7 ng/ml (0.4-0.8) and free testosterone- 3.9 pg/ml (<1.55). 1 mg dexamethasone suppression test and ACTH stimulation test were normal. Endovaginal ultrasound and abdominal CT scan showed no evidence of adrenal or ovarian masses. She was submitted to bilateral salpingo-oophorectomy. Histopathological studies revealed a left 1 cm ovarian Leydig cell tumor. Post-operatively testosterone declined to normal levels and an improvement in alopecia and hirsutism was obtained in the following 6 months.

In post-menopausal women the appearance of signs of masculinization and high testosterone levels are suggestive of an ovarian virilizing tumor. Although endovaginal ultrasound is useful for the diagnosis, it was negative in this patient, and clinical and biochemical criteria were determinant for surgery.

P589
Agensis of the dorsal pancreas, a rare cause of diabetes: a case report and review of 25 Japanese patients
Masanori Shimodaira, Naoko Kumagai, Kaoru Tsuzawa, Erisa Sorimachi, Minako Kametaka & Kazufumi Honda
Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.

Introduction
Agenesis of the dorsal pancreas, with the absence of the pancreatic body and tail, is a very rare developmental anomaly. To date, only 51 cases have been reported in the English literature. This anomaly can be a cause of diabetes mellitus.
Case report
A 19-year-old Japanese male visited our department because of glucosuria that had been detected during a routine school health check. The patient had undergone cardiac surgery for atrial and ventricular septal defects at the age of 4 years. He denied any history of abdominal trauma, alcohol intake or gastrointestinal problems. Laboratory investigations showed that his fasting hyperglycaemia was 19.7 mmol/l (3.54 mg/dl), HbA1c level was 12.1% and daily urinary excretion of C-peptide was 43.9 µg/day (normal range: 50–100 µg/day). Anti-islet cell antibody and anti-glutamic acid decarboxylase antibody were negative. Computed tomography confirmed that the body and tail of the pancreas were absent, and a magnetic resonance cholangiopancreatography showed that the portal pathway was intact. Based on these findings, a diagnosis of agenesis of the dorsal pancreas was made. The patient’s blood glucose levels improved with insulin treatment.

Discussion
We found 25 Japanese patients (22–83 years, 12 males and 13 females) with clinical descriptions of agenesis of the dorsal pancreas by systematically searching the international and national Japanese medical database. In approximately 70% of the reported patients, glucose intolerance or diabetes was demonstrated, and dysfunction of the pancreatic exocrine was found in 60%. Moreover, 28% of the patients had other organ anomalies in cardiopulmonary, gastrointestinal or genitourinary systems.

Conclusion
Agenesis of the dorsal pancreas is rare. However, it is important not to overlook this anomaly, particularly in young patients with diabetes and a history of other congenital organ anomalies.

---

**P590**

A case of two novel mutations in the LHHCGR gene in a patient with 46,XY DSD
Anastasia Athanasoulia1, Sebastian Noe2 & Günter Stalla1
1Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany; 2Klinikum rechts der Isar, II. Med. Klinik, Technische Universität Munich, Munich, Germany.

**Introduction**
Leydig cell hypoplasia (LCH) is a rare autosomal recessive condition that interferes with normal development of male external genitalia in 46,XY individuals. It is mediated by mutations in the luteinizing hormone receptor gene (LHCGR), most frequently located in the coding sequence, resulting in impairment of either LH/CG binding or signal transduction.

**Case report**
We report a 32-year-old female which presented with primary amenorrhea, female external genitalia and 46,XY karyotype. Breast and pubic hair development were B2 and PH2 respectively. Magnetic resonance imaging revealed inguinal testicles in the absence of uterus and ovaries. At first presentation serum luteinizing hormone (LH) was about threefold upper the normal limit while testosterone was in the female adult normal range. Estradiol had been detected during a routine school health check. The patient has the Tanner stage P2G4; triptorelin test reveals the presence of a pituitary tumour. Excess of free testosterone serum level indicated a testicular origin. The testis was removed and genetic analysis of the parents is planned.

**Conclusions**
This case-report is the first demonstrating two novel different homozygote mutations in the same hormone binding domain and therefore expands the genotypic spectrum of LHCGR mutations.

---

**P591**

X-linked adrenomieloneuropathy presenting as Addison’s disease
I Bilbao, A Yoldi, T Matteucci, C García, M Aranburu, N Egaña, M Alvarez-Coca & M Goena
Hospital Donostia, San Sebastian, Spain.

**Introduction**
It has been estimated that up to 30% of idiopathic Addison disease in young boys is due to X-linked Adrenoleukodystrophy. We report the case of a 31-year-old previously asymptomatic man, who presented with hyperpigmentation and fatigue. Investigations revealed hyponatraemia (116 mEq/l), low serum cortisol (2.6 µg/ml) and high ACTH levels (>2000 pg/ml), plasma potassium was 4.37 mEq/l. Adrenal antibodies were absent and abdominal computerized tomography scan showed only atrophied adrenal glands. He started hormone replacement therapy but 2 months later he developed, mild cognitive impairment, behavioural disturbances and abnormal sphincter control. Cerebral MRI imaging showed altered signal intensities on the pontine area. The diagnosis of adrenomieloneuropathy was confirmed by raised circulating concentrations of very long chain fatty acids (VLCFA). (C22: 2.13 mcg/ml (0.18–0.48) C24:O/C22:O: 1.38 (<1.00) C26:0/C22:O: 0.09 (<0.02)). Genetic testing showed a missense mutation causing asparragine to tyrosine exchange at position 289 (A289T) of ALD protein, that to our knowledge has not yet been described.

**Discussion**
Lorenzo’s oil may be effective in reducing very long chain fatty acids in plasma. Although no clinically significant neurological improvement was observed in our patient, more studies are clearly needed to establish a potential role of this therapy.

---

**P592**

Central precocious puberty related to a tuber cinereum hamartoma in neurofibromatosis type 1 (NF1): case report
L Vijia, C Dumitrescu, C Procopciu, I Gherlan & A Caragheorgheopol
‘C I Parhon’ National Institute of Endocrinology, Bucharest, Romania.

**Introduction**
Tubercinereum hamartoma is a rare cause of central precocious puberty (CPP) due to tumours in patients suffering from neurofibromatosis type 1 (NF1). The prevalence of CPP and its relationship to optic pathway tumours in patients suffering from neurofibromatosis type 1 (NF1) is significantly greater than in normal population.

**Objectives**
We present a rare case of precocious puberty in neurofibromatosis type 1 which is not associated with optic pathway tumour but with a tuber cinereum hamartoma.

**Case report**
We present the case of a 5-year and 5-month old male subject examined in pediatric endocrinology for growth spurt, testicular enlargement, pubic hair appearance in association with diffuse disseminated ‘café au lait spots’. Family history of confirmed neurofibromatosis type 1 reveals the associated pathology of our case. The patient has the Tanner stage P2G4; triptorelin test reveals the diagnosis of central precocious puberty (LH has increased from 2.85 to 21.89 mIU/ml, FSH increased from 1.98 to 3.52 mIU/ml and testosterone from 3.36 to 8.16 ng/ml). Cerebral MRI revealed a tuber cinereum hamartoma in the floor of the third ventricle in intimate contact with the optic chiasm. Triptorelin treatment has been successfully initiated, with limitation of growth velocity and puberty signs at 3-month interval.

**Conclusions**
Precocious puberty is a frequent endocrinologic feature in patients with genetically confirmed NF1, and is not related only to optic nerve gliomas. Children with NF1 need early hormonal screening, in order to unravel precocious puberty even at a preclinical level, which is critical for rapid diagnosis and introduction of a proficient treatment.
Hypoparathyroidism and Morbus Fahr case report
Biljana Jovanoska, Katerina Adamova, Slavica Subeska Stratrova & Iskra Bitoska
Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, The Former Yugoslav Republic of Macedonia.

Hypoparathyroidism is rare endocrine-metabolic disease, characterized by hypocalcemia, hyperphosphatemia and low level of the parathyroid hormone (PTH). Hypocalcemia sometimes is associated with calcifications at the basal ganglia (Morbus Fahr), leading to epileptic seizures, hypocalcemic catharcata and depression. The patient was admitted at the Clinic of endocrinology in Skopje, due to history of long term epileptic seizures, treated with antiepileptic therapy, operated from catharacta on both eyes by unknown origin and episodes of depression and complete clinical confirmation of this disease. His laboratory results showed low level of ionized Ca^{2+} <0.47 mmol/l (1.3–1.6 mmol/l), total Ca 0.83 mmol/l (2.1–2.6 mmol/l), hyperphosphatemia P- 3.1 mmol/l (0.8–1.4 mmol/l), hypophosphaturia 10 mmol/l (20–60 mmol/l), hypocalciuria 1 mmol/l (1.3–10 mmol/l), low level of PTH 1.76 g/ml (15–65 g/ml), high level of LDH 1332 U/l (213–423 U/l) and CKP 1204 U/l (24–173 U/l), creatinine level 79 mmol/l (45–109 mmol/l), total proteins 76 g/l (63–83 g/l).

Chvostek and Trousseau were negative. Calcifications at the basal ganglia were proven by computed tomography and nuclear magnetic resonance. Dual-energy X-ray absorptiometry (DXA) showed osteosclerosis. During the hospitalization, he was substituted with calcium gluconate parenterally, later orally with calcium carbonate a 1.5 g, Tabl.Rocaltrol a 0.5 g and Sol.Vigantol 1200 IU. As a result of this treatment, the seizures disappeared and the antiepileptic therapy was discontinued.

Conclusion
Patients with epileptic seizures and catharacta should always be clinically and laboratory evaluated for calcium, phosphates and PTH, in order to diagnose properly and to avoid inadequate treatment.

Intrathoracically located parathyroid carcinoma is extremely rare cause of primary hyperparathyroidism. Multifocal papillary and follicular thyroid carcinomas are rather common.

We report a case of 40-year old man presenting with substantial weight loss, anorexia, and multiple osteolytic lesions of both tibias. Peak serum calcium level was 5.0 mmol/l, parathyroid hormone (PTH) level was 989 pg/ml. Left thyroid lobe was firm and enlarged. Routine percutaneous fine needle aspiration (FNA) of intrathoracic mass disclosed poorly differentiated follicular thyroid carcinoma. FNA of the nodule beneath the left lobe indicated parathyroid origin, possibly parathyroid neoplasms. We performed en block resection of the left thyroid lobe and the nodule beneath it. Frozen section identified likely medullary carcinoma, as well proven in mediastinal lymph node which was previously misinterpreted as enlarged parathyroid gland. Total thyroidectomy and bilateral modified radical neck dissection were then performed. Negative thyroglobulin and calcitonin, but positive PTH expression confirmed parathyroid carcinoma with a single upper mediastinal lymph node metastasis and multiple diffuse microscopic metastases in both thyroid lobes.

This is the first reported case of parathyroid carcinoma with multiple foci within thyroid tissue. Presurgical and intraoperative diagnosis of parathyroid carcinoma can be difficult, especially if located within thyroid gland. In patients with primary hyperparathyroidism and intrathoracic suspicion of malignancy finding, parathyroid carcinoma should be considered. The exact mechanism of intrathoracic multifocal thyroid carcinomas has not been determined yet. The first reported presence of multiple foci of intrathoracic parathyroid carcinoma, suggests the intraglandular dissemination of the primary tumor is the main mechanism of multifocality.

Multifocal intrathyroid parathyroid carcinoma
Ivan Krujlic, Petra Sulentic, Maja Berkovic Cigrovski, Davorka Herman Mahecic, Gorana Mirosevic, Mirko Ivicevic & Milan Vrkljan
University Hospital Sisters of Mercy, Zagreb, Croatia.

Intrathoracically located parathyroid carcinoma is extremely rare cause of primary hyperparathyroidism. Multifocal papillary and follicular thyroid carcinomas are rather common.

We report a case of 40-year old man presenting with substantial weight loss, anorexia, and multiple osteolytic lesions of both tibias. Peak serum calcium level was 5.0 mmol/l, parathyroid hormone (PTH) level was 989 pg/ml. Left thyroid lobe was firm and enlarged. Routine percutaneous fine needle aspiration (FNA) of intrathoracic mass disclosed poorly differentiated follicular thyroid carcinoma. FNA of the nodule beneath the left lobe indicated parathyroid origin, possibly parathyroid neoplasms. We performed en block resection of the left thyroid lobe and the nodule beneath it. Frozen section identified likely medullary carcinoma, as well proven in mediastinal lymph node which was previously misinterpreted as enlarged parathyroid gland. Total thyroidectomy and bilateral modified radical neck dissection were then performed. Negative thyroglobulin and calcitonin, but positive PTH expression confirmed parathyroid carcinoma with a single upper mediastinal lymph node metastasis and multiple diffuse microscopic metastases in both thyroid lobes.

This is the first reported case of parathyroid carcinoma with multiple foci within thyroid tissue. Presurgical and intraoperative diagnosis of parathyroid carcinoma can be difficult, especially if located within thyroid gland. In patients with primary hyperparathyroidism and intrathoracic suspicion of malignancy finding, parathyroid carcinoma should be considered. The exact mechanism of intrathoracic multifocal thyroid carcinomas has not been determined yet. The first reported presence of multiple foci of intrathoracic parathyroid carcinoma, suggests the intraglandular dissemination of the primary tumor is the main mechanism of multifocality.
Use of our last pills of iopanoic acid in a 33-year-old patient in acute refraactory pulmonary edema and thyroid storm: requiem for a useful therapeutic agent

E Gómez Hoyos, P de Miguel Novoa, C Montañez Zorrilla, N Garcia de la Torre, M Curra Freixes, R Bover Freire, A Calle Pascual & I Runkle de la Vega
Hospital Clinico San Carlos, Madrid, Spain.

Introduction

The contrast agents iopanoic acid and ipodate are potent inhibitors of thyroid function, reducing type I deiodinase T3 generation, inhibiting thyroid liberation of T4 and T3, and T3 receptor binding, with off-label use in hyperthyroid emergencies. However, since the interruption of iopanoic acid production this year, neither agent is currently available in Spain.

Case report

A 34-year-old male was admitted to our hospital’s ICU in acute pulmonary edema. He had noted weight loss, palpitations, nervousness, fatigue and hyperventilation during the previous months. Dyspnea at rest. Physical examination: Temperature(T) was 39°C; heart rate (HR) 133/min; irregular; bilateral exophthalmos; pronounced eyelid retraction, positive Graefe and Moebius signs; firm grade III goiter; intense thyroid bruit; precordial thrill; systolic IV/V1 mitral murmur; bilateral wet rales; peripheral edema reaching knees; signs; firm grade III goiter; intense thyroid bruit; precordial thrill; systolic hyperhidrosis during the previous months. Dyspnea at rest. Physical examination: edema. He had noted weight loss, palpitations, nervousness, fatigue and

A 34-year-old male was admitted to our hospital’s ICU in acute pulmonary edema. He had noted weight loss, palpitations, nervousness, fatigue and

Thyroid storm is a potentially fatal disorder if treatment is not initiated promptly upon assessment at the emergency department (ED).

Case

A 20-year-old young woman is referred to the ED with rapid acceleration of complaints of palpitations, fever, diarrhoea and agitation, which had been present since several weeks.

On physical examination we saw an uncomfortable, restless woman with a tachycardia of 170/min, and a fever of 38.5°C. Palpation of the neck revealed a small ventral, painless, solid elastic mass, more prominent on the right side, clinically suspicious for goiter. ECG showed an Atrial Flutter of 150/min. Initial laboratory results showed an ESR of 35 mm/h (0–20 mm/h) and urine analysis tested positive for ketones.

We presumed the patient was suffering from a thyroid storm for which we promptly started treatment at the ED with propanolol and thiamazole.

The next day she was diagnosed with graves disease. Lab results showed a TSH of <0.01 mIU/l (0.4–4.0 mIU/l) and a free T4 of >73 pmol/l (10–22 pmol/l).

Discussion

Thyroid storm is an acute, life-threatening, hypermetabolic state induced by excessive release of thyroid hormones. The adult mortality rate is extremely high (90%) if early diagnosis is not made and the patient is left untreated.

Therefore it is critical in case of clinical suspicion for Thyroid storm to start prompt treatment with beta blockade and thiamazole before the diagnosis can be confirmed biochemically.

Conclusion

- Recognition of thyroid storm can be challenging, especially if there are no clues on physical examination.
- Prompt treatment of thyroid storm is vital for outcome.
- Definitive diagnosis of thyroid storm can only be made after treatment has been started.

Hypocalcemic laryngospasm in the emergency department

M J van Veelen, M F Visser, M G A Baggen & A Dees
Ikazia Hospital, Rotterdam, The Netherlands.

Introduction

Severe hypocalcemia is a life threatening condition, usually symptomatic with cardiovascular and neuromuscular manifestations. Varying clinical presentations and concomitant infections, however, might obscure the right diagnosis, delaying early treatment.

Case

A 51-year-old African male presents himself at the emergency department (ED) with complaints of a sore throat, a productive cough and a striking pinched voice. Investigation revealed a severe corrected hypocalcemia (0.97 mmol/l) with a prolonged QTc interval on ECG of 515 ms. We administered intravenous calcium at the ED, which instantly improved the quality of his voice. He was eventually diagnosed with primary hyperparathyroidism for which he has been treated with aflacalcidol and calcium supplementation and an upper airway infection as well.

Discussion

The hallmark of hypocalcemia is tetany. In spite of severe hypocalcemia, tetany was not the presenting symptom in our patient. Laryngospasm is rare to be the presenting symptom of hypocalcemia, especially without signs of overt tetany or seizures.

Failure to recognize hypocalcemia by interpreting the complaints to be caused by an upper airway infection can lead to discharging a patient at risk for serious complications like seizures, dysrythmias such as torsade de pointes and even cardiac arrest.

Conclusion

Laryngospasm is a rare presenting symptom of hypocalcemia.

- In patients with nonspecific complaints of the throat and voice, laboratory serum calcium and an ECG should be part of routine investigation in the ED.
- Concomitant infections might obscure the diagnosis of hypocalcemia.
- In case of severe hypocalcemia, calcium should instantly be administered intravenously in the ED.

Endocrine Abstracts (2011) Vol 26
P601
Primary hyperparathyroidism due to an ectopic intrathymic parathyroid adenoma: case report
M Vladi1, M Balas1, Al Nicodin2, M Cornianu3, D Onet4, A Popa1 & I Zosin1
1Clinic of Endocrinology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania; 2Clinic of Thoracic Surgery, Victor Babes’ University of Medicine and Pharmacy, Timisoara, Romania; 3Department of Pathology, Victor Babes’ University of Medicine and Pharmacy, Timisoara, Romania; 4Department of Radiology, County Hospital, Timisoara, Romania.

Introduction
The most common cause of primary hyperparathyroidism is parathyroid adenoma. Unfortunately, between 11 and 22% of these adenomas are located in ectopic positions. In this report, we describe a case diagnosed in our department with symptomatic primary hyperparathyroidism due to an ectopic parathyroid adenoma localized in thymus.

Case presentation
A 21-year-old woman was referred to our clinic for investigations, due to multiple osteoclastomas in the maxillary bones. Physical examination performed on admission revealed, in addition to the facial lesions, multiple lumps on ribs and lower limbs. Biochemical investigations confirmed primary hyperparathyroidism: hypercalcemia, hypophosphatemia and significant elevated levels of parathormone (PTH) and alkaline phosphatase. By using ultrasound examination of the neck no extrathyroidal or thyroidal masses, suggestive of a parathyroid adenoma, were detected. The patient was submitted to magnetic resonance imaging of the cervical region and mediastinum. The results revealed an enlarged thymus, which was suspected to be the site of the ectopic parathyroid adenoma. The investigations performed didn’t reveal any other clinical manifestations of hyperparathyroidism besides advanced bone lesions.

A thymectomy by using video-assisted thoracic surgery was performed in the Clinic of thoracic surgery. The pathological exam revealed a parathyroid adenoma surrounded by normal thymic tissue. Postoperatively, the plasma level of calcium and PTH decreased significantly. The patient developed hungry bone syndrome that required high amounts of oral calcium (3500 mg daily) and vitamin D for maintaining a low-normal serum calcium level.

Conclusion
This case, with an ectopic parathyroid adenoma in thymus confirmed by postoperative histology, presented advanced bone lesions, only, as clinical manifestation of hyperparathyroidism. The presentation illustrates the importance of postoperative imaging localization of parathyroid adenoma, which allows an optimal surgical approach. Mediastinal ectopic parathyroid adenoma as a cause of primary hyperparathyroidism must be always considered if cervical pathological masses are not detected.

P602
Clinical case of 48 years old man with panhypopituitarism of unclear etiology
K Y Vdovich, Y E Poteshkin & V S Pronin
I.M. Sechenov First Moscow State Medical University, The Endocrinology Clinic, Moscow, Russian Federation.

When patient was an 14-year-old, he presented with a short stature and underdeveloped external genitalia. The patient had not undergone normal pubertal development. Hormonal studies and clinical examination revealed the findings of anterior and posterior pituitary hormone deficiency: ADH, LH (0.2 mIU/l), FSH (1.22 mIU/l). Since then patient took different therapy for diabetes insipidus. Secondary sexual characters developed during patient received gonadotropin for a very short time for hypogonadism. Some involution in development showed after patient stopped receiving gonadotropin. Nowadays, patient came to medical attention with complaints about fatigue, mood lowering and complete sex appetite absence. Clinical examination revealed a sick-looking, pale and dehydrated middle-aged man with decreased muscle mass. His face looked like kewpie doll (fine, children’s facial features). And the same time he looks ‘elder’: his skin is thinned, with fine wrinkles (gerodermal). Patient had absolutely no hair in the groin area, armpit and on the chin. Testicular dimensions was 1.7×0.8 cm (left one) and 1.7×0.7 cm (right one) by the results of ultrasound. Owing to low cortisol, GH and IGF1 pituitary provocative test with insulin was performed, secondary adrenal insufficiency and GH deficiency was shown: ACTH – 48.6 pmol/l (6–82), cortisol – 116 nmol/l (550), GH – not exceeding 0.11 ng/ml, MRI with contrast showed: pituitary volume is 0.01 cm³ (0.15–0.51 cm³) structure is homogenous, no signs of structural alterations and space-occupying lesions was shown. Patient denies any head trauma/surgery in past. Owing to clinical signs we considered deficiency PROP1 or PIT1 factors.

P603
Unusual case of congenital adrenal hyperplasia: polymenorrhagia and markedly high 17-OH progesterone levels in a lady with non classic congenital adrenal hyperplasia
A Rizwan1,2, M Hayat1 & Z Sheikh1
1National Institute Diabetes and Endocrinology, Dow University Health Sciences, Karachi, Sindh, Pakistan; 2Aga Khan University Hospital, Karachi, Sindh, Pakistan.

Introduction
Congenital adrenal hyperplasia (CAH) due to 21 hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. There are two main forms of CAH: early onset, the classic variety, and late onset or non classic type. Here, we aim to describe the case of a young lady with features of both varieties of CAH.

Case report
Twenty-three-year-old lady of Asian descent presented with polymenorrhagia since menarche (age 13 years), hirsutism and clitoromegaly since 7 years. There was no history of ambiguous genitalia or salt wasting crisis at birth. She had previously been labelled as a case of ‘polycystic ovaries’ and been placed on Diane 35, with some regularization of her cycles. On examination, she had moderate hirsutism (Ferriman Galloway score (FG) score 20/36, normal <8/36), marked clitoromegaly (clitoral index 50 mm², normal: <35 mm²). Serum testosterone was 145.8 ng/dl (6–82), while 17-hydroxy progesterone 170.0 ng/ml (0.19–1.82). ACTH stimulation test uncovered borderline cortisol deficiency, with 60 min post synacthen cortisol: 17.0 ng/dl (>18 ng/dl). Oral dexamethasone was commenced in reverse rhythm, with advice to double the dose at times of stress.

Conclusions
Prior to labelling a subject with hirsutism and menstrual irregularity as a case of polycystic ovaries, other hormonal dysfunction requires exclusion. Congenital adrenal hyperplasia is an important consideration in the differentials, which is all too often overlooked by physicians. Clinicians need to be aware of the possibility of non-classic CAH presenting with the unusual history of polymenorrhagia, versus the usual presentation of oligo/anovulation. Phenomenally high 17-OH progesterone levels can also be associated with the non classic variety.

P604
Schmidt’s syndrome: unveiling step-by-step
A Rizwan1,2, M Hayat1 & Z Sheikh1
1National Institute Diabetes and Endocrinology, Dow University Health Sciences, Karachi, Sindh, Pakistan; 2Aga Khan University Hospital, Karachi, Sindh, Pakistan.

Introduction
Autoimmune polyendocrine syndrome type II (APSII) is more common than APSI. It occurs more frequently in female than in male patients, often has its onset in adulthood, and has familial aggregation. Schmidt’s syndrome is a subset of APSII, usually associated with primary hypothyroidism, primary adrenal insufficiency, and often, type 1 diabetes. This case describes the interesting evolution of autoimmune polyendocrine disease (APED) in a young lady with long standing type 1 diabetes.

Case report
Twenty-three-year Asian lady with type 1 diabetes since 11 years presented with irregular menses, reduced appetite, nausea, constipation, weight loss and cold intolerance for the past 3 months. Her mother had noticed a progressive darkening of her complexion. She was experiencing frequent hypoglycaemic episodes on minimal doses of insulin. Examination revealed a postural drop, generalized hyperpigmentation and grade 2 goitre. Laboratory investigations confirmed autoimmune hypothyroidism and primary adrenal insufficiency. She was treated with hydrocortisone and mineralocorticoid, followed by thyroxine replacement. Insulin was adjusted. Having initially improved, she began experiencing generalized weakness and exertional shortness of breath. Work up revealed hypertensive microcystic anemia. Celiac disease screen was positive. The patient declined to undergo an esophageogastroduodenoscopy (EGD), therefore, a trial of gluten-free diet was commenced.
Conclusions
Clinicians should avoid tunnel vision when treating patients with type 1 diabetes as risk of concomitant/subsequent autoimmune phenomena is high, particularly thyroid and celiac disease. Frequent hypoglycaemic episodes in a previously well type 1 diabetic should raise suspicion of adrenal insufficiency and alert the clinician to the possible development of other components of APED.

P605
Primary hyperparathyroidism in pregnancy: a case report
D Grigorie1, ASucaliiu1, A Ranetti2 & M Ivan3
1National Institute of Endocrinology, Bucharest, Romania; 2Central Military Hospital, Bucharest, Romania.

Introduction
It is supposed that primary hyperparathyroidism (pHPT) during pregnancy is associated with significant maternal and fetal risks as high as 67 and 80%, respectively. The very few case reports published referred mainly to unrecognized pHPT or diagnosed during pregnancy. We report the case of a woman with known asymptomatic pHPT who became pregnant.

Case report
A woman, 29 years, was diagnosed with pHPT a year before becoming pregnant; her biochemistries were: serum total Ca = 11.1 mg/dl (8.6-10.3); P = 2.52 mg/dl; PTH = 120.8 pg/ml (15–65); 25OHD = 4 ng/dl (end of spring) and Ca = 11.5 mg/dl; PTH = 126.3 pg/ml; 25OHD = 24.9 ng/dl (end of summer). She had normal lumbar spine (LS) BMD despite a very high remodeling rate, with serum crosslaps=1.273 ng/ml and osteocalcin = 33.42 ng/ml; localization studies were negative and surgery was postponed. She became pregnant and her biochemistries were: Ca = 11.1 mg/dl; PTH = 144.8 pg/ml; 25OHD = 28.6 ng/ml (summer). During the last trimester of pregnancy, she was supplemented with oral vitamin D 1000 IU/day; corrected total Ca was 11 mg/dl, PTH 143 pg/ml. The pregnancy was uneventful until the 36th week of gestation, when premature rupture of the membranes occurred and a caesarian section was performed. The male newborn weighed 3200 g and no abnormalities were noted on physical examination. I. v. calcium and oral vitamin D (500 U/day) were started immediately; ionized calcium had a nadir at 1.28 mmol/l (total calcium 8.12 mg/dl) in the 5th day, when oral calcium was started. After 1 month his biochemistries were: total Ca = 10.59 mg/dl (9–11); P = 6.68 mg/dl (3.1–6); PTH = 12.1 pg/ml (15–68); 25OHD = 19.5 ng/ml. One month after delivery, the mother had a total Ca = 10.9 mg/dl; P = 2.7 mg/dl; PTH = 211 pg/ml; 25OHD = 34.5 ng/ml and lost 11.6% of LS BMD.

Conclusion
Vitamin D repletion of the mother with mild pHPT is safe and could prevent neonatal hypocalcemia.

P606
Primary hypothyroidism due to sublingual thyroid associated with growth failure, hyperprolactinemia and pituitary enlargement
A Loghin1, A Florescu1, I Moisii2, C Stefanescu1 & C Galesanu3
1Endocrinology Department, University of Medicine and Pharmacy ‘Gr. T. Popa’, Iasi, Romania; 2Radiology Department, University of Medicine and Pharmacy ‘Gr. T. Popa’, Iasi, Romania; 3Nuclear Medicine Department, University of Medicine and Pharmacy ‘Gr. T. Popa’, Iasi, Romania.

Introduction
Thyroid tissue may be found anywhere along the course of thyroglossal duct. Sublingual thyroid is a rare type of ectopic thyroid tissue resulting from failure of the embryonic development and migration of the thyroid gland to its normal pre-laryngeal site, reaching between genio-hioid and mylohyoid muscles. In most cases, hypothyroidism develops due to inadequate hormone production. Hypothyroidism may produce pituitary enlargement secondary to thyroid hyperplasia. Hyperprolactinemia may occur in these cases.

Case report
We present a case of a 13-year-old girl with growth failure and severe headache. At clinical examination: height = 121 cm (–4 S.D.), weight = 22 kg (–3 S.D.), there was no palpable thyroid gland in the pre-tracheal region. Biochemical findings were high serum cholesterol and triglycerides. Hormonal profile diagnosed primary hypothyroidism based on high levels of TSH (37.9 IU/ml with normal values of 0.4–7 IU/ml) and low FT4, associated with hyperprolactinemia; GH levels were low but responded to stimulating tests. The cervical US examination showed the absence of the thyroid tissue in its normal location and a well defined, heterogeneous and hypoechogenic mass in sublingual region. The thyroid scan with Tc-99m O4 and the MRI confirmed the presence of sublingual thyroid tissue. Pituitary imaging by X-ray revealed an enlarged sella turcica, confirmed by MRI that described a homogenous enhancement of the pituitary gland. l-T4 treatment was initiated and after 5 months TSH, FT4 and PRL returned to normal levels. At 2 years follow-up the height increased by 24 cm and menarche installed.

Conclusions
In this case the diagnosis of growth disorder was challenging, having to distinguish between pituitary tumor and primary hypothyroidism. The efficacy of the l-T4 treatment proved that pseudoprolactinoma was caused by hyperplasia of the TSH and PRL-producing cells.

P607
Hypoglycemia in patient with large intraabdominal tumor
Miomira Ivovic1, Svetlana Vujovic1, Milina Tancic-Gajic1, Lijiliana Marina2, Vladimir Djukic3, Dusan Micic2 & Dragan Micic2
1Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia; 2Emergency Center, Clinical Center of Serbia, Belgrade, Serbia.

Introduction
Various non pancreatic tumors can cause hypoglycemia. Usually they are mesenchymal, retroperitoneal tumors or fibrosarcomas. Hemangiopericytoma is a rare type of mesenchymal tumor, which mostly develops in soft tissue and originates from the Zimmermann’s pericyte (modified smooth muscle cells).

Case report
Fifty-nine-years old female patient with hypoglycemia was addmited to our department. Physical finding showed mild obesity and hypertension. Endocrine testing confirmed fasting hypoglycemia (about 2.0 mmol/l). Seventy-two hours fasting test was interrupted after 12 h with glycemia 0.8 mmol/l, and low levels of insulin. C peptide and IGF1. Ultrasound and multi slice computed tomography (MSCT) showed massive vasculated intraperitoneal tumor, size 120×175×196 mm. She underwent surgery and large lobulated vasculated tumor was found in lower right hemiabdomen connected to the omentum. Histological and immunohistological finding confirmed hemangiopericytoma (grade II-Trojani-Coindre score: 5/9 with Ki67:10%). Postoperatively, no hypoglycemia was detected. Insulin, C peptide and IGF1 were in the normal range.

Conclusion
Hypoglycemia, detected in patients with large non pancreatic tumors occurs due to expression and release of immature form of IGF2 molecules, pro-IGF2, which binds to IGF binding protein 3 (IGFBP3) and remains active. This complex binds to insulin receptors in muscles to promote glucose transport and to insulin receptor in liver and kidney to reduce glucose output. Also, it binds to receptors for IGF1 in the pancreatic beta cells and in pituitary which leads to inhibition of insulin secretion and suppression of GH release, respectively. GH and IGF1 values are decreased, IGF2 values may be increased but often are normal. Immature higher-molecular-weight form of IGF2 can only be detected by special laboratory techniques.

P608
Phaeochromocytoma and paraganglioma in patient with extirpated ganglioneuroma
Lijiliana Marina, Miomira Ivovic, Svetlana Vujovic, Milina Tancic-Gajic, Vlada Zivalkovic, Zorana Arizanovic, Ana Nenezic & Dragan Micic
Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia.

Ganglioneuromas are benign sympathetic tissue tumors originating from neural crest cells. A 40-year-old female patient, was admitted to our department for endocrinological evaluation of incidentally discovered tumor of right adrenal gland. For about a year before admission she had a pain under the right costal arch. An ultrasound and computed tomography (CT) showed 2 ovoid cystical tumors of right adrenal (34 and 32 mm, respectively). Three months prior admission she had several hypertensive crises with vertigo, with average blood pressure values of 120/80 mmHg. At 27 years of age she had a surgery because of a mediastinal tumor. Pathohistological (PH) finding confirmed ganglioneuroma. In family history her father, brother and a cousin suffered from heart disease and hypertension. Physical finding showed Horner Sy as a consequence of previous
surgery. Careful endocrine testing showed very high levels of noradrenalin in urine, and metaiodobenzylguanidine (MIBG) scintigraphy of whole body showed accumulation in both adrenal glands. After preparation with phenoxybenzamine she underwent surgery and right adrenal gland was extirpated along with another tumor. PH confirmed pheochromocytoma of right adrenal and paraganglioma of the same side. Genetic testing showed presence of Von Hippel-Lindau mutation VHLMet, and one of her two tested children was also positive. Postoperative testing showed high levels of catecholamines and CT scan revealed new tumor in the left side in front of abdominal aorta, left renal artery and left renal vein behind splenal vein. After preparation with phenoxybenzamine she underwent another surgery, tumor was extirpated and PH confirmed paraganglioma. Levels of postoperative catecholamines showed normal. In our case ganglioneuroma occurred in patient with VHL, mutation whereas in literature they are usually found in patients with MEN2B.

P609
Cushing syndrome due to macronodular adrenal hyperplasia or bilateral adrenocortical adenomas? Case report
A Lopes, F Fonseca, L Duarte, A Milheiro & A Agapito
Hospede de Curry Cabral, Lisbon, Portugal.

Introduction
Adrenal incidentaloma are becoming very frequent. Bilateral adrenocortical adenomas are a rare cause of ACTH-independent Cushing syndrome.

Case report
A 64-year-old hypertensive woman presented with bilateral adrenal incidentaloma detected on the evaluation as a living kidney donor candidate. She was normotensive (129/87 mmHg) on monotherapy, BMI = 24.8 kg/m², with no recent weight gain, hirsutism, striae or mood disturbances. Angio-TC scan revealed a 16 x 11 mm right adrenal nodular enlargement and a left 53 x 51 mm one, with an enhancement washout > 50% at 15 min. Hormonal tests were as follow: ACTH <5 pg/ml; serum cortisol 17 μg/dl; urinary cortisol 95 μg/24 h (r.v. 20-90); DHEA-S, 170HP, renin, urinary aldosterone and metanephrines within normal ranges. After overnight and low dose DEXA suppression tests serum cortisol were 7.8 and 7.5 μg/dl respectively and diagnostic of Cushing syndrome. Nor-iodo-cholesterol scintigraphy showed an intense uptake by the left adrenal and a nodular fixation on the right. Laparoscopic left adrenalectomy was done and histopathology revealed a single 6 cm adenoma. Four months later, she is eucortisolemic.

Conclusion
A serendipitous diagnosis of Cushing syndrome due to macronodular bilateral adrenal hyperplasia was first made in this patient. Decision of unilateral adrenalectomy was based on dimension criteria and the assumption of resolution which can lead to unnecessary evaluation and unsuccessful treatment if not FHH is considered.

P611
Remind familial hypocalciuric hypercalcaemia as a cause of elevated parathyroid hormone and serum calcium: 5 patients
I E Bonapart, A Boumpaki & A Stamatakis
Venizelleio-Pananeio Hospital, Heraklion, Crete, Greece.

Introduction
Familial hypocalciuric hypercalcaemia (FHH) is a benign disorder, with inappropriately elevated parathyroid hormone, without the complications of hypercalcaemia (1). It is important to discriminate FHH from primary hyperparathyroidism (PHPT), because of the consequences on symptomatic disease and therapeutic approach. Ca/Cr clearance ratio will be <0.01 in FHH and most often >0.02 in PHPT (2). In patients with PHPT and vitamin D deficiency, low urinary calcium level will increase after vitamin D repletion, thereby differentiating it from FHH.

Case reports
Five female patients, mean age 54.4 years, without specific clinical symptoms had elevated PTH (mean value 89.2 pg/ml), elevated or at the upper limit of normal serum calcium (10.3 mg/dl) and low urine calcium (mean value 80.5 mg/24 h). Their Ca/Cr clearance ratio was <0.01 (mean value 0.006). Vitamin D 25 OH deficiency coexisted in 2 patients was supplied without substantial increase in calcium urine values. The lack of symptoms and Ca/Cr clearance ratio <0.01 confirmed the diagnosis of FHH. No further evaluations and treatment was necessary.

Conclusion
In clinical practice, frequently we see elevated levels of PTH and serum calcium, which can lead to unnecessary evaluation and unsuccessful treatment if not FHH is considered.

P612
Iatrogenic hypoadrenalism: a case report
J Mesquita1,2, A Varela1,2, A Magalhães1,2, F Correia1,2 & D Carvalho1,2
1Department of Endocrinology, Diabetes and Metabolism of São João Hospital, Porto, Portugal; 2Faculty of Medicine, Porto University, Porto, Portugal; 3Faculty of Nutrition and Food Science, Porto University, Porto, Portugal.

Introduction
Psoriasis is a chronic skin disease with a prevalence of 0.6 to 4.8%. Among the possible treatments, we highlight topic corticosteroids that can cause not only different local side effects (skin fragility and atrophy, striae, purpura, acne, telangiectasia, hypertrichosis) but also systemic side effects, including diabetes mellitus (DM), hypertension (HT), Cushing’s syndrome and hypohalamic–pituitary–adrenal (HPA) axis suppression.

Case report
A male patient 47 years old, smoker, with psoriasis for nearly 20 years, followed Iatrogenic hypoadrenalism: a case report

Woman, 64 years, history of hyperthyroidism since August 2009, under therapy with methimazole 5 mg/day. The patient was referred to endocrinology department in March 2010, with history of heart failure, atrial fibrillation, type 2 diabetes mellitus, penicillin allergy, and allropurinol and fenofibrate toxicodermia. In April 2010, she visited the emergency department complaining of worsening of dyspnea and peripheral edema. Her chest X-ray showed a left pleural effusion and thyroid function revealed (TSH – 44.19 μIU/ml (0.35-4.94), FT4 – 0.48 ng/dl (0.70-1.48), FT3 – 2.60 pg/ml (1.71-3.71)). She was hospitalized due to acute decompensate heart failure probably due to hyperthyroidism. Methimazole was used. Four days after she developed sclerotic jaundice, with elevation of alkaline phosphatase (148 U/l (38-145)) and bilirubins (total = 17.8 mg/dl (<12), direct = 7.9 mg/dl (<4)). Abdominal ultrasonography and magnetic resonance cholangiography revealed biliary obstruction. Concomitant liver diseases, e.g. viral hepatitis, autoimmune hepatitis, and primary biliary cirrhosis, were also excluded by proper serology. The possibilities of cholestatic etiology were hepatic congestion in heart failure or methimazole toxicity. The hyperthyroidism study revealed a Graves disease, and the patient was submitted to radioactive iodine therapy. Twelve weeks after methimazole withdrawal maintained cholestasis.

Discussion
Methimazole-induced cholestasis is unlikely due the absence of a clear chronological relationship between drug initiation and the development of jaundice. Cholestasis due to hyperthyroidism usually occurs in association with marked elevation of thyroid hormones. In this case report, liver biopsy could be relevant to exclude others causes of cholestasis.
**P613**

**Diabetes insipidus in the context of sarcoidosis: a case report**

J Mesquita1,2, P Rodrigues1,2, S Bele1,2, Sousa1,2, A Varel1,2, A Magalhães1,2, J L Castedo1,2, N Melo1,2, Patricia Mota1,2, & Davide Carvalho1,2

1São João Hospital, Porto, Portugal; 2Faculty of Medicine, Porto University, Porto, Portugal.

**Introduction**

Sarcoidosis is a systemic granulomatous disease of unknown etiology with a prevalence of 10–20/100,000 individuals and affects mainly young adults. Neurological involvement occurs in about 5% of the cases and it can affect the hypothalamic–pituitary axis. In this case, the most common endocrine manifestations are hyperprolactinemia and diabetes insipidus.

**Case report**

A 44-year-old male patient complaining of not feeling well and dyspnea was diagnosed with sarcoidosis about 6 years ago and was medicated with deflazacort 60 mg orally daily. He developed diabetes mellitus secondary to corticosteroid therapy about 4 years later and started insulin therapy. He was referred to an Endocrinology consultation due to polyuria and polydipsia for about 1.5 years. He ingested up to 5 l of water in a single day. In physical examination he had a cushingoid phenotype. Analytic baseline study revealed plasma osmolality = 294 mOsm/kg (n: 282–300), normal renal function, normalcalcemia, urine osmolality = 179 mOsm/kg (n: 50–200), urinary volume = 5700 ml, mild hyperprolactinemia = 17.9 ± 17.7 μg/ml (n: 4.0–15.2), hypopituitarism: hypogonadism – FSH = 0.70 μIU/ml (n: 1.5–12.4), LH < 0.10 μIU/ml (n: 1.7–8.6), total testosterone < 0.03 ng/ml (n: 2.8–8.0); hypothryroidism – TSH = 2.05 μIU/ml (n: 0.35–4.94), FT3 = 0.66 ng/dl (n: 0.7–1.48) and hypoadrenalism – 0900 h. ACTH < 1.0 ng/ml (n: 0.63–3), 0900 h. cortisol < 0.6 μg/dl (n: 6.2–19.4). It was performed a water restriction test that confirmed the diagnosis of central diabetes insipidus (urine osmolality during the test was always less than 200 mOsm/kg) and urinary osmolality increased about 97.5% at 120 min after administration of s.c. desmopressin) and the patient was discharged with intranasal DDAVP solution 5 μg twice a day. Pituitary MRI showed hypothalamic and pituitary stalk thickening. Contrast administration revealed multiple nodules of contrast uptake consistent with the diagnosis of granulomatous meningitis.

**Conclusion**

Patients with multisystemic diseases, such as sarcoidosis, should have an appropriate follow-up for early diagnosis of complications.

---

**P615**

**Evaluation of autoimmune endocrine disturbances in celiac patients**

Ayten Oguz, Ebru Akin, Dilek Tuzun, Aylin B Demirezer, Osman Ersoy, Reyhan Ersoy & Bekir Cakir

Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

**Aim**

Celiac disease is closely related with other autoimmune diseases. Our purpose is to examine the existence of endocrine diseases in Celiac patients.

**Materials and methods**

Celiac patients admitted to gastroenterology clinic were referred to our endocrinology clinic between the dates of September of 2009 and June of 2010. This patient group was evaluated to see if they had autoimmune thyroiditis, type 1 DM, primary hypoparathyroidism and primary adrenal insufficiency.

**Results**

Twenty-seven patients were registered in our study and 6 of them (22%) were male where as 21 (78.8%) of them were female. Mean age was 35 ± 11 years (20–61). Mean body mass index was 22.61 ± 4.45 kg/m² (17.9–34.9). We have detected chronic thyroiditis in 6 and type 1 diabetes mellitus in 2 of patients. All patients with endocrinopathy were female. Plasma cortisol levels were normal. We have made low dose ACTH test to all patients and the results were normal. Moreover we have detected vitamin D deficiency in 23 of the patients (85.2%) and there was secondary hyperparathyroidism in 17 of these patients. We haven’t detected primary hyperparathyroidism in any patient. In addition to endocrinopathies we have detected vitamin B12 deficiency in 13 (48.1%) patients and in 3 (11.1%) of them antiparietal antibody was positive.

**Discussion**

Endocrinological pathologies especially type 1 DM, autoimmune thyroiditis, rarely Addison’s disease, chronic autoimmune hepatitis, primary biliary cirrhosis, cystic fibrosis and lastly SLE have been known to accompany celiac disease. We have detected in our study group that the occurrence rate of type 1 DM in celiac patients was 7.4% and chronic thyroiditis was 22%. We assume that periodic screening for endocrinopathies should be done in Celiac patients.

---

**P616**

**Autoimmune polyglandular endocrinopathy associated with collagenous sprue: a case report**

Serap Soytaç Inancli1, Arza Ensari2, Esin Beyan3, Berna Savas2 & Ekreem Abayli1

1Ankara Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey; 2Numune Education and Training Hospital, Ankara, Turkey.

**Introduction**

Polyglandular autoimmune syndrome (PAS) is a syndrome that is characterized by the association of two or more organ specific autoimmune disorders. Collagenous mucosal inflammatory diseases involve the columnar-lined gastric and intestinal mucosa. The coexistence of the two disease has not been reported.
We have encountered a patient with a rare combination of autoimmune thyroiditis, hypoparathyroidism, primary ovarian failure and collagenous sprue. To our knowledge this is the first case of collagenous sprue in association with polyglandular syndromes in the literature.

Case report
A 32-year-old woman was admitted to our outpatient clinic with weakness, myalgia, muscle cramps and carpopedal spasm. Her past medical history included diabetes since 1 year and she had the diagnosis of primary amenorrhea since 15 years. Laboratory investigations revealed hypocalcemia, hypopotasemia, hypophosphatemia. Hematologic tests revealed anemia. Parathyroid hormone was low. The patient had hypothyroidism. Anti TG antibody and anti TPO antibodies were high. Morning cortisol level was 18 μg. ACTH stimulation test could not be done. Upper gastrointestinal endoscopy and histological examination revealed celiac disease and the patient was diagnosed as gluten enteropathy. She had no response to the medications, gluten free diet, her clinical course deteriorated with worsening malabsorption, diarrhea, and weight loss. Second endoscopic examination pathology of the duodenum revealed collagenous sprue. The patient died 4 days after the initialization of steroid therapy.

Conclusion
Collagenous sprue must be considered in patients who have polyglandular endocrinopathy with resistant diarrhea to avoid life threatening complications. The presence of other immune-related diseases in this case also suggests that an immunological mechanism may play a causative role in collagenous sprue. This is important and must be kept in mind.

P617
Iatrogenic lymphocytic hypophysitis
P Shillo, R Evans, J Wright & J Newell Price
Royal Hallamshire Hospital, Sheffield, UK.

A 61-year-old was diagnosed with CLL in 1986 but received no active treatment until 2006, when the WCC became elevated and bone marrow biopsy showed a dense B cell infiltrate. Despite initial treatment with chemotherapy there was disease progression, hence started on Alemtuzumab (Campath) on 24/5/2010. This was stopped on 18/6/2010 because of recurrent neutropenic sepsis. He was readmitted on 18/7/2010 because of left eye cellulitis and hyponatremic with serum sodium of 122 mmol/l, which was investigated and treated appropriately as SIADH with fluid restriction and discharged with normal sodium. He was readmitted on 29/10 with lethargy, hypotension and sodium 119 mmol/l. He had not received any glucocorticoids for 5 months and biochemistry revealed pan hypopituitarism. He was treated with hydrocortisone and then thyroxine and desmopressin. He was treated with hydrocortisone and then thyroxine and desmopressin. He was readmitted 2/9/10 with lethargy, hypotension and sodium 119 mmol/l. He had not received any glucocorticoids for 5 months and biochemistry revealed pan hypopituitarism. He was treated with hydrocortisone and then thyroxine and desmopressin. He was re-admitted on 2/9/10 with lethargy, hypotension and sodium 119 mmol/l. He had not received any glucocorticoids for 5 months and biochemistry revealed pan hypopituitarism. He was treated with hydrocortisone and then thyroxine and desmopressin.

Discussion
Iatrogenic lymphocytic hypophysitis is a rare complication of cancer chemotherapy and immunotherapies. The exact pathogenesis of lymphocytic hypophysitis is unknown. However, the high occurrence of lymphocytic hypophysitis in patients with lymphomas makes a lymphocytic origin plausible. In this case, lymphocytic hypophysitis was induced by Alemtuzumab treatment in a CLL patient with lymphocytic hypophysitis. The clinical presentation of lymphocytic hypophysitis is often confused with SIADH, which is a consequence of lymphocytic hypophysitis. In this case, lymphocytic hypophysitis was diagnosed by the presence of lymphocytic infiltrate and by the lack of SIADH symptoms.

P619
Our clinical experience in percutenous ethanol injection into cystic thyroid nodules
Bekir Cakir, Rifki Ucler, Dilek Arpaci, Fevzi Balkan, Ahmet Dirikol & Reyhan Ersoy
Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

Aim
Percutaneous ethanol injection (PEI) is a minimally invasive method which can be preferred in treatment of cystic thyroid nodules. We have presented our cases of PEI below.

Material and methods
We have performed PEI to 8 patients in our clinic. We have made ultrasound guided fluid aspiration from the cysts which were confirmed to be benign. We have injected ethanol (98%) into the pushe of the cyst in an amount that is 20–40% of the cystic fluid volume with ultrasound guidance.

Results
The mean volume of cystic nodules was 13.6 ml (3.8–36.7 ml) and mean ethanol volume injected was 6.5 ml (1.5–15 ml). After the first performance of PEI, we have recorded 50% reduction in nodule sizes at the first control visit of 2 patients. We had to perform PEI for the second time because we couldn’t record any significant reduction in nodule size in 6 patients. During the second PEI performance, mean nodule volume was 10.7 ml (6.5–32.4 ml) where as mean ethanol volume used was 4.5 ml (3–15 ml). After the second PEI, we observed almost 50% reduction in thyroid nodule sizes of extra 4 patients. In two patients, we could not record any effective size reduction even after the 2nd PEI. They were referred to a surgeon for thyroidectomy. At the control visit, made 6 months after PEI, in 4 of 6 patients the cystic component of the nodules completely disappeared. Mean nodule size of these 6 patients was calculated as 0.36 ml (0.25–0.54 ml). One year after PEI, we made fine needle aspiration to the nodules previously received ethanol injection and the cytology results were all benign.

Discussion
PEI may be an alternative to surgery in complex nodules which are dominantly cystic in nature after eliminating the malignancy probability with fine needle aspiration.

P618
A rare cause of nontraumatic rhabdomyolysis: central diabetes insipidus
Dilek Tuzun, Ayten Oguz, Sedat Caner, Ali A Tam, Neshlan Cuhaci, Reyhan Ersoy & Bekir Cakir
Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

Nontraumatic rhabdomyolysis is mostly caused by drugs, alcohol consumption or compression of muscles. Severe hyperosmolality rarely can cause rhabdomyolysis. Our case has santral diabetes insipidus that has admitted with the clinical picture of rhabdomyolysis.

Case
Twenty-six-year-old male has admitted to our clinic with the complaint of weakness, nausea, vomiting, polydipsia, polyuria, difficulty in walking and tendency to sleep. Neurologic examination was normal. In laboratory glucose: 166 mg/dl, Na: 168 mEq/l, Urea: 19 mg/dl, Cr: 1.6 mg/dl, K: 2.8 mEq/l, CK: 2916 IU/l, plasma osmolality 348 mosmol/l, and urine density 1005 were. Serum CK level have increased progressively up to 15 000 IU/l during the follow up. We have thought that rhabdomyolysis might have been due to hyperosmolality caused by high Na and low K levels. We have administered hypertonic fluids and followed the urine output and fluid intake of the patient. His general condition was not well enough to tolerate fluid restriction test and he had severe polyuria that is why we have directly made the desmopressin administration test. Plasma osmolality was 348 mosmol/l before desmopressin administration and it regressed to 330 mosmol/l thereafter. Urine osmolality has increased to 330 mosmol/l from 77 mosmol/l after desmopressin administration. Amount of urine per hour has decreased significantly after desmopressin. Consequently the patient has been diagnosed to have central DI. In pituitary MRI a lesion was detected at the level of hypothalamus in right anterolateral neighborhood of 3rd ventricle and 14×18×11 in size. It was interpreted as low grade glial lesion. Desmopressin was started po 0.1 mg three times daily and clinical picture has improved thereafter. Serum Na, K and CK levels have returned to normal values after the treatment.

Conclusion
Rhabdomyolysis is a rare but very important complication of hyperosmolality due to DI. CK levels should be monitor strictly in hyperosmolar states.

P620
Two cases of allergic reactions which has developed due to usage of insulin analogues
Ayten Oguz, Serap Inancli, Gulfem Kaya, Burcak Polat, Ahmet Metin, Reyhan Ersoy & Bekir Cakir
Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.

We have presented two cases of allergic reactions developed due to usage of insulin aspart.
**P621**
Sheehan’s syndrome primary presenting as central diabetes insipidus: case report

R Rangel1,2, A Borges1,2, A Afonso1,2 & A Agapito1,2
1Curry Cabral Hospital, Lisbon, Portugal; 2Maternidade Alfredo da Costa, Lisbon, Portugal.

**Introduction**
Sheehan’s syndrome is a rare case of hypopituitarism secondary to an intra or postpartum severe bleeding. Manifestations are most often caused by deficiencies of hormones of anterior pituitary; involvement of posterior pituitary is rarely described.

**Case report**
We report a case of a 45 years old hypertensive, multipara, premenopausal woman, who underwent fertilization by oocyte donation, that resulted in twin pregnancy. Prenatal vaginal delivery was complicated with severe post partum hemorrhage and shock due to surgical placentical fragments removal. Agalactia and a persistent polyuric–polydipsic syndrome, with daily diuresis > 5 l, developed on the immediate post partum. MRI showed ectopic neurohypophysis; serum osmolality 288 mosm/kg; urinary osmolality 89 mosm/kg. After intranasal desmopressin urinary osmolality raised to 372 mosm/kg and diuresis normalised.

Four months after delivery, she was still amenorrhoeic and presented asthenia and swelling. Multiple hypothalamic–pituitary axis evaluation resulted ACTH, TSH, FSH, LH, PRL, and GH deficiencies. Started treatment on prednisone and levothyroxine with clinical status improvement. At 6 months of follow-up she is asymptomatic and the MRI showed normal pituitary.

**Conclusion**
Central diabetes insipidus is rare in Sheehan’s syndrome; in this patient it was the primary manifestation. The rapid onset of the anterior pituitary hormones deficiency is also not frequent.

---

**P622**
Hepatic metastasis of parathyroid carcinoma: case report

F Fonseca1,2, J Narcise1, A Agapito1, C Gasparinho1, P Guerra1, J Coutinho1 & C Gomes da Costa1
1Curry Cabral Hospital, Lisbon, Portugal; 2SAM’s Hospital, Lisbon, Portugal.

**Introduction**
Parathyroid carcinoma is a rare cause of primary hyperparathyroidism. Initial complete surgical resection is crucial. Recurrence is common and primary cause of mortality is severe hypercalcemia.

**Clinical case**
In 2006, a 51 years old male presented with multiple bone pain, anorexia and weight loss, calcium 11.7 mg/dl, PTH 189 pg/ml. Eight years before a diagnosis of atypical parathyroid adenoma was made after left inferior parathyroidectomy and genetic analysis revealed HRPT2 gene mutation. He was lost for follow-up soon after surgery. On reevaluation, it was not possible to localize any eutopic or ectopic parathyroid mass or metastasis by ecography, CT scan, MRI, and Sestamibi scintigraphy. Surgical cervical exploration was negative, nevertheless a right superior and inferior parathyroidectomy were done and histology revealed no tumor. Calcium levels increased steadily (14.7 mg/dl), PTH 444 pg/ml. Cinacalcet was badly tolerated and unable to reduce hypercalcemia. A good response to Zoledronic acid was obtained, but tachyphylaxis developed in the next four months. Selective venous catheterization could not demonstrate any PTH gradient. A trial of anti PTH immunization (Liège University Hospital) was then made (June 2007), but soon after he was hospitalized in our center due to symptomatic severe hypercalcemia (15.2 mg/dl). A 12 mm solid hepatic nodule was then seen on CT and MRI but not on PET-scan. Surgical enucleation confirmed a hepatic parathyroid metastasis. PTH became immediately undetectable and on the third post operative day calcium normalized and hypocalcemia developed. After 42 months, he is asymptomatic on calcium and vitamin D therapy.

**Conclusion**
Parathyroid carcinoma as a variable course and tends to recur locally. In this case a unique small hepatic metastasis was responsible for severe hypercalcemia. After its resection a new remission was obtained.

**P623**
IGF2 producing prostate tumour causing severe hypoglycaemia: case report

Gy Bartal1, J Vadasz1, G Krasznai2, A zalatnai2 & L Fink3
1Hetenyi Geza County Hospital, Szolnok, Hungary; 2Semmelweis University, Budapest, Hungary; 3Justus-Liebig Universität, Giessen, Germany.

**Introduction**
The IGF1 and 2 are polypeptides that share structural similarities to insulin and affect carbohydrate metabolism mainly by activating the IGF1 receptor. We report a patient presenting with prostate tumour and severe hypoglycaemia.

**Case presentation**
An 82-year-old male presented with frequent seizures and severe hypoglycaemia. Four year prior to the current presentation the patient had been diagnosed with prostate carcinoma, however, he refused surgical treatment. Our laboratory tests confirmed severe hypoglycaemia with low insulin levels at admission. Similarly, during fasting low glucose and low serum insulin levels were documented. Standard oral glucose load showed a diabetoid response, but the insulin response was delayed. An insulinoma could be excluded by various imaging techniques. Moreover, both glucagon and somatostatin tests showed negative results. Furthermore, physiological hypophysis and peripheral hormone concentrations, as well as normal IGF1 serum levels and chromogranin A were measured. Therefore, we hypothesised that the severe hypoglycaemia might have resulted from IGF2 (or its prohormone) synthesis by the previously diagnosed prostate tumour and thus a prostatectomy was recommended. The patient required continuous glucose substitution and diazoxide therapy under which the previously diagnosed prostate tumour and thus a prostatectomy was recommended. The patient required continuous glucose substitution and diazoxide therapy under which the hypoglycaemia could be controlled, however, due to the poor general condition a surgical procedure was not feasible and the patient deceased. The subsequent immunohistochemistry of the prostate sections showed a carcinoma with strong IGF2 staining, further suggesting that the IGF2-secreting prostate tumour caused the severe hypoglycaemia.

**Conclusions**
To our knowledge, this is only the second reported case of an IGF2 secreting prostate tumour. It has been previously reported that some mesenchymal tumours secrete IGF2 at high levels causing severe, therapy refractory hypoglycaemia. Increased awareness of IGF2 may improve diagnosis and treatment of hypoglycaemia.
Deficiency of 17β-hydroxysteroid dehydrogenase type 3 (17βHSD3), an enzyme converting androstenedione (A) to testosterone (T) in the Leydig cells of the testes, is a rare cause of autosomal recessive disorders of sexual development (DSD). A 18-year-old phenotypically female patient presented with primary amenorrhea. She had deep voice, macrocephaly, broad forehead, enlarged nasal tip, macrostomia, facial acne, gynecomastia, left-convex dorsal scoliosis, hypoplasia of the first finger of right hand, proximal implant of the fifth metatarsus bilaterally and an increased muscle mass and increased distribution of hair on face, neck, abdomen, pubic region and on upper and lower limbs. Genital exam showed thickened labra majora with absence of labra minora. Gynaecological exam shows a blind-ending pseudo-vagina (15 cm) with microepithelium. Karyotype analysis showed a male genotype (46,XY). Hormonal evaluation showed decreased T (188 ng/dl) and increased A (10 ng/ml), considering male reference ranges, resulting in a decreased T/A ratio (0.188). MRI identified testicles in inguinal regions. Human Chorionic Gonadotropin test showed the lack of response of A although T/A ratio remained permanently under 0.8, as classically expected. These evidences were suggestive of a 46,XY DSD due to 17βHSD3 deficiency. A mutation (IVS3 -1 G>C or c.326–1G>C) which alter the splicing of exon 4 of the 17βHSD3 gene was discovered at the genetic evaluation. This mutation was previously reported in Dutch and Brazilian population and is one of 27 actually known mutations of 17βHSD3 gene. Psychologist identified a well determined female gender identity so was decided to proceed with surgical removal of the gonads and of micropenis with vaginal approach should be more thorough in normal-weight individuals with recent onset of gynecomastia at puberty, which had fully recovered. A painless enlargement of the left breast, without any palpable nodules, was noticed. Physical examination was otherwise unremarkable. Mammary ultrasound showed left mammary gland hyperplasia, without any nodule. PRL level was normal. In the absence of testicular ultrasound, a testicular microlithiasis (TM) was suspected. Ultrasound showed left and right testis of normal size and consistency. Standard laboratory procedures to assess liver and kidney functions were normal. Serum levels of LH and FSH were high; androgen levels were very low. Semen analysis showed azoospermia in 2 different determinations, even after ejaculate centrifugation.

Conclusions
Despite the association between TM and testicular germ cell tumor, the malignant potential of the former is not yet completely understood. There is also no consensus on the best follow-up strategy for patients with TM, but it is necessarily important to identify those with at least one risk factor for testicular germ cell tumor.
P628

Five year follow-up of recurrent parathyroid carcinoma in a young man: a case report

D. Grigorie, M. Ivan, M. Ionescu, M. Ghemigian, B. Stanescu, D. Ioachim, A. Suculic, & A. Diaconescu
National Institute of Endocrinology, Bucharest, Romania.

Introduction
Parathyroid carcinoma is a rare cause of hyperparathyroidism.

Case report
We report the case of a 25-year-old man who presented with acute severe hypercalcaemia (19 mg/dl) and extremely high serum PTH (2737 pg/ml). He was initially treated with i.v. fluids, calcitom and pamidronate and total calcium decreased to 12.7 mg/dl. A left lower parathyroideectomy (tumour with microvascular invasion and intact capsule) was performed with a prompt decrease in PTH (89.8 pg/ml) and calcium (6.8 mg/dl), followed by severe and prolonged hungry bone syndrome (6-months). During the 5 years follow-up, he developed 4 recurrences, the first after 2 years, and then at shorter intervals of 10 months, 6 and 5 months. Preoperative calcium and PTH levels were higher than initially (18.6–20 mg/dl and 1601–3402 pg/ml, respectively), with incomplete response to i.v. bisphosphonates (patidronate, zoledronate) and surgery (serum calcium 12.3–15.9 mg/dl and PTH 107–166 pg/ml). Each time, extensive local invasion required en bloc resection of all involved tissues, including the thyroid.

The clinical course was aggravated by the occurrence of ischemic heart disease and by severe skeletal involvement with long-bone fractures (humerus, femur) from minimal trauma. The very high bone remodelling (cross-laps up to 19 ng/ml) was only attenuated by BP and surgery. A differential diagnosis with bone metastasis was unsuccessful with MiBI scan and a FDG-PET scan was scheduled.

Conclusion
This case confirms that the diagnosis of parathyroid carcinoma is difficult even after histopathologic evaluation and is often established by the presence of recurrences. The clinical course was marked by severe and difficult to control hypercalcaemia, severe bone disease (possible bone metastasis), and ischemic cardiac involvement.

P629

Unexpected association: Turner syndrome and hypopituitarism: a case report

C. Căcău1,2, C. Poiana1,2, D. Hopton2, A. Dumitrascu2, O. Popa2, S. Gurau2, R. Danciulescu1,2 & M. Musat1,2
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 2C.I.Parhon National Institute of Endocrinology, Bucharest, Romania.

Introduction
Turner syndrome is a common cause of dwarfism and hypogonadism as is pituitary failure. However the association of the two is rarely thought and reported in the literature. We present two cases of women with hypogonadism diagnosed with Turner syndrome with various degrees of pituitary insufficiency.

Case report
The first case presented at 16 years with secondary amenorrhea and showed: mosaicism 45X0 (30%)/46XX (70%). During and after insulin induced hypoglycemia provided additional proves of hypopituitarism. The MRI scan denied pituitary mass and showed pituitary hypoplasia, and ectopic posterior pituitary. Abnormal karyotype was also revealed: mosaicism 45X0 (30%) / 45X0 (70%).

The second case presented at 48 years, with a diagnosis of Turner syndrome since the age of 5. She had had estrogen-induced puberty then discontinuated hormone therapy at 7.5 mIU/l and a CT scan of the pituitary revealed empty sella with partial hearing loss, renal duplication, and hypertension, impaired glucose tolerance test and osteoporosis. FSH level was inappropriately normal for her age of 5. She had had estrogen-induced puberty then discontinuated hormone therapy at 7.5 mIU/l and a CT scan of the pituitary revealed empty sella with partial hearing loss, renal duplication, and hypertension, impaired glucose tolerance test and osteoporosis. FSH level was inappropriately normal for her age of 5.

Conclusion
This case confirms that the diagnosis of parathyroid carcinoma is difficult even after histopathologic evaluation and is often established by the presence of recurrences. The clinical course was marked by severe and difficult to control hypercalcaemia, severe bone disease (possible bone metastasis), and ischemic cardiac involvement.

P630

A rare variant of Wolfram syndrome with diabetic microvascular disease, hypergonadotropic hypogonadism and palmar fibromatosis: case report

University of Medicine and Pharmacy Gr. T. Popa, Iasi, Romania.

Introduction
Wolfram syndrome, a very rare condition, is a neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) which appear in childhood, hampering diagnosis and treatment. Others less frequent features as hypergonadotropic hypogonadism, microvascular disease and local fibromatosis are reported in a male patient diagnosed at the age of 18 years.

Case report
An 18-year-old male patient diagnosed with Wolfram syndrome at the age of 5 due to association of diabetes mellitus, deafness and diabetes insipidus is admitted to endocrinological clinic due to short stature and lack of secondary sexual characteristics. The clinical examination revealed a height at ~2.5 s.d., Tanner II puberty stage and palmar fibromatosis (Dupuytren’s contracture).

Hormonal profile was normal for TSH, fT4, cortisol and prolactin but suggestive for hypergonadotropic hypogonadism due to high levels of FSH and LH in association with low levels of testosterone. On fundoscopic examination, he has bilateral optic atrophy and diabetic retinopathy. The urological exam. (ultrasound and urography) diagnosed bilateral hydronephrosis and atomic bladder. Audiometry showed bilateral high frequency hearing loss. The cranial CT scan confirms the optic atrophy without other abnormalities.

Conclusion
The presence of diabetes insipidus and sensorineural deafness in the first decade not in the second, dilated renal outflow tracts in the second decade not in the third, the hypergonadotropic hypogonadism, diabetic retinopathy and palmar fibromatosis makes this case particular and emphasize the requirement of complete and complex evaluation of the patient with Wolfram syndrome regardless the age.

P631

‘Uterine neuroendocrine tumour: an unusual cause of hyponatraemia’ and the role of tolvaptan, a vasopressin V2 receptor antagonist

G. Mlawa, S. Price, L. Fraser, R. Green, B. Turner & R. Guy Basingstoke Hospital, Basingstoke, UK.

Background
Hyponatraemia is the commonest electrolyte abnormality in clinical practice, and may be a biochemical manifestation of different diseases including malignancy. About 14% of hyponatraemia in medical inpatients is due to underlying tumour related conditions. We present a case of 68 years widow who was referred by her General Practitioner with 3 weeks history of nausea, occasional vomiting, confusion, increased urinary frequency, and urinary incontinence but no dysuria. She also complained of chronic constipation and weight loss. Her past medical history included left knee arthroscopy, cochlea implant and sterilisation in 1976. She was non smoker but her husband was a heavy smoker. On admission she was haemodynamically stable with normal observations. Blood test revealed profound hyponatraemia (Na 118 mmol/l), and serum osmolarity of 247 mOsm/kg, urine osmolarity of 701 mOsm/kg, urinary sodium of 110 mmol/l, normal cortisol of 542 nmol/l, in keeping with SIADH. Tumour markers were negative. Chest X-ray was unremarkable but abdominal ultrasound revealed a uterine heterogeneous enhancing mass which was also confirmed on staging CT of chest, abdomen and pelvis. Flexible sigmoidoscopy was normal. Her medications included Paracetamol and Codeine Phosphate. She was started on fluid restriction of 750 ml/24 h. She remained hyponatraemic (116–117 mmol/l) despite this. Oral Demeclocycline 300 mg TDS was added, but she was unable to tolerate it and she was changed to tolvaptan (30 mg od). She was discharged home on tolvaptan (30 mg) and was reviewed by gynaecology team in outpatient clinic; cervical biopsy histology showed a high grade neuroendocrine malignant tumour confirmed by positive immun labelling for chromogranin, AE1/3 and CAM5.2. She is currently undergoing chemotherapy and still on tolvaptan. Her sodium remains low but at safer levels of 127–130 mmol/l.

Discussion
Hyponatraemia secondary to uterine neuroendocrine tumours is rare and generally associated with chemotherapy treatment rather than being related to the uterine neuroendocrine tumour. Conventional treatment for hyponatraemia due to SIADH was ineffective or not tolerated. Tolvaptan treatment was more successful even though it is mainly used in patient with mild to moderate volume hyponatraemia. This possible hyponatraemia.

Endocrine Abstracts (2011) Vol 26
P632

Diagnosis of Bruns–Garland syndrome in a patient with McArdle disease and type 2 diabetes mellitus
Rafael Martins*, 1 Celestino Neves*, 2. Manuel Vaz-da-Silva†, 1, Pedro Rodrigues*, 1, Sandra Belo*, 1, Georgina Jorge*, 1, Angela Magalhães*, 1, José Luís Castedo*, 1 & David Cavalcão* 1Portuguese Institute of Oncology of Porto, Porto, Portugal; 2Faculty of Medicine, University of Porto, Porto, Portugal; 3São João Hospital, Porto, Portugal.

Introduction

McArdle disease is a rare recessive disorder of glycogen metabolism, related to muscle phosphorylase deficiency. It usually presents in adolescence or early adulthood with muscle cramps, exercise intolerance, easy fatigability, and progressive weakness as glycogen is the primary source of energy for intense muscle activity. Few reports described the association of McArdle disease and type 2 diabetes and some authors suggested that hyperglycemia and hyper-insulinemia may improve muscle symptoms. In fact, sucrose ingestion before exercise is one of the proposed treatments for this disease.

Case report

A 69-year-old caucasian male with previous medical history of insulin-treated type 2 diabetes mellitus (diagnosed 30 years before), McArdle disease (diagnosed 15 years before, by muscle biopsy) and colon carcinoma (6 years before, treated with surgery and chemotherapy, without evidence of recurrence) presented with severe pain and weakness in left lower extremity (during last 4 months) and weight loss. Previously, he did routine moderate exercise, without symptoms. On physical examination, he had proximal muscular atrophy (more in anterior compartment of left thigh), very reduced reflexes (more in left limb), and a small antero-lateral area of hypoaesthesia in left thigh. HbA1c was 9.4%. Electro-myography revealed a sensitive and motor polyradiculoneuropathy (with predominantly lombar expression) compatible with the diagnosis of Bruns–Garland syndrome. Patient was submitted to symptomatic treatment (gabapentin and duloxetine), physiotherapy and glycemic control optimization.

Discussion

In this patient with simultaneous myopathy and neuropathy predisposing disease, this clinical presentation originated a challenging differential diagnosis. Bruns–Garland syndrome is a rare complication of diabetes and more frequent in patients under good metabolic control. Another relevant point is related to the eventual contribution of hyperglycemia to McArdle disease absence of symptoms. This fact may be taken into account in deciding glycemic treatment goals in this patient with long duration diabetes.

Conclusions

This clinical case describes a Merkel cell carcinoma with a single thyroid metastasis in a previously known nodule with a benign result in FNA biopsy. In oncologic patients, thyroid secondary involvement is an important differential diagnosis in initial evaluation and follow-up of thyroid nodules.
Glycated hemoglobin A1c (A1C) is used for diagnosis and monitoring diabetic patients. It reflects the average plasma glucose concentration over the preceding 2–3 months.

**Introduction**

M Alves1, M Bastos1, M Ribeiro2, J Santos1, A Vieira1, S Gouveia1, J Saraiva1 & M Carvalheiro1

1Servicio de Endocrinología, Diabetes e Metabolismo, Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal; 2Servicio de Hematología, Centro Hospitalar de Coimbra, EPE, Coimbra, Portugal.

Introduction

Glycated hemoglobin A1c (A1C) is used for diagnosis and monitoring diabetic patients. The precision of A1C assay methods is affected by the presence of hemoglobin variants. About 7% of world population is asymptomatic carrier of these variants.

Case report

PCDM, a woman, 42 years old, caucasian, followed in consultation for obesity, primary hypothyroidism and bipolar disorder. Had family history of obesity and sudden death of her father at 50 years old. Was treated with levothyroxine and psychotropic drugs. She reported recent hypertension and weight gain. Presented with BMI 32.5 kg/m² and BP 140/90 mmHg. Laboratory study showed, TSH 5.6 μU/ml (NR: 0.4–4.0), FT₄ 1.2 ng/dl (NR: 0.8–1.9), fasting plasma glucose 108 mg/dl, total cholesterol 182 mg/dl (NR: ≤190), LDL 124 mg/dl (NR: <115), triglycerides 119 mg/dl (NR: <150). Reassessment analysis showed: plasma fasting glucose 106 mg/dl and A1C 14% (NR: 4.0–6.0). After confirmation (A1C 18.5%), we initiated investigation for a hematologic disease.

Results

Hb 14.6 g/dl (NR: 11.5–15.5), hematocrit 42.8% (NR: 37–47), MCV 85.4 fl (NR: 76–96), MCH 29.2 pg (NR: 27–32), RDW 11.3%, reticulocyte 1.52%; normal iron metabolism. Suspecting of interference with A1C test, we studied hemoglobins and identified an X variant, with AXA2 hemoglobins profile: Hb A2 2.1% (NR<2), Hb B 0.1% (NR<2), Hb variant 13.8 g/dl. The HBA1 gene sequencing revealed heterozygosity for mutation of α₁ CD40 AAG-AAT (Lys–Asn) → Hb Saratoga variants. Given the familial transmission risk, we performed family screening in order to genetic counseling.

Conclusions

In this patient, we found abnormal fasting plasma glucose associated with discrepancy of A1C value. We identified a rare variant of hemoglobin A (Hb Saratoga Springs). Despite the advantages of A1C in the diagnosis and monitoring of diabetes, limitations of the method must be taken into account.
P639
GH in Prader–Willi syndrome: to treat or not to treat
C Vulpoi, C Rusu, D Boisteau, I Vasiliu, J Idriceanu, R Balcan, I Potorac & V Mogos
UMF Gr. T. Popa, Iasi, Romania.

Introduction
Prader–Willi (PWS) is a complex genetic syndrome characterized by dysmorphic features, hypotonia, mental retardation, behavioral abnormalities, hypoplasia with progressive obesity, and endocrine dysfunctions as hypogonadism and GH deficiency. GH treatment is recommended, the major concern being aggravation of sleep apnea.

Cases report
We present 2 cases with specific clinical features and genetically confirmed PWS (del 15q11.2–q13), who had normal stature in spite of confirmed GH deficiency. Both cases are girls of 14 (PD), respectively 6-year-old (MF), born in non-sanguineous couples, with low birth weight and important hypotonia. After the age of 1, they both presented hypotrophy with rapid and important weight gain. At 10 years of life, PD had important obesity (+10 s.d.) and a surprising height at +2 s.d. despite of low GH, insufficiently stimulated, and normal low IGF1 (138 ng/ml). Sleep apnea could not be assessed because of agitation. At the age of 14, with rigorous alimentation, her weight did not excessively increased, being at +8 s.d. She had no puberty signs, low hormones of gonadal axis, and a low height velocity, however her actual height remains higher than expected (+1 s.d.). Bazal GH remained low and IGF1 at the inferior limit for the age (+123 ng/ml). At the first endocrinological examination, in 2010, MF presented obesity, moderate for the disease (+3 s.d.) and, again, high normal height (+2 s.d.) despite low basal GH and low IGF1 (37.6 ng/ml). She had moderate obstructive sleep apnea. With possible sleep apnea in the first case and confirmed in the second, in front of their normal height, the decision of monitoring of height velocity without treatment was taken.

Conclusion
Short stature is common in PWS. Our patients presented unexplained high stature, despite partial GH deficiency. GH treatment remains controversial and armed expectative is probably preferable in these two cases.

P640
Subacute onset in severe Riedel thyroiditis associated with hypoparathyroidism and left recurrent palsy
Simona Verzea-Jercalau,1 Bogdan Stanescu,2,3 & Corin Badiu1,2
1Institute of Endocrinology, Bucharest, Romania; 2University of Medicine and Pharmacy, Bucharest, Romania.

A 42-years woman presented with hypothyroidism, a large, firm, irregular goiter, severe cervical and preauricular pain, 2 weeks after an episode of respiratory infection. Laboratory findings certified subacute thyroiditis and autoimmune hypothyroidism. TSH = 37.6 µIU/mL, FT3 = 6.5 pmol/l, ATPO > 1000 U/ml, ATGL > 1000 µU/ml, ESR = 115 mm/h. Ultrasound showed hypoechoic pattern with a nodule in the right lobe and Doppler signal. Fine needle aspiration biopsy showed features of chronic thyroiditis and fibrosis. Prednisone 30 mg/day and levothyroxine replacement treatment were started temporary relief as aggressive clinical course.

Macroprolactinomas, particularly in men, may occasionally exhibit a very symptomatic dysfunction occurs in >10% of patient with primary empty sella. Case report
A 27-years-old man presented to our department in 2008 with impuberism, microenopon, hypoplastic scrotum, inguinal gonads. He presented an eunucoid habitus but the karyotype was 46xy and the Barr test was negative. Laboratory tests showed prepubertal levels of FSIIHL and testosterone. The IGF1 level was also normal. The MRI revealed an empty sella. He started treatment with testosterone-gei which was stopped 2 months later due to upper arms acne. In 2010, without any treatment, the evaluation reconfirmed the hypothalamic hypogonadism (LH = 1.2 µUI/mL, FSH = 0.7 µUI/ml, testosterone = 0.9 ng/ml). PRL level was slightly elevated (15.8 µg/ml, n < 15). But further tests showed thyreotrop and corticotrop deficit (FT4 = 7.44 pmol/l, n = 12–22 pmol/l and cortisol = 9.4 ng/ml, n = 60–230). Clinically, the patient didn’t show symptoms of adrenal or thyroid hypofunction. The MRI revealed empty sella with compression of the pituitary gland. He received treatment with testosterone enanmate, prednisone and levothyroxinum.

Conclusion
Considering the possibility for the development in time of global pituitary hypofunction, when empty sella is confirmed, the early diagnosis of the deficits leads to proper treatment therapy avoiding potential life-threatening situations for the patient.

P641
Multiple pituitary deficiencies in a young patient with primary empty sella
A Rusu, C Crisтеa, L Gheorghiu, R Balcan & V Mogos
UMF Gr. T. Popa, Iasi, Romania.

Introduction
Usually, the hormonal profile is normal in patients with empty sella. However, when present, hormonal deficiency most commonly consist in growth disturbance in children and mild hyperprolactinaemia in adults. Hypopituitarism with signs of symptomatic dysfunction occurs in <10% of patient with primary empty sella. Case report
A 27-years-old man presented to our department in 2008 with impuberism, microenopon, hypoplastic scrotum, inguinal gonads. He presented an eunucoid habitus but the karyotype was 46xy and the Barr test was negative. Laboratory tests showed prepubertal levels of FSIIHL and testosterone. The IGF1 level was also normal. The MRI revealed an empty sella. He started treatment with testosterone-gei which was stopped 2 months later due to upper arms acne. In 2010, without any treatment, the evaluation reconfirmed the hypothalamic hypogonadism (LH = 1.2 µUI/mL, FSH = 0.7 µUI/ml, testosterone = 0.9 ng/ml). PRL level was slightly elevated (15.8 µg/ml, n < 15). But further tests showed thyreotrop and corticotrop deficit (FT4 = 7.44 pmol/l, n = 12–22 pmol/l and cortisol = 9.4 ng/ml, n = 60–230). Clinically, the patient didn’t show symptoms of adrenal or thyroid hypofunction. The MRI revealed empty sella with compression of the pituitary gland. He received treatment with testosterone enanmate, prednisone and levothyroxinum.

Conclusion
Considering the possibility for the development in time of global pituitary hypofunction, when empty sella is confirmed, the early diagnosis of the deficits leads to proper treatment therapy avoiding potential life-threatening situations for the patient.

P642
Giant invasive macroprolactinoma
M Alves, C Neves, J Pereira, M Ayres Bastos, I Bernardes, D Carvalho-Braga & D Carvalho
1Endocrinology, Diabetes and Metabolism Department, Faculty of Medicine, São João Hospital, University of Porto, Porto, Portugal; 2Neurosurgery Department, São João Hospital, Porto, Portugal; 3Radiology Department, Faculty of Medicine, São João Hospital, University of Porto, Porto, Portugal.

Background
Apart from signs of hyperprolactinaemia, patients with macroadenomas with extrasellar extension generally seek medical attention due to mass effect. Macroprolactinomas, particularly in men, may occasionally exhibit a very aggressive clinical course.

Case report
Male 37 years old that went to a Neurology consultation complaining of progressively more frequent self-limiting episodes of restraint, silence and time and space disorientation in the last 3.5 years. CT scan revealed a large and infiltrative mass lesion centered to the skull base, associated with destruction of surrounding bone structures, including the limits of the sella turcica and sphenoid body, and compression of brain parenchyma (left temporal lobe) and bulge, with marked deformation of these structures. He was immediately sent to the emergency room of this hospital by the Imaging Center, to be examined by a neurosurgeon. No significant changes were detected on neurological examination, although he mentioned minor hearing impairment and lower visual acuity for objects in the right visual field. MRI favored the hypothesis of chordoma. He was evaluated by endocrinology and hormonal study revealed hyperprolactinaemia (> 2000 ng/ml). He had no signs or symptoms of hypothyroidism, hypocortisolemia or hypogonadism. Treatment with dopamine agonist and an anti-epileptic was begun. Prolactin levels stabilized at 1.5 times the upper limit of normal. We also observed partial reduction (30%) of tumour volume, recovery of visual acuity and remission of seizures.

Conclusion
With this case, we stress the importance of hormonal evaluation in the differential diagnosis of tumours of the diencephalon–pituitary region. The clinical response, analytical and imaging data, 1.5 years after starting treatment, reinforces the diagnosis of invasive prolactinoma. The extent of the injury prevents, at present, its surgical resection. The good response to therapy reaffirms the concept long ago established that there are patients in whom surgical treatment is never an option.

**P643**

Bexarotene associated dyslipidaemia and central hypothyroidism in a patient with Sézary syndrome

M Alves1, C Neves1, F Azevedo2, O Correia2, D Carvalho-Braga1

1Endocrinology, Diabetes and Metabolism Department, Faculty of Medicine, São João Hospital, University of Porto, Porto, Portugal;
2Dermatology Department, São João Hospital, Porto, Portugal;
3Dermatology Center Epidermis, Porto, Portugal.

**Background**

Sézary syndrome (SS) is a more aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL). Bexarotene (Targetretin) is a synthetic rexinoid analogue designed for the treatment of advanced stages of cutaneous manifestations of CTCL. Bexarotene selectively suppresses thyrotropin secretion and up to 40% of patients develop reversible idiopathic central hypothyroidism. Severe mixed dyslipidemia may be present in up to 70%.

**Case report**

Seventy-year-old female who started development of skin changes on the trunk and limbs at 51 years of age, and 3 years later parapsoriasis in large plates was diagnosed. The evolution of the lesions led to deepening of endocrinological study, and 2 years later, CTCL in the form of SS was diagnosed. Multiple treatments were tried without satisfactory clinical improvement. She began bexarotene (Targetretin) 300 mg/day in December 2002. Periodic laboratory surveillance, including lipid profile and thyroid function was performed. We detected maximum levels of triglycerides of 618 mg/dl, controlled with antidyplmedic therapy, and fluctuations in the levels of TSH and free T4 were mostly compatible with the diagnosis of central hypothyroidism. She was not treated for several years. Fluctuations in values of thyroid function and lipid profile were associated with changes in disease evolution and use of varying doses of bexarotene. She was sent to the consultation of Endocrinology for diabetes mellitus, nodular goiter and assessing need for treatment with levothyroxine. There was need for treatment with levothyroxine and adjustment of oral antidiabetic treatment.

**Conclusions**

For the rarity of the disease and the endocrine-metabolic consequences of treatment it is important to expose this case. The evaluation of thyroid function and lipid profile should be performed before and during treatment with bexarotene. Dyslipidemia is favored both by treatment with bexarotene and treatment with levothyroxine and adjustment of oral antidiabetic treatment.

**P644**

Diffuse nodular hyperplasia of the adrenal cortex in a patient with renal cysts

A Michou, I Kostoglou-Athanasiiou, A Chroniou, S Tagara, V Triantí, A Stefanaki, O Karagianni & A Karfi

Department of Endocrinology, Red Cross Hospital, Athens, Greece.

Nodular hyperplasia of the adrenal as a cause of Cushing’s syndrome is rare. Adrenal tumors, frequently causing syndromes such as hyperaldosteronism due to autonomous hormone secretion, have been described in patients with renal cysts. The aim was to describe the case of a female patient with diffuse adrenal hyperplasia, subclinical Cushing’s syndrome and renal cysts.

A female patient aged 69 years presented with hyperplasia of the right adrenal cortex. In computer tomography evaluation a mass measuring 2 cm was observed in the right adrenal. ACTH was 9 pg/ml, serum cortisol 16.5 mcg/dl and a dexamethasone suppression test with 0.5×4×2 mg dexamethasone was abnormal serum cortisol being 4 mcg/dl after the test. Renin and aldosterone were 16 and 184 pg/ml respectively, in the supine position and 22 and 548 pg/ml respectively in the standing position. The mass was surgically excised and histology showed diffuse hyperplasia of all zones of the adrenal cortex, hyperplasia of the fasciculata zone being more prominent. In a subsequent evaluation, a year later, the dexamethasone suppression test with 0.5×4×2 mg dexamethasone remained mildly abnormal, serum cortisol being 2.1 mcg/dl after the test. The patient had renal cysts in the right kidney.

In conclusion, an extremely rare case of a patient with diffuse hyperplasia of all zones of the adrenal, subclinical Cushing’s syndrome and renal cysts is described. Renal cysts have been observed in patients with hyperaldosteronism and adrenal tumors. The case described is interesting as it is characterized by subclinical Cushing’s syndrome, hyperplasia of all zones of the adrenal cortex and functional hyperaldosteronism.
Ovarian hyperthecosis with type 2 diabetes mellitus and severe insulin resistance in postmenopausal woman

Vadim Gavan1, Anda Caragheorghiceopol1, Adrian Vadava2, Cristian Poalelungi2, Radu Lichardopol1,4 & Corin Badiu1,4
1National Institute of Endocrinology, Bucharest, Romania; 2Cantacuzino Hospital, Bucharest, Romania; 3University of Medicine and Pharmacy, Bucharest, Romania; 4Institute of Diabetes, Nutrition and Metabolic Disorders, Bucharest, Romania.

Introduction
Ovarian hyperthecosis is a rare cause of severe hyperandrogenism. Unlike PCOS, it is also described in postmenopausal women. We report the case of a 67-year-old obese (BMI = 37.5 kg/m²) and dyslipidemic woman, gravid 5 para 3, menopause at 49, with poorly controlled type 2 diabetes mellitus (HbA1c = 10%). She was in treatment with insulin for the last 12 years, currently on 168 U24 h (1.71 U/kg), indicating severe insulin resistance, complicated with stage III diabetic nephropathy, hypertension, ischemic heart disease with history of coronary artery bypass surgery and class III NYHA heart failure. She was admitted for severe hirsutism and balding, symptoms that developed progressively in the last 2 years. Physical examination revealed androgenic rash, male type alopecia, severe facial and thoracic hirsutism, deepening of the voice, acanthosis nigricans, mild ankle edema, dyspnea at minimal effort, BP = 130/80 mmHg, HR = 74/min. Biochemical profile: erythrocytosis (Hb = 16.6 g/dl), renal failure (creatinine = 2.9 mg/dl, BUN = 159 mg/dl), hyperglycemia (Glyc = 240 mg/dl), dyslipidemia (triglycerides = 435 mg/dl). Basal total testosterone level was high (2.74 ng/ml), with normal plasma cortisol (15.7 μg/dl) and DHEAS (25.2 μg/dl). Multilienal inhibiting substance was in the fertile female range (1.27 mg/ml), h-CG and CA125 were normal. A two days low dose dexamethasone suppression test indicated normal suppression of the adrenal axis (plasma cortisol = 1.26 μg/dl), with no significant reduction (<40%) of the total testosterone (1.85 ng/ml), reflecting autonomous androgen secretion of ovarian source. Transvaginal ultrasound examination showed enlarged uterus (57/46 mm) and ovaries (left ovary 30/26 mm, right ovary 29/30 mm) for age. The patient was transferred to the gynecological department where total hysterectomy with bilateral anexectomy was performed. Two weeks after surgery the insulin requirement dropped by 39% (102 U24). Total testosterone was under the detectable range of the laboratory.

Conclusion
Etiologic treatment of hyperandrogenism in cases of insulin-treated type 2 diabetes mellitus can lower the insulin resistance.

Ovarian hyperthecosis with type 2 diabetes mellitus

P647

M Melo, F Carrilho, C Ribeiro & M Carvalheiro
Department of Endocrinology, Diabetes and Metabolism, University Hospital of Coimbra, Coimbra, Portugal.

Introduction
Poorly differentiated thyroid cancers are usually aggressive tumors that lack many of the characteristics of differentiated thyroid tissue, including the ability to uptake and process iodine.

Case report
A 75-year-old male presented with weight loss, tiredness, asthenia, tremor, increased perspiration, tachycardia and bone pain in several locations. A hard and fixed thyroid nodule was palpable in the left lobe (FNA «folicular tumor»). Laboratory and Imaging workup showed: TSH < 0.004 mU/L, fT3 = 7.3 pmol/l (1.8–2.4), fT4 = 1.6 mg/dL (0.8–1.9), and AFCG and a subcutaneous CT scan: nodule in the left lobe of thyroid gland with 57 mm; lytic lesion on right clavicle; multiple pulmonary nodules. The patient was treated with methimazole and then underwent total thyroidectomy. The pathology examination revealed a poorly differentiated thyroid carcinoma, an H211 therapeutic activity of 108 mCi was administered. Post-therapeutic whole body scan showed metastatic lymph node involvement in the mediastium, lung uptake and bone metastatic lesions in the basis of the skull, right orbit, several rib bones, left scapula, T10 and T11 vertebrae, right humerus, left iliac bone and left femur; some of these lesions did not have iodine uptake. Thyroglobulin = 158 028 ng/ml (undetectable Tg-Abs). Head CT showed a supra-sellar mass with sellar invasion. Prolactin = 82 ng/ml (n < 22), basal/stimulated cortisol = 8/17 μg/dl. After surgery, treatment with l-T4 was started (100 μg/d). This dose was progressively decreased to 12.5 μg/day, as the patient developed atrial fibrillation along with persistently high fT4 levels. The patient died from pneumonia 4 months after surgery.

Conclusions
This case illustrates two rare clinical manifestations of thyroid cancer: hyperthyroidism (functioning metastasis) and secondary adrenal insufficiency. Despite being considered as a poorly differentiated tumor and having an aggressive behavior, some metastasis seem to preserve the ability to produce/convert T3.

P648

How differentiated can a poorly differentiated thyroid cancer be?

A rare case presenting with hyperthyroidism and secondary adrenal insufficiency

Melo, F Carrilho, C Ribeiro & M Carvalheiro
Department of Endocrinology, Diabetes and Metabolism, University Hospital of Coimbra, Coimbra, Portugal.

Introduction
Poorly differentiated thyroid cancers are usually aggressive tumors that lack many of the characteristics of differentiated thyroid tissue, including the ability to uptake and process iodine.

Case report
A 75-year-old male presented with weight loss, tiredness, asthenia, tremor, increased perspiration, tachycardia and bone pain in several locations. A hard and fixed thyroid nodule was palpable in the left lobe (FNA «follicular tumor»). Laboratory and Imaging workup showed: TSH < 0.004 mU/L, fT3 = 7.3 pmol/l (1.8–2.4), fT4 = 1.6 mg/dL (0.8–1.9), and AFCG and a subcutaneous CT scan: nodule in the left lobe of thyroid gland with 57 mm; lytic lesion on right clavicle; multiple pulmonary nodules. The patient was treated with methimazole and then underwent total thyroidectomy. The pathology examination revealed a poorly differentiated thyroid carcinoma, an H211 therapeutic activity of 108 mCi was administered. Post-therapeutic whole body scan showed metastatic lymph node involvement in the mediastium, lung uptake and bone metastatic lesions in the basis of the skull, right orbit, several rib bones, left scapula, T10 and T11 vertebrae, right humerus, left iliac bone and left femur; some of these lesions did not have iodine uptake. Thyroglobulin = 158 028 ng/ml (undetectable Tg-Abs). Head CT showed a supra-sellar mass with sellar invasion. Prolactin = 82 ng/ml (n < 22), basal/stimulated cortisol = 8/17 μg/dl. After surgery, treatment with l-T4 was started (100 μg/d). This dose was progressively decreased to 12.5 μg/day, as the patient developed atrial fibrillation along with persistently high fT4 levels. The patient died from pneumonia 4 months after surgery.

Conclusions
This case illustrates two rare clinical manifestations of thyroid cancer: hyperthyroidism (functioning metastasis) and secondary adrenal insufficiency. Despite being considered as a poorly differentiated tumor and having an aggressive behavior, some metastasis seem to preserve the ability to produce/convert T3.

Endocrine Abstracts (2011) Vol 26
Adrenal rest in a patient with late onset 21-hydroxylase deficiency

A Chronaou1, K Kostoglou-Atanassiou1, A Michou1, S Kotonoglou2, G Vassiliou1, K Tzioras1, V Loi1 & A Karfi2

Department of Endocrinology, Red Cross Hospital, Athens, Greece.

Adrenal rests, nodules of the adrenal, in patients with chronic elevation of ACTH levels have been previously described. The aim was to describe the case of a patient with an adrenal tumor and late onset 21-hydroxylase deficiency.

A female patient, aged 76 years, presented with an incidentally discovered mass of the left adrenal measuring 1.2 cm. The patient was short with a height of 152 cm. Morning serum ACTH levels were 31 pg/ml, serum cortisol 16.8 µg/dl, serum aldosterone 14.7 µg/ml and serum renin 17 pg/ml, urine free cortisol 6.5 µg/day and 17(OH)progesterone 5 ng/ml. An intravenous ACTH stimulation test was performed. Cortisol levels before the administration of ACTH, 30 and 60 min later were 12, 13.7 and 14 µg/dl respectively. Serum 17(OH)progesterone levels before the administration of ACTH, 30 and 60 min later were 10, 50 and 50 ng/ml. The elevation of 17(OH)progesterone after the administration of ACTH was diagnostic of the presence of non classical 21-hydroxylase deficiency. The insufficient cortisol increase after the administration of ACTH was suggestive of partial adrenal insufficiency. In conclusion, the rare case of a patient with non classical 21-hydroxylase deficiency is described. The patient presented in old age with an adrenal rest. It is possible that the chronic stimulation of the adrenal cortex from ACTH as a result of the partial cortisol insufficiency was involved in the pathogenesis of the adrenal tumor.

Maltose interference in the determination of blood glucose levels by test strips based on glucose dehydrogenase-PQQ method: a case report

S Belo1,2, P Rodrigues1,2, M Alves1,2, C Neves1,2, A Magalhães1,2 & D Carvalho1,2

1Serviço de Endocrinologia, Hospital de São João, Porto, Portugal; 2Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Background

The different systems for monitoring capillary blood glucose levels may suffer interference from various substances. Case report

Male patient, 48 years old, with history of hypertension, dyslipidemia and previous smoking. He presented also type 1 diabetes mellitus, with 37 years of progress, with diabetic retinopathy, kidney failure, in peritoneal dialysis since 2009, and ischemic heart disease (myocardial infarction in 2005). He was treated with insulin, angiotensin receptor antagonists, beta blockers, calcium channel blockers, darbepoetin, metolazone, loop diuretics, aspirin, proton pump inhibitors, folic acid. Because of glycemic instability, with frequent hypoglycemic events, he was proposed for therapy with insulin infusion pump. As an inpatient, at the time of therapy adjustment with insulin pump, he frequently referred symptoms suggestive of hypoglycemia. However, determinations of capillary glycaemia (CG) with test strips based on glucose dehydrogenase-PQQ method revealed persistently high glucose levels. At the 4th day of hospitalization, capillary glycaemia determinations were performed simultaneously with test strips based dehydrogenase-PQQ method and with test strips based glucose oxidase method. A significant difference, of about 100 units, was found between the two values (dehydrogenase-PQQ method CG = 147 mg/dl; glucose oxidase method CG = 45 mg/dl). Conclusions

Some sugars, such as maltose, interfere with blood glucose monitoring systems based on dehydrogenase-PQQ method. This interference occurs solely through the use of maltose in preparations administered parenterally or used in peritoneal dialysis. Maltose administration orally does not interfere with the determinations of the CG. Thus, CG determination by test strips based on glucose dehydrogenase method should not be used in patients on peritoneal dialysis using solutions containing isodextrin, which has maltose as an intermediate metabolite.
the combination of chronic autoimmune adrenal insufficiency with autoimmune thyroid disease, type 1 autoimmune diabetes mellitus, or both. In patients with type 1 diabetes, a sudden drop in insulin requirement point out to early adrenal insufficiency.

**P655**

**Impact of two novel mutations of calcium sensing receptor (CaSR) gene on calcium metabolism: two clinical case reports**

Elena Livadarii1, Renata Simona Auriemma1, Catherine Rydlewski2, Silvia Vandeva1, Anie Sophie Thonnard1, Daniela Betea1, Adrian F Daly1 & Albert Beckers1

1Department of Endocrinology, University of Liege, Liege, Belgium; 2Division of Molecular Genetics, Department of Clinical Biology, University Hospital Erasme of Bruxelles, Bruxelles, Belgium.

Disorders of calcium metabolism arise in a familial or sporadic setting. The resulting hypo- or hypercalcemia can induce serious clinical features. Calcium sensing receptor (CaSR) plays a key role in maintaining this balance and its molecular investigation is useful to determine the nature of a certain condition or to choose the appropriate therapeutic approach.

In the present study we reported two clinical cases. A 16-year-old patient had a mild hypercalcemia associated with normal-to-low urinary calcium excretion and normal-to-high parathyroid hormone (PTH) levels. Because of family negative phenotype, familial hypocalciuric hypercalcaemia was originally excluded and bilateral inferior parathyroidectomy was realized. Conversely, a 54-year-old man showed a symptomatic hypocalcemia, low PTH levels, hyperphosphatemia and slight hypercalciuria. The evaluation of all family members revealed the same phenotype in the sister. The whole coding region of the CaSR gene of both probands and their first-degree relatives was sequenced. In the first patient a novel double mutation predicting a change from alanine to lysine was found in codon 423 (A423K) of exon 4, with genetic analysis being negative in the parents. The latter patient showed a heterozygous novel missense mutation resulting in a change from glutamic acid to lysine in codon 556 (E556K) of exon 6, his sister also being positive. In conclusion, we reported two novel mutations of the CaSR gene, a double inactivating mutation in exon 4 and the first activating mutation in exon 6. This study demonstrates the importance of genetic testing of CaSR to assist in management and therapeutic decision.

**Developmental endocrinology**

**P656**

**Comparative levels of serum/plasma concentrations of hormones in Juvenile periodontitis patients of Pakistan**

Ayesha Anwar & Hamid Qureshi

UHS, Lahore, Pakistan.

Gums inflammation (gingivitis) if not treated on time and permitted to grow, ends into periodontitis in which alveolar bone that supports teeth is invaded and destroyed. Juvenile periodontitis is a genetic disorder and can occur without plaque and calculus. It is a disease of people below 30 years of age.

Subjects and methods

This cross sectional study involved a total of 160 subjects including 80 chronic periodontitis were selected using community periodontal index of treatment needs (CPITN).

Blood sample were drawn and serum/plasma concentrations of LH, GH, cortisol, triiodothyronine (T3), thyroxine (T4), TSH, ADH, parathyroid hormone (PTH), aldosterone, melatonin, calcitonin, insulin, cortisol, epinephrine, norepinephrine, estrogen, progesterone, testosterone, thyromins were measured by using standard ELISA method.

Results

The results of this study showed that serum/plasma concentrations of all the hormones were statistically significantly different in patients of Juvenile periodontitis. The correlation between them and severity of Juvenile periodontitis was also evaluated and a highly significant positive correlation with the severity of periodontitis was found.

Conclusions

Under the influence of Juvenile periodontitis in otherwise healthy young population, the probability of being at hormonal imbalance had appreciably augmented.
Disabetes therapy

P660

Method of myocardial preconditioning during exercise tests in patients with type 2 diabetes mellitus after acute myocardial infarction

Tatiana Chernyavskaya, Ekaterina Meskhidze & Igor Boravkov
Russian State Medical University, Moscow, Russian Federation.

Patients type 2 diabetes mellitus and MI need multimodality treatment including, besides of drug therapy, non-drug approaches. Repeated Treadmil exercise test is open second window of preconditioning. Ischemic preconditioning limits infarct size in the heart, increase level of physical activity.

Study aim

To study the effect of early started repeated Treadmil exercise tests in patients with type 2 diabetes mellitus and MI.

Design

Open, randomized study on 124 MI and type 2 diabetes mellitus patients, 52.3 ± 3.6 years old. Patients were on 5–7 day of MI and received a basic cardiovascular and dietary therapy with ACEI, aspirin, β-blockers and statins and were randomized to two treatment groups (62 patients in each) at 1:1 ratio. Group 1 (control (CG)) – received a standard drug and dietary therapy and standard physical rehabilitations; group 2 (training (TG)) – received a standard drug and dietary therapy and 10 repeated exercise tests twice a day. The follow-up period was 12 months.

Study results

Characteristics ST depression did not differ significantly in both groups at the beginning. However after 10 days in TG durations of the ST depression significantly changed. Times for onset of ischemic changes (228 ± 94 vs 365 ± 103 s, P = 0.01) and appearance of angina (282 ± 153 vs 428 ± 177 s, P = 0.04) were observed. In CG ST depression characteristics were not significantly changed (238 ± 96 vs 265 ± 99 s) and appearance of angina (276 ± 148 vs 293 ± 153 s) were observed.

Physical activity tolerance were increase significantly in TG (42%), and increase not significantly in CG (8%).

Patients in TG had significantly less duration hospitalizations 15.1 ± 2.3 and 18.6 ± 2.2 days in the comparison group.

Total of 48 hospitalizations occurred during the follow-up period, 15 in the TG and 33 in the CG. Training group patients had significantly less hospitalizations due to cardiovascular cause (7.5 vs 37.9).

Conclusion

Repeated exercise tests in patients with type 2 diabetes mellitus and myocardial infarction can be started in their acute period. It decrease myocardial ischemia, decrease duration of hospitalizations and number of hospitalizations and cardiovascular events during 12 month after MI.
P663
Evaluation of adolescents type 1 diabetic patients after transition from paediatric to adult care
M Dominguez-Lopez1, I Gonzalez-Molero1, S RuizdeAdana-Navas1, A. delPino2, J P Lopez2, J D Fernandez1, G Oliveira1 & F Soriguer1
1Endocrinology Department, Carlos Haya Hospital, Malaga, Spain; 2Paediatric Department, Carlos Haya Hospital, Malaga, Spain.

Objective
Our objective in this study was to identify the type of clinical care received by young type 1 diabetic patients who have made the transition from paediatric to adult care, and to assess the metabolic status of the patients. The research aimed to develop a sustainable and coordinated approach to facilitating the transition between diabetes services for adolescents and reveal from the perspective of the adolescents living with type 1 diabetes their experiences surrounding the process of transition.

Material and methods
We evaluated all the patients transferred to our adult unit during the last year. 23 type 1 diabetic patients were analysed. A questionnaire was used to evaluate the opinion of the patients concerning the transitional process.

Results
Twenty-three type 1 diabetic patients (63%F/36%M) with mean evolution of diabetes 9.5 years (6-14 years). Mean BMI was 23.68 kg/m², having 44.4% of the patients BMI higher than 25 kg/m². Mean HbA1c was 7.58% (6.5-8.6%). The patients were treated with MDI (18.18% with NPH and rapid insulin and 81.8% with glargina/Detemir and rapid insulin). 9% had incident nephropathy. No other chronic complications were found. The patients were quite satisfied with the transitional process.

Conclusions
Transition marks a critical phase for young, diabetic patients as they may frequently switch from one physician or centre to another. The individual optimization of therapy, established during paediatric care, provides the decisive groundwork for disease control in young adults. It’s important to prepare, coordinate and evaluate transitional processes between paediatric and adult units.

P664
Clinical effectiveness of a bolus calculator in patients with type 1 diabetes mellitus treated with insulin pump
M Dominguez-Lopez, I Gonzalez-Molero, M RuizdeAdana, M Guerrero, I Cardena, N Colomo & F Soriguer
Endocrinology Department, Carlos Haya Hospital, Malaga, Spain.

Objective
Calculation of accurate insulin boluses is one of the major problems related to intensive insulin regimens. A bolus calculator (BC) incorporated into the insulin pump estimates the dose of insulin to be administered at the meal and makes calculation easier and more precise.

The aim of the present study was to assess the efficacy of a BC on glycaemic control of patients with DM1 on CSII.

Material and methods
We enrolled 20 DM1 patients >18 y and treated for >12 months with CSII (Minimed 722, Medtronic). They received an infrared-linked glucometer (Contour Bayer), being glycaemic values directly transmitted to the pump to be used by the BC, with possibility to download all the recorded data.

Data evaluated baseline and after 3 months using the BC were: HbA1c, daily control of patients with DM1 on CSII.

Calculation of accurate insulin boluses is one of the major problems related to intensive insulin regimens. A bolus calculator (BC) incorporated into the insulin pump estimates the dose of insulin to be administered at the meal and makes calculation easier and more precise.

The aim of the present study was to assess the efficacy of a BC on glycaemic control of patients with DM1 on CSII.

Material and methods
We enrolled 20 DM1 patients >18 y and treated for >12 months with CSII (Minimed 722, Medtronic). They received an infrared-linked glucometer (Contour Bayer), being glycaemic values directly transmitted to the pump to be used by the BC, with possibility to download all the recorded data.

Data evaluated baseline and after 3 months using the BC were: HbA1c, daily control of patients with DM1 on CSII.

Calculation of accurate insulin boluses is one of the major problems related to intensive insulin regimens. A bolus calculator (BC) incorporated into the insulin pump estimates the dose of insulin to be administered at the meal and makes calculation easier and more precise.

The aim of the present study was to assess the efficacy of a BC on glycaemic control of patients with DM1 on CSII.

Material and methods
We enrolled 20 DM1 patients >18 y and treated for >12 months with CSII (Minimed 722, Medtronic). They received an infrared-linked glucometer (Contour Bayer), being glycaemic values directly transmitted to the pump to be used by the BC, with possibility to download all the recorded data.

Data evaluated baseline and after 3 months using the BC were: HbA1c, daily control of patients with DM1 on CSII.

Calculation of accurate insulin boluses is one of the major problems related to intensive insulin regimens. A bolus calculator (BC) incorporated into the insulin pump estimates the dose of insulin to be administered at the meal and makes calculation easier and more precise.

The aim of the present study was to assess the efficacy of a BC on glycaemic control of patients with DM1 on CSII.

Material and methods
We enrolled 20 DM1 patients >18 y and treated for >12 months with CSII (Minimed 722, Medtronic). They received an infrared-linked glucometer (Contour Bayer), being glycaemic values directly transmitted to the pump to be used by the BC, with possibility to download all the recorded data.

Data evaluated baseline and after 3 months using the BC were: HbA1c, daily control of patients with DM1 on CSII.

Calculation of accurate insulin boluses is one of the major problems related to intensive insulin regimens. A bolus calculator (BC) incorporated into the insulin pump estimates the dose of insulin to be administered at the meal and makes calculation easier and more precise.

The aim of the present study was to assess the efficacy of a BC on glycaemic control of patients with DM1 on CSII.

Material and methods
We enrolled 20 DM1 patients >18 y and treated for >12 months with CSII (Minimed 722, Medtronic). They received an infrared-linked glucometer (Contour Bayer), being glycaemic values directly transmitted to the pump to be used by the BC, with possibility to download all the recorded data.

Data evaluated baseline and after 3 months using the BC were: HbA1c, daily control of patients with DM1 on CSII.
Results
Twenty patients received a simultaneous pancreas–kidney transplantation. The medium age was 38.08 (29–53) years and diabetes duration was 21.66 (17–28) years. 83.3% of the patients were in hemodialysis before the transplant (medium of time, 15.15 months). During the monitoring period, mean of capilar glucose was 127.9 ± 34.8 mg/dl (median 121 mg/dl). Interstitial mean glucose from sensor was 127.3 ± 32.2 mg/dl (median 124 mg/dl). A good correlation between capilar and interstitial glucose was observed (R = 0.93, P < 0.05).

Both glucose and glibenclamide decreased glucose concentrations versus basal glucose (−15.60, 90.120, 180, and 240 min; mmol/l): 12.6 ± 0.83 vs 12.2 ± 0.56 vs 12.1 ± 0.57, 15.3 ± 0.63 vs 13.5 ± 0.70 vs 13.0 ± 0.57, 14.8 ± 0.57 ± 13.8 ± 0.59 vs 13.4 ± 0.46, 14.6 ± 0.61 vs 12.3 ± 0.49 vs 12.4 ± 0.61, 12.8 ± 0.76 vs 10.1 ± 0.40 vs 10.3 ± 0.41, and 11.4 ± 0.57 vs 8.3 ± 0.40 vs 8.5 ± 0.46 (P < 0.05; P < 0.01; P < 0.001 versus basal glucose). Treatment with both glucose and glibenclamide increased insulin and c-peptide concentrations after 120 and 140 min (P < 0.001 and P < 0.01).

Conclusions
Real time continuous monitoring could be an effective and useful tool for intensive glycemic control during peritransplant period with good correlation with capilar glucose data.

P667
Uncalynated ghirelin improves insulin sensitivity in the early phase of obesity
P J D Delhanty1, M Huisman1, I van den Berge1, T Abrilat1, A P N Themmen1 & A J van der Lely1
1Erasmus MC, Rotterdam, The Netherlands; 2Alizé Pharma, Lyon, France.

In Europe more than 50 million adults are diabetic. Of these, 90-95% have type 2 diabetes (T2D). It is also recognized that an even larger population is insulin resistant and it is thought that treatment at this early phase of the metabolic syndrome may prevent the occurrence of overt diabetes and associated pathologies. We are in the process of developing unacylated ghrelin (UAG) analogues as therapeutics for T2D. Towards this goal, we have used a mouse protocol in which we pretreat mice with the analogues, then initiate a short-term high fat diet (HFD) to induce insulin resistance but not diabetes. Twelve week old C57BL/6 mice (n=10) were fed either normal chow (12% kcal from fat), or a HFD consisting of 41% kcal from fat, for 2 weeks. We assessed animal weight, food intake, fat mass, and fasting plasma glucose concentrations, and glucose tolerance (glucose tolerance tests) during the study, then insulin sensitivity (insulin tolerance tests, ITT) at the end of the study. Body weight was significantly increased by the HFD during the study period, and fat mass was markedly increased by ~2.5-fold compared with animals on control diets. This occurred despite a decrease in food intake in this group. The animals on the HFD became glucose intolerant, and insulin resistant. Infusion of UAG and analogues had no consistent effects on glycemia or glucose tolerance in this short-term model. Importantly, though, insulin sensitivity was significantly improved, as assessed by ITT, in agreement with our preliminary data in obese diabetic ob/ob mice. UAG agonists may be of use as therapeutics in the treatment of insulin resistant in metabolic syndrome.

P668
Antihyperglycemic action of creatine compared to glibenclamide in type II diabetic patients
M Vucic Lovrenovic1, A Znaor2, T Poljicanin3, P Rocic4, D S Weber4 & B Rocic5
1Institute of Clinical Chemistry and Laboratory Medicine, Merkur Clinical Hospital, Zagreb, Croatia; 2Croatian Institute of Public Health, Zagreb, Croatia; 3Vuk Vehovac University Clinic, Merkur Clinical Hospital, Zagreb, Croatia; 4University of South Alabama, Mobile, Alabama, USA.

Possible involvement of creatine in the regulation of glycemia in diabetic patients has been implicated.

The aim of this study was to investigate the short-term effect of creatine on the glycemic profile during standard meal in comparison to the oral sulfonylurea hypoglycaemic agent glibenclamide, in type II diabetic patients.

In a 14-day symmetrically randomized crossover trial, recently detected type II diabetic patients received either creatine (3 g) or glibenclamide (3.5 mg) for five successive days, followed by two days of washout, and crossover to the opposite treatment. Glucose, insulin, c-peptide, and creatine were measured before, and at 60, 90, 120, 180 and 240 min after a standard meal.

Both creatine and glibenclamide decreased glucose concentrations versus basal glucose (~15, 60, 90, 120, 180, and 240 min; mmol/l): 12.6 ± 0.83 vs 12.2 ± 0.56 vs 12.1 ± 0.57, 15.3 ± 0.63 vs 13.5 ± 0.70 vs 13.0 ± 0.57, 14.8 ± 0.57 ± 13.8 ± 0.59 vs 13.4 ± 0.46, 14.6 ± 0.61 vs 12.3 ± 0.49 vs 12.4 ± 0.61, 12.8 ± 0.76 vs 10.1 ± 0.40 vs 10.3 ± 0.41, and 11.4 ± 0.57 vs 8.3 ± 0.40 vs 8.5 ± 0.46 (P < 0.05; P < 0.01; P < 0.001 versus basal glucose). Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 140 min (P < 0.001 and P < 0.01).

P669
Impact of a DPP4-inhibitor on liver and heart lipid content and cardiovascular risk in type 2 diabetic patients
L Kosi1, M Chmèlek2, S Tratting2, A Lager1 & A Kautsky-Willer1
1Medical University Vienna Internal Medicine III Endocrinology and Metabolism, Vienna, Austria; 2Medical University Vienna Department of Radiodiagnostics, Vienna, Austria.

Background
Increased liver and cardiac fat are common in patients with type 2 diabetes mellitus (T2DM) and associated with increased risk for liver fibrosis and cardiovascular events. The effect of a DPP-4 inhibitor vildagliptin on the fat content of the liver and heart has not been evaluated.

Methods
A total of 40 patients, 20 males and 20 females, treated at our diabetes metabolic unit of the Medical University of Vienna with gliptins underwent magnetic resonance spectroscopy before and 6 months after start of therapy with vildagliptin twice a day 50 mg as standard add on to metformin. MRT was performed with 3 Tesla Siemens MRT.

Results
A total of 40 patients have been included, 10 patients have finished the study (5 males, 5 females). The mean age was 55.5 ± 7.2, weight 88.3 ± 17, BMI 31.6 ± 5.1 kg/m² and duration of diabetes 6.4 ± years. After 6 months mean weight loss was 5.1 ± 2.3 kg and −7.3 ± 1 cm in waist circumference. Systolic and diastolic RR improved significantly: 151.3 ± 2.6 vs 144.8 ± 10.2 ± 8.9 mmHg (P = 0.04, P = 0.05) respectively. Hba1c sunk significantly (8.3 ± 1.5 to 6.5 ± 0.4%, P = 0.004). Before therapy patients had increased liver fat 15.3 ± 9.1%, women significantly higher than men (30.2 ± 2.5 vs 15.3 ± 3.5, P < 0.05) which significantly decreased in the 10 finished patients to 8.8 ± 4.1, P = 0.0004, followed by a decrease of cardiac fat of 1.4 ± 0.4%. The cardiac ejection fraction greatly improved (51.4 ± 2.3 to 67.1 ± 0.5%, P < 0.0001 as well as the myocardial mass decreased for 10.1 ± 2.4 g.

Conclusion
Vildagliptin is very well tolerated an led a leads already after 6 months of therapy to significant decrease of liver and cardiac fat, improves the heart function, blood pressure and leads to weight loss where most of the other oral antidiabetics fail. These preliminary data could indicate vildagliptin as first line therapy of fatty liver with a special focus on cardiovascular function improvement.
randomized as follows: SMBG Group (patients currently using SMBG without a previous training to interpret the result); Control Group (patients who were asked to increase the dosage at visit 1 for a better control of diabetes). The patients were evaluated after 3 and 6 months and HbA1c and fasting plasma glucose (FPG) were monitored. 15 subjects (7 females and 8 males) aged 65 ± 7.7 years were randomized in the SMBG group and 15 (6 females and 9 males) aged 62.7 ± 9.7 years in the control group.

Results
HbA1c levels significantly dropped after 3 (7.7 ± 0.7%) and 6 (7.5 ± 0.7%) months from baseline (8.4 ± 0.6%) in the SMBG Group (P < 0.001); HbA1c levels significantly dropped after 3 (8.0 ± 1.1%) and 6 (7.7 ± 1.0%) months from baseline (8.5 ± 1.0) also in the control group (P < 0.05) but without a significant difference between the two Groups when compared at the same time (3 or 6 months) of control. The FPG progressively decreased in both Groups in a significant way from baseline in SMBG group just after 3 months, while in the control group 6 months were necessary for reaching significance; no significant difference between the two groups was found when compared each other at 3 and 6 months.

Conclusions
The SMBG is as effective as increasing oral antidiabetic therapy dosage in improving the glycaemic control in NIT-T2DM subjects with previous poor glycaemic control even without a detailed training for interpreting the results.

P671
Insulin resistance of multiple metabolic pathways in patients with type 1 diabetes on long term continuous s.c. insulin infusion therapy
E Donga1, M van Dijk 1, R P L M Hoogma2, E P M Corssmit1 & J A Romijn1
1Leiden University Medical Center, Leiden, The Netherlands; 2Groene Hart Hospital, Gouda, The Netherlands; 1Amsterdam Medical Center, Amsterdam, The Netherlands.

Objective
The aim of the present study was to determine whether insulin resistance is important in well controlled, uncomplicated patients with type 1 diabetes on long term CSII, compared to matched healthy controls.

Research design and methods
We studied 8 patients (4 men and 4 women) with type 1 diabetes on stable term CSII, compared to matched healthy controls.

Results
Endogenous glucose production (EGP) did not differ in the basal state between patients and controls. However, EGP was less suppressed during clamp conditions in patients compared to controls (64 vs 79%, P = 0.01), indicating decreased hepatic insulin sensitivity. During the clamp, glucose disposal rate was ~38% lower in patients compared to controls (24.4 ± 2.5 vs 39.7 ± 5.6 μmol.kg.LBM-1.min-1, P = 0.04). Accordingly, the rate of infusion of glucose was ~51% lower in patients (17.7 ± 2.8 vs 39.7 ± 5.7 μmol.kg.LBM-1.min-1, P = 0.02). Finally, NEFA levels were ~2.5 times higher in patients during steady state clamp conditions (150 ± 26 vs 58 ± 4 μmol/l, P = 0.01), reflecting decreased insulin sensitivity of lipolysis.

Conclusions
Insulin resistance is a prominent feature of patients with type 1 diabetes on long term and stable treatment with CSII. Insulin resistance involves multiple unrelated metabolic pathways in these patients.

P672
Factors related with the adherence of physicians to diabetes guidelines in type 2 DM patients in Turkey
I Satman1, S Imamoglu2, C Yilmaz3 & ADMIRE Study Group1
1Department of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; 2Department of Endocrinology and Metabolism, Faculty of Medicine, Uludag University, Bursa, Turkey; 3Department of Endocrinology and Metabolism, Ege University Faculty of Medicine, Izmir, Turkey; 4Department of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Background
Guidelines for management of diabetes mellitus (DM) provide standardization of care and treatment. National clinical practice guidelines on DM have been developed in 2006 by The Society of Endocrinology and Metabolism of Turkey and reviewed annually.

Methods
One hundred and eighty physicians evaluated previous 12 months’ medical records of their type 2 DM patients with special emphasis on whether the patients were followed consistently with national guidelines. This report depends on the analysis of 6032 visits of 1790 patients. Adherence to guidelines was scored to reach a total adherence score of 0–10 for three dimensions of adherence (taking medical history (HISTORY), physical examination (PHY_EXAM) and laboratory evaluation (LAB_EVAL)). Total adherence score was calculated by multiplying the mean of HISTORY, PHY_EXAM and LAB_EVAL scores by 10 (range: 0–100).

Results
Mean age was 58.7 ± 10.9 years and 62% were women. The mean duration of DM was 7.7 ± 7.5 years. Total adherence score didn’t show any relationship with gender and age, but LAB_EVAl score was better in male patients (6.84 vs 6.53 out of 10; P = 0.021) and differed between age groups (40–49 years was the group with the lowest general adherence score). All of the adherence dimensions were related with duration of DM; for 0–5 years of DM, total adherence score and HISTORY, PHY_EXAM and LAB_EVAl scores were significantly lower than groups with longer duration of DM (all P < 0.05). PHY_EXAM, LAB_EVAl and total adherence scores were better in patients with chronic complications (all P < 0.05). PHY_EXAM and LAB_EVAl scores were significantly higher in university hospitals versus state hospitals (P < 0.05). With the mean score of 84.5, total adherence of endocrinologists was significantly better than of both family physicians and internists (P < 0.005).

Comment
We suggest that in order to overcome barriers to increase the adherence to guidelines, factors related with patients and physicians should be studied and understood well.

P673
Effects of estradiol + drospirenone on sexual function in postmenopausal women with type 2 diabetes mellitus
A S Pogorelov1, T U Berkelova2 & A K Ragazin1
1I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation; 2Russian National Research Center of Surgery RAMS, Moscow, Russian Federation.

Introduction
Sexual dysfunction is more prevalent in postmenopausal women with diabetes mellitus.

Objective
The aim of the study was to prospectively evaluate the effects of oral estradiol + drospirenone on sexual function in postmenopausal women with type 2 diabetes mellitus.

Methods
The study included 86 postmenopausal women with type 2 diabetes mellitus who were randomized into two groups: 44 women received oral 17β-estradiol + drospirenone daily and 42 women received no treatment as served as a control group. Sexual function was evaluated with a detailed 34-item questionnaire, a sexual function questionnaire.

Results
After 6 months a high probability of sexual dysfunction was present in 26.19 vs 7.3 to 18.7 with p < 0.001. There were no significant changes in the control group. The highest improvement was achieved in libido score: from 12.5 ± 7.3 to 18.7 ± 5.67 in hormonal therapy group and decreased from 13.2 ± 8.5 to 5.7 ± 6.43 in the control group (P = 0.000 and P = 0.000, respectively). There was no association between probability of sexual dysfunction and HbA1c.

Conclusions
Hormonal therapy provided significant improvement in sexual function in postmenopausal women with type 2 diabetes mellitus.

Keywords: sexual function, diabetes mellitus, postmenopausal women.
**P674**

**Effect of sitagliptin monotherapy on serum total ghrelin levels in type 2 diabetic patients**

O Oz Gul, S Kiyici, C Ersoy, S Cander, O K Unal, E Erturk, E Tuncel & S Imamoglu

Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa, Turkey.

**Background**

Sitagliptin, unlike the some major antihyperglycaemic drugs, is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes. The aim of the present study was to assess the effect of sitagliptin on serum ghrelin levels in patients with type 2 diabetes mellitus.

**Methods**

Forty-four type 2 diabetic subjects were randomly assigned to receive sitagliptin (100 mg/day; n = 28) or medical nutrition therapy (MNT) (n = 16) for 12 weeks. Changes in anthropometric variables, glycemic control, insulin resistance, lipid parameters and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment.

**Results**

Significant decreases in body weight and body mass index were observed over the entire study period in both of the treatment groups. HbA1c and postprandial plasma glucose (PPG) levels were statistically significantly decreased in the sitagliptin group compared with baseline values, while they were unchanged in the MNT group. There was a significant decrease in total ghrelin in sitagliptin group (P = 0.04) compared with baseline values but not in MNT group (P = 0.46) at the end of the 12 weeks. Percentage change in total ghrelin levels was not statistically different between the sitagliptin and MNT groups (~9.3 ± 21.8 vs 21.4 ± 53.3, P = 0.082).

**Conclusions**

In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels. These results suggest that weight neutral effect of sitagliptin might be associated with the suppression of fasting serum ghrelin levels.

**P675**

**UK National Exenatide Guidelines (NICE:CG87) compared to clinical outcomes at a district general hospital’s diabetes department**

D Hughes, H Butterworth & R Mahto

Warwick Hospital, Warwick, UK.

**Objectives**

The aim of the audit was to determine how our current clinical practice differs from that of the national standard set out in the UK by NICE guidance CG87 in regards to the use of exenatide.

**Material and methods**

We measured weight and HbA1c at baseline and then again at 6 months from the date exenatide was started. The UK NICE guidelines recommends exenatide should only be considered in patients with a BMI ≥ 35.0 kg/m² with a HbA1c ≥ 7.5% (adjusted for ethnicity). We analysed data from all patients who had been followed up by the Diabetes Nurse Specialist for at least 6 months from initiating exenatide therapy.

**Results**

Complete data was available for 27 patients. 59% of patients were started on exenatide in a non-EMEA licensed combination with other diabetic drugs. 85% of patients were commenced on exenatide with a HbA1c ≥ 7.5%, but only 62% of patients had a BMI ≥ 35.0 kg/m² (adjusted for ethnicity). At 6 month follow up only 22% of patients had both a reduction of at least 1% in HbA1c and a weight loss of at least 3% of initial body weight.

**Conclusions**

According to UK NICE guidance, the target to continue exenatide beyond 6 months will only apply to 22% of our patients (~1 in 5). If targets were to be relaxed, so that exenatide could be continued in patients who achieved EITHER a reduction of at least 1% in HbA1c OR a weight loss of at least 3% of initial body weight then 65% of our patients would have been able to continue exenatide therapy beyond 6 months. These ‘relaxed’ targets might decrease patient dissatisfaction from discontinuing therapy and provide more freedom to clinicians in order to continue exenatide therapy.

**P676**

**Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control**

Y T Hsieh¹, M C Hsieh¹, S T Tu²

¹Department of Ophthalmology, Buddhist Tzu Chi General Hospital, Taipei Branch, New Taipei, Taiwan; ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

**Background**

Asian has higher prevalence of diabetic nephropathy and end-stage renal disease as compared to Caucasian. No study to date has evaluated whether multifactorial intervention was associated with remission of microalbuminuria in type 2 diabetic Asian population. We evaluated the effect of tightly controlling multiple factors on the remission of diabetic nephropathy in type 2 diabetic Chinese with microalbuminuria.

**Materials and methods**

A total of 587 type 2 diabetic patients with microalbuminuria were collected in a longitudinal cohort study. Cohort members received intensified treatment to meet the following ADA recommended goals: HbA1c < 7.0%, SBP < 130 mmHg, DBP < 80 mmHg, LDL-C < 100 mg/dl, TG < 150 mg/dl, HDL-C > 40 mg/dl for men and > 50 mg/dl for women. Remission of microalbuminuria was defined as shift of albumin-creatinine ratio (ACR) from microalbuminuria to normoalbuminuria.

**Results**

During the 4.5 year period, 210 (35.8%) patients achieved remission to normoalbuminuria. A significant association was found between remission of microalbuminuria and the achievement of ADA goals, including HbA1c < 7% (hazard ratio (HR) = 1.345; 95% confidence interval (CI): 1.010–1.792; P < 0.04), and systolic blood pressure < 130 mmHg (HR = 1.516; 95% CI: 1.100–2.089; P = 0.01). Intensive SBP control ( < 120 mmHg) was significantly associated with remission of microalbuminuria (HR = 2.076; 95% CI: 1.347–3.198; P < 0.001).

**Conclusion**

The remission of diabetic nephropathy could be achieved under multifactorial intervention. Therapeutic focus on remission by tight glycemic and blood pressure control should be considered in Asian population with diabetes and microalbuminuria.

**P677**

**Comparative study of combination therapy between metformin plus thiazolidinedione (TZD) and metformin plus DPP-4 inhibitor in type 2 diabetes**

Yonghyun Kim, Donghyun Shin & Eunjog Lee

Jesaeng Hospital, Seongnam, Kyeonggi-Do, Republic of Korea.

The pathogenesis of type 2 diabetes is explained by increment of insulin resistance and dysfunction of insulin secretion. If improvement of insulin resistance is not adequate in the early stage of diabetes especially in this country with more severe basal insulin secretion defect from the very beginning, diabetes rapidly progress to more aggressive stage with relative insulin deficiency. The most proper method of improving insulin resistance by prescription is metformin from the first and adding TZD class in terms of improvement of insulin resistance when the target of glucose control doesn’t reach by metformin alone. The next step when the target of glucose control doesn’t reach by improving insulin resistance prescription with metformin and TZD is not certain. Adding the other prescription that has different action or insulin is one of options and it is determined by degree of glucose control, insulin secretory capacity of β cell or economic status of patient in practice. The DPP-4 inhibitors that increase insulin secretion by glucagon dependent manner also relieve insulin resistance because they improve first phase insulin secretion defect and prevent late hyperinsuline-mia. When we can’t reach the target below 7% of HgA1c with metformin plus TZD combination that is best in terms of relieving insulin resistance in early diabetes, switching the TZD to the DPP-4 inhibitors that improve insulin secretory dysfunction can be the next useful step to attain glucose control goal. So we compared the effect of glucose control when we switched the TZD to the DPP-4 inhibitor in patients who can’t reach the HgA1c below 7.0% with metformin plus TZD. We also observed the change of insulin resistance index HOMA-IR and β cell function index HOMA-βCP between treatments. Total 84 patients were enrolled and mean age was 53 ± 11. The decrement of HgA1c 6 months after switching was 0.47 ± 0.61. Homa-IR was improved in 57% and mean change was
GHQ12 score and subjective grades of insulin-analogue effects negatively correlated ($r$). Metformin plus DPP-4 inhibitor can be a good treatment option in improving insulin resistance as well as glucose control as compared to Metformin plus TZD therapy.

### P678

**Insulin analogue management: subjective and objective assessment of life quality in patients previously managed with human insulin**

Zoran Gluvic$^1$, Zorica Rasic-Mituljovic$^1$, Jelena Tica$^1$, Milena Lackovic$^1$, Marina Vujovic$^1$, Vesna Popovic-Radinovic$^1$, Esma Isenovic-Milivojevic$^2$ & Jelena Jankovic$^3$

$^1$Zemun Clinical Hospital, Zemun, Serbia; $^2$Laboratory for Radioisotopes, Institute for Nuclear Sciences, Belgrade, Serbia; $^3$Unit for Social and Community Psychiatry, Barts and the London School of Medicine, Queen Mary University of London, London, UK.

**Aim**

By using insulin analogue, it is expected to improve glycemic regulation in poorly controlled type 2 diabetes (2DM). The aim of the study was to examine the quality of glycemic control and quality of life (QoL) of patients managed with insulin analogues, previously treated with human insulin.

**Materials and methods**

The pilot study included 30 2DM outpatients, divided into two groups (15 subjects) – the first group was treated with human insulin, while the second group was managed with insulin analogues during at least one year, but previously treated with human insulin. The following parameters were observed: sex, age, occupation, 2DM and insulin use duration, examiners estimation of insulin therapy effects, GHQ12 score, and HbA1c levels. Obtained data were analyzed by SPSS 17.0.

**Results**

The mean 2DM duration and duration of insulin therapy management was 5.5 ± 3.5 and 3.5 ± 3 years respectively. Twenty (66.6%) subjects assessed overall effects of insulin therapy as grades 3/4 of 5. The mean HbA1c levels were 9.1 and 7.2% respectively ($r$ = 4.869, $P$ < 0.01). HbA1c levels and subjective grades of insulin effects negatively correlated ($r$ = −0.568, $P$ < 0.01). GHQ12 score was 9.3 ± 3.5 and did not statistically differ between groups ($Z$ = −1.481, $P$ > 0.05).

**Conclusion**

Insulin analogue improves glycemic control of 2DM patients. The subjective assessment of the insulin therapy effects correlated with the objective QoL parameter – GHQ12 score.

### P679

**Twelve months exenatide treatment in type 2 diabetes and severe obesity**

M Diégez Felechosa$^1$, C Tusón Riverla$^1$, C Sánchez Ragnarsoon$^2$, E Suárez-Lledó Alemany$^1$, I Cacho García$^2$, N Valdes Gallego$^2$ & J Prieto Santiago$^1$

$^1$Hospital de Cabueñes, Gijón, Spain; $^2$Hospital Universitario Central de Asturias, Oviedo, Spain.

**Aim**

To assess the effectiveness, safety and tolerability of Exenatide twice daily treatment of type 2 diabetes and obesity.

**Material and methods**

Data analysis of obese type 2 diabetic patients initiated on Exenatide therapy in our Endocrine clinics who complete 1 year of treatment.

**Results**

We included 42 patients, 30 women (71.4%) and 12 men (28.6%), mean (± s.d.) age 57 ± 10 and 2.9 ± 7 years diabetes evolution. At baseline, mean HbA1c was 7.45 ± 1.4%, and mean weight 105.8 ± 16.76 kg with body mass index (BMI) 41.1 ± 5.7 kg/m$^2$. 57% of them being morbidly obese patients. 95.2% included Metformin in their basal treatment, alone or in combination with others oral antidiabetic drugs. Seven patients were receiving insulin therapy, stopped at the moment of Exenatide initiation. We did not include any modifications in previous lifestyle plans. After 12 months of treatment mean HbA1c reduction was 0.8 ± 1.8% with 69% of patients reaching HbA1c < 7%. Mean weight loss was 7.6 ± 8.4 kg, 4.5 ± 2.5 kg, 5.9 ± 7 kg, and 7.6 ± 8 kg at 3, 6, and 12 months respectively with a BMI reduction of 2.83 ± 2.9kg/m$^2$. All of these differences were statistically significant ($P$ < 0.01 Wilcoxon test). We did not find any significant change in blood pressure, lipid profile or renal function. Adverse effects occurred in 31% of patients, mainly mild to moderate gastrointestinal ones that conditioning

### P680

**New opportunity of treatment women with postmenopausal osteoporosis and diabetes mellitus type 2**

Elena Doskina, Irina Kochergina & Alexander Ametov

Russian Medical Academy for Advanced Studies Ministry of Health Russia, Endocrinology and Diabetology Chair, Moscow, Russian Federation.

**Purpose of the study**

Research dynamic of parameters of mineral metabolism, during 12 months therapy with Strontium ranelate (in dose – 2 g/day) at women with postmenopausal osteoporosis and diabetes type 2 (D2).

**Materials and methods**

Forty-two women (age 65.9 ± 3.2 years) in postmenopausal period with verified DM2 (DM2 longer from 1 to 12 years, all patients have standard on per oral therapy with ant diabetes drag – glazicladote, metformin or rosiglitazone) and postmenopausal osteoporosis (DEXA – T-score less – 2.5).

**Clinical results**

11.9% of patients have dyspeptic phenomena (regress was during 1–3 days). Nobody of the patients finish treatment in early stage of treatment. Bone mineral density at DEXA T-score grow on 21.5 ± 2.86% ($P$ = 0.05), lumbar spine L 1 – 16.5%, L2 – a 18.4%, L3 – 23%, femoral neck – 24.87%, Ward’s – 16.7%, Troch. – 27.3%, Total hip – 23.35% ($P$ = 0.05). Calcium, and alkaline phosphates are in normal range, on background of therapy negative dynamic is not revealed. Serum C- telopeptide cross link before treatment raised at 33%. And after one year treatment with Strontium ranelate was note regress on 33.5% ($P$ = 0.05).

88.1% of women had pain syndrome (in spine or in the hip), after 2 month of the therapy 2.4% mark its regress, 11.9% after 4 months, 23% after 6 months, 33% after one year treatment of Strontium ranelate. Nobody of the patient had hypoglycemia. Nobody have nonvertebral and vertebral fracture risks. Conclusions Strontium ranelate, being effective in reducing both nonvertebral and vertebral fracture risks. Strontium ranelate is a new first treatment of postmenopausal osteoporosis and diabetes type 2.

### P681

**Effects of lifestyle changes on incidents of type II diabetes in Tehran adult population**

Laleh Ghanei, Fereidoun Azizi & Farzad Hadaegh

Qazvin Medical University, Qazvin/Qazvin, Islamic Republic of Iran.

**Introduction**

Studies show that a change in lifestyle can prevent or delay progression to diabetes in those with glucose intolerance. This study aimed to survey the effects of lifestyle changes on incidents of type II diabetes in Tehran adult population.

**Materials and methods**

This was a community based interventional study. Non-diabetic participants of Tehran Lipid and Glucose Study aged ≥ 20 years (6437 in control group and 2931 in intervention group) were followed for a mean duration of 3.5 years. The changes in lifestyle include an improvement in diet, increase in the level of physical activity and quitting of smoking. Mantel-Cox method was used to compare the incidents of diabetes between the groups. The Cox proportional hazard was used to obtain the proportional risk of incidents of diabetes in the intervention group.

**Results**

After an average period of 3.5 years follow up 58% of subjects completed the follow-up examination. The mean age of the population was 43 ± 11 years and there were 41% males. The percentage of increase in weight, waist circumference, serum triglyceride and blood glucose in the intervention group was lower than controls (0.6 vs 3.3% for fasting glucose, 5.4 vs 10.6% for 2-h glucose, 1.2 vs 6.4% for triglyceride, 4.5 vs 5.7% for waist circumference ($P$ < 0.01) and 2.5 vs 3.2% for weight ($P$ < 0.01)). Incidence of diabetes was 12.2/1000 person-year in
control group and 8.2/1000 person-year for case group. Relative risk of developing diabetes was significantly lower in the intervention groups after adjusting for confounding factors (hazard ratio 0.34, 95% CI: (0.25–0.47), P < 0.001). Number needed to treat to prevent one case of diabetes was 25.57, and 6.7 respectively for the whole population, those with impaired glucose tolerance, and those with body mass index ≥ 25 kg/m².

Conclusion
This study showed that after changes in lifestyle for 3.5 years, there was more than 65% reduction in incidents of diabetes in the Iranian adult population.

P682
The addition of acipimox in patients with type 2 diabetes with triglyceride level over 150 mg/dl in spite of fenofibrate therapy
D-M Kim & J R Park
Kangdong Sacred Heart Hospital, Seoul, Republic of Korea.

Patients with type 2 diabetes have an increased risk of premature coronary heart disease (CHD). One of the underlying reasons for this increased risk is atherogenic dyslipidemia. Current management strategies focus on the initial use of statin or fibrate therapy (the latter approach indicated in patients with pronounced hypertriglyceridemia).

American Diabetes Association recognizes serum triglycerides as a surrogate for atherogenic triglyceride-rich lipoproteins and suggests a target of <150 mg/dl. This target goal of TG is often very difficult to achieve in spite of fenofibrate treatment. So we tried to evaluate the effect of combination with acipimox, which is an an analog of nicotinic acid. Acipimox is also believed to improve glucose control by enhancing insulin sensitivity unlike the case of nicotinic acid. We selected seventeen patients with type 2 diabetes whose glycemic control was stable for 6 months, but elevated serum TG level >150 mg/dl with fenofibrate monotherapy. In this study acipimox 250 mg capsule was administered twice daily for 2 months, and we measured lipid profile and glycated hemoglobin, creatine kinase and myoglobin concentration before and after the addition of acipimox.

Results
1. One female patient was withdrawn because of myalgia in both thigh muscle after 3 days of acipimox combination treatment, but her serum CK and MB concentration were normal.
2. Sixteen patients were completed, and serum TG level was decreased significantly from 328.3±35.29 to 192.4±30.59 mg/dl, and total cholesterol decreased significantly also. But other lipid parameters were not changed significantly.
3. There were no side-effects such as myositis, rhabdomyolysis and liver dysfunction.

Conclusion
This preliminary study showed clearly that in patients with type 2 diabetes who have elevated TG level in spite of fenofibrate monotherapy we can decrease serum TG level significantly with the addition of acipimox.

P683
Monitoring thyroid function in diabetic patients on treatment with glucagon-like peptide 1 analog
R Danculescu1, M Musat1, R Rosca1, V Cristescu2 & C Poiana1
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 2Titu Maiorescu University, Bucharest, Romania.

Background and aims
Incretin mimetics are a new class of pharmacological agents with antihyperglycemic actions that mimic the actions of incretin hormones originating in the gut, such as glucagon-like peptide (GLP)-1. The thyroid gland exhibit a strong GLP-1 receptor expression in rodents but only low receptor levels in humans. GLP-1 receptors activation stimulates calcitonin secretion and promotes the development of C cell hyperplasia and medullary thyroid cancer in rodents. We have monitored the thyroid function in diabetic patients on treatment with exenatide.

Materials and methods
Thirty-three patients with type 2 diabetes mellitus were recruited for this study. The subjects were between 40 and 64 years. Patients were screened initially with a questionnaire detailing their medical history, hereditary or familial medullary disease and death rate from cardiovascular disease (CVD) at diabetes mellitus type 2 (DM 2).

Endocrine Abstracts (2011) Vol 26
Diabetes complications

P686

Diabetic retinopathy in type 1 diabetes mellitus patients with depression
Yana Navmenova1, Tatiana Mokhort & Marina Kapliova1
1Gomel State Medical University, Gomel, Belarus; 2Belarussian State Medical University, Minsk, Belarus.

Aim
To define the frequency of diabetic retinopathy course in type 1 diabetes mellitus (T1DM) patients with and depression; to study the relation between depression and diabetic retinopathy severity.

Materials and methods
One hundred and thirty-three T1DM patients aged 40.27 ± 12.17 years (56 males and 77 females) without exacerbation of chronic and acute inflammatory diseases and verified mental disorders were included into the study. The duration of T1DM before the moment of inclusion into the study was 12.16 ± 3.65 years. The hospital scale of anxiety and depression was used for detection of depression.

The depression was estimated at indicators of 8-21 scores. Statistical processing of the material was performed using STATISTICA 6.0.

Results
For definition of frequency of development of diabetic retinopathy in patients with depression the study group was divided into subgroups: patients without diabetic retinopathy, patients with non-proliferative diabetic retinopathy, and patients with diabetic proliferative and proliferative retinopathy. In T1DM patients with depression the frequency of diabetic proliferative and proliferative retinopathy was 55.3% and was significantly higher than in patients without depression (44.5% (χ² = 5.60; P = 0.018). There were no differences among subgroups of patients with non-proliferative retinopathy and diabetic proliferative and proliferative retinopathy (χ² = 2.81; P = 0.094). For analysis of the frequency of laser coagulation execution there were singled out the following subgroups: T1DM patients with diabetic retinopathy without laser coagulation and with laser coagulation. In patients with depression the frequency of execution of retina laser coagulation is 70% that is higher to compare patients without depression (30%) (χ² = 3.90; P = 0.048).

Conclusions
In T1DM and depression patients the frequency of diabetic retinopathy is higher to compare patients without depression.

P687

The frequency distribution of PPARγ2 Pro12Ala polymorphism in type 2 diabetic, cardiac patients and healthy subjects of Bangladeshi population
Abdullah Emran1, Abulkalam Azad Chowdhury2 & Colin Palmer1
1University of Dhaka, Dhaka, Bangladesh; 2University of Dundee, Dundee, UK.

The prevalence of diabetes is increasing worldwide. According to the recent World Health Organization (WHO) estimates, more than 180 million people worldwide have diabetes. This number is likely to be more than the double by 2030. It is estimated that the developing countries will bear the brunt of diabetes epidemics in the 21st century. It is well known now that increased rates of other chronic diseases, such as hypertension, obesity, cardiovascular diseases are highly associated with type 2 diabetes (T2D). Besides other risk factors, genes play a crucial role in progression of type 2 diabetes. In this study, the Pro12Ala polymorphism of PPARγ2 gene was studied in type 2 diabetic, cardiac patients and healthy people of Bangladesh. Here, 62 diabetic patients, 73 diabetic and cardiac patients and 48 control subjects were investigated. PCR and RFLP analysis were used for identification of individual genotype. In type2 diabetes patient 46 samples (74.19%) were identified as homozygous Pro/Pro genotype and 16 samples (25.80%) as heterozygous Pro/Ala genotype. In cardiac patients those also have type 2 diabetes 63 samples (88.73%) were homozygous for Pro/Pro genotype and 8 samples (11.26%) were heterozygous for Pro/Ala genotype. In the control group, 26 samples (54.16%) were Pro/Pro homozygous, 21 samples (43.75%) Pro/Ala heterozygous and 1 sample was Ala/Ala homozygous genotype. Previous studies showed that, Pro12 allele is the risk factor for onset of diabetes and Ala12 allele is the protective factor for diabetes. In control subject this Pro12Ala polymorphism was significantly higher than patients thus proving Ala12 allele play the protective role. Most significant finding of this study is Pro12 allele was significantly higher in cardiac patients having type 2 diabetes further emphasises the fact that, diabetes increases the risk of heart disease and stroke.

P688

The risk factors for cardiovascular disease in type 2 diabetes patients
V Mladenovic, A Djukic, J Petrovic & S Sipetic
Clinical Center Kragujevac, Kragujevac, Serbia.

Introduction
Diabetes mellitus is equivalent of coronary artery disease (CAD), plenty of patients with CAD already has diabetes or prediabetes. Diabetes originate as result of interactions between different factors, like genetic and environment. The risk factors for type 2 diabetes are: positive family history for type 2 diabetes, obesity, age over 45 years, previous glucose intolerance or impaired fasting glucose, previous gestational diabetes or birthweight of children over 4 kg in women, hypertension (> 140/90 mmHg), HDL cholesterol < 0.9 mmol/l, and/or tryglicerides > 2.8 mmol/d, polycystic ovary syndrome. Primary characteristics of CAD in diabetic patients are: younger age than in patients without DM, rapid progression, and diffuse and extended changes on blood vessels.

Aim
The aim of our study was to determinate presence of risk factors for cardiovascular disease in type 2 diabetes patients in Kragujevac, and the difference depending on gender.

Material and method
The study included all patients with type 2 diabetes patients in Kragujevac, we collected demographic data about patients, and about risk factors related to this disease.

Results
This examination registered 3108 type 2 diabetic patients, 1248 (40.1%) men and 1860 (59.9%) women. The prevalence of obesity in this population was 36.77%, in 40.4% women versus men 31.3% (P < 0.001), hypertension 55.5%, women 59.7% versus men 49.2% (P < 0.001), hyperlipidemia 23.5%, women 24.4% versus men 22.1% (P = 0.076), smoking 10.88%, women 8.3% versus men 14.7% (P < 0.001), alchocol consumers 3.76%, women 0.17% versus men 8.8%, P < 0.001), birthweight of children over 4 kg in type 2 diabetic women 7.47%. Positive family history for diabetes was in 28.1%, women 29.2% versus men 26.4% (P = 0.052), positive family history for CAD was in 24.3%, women 27.0% versus men 20.27% (P < 0.001).

Conclusion
The prevalence of obesity and hypertension is significantly higher in women, the prevalence of smoking and alchocol consuming is higher in men with type 2 diabetes in Kragujevac.
Study of endothelial dysfunction in diabetes. assessment of ANP levels in patients without vascular disease

Maria Rosa Villar Vicente, Noemi Gonzalez Perez De Villar, Carmen Alameda Hernando & Antonio Becerra Fernandez
Hospital Universitario Fuenlabrada, Madrid, Spain.

Background
Endothelial dysfunction may have deleterious effect cardiovascular pathology in diabetic patients.

Atrial natriuretic peptide (ANP) exerts beneficial effects on the cardiovascular system in part by exerting antioxidant activity. Recently it was reported that ANP is able to exert an antihypertrophic effect in myocitos at least in part due to inhibition of NADPH oxidase and superoxide generation.

It seems that hyperglycemia acute is accompanied by a rapid increase in circulating ANP and in this metabolic interaction, ANP might counteract the renal sodium-retaining effect of hyperglycemia and hyperinsulinaemia.

Given that oxidant stress is a key cause of endothelial dysfunction in diabetes we investigated whether there is a relation between ANP levels and the presence of vascular disease and his relation with the HbA1c.

Methods and patients
We analysed 21 diabetic patients, 8 woman and 13 men, with ages (X ± SD) 61.3 ± 12.6 and 8.4 ± 9 years of diabetes evolution. Two were diabetic Type 1 and 19 type 2. The control group were 34 subjects. ET1 and ANF were measured by RIA. There were no statistically significant differences between ANP levels in the group of diabetic patients depending on the Hba1c group (ANP: 9.24 ± 5.30 and 12.04 ± 7.79 pg/ml in patients diabetic with HbA1c<9 y HbA1c>9% (NS)). However ANP levels was increased in the both groups of patients with diabetes without vascular disease compared with healthy controls (ANP: 5.84 ± 3.96 pg/ml) P<0.05; r: 0.43.

Conclusion
ANP levels was increased significantly in diabetic patients without vascular disease compared to controls but not directly related to HbA1c levels. Elevation of ANP levels may precede vascular complications associated with diabetes and offers a protective actions on endothelium-dependent and independent vasodilatation. This may represent new, more effective means of treating vascular disease specifically in the setting of diabetes.

Obese diabetics and left ventricular hypertrophy

Ergita Nelaj, Margarita Gjata, Ledio Collaku & Mihal Tase
Department of Internal Medicine, University Hospital Center, Tirana, Albania.

Introduction
Type 2 diabetes mellitus (DM) is independent risk factors for micro and macrovascular disease. So, it has been associated with abnormalities of cardiac function and left ventricular hypertrophy (LVH). Type 2 diabetic individuals, particularly obese women, had higher heart rates, greater left ventricular wall thicknesses and greater cardiac mass than subjects without diabetes. The objective of the present study was to investigate association between waist circumference-body mass index (BMI) and left ventricle mass (LVm)-left ventricle mass index (LVMi) in patients with type 2 DM and without known cardiac disease.

Methods
The study group comprised of 65 patients, 22 men and 43 women with mean age 58.6 ± 10.09, with type 2 diabetes. Patients with presence of renal failure or heart failure of any stage, known cardiac diseases, pulmonary diseases, anemia, were excluded. DM was defined by fasting plasma glucose levels 126 mg/dl or by specific treatment. BMI was calculated by standard formula and abdominal circumference was measured. Two-dimensional echochardiograms of the LV were performed. LVMi was calculated by the formula introduced by Devereux and Reichek and was indexed for body surface area to obtain LVMi. LVH was diagnosed when LVMI was > 134 g/m² in men and > 110 g/m² in women.

Results
In all patients, there were significant correlation between abdominal circumference and LVM; between BMI and LVM; between BMI and LVMI. According to sex, were significant relations between BMI and LVM (P< 0.03), BMI and LVMI (P< 0.007), only in woman. These parameters were not associated in men.

Conclusion
In diabetic patients, high BMI and abdominal circumference were associated with increasing LVM and LVMI, especially in women. So, in obese diabetics these parameters are important risk factors, for heart disease.

Keywords: diabetes, hypertrophy, left ventricle, BMI, risk factors.

Psychoemotional status and quality of life of T1DM patients

Maria Rusalenko1, Tatiana Mokhori1, Aleksander Rozhko1, Tamara Sharshakova2, Irina Davydova2 & Yana Navmenova2
1Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus; 2Belarusian State Medical University, Minsk, Belarus; 3Gomel State Medical University, Gomel, Belarus; 4Gomel State University of F. Skorina, Gomel, Belarus.

Aim
To estimate QOL and intensity of depression symptoms in T1DM patients.

Materials and methods
Total 53 T1DM patients (26m, 27f), mean age (M±σ) 33.6±2.7 years (20.00–54.00) and 35 of the control group (17m, 18f), mean age 34.8±2.9 years (22.00–50.00) were provided with the questionnaire of Medical Outcomes Study 36-Item Short-Form Health-Survey, Beck depression inventory and Test for estimation of subjective control level.

Results
The patients with HbA1c <7% the parameters of Role-Physical, Role-Emotional, Mental Health (P<0.05) were higher than in patients with HbA1c ≥7%.

The negative correlation of expressiveness of depression symptoms with GH (r=-0.54; P<0.05) was obtained. The expressiveness of depression symptoms is lower in HbA1c <7% T1DM patients to compare with HbA1c ≥7% Me 21.8 (11.3; 45.2) vs Me 11.3 (8.1; 11.3), (t=-2.053; P=0.057).

At the scale of ‘Total internality’ the average level was 73%, the high level – 27%, the low level – 0%; by the scale of ‘Responsibility of achievements’ the average level consisted 36.5%, the high level – 63.5%; ‘Responsibility of failures’ the average level – 54.5%, the high level – 45.5%, the low level – 0%; ‘Internality of family relations’ the average level was 54.5%, the high level – 27.3%, the low level – 18.2%; ‘Internality of industrial relations’ the average level was 82%, the high level – 18%, the low level – 0%; ‘Internality of interpersonal attitudes’ the average level – 27.2%, the high level –27.2%, the low level – 43.8%; ‘Internality of health and disease’ the average level was 64%, the high level – 36%, the low level – 0%.

Conclusion
The evident depression in 38% of patients testifies to the unfavorable emotional state at T1DM. Higher physical, emotional, psychological health and less expressiveness of depression symptoms in compensation patients underline the urgency of achievement of aim levels of T1DM compensation.
P693
Diabetic foot with risk for ulceration associated with diabetic retinopathy in type 2 diabetes
I Ahmets, N Laban - Gucev, B Jovanovska, T Milenkovic & K Adamova
Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, Former Yugoslav Republic of Macedonia.

Aim
To define impact of diabetic retinopathy as a risk factor at peoples with type 2 diabetes and diabetic foot.

Material and methods
One hundred hospitalized patients with type 2 diabetes, screened for diabetic foot and diabetic retinopathy for 1 year. Clinical examination and laboratory investigations were evaluated.

Results
From 100 patients, 53% were female and 47% male, duration of diabetes 10.47 ± 4.77 years. Mean HbA1c was 8% ± 1.2%. HbA1c < 7% had 18%, HbA1c 7–8% had 43% and HbA1c > 8% had 49% of patients. At visit 1, risk score for diabetic foot ulceration is: low risk (0) 29%, medium risk (1) 35%, high risk (2) 18% and very high risk (3) 18%. Retinopathy was present with 68% – 53% non-proliferative and 15% proliferative. Accoding the risk score at visit 1 retinopathy had: in score 0 – 15% non-proliferative and 0% proliferative, score 1 – 18% non-proliferative and 1% proliferative, score 2 – 11% non-proliferative and 6% proliferative, and score 3 – 9% non-proliferative and 8% proliferative. After 12 months risk score for diabetic foot was: 0% – 17%; 1 – 39%; 2 – 19% and 3 – 27%. Diabetic retinopathy was present after 12 months 72% of which 51% non-proliferative and 21% proliferative. According the risk score after 1 year diabetic retinopathy were present: in score 0 – 0% non-proliferative and 0% proliferative, score 1 – 22% non-proliferative and 3% proliferative, score 2 – 10% non-proliferative and 7% proliferative, and score 3 – 13% non-proliferative and 11% proliferative.

Conclusions
Association between risk score for foot ulceration and diabetic retinopathy was present. Group with risk score 0 and 1 have more non-proliferative retinopathy and group with score 2 and 3 have more proliferative retinopathy (Cross tabulation: Kruskall Wallis test P<0.01).

Keywords: diabetic foot, score, diabetic retinopathy.

P694
Type 2 diabetes mellitus and testosterone: a meta-analysis study
Giovanni Corona1,2, Matteo Monani1, Giulia Rastrelli1, Antonio Aversa1, Andrea Lenzi1, Gianni Forti1, Edordo Mannucci1 & Mario Maggi1
1Andrology and Sexual Medicine Unit, University of Florence, Florence, Italy; 2Department of Medical Pathophysiology (DFM-Fisiopatologia Medica), Sapienza University, Rome, Italy; 3Endocrinology Unit, University of Florence, Florence, Italy; 4Endocrinology Unit, Azienda Usl di Bologna, Ospedale Maggiore, Bologna, Italy.

Introduction
Type 2 diabetes mellitus (T2DM) is often associated with male hypogonadism. The role of testosterone replacement therapy (TRT) in T2DM has not been completely clarified. To systematically analyse the relationship between androgen levels and T2DM by reviewing and meta-analyzing available prospective and cross-sectional studies. In addition, a specific meta-analysis on the metabolic effects of TRT in available randomised clinical trials (RCTs) was also performed.

Methods
An extensive Medline search was performed including the following words ‘testosterone’, ‘type 2 diabetes mellitus’ and ‘males’. Out of 742, 37 articles were included in the study. In particular 28, 5, and 3 were cross-sectional, longitudinal, and interventional studies, respectively. A further unpublished RCT was retrieved on www.clinicaltrials.gov.

Results
T2DM patients showed significantly lower T plasma levels in comparison with non-diabetic individuals. Similar results were obtained when T2DM subjects with and without ED were analyzed separately. Meta-regression analysis demonstrated that aging reduced, while obesity increased, these differences. However, in a multiple regression model, after adjusting for age and BMI, T2DM was still associated with lower total T (TT) levels (adj. r2 = 0.568, P<0.0001). Analysis of longitudinal studies demonstrated that baseline TT was significantly lower among patients with incident diabetes in comparison to controls (−2.8 (3.57; −0.59), P<0.001). Combining the results of RCTs, TRT was associated with a significant reduction of fasting plasma glucose, HbA1c, fat mass, and triglycerides.

Conclusions
T2DM can be considered independently associated with male hypogonadism. Although only few RCTs have been reported, TRT seems to improve glycometabolic control as well as fat mass in T2DM subjects.

P695
Early diagnostics of diabetic peripheral neuropathy manifestations in patients with diabetes mellitus
Elena Vashchenko, Irina Savastseva & Heori Ramanau
Republican Research Centre for Radiation Medicine and Human Ecology, Gomel, Belarus.

Introduction
Purpose of this research was the study of peculiarities of early diabetic peripheral neuropathy (DPN) manifestations in patients with diabetes mellitus depending on diabetes manifestation age, indicators of antibody level of S100B.

Description of methods
Sixty-two patients with diabetes mellitus (DM) at the age of 21.4 to 75.2 (the average age was 47.7 ± 14.1 years) including 34 males (54.8%) and 28 females (45.2%) with longevity of DM more than 1 year (age duration is 13.2 ± 8.4 years) were examined. S100B-antibodies were determined with use of CanAg S100 EIA reactive (CanAg Diagnostics AB, Sweden). The average value for the control group (N=30) was 54.00 ± 15.60 ng/l. The laboratory data were presented in the form of mean ± s.d., nonparametric – median, 25th and 75th percentiles.

Results
The patients were divided into 4 groups by the disease manifestation age. The first group was represented by the patients with DM manifestation age before 14 years (9 individuals), the second group was composed of patients with disease manifestation age 14–20 years (14 individuals), the third group was represented by the patients with manifestation age 20–30 years (16 individuals), the fourth group was composed of patients with disease manifestation age after 40 years (25 individuals). DM longevity in patients fallen ill before 14 years was significantly higher (Me=20.17 (12.00; 23.50)) versus disease longevity in patients fallen ill after 40 years (Me= 10.00 (6.00; 15.00)); (Um=122.50; P=0.02).

In spite of the smaller disease longevity, the S100B level in patients fallen ill after 40 years was significantly higher (Me=31.11 (26.94; 35.03)) versus patients fallen ill before 14 years (Me = 24.00 (21.06; 30.37)); (Um=60.50; P=0.04).

Conclusion
The additional early laboratory predictor of DPN in patients at the age of 40 years regardless disease longevity is the increased level of S100B.

P696
Changes in GLUT1 expression under metformin treatment in rat models of severe and mild streptozotocin diabetes mellitus
Jelizaveta Sokolovska1,2, Sergejs Isajëvs3, Olga Sugoka1, Jelena Sharipova1, Lasma Lauberle1, Darja Svirina2, Evija Rostoka1, Tatjana Sjakste1,2, Ivars Kalvinš1 & Nikolais Sjakstē1,2
1Latvian Institute of Organic Synthesis, Riga, Latvia; 2Faculty of Medicine, University of Latvia, Riga, Latvia; 3Genomics and Bioinformatics Group, Institute of Biology of the University of Latvia, Riga, Latvia.

Introduction
Metformin improves hyperglycaemia via mechanisms which include activation of AMP-activated protein kinase (AMPK). Recent findings indicate that some metabolic actions of metformin occur also by AMPK-independent mechanisms. Objective
To study the action of metformin on expression of GLUT1 glucose transporter in rat models of severe and mild streptozotocin diabetes mellitus.

Materials and methods
Severe diabetes mellitus in rats was induced by single injection of streptozotocin 50 mg/kg, i.v. To induce mild diabetes mellitus with hyperlipidaemia, rats were fed by high-fat chow for 2 weeks, then two i.p. injections of streptozotocin (35 and 30 mg/kg) followed with a week interval. Rats were treated with metformin (100 mg/kg daily, per os) for 6 weeks while monitoring parameters of carbohydrate and lipid metabolism. GLUT1 mRNA and protein expression in kidneys, heart and liver were studied by means of real time RT-PCR and immunohistochemistry correspondingly.

Endocrine Abstracts (2011) Vol 26
In severely diabetic rats, metformin treatment decreased glucose concentration, glycated haemoglobin % and improved glucose tolerance. In mildly diabetic rats, only decrease in glycated haemoglobin % was observed in the end of the metformin treatment. Streptozotocin diabetes provoked increase of both GLUT1 gene and protein expression in kidneys of both severely and mildly diabetic rats. Metformin treatment produced normalization of the GLUT1 gene and protein expression levels in severely diabetic rats, in mildly diabetic rats only GLUT1 protein expression was normalized. In the liver, severe (but not mild) diabetes triggered an increase in GLUT1 protein expression, which was normalized by metformin. GLUT1 protein expression was increased in the hearts of severely and mildly diabetic rats. Metformin normalized the parameter only in severely diabetic rats.

Conclusion
Metformin decreases GLUT1 hyperexpression in kidneys, induced by streptozotocin severe diabetes mellitus and mild diabetes mellitus with hyperlipidaemia. Therefore, it is prospective for treatment of diabetic nephropathy.

P699
Gilbert syndrome and diabetes: a perfect union?
M J Matos, S B Souto, A I Oliveira, S Silva, E Vinha, P Freitas, J Queirós, D C Braga & D Carvalho
Hospital de São João, Porto, Portugal.

Introduction
Gilbert syndrome is one of the most common inherited diseases, with a prevalence of 5-7%. It is caused by a mutation in UGT1A1 gene, which is in turn responsible for a deficiency in bilirubin glucuronidation. It courses with unconjugated hyperbilirubinemia, and jaundice may occur in adolescence, after fasting, exercise, or in menses, and also with certain drugs. Individuals with Gilbert syndrome seem to have a reduction in the prevalence of micro- and macrovascular complications due to the anti-oxidant effects of bilirubin.

Clinical case
A 20-year old male patient, smoker, with type 1 diabetes mellitus diagnosed at the age of 6 and long standing poor metabolic control. He had a history of episodes of mild jaundice that had never been valued by the patient. Despite the poor compliance to diet and insulin therapy, with persistent poor glycemic control, he had no target organ complications. The patient was hospitalized in the Endocrinology Department for significant glycemic instability. A1c on admission was 10.7%. During hospitalization, gastroenterological advice was requested for persistent unconjugated hyperbilirubinemia, with jaundice may occur in adolescence, after fasting, exercise, or in menses, and also with certain drugs. Individuals with Gilbert syndrome seem to have a reduction in the prevalence of micro- and macrovascular complications due to the anti-oxidant effects of bilirubin.

Discussion
It has been recently documented a lower prevalence of vascular complications in patients with diabetes mellitus and Gilbert syndrome, as well as reduced markers of oxidative stress and inflammation. Bilirubin appears to have an inhibitory effect on NADPH oxidase activity, which may be an important source of increased superoxide production in diabetic vascular tissues. It is possible that sustained hyperbilirubinemia inhibits oxidative stress and prevents vascular complications in patients with both diseases.

P700
Influence of metabolic disorders in children with diabetes mellitus type 1 on changes of QT interval
Galina Meraiu & Angelika Solntseva
Belarus State University of Medicine, Minsk, Belarus.

Diabetes mellitus disturbs cellular metabolism of all organs and systems, including myocardium. The disturbances in cardiomyocytes lead to changes of QT and QTC intervals prolongation. Research: to evaluate values of intervals QT and QTC in children with diabetes mellitus type 1 (DM1) and to reveal interrelation of the given changes with the duration of disease, age, sex, indices of metabolic control.

Endocrine Abstracts (2011) Vol 26
P701
Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in the patients with diabetic nephropathy
Cigdem Kuzuguden1, Sibel Guldiken2, Sedat Ustundag3, Zeren Ozgen3 & Muzaffer Demir4
1Medical Faculty, Internal Medicine, Trakya University, Edirne, Turkey; 2Medical Faculty, Internal Medicine, Endocrinology Department, Trakya University, Edirne, Turkey; 3Medical Faculty, Internal Medicine, Nephrology Department, Trakya University, Edirne, Turkey; 4Medical Faculty, Internal Medicine, Hematology Department, Trakya University, Edirne, Turkey.

Aim
The aim of this study was to investigate the relationship between the clinical and laboratory findings of metabolic bone disease regarding the levels of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappa B ligand (RANKL) in the patients with diabetic nephropathy.

Material and method
This study includes 61 type 2 diabetic patients and age-, sex-matched 20 healthy subjects. Diabetic patients were divided into three groups according to a modification of Mogensen’s clinical classification (stage III, stage IV, stage V). In addition, diabetic patients were further divided into two groups according to glomerular filtration rate (GFR) as follows: group 1: GFR < 60 ml/min per 1.73 m², group 2: GFR = 60 ml/min per 1.73 m². The serum OPG and RANKL levels were determined by ELISA according to manufacturer’s manual.

Results
The serum iPTH, P and RANKL level in diabetic patients was found significantly higher than in control group (P<0.05). There were no significant differences in the serum OPG levels and RANKL/OPG ratio among the groups. No significant differences were determined between levels of OPG, RANKL, and RANKL/OPG ratio in diabetic nephropathy stages. The serum RANKL levels were significantly higher in group 1 diabetes than in the group 2 diabetic patients (P<0.05), whereas there were no significant differences in serum OPG level and RANKL/OPG ratio between the group 1 and group 2 diabetics. In addition, RANKL levels and RANKL/OPG ratio were found to be correlated positively with ALP levels in group 1 diabetic patients (P<0.05).

Conclusion
Our results suggest that increased serum RANKL levels might play role in development of the metabolic bone disease in patients with diabetic nephropathy.
Conclusions
The cause of early anemia in patients with diabetes, is not only the renal nephropathy. As diabetes progresses, the basement membrane of glomeruli thickens as a result of glycosylation, leading to increased intrarenal pressure. Factors other than CKD contributed to anemia development. Autonomic neuropathy maybe showing the need of erythropoietin treatment, as hyperglycemia affects the function of nerves and muscles acutely and possibly all other tissues as well. Therefore, erythropoietin responses to anemia in diabetes may also be disturbed. Determining the causes of early anemia in evidence of the need for early anemia screening and treatment in patients with diabetic and early stages of renal failure.

P704
Beta estrogen receptors inhibition improves wound healing in diabetes
I R Botusani1,2, V G Sunkari1, J Grunler1, S Lindberg2, O Savu3,4, K Steffensen2, K Brismar1 & S B Catrina1
1Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; 2Department of Molecular Medicine and Bionutrition, Karolinska Institute, Stockholm, Sweden; 3Department of Endocrinology, UMF ‘Carol Davila’, Bucharest, Romania; 4National Institute for Diabetes ‘N.C. Paulescu’, Bucharest, Romania.

Diabetic wounds represent a medical and economical burden with a high need to develop more efficient therapies.

Estrogens have a positive effect on cutaneous wound healing. Their decreased levels could count for impaired wound healing in elderly. The biological estrogen’s effects are mediated by two nuclear receptors subtypes (ERα and ERβ) and they were differently implied for the wound healing benefit processes. However, the estrogen effects on diabetic wounds have not yet been studied. Here, we investigate the role of estrogen receptors subtypes on the wound healing rate in diabetes.

Methods
Diabetes was induced with streptozotocin in knock out for alpha (ERKO) or beta (BERKO) estrogen receptors mice and in wild type controls. Wounds were performed on the dorsum of animals, and evaluated by photos taken every second day. At the end of the experiment, wounds biopsies were analyzed for granulation, dermal regeneration (hematoxilin eosin), angiogenesis (isolectin staining), markers for inflammation and recruitment of endothelial precursor cells (EPC) (qRT-PCR). In vitro, migration and angiogenesis assays were evaluated on primary dermal fibroblasts and endothelial cells in the presence of specific estrogen subtype receptors modulators.

Results
Wound healing rate in diabetic BERKO, but not diabetic ERKO mice was significantly faster than in diabetic controls (50% wound closure at 3.4 ± 0.3 days (P < 0.05), 4.5 ± 0.5 days respectively 4.7 ± 0.5 days). This correlated with levels of granulation tissue and with recruitment of EPCs in the wounds of BERKO mice. Agonists for both specific estrogen receptors significantly increased fibroblasts migration rate, while angiogenesis was accelerated only by blocking the beta estrogen receptor.

Conclusion
In diabetes, BERKO mice display an accelerated wound healing when compared to ERKO or control mice. Moreover, beta estrogen receptor inhibition leads to better recruitment of EPC and angiogenesis suggesting the use of specific ER modulators for therapeutic trials.

P705
Diabetes mellitus and risk of fracture
A A Gusova1, M G Pavlova1, G A Melnichenko1, G M Kavalersky1, L L Silin1 & Yu I Sontsov1,2
1M. Sechenov First Moscow State Medical University, Moscow, Russian Federation; 2FSE Research Centre of Endocrinology, Moscow, Russian Federation.

Objective
To examine association between diabetes properties (type, duration, treatment regimen etc.) and risk of any fracture in diabetic population.

Methods
We analyzed local trauma clinic data for 3 sequential years from 2662 diabetic persons who were entered The National Register of diabetes mellitus patients (133 subjects with type 1 diabetes mellitus (T1DM) and 1995 ones with T2DM).

Results
Fracture risk was higher in T1DM people compared to T2DM ones (relative risk 1.67; 95% CI 1.22–3.40). In T1DM subjects, fractures of foot and hand were more frequently found (P = 0.028). We haven’t found in T2DM population any significant influence on fracture risk of gender, age, body mass index, diabetes duration and use of any antidiabetic drugs. Presence of diabetic retinopathy, nephropathy or macrogloiapathy (atherosclerosis of coronal, cerebral and/or lower limb arteries) was associated with two-fold higher risk of all fractures while diabetic neuropathy was not (RR 1.77; 95% CI 0.96–3.25). Among 149 T2DM patients who were interviewed via telephone, fracture risk was increased in current smokers (RR 3.1, 95% CI 1.08–8.88) and daily coffee drinkers (> 7 cups a week) compared with rarely drinkers (< 1 cup a week: RR 10.9; 95% CI 1.18–101.13). Fracture risk was also observed for women with short period of lactation (1–5 months: RR 3.06; 95% CI 1.02–9.16). The risk was decreasing along either with prolongation of breastfeeding and for women with two or more children whereas this reduction wasn’t statistically significant.

Conclusion
These results indicate that main fracture risk factors in diabetic population are diabetic complications, suggesting that fracture prevention strategy should be a consideration in the treatment of diabetes. Influence of lifestyle factors are also significant and should be took into account for vulnerable group definition.

P706
Health illiteracy as a challenge in contemporary endocrinology
K Maczechewski1,2, M Rebius1 & J Wrobel1
1John Paul the II Regional Hospital, Zamosc, Poland; 2Institute of Physiotherapy University of Management and Administration, Zamosc, Poland.

Introduction
According to American Medical Association Health literacy means a group of skills, including reading and basic math skills that allow smooth functioning in the health care system. Despite the universality of schools in Europe, the problem of secondary or functional illiteracy did not only exist but seems to be growing. This is also a great ethical problem, because the illiteracy makes, e.g., fictive so basic patients right as informed consent. The reasons for this are ‘external’ to the endocrinology or closely linked to it. ‘Internal’ are the quality of the education system, the omnipresence of the images in interpersonal communication, overwhelming tendency of lawyers to write more and more difficult texts and …internet. This is a useful medium for teaching us a very selective reading, often only the headlines. ‘Internal’ reasons means limited efficacy of our treatment especially for diabetes, arteriosclerosis and Alzheimer’s disease. Especially in the elderly, this also applies to thyroid disease and/or electrolyte imbalance. Important problem is also hidden nature of the phenomenon, which illustrated our small study. In our Department of Endocrinology, we investigated consecutive patients who are willing to participate and did not declare some problems with reading. The ability to read and understand was examined based on 2 texts: health impact of salt, patient’s information about one medicament and commonly used pictograms.

Results
About 30% of patients had some difficulties with these texts. Surprising the most difficult task was the interpretation of pictograms (25%) and most easy the consideration about salt (4%).

Conclusion
The quantitative extrapolation of our data would be ineligible, but our observation maybe could stimulate other studies and more wide reading examination, at least before we give our patients to read medical information or card of his/her fundamental rights.
by low-dose Synacthen test, pituitary function was tested by CRH test and periferal metabolism of cortisol was evaluated by supression of cortisol endogenous production by dexametasone administered orally and followed by cortisone acetate (25 mg) administration. We evaluated serum ACTH, serum cortisol, salivary cortisol, aldosterone, DHEA, cortisone during these tests, cortisol binding globulin, adrenal autoantibodies, thyroid function and metabolic parameters of diabetics. We have found a subnormal response in 25% of patients (<500 nmol/l) of the serum cortisol during low-dose Synacthen test, accompanied by significantly decreased stimulated values of aldosterone and salivary cortisol. Basal serum cortisol, aldosterone, were significantly reduced, while ACTH, cortisol binding globulin and salivary cortisol did not differ. The CRH test displayed the low response in serum cortisol and ACTH as well in group of these patients. As compared with group of patients with sufficient response to Synacthen, the course of cortisol after cortisone acetate administration was delayed and significantly different from cortisol response in diabetics with hypocaloricism. The results indicate that the disorder of adrenocortical function occurs in all adrenocortical zones, on pituitary level and periferal adrenal metabolism could be change as well. These result may contribute to better understanding latent adrenal insufficiency adaptation in diabetics type 1.

The study was supported by grant no. NT 11 277 of the IGA MZCR.

---

**P708**

**Effect of oxytocin on the blood glucose level in rat**

Y Dezhkam1, E P López-Damiani2, N Dezhkam2, & S Naﬁsi3
1Islamic Azad University Young Researchers Club, Iran, Islamic Republic of
2CECNID Fisiología y Mejoramiento Animal, Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias (INIFAP), Mexico, Mexico; 3Medical School of Tabriz Islamic Azad University, Azad, Islamic Republic of Iran; 4Veterinary Physiology Department of Urmia University, Urmia, Islamic Republic of Iran.

Background

Oxytocin is a nonapeptide hormone synthesized in the supraoptic and paraventricular nuclei of the hypophalamus. Oxytocin has an effect on uterine smooth muscle contraction, blood pressure, memory, learning capability, nursing, sexual and feeding behavior. Oxytocin and vasopressin stimulate the release of insulin and glucagon from the rat pancreas. Multi organelle effects of oxytocin make it as important hormone in body.

Objective

The aim of the present study was to investigate the effect of exogenous oxytocin injection on blood glucose level in rat.

Material and methods

Eight adult female rats were divided into 3 groups, one as control and two experimental models have been used to study the effects of oxytocin hormone on the blood glucose level. The rats received 0.2 IU/kg oxytocin via intrappleural (IP) in treatment 1 (T1) and the same volume of normal saline solution in control group. Blood glucose level measured 20 min after injection by collecting the blood from tail. For treatment 2 (T2), animals survived for four month with condition of standard humidity and temperature and they were used for second experimental model. The rats received 0.4 IU/kg oxytocin via IP and the same volume of normal saline solution for control group. Blood glucose level measured same as first treatment.

Results

The results showed that blood glucose level in T1 (99.45 ± 4.86) and T2 (68.08 ± 4.86) were significantly lower compared to the control group (170.2 ± 4.86) (P < 0.05). Also blood glucose level in T1 (99.45 ± 4.86) was significantly higher than T2 (68.08 ± 4.86) (P < 0.05).

Conclusions

These in vivo results suggest that oxytocin dose has significant effect on the blood glucose level. With respect to results of this study with increasing the dose of oxytocin in animals the level of blood glucose decreased.

---

**P709**

**To develop non-invasive cytochemical diagnostic technique and monitoring of compensation of diabetes mellitus type 2**

Rudolf Yuy Tsun-Shu, Alma Mansharipova & Sholpan Mulikbayeva
Kazakh National Medical University, Almaty, Kazakhstan.

**Aim**

To develop non-invasive cytochemical diagnostic technique and monitoring of compensation of diabetes mellitus type 2.

---

**P710**

**Continuous glucose monitoring enhances the diagnostic value of mixed meal test in reactive hypoglycemia**

Ilaria Olivetti, Giorgio Grassi, Veronica Lambertenghi, Michela Tomelini, Valentina Ramella Gigliardi, Elena Gramaglia, Ezio Ghigo & Fabio Broglio
Endocrinology, Diabetology and Metabolism, Turin, Italy.

**Background**

Clinical reactive hypoglycemic events are defined as the coexistence of plasma glucose <60 mg/dl and autonomic and/or neuroglycopenic symptoms occurring in fed conditions. The diagnosis is based on tests aiming to simulate the causative triggers (i.e. mixed meal test). In clinical practice, however, a high percentage of symptomatic patients results negative to such diagnostic approach, leading to the impression of an inadequate sensitivity of this diagnostic tool. Based on this background, aim of the present study was to evaluate the diagnostic value of continuous glucose monitoring (CGM) associated to standard mixed meal test in the diagnosis of reactive hypoglycemia.

**Methods**

Thirteen subjects referring to our Center for symptoms suggestive for hypoglycemia were included in this study. All these subjects underwent i) mixed meal test (MMT); ii) CGM for 5 days for the evaluation of plasma or interstitial glucose level, respectively. We considered as positive the presence of symptoms and low glucose concentrations (< 60 mg/dl for MMT and < 70 mg/dl for CGM).

**Results**

Mean plasma glucose and the glycemic nadir during MMT (79.9 ± 9.6 and 55.3 ± 15.3 mg/dl) were similar to those during CGM (92.2 ± 11.2 and 53.9 ± 7.6 mg/dl). Four patients were positive to both MMT and CGM while 9 patients were negative to MMT but positive to CGM. The sensitivity of CGM turned out to be 44%, the specificity 100% and the predictive positive value 80%.

**Conclusion**

The present study supports that CGM could be a relevant adjunctive tool in the diagnosis of reactive hypoglycemia. In fact, CGM is likely to be a diagnostic tool able to detect hypoglycaemic events during real life that are not adequately triggered by a standard MMT.

---

**P711**

**Vitamin D and gestational diabetes**

J Pi, I F Vallina, F Alonso, I Peñuela, B Catón, E Tutor & E Santos
Complejo Hospitalario De Burgos, Burgos, Spain.

**Introduction**

There is increasing evidence of vitamin D role in maintaining normal glucose homeostasis. Gestational diabetes (GD) is related to insulin resistance and vitamin D deficiency has been linked with GD risk in some studies.

---

**Endocrine Abstracts (2011) Vol 26**
Aims
To assess whether vitamin D levels are related with gestational diabetes in a group of healthy pregnant women.

Subjects
The whole group included 845 pregnant women recruited from April 2009 to April 2010 initially selected to study vitamin D (25(OH)D) status. We also selected a subgroup (OGTT group) of 273 with abnormal O’Sullivan test who performed an oral 100-g glucose tolerance test (OGTT) according to the American Diabetes Association (ADA) recommendations. Sixty-two of them were diagnosed of GD (GD+) group and in 190 the OGTT was normal (GD− group). The 21 remained didn’t complete the test.

Methods/meanings
25(OH)D were measured at weeks 11–23 (D1) and 24–28 (D2) in the whole group and basal levels of glucose and insulin (minute 0 of the curve) in the OGTT group. Insulin resistance was calculated using the homeostasis model assessment (HOMA-IR) index. We compared 25(OH)D levels between GD+ and GD−. Pearson correlation analysis was used to test for univariate linear relationship between 25(OH)D and insulin, glucose and HOMA-IR.

Results
i) Median serum 25(OH)D concentration (ng/ml): weeks 11–13: GD+: 24.07 (6.07–39.70); DG−: 22.49 (4.53–55.56); (P = 0.175); weeks 24–26: GD+: 23.2 (4.5–39.70); GD−: 25.60 (4–52.40); (P = 0.27). ii) The relationship between 25(OH)D and glucose (r = 0.12), insulin (r = 0.047) and HOMA-IR (r = 0.23) was not statistically significant.

Conclusions
i) Vitamin D levels were insufficient in both periods of pregnancy; ii) vitamin D levels were similar in women with and without gestational diabetes; iii) we didn’t find correlation between vitamin D levels and the parameters of glucose metabolism studied.

P712
The frequency of Cushing’s disease among obese, type 2 diabetes mellitus patients: a single center experience in Turkey
Ozcan Karaman, Sayid Shafi Zuhur, Esra Cil, Aysemur Ozderya, Feyza Yener Ozturk & Yuksel Altuntas
Sisli Etfal Training and Research Hospital, Endocrinology and Metabolism Clinic, Istanbul, Turkey.

Background
Obesity and diabetes mellitus (DM) are the features of Cushing’s disease (CD). Studies indicated different frequencies of CD among obese, type 2 DM patients. The frequency of CD among obese, type 2 DM have’nt been studied in Turkey. Therefore, we aimed to assess the frequency of CD among obese (BMI > 30 kg/m²) type 2 DM patients that had not classical morphological findings of CD.

Patients and methods
Two hundred consecutive obese (BMI > 30 kg/m²) type 2 DM patients included into the study (172 female (86%), 28 male (14%), mean age 51.7 ±8.5). All patients underwent 1 mg low dose dexamethasone suppression test (LDDST). Patients with 0800 h cortisol level > 1.8 µg/dl underwent further investigation for diagnosis of CD.

Results
LDDST filed to suppress cortisol levels in 19 (9.5%) of 200 patients. After 2 days 2 mg dexamethasone suppression test (DST) cortisol levels suppressed to <1.8 µg/dl in 16 of 19 patients with unsupressed cortisol levels. Patients with suppressed cortisol levels after 2 days 2 mg DST underwent repeat LDDST after 3 months. Cortisole levels suppressed to <1.8 µg/dl in all of these patients with LDSST. With further investigation, CD diagnosed in 3 (1.5%) patients with unsuppressed cortisol levels after 2 days 2 mg DST (2 pituitary CD and one adrenal Cushing).

Conclusion
According to our study results the frequency of CD is higher in type 2 DM patients with BMI>30 kg/m² than in general population. We advise LDDST as screening test in all obese type 2 DM patients.
**P715**

Autoimmune markers in patients with type 1 diabetes mellitus

Didem Ozdemir, Husniye Baser, Rifki Ucier, Alper Usluogullari, Reyhan Ersoy & Bekir Cakir

Department of Endocrinology and Metabolism, Ataturk Education and Research Hospital, Ankara, Turkey.

Introduction

Type 1 diabetes mellitus (DM) is frequently associated with other autoimmune diseases. In this study, we aimed to evaluate thyroid autoantibodies, celiac antibodies and antiparietal antibody in patients with type 1 DM.

Methods

Thyroid antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) antibodies, antiinsulin, antiinsulin cell and anti-glutamic acid decarboxylase (anti-GAD) antibodies, antiparietal antibody, antitissue transglutaminase, antigliadin IgA and IgG antibodies were obtained from the records in patients diagnosed and followed with type 1 DM in our clinic. Also, thyroid functional status and serum vitamin B12 levels were evaluated. In available patients, thyroid ultrasonography (US) findings were recorded.

Results

One hundred and sixty-one patients with type 1 DM were included in the study. Antibodies related to type 1 DM were obtained in 117 patients and 63 (53.80%) had positive anti-GAD, 4 (3.42%) had positive antiinsulin, 13 (11.11%) had positive antiparietal cell antibodies. Thyroid functions were normal in 138 (85.71%) patients, 18 (11.18%) had hypothyroidism and 5 (3.11%) had thyrotoxicosis. Anti-TPO antibody was positive in 55 (34.16%), Anti-Tg was positive in 31 (19.23%) patients, and in 58 (36.02%) patients at least one of these antibodies was positive. Thyroid US was performed in 113 patients, 59 (52.21%) had normal thyroid US findings, 49 (43.37%) had chronic thyroiditis with or without nodules, 18 (15.93%) had solitary or multiple nodules. Celiac antibodies were positive in 15 (14.42%) of 104 patients. Among 77 patients with available antiparietal antibody, it was positive in 9 (11.69%) and negative in 68 (88.31%) patients. Forty-six (28.57%) patients had vitamin B12 levels lower than 250 pg/ml.

Conclusion

Autoantibodies related to various diseases may be observed with high frequency in patients with type 1 DM. It seems reasonable to screen for concomitant diseases, celiac disease and vitamin B12 deficiency by measuring specific antibodies in a patient newly diagnosed with type 1 DM.

**P717**

The fed to fasting transition differentially affects PEPCK protein expression in pericentral and periportal murine hepatocytes

H Herrema, J F W Baller, F Kuipers, A K Groen & A Greffhorst

University Medical Center Groningen, Groningen, The Netherlands.

Hepatic glucose metabolism is zonated. Glycolysis is mainly localized in hepatocytes surrounding the hepatic vein (pericentral zone) whereas gluconeogenesis is mainly carried out by hepatocytes surrounding the portal vein (periportal zone). Expression of the gene encoding the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK, PCK1) is induced upon feeding, an effect mainly controlled by insulin. PEPCK is considered a peri-portal enzyme. However, the differential effects of feeding and fasting and thus changes in plasma insulin concentrations on PEPCK zonation are unknown. In the present study, laserdissection microscopy, immunohistochemistry and primary periporal and pericentral hepatocytes were used to assess the effects of feeding and fasting on PEPCK gene and protein zonation. The reduced hepatic Pepck mRNA concentrations in fed mice resulted in reduced PEPCK protein expression in pericentral but not in periportal hepatocytes. In alloxan-induced type 1 diabetic mice, which lack insulin, Pepck mRNA expression and PEPCK protein levels did not increase upon fasting, confirming the regulatory role of insulin. Nevertheless, PEPCK was still zonated along the liver acinus suggesting that other factors than insulin mediate PEPCK zonation. In conclusion, our data show that the feeding to fasting response affects PEPCK protein expression and this is mediated by insulin. This transition mostly affects pericentral hepatocytes. However, not insulin but other yet to be determined factor(s) regulate PEPCK zonation along the liver acinus.

**P716**

Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes

M Boyano1, J Boneva2, D Bakalov1, G Sheinkova1 & G Prodanova1

1Alexandrovska Hospital, Medical University Sofia, Sofia, Bulgaria; 2Medical Institute, MVR, Sofia, Bulgaria.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a key component of the insulin resistance, the metabolic syndrome and type 2 diabetes mellitus (DM2). The aim was to study the prevalence of NAFLD in women and men with DM2.

Methods/design

This is a retrospective, cross-sectional, observational study. We analyzed data from in-hospital patients: 96 women (mean age 63.2 ± 11.4 years) and 80 men with DM2 (mean age 59.0 ± 10.7 years). Body weight, height, BMI, waist circumference, systolic and diastolic blood pressure were analyzed as well as laboratory parameters such as fasting plasma glucose (FPG), HbA1c, serum concentrations of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT), uric acid, total cholesterol, LDL cholesterol and HDL cholesterol. Between group differences (with/without NAFLD) were significant for ALT in women with DM2 and for BMI (P = 0.027), diastolic blood pressure (P = 0.031), and GGT (P = 0.044) in men. If a diagnostic threshold for detecting NAFLD of 40 IU/l is set the sensitivity of GGT is around 15% in women and 29% in men and that of GGT – around 20% in women and around 33% in men with DM2.

**P718**

Disturbed subjective sleep characteristics in adult patients with type 1 diabetes mellitus

M van Dijk, E Donga, J G van Dijk, G J Lammers, K W van Kralingen, O M Dekkers, E P M Corsmmit & J A Romijn

Leiden University Medical Center, Leiden, The Netherlands.

Introduction

Sleep restriction and/or impaired sleep quality negatively influence glucoregulation. The aim of this study was to assess subjective sleep parameters in patients with type 1 diabetes, to relate sleep parameters to long-term glycaemic control, and to assess possible risk factors for impaired sleep.

Research design and methods

We studied 99 adult patients with type 1 diabetes (55M, 44F, duration of diabetes 26.9 ± 1.2 years) and 99 age-, gender-, and BMI- matched non-diabetic controls. Subjective sleep characteristics were assessed by validated questionnaires, i.e. Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and the Berlin Questionnaire (BQ). Glucoregulation was assessed by HbA1c-values. Clinical parameters were obtained from medical charts. Depression was assessed by the Hospital Anxiety and Depression Scale (HADS). Peripheral polynuropathy was assessed by neurological examination and quantitative sensory testing.

Results

Thirty-five percent of the patients with type 1 diabetes had subjective poor sleep quality compared to 20% of the control subjects (P = 0.021). A higher proportion of the patients with type 1 diabetes were at increased risk for obstructive sleep apnoea (OSA) (17.2 vs 5.1%, P = 0.012). There was no significant association between individual sleep characteristics and HbA1c-values. On logistic regression analysis, HADS depression score, presence of polyneuropathy, habitual snoring, and other sleep disturbances, i.e. hypoglycaemia, were independently associated with poor sleep quality.

Conclusion

Adult patients with longstanding type 1 diabetes have disturbed subjective sleep quality and a higher risk for OSA, compared to control subjects. Subjective sleep disturbances are part of the complex syndrome of longstanding type 1 diabetes.
Prevalence of depressive syndrome in type 2 diabetes.

Sociodemographic, clinical and biochemical differences

Joana Nicolau Ramis, Rosmeri Rivera Irigoíen, Carla Francés Artigas, Josefinna Olivares Alcolea, Irene Rodríguez Rodríguez, Luis Alberto Gómez Gómez, Apolonia Gil Palmer & Lluís Masmiquel Comas Hospital Son Llàtzer, Palma de Mallorca, Spain.

Background

Depressive syndrome is a common psychiatric disorder in type 2 diabetic patients (T2DM), with negative outcomes in metabolic control and risk of developing chronic complications among these patients.

Aims

i) To know the prevalence of depressive syndrome in a group of 113 T2DM seen consecutively in an endocrinologic outpatient clinic. ii) To analyze if there are any sociodemographic, clinical or biochemical differences between T2DM with positive screening for depressive syndrome and/or antidepressant treatment and T2DM who do not meet these criteria.

Materials and methods

One hundred and thirteen T2DM (68.1% men, age 59.5±8.3 years, diabetes duration 11.2±8.4 years) were evaluated for depressive symptoms using the Beck Depression Inventory Questionnaire (BDI).

Results

We found a positive screening for depression in 54.9% T2DM evaluated. Only 50% of these patients positively screened were treated with antidepressants. Moreover, we found that the greater the duration of T2DM, the higher the risk of depression existed (P<0.001). As in the general population, we found more risk for depression in females (P<0.001), smoking (P<0.01) and being single (P<0.02).

Conclusion

There is a high prevalence of depressive syndrome in T2DM and it’s often undertreated. However, we did not find any differences in metabolic control.

Diagnostic criteria for glucose homeostasis abnormalities in obese patients: are there any differences?

J Mesquita1,2, P Rodrigues1,2, C Nogueira1, S Belo1, C Estes1, M J Matos1,2, A Varela1,2, P Freitas1,2, Joana Queiroz1, Flora Correia1,3, Bruno Oliveira1, Manuel Ferreira de Almeida1, João Tiago Guimarães1, José Luís Medina1,2 & Davide Carvalho1,2

1Hospital São João, Porto, Portugal; 2Faculty of Medicine, Porto University, Porto, Portugal; 3Faculty of Nutrition and Food Science, Porto University, Porto, Portugal.

Introduction

The course of type 2 diabetes mellitus (DM) is insidious and, before its development, other glucose homeostasis abnormalities can be detected: impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevation of HbA1c.

Aims

To compare the prevalence of glucose homeostasis abnormalities in obese patients, using diagnostic criteria of American Diabetes Association (ADA) 2009, ADA 2010 and International Diabetes Federation (IDF) 2005.

Methods

Patients were 39.9 (10.6) years old and had a body mass index (BMI) of 45.5 (5.4) kg/m². Mean fasting glycaemia was 99.1 (20.1) mg/dl, mean glycaemia at 120 minutes of OGTT was 147.5 (52.0) mg/dl and mean A1c was 5.8 (0.8)%. Considering ADA criteria, 221 patients (53.8%) had normal HbA1c, 151 (36.2%) prediabetes and 45 (10.8%) diabetes.

Results

Using ADA criteria, the percentage of DM rose from 5.7% to 6.1% (Z=124.7 6.4%). Finally, using the criteria of IDF, 135 (32.4%) prediabetes (impaired fasting glucose IFG=49, impaired glucose tolerance IGT=53, IFG + IGT=33) and 50 (12%) diabetes. Based on HbA1c criteria, 232 patients (55.6%) showed normoglycemia, 135 (32.4%) prediabetes, 30 (7%) diabetes. Comparing both criteria classifications, there was a significant difference (P<0.001) between diagnostic groups. HbA1c as diagnostic criteria for diabetes and prediabetes showed, respectively, a sensitivity of 90 and 45.2 and a specificity of 55.6 and 40.4%. Comparing both diagnostic methods, no significant difference for gender was found.

Conclusion

Diabetes and prediabetes are highly prevalent in the obese population, by either HbA1c or glucose criteria. However, each method identifies different groups of patients with abnormal control of carbohydrate metabolism. Comparing with the standard criteria for diabetes and prediabetes (based on glucose values), HbA1c shows low sensitivity and specificity as diagnostic criteria for carbohydrate dysmetabolism in the obese population.

Impact of INSR His1085 and IRS1 Gly972Arg genetic variability on dyslipidemia in patients with metabolic syndrome and type 2 diabetes

D Katalinić1, N Nikolić2, V Zujic-Rotkovic1, M Solter1, E Topic1, M Vrkljan1 & S Plestina1

1University Hospital Centre (KBC Zagreb), Zagreb, Croatia; 2Sisters of Charity University Hospital, Zagreb, Croatia.

Introduction

The metabolic syndrome is increasingly recognized as a powerful predictor of patient risk for developing cardiovascular and cerebrovascular complications. It is viewed as the phenotypic confluence of atherogenic dyslipidaemia, hypertension, central obesity and insulin resistance (with or without type 2 diabetes) resulting from dysregulated gene expression and lifestyle behaviours. Aim Because insulin resistance is a core defect in type 2 diabetes and the metabolic syndrome and may cause the atherogenic dyslipidaemia, the aim of the study was to establish a possible correlation between INSR His1085 (C/C, C/T, T/T) and IRS1 Gly972Arg (G/G, G/A, A/A) genetic variability and levels of triglycerides, high-density lipoprotein cholesterol (HDL-C) and small dense low-density lipoprotein (LDL) particles.

Methods

We enrolled 214 patients (125 men and 89 women) average age of 66.±10 years with average duration of type 2 diabetes and metabolic syndrome of 9 years (5–13). Genomic DNA was extracted from peripheral blood leukocytes while analysis of His1085 and Gly972Arg gene mutations was performed with PCR restriction fragment length polymorphism method (PCR-RFLP). Lipid parameters were determined in an automatic analyzer using original reagents for measurement.

Results

We did not found statistical significance between carriers of examined genotypes and levels of lipid parameters.

ENDOCRINE ABSTRACTS (2011) VOL 26
Conclusion
Our study has shown that the INSNR H1s1085 (C/C, C/T, T/T) and IRS1 Gly972Arg (G/G, G/A, A/A) genetic variability is not associated with different lipid profile of the examinees.

Results
According to rs7903146 genotypes, the wild type (CC) was present in 43% and the risk-conferring genotypes (CT e TT) were present in 47.1 and 9.9% respectively. The results between groups TT \times CT \times CC were respectively: glucose (mmol/l) \((.65 \pm 1.16 \times 0.68 \pm 1.66\%\times 7.00 \pm 1.22)\) NS; C-peptide (ng/ml) \((2.5 \pm 0.2 \times 2.6 \pm 0.6 \times 3.6 \pm 0.9)\) \(P < 0.04\) insulin (\(\mu U/ml\)) \((8.75 \pm 13 \times 11.65 \pm 7 \times 10.95 \pm 6.9)\) NS.

Conclusion
C-peptide plasma concentration was lower in DM2 patients carriers of TCF7L2 gene polymorphism rs7903146 TT genotype. There were no differences on insulin and glucose plasma concentrations among no-risk (CC), medium-risk (CT) and high risk (TT) DM2 carriers.

P724

TCF7L2 gene variants and plasma C-peptide concentrations in diabetes type 2
M C Ferreira1,2, M C A Marques1, R T Fukui1, M R Correia1, M E R Silva1, D M Rocha1 & R F Santos1
1Laboratório de Investigação Medica – LIM-18, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; 2Universidade Comunitária Regional de Chapecó-UNOCHAPECO, Chapecó, SC, Brazil.

Aims/hypothesis
Several data have shown the association between diabetes type 2 (DM2) and transcription factor 7-like 2 (TCF7L2) gene polymorphisms, in several and different ethnic populations. Although the pathophysiology is not completely clear, it seems that beta and alpha cell functions are abnormal. Up to these days there is no clinical data showing association between TCF7L2 gene polymorphism allele rs7903146 T and beta cell insulin and C-peptide contents in DM2 patients.

Methods
The present study evaluated the association of rs7903146 TT genotype (high risk) and rs7903146 CC genotype (low risk) with fasting plasma glucose (G), insulin (IN), C-peptide (C-Ppt), in DM2 patients carriers of TCF7L2 gene polymorphism population characteristics: age (55 \pm 5) years; BMI (29 \pm 3) kg/m², gender (80 F/50 M).The genetic analysis by ABI-TaqMan genotyping assays. Statistics (Kruskal–Wallis one way ANOVA).

P725

Risk factors of conversion from IGT and IFG to diabetes type 2
B P S Pwowonska-Solska, D P Pach, A G J Gilis-Januszewska & A H D Hubalewska-Dydejczyk
Jagiellonian University, Krakow, Poland.

Objective
To determine the predictive risk factors for the development of type 2 diabetes mellitus (DM) in patients with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) during a 8.5 follow up.

Research design and methods
This is an 8-year prospective study in a randomly selected urban population including 2383 subjects aged \(\geq 40\) years living in Krakow. Seven hundred and six had IGT (387) or IFG (319) based on WHO criteria and 264 of them attended the follow-up assessment eight years later. Subjects underwent a physical examination including weight/height, waist circumference, biochemical examination including glucose, insulin in 0', 120' OGTT and questionnaire examination concerning CVD health history and family history of type 2 diabetes.

The prevalence of type 2 diabetes in examined population of 264 people with previously (1998–2000) found IGT or IFG was 17%. Diabetes type 2 was found in 22% of people with previously diagnosed IGF and in 13% of people with previously found IGT. Among people with diagnosed diabetes, 51% had newly diagnosed diabetes during the control study, in 49% participants diabetes was diagnosed before in the period between the baseline and control study. In the studied population, statistically significant predictive factors of the progression to type 2 diabetes were fasting glicemia (RR 3.27; \(P < 0.001\)), fasting hiperinsulinemia (RR 2.1; \(P < 0.05\)), insulin resistance measured as HOMA IR index (RR 1.66; \(P < 0.05\), WHR, (RR 1.67, \(P < 0.01\)) and family history of diabetes type 2 (RR 2.21; \(P < 0.01\)).

Conclusion
In the studied population, important predictive factors of the progression to type 2 diabetes were fasting glicemia, fasting hiperinsulinemia, insulin resistance measured as HOMA IR index, WHR, and family history of type 2 diabetes.

P726

Effects of the ghrelin gene products on glucose metabolism in C2C12 muscle cells
Cristina Grande, Fabio Settanni, Iacopo Gesmundo, Marina Taliano, Ezio Ghigo & Riccarda Granata
University of Turin, Turin, Italy.

Type II diabetes is a clinical disorder of glucose and fat metabolism, caused by an inability of insulin to promote sufficient glucose uptake into adipose tissue and striated muscle and to prevent glucose output from the liver. Skeletal muscle is an important element for the maintenance of glucose homeostasis because it can increase, after stimulation, glucose uptake from the blood. In previous experiments we found that acylated ghrelin (AG), unacylated ghrelin (UAG), obestatin (Ob) exert antiapoptotic and protective effects on β-cells and human pancreatic islets; moreover they enhance insulin secretion and stimulate glucose uptake in β-cells and human pancreatic islets. The aim of this study is to gain further insight on the metabolic role of AG, UAG and Ob in peripheral tissues, in particular on a muscle cell line (C2C12). Cells were grown in DMEM containing 10% FCS. At 80% confluence, cells were switched to a 2% heat-inactivated horse serum in DME M, for differentiation of myoblast into myotubes. During this time, medium was changed every 24 h, and treatments began on day 5. All the experiments were conducted on myotubes. Gene expression was evaluated by RT-PCR or real time PCR, while the activation of specific signaling pathways by western blotting. To assess the effects of the peptides, we performed metabolic

Endocrine Abstracts (2011) Vol 26
studies: free fatty acid (FFA) and glucose uptake, respectively using QBT Fatty acid uptake kit and \[^{1}H\]-2-deoxyglucose (with liquid scintillation counting). In C2C12 AG, UAG and Ob increased expression of GLUT-4 and CD36, which binds long-chain fatty acids and facilitates their transport into cells. These effects involved PI3K/Akt and AMPK phosphorylation. These findings indicate that AG, UAG and Ob promote glucose and FFA uptake in C2C12 muscle cells and suggest that they may exert beneficial effects in vivo in disorders such as insulin resistance and type II diabetes.

**P727**

**Effects of Ramadan fasting on resting energy expenditure in T2DM**

Mohsen Khoshniani\(^1\),\(^2\) & Sassan Sharghi\(^1\),\(^2\)

\(^1\)Endocrinology and Metabolism Research Center, Tehran, Islamic Republic of Iran; \(^2\)Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

**Introduction**

Ramadan fasting may alter fuel metabolism and energy expenditure by inducing changes in the meal timing, sleep–wake patterns and physical activity. It could affect blood glucose through disrupting energy balance. Evaluation of resting energy expenditure (REE) could help to recommend best nutrition advices to diabetics for maintaining acceptable metabolic control.

**Methods**

Thirteen type 2 diabetics who were fasted in Ramadan were compared with 18 non fasting patients and 15 fasted healthy volunteers. Well controlled diabetics were allowed and uncontrolled patients were advised to avoid fasting. REE, body mass index (BMI), HbA1c and fructosamine were measured in the first and last week of Ramadan and one week later. REE decreased significantly in all three groups during Ramadan. (13.5% (P = 0.002), 10.2% (P = 0.007) and 9.5% (P=0.007) in fasting and non fasting diabetics and fasting healthy subjects respectively). HbA1c and fructosamine decreased significantly in non fasting diabetics (P = 0.008), because baseline HbA1c was higher in this group. Since HbA1c was in acceptable range in fasting diabetics, it didn’t change significantly. BMI did not change significantly in any of the groups.

**Conclusion**

Ramadan fasting reduces REE, and this reduction in diabetic and healthy subjects is merely a consequence of fasting itself and is not affected by BMI or HbA1c changes. REE reduction in non fasting diabetic patients may be the result of close supervision during study and lifestyle changes brought about by alterations in everyday life of people in Ramadan. So, reduced REE may call for specific diet plans for diabetic patients who are willing to fast, and still maintain good metabolic control during Ramadan.

**Keywords:** Diabetes Mellitus, Resting Energy Expenditure, Ramadan Fasting, blood glucose, HbA1c.

**P728**

**Chronic supplementation of \(\beta\)-hydroxy-\(\beta\)-methylbutyrate (HMB) impairs glucose homeostasis in rats under normal conditions**

F G-R Gerlinger-Romero, C Y Y Yogi Yonamine, R S C Saldanha Campello, L G-F Guimarães-Ferreira, U F M Fabres Machado & M T N Tereza Nunes

University of São Paulo, São Paulo, SP, Brazil.

**Aim**

HMB is a metabolite of leucine commonly used by athletes and in medical practice in order to increase muscle mass and/or minimize protein degradation. We have previously shown that chronic intake of HMB increases GH synthesis and secretion in rats, which might account to its anabolic effect. However HMB-treated rats, although normoglycemic, exhibited hyperinsulinemia, suggesting an apparent insulin resistance (IR) state. The present study attempted to investigate this possibility.

**Methods**

Rats were treated with HMB (320 mg/kg BW) or vehicle, by gavage, for 4 weeks, during which the body weight was monitored. After this period, part of the animals was subjected to glucose tolerance test (GTT), and the remainder was sacrificed by decapitation for removal of the soleus and extensor digitorum longus (EDL) muscles to evaluate the GLUT4 content (GLUT4/g tissue), dry/wet weight ratio and cross-sectional area (CSA). Data were analyzed by unpaired Student’s \(t\)-test. The HMB chronic administration resulted in IR, as shown by the GTT (\(P<0.001\)). No alterations were observed in the animals’ weight gain and in the dry/wet weight ratio of soleus and EDL muscles between groups. However, it was found a significant reduction of CSA and total GLUT4 content (\(P<0.05\)) in soleus muscle of the HMβ-treated rats.

**Conclusion**

The chronic administration of HMβ induces an apparent IR state in a stage in which the hyperinsulinemia seemed to account for normoglycemia. However the reduction of GLUT4 content and CSA in soleus muscle strongly indicates that the repercussions of the IR state are taking place, which might limit the recognized beneficial effects of HMβ, at least in rats under normal conditions.

**P729**

**Serum levels of fetuin-A correlate with bone turnover biomarkers in patients with type 2 diabetes mellitus**

Sazan Rasul, Jelena Todoric, Aysegil Ilhan, Harald Esterbauer & Alexandra Kautzky-Willer

Medical University of Vienna, Vienna, Austria.

**Objective**

Fetuin-A, which is a blood protein produced by liver and promotes bone mineralization, is an independent risk factor for type 2 diabetes. Whether Fetuin-A levels relate to the bone metabolism in type 2 diabetic patients is still not clear. Our study aimed to evaluate the relationship of fetuin-A to the markers of bone metabolism and bone turnover in male and female type 2 diabetic patients.

**Participants and methods**

Eighty type 2 diabetic patients, 40 males and 40 post-menopausal females (matched for age, body mass index (BMI) and duration of diabetes) were studied.

Fetuin-A (using commercially available ELISA test) together with metabolic, bone, lipid, renal, and liver function parameters and sex hormones were measured in all participants.

**Results**

Levels of Fetuin-A did not differ significantly between male and female diabetic patients. Fetuin-A correlated significantly negatively with blood levels of C-telopeptide \((r = -0.33, P<0.04)\) and positive with estradiol \((r = 0.44, P<0.009)\) among female group. In males, a significant positive correlation was observed between fetuin-A and the blood levels of bone alkaline phosphatase (ALP) \((r = 0.33, P<0.03)\). Controlling for age, BMI, fatty liver index (FLI), blood protein, albumin, calcium, gamma glutamyl-transferase (GGT) and C-reactive protein (CRP) did not alter the significance of these correlations.

**Conclusions**

Our results suggest significant correlations of fetuin-A levels with markers of bone turnover and bone metabolism in type 2 diabetic patients independent of age and BMI. More studies are needed to determine whether fetuin-A levels could indicate or predict risk of osteoporosis among them.

**P730**

**The stress influence on the diabetes mellitus occurrence in the territory of northern Kosovo and Metohija in the period of 2000–2002**

Slavica Pajovic

Medical Faculty, Kosovska Mitrovica, Serbia.

The paper shows the data on diabetes mellitus occurrence in the population of northern Kosovo and Metohija (local inhabitants and displaced person). The research comprises results of 42 495 examinations in Unit of Internal Diseases of Medical Centre in Kosovska Mitrovica in the period of January 2000–December 2002 (14 000 examinations on average, annually). Diabetes was diagnosed and classified on the basis of the latest internationally recognized criteria in 280 580, that is 542 persons in the period studied. A particularly high occurrence of diabetes in the population examined was recorded in 2001 (4.05%). Recently diagnosed patients with diabetes make up around 30% of patients with diabetes examined in this period. Such high percentage of recent patients with diagnosed diabetes, particularly in 2001, indicates stress influence and change of live environment as highly probable causes of this disease.

**Keywords:** Diabetes mellitus, stress.
Prevalence of a gestational diabetes and its risk factors estimation

Ekaterina N Giniyatullina, Hyady M Torshkoeva, Rosa M Esayan, Oksana I Kolegaeva & Olga N Tkacheva
National Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russian Federation.

The medical and social importance of a problem of a gestational diabetes (GD) is caused by higher probability of occurrence of the complicated current of pregnancy and delivery. Frequency of a GD varies within 1.5–13% from total pregnancies, essentially increasing in risk groups.

Materials and methods

One hundred and fifty-six pregnant women in different periods of gestation were examined. The estimation of GD’s risk factors was spent to all women. Low risk was revealed in 7 women, medium – in 43 pregnant women, high – in 62 patients. 75-g OGTT was spent between 24 and 28 weeks' gestation to women at low and medium GD risk. Women at high risk of GD were screened using the 75-g OGTT at first antepartum visit.

Results

GD was diagnosed in 10/156 (15.6%) in women at high risk for GD. Fasting glucose level in women with GD was 5.4 ± 1.7 vs 4.8 ± 0.4 mmol/l in women without GD (P = 0.293). Two-hours glucose level in women with GD was 8.3 ± 1.4 vs 5.5 ± 1.2 mmol/l in women without GD (P = 0.001). GD was diagnosed in 42/146 (28.7%) women at low and medium risk for GD. Fasting glucose level in group was 4.9 ± 0.6 vs 4.6 ± 0.6 mmol/l in women without GD (P = 0.005). Two-hours glucose level in GD group – 8.9 ± 0.9 vs 5.8 ± 1.2 mmol/l in women without GD (P = 0.001). 45.2% of GD women had parents with diabetes versus 26.3% women without GD (P = 0.024). Other risk factors for GD statistically didn’t differ among groups.

Conclusion

GD prevalence at pregnant women has made of 15.6%. In group with high risk for GD should be included pregnant with singular risk factor – burdened heredity on a diabetes.

Relationship between diabetes and pancreatic cancer

M Alves, M Bastos, J Santos, A Vieira, S Gouveia, J Saraiva & M Carvalheiro
Serviço de Endocrinologia, Diabetes e Metabolismo, Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal.

Background

Pancreatic cancer (PC) is rare, representing 6.8% of mortality in our country. Diabetes mellitus (DM) is often associated. Main hypothesis include: PC triggers DM; DM is a risk factor for PC; diabetes treatment modifies cancer risk.

Objective

To evaluate DM and PC association.

Methods

Evaluation of patients with PC (2006–2009), divided into: group A (without DM) and group B (with DM). Parameters evaluated: age, gender, BMI, hypertension, dyslipidaemia, hyperuricaemia, smoking, alcoholism and pancreatitis; location, tumour size and invasion at diagnostic; treatment and survival. Group B was subdivided according to DM treatment and duration (subgroup B1 ≤ 1 year, subgroup B2 > 1 year).

Results

A total of 132 patients evaluated with PC: 70 male (53%), 62 female (47%). Group A: 59.8% (n = 79); at diagnosis: 67.8 ± 14.6 years old, BMI 25.2 ± 3.9 kg/m², hypertension 38.0%, dyslipidaemia 17.7%, hyperuricaemia 2.5%, alcoholism 80.8%, tumor size 4.1 cm. Group B: 40.2% (n = 53); at diagnosis: 66.7 ± 12.2 years old, BMI 26.0 ± 4.7 kg/m², hypertension 69.8%, dyslipidaemia 50.9%, hyperuricaemia 17.0%, alcoholism 53.8%, tumor size 3.4 cm. There was statistical difference for: hypertension (OR = 3.78), dyslipidaemia (OR = 4.82), hyperuricaemia (OR = 7.86), alcoholism (OR = 5.60) and tumor size. There was no statistical difference for smoking, pancreatitis, tumor location, invasion and mortality. Diabetes treatment in group B: 58.5% on oral agents, 56.6% on insulin. Subgroup B1: 72.0%; subgroup B2: 28.0%. Diabetes duration didn’t influence tumor invasion, but influenced tumor size (subgroups B1 4.55 cm; B2 2.99 cm, P = 0.01). Overall survival was 15.3 ± 1.9 months. There was no survival difference between: groups A and B (18.5 ± 11.7 months), treatment with insulin or oral agents (16.9 vs 13.5 months), subgroups B1 and B2 (15.4 vs 15.8 months).

Conclusions

Diabetes may be a consequence of pancreatic cancer since most patients had diabetes for < 1 year. There was no difference in survival between groups, irrespective of hypoglycemic therapy. Relationship between DM and PC is complex and needs further investigation.

Vaspin circulating levels in severely obese women with type 2 diabetes mellitus (T2DM): early changes following restrictive bariatric surgery

I Kyrova1, M Fried2, S Tejmasova2, K Dolezalova2, O Bradnova3, V Hainer1, P Tremern1, S Kumar1 & Jana Vribkova1
1 University Hospital Coventry and Warwickshire, WISDEM, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, UK, 2 OB Klinika, Prague, Czech Republic, 3 Institute of Endocrinology, Prague, Czech Republic.

Introduction

Vaspin, identified as a novel insulin-sensitizing adipokine, is suggested to be dysregulated in T2DM patients with loss of association between circulating vaspin levels, BMI and insulin resistance (IR). The aim of this study was to examine whether restrictive bariatric surgery in severely obese women with T2DM leads to a realignment of vaspin and metabolic factors early following surgery and before complete resolution of diabetic status.

Methods/design

Therefore 9 women with T2DM and BMI > 35 kg/m² underwent restrictive bariatric surgery. Anthropometric and biochemical assessments were performed prospectively at baseline and 4 weeks post surgery. An age-matched control group of 13 non-diabetic women with BMI < 25 kg/m² was included in the study. (Data shown as mean ± s.e.m.; P < 0.05 was considered statistically significant).

Results

Circulating vaspin in controls correlated with HOMA-IR and fasting insulin (P < 0.05), whereas vaspin serum levels in obese T2DM subjects did not correlate with IR indices and BMI. Obese T2DM subjects had almost fourfold higher circulating vaspin levels compared with controls (0.42 ± 0.15 vs 0.11 ± 0.03 ng/ml; P < 0.01). One month post bariatric surgery vaspin decreased by 48% compared to baseline (post-op levels: 0.22 ± 0.06 ng/ml, P < 0.05); still twofold higher than controls. Obese T2DM women 4 weeks post surgery significantly reduced BMI, percent body fat, HOMA-IR, fasting insulin and fasting glucose (P < 0.05), however vaspin remained uncorrelated with these post surgery reductions.

Conclusion

Despite a 48% reduction, circulating vaspin remained uncorrelated with fat loss and IR improvement in obese T2DM women early after restrictive bariatric surgery. Further studies need to examine whether vaspin regains correlational status at later time-points post bariatric surgery following T2DM resolution. Supported by EFSN New Horizons research grant.

Does anxiety influence food preference and insulin resistance in healthy men?

Ladimila Brunerova1,2, Jana Potokova2, Jiri Horacek3 & Michal Andel2
1 Medical, Prague, Czech Republic; 2 Internal Department, Faculty Hospital Kralove Vinohrady and 3rd Faculty of Medicine, Diabetology Centre, Charles University, Prague, Czech Republic; 3rd Faculty of Medicine, Psychiatric Centre Prague, Charles University, Prague, Czech Republic.

Introduction

We tested our hypotheses that higher anxiety/depression scores can be connected with food preference of carbohydrates and higher insulin resistance.

Methods

We examined 42 healthy men (average age 43.5 ± 7.4 years, average BMI 27.4 ± 5.7 kg/m²). Study protocol included filling in the self-assessing scores of anxiety (SAS) resp. depression (SDS), carbohydrate-craving questionnaire (CCQ); assessment of 3-days diet records, hyperinsulinemic euglycemic clamp on two levels of insulinemia (1 and 10 mU/kg per min) with calculation of glucose disposal resp. metabolic clearance rate of glucose for both insulin levels (M1, M2 resp. MCR1 a MCR2) and citiopram challenge test (infusion of 0.3 mg/kg of citiopram with measurement of prolactin levels in minutes: −30, −15, 0, 15, 30, 45, 60, 90, 120, 150 and with calculation of area under the curve for prolactin levels. Student’s t-test, Kolmogorov-Smirnov test and Spearman’s correlation coefficient were used for statistical analyses.
The study was supported by VZ MSM 0021620814.

Results
We observed positive correlations between SAS resp. SDS scores and intake of monosaccharides in food: \( r=0.44, P<0.02 \); resp. \( r=0.4, P=0.03 \), but no correlation between MCR2 and SAS resp. SDS in the whole studied group: \( r=-0.38, P<0.04 \); resp. \( r=-0.04, P=0.03 \), whereas in the subgroup of insulin sensitive subjects MCR2 and SAS correlated positively: \( r=0.55, P<0.05 \). We did not find any relationship between response in citalopram challenge test and either food preference of carbohydrates or parameters of insulin resistance.

Conclusions
Subjects with higher depression/anxiety scores prefer more carbohydrates in the food. In general, subjects with higher depression/anxiety scores are more insulin resistant in comparison with those less anxious/depressive while the subjects from insulin sensitive subgroup seem to be more anxious than those insulin resistant. The study was supported by VZ MSM 0021620814.

P735
Insulin restores salivary secretion in diabetic rats: involvement of Na +/glucose cotransporter SGLT1
R Sabino-Silva, R S Campello, H K Nakamura, H S Freitas, M M Okamoto, R C Mori & U F Machado
Department of Physiology and Biophysics, Sao Paulo, SP, Brazil.

Introduction
Considering the high capacity of water transport of Na +/glucose cotransporter SGLT1, the aim of this study was to investigate the potential role the SGLT1 in salivary membrane of ductal cells of salivary glands upon the non-stimulated salivary secretion of diabetic rats. The present study also investigates the presence of glucose transporter GLUT1 in salivary glands of rats.

Methods
Non-stimulated salivary secretion and SGLT1/GLUT1 protein (western blotting and immunohistochemistry) in parotid and submandibular glands were analyzed in non-diabetic and non-treated or insulin-treated (3, 6 and 9 U/day) diabetic Wistar rats.

Results
Diabetes increased SGLT1 protein in luminal membrane of ductal cells, which was accompanied by ~80% reduction (\( P<0.001 \)) in salivary flow. Insulin treatment (6 and 9 U) decreased the SGLT1 protein expression in ductal cells of glands of diabetic rats, as compared to non-treated diabetic rats. These treatments were also able to revert (\( P<0.05 \) and \( P<0.01 \) respectively for 6 and 9 U) the diabetes-induced decrease in salivary secretion. Moreover, GLUT1 staining was observed mainly in basolateral membrane of ductal cells of salivary glands of non-diabetic and diabetic rats.

Conclusions
We propose that in the salivary glands GLUT1 participate of reabsorption of glucose in basolateral membrane, together with the SGLT1 in luminal membrane. In diabetes, reduced salivary flow was associated with increased SGLT1 protein in luminal membrane of ductal cells of salivary glands. Furthermore, insulin treatment reduced SGLT1 in luminal membrane of ductal cells, and increased salivary flow. These SGLT1 regulations, by modulating water reabsorption, might explain the alterations of salivary secretion observed in insulin-treated or untreated diabetic rats.

P736
The prevalence of diabetes mellitus in patients infected with human immunodeficiency virus on treatment with antiretroviral drugs
R Danculescu1, M Musat1, V Cristescu2 & C Poiana1
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 2Titu Maiorescu University, Bucharest, Romania.

Background and aims
Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). The therapy with antiretroviral drugs is associated with increasing reports of metabolic abnormalities such as body fat abnormalities, impaired glucose metabolism and insulin resistance, dyslipidemia. We investigated the prevalence of diabetes mellitus in patients with AIDS in treatment with antiretroviral drugs.

Materials and methods
Forty-six patients (22 women and 24 men) with AIDS in treatment with antiretroviral drugs (2 nucleoside and nucleotide reverse transcriptase inhibitors + a protease inhibitor) after 5 years were recruited for this study. Fasting glyceremia and 2 h OGTT (oral glucose tolerance test: ingestion of 75 g glucose dissolved in 250–300 ml water) were assessed. Glyceremia has been measured by glucose-oxidase method. Glyceremia levels have been classified as recommended by World Health Organization definition. Results were compared with measurements in 38 patients with AIDS but without treatment with antiretroviral drugs.

Results
The prevalence of impaired fasting glucose was 4.34% (2 patients), of impaired glucose tolerance was 6.9% (4 patients), and of diabetes mellitus was 10.86% (5 patients), in patients with AIDS treatment with antiretroviral drugs. The prevalence of impaired fasting glucose in patients with AIDS without treatment with antiretroviral drugs was 2.63% (1 patient) and of diabetes mellitus 2.63% (1 patient).

Conclusions
This study showed that patients with AIDS in treatment with antiretroviral drugs have a greater prevalence of diabetes mellitus than patients with AIDS without treatment with antiretroviral drugs (level more than 3 times). Patients with AIDS in treatment with antiretroviral drugs should be routinely screened for diabetes mellitus.

P737
Linking CERN and TERM: testing the acceleration hypothesis
S Dautovic & R Dautovic
Institute for Child and Youth Health Care of Vojvodina, Novi Sad, Vojvodina, Serbia.

Objective
Catch-up growth might be associated with metabolic risk later in life. The β-cell has a higher energy requirement and poor antioxidant defense. The accelerator hypothesis predicts earlier onset in heavier people, without necessarily a change in risk, and views diabetes as the one disorder of insulin resistance, set against different genetic backgrounds. Insulin resistance is a function of fat mass, and increasing body weight is accompanied by earlier presentation (acceleration) of diabetes. We wanted to establish whether increasing body weight was associated with the earlier presentation of type 1 diabetes, as the hypothesis would predict.

Research design and methods
The relationships between fatness and age at diagnosis were examined in context of birth weight, weight change since birth, weight and BMI at diagnosis in 130 children aged 1–16 years presenting for management of acute-onset type 1 diabetes.

Results
BMI SDS at diagnosis and weight SDS change since birth were inversely related to age at presentation in mostly children. The girls were fatter than the boys and presented with diabetes at a younger age. The sex difference in age at diagnosis were not significant when corrected for BMI suggesting that something related to fatness was the responsible factor.

Conclusions
The important question is how we can best fine-tune the nutritional intakes while maintaining neurodevelopment without cause long-term metabolic consequences. The implications for prevention of type 1 diabetes may be important.

Abbreviations: SDS, BMI, acceleration, diabetes mellitus, prevention.

Endocrine Abstracts (2011) Vol 26
lipids profile were measured in fasting blood samples. Individuals were identified using the two definitions of metabolic syndrome, and their anthropometric, demographic and biochemical characteristics were compared statistically to the rest of the population.

Results
Two hundred and thirty-three subjects satisfied the selection criteria. Using the IDF definition, 45.9% had abdominal obesity, 45.5% had high glucose, 21.7% had high triglycerides, 30.0% had low HDL-cholesterol, 12.0% had high BP, and 39 subjects (18.9%) were diagnosed with MS. These were significantly older, with higher BMI and fasting insulin. Using the ATP III definition more subjects (16.7%) were diagnosed. High glucose appeared in 45.5% of the population, low HDL cholesterol in 30%, high triglycerides in 21.7%, abdominal obesity in 25.3%, and higher BP in 12.0%.

Conclusion
Due to absence of local cutoff points for waist circumference, subjects might escape diagnosis if the IDF definition is used. More studies are needed to reach a more accurate definition of MS in Saudis.

P739
Cost of treating diabetes in a developing economy
B A Kolawole & A A Olugbodi
Obafemi Awolowo University, Ile-Ife, Nigeria.

Objective
The study set out to determine the out-of-pocket and indirect costs of treating diabetes mellitus in Nigeria.

Method
The study was conducted at two tertiary health facilities that are 25 km apart and operate under the same management, the Wesley Guild Hospital (WGH) and the Ile Hospital Unit (IHU) both in southwestern Nigeria. An interview-structured questionnaire and case note records were used to determine demographic variables, how much patients had expended on diabetes care, sources of funds for care, ability to cope with paying, number of clinic attendance and number of days spent on admission all in the preceding 12 months.

Results
There were 94 patients in all (M: F = 1:1), the average age was 62 years, 29 were retirees and 85% of the patients were in the low socioeconomic class. The average clinic attendance was 8/12 months while the average duration of hospital stay was 38 days. The total cost of insulin, oral hypoglycaemics, other drugs and laboratory test was $51,986.00. Only six patients had their own glucometer. With respect to the ability to cope with paying for care, 56% of the patients reported that they cope with difficulty or great difficulty while a third had to depend on relations for fund their own care. This results inevitably to poor outcomes hence creating a vicious circle for perpetuating poverty.

The out-of-pocket and indirect cost of diabetes care appeared intolerably high to these mostly indigent patients. An effective health insurance scheme might ameliorate this presently unacceptable situation.

P740
Comparison of the diagnostic criteria for PreDiabetes on a overweight population
Mafalda Marcelino, Paula Chambel, Manuel Paradinha, Andreia Domingues, Dolores Passos, Luis Lopes, Maria Lopes & Joao Castro
Military University Hospital, Lisbon, Portugal.

Introduction
‘PreDiabetes’ was considered as a categories of increased risk for diabetes on the last ADA recommendations in 2010. The proposed diagnostic criteria include an HbA1c value between 5.7 and 6.4%, impaired fasting glucose (IFG) (100–125 mg/dl) and impaired glucose tolerance (IGT) levels (2-h values in the oral glucose tolerance test (OGTT) of 140 to 199 mg/dl). The HbA1c as new diagnostic criteria may actually increase the number of patients diagnosed with PreDiabetes. Although this issue is controversial, originating a large discussion from different authors.

Objective
To compare the 3 mentions tests for the evaluation of dysglycemia on overweight population, without previous the diagnosis of PreDiabetes or Diabetes.

Methods
Observational study performed in our department. Clinical history was recalled and anthropometric measurements were performed in all participants: weight, height, waist circumference (WC) and % fat mass (FM). Glycaemia, lipids and blood pressure levels were measured in all patients. Three diagnostic criteria were considered: IFG, IGT and HbA1c value. Statistic tests (T-test, X² test, Fisher test) were used to compare the differences between variables.

Results
The study included 53 individuals, with a mean age of 52 years, 66% being females. Between females and males, the mean weight was 81 vs 90 kg, BMI of 33 vs 31 kg/m², WC 99.5 vs 104 cm and % FM of 40.5 vs 28.3%. Using only one diagnostic criteria, the PreDiabetes prevalence was 13.2% with FG, 9.4% with OGTT and 26.4% with HbA1c. Using the 3 criteria simultaneously, only 3.8% of the patients had PreDiabetes and none has diabetes.

Conclusions
Despite the high percentage of possible PreDiabetes based on HbA1c levels, this is not confirmed when all criteria are simultaneously used. Due to the low concordance between the 3 methods, other studies are required to evaluate the interests of HbA1c as new criteria for PreDiabetes diagnosis.
Author Index

Abayli, E P616
Abaza, DM P502
Abbasi, H OCl.4
Abbondanza, C P289
Abdel Hamid, KM P502
Abdelrazek, S P407, P408 & P409
Abdulkader, I P454
Abdullah, AR P316
Aben, KKH P456
Abersa, A P315
Abrahamsen, B S6.1
Abribat, T P667
Abs, R P246
Abylaluly, Z P394
Ackermans, M P176
Ackermans, MT OC4.2
Acs, B P19
Adam, M P142
Adamek, D P272 & P273
Adamidou, A P344 & P345
Adamova, K P593 & P693
Adams, C P96
Adamova, K P344 & P345
Adams, C P96
Adan, RAH P175
Adelmann, DT P62
ADMIRE Study Group, P672
Afeltra, L P624
Afolei, D P105 & P266
Afonso, A P471, P472 & P621
Agapito, A P360, P471, P472, P587, P609, P621, P622 & P721
Agora, V P321
Agretti, P P381
Ahmed, S P563
Ahmadi, I P693
Ahn, H P101
Aimaretti, G P166
Ajdzhanovic, V P1 & P194
Akersu, E P463
Akbar, D P738
Akdogan, MF P774
Akin, E P615
Akin, S P444
Akkurt, A P482
Aksionava, EA P314
Akturk, M P438 & P446
Al Chuzian, A P27
Al Raddadi, R P738
Al-Hamali, S P24
Alarslan, P P577
Alastrué, A P319
Alastrue, A P270
Albert, B MTE21
Alberte-Lista, L P454
Albu, A P105
Alcaloja, J P520 & P719
Alegre, C P225
Alemany, ES P679
Alevizaki, M P177, P356 & P572
Alexandrescu, D P297
Alexandru, F P525 & P526
Algunk, E P107, P634, P635 & P636
Ali, A P58
Ali, I P600
Aliabrandi, A P270
Alieva, DA P156 & P161
Alkemade, A OC2.3
Allemann, S P553
Alloolio, B OC1.5, OC2.1, P27, P29, P40, P224, & P232
Almorza, MR P57
Almeida, M P213 & P594
Aloi, L P73
Alonso, F P711
Alonso, N P392
Alonso, O P461
Altaner, S P380
Altay, M P438, P446, P487 & P714
Altinors, D P281
Altun, B P562
Altuntas, Y P5, P206, P550, P583, P585 & P712
Álvarez, C MTE24
Álvarez, C P191
Álvarez-Coca, M P591
Álvarez-Escáol, C P258
Alves, LM P292
Alves, MM P455
Alviggi, C MTE24
Alwani, A P37
Amado, JA P500 & P512
Amazit, L P178
Ambrosi, B P56 & P137
Ambrosio, MR P181, P361 & P486
Ameri, P OCl.5
Ametov, A P680 & P685
Amit, S P698
Amrein, K P580
Amzar, D P65 & P293
Anafaroglou, I P107, P634, P635 & P636
Ananie, T P154
Anarte, M P662
Anastasiou, E IS1.2
Anelce, D P269
Anelce, DA P218
Andel, M P734
Andersen, C P268
Andersen, M P120, P268 & P305
Andjelkovic, Z P325
Andor, D P404
Andra Iulia, L P526
André, S P448
Andreasen, M P242
Andrei, F P596
Angelotti, G P247
Anhê, GF P359
Anil, C P281 & P548.1
Annane, D S13.1
Antic, J P567
Antic, S P278
Antoniou, S P81 & P82
Antoniou-Tsigos, A P220
Antoniou-Tsigos, AA P221
Anwar, A P656
Anyfandakis, K P320
Arafat, AM P344 & P345
Arf, F P490
Aranburu, M P591
Ararpoval, S P36 & P204
Ariz, M P463
Arditò, A P27
Argente Pla, M P57
Argente Pla, M P211
Argyropoulos, AA P220, P221 & P466
Aripova, V P156 & P161
Aryanovic, Z P608
Arnaldi, G P23 & P247
Arosa, V P478
Arosto, M P224 & P283
Arpaci, D P230, P459, P460, P506 & P619
Arsenovic, B P533 & P574
Arslan, M P438, P446 & P487
Arslan, POC2.5
Aussinger, R P305
Artiga, C MTE21
Artigas, CF P520 & P719
Arvigo, M P132
Arwert, LI P234
Aserin, N P554 & P555
Aso, S P473
Astrup, I P268
Atai, L P385
Atasever, E P395
Athanasouli, F P752
Athanasouli, A P590
Athanasoullis, T P372
Atile, NS P395 & P713
Aubert, S P70
Aukrust, P P192
Aurierma, RS P527, P298 & P655
Aversa, A P694
Avetisian, I P453
Aydin, C P230, P468 & P469
Aydin, K P444
Aydogdu, A P562
Azevedo, F P643
Azevedo, T P213, P484, P485, P488 & P594
Aziz, F P549
Aziz, F P385 & P681
Azizov, BA P160
Azizi, D P317
Babakhanov, BK P396
Bacca, A P361
Baccini, M P13 & P330
Baciu, I P266
Baculescu, N P105
Bacynska, EB P76
Badescu, M P373
Badiu, C P187, P297, P366, P541, P640 & P647
Baek, JE P503
Baek, WY P503
Bafionio, CB P505
Baggen, MGA P598 & P599
Bagir, GS P281
Baglioni, S P323
Bahadori, B P555
Bahi, I P738
Bali, S P263
Bajkin, I P531 & P532
Balakov, D P716
Bakiner, O P281
Take a new look at...

Endocrine-Related Cancer

Need to know more?

The established global forum on hormones and cancer with a high 5-year impact factor of 5.683

Publishing basic, translational and clinical research on hormone-dependent cancers and cancers of endocrine organs

Reviews free online at www.try-erc.org

- Introducing the new Editor-in-Chief, Professor Charis Eng, Cleveland Clinic, USA
- Now publishing bi-monthly
- Continuous online publication of NEW ARTICLES
- Accepted pre-prints online in 24 hours
- Online with HighWire Press
- Easy online submission with ScholarOne
- An official journal of the European Society of Endocrinology

Sign up for free tables of contents alerting
www.endocrinology-journals.org

Society for Endocrinology

Published by BioScientifica
Applications are invited for

Editor-in-Chief

for European Journal of Endocrinology

European Journal of Endocrinology is the official clinical journal of the European Society of Endocrinology. It publishes original research papers, reviews and case reports in clinical and translational endocrinology. Invited commentaries also feature regularly. It is owned solely by the European Society of Endocrinology, a registered charity, and is published both in print and online. The current Impact Factor is 3.539.

Applications are invited for the role of Editor-in-Chief for a four-year term starting on 1 August 2011. Candidates should have globally recognised expertise relevant to the journal’s broad-ranging scope, and creative ideas about how its subject coverage should be developed over the coming years.

The journal is published by BioScientifica Limited who provide strong administrative support from their UK office. Please send your CV and a covering letter by email to Professor Paolo Beck-Peccoz, Chair of the ESE Publications Sub-Committee, at paolo.beckpeccoz@unimi.it

The deadline for applications is 31 May 2011.

European Society of Endocrinology
Euro House, 22 Apex Court, Woodlands
Bradley Stoke, Bristol. BS32 4JT
Website: www.euro-endo.org
Email: info@euro-endo.org
For the long-term treatment of acromegaly, Sandostatin® LAR® delivers...

POWERFUL EFFICACY.

Important note: Before prescribing, consult full prescribing information. Presentation: Octreotide acetate. Vials containing 10 mg, 20 mg or 30 mg octreotide base supplied as powder in vials for suspension for injection together with a pre-filled syringe for parenteral use, containing: sodium carbonate/methylcellulose 12.5 mg, mannitol 15 mg. Water for injection as ad 2.5 mL two needles (40 mm 0.5 inch), 18 gauge. Sandostatin LAR suspension contains less than 1 IU/mL (25 mcg of sodium per dose), i.e., essentially 'leuprolide-free'. Indication: Acromegaly in patients who are adequately controlled on s.c. treatment with Sandostatin; in patients in whom surgery or radiotherapy is inappropriate or ineffective; in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastro-entero-pancreatic endocrine tumors: carcinoid tumors with features of the carcinoid syndrome. Vomiting, glucagonomas, gastrinomas/Sipple's syndrome; insulinomas; GIPomas. Dose: 10 to 30 mg every 4 weeks, administered as a deep intramuscular injection. Contraindications: Known hypersensitivity to octreotide or to any of the excipients. Warnings/Precautions: Tumor-related adjustments of drugs such as beta-blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary: caution in patients with insulinomas. Diabetes mellitus: thyroid function should be monitored in patients receiving prolonged treatment with octreotide. Periodic examination of gallbladder, monitoring of vitamin B12 levels in patients who have a history of vitamin B12 depletions. Caution in patients with pregnancy; patients should be advised to use adequate contraception if necessary. Patients should not breast-feed during Sandostatin LAR treatment. Interactions: Increased renal absorption of digoxin, chlorpromazine; increased bioavailability of transcobalamine. Caution with concomitant use of drugs mainly metabolized by CYP3A4 and which have a therapeutic index. Adverse reactions: Very common (≥1/10) adverse drug reactions are diarrhea, abdominal pain, nausea, constipation, flatulence, headache, cholelithiasis, hyperglycaemia, and injection-site localized pain. Common (≥1/100, <1/10) adverse drug reactions are dyspepsia, vomiting, abdominal distention, stenostomia, loose stools, discoloration of faeces, flushing, hypotension, hypothermia, increased iridodilatation, increased thyroid-stimulating hormone (TSH), decreased T4, and decreased T3. Other rare adverse drug reactions are leukopenia, neutropenia, aminotransferase, alkaline phosphatase, phosphorus, calcium, creatine kinase, alanine transaminase, bilirubin, uric acid, concomitant therapy with drugs other than Sandostatin LAR, and hypertension. Less common (≥1/1000, <1/100) adverse drug reactions are abdominal pain, polyuria, dizziness, and tachycardia. Uncommon (≥1/10000, <1/1000) adverse drug reactions are urticaria, acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, jaundice, cholestatic jaundice, hyperbilirubinemia, increased alkaline phosphatase levels, and increased gamma glutamyl transpeptidase levels. PACK and prices: Country specific. Legal classification: Country specific.

www.ice-ece2012.com